<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) - Iffland, M - 2023 | Cochrane Library</title> <meta content="Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) - Iffland, M - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011769.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) - Iffland, M - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011769.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011769.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)" name="citation_title"/> <meta content="Michelle Iffland" name="citation_author"/> <meta content="NDIS Quality and Safeguards Commission" name="citation_author_institution"/> <meta content="Nuala Livingstone" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Mikaela Jorgensen" name="citation_author"/> <meta content="NDIS Quality and Safeguards Commission" name="citation_author_institution"/> <meta content="Philip Hazell" name="citation_author"/> <meta content="University of Sydney School of Medicine" name="citation_author_institution"/> <meta content="Donna Gillies" name="citation_author"/> <meta content="donna.gillies@ndiscommission.gov.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD011769.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/10/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011769.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011769.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011769.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aggression; Antidepressive Agents [therapeutic use]; *Antipsychotic Agents [therapeutic use]; *Autism Spectrum Disorder [drug therapy]; Fatigue; Neurotransmitter Agents [pharmacology]; Quality of Life; *Self-Injurious Behavior [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011769.pub2&amp;doi=10.1002/14651858.CD011769.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Ko3zGe0H";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011769\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011769\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ko","ms","ja","hr","fa","id","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011769.pub2",title:"Pharmacological intervention for irritability, aggression, and self\\u2010injury in autism spectrum disorder (ASD)",firstPublishedDate:"Oct 9, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Developmental, Psychosocial and Learning Problems Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011769.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011769.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011769.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011769.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011769.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011769.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011769.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011769.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011769.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011769.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6032 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011769.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-sec-0378"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-sec-0032"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-sec-0033"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-sec-0069"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-sec-0360"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/appendices#CD011769-sec-0383"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/supinfo/CD011769-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/supinfo/CD011769-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/information#CD011769-cr-0004">Michelle Iffland</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/information#CD011769-cr-0005">Nuala Livingstone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/information#CD011769-cr-0006">Mikaela Jorgensen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/information#CD011769-cr-0007">Philip Hazell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011769.pub2/information#CD011769-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Donna Gillies</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/information/en#CD011769-sec-0427">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 October 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011769.pub2">https://doi.org/10.1002/14651858.CD011769.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011769-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011769-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011769-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011769-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011769-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011769-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011769-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011769-abs-0001" lang="en"> <section id="CD011769-sec-0001"> <h3 class="title" id="CD011769-sec-0001">Background</h3> <p>Pharmacological interventions are frequently used for people with autism spectrum disorder (ASD) to manage behaviours of concern, including irritability, aggression, and self‐injury. Some pharmacological interventions might help treat some behaviours of concern, but can also have adverse effects (AEs). </p> </section> <section id="CD011769-sec-0002"> <h3 class="title" id="CD011769-sec-0002">Objectives</h3> <p>To assess the effectiveness and AEs of pharmacological interventions for managing the behaviours of irritability, aggression, and self‐injury in ASD. </p> </section> <section id="CD011769-sec-0003"> <h3 class="title" id="CD011769-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, 11 other databases and two trials registers up to June 2022. We also searched reference lists of relevant studies, and contacted study authors, experts and pharmaceutical companies. </p> </section> <section id="CD011769-sec-0004"> <h3 class="title" id="CD011769-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials of participants of any age with a clinical diagnosis of ASD, that compared any pharmacological intervention to an alternative drug, standard care, placebo, or wait‐list control. </p> </section> <section id="CD011769-sec-0005"> <h3 class="title" id="CD011769-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Primary outcomes were behaviours of concern in ASD, (irritability, aggression and self‐injury); and AEs. Secondary outcomes were quality of life, and tolerability and acceptability. Two review authors independently assessed each study for risk of bias, and used GRADE to judge the certainty of the evidence for each outcome. </p> </section> <section id="CD011769-sec-0006"> <h3 class="title" id="CD011769-sec-0006">Main results</h3> <p>We included 131 studies involving 7014 participants in this review. We identified 26 studies as awaiting classification and 25 as ongoing. Most studies involved children (53 studies involved only children under 13 years), children and adolescents (37 studies), adolescents only (2 studies) children and adults (16 studies), or adults only (23 studies). All included studies compared a pharmacological intervention to a placebo or to another pharmacological intervention. </p> <p><b>Atypical antipsychotics versus placebo</b> </p> <p>At short‐term follow−up (up to 6 months), atypical antipsychotics probably reduce irritability compared to placebo (standardised mean difference (SMD) −0.90, 95% confidence interval (CI) −1.25 to −0.55, 12 studies, 973 participants; moderate‐certainty evidence), which may indicate a large effect. However, there was no clear evidence of a difference in aggression between groups (SMD −0.44, 95% CI −0.89 to 0.01; 1 study, 77 participants; very low‐certainty evidence). Atypical antipsychotics may also reduce self‐injury (SMD −1.43, 95% CI −2.24 to −0.61; 1 study, 30 participants; low‐certainty evidence), possibly indicating a large effect. </p> <p>There may be higher rates of neurological AEs (dizziness, fatigue, sedation, somnolence, and tremor) in the intervention group (low‐certainty evidence), but there was no clear evidence of an effect on other neurological AEs. Increased appetite may be higher in the intervention group (low‐certainty evidence), but we found no clear evidence of an effect on other metabolic AEs. There was no clear evidence of differences between groups in musculoskeletal or psychological AEs. </p> <p><b>Neurohormones versus placebo</b> </p> <p>At short‐term follow‐up, neurohormones may have minimal to no clear effect on irritability when compared to placebo (SMD −0.18, 95% CI −0.37 to −0.00; 8 studies; 466 participants; very low‐certainty evidence), although the evidence is very uncertain. No data were reported for aggression or self ‐injury. </p> <p>Neurohormones may reduce the risk of headaches slightly in the intervention group, although the evidence is very uncertain. There was no clear evidence of an effect of neurohormones on any other neurological AEs, nor on any psychological, metabolic, or musculoskeletal AEs (low‐ and very low‐certainty evidence). </p> <p><b>Attention‐deficit hyperactivity disorder (ADHD)‐related medications versus placebo</b> </p> <p>At short‐term follow‐up, ADHD‐related medications may reduce irritability slightly (SMD −0.20, 95% CI −0.40 to −0.01; 10 studies, 400 participants; low‐certainty evidence), which may indicate a small effect. However, there was no clear evidence that ADHD‐related medications have an effect on self‐injury (SMD −0.62, 95% CI −1.63 to 0.39; 1 study, 16 participants; very low‐certainty evidence). No data were reported for aggression. </p> <p>Rates of neurological AEs (drowsiness, emotional AEs, fatigue, headache, insomnia, and irritability), metabolic AEs (decreased appetite) and psychological AEs (depression) may be higher in the intervention group, although the evidence is very uncertain (very low‐certainty evidence). There was no evidence of a difference between groups for any other metabolic, neurological, or psychological AEs (very low‐certainty evidence). No data were reported for musculoskeletal AEs. </p> <p><b>Antidepressants versus placebo</b> </p> <p>At short‐term follow‐up, there was no clear evidence that antidepressants have an effect on irritability (SMD −0.06, 95% CI −0.30 to 0.18; 3 studies, 267 participants; low‐certainty evidence). No data for aggression or self‐injury were reported or could be included in the analysis. </p> <p>Rates of metabolic AEs (decreased energy) may be higher in participants receiving antidepressants (very low‐certainty evidence), although no other metabolic AEs showed clear evidence of a difference. Rates of neurological AEs (decreased attention) and psychological AEs (impulsive behaviour and stereotypy) may also be higher in the intervention group (very low‐certainty evidence) although the evidence is very uncertain. There was no clear evidence of any difference in the other metabolic, neurological, or psychological AEs (very low‐certainty evidence), nor between groups in musculoskeletal AEs (very low‐certainty evidence). </p> <p><b>Risk of bias</b> </p> <p>We rated most of the studies across the four comparisons at unclear overall risk of bias due to having multiple domains rated as unclear, very few rated as low across all domains, and most having at least one domain rated as high risk of bias. </p> </section> <section id="CD011769-sec-0007"> <h3 class="title" id="CD011769-sec-0007">Authors' conclusions</h3> <p>Evidence suggests that atypical antipsychotics probably reduce irritability, ADHD‐related medications may reduce irritability slightly, and neurohormones may have little to no effect on irritability in the short term in people with ASD. There was some evidence that atypical antipsychotics may reduce self‐injury in the short term, although the evidence is uncertain. There was no clear evidence that antidepressants had an effect on irritability. There was also little to no difference in aggression between atypical antipsychotics and placebo, or self‐injury between ADHD‐related medications and placebo. However, there was some evidence that atypical antipsychotics may result in a large reduction in self‐injury, although the evidence is uncertain. No data were reported (or could be used) for self‐injury or aggression for neurohormones versus placebo. Studies reported a wide range of potential AEs. Atypical antipsychotics and ADHD‐related medications in particular were associated with an increased risk of metabolic and neurological AEs, although the evidence is uncertain for atypical antipsychotics and very uncertain for ADHD‐related medications. The other drug classes had minimal or no associated AEs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011769-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011769-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011769-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011769-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011769-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011769-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011769-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD011769-abs-0014">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011769-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011769-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011769-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011769-abs-0017">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011769-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011769-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011769-abs-0002" lang="en"> <h3>Which medications reduce irritability, aggression or self‐harm in people with autism spectrum disorder (ASD)? </h3> <p><b>Key messages</b> </p> <p>• Only 3 classes of medications showed any reduction in irritability, aggression or self‐harm when compared to placebo (a dummy medication). Atypical (second‐generation) antipsychotic medications probably reduce irritability and aggression, but appear to have little to no effect on self‐injury. Attention deficit hyperactivity disorder (ADHD)‐related medications may reduce irritability, although the evidence is uncertain. Neurohormones (oxytocin and secretin) may also reduce irritability, but we are very uncertain about the evidence. </p> <p>• Antidepressants appear to have no effect on irritability. Studies did not report on the effects of antidepressants, ADHD‐related medications and neurohormones on aggression or self‐injury. </p> <p>• Studies reported a wide range of unwanted effects, but only atypical antipsychotics, ADHD‐related medications, and neurohormones showed evidence of a higher risk of any unwanted effects compared to placebo. </p> <p><b>What is autism spectrum disorder (ASD)?</b> </p> <p>Autism is a disorder that affects a child's physical, mental and behavioural development. It is a lifelong disability that starts in childhood but continues throughout adulthood. People with autism may find it difficult to communicate and interact with the world. However, autism affects each person differently and may be more or less severe in different people, so it is described as a 'spectrum' disorder. Some people with autism spectrum disorder (ASD) may be irritable, angry or aggressive, or hurt themselves physically (self‐injury), which are 'behaviours of concern' that can be difficult to manage and distressing for the person. </p> <p><b>How are behaviours of concern managed?</b> </p> <p>Behaviours of concern are frequently managed with various types of medications that have been developed to treat other conditions. This means that their effectiveness for behaviours of concern is largely unknown, and they may cause serious and varied unwanted effects that affect all parts of the body. For example: </p> <p>• the heart and lungs;</p> <p>• the stomach and digestive system;</p> <p>• the immune system;</p> <p>• movement, joints and bones; and</p> <p>• mood and emotion.</p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know which types of medication were effective in reducing behaviours of concern in people with ASD and whether they caused unwanted effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that investigated any medication used to manage behaviours of concern. Studies compared the medication with placebo (a dummy medication) or another medication. People in the studies could be adults or children, but all had ASD with behaviours of concern. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 131 studies with 7014 people. Most studies involved children, although some studies involved both children and adults, or adults only. Studies looked at a wide range of medications, including those usually used to treat schizophrenia or bipolar disorder, depression, attention deficit hyperactivity disorder (ADHD), convulsions, emotional problems, heart and lungs, dementia, Parkinson's, and anxiety. </p> <p>Atypical (second‐generation) antipsychotics are usually used to treat schizophrenia or bipolar disorder. They probably reduce irritability, but they may have little to no effect on aggression and self‐injury. People receiving antipsychotics might be more likely to experience unwanted effects such as increased appetite, dizziness, sedation (slowed thought and movement), sleepiness, tiredness and tremor compared to those receiving no treatment or other medications. People receiving antipsychotics may be no more or less likely than those receiving placebo to experience other unwanted effects. </p> <p>Neurohormones (such as oxytocin and secretin) may have a minimal to small effect on irritability but no studies reported data for the effects of neurohormones on self‐harm or aggression. People receiving neurohormones may be no more or less likely than those receiving placebo to experience unwanted effects. </p> <p>ADHD‐related medications may reduce irritability but may have no effect on self‐injury. No studies reported data for aggression. People receiving ADHD‐related medications might be more likely to experience unwanted effects such as drowsiness, tiredness, headache, difficulties sleeping, and decreased appetite. But they may be no more or less likely than those receiving placebo to experience other unwanted effects. </p> <p>Antidepressants may have little to no effect on irritability. No studies reported useful data for aggression and self‐injury. People receiving antidepressants might be more likely to experience unwanted effects such as impulsive behaviour and making repetitive movements or sounds (stereotypy) compared to placebo. But they may be no more or less likely than those receiving placebo to experience other types of unwanted effects. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Most of the studies lasted less than 3 months, and very few studies involved adults. Therefore, we are uncertain if the same effects would be seen over a longer period of time or in adults. </p> <p><b>How up‐to‐date is the evidence?</b> </p> <p>The review authors searched for studies that had been published up to June 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011769-sec-0378" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011769-sec-0378"></div> <h3 class="title" id="CD011769-sec-0379">Implications for practice</h3> <section id="CD011769-sec-0379"> <p>Based on data from all identified trials, atypical antipsychotics (risperidone and aripiprazole) appear to reduce behaviours of concern in people with autism spectrum disorder (ASD) by approximately 34% and attention deficit hyperactivity disorder (ADHD)‐related medications by approximately 32% in the short term. However, there was also evidence that certain adverse effects (e.g. sedation and weight gain) may be associated with their use. Consideration should be given to whether prescribing and administration is warranted given the risk of adverse events. There were inadequate data to draw conclusions about their effectiveness in the medium or long term. </p> <p>There was little to no evidence of an effect of anticonvulsants, antidepressants, anxiolytics, antidementia medications, antiparkinsonian medications, neurohormones, or 'experimental' interventions on behaviours of concern (irritability, aggression or self‐injury) in the short term. In addition, there was little to no evidence of a difference in adverse effects between these intervention groups and placebo groups. There were inadequate data to draw conclusions about their effectiveness in the medium or long term. </p> <p>Before considering medications to manage a person’s behaviour of concern, a comprehensive assessment to gain a functional understanding of their behaviours should be undertaken and non‐pharmacological interventions trialled, which supports the National Institute for Health and Care Excellence (NICE) guidance on interventions for people with intellectual disability and behaviours of concern (<a href="./references#CD011769-bbs2-0395" title="National Institute for Health and Care Excellence. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. NICE guideline (NG11); May 2015. Available at www.nice.org.uk/guidance/ng11.">NICE 2015</a>). In addition, clinicians should seek informed consent to use medications to manage behaviour from the person, or their substitute decision maker, and should discuss with them the risks and benefits associated with these medications to ensure that they are clearly understood. </p> </section> <h3 class="title" id="CD011769-sec-0380">Implications for research</h3> <section id="CD011769-sec-0380"> <p>Length of follow‐up emerged as a major theme in the included studies, with only 12 studies following up participants for more than three months, one of which followed up participants for more than six months. This highlights the need for studies of longer than six months' duration to identify the long‐term health effects of pharmacological interventions in people with ASD. </p> <p>Another major theme to emerge is the lack of studies involving adults; only 23 of 131 trials included adults as the target population. This highlights the need for more studies with adults to identify the effectiveness and adverse effects associated with pharmacological intervention use amongst adults with ASD and behaviours of concern. </p> <p>A total of 95 (72%) of the included studies across all comparisons reported irritability as an outcome, whereas only four studies reported aggression and only 13 studies reported self‐injurious behaviour. This highlights the need for more studies to measure 'behaviour of concern' outcomes. Further, only 10 studies reported the outcome of quality of life. In addition, the consistent use of validated scales for each of these outcomes is important. </p> <p>Adverse effects were reported by 110 (83%) of the studies, however, the inconsistency in reporting of adverse effects has highlighted the need for the use of consistent and validated scales particularly in relation to adverse effects associated with antipsychotic use. Consistent use of a validated adverse effect scale may lead to greater consistency in reporting and increase the relevance and usability of outcome data. </p> <p>We downgraded certainty of evidence for most of the comparisons due to small sample sizes, as many of the studies included in this review involved fewer than 50 participants. Future studies should aim to involve at least 100 participants to increase the certainty of the evidence. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011769-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011769-sec-0008"></div> <div class="table" id="CD011769-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Atypical antipsychotics compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Atypical antipsychotics compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline assessment<br/><b>Setting:</b> hospital inpatient or outpatient centres, education or disability settings, mental health settings, or clinics and research centres associated with universities<br/><b>Intervention:</b> atypical antipsychotics <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with atypical antipsychotics</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Irritability</b> </p> <p>Follow‐up: short term (up to 6 months)</p> <p>Measured via Aberrant Behaviour Checklist (Irritability subscale (ABC‐I), score range 0‐45; <a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>) and the Ritvo Freeman RealLife Rating Scale (RFRLRS; <a href="./references#CD011769-bbs2-0323" title="FreemanBJ , RitvoER , YokotaA , RitvoA . A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the American academy of child psychiatry1986;25(1):130-6. [DOI: 10.1016/S0002-7138(09)60610-5] [PMID: 3950262]">Freeman 1986</a>). </p> <p>Lower scores indicate lower severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the placebo group ranged from −8.40 to 25.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.90 lower<br/>(95% CI 1.25 lower to 0.55 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>973<br/>(12 studies: risperidone 6 studies; aripiprazole 5 studies; lurasidone 1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.90 may represent a large effect</p> <p>(small = 0.2; medium = 0.5; and large = 0.8; <a href="./references#CD011769-bbs2-0295" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Erlbaum, 1988. [ISBN: 0-8058-0283-5]">Cohen 1988</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Aggression</b> </p> <p>Follow‐up: short term (up to 6 months)</p> <p>Measured via: Nisonger Child Behaviour Rating Form (conduct problem subscale; <a href="./references#CD011769-bbs2-0267" title="AmanMG , TasseMJ , RojahnJ , HammerD . The Nisonger CBRG: a child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities1996;17(1):41-57. [DOI: 10.1016/0891-4222(95)00039-9] [PMID: 8750075]">Aman 1996</a>) </p> <p>Score range 0‐48: lower scores indicate lower severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the placebo group was −6.6</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.44 lower<br/>(95% CI 0.89 lower to 0.01 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/>(1 study, risperidone) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no clear evidence of a difference however, results are uncertain.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Self‐injury</b> </p> <p>Follow‐up: short term (up to 6 months)</p> <p>Measured via: Self‐Injurious Behaviour Questionnaire (SIB‐Q Self‐injury subscale; <a href="./references#CD011769-bbs2-0335" title="GualtieriCT . Psychopharmacology of brain injured and mentally retarded patients. Philadelphia: Lippincott Williams and Wilkins, 2002.">Gualtieri 2002</a>) </p> <p>Score range 0‐20; lower scores indicate lower severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the placebo group was −4.90</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 1.43 lower<br/>(95% CI 2.24 lower to 0.61 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study, risperidone) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 1.43 may represent a large effect (small = 0.2; medium = 0.5; and large =0.8; <a href="./references#CD011769-bbs2-0295" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Erlbaum, 1988. [ISBN: 0-8058-0283-5]">Cohen 1988</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p><b>Adverse effects (AEs)</b> </p> <p>Follow‐up: short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Neurological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>dizziness</b> (14% vs 3%, P = 0.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 4.19 (95% CI 1.10 higher to 16.00 higher; 2 studies, risperidone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>974</p> <p>(11 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>fatigue</b> (15% vs 5%, P &lt; 0.001) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.58 (95% CI 1.68 higher to 3.97 higher; aripiprazole 2 studies; risperidone 4 studies) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>sedation</b> (18% vs 3%, P = 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.98 (95% CI 1.15 higher to 7.73 higher; aripiprazole 1 study; lurasidone 1 study; risperidone 4 studies) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>somnolence</b> (26% vs 6%, P &lt; 0.00001) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.84 (95% CI 3.18 higher to 7.36 higher; aripiprazole 3 studies; lurasidone 1 study; risperidone 5 studies) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>tremor</b> (10% vs 1%, P = 0.003) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.99 (95% CI 1.87 higher to 19.19 higher; aripiprazole 3 studies; risperidone 2 studies) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>There was little to no evidence of a difference between groups for: <b>drowsiness</b> (P = 0.06); <b>extrapyramidal</b> disorder (P = 0.15); <b>hypersomnia</b> (P = 0.29); <b>lethargy</b> (P = 0.19); <b>restlessness</b> (P = 0.98); or <b>agitation</b> (P = 0.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psychological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There was little to no evidence of a difference between groups for <b>anxiety</b> (P = 0.42) or <b>depression</b> (P = 0.21). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Metabolic</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>increased appetite</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.38 (95% CI 1.69 higher to 3.34 higher; aripiprazole 3 studies; risperidone 5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>702</p> <p>(8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>There was little to no evidence of a difference between groups for <b>decreased appetite</b> (P = 0.11), <b>weight gain</b> (P = 0.10) or <b>thirst</b> (P = 0.39). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Musculoskeletal</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There was little to no evidence of a difference between groups for <b>rigidity</b> (P = 0.13), <b>movement disorder</b> (P = 0.27) or <b>dyskinesia</b> (P = 0.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>AE:</b> adverse effect; <b>ASD:</b> autism spectrum disorder; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains). Not downgraded for inconsistency, as high I<sup>2</sup> statistic (83%) can be attributed to 2 outlier studies.<br/><sup>b</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), 1 level for imprecision (small sample size of 77 participants) and 1 level for imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>c</sup>Downgraded 1 level for imprecision (small sample size of 30 participants), and 1 level for indirectness (available evidence relates to adults only).<br/><sup>d</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains) and 1 level for inconsistency (direction of effect varies across studies).<br/><sup>e</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), 1 level for imprecision (small sample size of 79 participants), and 1 level for indirectness (available evidence relates to children only).<br/><sup>f</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), and 1 level for indirectness (available evidence relates to children only) and 1 level for imprecision (small sample size of 182 participants). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011769-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Neurohormones compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Neurohormones compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline assessment <br/><b>Setting:</b> hospital inpatient or outpatient centres, education or disability settings, mental health settings, or clinics and research centres associated with universities<br/><b>Intervention:</b> neurohormones <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with neurohormones</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Irritability</b> </p> <p>Follow‐up: short term (up to six months)</p> <p>Measured via Aberrant Behaviour Checklist (Irritability subscale) (ABC‐I) (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>, Score range (0‐45)). </p> <p>Lower scores indicate lower severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.18 lower<br/>(95% CI 0.37 lower to 0.00 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>466<br/>(8 studies: secretin 3 studies; ACTH 1 study; oxytocin 3 studies; vasopressin 1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.18 may represent a small effect</p> <p>(small = 0.2; medium = 0.5; and large = 0.8; <a href="./references#CD011769-bbs2-0295" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Erlbaum, 1988. [ISBN: 0-8058-0283-5]">Cohen 1988</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Aggression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data were reported for this outcome in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Self Injury</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data were reported for this outcome in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Adverse effects</b> </p> <p>Follow‐up: short term (up to six months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a lower rate of AEs for <b>headaches</b> in the neurohormone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58 (95% CI 0.38 to 0.89) (7 studies: oxytocin 6 studies; balovaptan 1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>863 participants</p> <p>(10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The was little to no evidence of a difference between groups for <b>absence seizures</b> (P = 0.52), <b>aggression</b> (P = 0.68), <b>agitation</b> (P = 0.67), <b>decreased attention</b> (P = 0.68), <b>dizziness</b> (P = 0.69), <b>dysphoria</b> (P = 0.49); <b>excessive talking</b> (P = 0.52), <b>fatigue</b> (P = 0.76), <b>forgetfulness</b> (P = 0.52), <b>insomnia</b> (P = 0.08), <b>irritability</b> (P = 0.22), <b>leg shaking</b> (P = 0.52), <b>nervous sytem disorders</b> (P = 0.47), <b>oppositional</b> (P = 0.69), <b>restlessness</b> (P = 0.67), <b>seizure</b> (P = 0.52), <b>sedation</b> (P = 0.16), <b>somnolence</b> (P = 0.22), <b>tics</b> (P = 0.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psychological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The was little to no evidence of a difference between groups for <b>anxiety</b> (P = 0.23), <b>depression</b> (P = 0.83), <b>panic attacks</b> (P = 0.45), <b>psychiatric events</b> (P = 0.21), or <b>self‐injury</b> (P = 1.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>570 participants</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metabolic</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The was little to no evidence of a difference between groups for any of the metabolic AEs including <b>decreased appetite</b> (P = 0.19), <b>increased appetite</b> (P = 0.07), <b>metabolism and nutrition disorders</b> (P = 0.57), thirst (P = 0.62), <b>weight change</b> (P = 0.50), <b>weight gain</b> (P = 0.67), and <b>weight loss</b> (P = 0.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>515 participants</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Musculoskeletal</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The was little to no evidence of a difference between groups for <b>muscle spasms</b> (P = 0.52), <b>musculoskeletal and connective tissues disorder</b> (P = 0.50) and <b>rhabdomyolysis</b> (P = 0.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355 participants</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>AE:</b> adverse effect; <b>ASD:</b> autism spectrum disorder; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level for imprecision (95% CI includes both benefit and harm), 1 level for study limitations (all studies involved children) and 1 level for imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>b</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), 1 level due to inconsistency (direction of effect varies across studies) and 1 level for imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>c</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), and 1 level for imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>d</sup>Downgraded 1 level for imprecision (95% CI includes both benefit and harm), 1 level for study limitations (high risk of bias across multiple domains) and 1 level for imprecision (95% confidence intervals includes both benefit and harm). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011769-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Attention deficit hyperactivity disorder (ADHD)‐related drugs compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ADHD‐related medications compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline assessment<br/><b>Setting:</b> hospital inpatient or outpatient centres, education or disability settings, mental health settings, or clinics and research centres associated with universities<br/><b>Intervention:</b> ADHD‐related medications<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ADHD‐related drugs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Irritability</b> </p> <p>All ADHD‐related medications</p> <p>Follow‐up: short term (up to six months)</p> <p>Measured via Aberrant Behaviour Checklist (Irritability subscale) (Score range (0‐45))</p> <p>(<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>) and the Ritvo‐Freeman Real Life Rating Scale (<a href="./references#CD011769-bbs2-0323" title="FreemanBJ , RitvoER , YokotaA , RitvoA . A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the American academy of child psychiatry1986;25(1):130-6. [DOI: 10.1016/S0002-7138(09)60610-5] [PMID: 3950262]">Freeman 1986</a> (score range 0‐15). </p> <p>Lower scores indicate lower severity.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.20 lower<br/>(95% CI 0.40 lower to 0.01 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/>(10 studies: methylphenidate 2 studies; clonidine 2 studies; guanfacine 2 studies; atomoxetine 4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.20 may represent a small effect size (small = 0.2; medium =0.5; large = 0.8, <a href="./references#CD011769-bbs2-0295" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Erlbaum, 1988. [ISBN: 0-8058-0283-5]">Cohen 1988</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aggression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data were reported for this outcome in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐injury</b> </p> <p>Follow‐up: short term (up to six months)</p> <p>Measured via the Repetitive Behaviour Scale ‐ Revised (self‐injury subscale) (<a href="./references#CD011769-bbs2-0281" title="BodfishJW , SymonsFS , ParkerDE , LewisMH . Varieties of repetitive behavior in autism: comparisons to mental retardation. Journal of Autism and Developmental Disorders2000;30(3):237-43. [DOI: 10.1023/A:1005596502855] [PMID: 11055459]">Bodfish 2000</a>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.62 lower (95% CI 1.63 lower to 0.39 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no clear evidence of a difference, but results are uncertain.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Adverse effects</b> </p> <p>Follow‐up: short term (up to six months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="7" valign="top"> <p><b>Neurological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>drowsiness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.42 (95% CI 1.54 higher to 7.59 higher); atomoxetine 2 studies; guanfacine 1 study; methylphenidate 1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>511</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>emotional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 6.32 (95% CI 2.47 higher to 16.18 higher); methylphenidate 1 study; guanfacine 1 study </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.73 (95% CI 1.98 higher to 7.03higher); atomoxetine 3 studies; guanfacine 1 study</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>headache</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.63 (95% CI 1.09 higher to 2.44 higher); atomoxetine 4 studies; methylphenidate 2 studies; guanfacine 1 study; amphetamine 1 study </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>insomnia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.58 (95% CI 1.01 higher to 2.47 higher); methylphenidate 2 studies; atomoxetine 3 studies; guanfacine 1 study; amphetamine 1 study </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>irritability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.61 (95% CI 1.25 to 2.07 higher); atomoxetine 3 studies; guanfacine 1 study; methylphenidate 2 studies </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>There was little to no evidence of a difference between groups for <b>aggression</b> (P = 0.82), <b>agitation</b> (P = 0.85), <b>dizziness</b> (P = 0.22), <b>drowsiness</b> (P = 0.003), <b>hyperactivity</b> (P = 0.75), <b>increased motor activity</b> (P = 0.36), <b>motor tics</b> (P = 0.28), <b>nightmares</b> (P = 0.57), <b>repetitive behaviour</b> (P = 0.23), <b>restlessness</b> (P = 0.80), <b>sleep disturbance</b> (P = 0.76), <b>talking excessively</b> (P = 0.05), <b>waking</b> (P = 0.59), or <b>tremor</b> (P = 0.48). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Psychological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of <b>depression</b> in the intervention group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.45 higher (95% CI 1.12 higher to 5.36 higher); methylphenidate 2 studies; guanfacine 1 study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>252</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>There was little to no evidence of a difference between groups for <b>anxiety</b> (P = 0.30); <b>mood change</b> (P = 0.07), "<b>silly behaviour</b> " (P = 0.51), <b>self‐injury</b> (P = 0.19), or <b>social withdrawal</b> (P = 0.36). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Metabolic</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>decreased appetite</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.15 (95% CI 1.55 higher to 2.99 higher); atomoxetine 5 studies; guanfacine 1 study; amphetamine 1 study; methylphenidate 2 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>511</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>There was little to no evidence of a difference between groups for increased appetite (P = 0.63) and increased energy (P = 0.31). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Musculoskeletal</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data were reported for this outcome in this comparison.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AE:</b> adverse effect; <b>ASD:</b> autism spectrum disorder; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level due to study limitations (high risk of bias across multiple domains) and 1 level due to imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>b</sup>Downgraded 1 level due to study limitations (high risk of bias across multiple domains) and 1 level for indirectness (available evidence relates to children only) and 1 level for imprecision (small sample size of n = 16 and 95% confidence intervals includes both benefit and harm).<br/><sup>c</sup>Downgraded 1 level due to study limitations (only involving children), 1 level due to inconsistency (direction of effect varies across studies) and 1 level due to imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>d</sup>Downgraded 1 level due to study limitations (high risk of bias across multiple domains), 1 level due to inconsistency (direction of effect varies across studies) and 1 level due to imprecision (95% confidence intervals includes both benefit and harm). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011769-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antidepressants compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Antidepressants compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline assessment <br/><b>Setting:</b> hospital inpatient or outpatient centres, education or disability settings, mental health settings, or clinics and research centres associated with universities<br/><b>Intervention:</b> antidepressants <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressants</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Irritability</b> </p> <p>Follow‐up: short term (up to six months)</p> <p>Measured via Aberrant Behaviour Checklist (Irritability subscale) (ABC‐I) (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>), Score range (0‐45) </p> <p>Lower scores indicate lower severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the placebo group ranged from 10.2 to 13.8</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.06 lower<br/>(95% CI 0.30 lower to 0.18 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>267<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no evidence of a difference, but results are uncertain.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Aggression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No data were reported for this outcome in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Self‐injurious behaviour</b> ‐ no data could be used for this outcome because of skewness (see <a href="./full#CD011769-tbl-0005">Table 1</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p><b>Adverse effects</b> </p> <p>Follow‐up: short term (up to six months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Neurological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of <b>decreased attention</b> in the intervention group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.16 (95% CI 1.07 higher to 16.11 higher); citalopram 1 study; clomipramine 1 study; fluoxetine 5 studies; fluvoxamine 1 study; sertraline 1 study; tianeptine 1 study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>815</p> <p>(10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The was little to no evidence of a difference between groups for any of the other neurological adverse effects including <b>activation syndrome</b> (P = 0.64), agitation (P = 0.96), <b>aggression or hostility</b> (P = 0.83), <b>anger or irritability</b> (P = 0.35), <b>autonomic disturbance</b> (P = 0.83), <b>CNS disturbance</b> (P = 0.50), <b>diaphoresis</b> (sweating) (P = 0.49), <b>drowsiness</b> (P = 0.50), <b>headache</b> (P = 0.23), <b>hyperactivity</b> (P = 0.36), <b>insomnia</b> (P = 0.29), <b>sedation</b> (P = 0.16), <b>sleep disturbance</b> (P = 0.76), <b>mood lability</b> (P = 0.43), <b>restlessness</b> (P = 0.13), <b>twitching</b> (P = 0.17), <b>tremor</b> (P = 0.22), or <b>vertigo</b> (P = 0.65) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Psychological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The was evidence of a higher rate of AEs in the intervention group for</p> <p><b>impulsive behaviour</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.92 (95% CI 1.11 higher to 7.68 higher); citalopram 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>243</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The was evidence of a higher rate of AEs in the intervention group for <b>stereotypy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 8.33 (95% CI 1.07 higher to 64.95 higher); citalopram 1 study</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The was little to no evidence of a difference between groups for <b>anorexia</b> (P = 0.42), <b>verbal aggression</b> (P = 0.36), <b>suicidal ideation</b> (P = 0.65), <b>bad dreams</b> (P = 0.28), <b>unstable mood</b> (P = 0.66), <b>anxiety</b> (P = 0.16) and <b>depression</b> (P = 0.79) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metabolic</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of <b>decreased energy</b> in the antidepressant group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.94 (95% CI 1.13 higher to 3.33 higher); citalopram 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>512</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The was little to no evidence of a difference between groups for <b>appetite disturbance</b> (P = 0.40), <b>decreased appetite</b> (P = 0.39), <b>increased appetite</b> (P = 0.85), and <b>weight gain</b> (P = 0.80) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Musculoskeletal</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The was little to no evidence of a difference between groups for <b>motor disturbance</b> (P = 0.30) or <b>neck pain</b> (P = 0.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>AE:</b> adverse effect; <b>ASD:</b> autism spectrum disorder; <b>CI:</b> confidence interval; <b>CNS:</b> central nervous system; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level for imprecision (95% confidence intervals includes both benefit and harm), and 1 level for imprecision (small sample size of n = 267). <br/><sup>b</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains) and 1 level for imprecision (95% confidence intervals include both benefit and harm).<br/><sup>c</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), 1 level for inconsistency (direction of effect varied across studies) and 1 level for imprecision (small sample size of n = 279). <br/><sup>d</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), 1 level for inconsistency (direction of effect varied across studies and 1 level for imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>e</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), 1 level for imprecision (small sample size of n=202), and 1 level for imprecision (95% confidence intervals includes both benefit and harm). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011769-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">1.</span> <span class="table-title">Antidepressant versus placebo: self‐injurious behaviour results that could not be used in meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/ medium‐/ long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0216" title="CarminatiGG , GerberF , DarbellayB , KoselMM , DeriazN , ChabertJ , et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2016;65:85-95. [DOI: 10.1016/j.pnpbp.2015.09.002] [PMID: 26361994]">Carminati 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venlafaxine 18.75 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 1 (range 0‐13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 3 (range 0‐8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0064" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McmahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2001;40(6):658-65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Citalopram (max 20 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4 (2.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 (2.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine (max 20‐30 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.09 (3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.55 (4.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011769-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011769-sec-0009"></div> <section id="CD011769-sec-0010"> <h3 class="title" id="CD011769-sec-0010">Description of the condition</h3> <p>Autism spectrum disorder (ASD) is characterised by persistent deficits in social communication and social interaction across multiple contexts, as well as restricted repetitive patterns of behaviour, interests, or activities (<a href="./references#CD011769-bbs2-0313" title="American Psychiatric Association. DSM-5. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">DSM‐5 2013</a>). There are currently five diagnostic criteria used by the <i>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition</i> (<a href="./references#CD011769-bbs2-0313" title="American Psychiatric Association. DSM-5. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">DSM‐5 2013</a>), for the diagnosis of ASD, including 1) persistent deficits in social communication and social interaction across multiple contexts; 2) restricted, repetitive patterns of behaviour, interests, or activities; 3) presentation of symptoms in the early developmental period; 4) symptoms that cause clinically significant impairment in important areas of current functioning; and 5) disturbances that are not better explained by intellectual disability (intellectual developmental disorder) or global developmental delay (<a href="./references#CD011769-bbs2-0313" title="American Psychiatric Association. DSM-5. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">DSM‐5 2013</a>). </p> <p>Thirty years ago, research suggested that ASD was a rare categorical disorder with a prevalence of 4 in 10,000 (<a href="./references#CD011769-bbs2-0278" title="Baron-CohenS . Autism and Asperger Syndrome. New York: Oxford University Press, 2008.">Baron‐Cohen 2008</a>); more recent prevalence studies show it to be a common condition with a prevalence of approximately 1% of the population across most countries (<a href="./references#CD011769-bbs2-0272" title="AroraNK , NairMK , GulatiS , DeshmukhV , MohapatraA , MishraD , et al. Neurodevelopmental disorders in children aged 2-9 years: population-based burden estimates across five regions in India. PloS Medicine2018;15(7):e1002615-e. [DOI: 10.1371/journal.pmed.1002615] [PMCID: PMC6057634] [PMID: 30040859]">Arora 2018</a>; <a href="./references#CD011769-bbs2-0294" title="CleatonMA , KirbyA . Why do we find it so hard to calculate the burden of neurodevelopmental disorders?Journal of Childhood and Developmental Disorders2018;4(3):10-20. [DOI: 10.4172/2472-1786.100073]">Cleaton 2018</a>; <a href="./references#CD011769-bbs2-0315" title="ElsabbaghM , DivanG , Koh Y-J, KimYS , KauchaliS , MarcínC , et al. Global prevalence of autism and other pervasive developmental disorders. Autism Research2012;5(3):160-79. [DOI: 10.1002/aur.239] [PMCID: PMC3763210] [PMID: 22495912]">Elsabbagh 2012</a>; <a href="./references#CD011769-bbs2-0414" title="RitchieH . Neurodevelopmental disorders. www.ourworldindata.org/neurodevelopmental-disorders (accessed 27th April 2022).">Ritchie 2020</a>). However, prevalence varies between countries, with higher rates in high‐income countries such as the USA and UK, estimated to be 1% to 3%, whereas rates in lower‐income countries are 0.5% or less (<a href="./references#CD011769-bbs2-0294" title="CleatonMA , KirbyA . Why do we find it so hard to calculate the burden of neurodevelopmental disorders?Journal of Childhood and Developmental Disorders2018;4(3):10-20. [DOI: 10.4172/2472-1786.100073]">Cleaton 2018</a>; <a href="./references#CD011769-bbs2-0414" title="RitchieH . Neurodevelopmental disorders. www.ourworldindata.org/neurodevelopmental-disorders (accessed 27th April 2022).">Ritchie 2020</a>). </p> <p>Some have attributed this rise to a true increase in the problems seen in ASD. Others have disputed this, attributing the rise to factors such as earlier diagnosis, broadening of diagnostic criteria (<a href="./references#CD011769-bbs2-0382" title="MayT , BrignellA , WilliamsK . Autism spectrum disorder prevalence in children aged 12-13 years from the Longitudinal Study of Australian Children. Autism Research2020;13(5):821-7. [DOI: 10.1002/aur.2286] [PMID: 32124539]">May 2020</a>; <a href="./references#CD011769-bbs2-0437" title="TantamD . Autism Spectrum Disorders through the Life Span. Philadelphia (PA): Jessica Kingsley Publishers, 2012.">Tantam 2012</a>) and changes in diagnostic attribution (<a href="./references#CD011769-bbs2-0381" title="MayT , SciberrasE , BrignellA , WilliamsK . Autism spectrum disorder: updated prevalence and comparison of two birth cohorts in a nationally representative Australian sample. BMJ Open2017;7(5):e015549. [DOI: 10.1136/bmjopen-2016-015549] [PMCID: PMC5623420] [PMID: 28490562]">May 2017</a>; <a href="./references#CD011769-bbs2-0443" title="TurowetzJ , MaynardDW . Category attribution as a device for diagnosis: fitting children to the autism spectrum. Sociology of Health &amp; Illness2015;38(4):610-26. [DOI: 10.1111/1467-9566.12382] [PMID: 26589878]">Turowetz 2015</a>). The prevalence of ASD in men is reported to exceed that in women, although the exact ratio may be impossible to specify; a recent review reported an overall male to female ratio of 3:1 (<a href="./references#CD011769-bbs2-0369" title="LoomesR , HullL , MandyWP . What is the male-to-female ratio in autism spectrum disorder? A systematic review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry2017;56(6):466-74. [DOI: 10.1016/j.jaac.2017.03.013] [PMID: 28545751]">Loomes 2017</a>). </p> <p>The lower prevalence of ASD in lower‐income countries has been attributed to a relative lack of epidemiological studies in low‐income countries (<a href="./references#CD011769-bbs2-0379" title="MatosMB , BaraTS , CordieroML . Autism spectrum disorder diagnoses: a comparison of countries with different income levels. Clinical Epidemiology December 2022;14:959-69. [DOI: 10.2147/CLEP.S373186] [PMID: 35992506]">Matos 2022</a>), and multiple factors including community awareness, cost and capacity of health and other services, information seeking, and socio‐demographic factors (<a href="./references#CD011769-bbs2-0468" title="ZeidanJ , FombonneE , ScorahJ , IbrahimA , DurkinMS , Saxena S. Global prevalence of autism: a sysyematic review update. Autism Research February 2022;15(5):778-90. [DOI: 10.1002/aur.2696] [PMID: 35238171]">Zeidan 2022</a>). In addition, some have suggested that due to financial restraints, low‐income countries often use their own or other criteria compared to more widely‐used criteria such as the <a href="./references#CD011769-bbs2-0313" title="American Psychiatric Association. DSM-5. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">DSM‐5 2013</a> to diagnose ASD (<a href="./references#CD011769-bbs2-0402" title="PeirisH , WickramarachchiDS , SamarasingheP , VanceP , DahanayakeD , KulasekaraV . Diagnosing autism in low-income countries: clinical record-based analysis in Sri Lanka. Autism Research2022;15(7):1358-67. [DOI: 10.1002/aur.2765] [PMID: 35707912]">Peiris 2022</a>). Because various ASD criteria and diagnostic tools are being used, this may explain the lack of consistency particularly between low‐income and high‐income countries. </p> <p>The authors of this review are aware that a substantial proportion of the autistic community prefer to describe themselves as autistic, an autistic person, or on the spectrum, rather than person with autism or ASD (<a href="./references#CD011769-bbs2-0273" title="Autism Spectrum Australia. How do we describe autism?https://www.autismspectrum.org.au/blog/how-do-we-describe-autism .">Autism Spectrum Australia 2023</a>; <a href="./references#CD011769-bbs2-0274" title="Identity-first language. https://autisticadvocacy.org/about-asan/identity-first-language/.">Autistic Self Advocacy Network 2023</a>; <a href="./references#CD011769-bbs2-0394" title="National Autistic Society. How to talk and write about autism. https://www.autism.org.uk/what-we-do/help-and-support/how-to-talk-about-autism.">National Autistic Society 2023</a>). However, preferences vary and throughout this review the authors will be using standard notation of 'person with ASD'. </p> <section id="CD011769-sec-0011"> <h4 class="title">Behaviours of concern</h4> <p>The terms 'challenging behaviour' (<a href="./references#CD011769-bbs2-0316" title="EmersonE , BromleyJ . The form and function of challenging behaviours. Journal of Intellectual Disability Research1995;39(5):388-98. [DOI: 10.1111/j.1365-2788.1995.tb00543.x] [PMID: 8555715]">Emerson 1995</a>), and 'behaviours that challenge' (<a href="./references#CD011769-bbs2-0395" title="National Institute for Health and Care Excellence. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. NICE guideline (NG11); May 2015. Available at www.nice.org.uk/guidance/ng11.">NICE 2015</a>), are widely used in the literature to describe behaviours such as irritability, aggression, and self‐injury. However, many behaviours seen as being challenging and framed as inherent to the person with autism could be better understood as legitimate responses to difficult environments and situations (<a href="./references#CD011769-bbs2-0409" title="RamcharanP , NankervisK , StrongM , RobertsonA . Experiences of restrictive practices: a view from people with disabilities and family carers. A final research report to the office of the Senior Practitioner; May 2009. Available at vgls.sdp.sirsidynix.net.au/client/search/asset/1297931 .">Ramcharan 2009</a>). 'Challenging behaviours', therefore, have also been described as reactive and responsive behaviours, distressed behaviours, expressions of unmet need, and in Australia, behaviours of concern. Throughout this review we use the term 'behaviours of concern', because it is a term that is increasingly being used internationally. </p> <p>Irritability is an ambiguous term that is often not well‐defined. Irritability is defined by the <a href="./references#CD011769-bbs2-0313" title="American Psychiatric Association. DSM-5. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">DSM‐5 2013</a> as "persistent anger, a tendency to respond to events with angry outbursts or blaming others, an exaggerated sense of frustration over minor matters". Other emotions and behaviours such as anger and aggression are often associated with irritability, however, they are usually consequences of irritability rather than a trait of irritability (<a href="./references#CD011769-bbs2-0279" title="BenarousX , ConsoliA , CohenD , RenaudJ , LahayeH , Guilé J-M. Suicidal behaviors and irritability in children and adolescents:a systematic review of the nature and mechanisms of the association. European Child and Adolescent Psychiatry October 2018;28(5):667-83. [DOI: 10.1007/s00787-018-1234-9] [PMID: 30293122]">Benarous 2019</a>; <a href="./references#CD011769-bbs2-0439" title="TooheyMJ , DiGiuseppeR . Defining and measuring irritability: construct clarification and differentiation. Clinical Psychology Review2017;53:93-108. [DOI: 10.1016/j.cpr.2017.01.009] [PMID: 28284170]">Toohey 2017</a>). </p> <p>In addition to the core symptoms, people with ASD may exhibit behaviours of concern. These can include behaviours such as agitation, aggression, self‐injury, destruction to property, disruptive behaviour, sexual misconduct, or arson (<a href="./references#CD011769-bbs2-0395" title="National Institute for Health and Care Excellence. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. NICE guideline (NG11); May 2015. Available at www.nice.org.uk/guidance/ng11.">NICE 2015</a>; <a href="./references#CD011769-bbs2-0427" title="SheehanR , HassiotisA , WaltersK , OsbornD , StrydomA , HorsfallL . Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ2015;351:h4326. [DOI: 10.1136/bmj.h4326] [PMCID: PMC4556752] [PMID: 26330451]">Sheehan 2015</a>). Neurodevelopmental disorders included in the DSM‐5 such as attention deficit hyperactivity disorder (ADHD), ASD, intellectual disability, specific learning disorders, or impairments in social interaction, communication, or movement are associated with behaviours of concern (<a href="./references#CD011769-bbs2-0294" title="CleatonMA , KirbyA . Why do we find it so hard to calculate the burden of neurodevelopmental disorders?Journal of Childhood and Developmental Disorders2018;4(3):10-20. [DOI: 10.4172/2472-1786.100073]">Cleaton 2018</a>; <a href="./references#CD011769-bbs2-0313" title="American Psychiatric Association. DSM-5. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">DSM‐5 2013</a>), with increasing severity of disability associated with an increased likelihood, frequency, and severity of behaviours of concern (<a href="./references#CD011769-bbs2-0317" title="EmersonE , KiernanC , AlborzA , ReevesD , MasonH , SwarbrickR , et al. The prevalence of challenging behaviours: a total population study. Research in Developmental Disabilities2001;22(1):77-93. [DOI: 10.1016/S0891-4222(00)00061-5] [PMID: 11263632]">Emerson 2001</a>; <a href="./references#CD011769-bbs2-0380" title="MatsonJL , BoisjoliJA . Restraint procedures and challenging behaviours in intellectual disability: an analysis of causative factors. Journal of Applied Research in Intellectual Disabilities2009;22(2):111-7. [DOI: 10.1111/j.1468-3148.2008.00477.x]">Matson 2009</a>; <a href="./references#CD011769-bbs2-0384" title="McTiernan A , LeaderG , HealyO , MannionA . Analysis of risk factors and early predictors of challenging behavior for children with autism spectrum disorder. Research in Autism Spectrum Disorders2011;5(3):1215-22. [DOI: 10.1016/j.rasd.2011.01.009]">McTiernan 2011</a>). </p> <p>The reported prevalence of behaviours of concern varies. It is estimated that between 5% and 15% of people with ASD develop behaviours of concern (<a href="./references#CD011769-bbs2-0395" title="National Institute for Health and Care Excellence. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. NICE guideline (NG11); May 2015. Available at www.nice.org.uk/guidance/ng11.">NICE 2015</a>), with a higher prevalence of greater than 25% reported in children (<a href="./references#CD011769-bbs2-0346" title="HillAP , ZuckermanKE , HagenAD , KrizDJ , DuvallSW , Van SantenJ , et al. Aggressive behaviour problems in children with autism spectrum disorders: prevalence and correlates in a large clinical sample. Research in Autism Spectrum Disorders2014;8(9):1121-33. [DOI: 10.1016/j.rasd.2014.05.006] [PMCID: PMC4160737] [PMID: 25221619]">Hill 2014</a>; <a href="./references#CD011769-bbs2-0362" title="KanneSM , MazurekMO . Aggression in children and adolescents with ASD: prevalence and risk factors. Journal of Autism and Developmental Disorders2011;41(7):926-37. [DOI: 10.1007/s10803-010-1118-4] [PMID: 20960041]">Kanne 2011</a>; <a href="./references#CD011769-bbs2-0432" title="SokeGN , RosenbergSA , HammanRF , FingerlinT , RobinsonC , CarpenterL , et al. Brief report: prevalence of self-injurious behaviors among children with autism spectrum disorder—a population-based study. Journal of Autism and Developmental Disorders2016;46(11):3607-14. [DOI: 10.1007/s10803-016-2879-1] [PMCID: PMC5392775] [PMID: 27565654]">Soke 2016</a>). Prevalence tends to also be higher in particular circumstances such as in hospitals, amongst teenagers, people in their early twenties, men and boys, people with comorbid psychiatric diagnoses (<a href="./references#CD011769-bbs2-0395" title="National Institute for Health and Care Excellence. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. NICE guideline (NG11); May 2015. Available at www.nice.org.uk/guidance/ng11.">NICE 2015</a>), and people with dual diagnoses of intellectual disability and ASD (<a href="./references#CD011769-bbs2-0322" title="FitzpatrickSE , SrivorakiatL , WinkLK , PedapatiEV , EricksonCA . Aggression in autism spectrum disorder: presentation and treatment options. Neuropsychiatric Disease and Treatment2016;12:1525-38. [DOI: 10.2147/NDT.S84585] [PMCID: PMC4922773] [PMID: 27382295]">Fitzpatrick 2016</a>; <a href="./references#CD011769-bbs2-0362" title="KanneSM , MazurekMO . Aggression in children and adolescents with ASD: prevalence and risk factors. Journal of Autism and Developmental Disorders2011;41(7):926-37. [DOI: 10.1007/s10803-010-1118-4] [PMID: 20960041]">Kanne 2011</a>; <a href="./references#CD011769-bbs2-0444" title="TyrerF , McGrotherCW , ThorpCF , DonaldsonM , BhaumikS , WatsonJM , et al. Physical aggression towards others in adults with learning disabilities: prevalence and associated factors. Journal of Intellectual Disability Research2006;50(4):295-304. [DOI: 10.1111/j.1365-2788.2005.00774.x] [PMID: 16507034]">Tyrer 2006</a>). </p> <p>There appears to be a high co‐occurrence of other neurodevelopmental disorders with ASD, such as attention deficit hyperactivity disorder (ADHD; <a href="./references#CD011769-bbs2-0313" title="American Psychiatric Association. DSM-5. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">DSM‐5 2013</a>). People with co‐occurring ASD and ADHD may have a higher incidence of behaviours of concern, which is not surprising given that such behaviours are reported in both disorders (<a href="./references#CD011769-bbs2-0299" title="CraigF , LamannaAL , MargariF , MateraE , SimoneM , MargariL . Overlap between autism spectrum disorders and attention deficit hyperactivity disorder: searching for distinctive/common clinical features. 2015 8;3:328-37. [DOI: 10.1002/aur.1449] [PMCID: PMC4654237] [PMID: 25604000]">Craig 2015</a>; <a href="./references#CD011769-bbs2-0413" title="RingerN , WilderJ , SchejaM , GustavssonA . Managing children with challenging behaviours. Parents' meaning-making processes in relation to their children's ADHD diagnosis. International journal of disability, development and education2020;67(4):376-92. [DOI: 10.1080/1034912X.2019.1596228]">Ringer 2020</a>). Furthermore, there is also co‐occurrence of mental health disorders with ASD, notably anxiety and depression (<a href="./references#CD011769-bbs2-0349" title="HollocksMJ , LerhJW , MagiatiI , Meiser-StedmanR , BrughaTS . Anxiety and depression in adults with autism spectrum disorder: a systematic review and meta-analysis. Psychological Medicine2019;49(4):559-72. [DOI: 10.1017/S0033291718002283] [PMID: 30178724]">Hollocks 2019</a>; <a href="./references#CD011769-bbs2-0364" title="KoritsasS , IaconoT . Predictors of challenging behaviour in adults with intellectual disability. Advances in Mental Health and Intllectual Disabilities2015;9(6):312-26. [DOI: 10.1108/AMHID-06-2015-0029]">Koritsas 2015</a>; <a href="./references#CD011769-bbs2-0372" title="LordC , ElsabbaghM , BairdG , Veenstra-VanderweeleJ . Autism Spectrum Disorder. Lancet2018;392(10146):508-20. [DOI: 10.1016/S0140-6736(18)31129-2] [PMCID: PMC7398158] [PMID: 30078460]">Lord 2018</a>). Approximately 40% of children and 27% of adults with ASD are reported to also have at least one anxiety disorder (<a href="./references#CD011769-bbs2-0349" title="HollocksMJ , LerhJW , MagiatiI , Meiser-StedmanR , BrughaTS . Anxiety and depression in adults with autism spectrum disorder: a systematic review and meta-analysis. Psychological Medicine2019;49(4):559-72. [DOI: 10.1017/S0033291718002283] [PMID: 30178724]">Hollocks 2019</a>; <a href="./references#CD011769-bbs2-0447" title="Van SteenselFJ , BögelsSM , PerrinS . Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis. Clinical Child and Family Psychology Review2011;14(3):302-17. [DOI: 10.1007/s10567-011-0097-0] [PMCID: PMC3162631] [PMID: 21735077]">Van Steensel 2011</a>). Over 20% of adults with ASD are reported to have a current diagnosis of depression (<a href="./references#CD011769-bbs2-0447" title="Van SteenselFJ , BögelsSM , PerrinS . Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis. Clinical Child and Family Psychology Review2011;14(3):302-17. [DOI: 10.1007/s10567-011-0097-0] [PMCID: PMC3162631] [PMID: 21735077]">Van Steensel 2011</a>). When there are co‐occurring diagnoses, medications such as stimulants, anxiolytics or antidepressants may be prescribed to treat the co‐occurring condition. </p> <p>The presence of behaviours of concern add complexity to living with and supporting people with ASD. Not only can this result in families and informal carers experiencing high levels of stress, they can also create barriers to adult independence and community involvement (<a href="./references#CD011769-bbs2-0431" title="SmithLE , GreenbergJS , MailickMR . The family context of autism spectrum disorders: influence on the behavioral phenotype and quality of life. Child and Adolescent Psychiatric Clinics of North America2014;23(1):143-55. [DOI: 10.1016/j.chc.2013.08.006] [PMCID: PMC3891371] [PMID: 24231173]">Smith 2014</a>). </p> </section> </section> <section id="CD011769-sec-0012"> <h3 class="title" id="CD011769-sec-0012">Description of the intervention</h3> <p>Interventions that target core symptoms of ASD or co‐occurring difficulties can be associated with positive outcomes in areas such as cognitive functioning, language skills, social behaviours, and reduction of behaviours of concern (<a href="./references#CD011769-bbs2-0425" title="SeidaJK , OspinaMB , KarkhanehM , HartlingL , SmithV , ClarkB . Systematic reviews of psychosocial interventions for autism: an umbrella review. Developmental Medicine and Child Neurology2009;51(2):95-104. [DOI: 10.1111/j.1469-8749.2008.03211.x] [PMID: 19191842]">Seida 2009</a>; <a href="./references#CD011769-bbs2-0454" title="WeitlaufAS , McPheetersML , PetersB , SatheN , TravisR , AielloR , et al. Therapies for Children with Autism Spectrum Disorder: Behavioral Interventions Update. Rockville (MD): Agency for Healthcare Research and Quality (US), 2014. [BOOKSHELF ID: NBK241444] [PMID: 25210724]">Weitlauf 2014</a>). </p> <p>For individuals with ASD, environmental modifications, non‐pharmacological interventions (such as educational interventions and behavioural and psychological therapies) and pharmacological interventions (medication and other biological therapies) are commonly suggested treatments and can help reduce behaviours of concern such as irritability, aggression and self‐injury (<a href="./references#CD011769-bbs2-0403" title="PerezM , CarlsonG , ZivianiJ , CuskellyM . Contribution of occupational therapists in positive behaviour support. Australian Occupational Therapy Journal2012;59(6):428-36. [DOI: 10.1111/j.1440-1630.2012.01036.x] [PMID: 23174110]">Perez 2012</a>; <a href="./references#CD011769-bbs2-0405" title="PoseyDJ , McDougleCJ . Pharmacotherapeutic management of autism. Expert Opinion on Pharmacotherapy2001;2(4):587-600. [DOI: 10.1517/14656566.2.4.587] [PMID: 11336609]">Posey 2001</a>; <a href="./references#CD011769-bbs2-0426" title="SenguptaK , LoboL , KrishnamurthyV . Educational and behavioral interventions in management of autism spectrum disorder. Indian Journal of Pediatrics2017;84(1):61-7. [DOI: 10.1007/s12098-015-1967-0] [PMID: 26661442]">Sengupta 2017</a>). </p> <p>This review will focus solely on pharmacological interventions that are used to target irritability, aggression or self‐injury in people with ASD. The major drug classes of interest were typical and atypical antipsychotics, ADHD‐related medications, anticonvulsants, anti‐dementia medications, antidepressants, antiparkinsonian medications, anxiolytics, neurohormones, and a number of drugs that did not fall into any of these classes and that we grouped under an 'experimental' category. These drug classes were based on the major classes listed in the review protocol (<a href="./references#CD011769-bbs2-0471" title="LivingstoneN , MacdonaldG , WilliamsK , CaldwellDM , BakerLB , HazellP . Pharmacological intervention for irritability, aggression, and self‐injury in Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD011769. [DOI: 10.1002/14651858.CD011769]">Livingstone 2015</a>), as well as additional pharmacological classes identified from the search results (see <a href="./appendices#CD011769-sec-0384">Appendix 1</a> for search strategy). </p> <section id="CD011769-sec-0013"> <h4 class="title">Antipsychotics</h4> <p>Antipsychotics are medications that treat disorganised thinking and poor awareness of reality. The use of antipsychotics has also been associated with reduced irritability, social withdrawal, hyperactivity, and stereotypical behaviours in young people with ASD (<a href="./references#CD011769-bbs2-0359" title="JesnerOS , Aref-AdibM , CorenE . Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005040. [DOI: 10.1002/14651858.CD005040.pub2] [PMID: 17253538]">Jesner 2007</a>). First‐generation or 'typical antipsychotics' such as haloperidol were first used in the 1950s to treat people with schizophrenia. Second‐generation or 'atypical antipsychotics' such as aripiprazole and risperidone were introduced in the 1980s because of their reduced risk of long‐term and irreversible adverse effects (AEs) when compared to typical antipsychotics. Antipsychotic medications are psychotropic agents frequently prescribed for people with ASD (<a href="./references#CD011769-bbs2-0298" title="CouryDL , AnagnostouE , Manning-CourtneyP , ReynoldsA , ColeL , McCoyR , et al. Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics2012;130(Suppl 2):S69-76. [DOI: 10.1542/peds.2012-0900D] [PMID: 23118256]">Coury 2012</a>; <a href="./references#CD011769-bbs2-0352" title="HowesOD , RogdakiM , FindonJL , WichesRH , CharmanT , KingBH , et al. Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. Journal of Psychopharmacology2018;32(1):3-29. [DOI: 10.1177/0269881117741766] [PMCID: PMC5805024] [PMID: 29237331]">Howes 2018</a>; <a href="./references#CD011769-bbs2-0373" title="LoyJH , MerrySN , HetrickAE , StasiakK . Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database of Systematic Reviews2017, Issue 8. Art. No: CD008559. [DOI: 10.1002/14651858.CD008559.pub3] [PMCID: PMC6483473] [PMID: 28791693]">Loy 2017</a>; <a href="./references#CD011769-bbs2-0374" title="MaddenJM , LakomaMD , LynchFL , RusinakD , Owen-SmithAA , ColemanKJ , et al. Psychotropic medication use among insured children with autism spectrum disorder. Journal of Autism and Developmental Disorders2017;47(1):144-54. [DOI: 10.1007/s10803-016-2946-7] [PMCID: PMC5328123] [PMID: 27817163]">Madden 2017</a>; <a href="./references#CD011769-bbs2-0390" title="MurrayML , HsiaY , GlaserK , SimonoffE , MurphyDG , AshersonPJ , et al. Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology2014;231(6):1011-21. [DOI: 10.1007/s00213-013-3140-7] [PMCID: PMC3932167] [PMID: 23681164]">Murray 2014</a>; <a href="./references#CD011769-bbs2-0410" title="RasmussenL , PrattN , RougheadE , MoffatA . Prevalence of psychotropic medicine use in Australian children with autism spectrum disorder: a drug utilization study based on children enrolled in the longitudinal study of Australian children. Journal of Autism and Developmental Disorders2019;49(1):227-35. [DOI: 10.1007/s10803-018-3718-3] [PMID: 30136113]">Rasmussen 2019</a>), often in the absence of a diagnosed mental disorder (<a href="./references#CD011769-bbs2-0301" title="CvejicRC , ArnoldSR , Foley K-R, Troller Jn. Neuropsychiatric profile and psychotropic medication use in adults with autism spectrum disorder: results from the Australian Longitudinal Study of Adults with Autism. BJPsych Open2018;4(6):461-6. [DOI: 10.1192/bjo.2018.64] [PMCID: PMC6235990] [PMID: 30450225]">Cvejic 2018</a>; <a href="./references#CD011769-bbs2-0304" title="DebS , KwokH , BertelliM , Salvador-CarullaL , BradleyE , TorrJ , et al. International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry2009;8(3):181-6. [DOI: 10.1002/j.2051-5545.2009.tb00248.x] [PMCID: PMC2758582] [PMID: 19812757]">Deb 2009</a>; <a href="./references#CD011769-bbs2-0305" title="DebS , UnwinG , DebT . Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. Journal of Intellectual Disability Research2015;59(1):11-25. [DOI: 10.1111/jir.12119] [PMID: 24450426]">Deb 2015</a>; <a href="./references#CD011769-bbs2-0427" title="SheehanR , HassiotisA , WaltersK , OsbornD , StrydomA , HorsfallL . Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ2015;351:h4326. [DOI: 10.1136/bmj.h4326] [PMCID: PMC4556752] [PMID: 26330451]">Sheehan 2015</a>). Large‐scale studies have shown that around 5% to 15% of people with ASD are prescribed antipsychotics (<a href="./references#CD011769-bbs2-0298" title="CouryDL , AnagnostouE , Manning-CourtneyP , ReynoldsA , ColeL , McCoyR , et al. Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics2012;130(Suppl 2):S69-76. [DOI: 10.1542/peds.2012-0900D] [PMID: 23118256]">Coury 2012</a>; <a href="./references#CD011769-bbs2-0352" title="HowesOD , RogdakiM , FindonJL , WichesRH , CharmanT , KingBH , et al. Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. Journal of Psychopharmacology2018;32(1):3-29. [DOI: 10.1177/0269881117741766] [PMCID: PMC5805024] [PMID: 29237331]">Howes 2018</a>; <a href="./references#CD011769-bbs2-0367" title="LakeJK , DentonD , LunskyY , ShuiAM , Veenstra-VanderWheeleJ , AnagnostouE . Medical conditions and demographic, service and clinical factors associated with atypical antipsychotic medication use among children with an autism spectrum disorder. Journal of Autism and Developmental Disorders2017;47(5):1391-402. [DOI: 10.1007/s10803-017-3058-8] [PMID: 28210827]">Lake 2017</a>; <a href="./references#CD011769-bbs2-0390" title="MurrayML , HsiaY , GlaserK , SimonoffE , MurphyDG , AshersonPJ , et al. Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology2014;231(6):1011-21. [DOI: 10.1007/s00213-013-3140-7] [PMCID: PMC3932167] [PMID: 23681164]">Murray 2014</a>; <a href="./references#CD011769-bbs2-0410" title="RasmussenL , PrattN , RougheadE , MoffatA . Prevalence of psychotropic medicine use in Australian children with autism spectrum disorder: a drug utilization study based on children enrolled in the longitudinal study of Australian children. Journal of Autism and Developmental Disorders2019;49(1):227-35. [DOI: 10.1007/s10803-018-3718-3] [PMID: 30136113]">Rasmussen 2019</a>). Antipsychotics are commonly prescribed for hyperactivity, aggression, and other behaviours of concern (<a href="./references#CD011769-bbs2-0310" title="DinnissenM , DietrichA , Van der MolenJH , VerhallenAM , BuiteveldY , JongejanS . Prescribing antipsychotics in child and adolescent psychiatry - guideline adherence. European Child and Adolescent Psychiatry2020;29(12):1717-27. [DOI: 10.1007/s00787-020-01488-6] [PMID: 32052173]">Dinnissen 2020</a>; <a href="./references#CD011769-bbs2-0340" title="HendersonA , KinnearD , FlemingM , StanleyB , GreenlawN , Young-SouthwardG , et al. Antipsychotic and antidepressant prescribing for 704 297 children and young people with and without intellectual disabilities: record linkage study. Brtish Journal of Psychiatry2020;218(1):58-62. [DOI: 10.1192/bjp.2020.232] [PMID: 33541472]">Henderson 2020</a>), and antipsychotic prescribing is more prevalent amongst people with autism and/or intellectual disability compared to the general population (<a href="./references#CD011769-bbs2-0331" title="GloverG , WilliamsR , BranfordD , AveryR , ChauhanU , HoghtonM . Prescribing of psychotropic drugs to people with learning disabilities and/or autism by general practitioners in England. Public Health England2015.">Glover 2015</a>; <a href="./references#CD011769-bbs2-0340" title="HendersonA , KinnearD , FlemingM , StanleyB , GreenlawN , Young-SouthwardG , et al. Antipsychotic and antidepressant prescribing for 704 297 children and young people with and without intellectual disabilities: record linkage study. Brtish Journal of Psychiatry2020;218(1):58-62. [DOI: 10.1192/bjp.2020.232] [PMID: 33541472]">Henderson 2020</a>). </p> <p>Although antipsychotics are not recommended for the treatment of core symptoms of ASD (<a href="./references#CD011769-bbs2-0352" title="HowesOD , RogdakiM , FindonJL , WichesRH , CharmanT , KingBH , et al. Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. Journal of Psychopharmacology2018;32(1):3-29. [DOI: 10.1177/0269881117741766] [PMCID: PMC5805024] [PMID: 29237331]">Howes 2018</a>), there is increasing evidence that antipsychotics decrease behaviours of concern in people with ASD (<a href="./references#CD011769-bbs2-0352" title="HowesOD , RogdakiM , FindonJL , WichesRH , CharmanT , KingBH , et al. Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. Journal of Psychopharmacology2018;32(1):3-29. [DOI: 10.1177/0269881117741766] [PMCID: PMC5805024] [PMID: 29237331]">Howes 2018</a>; <a href="./references#CD011769-bbs2-0359" title="JesnerOS , Aref-AdibM , CorenE . Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005040. [DOI: 10.1002/14651858.CD005040.pub2] [PMID: 17253538]">Jesner 2007</a>). Since publication of the protocol for this review (<a href="./references#CD011769-bbs2-0471" title="LivingstoneN , MacdonaldG , WilliamsK , CaldwellDM , BakerLB , HazellP . Pharmacological intervention for irritability, aggression, and self‐injury in Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD011769. [DOI: 10.1002/14651858.CD011769]">Livingstone 2015</a>), seven systematic reviews reporting the effectiveness of antipsychotics on behaviours of concern in people with autism, predominantly children and adolescents, have been published (<a href="./references#CD011769-bbs2-0314" title="D’AlòGL , De CrescenzoF , AmatoL , CrucianiF , DavoliM , FulceriF , et al. Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Health and Quality of Life Outcomes2021;19(1):33. [DOI: 10.1186/s12955-021-01669-0] [PMCID: PMC7831175] [PMID: 33494757]">D’Alò 2021</a>; <a href="./references#CD011769-bbs2-0321" title="FallahMS , ShaikhMR , NeupaneB , RusieckiD , BennettTA , BeyeneJ . Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. Journal of Child and Adolescent Psychopharmacology2019;29(3):168-80. [DOI: 10.1089/cap.2018.0115] [PMID: 30707602]">Fallah 2019</a>; <a href="./references#CD011769-bbs2-0325" title="FungLK , MahajanR , NozzolilloA , BernalP , KrasnerA , JoB , et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics2016;137(Suppl 2):S124-5. [DOI: 10.1542/peds.2015-2851K] [PMID: 26908468]">Fung 2016</a>; <a href="./references#CD011769-bbs2-0347" title="HirschLE , PringsheimT . Aripiprazole for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2016, Issue 6. Art. No: CD009043. [DOI: 10.1002/14651858.CD009043.pub3] [PMCID: PMC7120220] [PMID: 2734413]">Hirsch 2016</a>; <a href="./references#CD011769-bbs2-0375" title="ManeetonN , ManeetonB , PutthisriS , SuttajitS , LikhitsathianS , Srisurapanont M. Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Neuropsychiatric Disease and Treatment2018;14:3063-72. [PMCID: PMC6237245] [PMID: 10.2147/NDT.S174622] [PMID: 30519027]">Maneeton 2018a</a>; <a href="./references#CD011769-bbs2-0376" title="ManeetonN , ManeetonB , PutthisriS , WoottilukP , NarkpongphunA , SrisurapanontM . Risperidone for children and adolescents with autism spectrum disorder: a systematic review. Neuropsychiatric Disease and Treatment2018;14:1811-20. [DOI: 10.2147/NDT.S151802] [PMCID: PMC6045903] [PMID: 30022830]">Maneeton 2018b</a>; <a href="./references#CD011769-bbs2-0377" title="Mano-SousaBJ , PedrosaAM , AlvesBC , GaldurózJC , BeloVS , ChavesVE , et al. Effects of risperidone in autistic children and young adults: a systematic review and meta-analysis. Current Neuropharmacology2021;19(4):538-52. [DOI: 10.2174/1570159X18666200529151741] [PMCID: PMC8206457] [PMID: 32469700]">Mano‐Sousa 2021</a>). Although results were mixed, the majority of evidence for the effectiveness of antipsychotic medications in reducing behaviours of concern was reported for the atypical antipsychotics, aripiprazole and risperidone. </p> <p>There is some concern regarding the long‐term health outcomes of antipsychotic use, such as significant weight gain (<a href="./references#CD011769-bbs2-0265" title="Alvarez-Jiménez M , González-BlanchC , Crerco-Facorro B , HetrickS , Rodríguez-SánchezJM , Pérez-IglesiasR , et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs2008;22(7):547-62. [DOI: 10.2165/00023210-200822070-00002] [PMID: 18547125]">Alvarez‐Jiménez 2008</a>; <a href="./references#CD011769-bbs2-0275" title="BakM , FransenA , JanssenJ , Van OsJ , DrukkerM . Almost all antipsychotics result in weight gain: a meta-analysis. PloS One2014;9(4):e94112. [DOI: 10.1371/journal.pone.0094112] [PMCID: PMC3998960] [PMID: 24763306]">Bak 2014</a>; <a href="./references#CD011769-bbs2-0367" title="LakeJK , DentonD , LunskyY , ShuiAM , Veenstra-VanderWheeleJ , AnagnostouE . Medical conditions and demographic, service and clinical factors associated with atypical antipsychotic medication use among children with an autism spectrum disorder. Journal of Autism and Developmental Disorders2017;47(5):1391-402. [DOI: 10.1007/s10803-017-3058-8] [PMID: 28210827]">Lake 2017</a>), increased risk of diabetes mellitus (<a href="./references#CD011769-bbs2-0350" title="HoltRI . Association between antipsychotic medication use and diabetes. Current Diabetes Reports2019;19(10):96. [DOI: 10.1007/s11892-019-1220-8] [PMCID: PMC6718373] [PMID: 31478094]">Holt 2019</a>), increased prevalence of cardiovascular disease such as stroke and heart attack (<a href="./references#CD011769-bbs2-0469" title="ZivkovicS , KohCH , KazaN , JacksonCA . Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis. BMC Psychiatry2019;19(1):189-203. [DOI: 10.1186/s12888-019-2177-5] [PMCID: PMC6585081] [PMID: 31221107]">Zivkovic 2019</a>), and increased risk of all‐cause mortality (<a href="./references#CD011769-bbs2-0430" title="SimonG . ACP Journal Club: new use of atypical antipsychotics was linked to acute kidney injury and all-cause mortality at 90 days. Annals of Internal Medicine2015;162(4):JC12. [DOI: 10.7326/ACPJC-2015-162-4-012] [PMID: 25686187]">Simon 2015</a>; <a href="./references#CD011769-bbs2-0440" title="TrifiròG , SpinaE , Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?Pharmacological Research2009;59(1):1-12. [DOI: 10.1016/j.phrs.2008.09.017] [PMID: 18977443]">Trifirò 2009</a>). The National Institute for Health and Care Excellence (NICE) Guidelines recommend that antipsychotic medications should only be considered if behaviours of concern have not been reduced by psychological or other interventions, treatment for any co‐existing psychiatric disorders and the person or others are at severe risk of harm (<a href="./references#CD011769-bbs2-0395" title="National Institute for Health and Care Excellence. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. NICE guideline (NG11); May 2015. Available at www.nice.org.uk/guidance/ng11.">NICE 2015</a>). Other guidelines recommend that antipsychotics are only a short‐term option (up to 8 weeks) if non‐pharmacological interventions did not reduce the behaviours of concern. Effectiveness should be reviewed after three or four weeks on the drugs before continuing (<a href="./references#CD011769-bbs2-0429" title="Scottish Intercollegiate Guidelines Network. SIGN145. Assessment, diagnosis and interventions for autism spectrum disorders: a national clinical guideline; June 2016. Available at www.sign.ac.uk/assets/sign145.pdf.">SIGN 2016</a>), and only one drug should be trialled at any one time to determine its effectiveness (<a href="./references#CD011769-bbs2-0304" title="DebS , KwokH , BertelliM , Salvador-CarullaL , BradleyE , TorrJ , et al. International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry2009;8(3):181-6. [DOI: 10.1002/j.2051-5545.2009.tb00248.x] [PMCID: PMC2758582] [PMID: 19812757]">Deb 2009</a>). </p> </section> <section id="CD011769-sec-0014"> <h4 class="title">ADHD‐related medications</h4> <p>ADHD‐related medications are often prescribed to people with ASD who exhibit behaviours of concern, at least in part due to some similarities between ASD and ADHD such as hyperactivity, inattention and social or communication deficits, or both (<a href="./references#CD011769-bbs2-0297" title="CorteseS , CastelnauP , MorcilloC , RouxS , Bonnet-BrilhaultF . Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders. Expert Review of Neurotherapeutics2012;12(4):461-73. [DOI: 10.1586/ern.12.23] [PMID: 22449217]">Cortese 2012</a>; <a href="./references#CD011769-bbs2-0339" title="HansonE , CerbanBM , SlaterCM , CaccamoLM , BacicJ , ChanE . Brief report: prevalence of attention deficit/ hyperactivity disorder among individuals with an autism spectrum disorder. Journal of Autism and Developmental Disorders2013;43(6):1459-64. [DOI: 10.1007/s10803-012-1677-7] [PMID: 23065101]">Hanson 2013</a>; <a href="./references#CD011769-bbs2-0386" title="MikamiAY , MillerM , LernerMD . Social functioning in youth with attention-deficit/hyperactivity disorder and autism spectrum disorder: transdiagnostic commonalities and differences. Clinical Psychology Review2019;68:54-70. [DOI: 10.1016/j.cpr.2018.12.005] [PMID: 30658861]">Mikami 2019</a>; <a href="./references#CD011769-bbs2-0417" title="RoselloB , BerenguerC , BaixauliI , ColomerC , MirandaA . ADHD symptoms and learning behaviors in children with ASD without intellectual disability. A mediation analysis of executive functions. PloS one2018;13(11):e0207286. [DOI: 10.1371/journal.pone.0207286] [PMCID: PMC6241124] [PMID: 30427902]">Rosello 2018</a>), as well as the high comorbidity rates of ADHD amongst people with ASD (<a href="./references#CD011769-bbs2-0270" title="AntshelKM , Zhang-JamesY , FaraoneSV . The comorbidity of ADHD and autism spectrum disorder. Expert Review of Neurotherapeutics2013;13(10):1117-28. [DOI: 10.1586/14737175.2013.840417] [PMID: 24117274]">Antshel 2013</a>; <a href="./references#CD011769-bbs2-0433" title="SokolovaE , OerlemansAM , RommelseNN , GrootP , HartmanCA , GlennonJC , et al. A causal and mediation analysis of the comorbidity between attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Journal of Autism and Developmental Disorders2017;47(6):1595-604. [DOI: 10.1007/s10803-017-3083-7] [PMCID: PMC5432632] [PMID: 28255761]">Sokolova 2017</a>). In the past, stimulant medications have been prescribed to people with ASD who show behaviours of concern and have hyperactivity (<a href="./references#CD011769-bbs2-0297" title="CorteseS , CastelnauP , MorcilloC , RouxS , Bonnet-BrilhaultF . Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders. Expert Review of Neurotherapeutics2012;12(4):461-73. [DOI: 10.1586/ern.12.23] [PMID: 22449217]">Cortese 2012</a>; <a href="./references#CD011769-bbs2-0339" title="HansonE , CerbanBM , SlaterCM , CaccamoLM , BacicJ , ChanE . Brief report: prevalence of attention deficit/ hyperactivity disorder among individuals with an autism spectrum disorder. Journal of Autism and Developmental Disorders2013;43(6):1459-64. [DOI: 10.1007/s10803-012-1677-7] [PMID: 23065101]">Hanson 2013</a>; <a href="./references#CD011769-bbs2-0386" title="MikamiAY , MillerM , LernerMD . Social functioning in youth with attention-deficit/hyperactivity disorder and autism spectrum disorder: transdiagnostic commonalities and differences. Clinical Psychology Review2019;68:54-70. [DOI: 10.1016/j.cpr.2018.12.005] [PMID: 30658861]">Mikami 2019</a>; <a href="./references#CD011769-bbs2-0417" title="RoselloB , BerenguerC , BaixauliI , ColomerC , MirandaA . ADHD symptoms and learning behaviors in children with ASD without intellectual disability. A mediation analysis of executive functions. PloS one2018;13(11):e0207286. [DOI: 10.1371/journal.pone.0207286] [PMCID: PMC6241124] [PMID: 30427902]">Rosello 2018</a>). Since 2013, when a dual diagnosis of ADHD and ASD was permitted, a high prevalence of co‐occurring ASD and ADHD has been reported (<a href="./references#CD011769-bbs2-0270" title="AntshelKM , Zhang-JamesY , FaraoneSV . The comorbidity of ADHD and autism spectrum disorder. Expert Review of Neurotherapeutics2013;13(10):1117-28. [DOI: 10.1586/14737175.2013.840417] [PMID: 24117274]">Antshel 2013</a>; <a href="./references#CD011769-bbs2-0433" title="SokolovaE , OerlemansAM , RommelseNN , GrootP , HartmanCA , GlennonJC , et al. A causal and mediation analysis of the comorbidity between attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Journal of Autism and Developmental Disorders2017;47(6):1595-604. [DOI: 10.1007/s10803-017-3083-7] [PMCID: PMC5432632] [PMID: 28255761]">Sokolova 2017</a>). Stimulants such as methylphenidate are the most commonly prescribed psychotropic medications for people with ASD aged six years and older, with prescribing rates up to 34% reported in large multinational studies (<a href="./references#CD011769-bbs2-0351" title="HoughtonR , OngRC , BolognaniF . Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States. Autism Research2017;10(12):2037-47. [DOI: 10.1002/aur.1848] [PMID: 28963809]">Houghton 2017</a>; <a href="./references#CD011769-bbs2-0354" title="HsiaY , WongAY , MurphyDG , SimonoffE , BuitelaarJK , WongIC . Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study. Psychopharmacology2014;231(6):999-1009. [DOI: 10.1007/s00213-013-3263-x] [PMID: 24005531]">Hsia 2014</a>; <a href="./references#CD011769-bbs2-0390" title="MurrayML , HsiaY , GlaserK , SimonoffE , MurphyDG , AshersonPJ , et al. Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology2014;231(6):1011-21. [DOI: 10.1007/s00213-013-3140-7] [PMCID: PMC3932167] [PMID: 23681164]">Murray 2014</a>), and 17% in an Australian study (<a href="./references#CD011769-bbs2-0410" title="RasmussenL , PrattN , RougheadE , MoffatA . Prevalence of psychotropic medicine use in Australian children with autism spectrum disorder: a drug utilization study based on children enrolled in the longitudinal study of Australian children. Journal of Autism and Developmental Disorders2019;49(1):227-35. [DOI: 10.1007/s10803-018-3718-3] [PMID: 30136113]">Rasmussen 2019</a>). </p> <p>Stimulants and non‐stimulants have also been reported to reduce symptoms of irritability and aggression in people with ASD (<a href="./references#CD011769-bbs2-0276" title="BanasK , SawchukB . Clonidine as a treatment of behavioural disturbances in autism spectrum disorder: a systematic literature review. Journal of the Canadian Academy of Child and Adolescent Psychiatry2020;29(2):110-20. [PMCID: PMC7213918] [PMID: 32405312]">Banas 2020</a>; <a href="./references#CD011769-bbs2-0338" title="HandenBL , SahlR , HardanAY . Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental and Behavioral Pediatrics2008;29(4):303–8. [DOI: 10.1097/DBP.0b013e3181739b9d] [PMID: 18552703]">Handen 2008</a>; <a href="./references#CD011769-bbs2-0387" title="MingX , GordonE , KangN , WagnerGC . Use of clonidine in children with autism spectrum disorders. Brain &amp; Development2008;30(7):454–60. [DOI: 10.1016/j.braindev.2007.12.007] [PMID: 18280681]">Ming 2008</a>), and are some of the most prescribed psychotropics for people with ASD (<a href="./references#CD011769-bbs2-0374" title="MaddenJM , LakomaMD , LynchFL , RusinakD , Owen-SmithAA , ColemanKJ , et al. Psychotropic medication use among insured children with autism spectrum disorder. Journal of Autism and Developmental Disorders2017;47(1):144-54. [DOI: 10.1007/s10803-016-2946-7] [PMCID: PMC5328123] [PMID: 27817163]">Madden 2017</a>). Stimulants such as methylphenidate, have also been recommended as adjuncts to behavioural interventions for hyperactivity in children or young people with co‐occurring ASD and ADHD (<a href="./references#CD011769-bbs2-0429" title="Scottish Intercollegiate Guidelines Network. SIGN145. Assessment, diagnosis and interventions for autism spectrum disorders: a national clinical guideline; June 2016. Available at www.sign.ac.uk/assets/sign145.pdf.">SIGN 2016</a>). However, a narrative synthesis by <a href="./references#CD011769-bbs2-0328" title="GhanizadehA , MollaM , OlangaGJ . The effect of stimulants on irritability in autism comorbid with ADHD: a systematic review. Neuropsychiatric Disease and Treatment2019;15:1547-55. [DOI: 10.2147/NDT.S194022] [PMCID: PMC6559223] [PMID: 31239689]">Ghanizadeh 2019</a> concluded there was inadequate evidence to support or refute the effect of methylphenidate on irritability, while a Cochrane Review found no evidence that rates of treatment‐emergent irritability were different in children and adolescents with ASD taking methylphenidate (<a href="./references#CD011769-bbs2-0435" title="SturmanN , DeckxL , Van DrielML . Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD011144. [DOI: 10.1002/14651858.CD011144.pub2] [PMCID: PMC6486133] [PMID: 29159857]">Sturman 2017</a>). </p> </section> <section id="CD011769-sec-0015"> <h4 class="title">Anticonvulsants</h4> <p>Anticonvulsants are primarily used to reduce seizures (<a href="./references#CD011769-bbs2-0453" title="WassenaarM , Van HeijlI , LeijtenFS , Van der LindenP , Uijl SG , EgbertsAC , et al. Treatment of epilepsy in daily clinical practice: have outcomes improved over the past 10 years?. Journal of Neurology2013;260(11):2736-43. [DOI: 10.1007/s00415-013-7058-0] [PMID: 23893002]">Wassenaar 2013</a>; <a href="./references#CD011769-bbs2-0461" title="WlodarczykBJ , PalaciosAM , GeorgeTM , FinnellRH . Antiepileptic drugs and pregnancy outcomes. American Journal of Medical Genetics. Part A2012;158A(8):2071-90. [DOI: 10.1002/ajmg.a.35438] [PMCID: PMC3402584] [PMID: 22711424]">Wlodarczyk 2012</a>). Seizures associated with epilepsy are caused by abnormal and asynchronous firing of neurons (nerve cells) which usually end abruptly (<a href="./references#CD011769-bbs2-0308" title="DeLorenzoRJ , SunDA , DeshpandeLS . Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintainance of epilepsy. Pharmacology &amp; Therapeutics2005;105(3):229-66. [DOI: 10.1016/j.pharmthera.2004.10.004] [PMCID: PMC2819430] [PMID: 15737406]">DeLorenzo 2005</a>; <a href="./references#CD011769-bbs2-0326" title="GeigerWJ , NieveraCC , MusilB , GoldsteinJT . Managing seizures: achieving control while minimizing risk. Journal of Family Practice2011;60(8):464-72. [PMID: 21814641]">Geiger 2011</a>; <a href="./references#CD011769-bbs2-0366" title="KusmakerS , KarmakerCK , YanB , O'BrienTJ , MathuganapathyR , PalaniswarmiM . Onset detection of epileptic seizures from acceloerometry signal. In: 40th Annual Internal Conference of the IEEE Engineering in Medicine and Biology Society (EMBC); 2018 Jul 18-12; Honolulu (HI), USA. 2018:1-4. [DOI: 10.1109/EMBC.2018.8513669]">Kusmaker 2018</a>; <a href="./references#CD011769-bbs2-0407" title="ProixT , JirsaVK , BartolomeiF , GuyeM , Truccolo W . Predicting the spatiotemporal diversity of seizure propagation and termination in human focal epilepsy. Nature Communications2018;9(1):1088. [DOI: 10.1038/s41467-018-02973-y] [PMCID: PMC5852068] [PMID: 29540685]">Proix 2018</a>). Most anticonvulsants such as carbamazepine, phenobarbital and valproate block voltage‐gated sodium channels to reduce the firing of neurons (<a href="./references#CD011769-bbs2-0451" title="VerrottiA , CoppolaG , ParisiP , MohnA , ChiarelliF . Bone and calcium metabolism and antiepileptic drugs. Clinical Neurology and Neurosurgery2010;112(1):1-10. [DOI: 10.1016/j.clineuro.2009.10.011] [PMID: 19913352]">Verrotti 2010</a>). Some anticonvulsants such as levetiracetam, topiramate or valproate also have a role in the release or modulation of the inhibitory neurotransmitter GABA (<a href="./references#CD011769-bbs2-0296" title="Cortes-AltamiranoJL , Olmes-Hernández A , Bonilla-JaimeH , BandalaC , González-MacielA , Alfaro-RodríguezA . Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug. Neurology India2016;64(6):1266-75. [DOI: 10.4103/0028-3886.193801] [PMID: 27841198]">Cortes‐Altamirano 2016</a>), decreasing the speed and firing of neurons. Some anticonvulsants are also used as mood stabilisers, for example, divalproex sodium, primarily in bipolar illness. Use of these medications has also been associated with reduction in affective instability, impulsivity and aggression in ASD (<a href="./references#CD011769-bbs2-0348" title="HollanderE , Dolgoff-KasparR , CartwrightC , RawittR , NovotnyS . An open trial of divalproex sodium in autism spectrum disorders. Journal of Clinical Psychiatry2001;62(7):530-4. [DOI: 10.4088/jcp.v62n07a05] [PMID: 11488363]">Hollander 2001</a>). </p> <p>In a systematic review of anticonvulsants for psychiatric disorders in children and adolescents, two trials of valproate and one of levetiracetam found no effect on aggression; however, an additional trial reported a decrease of irritability and aggression in the valproate group (<a href="./references#CD011769-bbs2-0302" title="DavicoC , CanaveseC , VittoriniR , GandioneM , VitielloB . Anticonvulsants for psychiatric disorders in children and adolescents: a systematic review of their efficacy. Frontiers in Psychiatry2018;9:270. [DOI: 10.3389/fpsyt.2018.00270] [PMCID: PMC6024111] [PMID: 29988399]">Davico 2018</a>). There was no difference in aggression in the remaining trial of participants with ASD, which compared to placebo. In another review of GABA modulators in autism by <a href="./references#CD011769-bbs2-0283" title="BrondinoN , Fusar-PoliL , PanisiC , DamianiS , BaraleF , PolitiP . Pharmacological modulation of GABA function in autism spectrum disorders: a systematic review of human studies. Journal of Autism and Developmental Disorders2016;46(3):825-39. [DOI: 10.1007/s10803-015-2619-y] [PMID: 26443675]">Brondino 2016</a>, there was no difference in aggression and irritability in one study that evaluated valproate, while the other found valproate reduced irritability. Similarly, in the systematic review of the pharmacologic treatment of severe irritability and aggression in 2‐ to 17‐year‐olds with ASD by <a href="./references#CD011769-bbs2-0325" title="FungLK , MahajanR , NozzolilloA , BernalP , KrasnerA , JoB , et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics2016;137(Suppl 2):S124-5. [DOI: 10.1542/peds.2015-2851K] [PMID: 26908468]">Fung 2016</a>, one of the two small trials comparing valproate to placebo found it reduced the Aberrant Behaviour Checklist Irritability subscale (ABC‐I; <a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>) scores, with no apparent effect in the other. </p> </section> <section id="CD011769-sec-0016"> <h4 class="title">Antidementia medications</h4> <p>Antidementia medications include cholinesterase inhibitors and N‐methyl‐D‐aspartate (NMDA) receptor antagonists, which are primarily used to treat individuals with Alzheimer’s dementia. Previous studies have shown that the cholinesterase inhibitor donepezil, has been associated with changes in aberrant behaviours of children with ASD (<a href="./references#CD011769-bbs2-0291" title="ChezMG , BuchanonTM , BeckerM , KesslerJ , AimonovitchMC , MrazekSR . Donepezil hydrochloride: a double-blind study in autistic children. Journal of Pediatric Neurology2003;1(2):83-8. [DOI: 10.1055/s-0035-1557175]">Chez 2003</a>). Research also indicates that the NMDA receptor antagonist, memantine, could improve social behaviour, self‐stimulatory behaviours (<a href="./references#CD011769-bbs2-0292" title="ChezMG , HungPC , ChinK , MemonS , KirschnerS . Memantine experience in children and adolescents with autistic spectrum disorders. Annals of Neurology2004;56(Suppl 8):S109. [DOI: 10.1002/ana.20263]">Chez 2004</a>), and irritability (<a href="./references#CD011769-bbs2-0319" title="EricksonCA , PoseyDJ , StiglerKA , MullettJ , KatschkeAR , McDougleCJ . A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology2007;191(1):141-7. [DOI: 10.1007/s00213-006-0518-9] [PMID: 17016714]">Erickson 2007</a>), in people with ASD. </p> </section> <section id="CD011769-sec-0017"> <h4 class="title">Antidepressants</h4> <p>Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants, are used to treat symptoms of depression, anxiety, and obsessionality and are commonly prescribed for people with ASD (<a href="./references#CD011769-bbs2-0298" title="CouryDL , AnagnostouE , Manning-CourtneyP , ReynoldsA , ColeL , McCoyR , et al. Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics2012;130(Suppl 2):S69-76. [DOI: 10.1542/peds.2012-0900D] [PMID: 23118256]">Coury 2012</a>; <a href="./references#CD011769-bbs2-0352" title="HowesOD , RogdakiM , FindonJL , WichesRH , CharmanT , KingBH , et al. Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. Journal of Psychopharmacology2018;32(1):3-29. [DOI: 10.1177/0269881117741766] [PMCID: PMC5805024] [PMID: 29237331]">Howes 2018</a>; <a href="./references#CD011769-bbs2-0390" title="MurrayML , HsiaY , GlaserK , SimonoffE , MurphyDG , AshersonPJ , et al. Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology2014;231(6):1011-21. [DOI: 10.1007/s00213-013-3140-7] [PMCID: PMC3932167] [PMID: 23681164]">Murray 2014</a>); often in the absence of a diagnosed mental disorder (<a href="./references#CD011769-bbs2-0301" title="CvejicRC , ArnoldSR , Foley K-R, Troller Jn. Neuropsychiatric profile and psychotropic medication use in adults with autism spectrum disorder: results from the Australian Longitudinal Study of Adults with Autism. BJPsych Open2018;4(6):461-6. [DOI: 10.1192/bjo.2018.64] [PMCID: PMC6235990] [PMID: 30450225]">Cvejic 2018</a>; <a href="./references#CD011769-bbs2-0427" title="SheehanR , HassiotisA , WaltersK , OsbornD , StrydomA , HorsfallL . Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ2015;351:h4326. [DOI: 10.1136/bmj.h4326] [PMCID: PMC4556752] [PMID: 26330451]">Sheehan 2015</a>; <a href="./references#CD011769-bbs2-0441" title="TsourisJA , Kim S-Y, BrownWT , PettingerJ , CohenIL . Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study. Journal of Autism and Developmental Disorders2013;43(3):719-31. [DOI: 10.1007/s10803-012-1617-6] [PMID: 22829245]">Tsouris 2013</a>). Large‐scale studies involving people with ASD have found that antidepressants are prescribed at similar rates to antipsychotics and stimulants, and often concurrently (up to 40%) with antipsychotics (<a href="./references#CD011769-bbs2-0282" title="BranfordD , GerrardD , SaleemN , ShawC , WebsterA . Stopping over-medication of people with intellectual disability, autism or both (STOMP) in England part 1 – history and background of STOMP. Advances in Mental Health and Intellectual Disabilities2019;13(1):31-40. [DOI: 10.1108/AMHID-02-2018-0004]">Branford 2019</a>; <a href="./references#CD011769-bbs2-0301" title="CvejicRC , ArnoldSR , Foley K-R, Troller Jn. Neuropsychiatric profile and psychotropic medication use in adults with autism spectrum disorder: results from the Australian Longitudinal Study of Adults with Autism. BJPsych Open2018;4(6):461-6. [DOI: 10.1192/bjo.2018.64] [PMCID: PMC6235990] [PMID: 30450225]">Cvejic 2018</a>; <a href="./references#CD011769-bbs2-0320" title="EsbensenAJ , GreenbergJS , SeltzerMM , AmanMG . A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. Journal of Autism and Developmental Disorders2009;39(9):1339-49. [PMCID: PMC2829244] [PMID: 10.1007/s10803-009-0750-3] [PMID: 19434487]">Esbensen 2009</a>). In addition, the use of antidepressants amongst people with ASD in large‐scale studies is approximately eight times higher than in people without ASD (<a href="./references#CD011769-bbs2-0374" title="MaddenJM , LakomaMD , LynchFL , RusinakD , Owen-SmithAA , ColemanKJ , et al. Psychotropic medication use among insured children with autism spectrum disorder. Journal of Autism and Developmental Disorders2017;47(1):144-54. [DOI: 10.1007/s10803-016-2946-7] [PMCID: PMC5328123] [PMID: 27817163]">Madden 2017</a>). However, there is no clear evidence of the effectiveness of antidepressants in reducing behaviours of concern in people with ASD (<a href="./references#CD011769-bbs2-0282" title="BranfordD , GerrardD , SaleemN , ShawC , WebsterA . Stopping over-medication of people with intellectual disability, autism or both (STOMP) in England part 1 – history and background of STOMP. Advances in Mental Health and Intellectual Disabilities2019;13(1):31-40. [DOI: 10.1108/AMHID-02-2018-0004]">Branford 2019</a>; <a href="./references#CD011769-bbs2-0355" title="HurwitzR , BlackmoreR , HazellP , WilliamsK , WoolfendenS . Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD008372. [DOI: 10.1002/14651858.CD008372.pub2] [PMID: 22419332]">Hurwitz 2012</a>; <a href="./references#CD011769-bbs2-0361" title="JohncoC , StorchEA . Anxiety in youth with autism spectrum disorders implications for treatment. Expert Review of Neurotherapeutics2015;15(11):1343-52. [DOI: 10.1586/14737175.2015.1111762] [PMCID: PMC4886863] [PMID: 26548429]">Johnco 2015</a>; <a href="./references#CD011769-bbs2-0460" title="WilliamsK , BrignellA , RandallM , SiloveN , HazellP . Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD004677. [DOI: 10.1002/14651858.CD004677.pub3] [PMID: 23959778]">Williams 2013</a>). </p> <p>Two Cochrane Reviews evaluated the effects of these two major classes of antidepressants on ASD. In one Cochrane Review of SSRIs for ASD (<a href="./references#CD011769-bbs2-0460" title="WilliamsK , BrignellA , RandallM , SiloveN , HazellP . Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD004677. [DOI: 10.1002/14651858.CD004677.pub3] [PMID: 23959778]">Williams 2013</a>), there was limited evidence that citalopram reduced irritability but no evidence that fenfluramine and fluoxetine had an effect. In a Cochrane Review of tricyclic antidepressants for ASD in children and adolescents, there was no evidence that clomipramine and tianeptine improved irritability relative to placebo (<a href="./references#CD011769-bbs2-0355" title="HurwitzR , BlackmoreR , HazellP , WilliamsK , WoolfendenS . Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD008372. [DOI: 10.1002/14651858.CD008372.pub2] [PMID: 22419332]">Hurwitz 2012</a>); however, the three included trials were very small. In an additional systematic review of antidepressant and antianxiety medications for people with ASD (<a href="./references#CD011769-bbs2-0306" title="DebS , RoyM , LeeR , MajidM , LimbuB , SantambrogioJ , et al. Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: systematic review and meta-analysis. BJPsych Open2021;7(6):e179. [DOI: 10.1192/bjo.2021.1003] [PMCID: PMC8503912] [PMID: 34593083]">Deb 2021</a>), there was no evidence that citalopram, clomipramine, venlafaxine or fluoxetine decreased behaviours of concern, but one of two trials of fluvoxamine showed reduced aggression. </p> </section> <section id="CD011769-sec-0018"> <h4 class="title">Antiparkinsonian medications</h4> <p>Antiparkinsonian medications are primarily used to treat individuals who have Parkinson's disease and Alzheimer’s dementia. Some antiparkinsonian medications, such as amantadine, have been studied for the treatment of people with ASD to address symptoms of irritability and aggression. A double‐blind, placebo‐controlled trial of children with ASD aged 5 to 19 years found that symptoms of irritability and aggression were reduced in those receiving amantadine as the active medication (<a href="./references#CD011769-bbs2-0363" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McMahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(6):658–65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a>). Other studies have reported that they may improve language function, social behaviour, and self‐stimulatory behaviours of some people with ASD (<a href="./references#CD011769-bbs2-0292" title="ChezMG , HungPC , ChinK , MemonS , KirschnerS . Memantine experience in children and adolescents with autistic spectrum disorders. Annals of Neurology2004;56(Suppl 8):S109. [DOI: 10.1002/ana.20263]">Chez 2004</a>). A smaller improvement in irritability symptoms has also been reported (<a href="./references#CD011769-bbs2-0319" title="EricksonCA , PoseyDJ , StiglerKA , MullettJ , KatschkeAR , McDougleCJ . A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology2007;191(1):141-7. [DOI: 10.1007/s00213-006-0518-9] [PMID: 17016714]">Erickson 2007</a>). In a systematic review of pharmacologic treatment in 2‐ to 17‐year‐olds with ASD (<a href="./references#CD011769-bbs2-0325" title="FungLK , MahajanR , NozzolilloA , BernalP , KrasnerA , JoB , et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics2016;137(Suppl 2):S124-5. [DOI: 10.1542/peds.2015-2851K] [PMID: 26908468]">Fung 2016</a>), there was no evidence that amantadine decreased ABC‐I scores in the one small identified placebo‐controlled trial. </p> </section> <section id="CD011769-sec-0019"> <h4 class="title">Anxiolytics</h4> <p>As anxiety is associated with behaviours of concern (<a href="./references#CD011769-bbs2-0361" title="JohncoC , StorchEA . Anxiety in youth with autism spectrum disorders implications for treatment. Expert Review of Neurotherapeutics2015;15(11):1343-52. [DOI: 10.1586/14737175.2015.1111762] [PMCID: PMC4886863] [PMID: 26548429]">Johnco 2015</a>; <a href="./references#CD011769-bbs2-0392" title="NadeauJ , SulkowskiML , UngD , WoodJJ , LewinAB , MurphyTK , et al. Treatment of comorbid anxiety and autism spectrum disorders. Neuropsychiatry2011;1(6):567-78. [DOI: 10.2217/npy.11.62] [PMCID: PMC3809000] [PMID: 24174992]">Nadeau 2011</a><i>;</i><a href="./references#CD011769-bbs2-0395" title="National Institute for Health and Care Excellence. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. NICE guideline (NG11); May 2015. Available at www.nice.org.uk/guidance/ng11.">NICE 2015</a>), anxiolytics may be effective in reducing behaviours of concern in people with ASD and anxiety (<a href="./references#CD011769-bbs2-0280" title="BitsikaV , SharpleyCF . Which aspects of challenging behaviour are associated with anxiety across two age groups of young males with an autism spectrum disorder?Journal of Developmental and Physical Disabilities2016;28(5):685-701. [DOI: 10.1007/s10882-016-9502-4]">Bitsika 2016</a>; <a href="./references#CD011769-bbs2-0361" title="JohncoC , StorchEA . Anxiety in youth with autism spectrum disorders implications for treatment. Expert Review of Neurotherapeutics2015;15(11):1343-52. [DOI: 10.1586/14737175.2015.1111762] [PMCID: PMC4886863] [PMID: 26548429]">Johnco 2015</a>). Anxiolytics such as buspirone are commonly used to treat generalised anxiety disorder (<a href="./references#CD011769-bbs2-0421" title="SchmittR , GazalleFK , LimaMS , CunhaA , SouzaJ , KapczinskiF . The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Revista Brasileira de Psiquiatria2005;27(1):18-24. [DOI: 10.1590/S1516-44462005000100007] [PMID: 15867979]">Schmitt 2005</a>). Compared to benzodiazepines, buspirone has a reduced risk of dependency, abuse and sedation, and so is sometimes considered a safer option for long‐term management of anxiety disorders, particularly amongst the young or elderly populations (<a href="./references#CD011769-bbs2-0300" title="CroccoEA , JaramilloS , Cruz-OrtizC , CamfieldK . Pharmacological management of anxiety disorders in the elderly. Current Treatment Options in Psychiatry2017;4(1):33-46. [DOI: 10.1007/s40501-017-0102-4] [PMCID: PMC5609714] [PMID: 28948135]">Crocco 2017</a>; <a href="./references#CD011769-bbs2-0421" title="SchmittR , GazalleFK , LimaMS , CunhaA , SouzaJ , KapczinskiF . The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Revista Brasileira de Psiquiatria2005;27(1):18-24. [DOI: 10.1590/S1516-44462005000100007] [PMID: 15867979]">Schmitt 2005</a>). Buspirone is also considered a treatment for older adults or children with aggression, irritability, or agitation (<a href="./references#CD011769-bbs2-0271" title="AronsonJK . Buspirone. In: AronsonJK , editors(s). Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. 16th edition. Amsterdam: Elsevier, 2016:1096-99. [DOI: 10.1016/B978-0-444-53717-1.00423-6]">Aronson 2016</a>; <a href="./references#CD011769-bbs2-0353" title="HowlandRH . Buspirone: back to the future. Journal of Psychosocial Nursing and Mental Health Services2015;53(11):21-4. [DOI: 10.3928/02793695-20151022-01] [PMID: 26535760]">Howland 2015</a>), and as such, may be effective in reducing behaviours of concern in people with ASD. In the systematic review by <a href="./references#CD011769-bbs2-0306" title="DebS , RoyM , LeeR , MajidM , LimbuB , SantambrogioJ , et al. Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: systematic review and meta-analysis. BJPsych Open2021;7(6):e179. [DOI: 10.1192/bjo.2021.1003] [PMCID: PMC8503912] [PMID: 34593083]">Deb 2021</a>, one of two parallel trials of buspirone showed a decrease in irritability. </p> </section> <section id="CD011769-sec-0020"> <h4 class="title">Neurohormones</h4> <p>Neurohormones are hormones produced by nerve cells and secreted into the circulation with varying mechanisms of action and sites of origin. Two neurohormones have been investigated in ASD, namely oxytocin and secretin. Secretin has been suggested as potentially beneficial in the management of ASD and related behaviours of concern (<a href="./references#CD011769-bbs2-0383" title="McQueenJM , HeckAM . Secretin for the treatment of autism. Annals of Pharmacotherapy2002;36(2):305-11. [DOI: 10.1345/aph.19113] [PMID: 11847953]">McQueen 2002</a>; <a href="./references#CD011769-bbs2-0436" title="TanakaA , FurubayashiT , AraiM , InoueD , KimuraS , KiriyamaA , et al. Delivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application. Molecular Pharmaceutics2018;15(3):1105-11. [DOI: 10.1021/acs.molpharmaceut.7b00991] [PMID: 29338251]">Tanaka 2018</a>). However, in an earlier Cochrane Review of intravenous secretin compared to placebo treatment in children or adults diagnosed with ASD, there was no effect of secretin in any of the three studies that reported irritability (<a href="./references#CD011769-bbs2-0459" title="WilliamsK , WrayJA , WheelerDM . Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2012, Issue 4. Art. No: CD003495. [DOI: 10.1002/14651858.CD003495.pub3] [PMCID: PMC7154585] [PMID: 22513913]">Williams 2012</a>). </p> </section> <section id="CD011769-sec-0021"> <h4 class="title">Experimental</h4> <p>Effects have previously been reported for a range of medications that do not fall into any of the previously mentioned categories. A systematic review of trials of GABA modulators in autism evaluated acamprosate, arbaclofen, bumetanide, carnosine, flumazenil, riluzole and valproate (<a href="./references#CD011769-bbs2-0283" title="BrondinoN , Fusar-PoliL , PanisiC , DamianiS , BaraleF , PolitiP . Pharmacological modulation of GABA function in autism spectrum disorders: a systematic review of human studies. Journal of Autism and Developmental Disorders2016;46(3):825-39. [DOI: 10.1007/s10803-015-2619-y] [PMID: 26443675]">Brondino 2016</a>). However, there was insufficient evidence to suggest that any of these medications were effective in people with autism (<a href="./references#CD011769-bbs2-0283" title="BrondinoN , Fusar-PoliL , PanisiC , DamianiS , BaraleF , PolitiP . Pharmacological modulation of GABA function in autism spectrum disorders: a systematic review of human studies. Journal of Autism and Developmental Disorders2016;46(3):825-39. [DOI: 10.1007/s10803-015-2619-y] [PMID: 26443675]">Brondino 2016</a>). In a review of the drug riluzole, which also appears to regulate glutamate activity (<a href="./references#CD011769-bbs2-0303" title="De BoerJN , VingerhoetsC , HirdesM , McAlonanGM , AmelsvoortTV , ZinkstokJR . Efficacy and tolerability of riluzole in psychiatric disorders: a systematic review and preliminary meta-analysis. Psychiatry Research2019;278:294-302. [DOI: 10.1016/j.psychres.2019.06.020] [PMID: 31254879]">De Boer 2019</a>), two of three studies in children and young adults reported that single and adjunct use of riluzole decreased irritability, although there was no effect in the remaining trial. In a meta‐analysis of n‐acetylcysteine in ASD (<a href="./references#CD011769-bbs2-0368" title="Lee T-M, Lee K-M, Lee C-Y, Lee H-C, Tam K-W, Loh E-W. Effectiveness of N-acetylcysteine in autism spectrum disorders: a meta-analysis of randomized controlled trials. Australian and New Zealand Journal of Psychiatry2021;55(2):196-206. [DOI: 10.1177/0004867420952540] [PMID: 32900213]">Lee 2021</a>), irritability scores were not different across all four identified studies, though a subgroup study indicated effects in one trial. </p> </section> </section> <section id="CD011769-sec-0022"> <h3 class="title" id="CD011769-sec-0022">How the intervention might work</h3> <p>While each of these medications works differently, broadly speaking, medications may act by reducing co‐occurring conditions, like ADHD, anxiety or depression, or will act directly to reduce behaviours of concern. However, there is limited evidence for the effectiveness of these medications at this stage. </p> <section id="CD011769-sec-0023"> <h4 class="title">Antipsychotics</h4> <p>ASD has been associated with abnormalities in both the dopaminergic system and serotoninergic systems (<a href="./references#CD011769-bbs2-0393" title="NakamuraK , SekineY , OuchiY , TsujiiM , YoshikawaE , FutatsubashiM , et al. Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Archives of General Psychiatry2010;67(1):59-68. [DOI: 10.1001/archgenpsychiatry.2009.137] [PMID: 20048223]">Nakamura 2010</a>). Dopamine over‐activation has also been linked with excessive motor activity and stereotyped behaviours, which are often observed in individuals with ASD (<a href="./references#CD011769-bbs2-0406" title="PrevicFH . Prenatal influences on brain dopamine and their relevance to the rising incidence of autism. Medical Hypotheses2007;68(1):46-60. [DOI: 10.1016/j.mehy.2006.06.041] [PMID: 16959433]">Previc 2007</a>). Altered serotonin levels have been found to lead to changes in several psychological processes, which are also altered in individuals with ASD, including mood, irritability, and aggression (<a href="./references#CD011769-bbs2-0465" title="YoungSN , LeytonM . The role of serotonin in human mood and social interaction: insight from altered tryptophan levels. Pharmacology, Biochemistry and Behavior2002;71(4):857-65. [DOI: 10.1016/s0091-3057(01)00670-0] [PMID: 11888576]">Young 2002</a>). Typical or first‐generation antipsychotics exert their action by blocking dopamine receptors. However, atypical (second‐generation) antipsychotics also have a range of actions at other neurotransmitter systems, including systems that modulate serotonin and norepinephrine receptors. </p> </section> <section id="CD011769-sec-0024"> <h4 class="title">Antidepressants</h4> <p>The two major classes of antidepressants prescribed for ASD (SSRIs and tricyclic antidepressants) have differing pharmacological actions. SSRIs exert their effects through increasing the availability of serotonin (<a href="./references#CD011769-bbs2-0460" title="WilliamsK , BrignellA , RandallM , SiloveN , HazellP . Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD004677. [DOI: 10.1002/14651858.CD004677.pub3] [PMID: 23959778]">Williams 2013</a>), whereas tricyclic antidepressants increase the availability of the neurotransmitters serotonin and noradrenaline (<a href="./references#CD011769-bbs2-0355" title="HurwitzR , BlackmoreR , HazellP , WilliamsK , WoolfendenS . Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD008372. [DOI: 10.1002/14651858.CD008372.pub2] [PMID: 22419332]">Hurwitz 2012</a>; <a href="./references#CD011769-bbs2-0428" title="ShojaieF . Quantum computations of interactions of most reactive tricyclic antidepressant drug with carbon nanotube, serotonin, and norepinephrin. Chemical Methodologies2020;4(4):447-66. [DOI: 10.33945/SAMI/CHEMM.2020.4.7]">Shojaie 2020</a>). Altered serotonin levels have been found to lead to changes in several psychological processes, which are also altered in individuals with ASD, including mood, irritability, and aggression (<a href="./references#CD011769-bbs2-0465" title="YoungSN , LeytonM . The role of serotonin in human mood and social interaction: insight from altered tryptophan levels. Pharmacology, Biochemistry and Behavior2002;71(4):857-65. [DOI: 10.1016/s0091-3057(01)00670-0] [PMID: 11888576]">Young 2002</a>; <a href="./references#CD011769-bbs2-0460" title="WilliamsK , BrignellA , RandallM , SiloveN , HazellP . Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD004677. [DOI: 10.1002/14651858.CD004677.pub3] [PMID: 23959778]">Williams 2013</a>). Antidepressants may be effective in treating some common comorbidities of ASD such as anxiety, depression, and obsessive compulsive disorder, which can in turn reduce behaviours of concern (<a href="./references#CD011769-bbs2-0460" title="WilliamsK , BrignellA , RandallM , SiloveN , HazellP . Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD004677. [DOI: 10.1002/14651858.CD004677.pub3] [PMID: 23959778]">Williams 2013</a>; <a href="./references#CD011769-bbs2-0467" title="ZaboskiBA , StorchEA . Comorbid autism spectrum disorder and anxiety disorders: a brief review. Future Neurology2018;13(1):31-7. [DOI: 10.2217/fnl-2017-0030] [PMCID: PMC5772195] [PMID: 29379397]">Zaboski 2018</a>). </p> </section> <section id="CD011769-sec-0025"> <h4 class="title">Anticonvulsants</h4> <p>The mechanism by which antiepileptic medications, such as carbamazepine and levetiracetam, could affect irritability and aggression remains unclear. What is known is that gabapentin reduces the excitability of nerve cells in the brain (<a href="./references#CD011769-bbs2-0336" title="GuglielmoR , IoimeL , GrandinettiP , JaniriL . Managing disruptive and compulsive behaviors in adult with autistic disorder with gabapentin. Journal of Clinical Psychopharmacology2013;33(2):273-4. [DOI: 10.1097/JCP.0b013e318285680c] [PMID: 23422383]">Guglielmo 2013</a>). </p> <p>Anticonvulsants such as divalproex sodium are also used as mood stabilisers. It has been suggested that mood stabilisers, such as divalproex sodium, work by enhancing GABA, inhibiting glutamate, acting on serotonin and norepinephrine systems, and via limbic kindling (<a href="./references#CD011769-bbs2-0348" title="HollanderE , Dolgoff-KasparR , CartwrightC , RawittR , NovotnyS . An open trial of divalproex sodium in autism spectrum disorders. Journal of Clinical Psychiatry2001;62(7):530-4. [DOI: 10.4088/jcp.v62n07a05] [PMID: 11488363]">Hollander 2001</a>). </p> </section> <section id="CD011769-sec-0026"> <h4 class="title">ADHD‐related medications</h4> <p>These include stimulants such as methylphenidate and dexamphetamine that increase dopamine and noradrenaline activity; and non‐stimulants such as atomoxetine, clonidine and guanfacine, which primarily increase noradrenaline activity (<a href="./references#CD011769-bbs2-0399" title="OslandST , SteevesTD , PringsheimT . Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD007990. [DOI: 10.1002/14651858.CD007990.pub3] [PMCID: PMC6513283] [PMID: 29944175]">Osland 2018</a>). </p> <p>Stimulant (<a href="./references#CD011769-bbs2-0328" title="GhanizadehA , MollaM , OlangaGJ . The effect of stimulants on irritability in autism comorbid with ADHD: a systematic review. Neuropsychiatric Disease and Treatment2019;15:1547-55. [DOI: 10.2147/NDT.S194022] [PMCID: PMC6559223] [PMID: 31239689]">Ghanizadeh 2019</a>; <a href="./references#CD011769-bbs2-0435" title="SturmanN , DeckxL , Van DrielML . Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD011144. [DOI: 10.1002/14651858.CD011144.pub2] [PMCID: PMC6486133] [PMID: 29159857]">Sturman 2017</a>), and nonstimulant (<a href="./references#CD011769-bbs2-0276" title="BanasK , SawchukB . Clonidine as a treatment of behavioural disturbances in autism spectrum disorder: a systematic literature review. Journal of the Canadian Academy of Child and Adolescent Psychiatry2020;29(2):110-20. [PMCID: PMC7213918] [PMID: 32405312]">Banas 2020</a>; <a href="./references#CD011769-bbs2-0327" title="GhanizadehA . Atomoxetine for treating ADHD symptoms in autism: a systematic review. Journal of Attention Disorders2013;17(8):635-40. [DOI: 10.1177/1087054712443154] [PMID: 22544388]">Ghanizadeh 2013</a>; <a href="./references#CD011769-bbs2-0401" title="PatraS , NebhinaniN , ViswanathanA , KirubakaranR . Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: a systematic review and meta-analysis. Autism Research2019;12(4):542-52. [DOI: 10.1002/aur.2059] [PMID: 30653855]">Patra 2019</a>), ADHD‐related medications have been administered to children with ASD with the aim of improving symptoms. It is thought that any effects on behaviours of concern with ADHD‐related medications are likely to be secondary to improvements in attention, concentration and hyperactivity (<a href="./references#CD011769-bbs2-0276" title="BanasK , SawchukB . Clonidine as a treatment of behavioural disturbances in autism spectrum disorder: a systematic literature review. Journal of the Canadian Academy of Child and Adolescent Psychiatry2020;29(2):110-20. [PMCID: PMC7213918] [PMID: 32405312]">Banas 2020</a>). </p> <p>ADHD is often associated with dopaminergic system dysfunction (<a href="./references#CD011769-bbs2-0324" title="FroehlichTE , DelgadoSV , AnixtJS . Psychostimulant and non-stimulant agents address the symptoms of ADHD substantial evidence shows. Current Psychiatry2013;12(12):21-9. [ISSN: 1537-8276] [URL: www.mdedge.com/psychiatry/article/78793/neurology/expanding-medication-options-pediatric-adhd]">Froehlich 2013</a>; <a href="./references#CD011769-bbs2-0356" title="HussM , ChenW , LudolphAG . Guanfacine extended release: a new pharmacological treatment option in Europe. Clinical Drug Investigation2016;36(1):1-25. [DOI: 10.1007/s40261-015-0336-0] [PMCID: PMC4706844] [PMID: 26585576]">Huss 2016</a>; <a href="./references#CD011769-bbs2-0462" title="WuJ , XiaoH , SunH , ZouL , Zhu L-Q. Role of dopamine receptors in ADHD: a systematic meta-analysis. Molecular Neurobiology2012;45(3):605-20. [DOI: 10.1007/s12035-012-8278-5] [PMID: 22610946]">Wu 2012</a>). Dopamine plays an important role in planning, motor and motivational processes, which are abnormal in people with ADHD (<a href="./references#CD011769-bbs2-0378" title="MarinhoV , OliveiraT , RochaK , RobeiroJ , MagalhãesF , BentoT , et al. The dopaminergic system dynamic in the time perception: a review of the evidence. International Journal of Neuroscience2018;128(3):262-82. [DOI: 10.1080/00207454.2017.1385614] [PMID: 28950734]">Marinho 2018</a>; <a href="./references#CD011769-bbs2-0462" title="WuJ , XiaoH , SunH , ZouL , Zhu L-Q. Role of dopamine receptors in ADHD: a systematic meta-analysis. Molecular Neurobiology2012;45(3):605-20. [DOI: 10.1007/s12035-012-8278-5] [PMID: 22610946]">Wu 2012</a>). Stimulants such as amphetamine and methylphenidate are thought to improve symptoms of ADHD by increasing dopamine activity (<a href="./references#CD011769-bbs2-0462" title="WuJ , XiaoH , SunH , ZouL , Zhu L-Q. Role of dopamine receptors in ADHD: a systematic meta-analysis. Molecular Neurobiology2012;45(3):605-20. [DOI: 10.1007/s12035-012-8278-5] [PMID: 22610946]">Wu 2012</a>). </p> <p>The neurotransmitter, noradrenaline, may also decrease symptoms of ADHD as it has an important role in the prefrontal cortex, an area associated with attention and executive functioning (<a href="./references#CD011769-bbs2-0401" title="PatraS , NebhinaniN , ViswanathanA , KirubakaranR . Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: a systematic review and meta-analysis. Autism Research2019;12(4):542-52. [DOI: 10.1002/aur.2059] [PMID: 30653855]">Patra 2019</a>). Non‐stimulants such as atomoxetine, clonidine and guanfacine, which primarily increase noradrenaline activity, are sometimes prescribed as an alternative to stimulant ADHD‐related medications. </p> <p>Atomoxetine is a dopamine and noradrenaline reuptake inhibitor (<a href="./references#CD011769-bbs2-0324" title="FroehlichTE , DelgadoSV , AnixtJS . Psychostimulant and non-stimulant agents address the symptoms of ADHD substantial evidence shows. Current Psychiatry2013;12(12):21-9. [ISSN: 1537-8276] [URL: www.mdedge.com/psychiatry/article/78793/neurology/expanding-medication-options-pediatric-adhd]">Froehlich 2013</a>; <a href="./references#CD011769-bbs2-0358" title="JanakP , Scott BowersM , CorbitL . Compound stimulus presentation and the norepinephrine reuptake inhibitor atomoxetine enhance long-term extinction of cocaine-seeking behavior. Neuropsychopharmacology2012;37(4):975-85. [DOI: 10.1038/npp.2011.281] [PMID: 22089320]">Janak 2012</a>). The increase in norepinephrine and dopamine in the pre‐frontal cortex by atomoxetine is thought to improve ADHD symptoms such as impaired attention and reduced executive function (<a href="./references#CD011769-bbs2-0401" title="PatraS , NebhinaniN , ViswanathanA , KirubakaranR . Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: a systematic review and meta-analysis. Autism Research2019;12(4):542-52. [DOI: 10.1002/aur.2059] [PMID: 30653855]">Patra 2019</a>; <a href="./references#CD011769-bbs2-0445" title="UlkeC , RullmannM , HuangJ , LudhardtJ , Becker G-A, PattM , et al. Adult attention-deficit/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[11C]methylreboxetine positron emission tomography study. Translational Psychiatry2019;9(1):301. [DOI: 10.1038/s41398-019-0619-y] [PMCID: PMC6858438] [PMID: 31732713]">Ulke 2019</a>). Clonidine and guanfacine are alpha‐2 adrenergic receptor agonists (<a href="./references#CD011769-bbs2-0330" title="Giovannitti JA Jr, ThomsSM , CrawfordJJ . Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesthesia Progress2015;62(1):31-9. [DOI: 10.2344/0003-3006-62.1.31] [PMCID: PMC4389556] [PMID: 25849473]">Giovannitti 2015</a>; <a href="./references#CD011769-bbs2-0356" title="HussM , ChenW , LudolphAG . Guanfacine extended release: a new pharmacological treatment option in Europe. Clinical Drug Investigation2016;36(1):1-25. [DOI: 10.1007/s40261-015-0336-0] [PMCID: PMC4706844] [PMID: 26585576]">Huss 2016</a>), and are thought to improve ADHD symptoms by increasing noradrenergic activity in the prefrontal cortex (<a href="./references#CD011769-bbs2-0286" title="CayeA , SwansonJM , CoghillD , Rohde LA. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Molecular Psychiatry2019;24(3):390–408. [DOI: 10.1038/s41380-018-0116-3] [PMID: 29955166]">Caye 2019</a>; <a href="./references#CD011769-bbs2-0385" title="MechlerK , BanaschewskiT , HohmannS , HägeA . Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacology &amp; therapeutics2022 ;230:107940. [DOI: 10.1016/j.pharmthera.2021.107940] [PMID: 34174276]">Mechler 2022</a>). </p> </section> <section id="CD011769-sec-0027"> <h4 class="title">Antidementia medications</h4> <p>As described above, impairments in the dopaminergic system have been associated with behavioural characteristics of several neurodevelopmental disorders, including ASD (<a href="./references#CD011769-bbs2-0309" title="DiCarloGE , AguilarJI , MatthiesHJ , HarrisonFE , BundschuhKE , WestA , et al. Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine dependent behaviors. Journal of Clinical Investigation2019;129(8):3407-19. [DOI: 10.1172/JCI127411] [PMCID: PMC6668686] [PMID: 31094705]">DiCarlo 2019</a>). Amantadine is an NMDA receptor antagonist with an indirect dopaminergic agonist role (<a href="./references#CD011769-bbs2-0363" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McMahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(6):658–65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a>; <a href="./references#CD011769-bbs2-0391" title="MüllerT . Drug therapy in patients with Parkinson’s disease. Translational Neurodegeneration2012;1(1):10. [DOI: 10.1186/2047-9158-1-10] [PMCID: PMC3514092] [PMID: 23211041]">Müller 2012</a>). </p> <p>The NMDA receptors play an important role in the cellular processes of the brain underlying learning and memory function (<a href="./references#CD011769-bbs2-0290" title="Chang C-H, Liu C-Y, Chen S-J, Tsai H-C. Effect of N‑Methyl‑D‑Aspartate receptor enhancing agents on cognition in dementia: an exploratory systematic review and meta‑analysis of randomized controlled trials. Scientific Reports2021;11(1):22996-22996. [DOI: 10.1038/s41598-021-02040-5] [PMID: 34836972]">Chang 2021</a>; <a href="./references#CD011769-bbs2-0396" title="OlivaresD , DeshpandeVK , ShiK , LahiriDK , GreigNH , RogersJT . N-Methyl D-Aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia, and Parkinson's disease. Current Alzheimer Research2012;9(6):746-58. [DOI: 10.2174/156720512801322564] [PMID: 21875407]">Olivares 2012</a>). NMDA also plays a role in regulating inflammation in the brain (<a href="./references#CD011769-bbs2-0290" title="Chang C-H, Liu C-Y, Chen S-J, Tsai H-C. Effect of N‑Methyl‑D‑Aspartate receptor enhancing agents on cognition in dementia: an exploratory systematic review and meta‑analysis of randomized controlled trials. Scientific Reports2021;11(1):22996-22996. [DOI: 10.1038/s41598-021-02040-5] [PMID: 34836972]">Chang 2021</a>), and it is thought that neuro inflammation is involved in neurological and neuropsychiatric disorders (<a href="./references#CD011769-bbs2-0412" title="RicciS , BusinaroR , IppolitiF , Lo VascoVR , MassoniF , OnofriE , et al. Altered cytokine and BDNF levels in autism spectrum disorder. Neurotoxicity Research2013;24(4):491-501. [DOI: 10.1007/s12640-013-9393-4] [PMID: 23604965]">Ricci 2013</a>). The precise mechanisms by which NMDA receptor antagonists work is not well known, however, it has been found that people with ASD often have abnormally high glutamate and activity levels of NMDA receptors (<a href="./references#CD011769-bbs2-0416" title="RojasDC . The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment. Journal of Neural Transmission2014;121(8):891-905. [DOI: 10.1007/s00702-014-1216-0] [PMID: 24752754]">Rojas 2014</a>). Therefore, it is thought that NMDA receptor antagonists such as memantine may play a role in reducing the core symptoms of ASD. </p> </section> <section id="CD011769-sec-0028"> <h4 class="title">Antiparkinsonian medications</h4> <p>Cholinergic neurotransmission, including nicotinic acetylcholine receptors, are involved in several functions including attention, memory, learning, social interactions, movement, and anxiety (<a href="./references#CD011769-bbs2-0400" title="Park J-E, Leem Y-H, Park J-S, Kim D-Y, Kang J-L, Kim H-S. Anti-inflammatory and neuroprotective mechanisms of GTS-21, an α7 nicotinic acetylcholine receptor agonist, in neuroinflammation and Parkinson’s disease mouse models. International Journal of Molecular Sciences2022;23(8):4420. [DOI: 10.3390/ijms23084420]">Park 2022</a>; <a href="./references#CD011769-bbs2-0446" title="VallésAS , BarrantesFJ . Dysregulation of neuronal nicotinic acetylcholine receptor - cholesterol crosstalk in autism spectrum disorder. Frontiers in Molecular Neuroscience2021;14:744597. [DOI: 10.3389/fnmol.2021.744597] [PMID: 34803605]">Vallés 2021</a>). The cholinergic system is thought to play a central role in Alzheimer's disease, particularly the associated cognitive decline (<a href="./references#CD011769-bbs2-0418" title="SabriO , KendziorraK , WolfH , Gertz H-J, BrustP . Acetylcholine receptors in dementia and mild cognitive impairment. European Journal of Nuclear Medicine and Molecular Imaging2008;35(Suppl 1):30-45. [DOI: 10.1007/s00259-007-0701-1] [PMID: 18228017]">Sabri 2008</a>), and nicotinic acetylcholine receptors are thought to have anti‐inflammatory and neuroprotective properties (<a href="./references#CD011769-bbs2-0400" title="Park J-E, Leem Y-H, Park J-S, Kim D-Y, Kang J-L, Kim H-S. Anti-inflammatory and neuroprotective mechanisms of GTS-21, an α7 nicotinic acetylcholine receptor agonist, in neuroinflammation and Parkinson’s disease mouse models. International Journal of Molecular Sciences2022;23(8):4420. [DOI: 10.3390/ijms23084420]">Park 2022</a>). </p> <p>According to recent studies, acetylcholine and nicotinic receptor activity may be lower in brain samples of people with ASD. It has been suggested, therefore, that acetylcholinergic enhancement through the use of donepezil hydrochloride — an acetylcholinesterase inhibitor — may improve some behaviours associated with ASD (<a href="./references#CD011769-bbs2-0291" title="ChezMG , BuchanonTM , BeckerM , KesslerJ , AimonovitchMC , MrazekSR . Donepezil hydrochloride: a double-blind study in autistic children. Journal of Pediatric Neurology2003;1(2):83-8. [DOI: 10.1055/s-0035-1557175]">Chez 2003</a>). </p> </section> <section id="CD011769-sec-0029"> <h4 class="title">Anxiolytics</h4> <p>People with ASD commonly have elevated levels of blood serotonin (<a href="./references#CD011769-bbs2-0269" title="AndersonGM , FreedmanDX , CohenDJ , VolkmarFR , HoderEL , McPhedranP . Whole blood serotonin in autistic and normal subjects. Journal of Child Psychology and Psychiatry and allied disciplines1987;28(6):885-900.">Anderson 1987</a>), however, people with ASD also have an increased risk of alterations to serotonin receptors and synthesis (<a href="./references#CD011769-bbs2-0450" title="Veenstra-VanderWeeleJ , BlakelyRD . Networking in autism: leveraging genetic, biomarker, and model system findings in the search for new treatments. Neuropsychopharmacology2012;37(1):196-212. [DOI: 10.1038/npp.2011.185] [PMID: 21937981]">Veenstra‐VanderWeele 2012</a>). Anxiolytics such as buspirone have a strong attraction to serotonin, both presynaptically and postsynaptically (<a href="./references#CD011769-bbs2-0287" title="CeranogluTA , WozniakJ , FriedR , GaldoM , HoskovaB , DeLeon FongM , et al. A retrospective chart review of buspirone for the treatment of anxiety in psychiatrically referred youth with high-functioning autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology2019;29(1):28-33. [DOI: 10.1089/cap.2018.0021] [PMCID: PMC6354602] [PMID: 30452283]">Ceranoglu 2019</a>; <a href="./references#CD011769-bbs2-0404" title="PoisbeauP , GazzoG , CalvelL . Anxiolytics targeting GABAA receptors: insights on etifoxine. World Journal of Biological Psychiatry2018;19(Suppl 1):S36-S45. [DOI: 10.1080/15622975.2018.1468030] [PMID: 30204559]">Poisbeau 2018</a>), thereby increasing the availability of serotonin. Serotonin plays a role in regulating mood and sleep, and medications that increase serotonin are often prescribed for anxiety due to the anxiolytic effect of serotonin (<a href="./references#CD011769-bbs2-0470" title="ŻmudzkaE , SałaciakK , SapaJ , PytkaK . Serotonin receptors in depression and anxiety: insights from animal studies. Life Sciences2018;210:106-24. [DOI: 10.1016/j.lfs.2018.08.050] [PMID: 30144453]">Żmudzka 2018</a>). </p> </section> <section id="CD011769-sec-0030"> <h4 class="title">Neurohormones</h4> <p>Oxytocin is produced in the hypothalamus (<a href="./references#CD011769-bbs2-0458" title="WilczyńskiKM , ZasadaI , SiwiecA , Janas-KozikM . Differences on oxytocin and vasopressin levels in individuals suffering from the autism spectrum disorders vs general population – a systematic review. Neuropsychiatric Disease and Treatment2019;15:2613-20. [DOI: 10.2147/NDT.S207580] [PMCID: PMC6750159] [PMID: 31571878]">Wilczyński 2019</a>), with the primary role of promoting lactation, facilitating contractions, and promoting bonding between mother and infant (<a href="./references#CD011769-bbs2-0268" title="AndariE , Duhamel J-R, ZallaT , HerbrechtE , LeboyerM , SiriguA . Promoting social behaviour with oxytocin in high-functioning autism spectrum disorders. Proceedings of the National Academy of Sciences of the United States of America2010;107(9):4389-94. [DOI: 10.1073/pnas.0910249107] [PMCID: PMC2840168] [PMID: 20160081]">Andari 2010</a>; <a href="./references#CD011769-bbs2-0334" title="GreenJJ , HollanderE . Autism and oxytocin: new developments in translational approaches to therapeutics. Neurotherapeutics2010;7(3):250-7. [DOI: 10.1016/j.nurt.2010.05.006] [PMCID: PMC5084228] [PMID: 20643377]">Green 2010</a>;<a href="./references#CD011769-bbs2-0438" title="TaylorJH , SchulteNA , FrenchJA , ToewsML . Binding characteristics of two oxytocin variants and vasopressin at oxytocin receptors from four primate species with different social behaviour patterns. Journal of Pharmacology and Experimental Therapeutics2018;367(1):101-7. [DOI: 10.1124/jpet.118.250852] [PMCID: PMC7250472] [PMID: 30068728]">Taylor 2018</a>). Oxytocin has been found to be reduced in children with ASD (<a href="./references#CD011769-bbs2-0360" title="JohnS , JaeggiAV . Oxytocin levels tend to be lower in autistic children: a meta-analysis of 31 studies. Autism2021;25(8):2152-61. [DOI: 10.1177/13623613211034375] [PMID: 34308675]">John 2021</a>; <a href="./references#CD011769-bbs2-0388" title="MoerkerkeM , PeetersM , De VriesL , DanielsN , SteyaertJ , AlaertsK , et al. Endogenous oxytocin levels in autism—a meta-analysis. Brain Sciences2021;11(11):1545. [DOI: 10.3390/brainsci11111545] [PMCID: PMC8615844] [PMID: 34827545]">Moerkerke 2021</a>), and oxytocin is thought to have a role in ASD behaviours (<a href="./references#CD011769-bbs2-0332" title="GottschalkMG , DomschkeK . Oxytocin and anxiety disorders. In: HurelmannR , GrinevichV , editors(s). Behavioral Pharmacology of Neuropeptides: Oxytocin. Cham: Springer International Publishing, 2017:467-98. [DOI: 10.1007/7854_2017_25]">Gottschalk 2017</a>; <a href="./references#CD011769-bbs2-0398" title="OoiYP , Weng S-J, KossowskyJ , GergerH , SungM . Oxytocin and autism spectrum disorders: a systematic review and meta-analysis of randomized controlled trials. Pharmacopsychiatry2017;50(1):5-13. [DOI: 10.1055/s-0042-109400] [PMID: 27574858]">Ooi 2017</a>; <a href="./references#CD011769-bbs2-0463" title="YamasueH , DomesG . Oxytocin and autism spectrum disorders. In: HurlemannR , GrinevichV , editors(s). Behavioral Pharmacology of Neuropeptides: Oxytocin. Cham: Springer International Publishing, 2017:449-65. [DOI: 10.1007/7854_2017_24]">Yamasue 2017</a>; <a href="./references#CD011769-bbs2-0464" title="YoonS , KimYK . The role of the oxytocin system in anxiety disorders. In: KimYK , editors(s). Anxiety Disorders: Rethinking and Understanding Recent Discoveries. Advances in Experimental Medicine and Biology. Vol. 1191. Singapore: Springer, 2020:103-20. [DOI: 10.1007/978-981-32-9705-07]">Yoon 2020</a>). It has been suggested that increasing oxytocin will reduce ASD behaviours and this could lead to a reduction of behaviours of concern. </p> <p>Secretin is produced in the gastrointestinal tract and has both digestive and neurological functions (<a href="./references#CD011769-bbs2-0277" title="BankoJL , TrotterJ, WeeberEJ . Insights into synaptic function from mouse models of human cognitive disorders. Future Neurology2011;6(1):113-25. [DOI: 10.2217/fnl.10.80] [PMCID: PMC4114080] [PMID: 25083141]">Banko 2011</a>; <a href="./references#CD011769-bbs2-0455" title="WelchMG , KeuneJD , Welch-HoranTB , AnwarN , AnwarM , LudwigRJ , et al. Secretin: hypothalamic distribution and hypothesized neuroregulatory role in autism. Cellular and Molecular Neurobiology2004;24(2):219-41. [DOI: 10.1023/B:CEMN.0000018618.59015.a2] [PMID: 15176437]">Welch 2004</a>). Because secretin receptors are also located in areas of the brain associated with emotion and behaviour, such as in the amygdala, which regulates emotions and mood, and in the hippocampus, which is associated with memory formation (<a href="./references#CD011769-bbs2-0277" title="BankoJL , TrotterJ, WeeberEJ . Insights into synaptic function from mouse models of human cognitive disorders. Future Neurology2011;6(1):113-25. [DOI: 10.2217/fnl.10.80] [PMCID: PMC4114080] [PMID: 25083141]">Banko 2011</a>; <a href="./references#CD011769-bbs2-0408" title="Qi X-R, ZhangL . The potential role of gut peptide hormones in autism spectrum disorder. Frontiers in Cellular Neuroscience2020;14:73. [DOI: 10.3389/fncel.2020.00073] [PMCID: PMC7136424] [PMID: 32296309]">Qi 2020</a>), impairments or irregularities in brain neurohormones may be associated with ASD (<a href="./references#CD011769-bbs2-0288" title="ChaddadA , DesrosiersC , HassanL , TanougastC . Hippocampus and amygdala radiomic biomarkers for the study of autism spectrum disorder. BMC Neuroscience2017;18(1):52. [DOI: 10.1186/s12868-017-0373-0] [PMCID: PMC6389224] [PMID: 28821235]">Chaddad 2017</a>; <a href="./references#CD011769-bbs2-0329" title="GibbardCR , RenJ , SkuseDH , ClaydenJD , ClarkCA . Structural connectivity of the amygdala in young adults with autism spectrum disorder. Human Brain Mapping2018;39(3):1270-82. [DOI: 10.1002/hbm.23915] [PMCID: PMC5838552] [PMID: 29265723]">Gibbard 2018</a>). Secretin has therefore been suggested as a potential intervention in the management of ASD (<a href="./references#CD011769-bbs2-0365" title="KrishnaswamiS , McPheetersML , Veenstra-VanderweeleJ . A systematic review of secretin for children with autism spectrum disorders. Pediatrics2011;127(5):e1322-5. [DOI: 10.1542/peds.2011-0428] [PMCID: PMC3387870] [PMID: 21464196]">Krishnaswami 2011</a>; <a href="./references#CD011769-bbs2-0383" title="McQueenJM , HeckAM . Secretin for the treatment of autism. Annals of Pharmacotherapy2002;36(2):305-11. [DOI: 10.1345/aph.19113] [PMID: 11847953]">McQueen 2002</a>; <a href="./references#CD011769-bbs2-0436" title="TanakaA , FurubayashiT , AraiM , InoueD , KimuraS , KiriyamaA , et al. Delivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application. Molecular Pharmaceutics2018;15(3):1105-11. [DOI: 10.1021/acs.molpharmaceut.7b00991] [PMID: 29338251]">Tanaka 2018</a>). </p> </section> </section> <section id="CD011769-sec-0031"> <h3 class="title" id="CD011769-sec-0031">Why it is important to do this review</h3> <p>To date, there have been five published Cochrane systematic reviews focusing on the use of pharmacological interventions in ASD. A review on risperidone found evidence that the medication may lead to significant improvements in irritability (<a href="./references#CD011769-bbs2-0359" title="JesnerOS , Aref-AdibM , CorenE . Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005040. [DOI: 10.1002/14651858.CD005040.pub2] [PMID: 17253538]">Jesner 2007</a>). Two reviews on aripiprazole also found evidence of improvements in irritability (<a href="./references#CD011769-bbs2-0293" title="ChingH , PringsheimT . Aripiprazole for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD009043. [DOI: 10.1002/14651858.CD009043.pub2] [PMID: 22592735]">Ching 2012</a>; <a href="./references#CD011769-bbs2-0347" title="HirschLE , PringsheimT . Aripiprazole for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2016, Issue 6. Art. No: CD009043. [DOI: 10.1002/14651858.CD009043.pub3] [PMCID: PMC7120220] [PMID: 2734413]">Hirsch 2016</a>). A review of tricyclic antidepressants found small positive effects in children and adolescents with ASD, particularly in reducing irritability, although results were inconsistent (<a href="./references#CD011769-bbs2-0355" title="HurwitzR , BlackmoreR , HazellP , WilliamsK , WoolfendenS . Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD008372. [DOI: 10.1002/14651858.CD008372.pub2] [PMID: 22419332]">Hurwitz 2012</a>). A review of SSRIs found evidence of improvement in an adult's aggression, but only from studies with a high risk of bias (<a href="./references#CD011769-bbs2-0460" title="WilliamsK , BrignellA , RandallM , SiloveN , HazellP . Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD004677. [DOI: 10.1002/14651858.CD004677.pub3] [PMID: 23959778]">Williams 2013</a>). To date, no Cochrane Review has focused on any of the remaining pharmacological interventions that can be used to address behaviours of concern in ASD. These previously conducted reviews of single medications or single classes of medications have provided useful information regarding their effectiveness and safety, however, these reviews now require updating. Furthermore, this review includes studies of children and adults with ASD, whereas previous reviews had focused only on either children or adults. </p> <p>Since the publication of the protocol (<a href="./references#CD011769-bbs2-0471" title="LivingstoneN , MacdonaldG , WilliamsK , CaldwellDM , BakerLB , HazellP . Pharmacological intervention for irritability, aggression, and self‐injury in Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD011769. [DOI: 10.1002/14651858.CD011769]">Livingstone 2015</a>), 17 systematic reviews have been published. Seven of these were on antipsychotics, three each on anticonvulsants and 'experimental' interventions, and an additional four systematic reviews on antiparkinsonians, anxiolytics, dementia‐related medications, and antidepressants respectively. Each of the systematic reviews reported on the effectiveness of only one class of drug. </p> <p>The extent to which the age of the person receiving the treatment will affect the intervention's efficacy remains unclear. ASD is a lifelong condition, and therefore it is important to understand the effect of interventions, including medication, across the lifespan (<a href="./references#CD011769-bbs2-0437" title="TantamD . Autism Spectrum Disorders through the Life Span. Philadelphia (PA): Jessica Kingsley Publishers, 2012.">Tantam 2012</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011769-sec-0032" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011769-sec-0032"></div> <p>To assess the effectiveness and AEs of pharmacological interventions for managing the behaviours of irritability, aggression, and self‐injury in ASD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011769-sec-0033" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011769-sec-0033"></div> <section id="CD011769-sec-0034"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011769-sec-0035"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), including cross‐over studies, that compare pharmacological interventions to an alternative drug, standard care, placebo, or wait‐list control. </p> </section> <section id="CD011769-sec-0036"> <h4 class="title">Types of participants</h4> <p>Studies were considered eligible for inclusion if they included participants of any age with a clinical diagnosis of ASD, who displayed one or more behaviours of concern at baseline assessment, specifically irritability, aggression and self‐injury. People with reported comorbidities were included in the analysis. We will also include studies that identify a subset of people with ASD. </p> <p>We included studies where participants were diagnosed according to the criteria of the <i>Diagnostic and Statistical Manual for Mental Disorders (DSM) Fourth</i> (DSM‐IV (<a href="./references#CD011769-bbs2-0311" title="American Psychiatric Association. DSM-4. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Arlington (VA): American Psychiatric Association, 1994.">DSM‐4 1994</a>); or DSM‐IV‐TR (<a href="./references#CD011769-bbs2-0312" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4-TR edition. Arlington (VA): American Psychiatric Association, 2000.">DSM‐4‐TR 2000</a>)) and <i>Fifth</i> (DSM‐5; <a href="./references#CD011769-bbs2-0313" title="American Psychiatric Association. DSM-5. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">DSM‐5 2013</a>) Editions, or the <i>International Classification of Diseases, 10th Revision</i> (ICD‐10; <a href="./references#CD011769-bbs2-0357" title="World Health Organization. ICD-10: International Classification of Diseases for Mortality and Morbidity Statistics. 10th edition. Geneva: World Health Organization, 2004.">ICD‐10 2004</a>); and those who had been diagnosed through use of a standardised diagnostic instrument, including the Autism Diagnostic Observation Schedule (ADOS; <a href="./references#CD011769-bbs2-0371" title="LordC , RisiS , LambrechtL , Cook EH Jr, LeventhalBL , DiLavorePC . Autism Diagnostic Interview Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders2000;30(3):205-23. [PMID: 11055457]">Lord 2000</a>) or the Autism Diagnostic Interview Revised (ADI‐R; <a href="./references#CD011769-bbs2-0370" title="LordC , RutterM , Le CouteurA . Autism Diagnostic Interview Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders1994;24(5):659-85. [DOI: 10.1007/BF021172145] [PMID: 7814313]">Lord 1994</a>). </p> </section> <section id="CD011769-sec-0037"> <h4 class="title">Types of interventions</h4> <p>Any pharmacological intervention used to manage behaviours of concern in children, adolescents or adults with ASD, specifically irritability, aggression, or self‐injury. Interventions may have been given at any dosage, for any duration, and any frequency of administration. Relevant pharmacological interventions included first‐generation ('typical') antipsychotics such as haloperidol, second‐generation ('atypical') antipsychotics such as risperidone and aripiprazole, ADHD‐related medications, anticonvulsants, antidementia medications, antidepressants (including selective SSRIs and tricyclic antidepressants), antiparkinsonian medication, anxiolytics, neurohormones, and a number of other drugs that did not fall into any of these classes that we grouped under an experimental category. </p> <p>It was possible that additional eligible interventions that review authors were not previously aware of may be identified in the course of the review. When we identified any pharmacological interventions that were not initially included, we considered them as eligible and included them in the review after assessing their comparability with those named above. </p> <p>Because pharmacological interventions could be used in addition to non‐pharmacological therapies, we included any studies in which participants received concurrent non‐pharmacological therapies, provided that they were used in all intervention arms. </p> <p>The interventions of interest for this review focus on the effectiveness and benefits and harms associated with pharmacological agents to address the behaviours of irritability, aggression and self‐injury for people with ASD. Interventions with different foci such as sleep interventions were not included in this review. </p> </section> <section id="CD011769-sec-0038"> <h4 class="title">Types of outcome measures</h4> <p>We classified outcome measures as either primary or secondary outcomes.</p> <p>Lower scores indicate a more positive response for all outcomes and measures used apart from quality of life, where higher scores indicate an improved quality of life. </p> <p>Where data were insufficient, we provided a narrative account of the outcomes.</p> <p>Where feasible, we made comparisons at the following specific follow‐up periods:</p> <p> <ul id="CD011769-list-0001"> <li> <p>short‐term follow‐up (less than 6 months);</p> </li> <li> <p>medium‐term follow‐up (6 to 12 months); and</p> </li> <li> <p>long‐term follow‐up (over 12 months).</p> </li> </ul> </p> <section id="CD011769-sec-0039"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0040"> <h6 class="title">Behaviours of concern</h6> <p>Behaviours of concern in ASD, specifically:</p> <p> <ul id="CD011769-list-0002"> <li> <p>irritability (including outcomes of irritability improvement and irritability relapse as defined by the study authors); </p> </li> <li> <p>aggression; and</p> </li> <li> <p>self‐injury.</p> </li> </ul> </p> <p>These outcomes needed to be measured by standardised instruments such as the 'irritability' subscale of the Aberrant Behaviour Checklist (ABC‐I; <a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>). Where possible, preference was given to analysing each of these three specific challenging behaviours separately. Where this was not possible, we combined measures across studies to create a composite 'challenging behaviour' outcome. In the event that study authors reported several similar scales, we established a hierarchy of preferred scales/instruments where the ABC‐I was the preferred scale. This hierarchy was established through discussion with the full review group. </p> </section> <section id="CD011769-sec-0041"> <h6 class="title">Adverse effects</h6> <p>AEs (including sedation and weight gain)</p> <p>Due to the wide range of AE data that we collected during this review, we made a postprotocol decision to categorise available data into the following groups: </p> <p> <ul id="CD011769-list-0003"> <li> <p>cardiovascular;</p> </li> <li> <p>gastrointestinal;</p> </li> <li> <p>immune;</p> </li> <li> <p>metabolic system;</p> </li> <li> <p>musculoskeletal;</p> </li> <li> <p>neurological;</p> </li> <li> <p>psychological;</p> </li> <li> <p>respiratory system;</p> </li> <li> <p>skin;</p> </li> <li> <p>urinary; and</p> </li> <li> <p>other.</p> </li> </ul> </p> </section> </section> <section id="CD011769-sec-0042"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0043"> <h6 class="title">Quality of life</h6> <p>Quality of life for both the child and the parents or informal carers or family (as measured by standardised instruments such as the Pediatric Quality of Life Inventory (PedsQL; <a href="./references#CD011769-bbs2-0448" title="VarniJW , SeidM , RodeCA . The PedsQL - measurement model for the pediatric quality of life inventory. Medical care1999;37(2):126-39. [DOI: 10.1097/00005650-199902000-00003] [PMID: 10024117]">Varni 1999</a>), or through quality‐of‐life questionnaires). </p> </section> <section id="CD011769-sec-0044"> <h6 class="title">Tolerability and acceptability</h6> <p>Tolerability and acceptability of the intervention (as measured by self‐reported or clinician‐reported adherence to treatment). </p> </section> <section id="CD011769-sec-0045"> <h6 class="title">Summary of findings tables</h6> <p>We used the following outcomes to populate the summary of findings tables for the main comparison: </p> <p> <ul id="CD011769-list-0004"> <li> <p>irritability;</p> </li> <li> <p>aggression;</p> </li> <li> <p>self‐injury;</p> </li> <li> <p>AEs.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD011769-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <p>We ran searches in 2020 using the search strategies in <a href="./appendices#CD011769-sec-0402">Appendix 2</a>. We also ran updated searches in 2022, in which we made changes to the original MEDLINE search strategy by adding the MeSH term for neurodevelopmental disorders to the population section, and included more search terms for pharmacological interventions. We adapted the revised MEDLINE search for all databases (<a href="./appendices#CD011769-sec-0384">Appendix 1</a>), and ran the searches from inception for each source before de‐duplicating these with the records retrieved by the previous search. </p> <section id="CD011769-sec-0047"> <h4 class="title">Electronic searches</h4> <p>We searched all available years of the following databases.</p> <p> <ul id="CD011769-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2022, Issue 5), in the Cochrane Library. Searched 6 June 2022 </p> </li> <li> <p>MEDLINE Ovid (1946 to 6 June 2022)</p> </li> <li> <p>MEDLINE In‐Process and Other Non‐indexed Citations Ovid (6 June 2022)</p> </li> <li> <p>MEDLINE Epub Ahead of Print Ovid (6 June 2022)</p> </li> <li> <p>Embase Ovid (1974 to 6 June 2022)</p> </li> <li> <p>CINAHL EBSCOhost (1937 to 6 June 2022)</p> </li> <li> <p>APA PsycINFO Ovid (1967 to 6 June 2022)</p> </li> <li> <p>ERIC EBSCOhost (1966 to 6 June 2022)</p> </li> <li> <p>Epistemonikos (<a href="https://www.epistemonikos.org/en/" target="_blank">www.epistemonikos.org/en/</a>). Searched 6 June 2022 </p> </li> <li> <p>Sociological Abstracts Proquest, 1952 to 6 June 2022</p> </li> <li> <p>Science Citation Index (SCI) Web of Science Clarivate (1970 to 6 June 2022)</p> </li> <li> <p>Conference Proceedings Citation Index – Science (CPCI‐S) Web of Science Clarivate (1990 to 6 June 2022) </p> </li> <li> <p><i>Cochrane Database of Systematic Reviews</i> (CDSR; 2020, Issue 11), in the Cochrane Library. Searched 6 June 2022 </p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE), in the Centre for Reviews and Dissemination (CRD) databases. Searched 6 June 2022 </p> </li> <li> <p>LILACS (<a href="http://lilacs.bvsalud.org/en/" target="_blank">lilacs.bvsalud.org/en/</a>). Searched 6 June 2022 </p> </li> <li> <p>AutismData (<a href="http://autism.org.uk/autismdata" target="_blank">autism.org.uk/autismdata</a>). Not available 6 June 2022 </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>). Searched 6 June 2022 </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://isrctn.com/" target="_blank">isrctn.com/</a>). Searched 6 June 2022 </p> </li> </ul> </p> <p>We used search filters for RCTs where appropriate. We did not apply any language or date restrictions. We did not restrict by publication status, and we sought translation of documents where necessary. </p> </section> <section id="CD011769-sec-0048"> <h4 class="title">Searching other resources</h4> <p>We scanned bibliographies of included and excluded studies for possible additional references of interest. </p> <p>We contacted relevant pharmaceutical companies, authors, and key scholars to identify any additional ongoing or missed studies. </p> </section> </section> <section id="CD011769-sec-0049"> <h3 class="title" id="CD011769-sec-0049">Data collection and analysis</h3> <p>The protocol of this review planned to conduct a network meta‐analysis on the available data. After assessing the plausibility of the transitivity assumption, we decided that a network meta‐analysis would not be appropriate with the available data. </p> <p>This was due to the variation across studies in participants, interventions and comparators, that did not allow scope for linking nodes to produce a network for a network meta‐analysis. It was felt that the heterogeneity would have led to issues with transitivity that would have rendered the network unstable. </p> <p>Network meta‐analyses may still be performed in future updates if more appropriate data become available. In the following sections, we have only reported the methods that were used in this version of the review. For unused methods, please refer to the published protocol for this review (<a href="./references#CD011769-bbs2-0471" title="LivingstoneN , MacdonaldG , WilliamsK , CaldwellDM , BakerLB , HazellP . Pharmacological intervention for irritability, aggression, and self‐injury in Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD011769. [DOI: 10.1002/14651858.CD011769]">Livingstone 2015</a>), and <a href="./appendices#CD011769-sec-0404">Appendix 3</a>. </p> <section id="CD011769-sec-0050"> <h4 class="title">Selection of studies</h4> <p>Two of the four review authors (DG, MI, MJ, NL) independently selected and assessed every study at abstract and title level and then full‐text level to determine whether they met the inclusion criteria for this review. We resolved any disagreements between the authors through discussion with the full review group. The selection process is presented in two PRISMA diagrams (<a href="#CD011769-fig-0001">Figure 1</a>; <a href="#CD011769-fig-0002">Figure 2</a>; <a href="./references#CD011769-bbs2-0389" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ2009;339:b2535. [DOI: https://doi.org/10.1136/bmj.b2535]">Moher 2009</a>). </p> <div class="figure" id="CD011769-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Original search November 2020" data-id="CD011769-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Original search November 2020</p> </div> </div> </div> <div class="figure" id="CD011769-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Search update June 2022" data-id="CD011769-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Search update June 2022</p> </div> </div> </div> </section> <section id="CD011769-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (DG, MI, MJ, NL) extracted data independently and entered them into a piloted data extraction form. We resolved any disagreements between the review authors through discussion with the full review group. We extracted the following data. </p> <section id="CD011769-sec-0052"> <h5 class="title">Outcome data</h5> <p>From each included study, we extracted relevant details on all primary and secondary outcome measures used, as defined by the review authors; and length of follow‐up and summary data, including means, standard deviations, confidence intervals and significance levels for continuous data, and proportions for dichotomous data. We extracted arm‐level data. </p> </section> <section id="CD011769-sec-0053"> <h5 class="title">Data on potential effect modifiers</h5> <p>From each included study, we extracted data on the following study, participant, intervention, and comparison characteristics that may have acted as effect modifiers. </p> <p> <ul id="CD011769-list-0006"> <li> <p>Study characteristics (study design, study duration, details of attrition, and risk of bias concerns) </p> </li> <li> <p>Participant characteristics (number randomised, age of participants, specific diagnosis, comorbidities, gender distribution, geographical location of study) </p> </li> <li> <p>Intervention characteristics (type of antidepressant or antipsychotic, dose, duration, frequency, age medication began, concurrent interventions) </p> </li> <li> <p>Comparison characteristics (form, frequency, and duration of 'standard care')</p> </li> </ul> </p> </section> <section id="CD011769-sec-0054"> <h5 class="title">Other data</h5> <p>From each included study, we extracted data on the following additional information.</p> <p> <ul id="CD011769-list-0007"> <li> <p>Study author(s), year of publication, citation, and contact details</p> </li> <li> <p>Sources of funding and other potential commercial interests</p> </li> </ul> </p> </section> </section> <section id="CD011769-sec-0055"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two of the four review authors (DG, MI, MJ, NL) independently assessed the seven risk of bias domains for each study and assigned each domain to one of the following categories as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011769-bbs2-0342" title="HigginsJP , AltmanDG , Sterne JA editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. https://training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>): </p> <p> <ul id="CD011769-list-0008"> <li> <p>high risk of bias;</p> </li> <li> <p>low risk of bias; or</p> </li> <li> <p>unclear or unknown risk of bias.</p> </li> </ul> </p> <p>When determining quality of evidence, the overall risk of bias of each trial was assessed independently by two of the review authors and then agreed by consensus or referral to a third review author. Assessments of risk of bias for each study were based on the following criteria as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011769-bbs2-0342" title="HigginsJP , AltmanDG , Sterne JA editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. https://training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p> <ul id="CD011769-list-0009"> <li> <p>Sequence generation (was the allocation sequence adequately generated?)</p> </li> <li> <p>Allocation concealment (was allocation adequately concealed?)</p> </li> <li> <p>Blinding of participants and personnel (was knowledge of the allocated intervention adequately prevented during the study?) </p> </li> <li> <p>Blinding of outcome assessors (was knowledge of the allocated intervention adequately prevented during the study?) </p> </li> <li> <p>Incomplete outcome data (were incomplete outcome data adequately addressed?)</p> </li> <li> <p>Selective outcome reporting (are reports of the study free of suggestion of selective outcome reporting?) </p> </li> <li> <p>Other sources of bias (was the study apparently free of other problems that could put it at a high risk of bias?) </p> </li> </ul> </p> <p>We resolved any disagreements between the review authors through discussion with the full review group. We reached overall risk of bias judgements by considering the results from each relevant risk of bias domain for the outcome being considered. </p> </section> <section id="CD011769-sec-0056"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011769-sec-0057"> <h5 class="title">Continuous data</h5> <p>We calculated standardised mean differences (SMDs) with 95% confidence intervals (CIs) for continuous outcome data (e.g. scores on standardised measures). We used Cohen's standards for interpreting effect sizes (small = 0.2, medium = 0.5, large = 0.8 (<a href="./references#CD011769-bbs2-0295" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Erlbaum, 1988. [ISBN: 0-8058-0283-5]">Cohen 1988</a>)). </p> </section> <section id="CD011769-sec-0058"> <h5 class="title">Dichotomous data</h5> <p>We estimated the pairwise relative treatment effects of the competing interventions by calculating effect sizes as odds ratios (ORs) with 95% CIs for dichotomous outcome data (e.g. adherence). </p> </section> </section> <section id="CD011769-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011769-sec-0060"> <h5 class="title">Cross‐over trials</h5> <p>We included cross‐over trials, in which all participants receive both the control and intervention treatment but in a random order. We had aimed only to use data reported during the first phase of the study, up to the point of the first cross‐over, to avoid any carry‐over effect from the first to second phase. However, the majority of studies did not differentiate data from first and second phases. Therefore, where first phase data were not reported in cross‐over studies, we included reported data from the study but undertook a sensitivity analysis to identify whether inclusion of these data had a differential effect on meta‐analytic estimates. </p> </section> <section id="CD011769-sec-0061"> <h5 class="title">Multiple treatment groups</h5> <p>If two or more eligible intervention groups were compared to a single eligible control group, we split the sample size for the shared comparator group to prevent the same comparator participants being included twice. We clearly documented decisions made during this process in the review. </p> </section> </section> <section id="CD011769-sec-0062"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the original investigators to request missing data. If we could not obtain the data, we made assumptions about whether the data appeared to be 'missing at random' or 'not missing at random' and followed the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011769-bbs2-0344" title="HigginsJP , LiT , Deeks JJ editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022a</a>). </p> <p>Data that are not missing at random are likely to be missing for reasons related to the outcomes of the missing data. For example, if a participant agrees to take part in a trial but is unhappy with the outcome of allocation, fails to adhere to the medication or experiences AEs as a result of the medication, then they may be unwilling to complete any follow‐up assessments. In such a situation, where dichotomous data are missing, we imputed data on the assumption that the participants experienced the less favourable outcome (e.g. 'participant did not adhere to the treatment'). </p> <p>When studies provided insufficient information regarding the exact number missing from each group, data imputation was not possible, in which case we analysed only the available data. Where continuous data were missing, we analysed only the available data. </p> <p>Where studies had missing summary data, such as missing standard deviations, we derived these where possible using calculations provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011769-bbs2-0344" title="HigginsJP , LiT , Deeks JJ editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022a</a>). </p> <p>We specified the methods used to address any missing data in the <a href="./references#CD011769-sec-0438" title="">Characteristics of included studies</a> tables. If imputation was not possible, we outlined the reasons for this in the text. </p> </section> <section id="CD011769-sec-0063"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined clinical heterogeneity within each pairwise comparison by inspecting each included study for variability in the participants, interventions or outcomes described. We examined methodological heterogeneity within each pairwise comparison by inspecting each included study for variability in the study design and risk of bias. We discussed in full any unexpected variability that arose. In pairwise analyses, we assessed statistically the presence of heterogeneity within each pairwise comparison using the Chi² statistic and its P value (<a href="./references#CD011769-bbs2-0307" title="DeeksJJ , HigginsJP , Altman DG editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>), and the I² statistic (<a href="./references#CD011769-bbs2-0341" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>), and its 95% CI. </p> </section> <section id="CD011769-sec-0064"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias and other reporting biases by visually inspecting the funnel plots of analyses with more than 10 trials and performing trim and fill analyses. </p> </section> <section id="CD011769-sec-0065"> <h4 class="title">Data synthesis</h4> <p>We performed standard pairwise meta‐analyses on the results when data from at least two included studies were available for any treatment comparison. Due to expected heterogeneity amongst the included studies, we performed a random‐effects meta‐analysis using an inverse variance weighting method (Chi<sup>2</sup> P value 0.05 or less) using Review Manager (RevMan) Web software (<a href="./references#CD011769-bbs2-0411" title="Review Manager Web (RevMan Web). Version 3.13.0. The Cochrane Collaboration, 2021. Available at revman.cochrane.org.">RevMan Web 2021</a>). We used an inverse‐variance approach to meta‐analysis in order to increase the certainty of the pooled effect estimate, as larger studies with smaller standard errors are weighted more heavily than smaller studies with larger standard errors (<a href="./references#CD011769-bbs2-0307" title="DeeksJJ , HigginsJP , Altman DG editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>). When pooling the data was inappropriate, we provided a narrative description of the individual study results. </p> </section> <section id="CD011769-sec-0066"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted the following subgroup analyses for comparisons with a sufficient number of studies that provided specific details: </p> <p> <ul id="CD011769-list-0010"> <li> <p>the differential effects of interventions by the age at which the drug was first administered; for example, infant/toddler (birth to six years of age) versus school age (6 to 12 years of age) versus adolescent (12 to 18 years of age), versus adult (18 years of age and over); </p> </li> <li> <p>the differential effects of interventions by communication ability; for example, low communication ability versus high communication ability; </p> </li> <li> <p>the differential effects of interventions by cognitive ability; for example, low cognitive ability versus high cognitive ability; </p> </li> <li> <p>the differential effects of interventions by the gender of the participant; for example, male versus female. </p> </li> </ul> </p> <p>Because most studies did not specify the ages of children, the subgroup analyses we conducted were children (up to 17 years of age) compared to children and adults, and adult‐only samples. </p> <p>We also undertook subgroup analyses that were not planned in the protocol. This was because we wanted to identify whether there were differences within subclasses of each pharmacological class that had differing mechanisms of action, that is, each of the atypical antipsychotics that have differing mechanisms of action, stimulant versus non‐stimulant ADHD‐related medications, SSRI versus dibenzoxazepine antidepressants, different neurohormones, and between each of the different experimental drugs. </p> </section> <section id="CD011769-sec-0067"> <h4 class="title">Sensitivity analysis</h4> <p>In the protocol (<a href="./references#CD011769-bbs2-0471" title="LivingstoneN , MacdonaldG , WilliamsK , CaldwellDM , BakerLB , HazellP . Pharmacological intervention for irritability, aggression, and self‐injury in Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD011769. [DOI: 10.1002/14651858.CD011769]">Livingstone 2015</a>), we stated our aim to perform sensitivity analyses to assess whether the findings of this review were robust to the following: </p> <p> <ul id="CD011769-list-0011"> <li> <p>reanalysis excluding studies according to study quality issues, including those with low sample size, high risk of bias, or high attrition; </p> </li> <li> <p>reanalysis without imputing data for the missing participants;</p> </li> <li> <p>reanalysis using a fixed‐effect model.</p> </li> </ul> </p> <p>In addition, as the majority of cross‐over studies did not differentiate data from first and second phases, we aimed to undertake sensitivity analyses to identify whether inclusion of these data had a differential effect on meta‐analytic estimates. </p> <p>We used the primary outcome irritability for the comparisons where there were significant differences between intervention and placebo groups. </p> <p>We were only able to undertake sensitivity analyses on the comparisons of antipsychotics versus placebo, and neurohormone versus placebo as there were inadequate data for other comparisons. We were unable to do sensitivity analyses for cross‐over studies in atypical antipsychotics as there were no cross‐over studies included in those comparisons. Also, we did not use imputed data, therefore we undertook sensitivity analysis excluding studies at: </p> <p> <ul id="CD011769-list-0012"> <li> <p>high risk of attrition bias;</p> </li> <li> <p>high risk of other bias; and</p> </li> <li> <p>with a sample size less than 50.</p> </li> </ul> </p> </section> <section id="CD011769-sec-0068"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created summary of findings tables using the system developed by the GRADE Working Group (<a href="./references#CD011769-bbs2-0423" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from https://gdt.gradepro.org/app/handbook/handbook.html.">Schünemann 2013</a>). </p> <p>We used <a href="./references#CD011769-bbs2-0333" title="GRADEpro. 3.2 for Windows. BrozekJ , OxmanA , SchünemannH , Version accessed 27 April 2022. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a> to import data from RevMan Web to create summary of findings tables for the main comparisons and outcomes indicated under '<a href="#CD011769-sec-0038">Types of outcome measures</a>' (<a href="./references#CD011769-bbs2-0411" title="Review Manager Web (RevMan Web). Version 3.13.0. The Cochrane Collaboration, 2021. Available at revman.cochrane.org.">RevMan Web 2021</a>). </p> <p>Three review authors (NL, MI, DG) independently assessed the certainty of the evidence using GRADE. We resolved any disagreements through discussion. </p> <p>For information regarding the GRADE approach, and factors that influence the assessment, see chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011769-bbs2-0424" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Schünemann 2022</a>). </p> <p>The main comparisons in this review as judged by clinical experts and for which we created summary of findings tables were as follows. </p> <p> <ul id="CD011769-list-0013"> <li> <p>Atypical antipsychotics versus placebo</p> </li> <li> <p>Neurohormones versus placebo</p> </li> <li> <p>ADHD‐related drugs versus placebo</p> </li> <li> <p>Antidepressants versus placebo</p> </li> </ul> </p> <p>We used the following outcomes to populate the summary of findings tables for the main comparisons. </p> <p> <ul id="CD011769-list-0014"> <li> <p>Irritability (short‐term)</p> </li> <li> <p>Aggression (short‐term)</p> </li> <li> <p>Self‐injury (short‐term)</p> </li> <li> <p>AEs (metabolic, musculoskeletal, neurological, and psychological; short‐term)</p> </li> </ul> </p> <p>During the course of this review, many different types of AEs were found to be reported by the included studies. To make the summary of findings tables more readable and useful, the clinical content experts on the review team were asked to prioritise the list of available AEs, to decide which should be presented in the summary of findings tables. The clinical experts were blinded to the type or availability of evidence available for each type of AE when they made this decision, to ensure their choice was based on clinical importance and not data availability. As a result of this prioritisation exercise, the decision was made to present a narrative summary of the most important AEs in the four most clinically important categories of AEs ‐ metabolic, musculoskeletal, neurological, and psychological. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011769-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011769-sec-0069"></div> <section id="CD011769-sec-0070"> <h3 class="title">Description of studies</h3> <p>For more information please see <a href="./references#CD011769-sec-0438" title="">Characteristics of included studies</a>, <a href="./references#CD011769-sec-0439" title="">Characteristics of excluded studies</a>, <a href="./references#CD011769-sec-0440" title="">Characteristics of studies awaiting classification</a>; and <a href="./references#CD011769-sec-0441" title="">Characteristics of ongoing studies</a>. </p> <section id="CD011769-sec-0071"> <h4 class="title">Results of the search</h4> <p>An electronic search conducted in November 2020 yielded 7403 possible references. This was reduced to 5002 possible references once duplicates were removed. These 5002 references were screened at the title and abstract level; 4600 were irrelevant, and we excluded them for reasons such as they were not RCTs, they used an ineligible study design, were reviews, involved an irrelevant population or were non‐pharmacological interventions. This left 402 full‐text articles (376 studies) to screen, after which we excluded 76 references (as 72 studies), leaving 326 references: 281 references (121 studies) included in the analysis; 26 references (22 studies) awaiting classification; and 19 references (16 studies) for ongoing studies (<a href="#CD011769-fig-0001">Figure 1</a>). </p> <p>A top‐up electronic search was conducted in June 2022, which yielded 1809 possible references. This was reduced to 1294 possible references once duplicates were removed. After initial screening, this was reduced to 48 full‐text records that needed screening, after which we excluded 12 references (9 studies), leaving 36 references (as 23 studies). These were 10 included studies, five studies 'awaiting classification', eight 'ongoing studies' and 13 secondary references of these studies. See <a href="#CD011769-fig-0002">Figure 2</a> for a flow diagram of the search process. </p> <p>We also contacted a number of study authors to request further information. See <a href="#CD011769-tbl-0006">Table 2</a> for information about the studies and contact person. </p> <div class="table" id="CD011769-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Authors contacted</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Name of contact author</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Response from author</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0009" title="AkhondzadehS , AsadabadiM . Risperidone plus celecoxib in children with autistic disorder: a double-blind, randomized trial. British Journal of Clinical Pharmacology2012;73(6):983-4. [DOI: 10.1111/j.1365-2125.2012.04253.x]AsadabadiM , Mohammadi M-R, GhanizadehA , ModabberniaA , AshrafiM , HassanzadehE , et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology2013;225(1):51-9. [DOI: 10.1007/s00213-012-2796-8] [PMID: 22782459]IRCT138711091556N2. Celecoxib and autism [A double-blind placebo controlled trial of celecoxib added to risperidone in patients with autistic disorder]. www.irct.ir/trial/852 (first received 12 February 2009). ">Asadabadi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0013" title="BelsitoKM , LawPA , KirkKS , LandaRJ , ZimmermanAW . Lamotrigine therapy for autistic disorder: a randomised, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders2001;31(2):175-81. [DOI: 10.1023/A:1010799115457] [PMID: 11450816]BelsitoK , KirkK , LandaR , LawP , ZimmermanA . Lamotrigine therapy for childhood autism: a randomized, double-blind, placebo-controlled trial. Neurology1998;50(4):A85. ">Belsito 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>K. Belsito</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0020" title="ChuganiDC , ChuganiHT , WiznitzerM , ParikhS , EvansPA , HansenRL , et al. Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial. Journal of Pediatrics2016;170:45-53.e1-4. [DOI: 10.1016/j.jpeds.2015.11.033] [PMID: 26746121]NCT00873509. Buspirone in the treatment of 2-6 year old children with autistic disorder (B-ACE) [A randomized, placebo-controlled, double-masked clinical trial of buspirone in the treatment of 2- 6 year old children with autistic disorder]. (first received 1 April 2009). ">Chugani 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D. Chugani</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0030" title="GhaleihaA , AsababadiM , Mohammadi M-R, ShaheiM , TabriziM , HajiaghaeeR , et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology2013;16(4):783-9. [DOI: 10.1017/S1461145712000880] [PMID: 22999292]IRCT1138901151556N10. A double-blind placebo-controlled trial of memantine added to risperidone in patients with autistic disorder. https://www.irct.ir/trial/860 (first received May 2010). ">Ghaleiha 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0033" title="GhaleihaA , RasaSM , NikooM , FarokhniaM , Mohammadi M-R, AkhondzadehS . A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism. Psychiatry Research2015;229(1-2):181-7. [DOI: 10.1016/j.psychres.2015.07.043] [PMID: 26208985]IRCT201202281556N37. Pioglitazone in the treatment of autism [Pioglitazone added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/887 (first received 1 March 2012). ">Ghaleiha 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0034" title="GhaleihaA , AlikhaniR , Kazemi M-R, Mohammadi M-R, MohammadinejadP , ZeinoddiniA , et al. Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology2016;26(9):784-91. [DOI: 10.1089/cap.2015.0175] [PMID: 27128958]IRCT201302201556N50. Minocycline in the treatment of autism [Minocycline added to risperidone in the treatment of autism: a double blind and placebo controlled trial ]. en.irct.ir/trial/900 (first received 21 February 2013). ">Ghaleiha 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0218" title="HandenBL , JohnsonCR , LubetskyM . Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders2000;30(3):245-55. [DOI: 10.1023/A:1005548619694] [PMID: 11055460]">Handen 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>B. Handen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0042" title="HandenBL , HofkoshD . Secretin in children with autistic disorder: a double-blind, placebo-controlled trial. Journal of Developmental and Physical Disabilities2005;17(2):95-107. [DOI: 10.1007/s10882-005-3682-7]">Handen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>B. Handen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0043" title="HandenBL , SahlR , HardanAY . Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental &amp; Behavioral Pediatrics2008;29(4):303-8. [DOI: 10.1097/DBP.0b013e3181739b9d] [PMID: 18552703]">Handen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>B. Handen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0044" title="HandenBL , JohnsonCR , McAuliffe-BellinS , HardanA . Safety and efficacy of donepezil in children - behavioural measures. International public health journal2010;2(1):125-34. HandenBL , JohnsonCR , Mcauliffe-BellinS , MurrayPJ , HardanAY . Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of Child and Adolescent Psychopharmacology2011;21(1):43-50. [DOI: 10.1089/cap.2010.0024] [PMCID: PMC3037196] [PMID: 21309696]HardanA , JohnsonC , HandenBL . Preliminary findings from a double-blind placebo=controlled study of donepezil in pervasive developmental disorders. Biological Psychiatry2006;59(8):50S-50S. NCT00047697. Donepezil HCl and cognitive deficits in autism. https://clinicaltrials.gov/ct2/show/results/NCT00047697?term=NCT00047697&amp;draw=2&amp;rank=1 (first received October 2002). ">Handen 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>B. Handen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0100" title="IRCT201110281556N29. N-acetylcysteine in the treatment of autism [N-acetyl cysteine added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/879 (first received 29 October 2011). NikooM , RadniaH , FarokhniaM , Mohammadi M-R, AkhondzadehS . N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clinical Neuropharmacology2015;38(1):11-7. [DOI: 10.1097/WNF.0000000000000063] [PMID: 25580916]">Nikoo 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD011769-bbs2-0056" title="HollanderE , SooryaL , ChaplinW , AnagnostouE , TaylorBP , FerrettiCJ , et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry2012;169(3):292-9. Erratum in: American Journal of Psychiatry. 2012 May;169(5):540. [DOI: 10.1176/appi.ajp.2011.10050764] [PMID: 22193531]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. https://clinicaltrials.gov/show/NCT00004486 (first received 19 October 1999). ">Hollander 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E. AnagNostou</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E. Hollander</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0224" title="KernJK , MillerVS , CaullerL , KendallR , MehtaJ , DoddM . Effectiveness of N,N-Dimethylglycine in autism and pervasive developmental disorder. Journal of Child Neurology2000;16(3):169-73. [DOI: 10.2310/7010.2001.17515] [PMID: 11305684]">Kern 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>J. Kern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0225" title="KernJK , Van MillerS , EvansPA , TravediMH . Efficacy of porcine secretin in children with autism and pervasive developmental disorder. Journal of Autism and Developmental Disorders2002;32(3):153-60. [DOI: 10.1023/A:1015441428154] [PMID: 12108616]">Kern 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>J. Kern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0363" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McMahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(6):658–65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>B. King</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0073" title="MaceCF , BlumNJ , SierpBJ , DelaneyBA , MaukJE . Differential response of operant self-Injury to pharmacologic versus behavioral treatment. Journal of Developmental &amp; Behavioral Pediatrics2001;22(2):85-91. [DOI: 10.1097/00004703-200104000-00001] [PMID: 11332784]">Mace 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. Blum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0079" title="HuffmanG . Fluvoxamine for the treatment of autistic disorders in adults. American Family Physician1997;55(4):1375-4. McDougleCJ , NaylorST , CohenDJ , VolkmarFR , HeningerGR , PriceLH . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry1996;53(11):1001-8. [DOI: 10.1001/archpsyc.1996.01830110037005] [PMID: 8911223]VegsoSJ . A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]. New Haven (CT): Southern Connecticut State University, 1995. ">McDougle 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C. McDougle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Email bounced</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0082" title="MiralS , GencerO , Inal-EmirogluFN , BaykaraB , BaykaraA , DirikE . Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. European Child &amp; Adolescent Psychiatry2008;17(1):1-8. [DOI: 10.1007/s00787-007-0620-5] [PMID: 18080171]">Miral 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Miral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0230" title="MolloyCA , Manning-CourtneyP , SwayneS , BeanJ , BrownJM , MurrayDS , et al. Lack of benefit of intravenous synthetic human secretin in the treatment of autism. Journal of Autism and Developmental Disorders2002;32(6):545-51. [DOI: 10.1023/A:1021202930206] [PMID: 12553591]">Molloy 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C. Molloy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M. O'Sullivan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A. Mouti</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Received response but referred to another author</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D. Reddinhough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Was provided with a full‐text paper containing the additional data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0087" title="MunesueT , NakamuraH , KikuchiM , MiuraY , TakeuchiN , AnmeT , et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study. Frontiers in Psychiatry2016;7:2. [DOI: 10.3389/fpsyt.2016.00002] [PMCID: PMC4720778] [PMID: 26834651]UMIN000007250. A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008548 (first received 9 February 2012). ">Munesue 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>T. Munesue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0233" title="NovotnyS , HollanderE , PhillipsA , AllenA , WassermanS , IyengarR . Increased repetitive behaviours and prolactin responsivity to oral m-chlorophenylpiperazine in adults with autism spectrum disorders. International Journal of Neuropsychopharmacology2004;7(3):249-54. [DOI: 10.1017/S146114570400433X] [PMID: 15132762]">Novotny 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E. Hollander</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G. Remington</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0111" title="IRCT138901141556N9. Topiramate in the treatment of autism [Tpoiramate added to risperidone in patint with autistic disorder: a double-blind placebo controlled trial]. www.irct.ir/trial/859 (first received 29 April 2010). RezaeiV , Mohammadi M-R, GhanizadehA , SahraianA , TabriziM , Rezazadeh S-A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2010;34(7):1269-72. [DOI: 10.1016/j.pnpbp.2010.07.005] [PMID: 20637249]">Rezaei 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0234" title="SandlerAD , SuttonKA , DeWesseJ , GirardiMA , SheppardV , BodfishJW . Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. New England Journal of Medicine1999;341(24):1801-6. [DOI: 10.1056/NEJM199912093412404] [PMID: 10588965]">Sandler 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD. Sandler</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0125" title="WassermanS , IyengarR , ChaplinWF , WatnerD , WaldoksSE , AnagnostouE , et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. International Clinical Psychopharmacology2006;21(6):363-7. [DOI: 10.1097/01.yic.0000224787.13782.0f] [PMID: 17012983]">Wasserman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Wasserman</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0125" title="WassermanS , IyengarR , ChaplinWF , WatnerD , WaldoksSE , AnagnostouE , et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. International Clinical Psychopharmacology2006;21(6):363-7. [DOI: 10.1097/01.yic.0000224787.13782.0f] [PMID: 17012983]">Wasserman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E. AnagNostou</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011769-sec-0072"> <h4 class="title">Included studies</h4> <p>We have included 131 studies (291 reports and 149 datasets) involving 7014 participants in this review. We identified 25 studies as awaiting classification (see <a href="./references#CD011769-bbs1-0003" title="">Studies awaiting classification</a>) and 25 ongoing studies (see <a href="./references#CD011769-bbs1-0004" title="">Ongoing studies</a>). All included studies compared a pharmacological intervention to a placebo or to another pharmacological intervention. </p> <p>The number of participants in each study ranged from 8 to 321 and most studies involved children, although some studies involved children and adults and some only adults; 53 studies involved only children under 13 years, 37 studies involved children and adolescents, two involved adolescents only, 16 involved children and adults, and 23 involved only adults. </p> <section id="CD011769-sec-0073"> <h5 class="title">Antipsychotics by comparison</h5> <section id="CD011769-sec-0074"> <h6 class="title">Atypical or typical antipsychotics versus placebo or alternative medication class</h6> <p>Twenty‐four studies (59 reports, 1225 participants, 29 datasets) compared an atypical or typical antipsychotic to a placebo or other treatment (see <a href="#CD011769-tbl-0007">Table 3</a> for further information). The number of participants ranged from nine (<a href="./references#CD011769-bbs2-0026" title="DollfusS , PetitM , MenardJF , LesieurP . Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. Journal of Autism and Developmental Disorders1992;22(1):47-60. [DOI: 10.1007/BF01046402] [PMID: 1350581]DollfusS , PetitP , MenardJF . Pharmacoclinical study of an agonist and an antagonist of dopamine in early infantile autism. Neuropsychiatrie de l'Enfance et de l'Adolescence1992;40(5-6):300-309. ">Dollfus 1992</a>), to 128 (<a href="./references#CD011769-bbs2-0071" title="LoebelA , BramsM , GoldmanRS , SilvaR , HernandezD , DengL , et al. Lurasidone for the treatment of irritability associated with autistic disorder. Journal of Autism and Developmental Disorders2016;46(4):1153-63. [DOI: 10.1007/s10803-015-2628-x] [PMCID: PMC4786592] [PMID: 26659550]NCT01911442. Lurasidone pediatric autism study. https://clinicaltrials.gov/ct2/show/results/NCT01911442?term=NCT01911442&amp;draw=2&amp;rank=1 (first received July 2013). ">Loebel 2016</a>), with an average age of 10.4 years. Apart from three studies that included a total of 44 adults (<a href="./references#CD011769-bbs2-0073" title="MaceCF , BlumNJ , SierpBJ , DelaneyBA , MaukJE . Differential response of operant self-Injury to pharmacologic versus behavioral treatment. Journal of Developmental &amp; Behavioral Pediatrics2001;22(2):85-91. [DOI: 10.1097/00004703-200104000-00001] [PMID: 11332784]">Mace 2001</a>; <a href="./references#CD011769-bbs2-0080" title="McDougleCJ , HolmesJP , CarlsonDC , PeltonGH , CohenDJ , PriceLH . A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry1998;55(7):633-41. [DOI: 10.1001/archpsyc.55.7.633] [PMID: 9672054]">McDougle 1998</a>; <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a>), all participants were children (&lt; 18 years). All the studies were short‐term (less than 6 months) and ranged from 34 days (<a href="./references#CD011769-bbs2-0073" title="MaceCF , BlumNJ , SierpBJ , DelaneyBA , MaukJE . Differential response of operant self-Injury to pharmacologic versus behavioral treatment. Journal of Developmental &amp; Behavioral Pediatrics2001;22(2):85-91. [DOI: 10.1097/00004703-200104000-00001] [PMID: 11332784]">Mace 2001</a>), to 16 weeks (<a href="./references#CD011769-bbs2-0029" title="FindlingRL , MankoskiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22-30. [DOI: 10.4088/JCP.13m08500] [PMID: 24502859]NCT01227668. Phase IV long-term maintenance study of aripiprazole in the treatment of irritability associated with autistic disorder. https://clinicaltrials.gov/ct2/show/NCT01227668?term=NCT01227668&amp;draw=2&amp;rank=1 (first received October 2010). ">Findling 2014</a>), although the average duration was between eight and 10 weeks. All trials were parallel RCTs apart from <a href="./references#CD011769-bbs2-0026" title="DollfusS , PetitM , MenardJF , LesieurP . Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. Journal of Autism and Developmental Disorders1992;22(1):47-60. [DOI: 10.1007/BF01046402] [PMID: 1350581]DollfusS , PetitP , MenardJF . Pharmacoclinical study of an agonist and an antagonist of dopamine in early infantile autism. Neuropsychiatrie de l'Enfance et de l'Adolescence1992;40(5-6):300-309. ">Dollfus 1992</a> and <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a>, which were cross‐over studies. </p> <div class="table" id="CD011769-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of all antipsychotic comparisons</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Antipsychotics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bromocriptine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Haloperidol</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Memantine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risperidone</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Amisulpride</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0026" title="DollfusS , PetitM , MenardJF , LesieurP . Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. Journal of Autism and Developmental Disorders1992;22(1):47-60. [DOI: 10.1007/BF01046402] [PMID: 1350581]DollfusS , PetitP , MenardJF . Pharmacoclinical study of an agonist and an antagonist of dopamine in early infantile autism. Neuropsychiatrie de l'Enfance et de l'Adolescence1992;40(5-6):300-309. ">Dollfus 1992</a> (n = 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0029" title="FindlingRL , MankoskiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22-30. [DOI: 10.4088/JCP.13m08500] [PMID: 24502859]NCT01227668. Phase IV long-term maintenance study of aripiprazole in the treatment of irritability associated with autistic disorder. https://clinicaltrials.gov/ct2/show/NCT01227668?term=NCT01227668&amp;draw=2&amp;rank=1 (first received October 2010). ">Findling 2014</a> (n = 85) </p> <p><a href="./references#CD011769-bbs2-0059" title="IchikawaH , MikamiK , OkadaT , YamashitaY , IshizakiY , TomodaA , et al. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study. Child Psychiatry &amp; Human Development2017;48(5):796-806. [DOI: 10.1007/s10578-016-0704-x] [PMCID: PMC5617873] [PMID: 28004215]NCT01617447. A short treatment study of aripiprazole in pediatric patients with autistic disorder [A short-term administration study of aripiprazole in children and adolescents (age: 6 to 17 years) with autistic disorder]. clinicaltrials.gov/ct2/show/NCT01617447 (first received 12 June 2012). ">Ichikawa 2017</a> (n = 92) </p> <p><a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a> (n = 105) </p> <p><a href="./references#CD011769-bbs2-0089" title="NCT00198107. Evaluating the effectiveness of aripiprazole and D-cycloserine to treat symptoms associated with autism [Novel pharmacological strategies in autism]. clinicaltrials.gov/ct2/show/NCT00198107 (first received 20 September 2005). ">NCT00198107</a> (n = 81) </p> <p><a href="./references#CD011769-bbs2-0090" title="NCT00468130. Efficacy of aripiprazole versus placebo in the reduction of aggressive and aberrant behavior in autistic children (Abilify) [Efficacy of aripiprazole versus placebo in the reduction of aggressive and aberrant behavior in autistic children]. clinicaltrials.gov/ct2/show/NCT00468130 (first received 2 May 2007). ">NCT00468130</a> (n=15) </p> <p><a href="./references#CD011769-bbs2-0102" title="EUCTR2016-005111-40. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A multicenter, double-blind, randomized, placebo-controlled, flexible-dosed parallel-group study of aripiprazole flexibly dosed in thetreatment of children and adolescents with autistic disorder]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-005111-40/results (first received 7 April 2017). LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of flexibly-dosed aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110-1. [DOI: 10.1002/ana.21853]LewisD , OwenR , CouchD . Efficacy and safety of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years): results from two 8-week randomized, double-blind, placebo-controlled trials. Neurology2009;72(11 (Supp 3)):A428. [ABSTRACT NO: S50.005]MankoskiR , StocktonG , ManosG , MarlorS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]NCT00365859. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A 52-week, open-label, multicenter study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder]. clinicaltrials.gov/ct2/show/NCT00365859 (first received 18 August 2006). OwenR , SikichL , MarcusRN , Corey-LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescent with autistic disorder. Pediatrics2009;124(6):1533-40. [DOI: 10.1542/peds.2008-3782] [PMID: 19948625]RobbAS , AnderssonC , BellocchioEE , ManosG , Rojas-FernandezC , MathewS , et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): results from a pooled analysis of 2 studies. Primary Care Companion for CNS Disorders2011;13(1):PCC.10m01008. [DOI: 10.4088/PCC.10m01008gry] [PMCID: PMC3121213] [PMID: 21731831]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. The effect of aripiprazole 2 to 15mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Owen 2009</a> (n = 98) </p> <p>6 studies (n = 476)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a> (n = 61) </p> <p><a href="./references#CD011769-bbs2-0036" title="GhanizadehA , SahraeizadehA , BerkM . A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development2014;45(2):185-92. [DOI: 10.1007/s10578-013-0390-x] [PMID: 23801256]IRCT201110233930N15. Aripiprazole versus risperidone for treatment of autism. www.irct.ir/trial/4094 (first received 12 December 2011). ">Ghanizadeh 2014</a> (n = 59) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haloperidol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0073" title="MaceCF , BlumNJ , SierpBJ , DelaneyBA , MaukJE . Differential response of operant self-Injury to pharmacologic versus behavioral treatment. Journal of Developmental &amp; Behavioral Pediatrics2001;22(2):85-91. [DOI: 10.1097/00004703-200104000-00001] [PMID: 11332784]">Mace 2001</a> (n = 7) </p> <p><a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a> (n = 36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lurasidone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0071" title="LoebelA , BramsM , GoldmanRS , SilvaR , HernandezD , DengL , et al. Lurasidone for the treatment of irritability associated with autistic disorder. Journal of Autism and Developmental Disorders2016;46(4):1153-63. [DOI: 10.1007/s10803-015-2628-x] [PMCID: PMC4786592] [PMID: 26659550]NCT01911442. Lurasidone pediatric autism study. https://clinicaltrials.gov/ct2/show/results/NCT01911442?term=NCT01911442&amp;draw=2&amp;rank=1 (first received July 2013). ">Loebel 2016</a> (n = 148) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Olanzapine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0054" title="HollanderE , WassermanS , SwansonEN , ChaplinW , SchapiroML , ZagurskyK , et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology2006;16(5):541-8. [DOI: 10.1089/cap.2006.16.541] [PMID: 17069543]">Hollander 2006b</a> (n = 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0076" title="MaloneRP , CaterJ , SheikhRM , ChoudhuryMS , DelaneyMA . Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(8):887-94. [DOI: 10.1097/00004583-200108000-00009] [PMID: 11501687]">Malone 2001</a> (n = 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risperidone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0062" title="KentJM , KushnerS , NingX , KarcherK , NessS , AmanM , et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind placebo-controlled study. Journal of Autism and Developmental Disorders2013;43(8):1773-83. [DOI: 10.1007/s10803-012-1723-5] [PMID: 23212807]NCT00576732. A study of the effectiveness and safety of two doses of risperidone in the treatment of children and adolescents with autistic disorder [Risperidone in the treatment of children and adolescents with autistic disorder: a double-blind, placebo-controlled study of efficacy and safety, followed by an open-label extension study of safety]. clinicaltrials.gov/ct2/show/NCT00576732 (first received 19 December 2007). ">Kent 2013</a> (n = 66) </p> <p><a href="./references#CD011769-bbs2-0072" title="LubyJ , MrakotskyC , StaletsMM , BeldenA , HeffelfingerA , WilliamsM , et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. Journal of Child and Adolescent Psychopharmacology2006;16(5):575-87. [DOI: 10.1089/cap.2006.16.575] [PMID: 17069546]">Luby 2006</a> (n = 23) </p> <p><a href="./references#CD011769-bbs2-0078" title="AmanM , RettigantiM , NagarajaHN , HollwayJA , McCrackenJ , McDougleCJ , et al. Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(6):482-93. [DOI: 10.1089/cap.2015.0005] [PMCID: PMC4545698] [PMID: 26262903]AmanMG , ArnoldLE , McDougleCJ , VitielloB , ScahillL , DaviesMD , et al. Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology2005;15(6):869-84. [DOI: 10.1089/cap.2005.15.869] [PMID: 16379507]AmanMG , HollwayJA , McDougleCJ , ScahillL , TierneyE , McCrackenJT , et al. Cognitive effects of risperidone in children with autism and irritable behavior. Journal of Child and Adolescent Psychopharmacology2008;18(3):227-36. [DOI: 10.1089/cap.2007.0133] [PMCID: PMC2935828] [PMID: 18582177]ArnoldLE , AmanMG , MartinA , Collier-CrespinA , VitielloB , TierneyE , et al. Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology. Journal of Autism and Developmental Disorders2000;30(2):99-111. [DOI: 10.1023/a:1005451304303] [PMID: 10832774]ArnoldLE , FarmerC , KraemerHC , DaviesM , WitwerA , ChuangS , et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. Journal of Child &amp; Adolescent Psychopharmacology2010;20(2):83-93. [DOI: 10.1089/cap.2009.0022] [PMCID: PMC2865212] [PMID: 20415603]ArnoldLE , VitielloB , McDougleC , ScahillL , ShahB , GonzalezNM , et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(12):1443-50. [DOI: 10.1097/00004583-200312000-00011] [PMID: 14627879]CaicedoC , WilliamsSH . Risperidone improves behavior in children with autism. Journal of Family Practice2002;51(11):915. [PMID: 12485538]FombonneE . Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents. Evidence-Based Mental Health2006;9(1):6. [DOI: 10.1136/ebmh.9.1.6] [PMID: 16436546]LevineSZ , KodeshA , GoldbergY , ReichenbergA , FurukawaTA , KolevzonA , et al. Initial severity and efficacy of risperidone in autism: results from the RUPP trial. European Psychiatry2016;32:16-20. [DOI: 10.1016/j.eurpsy.2015.11.004] [PMID: 26802979]McCrackenJT , McGoughJ , ShahB , CroninP , HongD , AmanMG , et al. Risperidone in children with autism and serious behavioural problems. New England journal of medicine2002;347(5):314-21. [DOI: 10.1056/NEJMoa013171] [PMID: 12151468]McDougleC , AmanM , McCrackenJ , ScahillL , TierneyE , VitielloB . A double-blind placebo-controlled trial of risperidone in autistic disorder. European Neuropsychopharmacology2003;13:S327-8. [DOI: 10.1016/S0924-977X(03)92062-1] [POSTER NO: P.2.109]McDougleCJ , ScahillL , AmanMG , McCrackenJT , TierneyE , DaviesM , et al. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry2005;16(2):1142-8. [DOI: 10.1176/appi.ajp.162.6.1142] [PMID: 15930063]NCT00005014. Treatment of autism in children and adolescents [Placebo-controlled study of risperidone for the treatment of children and adolescents with autism and negative behavioral symptoms]. www.clinicaltrials.gov/ct2/show/NCT00005014 (first received 3 April 2000). Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry2005;162(7):1361-9. [DOI: 10.1176/appi.ajp.162.7.1361] [PMID: 15994720]ScahillL , HallettV , AmanMG , McDougleCJ , ArnoldLE , McCrackenJT , et al. Brief report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. Journal of Autism and Developmental Disorders2013;43(3):739-46. [DOI: 10.1007/s10803-012-1689-3] [PMCID: PMC3886122] [PMID: 23104617]ScahillL , Koenig, CarrollDH , PachlerM . Risperidone approved for the treatment of serious behavioral problems in children with autism. Journal of Child &amp; Adolescent Psychiatric Nursing2007;20(3):188-90. [DOI: 10.1111/j.1744-6171.2007.00112.x] [PMID: 17688557]Study of risperidone with autistic children finds no detrimental cognitive effects. Brown University Child &amp; Adolescent Psychopharmacology Update2008;10(9):3. [DOI: 10.1002/cpu.20075]WilliamsSK , ScahillL , VitielloB , AmanMG , ArnoldLE , McDougleCJ , et al. Risperidone and adaptive behavior in children with autism. Journal of the American Academy of Child &amp; Adolescent Psychiatry2006;45(4):431-9. [DOI: 10.1097/01.chi.0000196423.80717.32] [PMID: 16601648]">McCracken 2002</a> (n = 101) </p> <p><a href="./references#CD011769-bbs2-0080" title="McDougleCJ , HolmesJP , CarlsonDC , PeltonGH , CohenDJ , PriceLH . A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry1998;55(7):633-41. [DOI: 10.1001/archpsyc.55.7.633] [PMID: 9672054]">McDougle 1998</a> (n = 31) </p> <p><a href="./references#CD011769-bbs2-0110" title="Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment for autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry2005;162(7):1361-9. [DOI: 10.1176/appi.ajp.162.7.1361] [PMID: 15994720]">Research Units 2005</a> (n = 32) </p> <p><a href="./references#CD011769-bbs2-0093" title="NCT01624675. A study to evaluate the efficacy and safety of risperidone (R064766) in children and adolescents with irritability associated with autistic disorder [A double-blind, placebo-controlled study, followed by an open-label extension study evaluating the efficacy and safety of risperidone (r064766) in children and adolescents with irritability associated with autistic disorder]. clinicaltrials.gov/ct2/show/NCT01624675 (first received 21 June 2012). ">NCT01624675</a> (n = 39) </p> <p><a href="./references#CD011769-bbs2-0113" title="LightM , DunbarE , SheaS . P2.104 Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. European Neuropsychopharmacology2004;14(Suppl 3):S278. [DOI: 10.1016/S0924-977X(04)80324-9]LightM , DunbarF , SheaM . Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. International Journal of Neuropsychopharmacology2004;7:S275. [DOI: 10.1016/S0924-977X(04)80324-9]PandinaGJ , BossieCA , YoussefE , ZhuY , DunbarF . Risperidone improves behavioural symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders2007;37(2):367-73. [DOI: 10.1007/s10803-006-0234-7] [PMID: 17019624]SheaS , TurgayA , CarrollA , SchulzM , OrlikH , SmithI , et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics2004;114(5):e634-41. [DOI: 10.1542/peds.2003-0264-F] [PMID: 15492353]">Shea 2004</a> (n = 79) </p> <p><a href="./references#CD011769-bbs2-0120" title="MaloneRP . Discontinuing risperidone results in relapse in children with autism spectrum disorders. Evidence-Based Mental Health2006;9(2):56. [DOI: 10.1136/ebmh.9.2.56] [PMID: 16638905]TroostPW , AlthausM , LahuisBE , BuitelaarJK , MinderaaRB , HoekstraPJ . Neuropsychological effect of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. Journal of Child and Adolescent Psychopharmacology2006;16(5):561-73. [DOI: 10.1089/cap.2006.16.561] [PMID: 17069545]TroostPW , LahuisBE , Steenhuis M-P, KetelaarsCE , BuitelaarJK , Van EngelandH , et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(11):1137-44. [DOI: 10.1097/01.chi.0000177055.11229.76] [PMID: 16239862]">Troost 2005</a> (n = 24) </p> <p>8 studies (n = 395)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0082" title="MiralS , GencerO , Inal-EmirogluFN , BaykaraB , BaykaraA , DirikE . Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. European Child &amp; Adolescent Psychiatry2008;17(1):1-8. [DOI: 10.1007/s00787-007-0620-5] [PMID: 18080171]">Miral 2008</a> (n = 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0101" title="IRCT201204037202N5. Comparing efficacy and side effects of memantine and risperidone in treating autistic patients. www.irct.ir/trial/7627 (first received 20 June 2012). NikvarzN , Alaghband-RadJ , Tehrani-DoostM , AlimadadiA , GhaeliP . Comparing efficacy and side effects of memantine vs risperidone in the treatment of autistic disorder. Pharmacopsychiatry2017;50(1):19-25. [DOI: 10.1055/s-0042-108449] [PMID: 27299475]">Nikvarz 2017</a> (n = 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>n:</b> number of participants </p> </div> </div> <p> <ul id="CD011769-list-0015"> <li> <p>Interventions: 16 studies compared an atypical antipsychotic to a placebo, two studies compared one atypical antipsychotic to another atypical antipsychotic, two studies compared a typical antipsychotic to a placebo, and two studies compared an atypical antipsychotic to a typical antipsychotic. A further two studies compared an atypical antipsychotic to an anti‐dementia drug and an atypical antipsychotic to an antiparkinsonian drug, respectively. Further information can be found in <a href="#CD011769-tbl-0007">Table 3</a>. </p> </li> <li> <p>Setting: most (17) of the studies were conducted in the USA apart from <a href="./references#CD011769-bbs2-0036" title="GhanizadehA , SahraeizadehA , BerkM . A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development2014;45(2):185-92. [DOI: 10.1007/s10578-013-0390-x] [PMID: 23801256]IRCT201110233930N15. Aripiprazole versus risperidone for treatment of autism. www.irct.ir/trial/4094 (first received 12 December 2011). ">Ghanizadeh 2014</a>; and <a href="./references#CD011769-bbs2-0101" title="IRCT201204037202N5. Comparing efficacy and side effects of memantine and risperidone in treating autistic patients. www.irct.ir/trial/7627 (first received 20 June 2012). NikvarzN , Alaghband-RadJ , Tehrani-DoostM , AlimadadiA , GhaeliP . Comparing efficacy and side effects of memantine vs risperidone in the treatment of autistic disorder. Pharmacopsychiatry2017;50(1):19-25. [DOI: 10.1055/s-0042-108449] [PMID: 27299475]">Nikvarz 2017</a>, which were conducted in Iran, <a href="./references#CD011769-bbs2-0059" title="IchikawaH , MikamiK , OkadaT , YamashitaY , IshizakiY , TomodaA , et al. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study. Child Psychiatry &amp; Human Development2017;48(5):796-806. [DOI: 10.1007/s10578-016-0704-x] [PMCID: PMC5617873] [PMID: 28004215]NCT01617447. A short treatment study of aripiprazole in pediatric patients with autistic disorder [A short-term administration study of aripiprazole in children and adolescents (age: 6 to 17 years) with autistic disorder]. clinicaltrials.gov/ct2/show/NCT01617447 (first received 12 June 2012). ">Ichikawa 2017</a> and <a href="./references#CD011769-bbs2-0093" title="NCT01624675. A study to evaluate the efficacy and safety of risperidone (R064766) in children and adolescents with irritability associated with autistic disorder [A double-blind, placebo-controlled study, followed by an open-label extension study evaluating the efficacy and safety of risperidone (r064766) in children and adolescents with irritability associated with autistic disorder]. clinicaltrials.gov/ct2/show/NCT01624675 (first received 21 June 2012). ">NCT01624675</a> in Japan, <a href="./references#CD011769-bbs2-0082" title="MiralS , GencerO , Inal-EmirogluFN , BaykaraB , BaykaraA , DirikE . Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. European Child &amp; Adolescent Psychiatry2008;17(1):1-8. [DOI: 10.1007/s00787-007-0620-5] [PMID: 18080171]">Miral 2008</a> in Turkey, <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a> in Canada, and <a href="./references#CD011769-bbs2-0026" title="DollfusS , PetitM , MenardJF , LesieurP . Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. Journal of Autism and Developmental Disorders1992;22(1):47-60. [DOI: 10.1007/BF01046402] [PMID: 1350581]DollfusS , PetitP , MenardJF . Pharmacoclinical study of an agonist and an antagonist of dopamine in early infantile autism. Neuropsychiatrie de l'Enfance et de l'Adolescence1992;40(5-6):300-309. ">Dollfus 1992</a> in France. </p> </li> <li> <p>Inclusion criteria: all studies required a clinical diagnosis of ASD and some studies (<a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a>; <a href="./references#CD011769-bbs2-0059" title="IchikawaH , MikamiK , OkadaT , YamashitaY , IshizakiY , TomodaA , et al. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study. Child Psychiatry &amp; Human Development2017;48(5):796-806. [DOI: 10.1007/s10578-016-0704-x] [PMCID: PMC5617873] [PMID: 28004215]NCT01617447. A short treatment study of aripiprazole in pediatric patients with autistic disorder [A short-term administration study of aripiprazole in children and adolescents (age: 6 to 17 years) with autistic disorder]. clinicaltrials.gov/ct2/show/NCT01617447 (first received 12 June 2012). ">Ichikawa 2017</a>; <a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a>; <a href="./references#CD011769-bbs2-0078" title="AmanM , RettigantiM , NagarajaHN , HollwayJA , McCrackenJ , McDougleCJ , et al. Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(6):482-93. [DOI: 10.1089/cap.2015.0005] [PMCID: PMC4545698] [PMID: 26262903]AmanMG , ArnoldLE , McDougleCJ , VitielloB , ScahillL , DaviesMD , et al. Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology2005;15(6):869-84. [DOI: 10.1089/cap.2005.15.869] [PMID: 16379507]AmanMG , HollwayJA , McDougleCJ , ScahillL , TierneyE , McCrackenJT , et al. Cognitive effects of risperidone in children with autism and irritable behavior. Journal of Child and Adolescent Psychopharmacology2008;18(3):227-36. [DOI: 10.1089/cap.2007.0133] [PMCID: PMC2935828] [PMID: 18582177]ArnoldLE , AmanMG , MartinA , Collier-CrespinA , VitielloB , TierneyE , et al. Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology. Journal of Autism and Developmental Disorders2000;30(2):99-111. [DOI: 10.1023/a:1005451304303] [PMID: 10832774]ArnoldLE , FarmerC , KraemerHC , DaviesM , WitwerA , ChuangS , et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. Journal of Child &amp; Adolescent Psychopharmacology2010;20(2):83-93. [DOI: 10.1089/cap.2009.0022] [PMCID: PMC2865212] [PMID: 20415603]ArnoldLE , VitielloB , McDougleC , ScahillL , ShahB , GonzalezNM , et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(12):1443-50. [DOI: 10.1097/00004583-200312000-00011] [PMID: 14627879]CaicedoC , WilliamsSH . Risperidone improves behavior in children with autism. Journal of Family Practice2002;51(11):915. [PMID: 12485538]FombonneE . Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents. Evidence-Based Mental Health2006;9(1):6. [DOI: 10.1136/ebmh.9.1.6] [PMID: 16436546]LevineSZ , KodeshA , GoldbergY , ReichenbergA , FurukawaTA , KolevzonA , et al. Initial severity and efficacy of risperidone in autism: results from the RUPP trial. European Psychiatry2016;32:16-20. [DOI: 10.1016/j.eurpsy.2015.11.004] [PMID: 26802979]McCrackenJT , McGoughJ , ShahB , CroninP , HongD , AmanMG , et al. Risperidone in children with autism and serious behavioural problems. New England journal of medicine2002;347(5):314-21. [DOI: 10.1056/NEJMoa013171] [PMID: 12151468]McDougleC , AmanM , McCrackenJ , ScahillL , TierneyE , VitielloB . A double-blind placebo-controlled trial of risperidone in autistic disorder. European Neuropsychopharmacology2003;13:S327-8. [DOI: 10.1016/S0924-977X(03)92062-1] [POSTER NO: P.2.109]McDougleCJ , ScahillL , AmanMG , McCrackenJT , TierneyE , DaviesM , et al. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry2005;16(2):1142-8. [DOI: 10.1176/appi.ajp.162.6.1142] [PMID: 15930063]NCT00005014. Treatment of autism in children and adolescents [Placebo-controlled study of risperidone for the treatment of children and adolescents with autism and negative behavioral symptoms]. www.clinicaltrials.gov/ct2/show/NCT00005014 (first received 3 April 2000). Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry2005;162(7):1361-9. [DOI: 10.1176/appi.ajp.162.7.1361] [PMID: 15994720]ScahillL , HallettV , AmanMG , McDougleCJ , ArnoldLE , McCrackenJT , et al. Brief report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. Journal of Autism and Developmental Disorders2013;43(3):739-46. [DOI: 10.1007/s10803-012-1689-3] [PMCID: PMC3886122] [PMID: 23104617]ScahillL , Koenig, CarrollDH , PachlerM . Risperidone approved for the treatment of serious behavioral problems in children with autism. Journal of Child &amp; Adolescent Psychiatric Nursing2007;20(3):188-90. [DOI: 10.1111/j.1744-6171.2007.00112.x] [PMID: 17688557]Study of risperidone with autistic children finds no detrimental cognitive effects. Brown University Child &amp; Adolescent Psychopharmacology Update2008;10(9):3. [DOI: 10.1002/cpu.20075]WilliamsSK , ScahillL , VitielloB , AmanMG , ArnoldLE , McDougleCJ , et al. Risperidone and adaptive behavior in children with autism. Journal of the American Academy of Child &amp; Adolescent Psychiatry2006;45(4):431-9. [DOI: 10.1097/01.chi.0000196423.80717.32] [PMID: 16601648]">McCracken 2002</a>), also required co‐occurring behaviours of concern such as aggression, agitation, irritability, or self‐injury to be assessed at baseline. </p> </li> <li> <p>Exclusion criteria: all studies excluded people with other DSM diagnoses or neurological disorders including schizophrenia, pervasive developmental disorder not otherwise specified (PDD‐NOS), Rett syndrome, psychosis, unstable seizure disorders, or other significant cardiac, renal or endocrine disorders. Some studies also excluded people who had previously been treated with the intervention or interventions of interest. </p> </li> <li> <p>Participant intellectual ability: the intellectual ability of participants varied between trials, with some trials not providing specific details (<a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a>; <a href="./references#CD011769-bbs2-0062" title="KentJM , KushnerS , NingX , KarcherK , NessS , AmanM , et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind placebo-controlled study. Journal of Autism and Developmental Disorders2013;43(8):1773-83. [DOI: 10.1007/s10803-012-1723-5] [PMID: 23212807]NCT00576732. A study of the effectiveness and safety of two doses of risperidone in the treatment of children and adolescents with autistic disorder [Risperidone in the treatment of children and adolescents with autistic disorder: a double-blind, placebo-controlled study of efficacy and safety, followed by an open-label extension study of safety]. clinicaltrials.gov/ct2/show/NCT00576732 (first received 19 December 2007). ">Kent 2013</a>). Most studies required participants to have a mental age of at least 18 months. Some studies included up to 83% of participants with an intellectual disability of varying severity (<a href="./references#CD011769-bbs2-0059" title="IchikawaH , MikamiK , OkadaT , YamashitaY , IshizakiY , TomodaA , et al. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study. Child Psychiatry &amp; Human Development2017;48(5):796-806. [DOI: 10.1007/s10578-016-0704-x] [PMCID: PMC5617873] [PMID: 28004215]NCT01617447. A short treatment study of aripiprazole in pediatric patients with autistic disorder [A short-term administration study of aripiprazole in children and adolescents (age: 6 to 17 years) with autistic disorder]. clinicaltrials.gov/ct2/show/NCT01617447 (first received 12 June 2012). ">Ichikawa 2017</a>; <a href="./references#CD011769-bbs2-0076" title="MaloneRP , CaterJ , SheikhRM , ChoudhuryMS , DelaneyMA . Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(8):887-94. [DOI: 10.1097/00004583-200108000-00009] [PMID: 11501687]">Malone 2001</a>; <a href="./references#CD011769-bbs2-0078" title="AmanM , RettigantiM , NagarajaHN , HollwayJA , McCrackenJ , McDougleCJ , et al. Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(6):482-93. [DOI: 10.1089/cap.2015.0005] [PMCID: PMC4545698] [PMID: 26262903]AmanMG , ArnoldLE , McDougleCJ , VitielloB , ScahillL , DaviesMD , et al. Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology2005;15(6):869-84. [DOI: 10.1089/cap.2005.15.869] [PMID: 16379507]AmanMG , HollwayJA , McDougleCJ , ScahillL , TierneyE , McCrackenJT , et al. Cognitive effects of risperidone in children with autism and irritable behavior. Journal of Child and Adolescent Psychopharmacology2008;18(3):227-36. [DOI: 10.1089/cap.2007.0133] [PMCID: PMC2935828] [PMID: 18582177]ArnoldLE , AmanMG , MartinA , Collier-CrespinA , VitielloB , TierneyE , et al. Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology. Journal of Autism and Developmental Disorders2000;30(2):99-111. [DOI: 10.1023/a:1005451304303] [PMID: 10832774]ArnoldLE , FarmerC , KraemerHC , DaviesM , WitwerA , ChuangS , et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. Journal of Child &amp; Adolescent Psychopharmacology2010;20(2):83-93. [DOI: 10.1089/cap.2009.0022] [PMCID: PMC2865212] [PMID: 20415603]ArnoldLE , VitielloB , McDougleC , ScahillL , ShahB , GonzalezNM , et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(12):1443-50. [DOI: 10.1097/00004583-200312000-00011] [PMID: 14627879]CaicedoC , WilliamsSH . Risperidone improves behavior in children with autism. Journal of Family Practice2002;51(11):915. [PMID: 12485538]FombonneE . Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents. Evidence-Based Mental Health2006;9(1):6. [DOI: 10.1136/ebmh.9.1.6] [PMID: 16436546]LevineSZ , KodeshA , GoldbergY , ReichenbergA , FurukawaTA , KolevzonA , et al. Initial severity and efficacy of risperidone in autism: results from the RUPP trial. European Psychiatry2016;32:16-20. [DOI: 10.1016/j.eurpsy.2015.11.004] [PMID: 26802979]McCrackenJT , McGoughJ , ShahB , CroninP , HongD , AmanMG , et al. Risperidone in children with autism and serious behavioural problems. New England journal of medicine2002;347(5):314-21. [DOI: 10.1056/NEJMoa013171] [PMID: 12151468]McDougleC , AmanM , McCrackenJ , ScahillL , TierneyE , VitielloB . A double-blind placebo-controlled trial of risperidone in autistic disorder. European Neuropsychopharmacology2003;13:S327-8. [DOI: 10.1016/S0924-977X(03)92062-1] [POSTER NO: P.2.109]McDougleCJ , ScahillL , AmanMG , McCrackenJT , TierneyE , DaviesM , et al. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry2005;16(2):1142-8. [DOI: 10.1176/appi.ajp.162.6.1142] [PMID: 15930063]NCT00005014. Treatment of autism in children and adolescents [Placebo-controlled study of risperidone for the treatment of children and adolescents with autism and negative behavioral symptoms]. www.clinicaltrials.gov/ct2/show/NCT00005014 (first received 3 April 2000). Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry2005;162(7):1361-9. [DOI: 10.1176/appi.ajp.162.7.1361] [PMID: 15994720]ScahillL , HallettV , AmanMG , McDougleCJ , ArnoldLE , McCrackenJT , et al. Brief report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. Journal of Autism and Developmental Disorders2013;43(3):739-46. [DOI: 10.1007/s10803-012-1689-3] [PMCID: PMC3886122] [PMID: 23104617]ScahillL , Koenig, CarrollDH , PachlerM . Risperidone approved for the treatment of serious behavioral problems in children with autism. Journal of Child &amp; Adolescent Psychiatric Nursing2007;20(3):188-90. [DOI: 10.1111/j.1744-6171.2007.00112.x] [PMID: 17688557]Study of risperidone with autistic children finds no detrimental cognitive effects. Brown University Child &amp; Adolescent Psychopharmacology Update2008;10(9):3. [DOI: 10.1002/cpu.20075]WilliamsSK , ScahillL , VitielloB , AmanMG , ArnoldLE , McDougleCJ , et al. Risperidone and adaptive behavior in children with autism. Journal of the American Academy of Child &amp; Adolescent Psychiatry2006;45(4):431-9. [DOI: 10.1097/01.chi.0000196423.80717.32] [PMID: 16601648]">McCracken 2002</a>; <a href="./references#CD011769-bbs2-0113" title="LightM , DunbarE , SheaS . P2.104 Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. European Neuropsychopharmacology2004;14(Suppl 3):S278. [DOI: 10.1016/S0924-977X(04)80324-9]LightM , DunbarF , SheaM . Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. International Journal of Neuropsychopharmacology2004;7:S275. [DOI: 10.1016/S0924-977X(04)80324-9]PandinaGJ , BossieCA , YoussefE , ZhuY , DunbarF . Risperidone improves behavioural symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders2007;37(2):367-73. [DOI: 10.1007/s10803-006-0234-7] [PMID: 17019624]SheaS , TurgayA , CarrollA , SchulzM , OrlikH , SmithI , et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics2004;114(5):e634-41. [DOI: 10.1542/peds.2003-0264-F] [PMID: 15492353]">Shea 2004</a>). </p> </li> <li> <p>Concomitant medications: most studies required participants to cease taking all psychotropic medications before commencing in the trial except for <a href="./references#CD011769-bbs2-0029" title="FindlingRL , MankoskiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22-30. [DOI: 10.4088/JCP.13m08500] [PMID: 24502859]NCT01227668. Phase IV long-term maintenance study of aripiprazole in the treatment of irritability associated with autistic disorder. https://clinicaltrials.gov/ct2/show/NCT01227668?term=NCT01227668&amp;draw=2&amp;rank=1 (first received October 2010). ">Findling 2014</a>, which allowed the use of sleep medications, <a href="./references#CD011769-bbs2-0120" title="MaloneRP . Discontinuing risperidone results in relapse in children with autism spectrum disorders. Evidence-Based Mental Health2006;9(2):56. [DOI: 10.1136/ebmh.9.2.56] [PMID: 16638905]TroostPW , AlthausM , LahuisBE , BuitelaarJK , MinderaaRB , HoekstraPJ . Neuropsychological effect of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. Journal of Child and Adolescent Psychopharmacology2006;16(5):561-73. [DOI: 10.1089/cap.2006.16.561] [PMID: 17069545]TroostPW , LahuisBE , Steenhuis M-P, KetelaarsCE , BuitelaarJK , Van EngelandH , et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(11):1137-44. [DOI: 10.1097/01.chi.0000177055.11229.76] [PMID: 16239862]">Troost 2005</a>, which allowed stimulant use for co‐occurring ADHD, and <a href="./references#CD011769-bbs2-0110" title="Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment for autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry2005;162(7):1361-9. [DOI: 10.1176/appi.ajp.162.7.1361] [PMID: 15994720]">Research Units 2005</a> and <a href="./references#CD011769-bbs2-0054" title="HollanderE , WassermanS , SwansonEN , ChaplinW , SchapiroML , ZagurskyK , et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology2006;16(5):541-8. [DOI: 10.1089/cap.2006.16.541] [PMID: 17069543]">Hollander 2006b</a>, both of which allowed anticonvulsants for participants with stable epilepsy. </p> </li> </ul> </p> <section id="CD011769-sec-0075"> <p><b>Interventions</b></p> <p> <ul id="CD011769-list-0016"> <li> <p>Amisulpride: one study compared amisulpride to an antiparkinsonian (bromocriptine; <a href="./references#CD011769-bbs2-0026" title="DollfusS , PetitM , MenardJF , LesieurP . Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. Journal of Autism and Developmental Disorders1992;22(1):47-60. [DOI: 10.1007/BF01046402] [PMID: 1350581]DollfusS , PetitP , MenardJF . Pharmacoclinical study of an agonist and an antagonist of dopamine in early infantile autism. Neuropsychiatrie de l'Enfance et de l'Adolescence1992;40(5-6):300-309. ">Dollfus 1992</a>). Further details are provided below. </p> </li> <li> <p>Aripiprazole: eight studies compared aripiprazole to a placebo or another atypical antipsychotic. Most studies administered the doses once daily in either a fixed or flexibly‐dosed manner to a maximum of 15 mg/day. The mean daily dose of aripiprazole was between 0.172 mg/day and 0.354 mg/kg/day. </p> </li> <li> <p>Lurasidone: one study compared lurasidone to a placebo (<a href="./references#CD011769-bbs2-0071" title="LoebelA , BramsM , GoldmanRS , SilvaR , HernandezD , DengL , et al. Lurasidone for the treatment of irritability associated with autistic disorder. Journal of Autism and Developmental Disorders2016;46(4):1153-63. [DOI: 10.1007/s10803-015-2628-x] [PMCID: PMC4786592] [PMID: 26659550]NCT01911442. Lurasidone pediatric autism study. https://clinicaltrials.gov/ct2/show/results/NCT01911442?term=NCT01911442&amp;draw=2&amp;rank=1 (first received July 2013). ">Loebel 2016</a>). Participants received either 20 mg or 60 mg once daily. </p> </li> <li> <p>Olanzapine: two studies compared olanzapine to a placebo (<a href="./references#CD011769-bbs2-0054" title="HollanderE , WassermanS , SwansonEN , ChaplinW , SchapiroML , ZagurskyK , et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology2006;16(5):541-8. [DOI: 10.1089/cap.2006.16.541] [PMID: 17069543]">Hollander 2006b</a>), or a typical antipsychotic (<a href="./references#CD011769-bbs2-0076" title="MaloneRP , CaterJ , SheikhRM , ChoudhuryMS , DelaneyMA . Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(8):887-94. [DOI: 10.1097/00004583-200108000-00009] [PMID: 11501687]">Malone 2001</a>). Participants who weighed less than 40 kg received a maximum of 2.5 mg of olanzapine once daily, and children 40 kg or heavier received a maximum of 5 mg of olanzapine once daily (<a href="./references#CD011769-bbs2-0054" title="HollanderE , WassermanS , SwansonEN , ChaplinW , SchapiroML , ZagurskyK , et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology2006;16(5):541-8. [DOI: 10.1089/cap.2006.16.541] [PMID: 17069543]">Hollander 2006b</a>). <a href="./references#CD011769-bbs2-0076" title="MaloneRP , CaterJ , SheikhRM , ChoudhuryMS , DelaneyMA . Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(8):887-94. [DOI: 10.1097/00004583-200108000-00009] [PMID: 11501687]">Malone 2001</a> administered olanzapine at 2.5 mg every second day for children who weighed 40 kg or less, and 2.5 mg once daily for children 41 kg and above with a maximum daily dose of 5 mg. </p> </li> <li> <p>Risperidone: a total of 10 studies compared risperidone to a placebo or other treatment. Nine studies compared risperidone to a placebo, one study (<a href="./references#CD011769-bbs2-0101" title="IRCT201204037202N5. Comparing efficacy and side effects of memantine and risperidone in treating autistic patients. www.irct.ir/trial/7627 (first received 20 June 2012). NikvarzN , Alaghband-RadJ , Tehrani-DoostM , AlimadadiA , GhaeliP . Comparing efficacy and side effects of memantine vs risperidone in the treatment of autistic disorder. Pharmacopsychiatry2017;50(1):19-25. [DOI: 10.1055/s-0042-108449] [PMID: 27299475]">Nikvarz 2017</a>), compared risperidone to an antidementia medication, and one study compared risperidone to haloperidol (<a href="./references#CD011769-bbs2-0082" title="MiralS , GencerO , Inal-EmirogluFN , BaykaraB , BaykaraA , DirikE . Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. European Child &amp; Adolescent Psychiatry2008;17(1):1-8. [DOI: 10.1007/s00787-007-0620-5] [PMID: 18080171]">Miral 2008</a>). Apart from the two discontinuation studies that required the intervention to be administered twice daily, doses were administered once daily. Mean daily dosage of risperidone for children who weighed less than 40 kg was 1.58 mg/day, 2.27 mg/day for children 40 kg or heavier, and 3.25 mg/day for adults. </p> </li> <li> <p>Haloperidol: two studies (<a href="./references#CD011769-bbs2-0073" title="MaceCF , BlumNJ , SierpBJ , DelaneyBA , MaukJE . Differential response of operant self-Injury to pharmacologic versus behavioral treatment. Journal of Developmental &amp; Behavioral Pediatrics2001;22(2):85-91. [DOI: 10.1097/00004703-200104000-00001] [PMID: 11332784]">Mace 2001</a>; <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a>), compared haloperidol (a typical antipsychotic) to a placebo. Both studies administered haloperidol two to three times daily, however, <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a> used fixed doses (mean daily dose of 1.3 mg) while <a href="./references#CD011769-bbs2-0073" title="MaceCF , BlumNJ , SierpBJ , DelaneyBA , MaukJE . Differential response of operant self-Injury to pharmacologic versus behavioral treatment. Journal of Developmental &amp; Behavioral Pediatrics2001;22(2):85-91. [DOI: 10.1097/00004703-200104000-00001] [PMID: 11332784]">Mace 2001</a> initiated haloperidol at 0.25 mg/day for children who weighed 40 kg or less, and 0.5 mg/day for children who weighed 40 kg or more up to a maximum of 5 mg/day (mean daily dose 1.4 mg). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0076"> <p><b>Comparator</b></p> <p> <ul id="CD011769-list-0017"> <li> <p>Placebo: the majority of antipsychotic studies compared to a placebo, however, apart from <a href="./references#CD011769-bbs2-0090" title="NCT00468130. Efficacy of aripiprazole versus placebo in the reduction of aggressive and aberrant behavior in autistic children (Abilify) [Efficacy of aripiprazole versus placebo in the reduction of aggressive and aberrant behavior in autistic children]. clinicaltrials.gov/ct2/show/NCT00468130 (first received 2 May 2007). ">NCT00468130</a>, which used sugar pills, the study authors did not provide details regarding the ingredients of the placebo. </p> </li> <li> <p>Haloperidol: two studies (<a href="./references#CD011769-bbs2-0076" title="MaloneRP , CaterJ , SheikhRM , ChoudhuryMS , DelaneyMA . Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(8):887-94. [DOI: 10.1097/00004583-200108000-00009] [PMID: 11501687]">Malone 2001</a>; <a href="./references#CD011769-bbs2-0082" title="MiralS , GencerO , Inal-EmirogluFN , BaykaraB , BaykaraA , DirikE . Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. European Child &amp; Adolescent Psychiatry2008;17(1):1-8. [DOI: 10.1007/s00787-007-0620-5] [PMID: 18080171]">Miral 2008</a>), compared an atypical antipsychotic (olanzapine and risperidone respectively) to haloperidol. Mean dose of haloperidol was 1.4 mg/day to 2.6 mg/day. Haloperidol was given up to twice daily. </p> </li> <li> <p>Bromocriptine: one study (<a href="./references#CD011769-bbs2-0026" title="DollfusS , PetitM , MenardJF , LesieurP . Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. Journal of Autism and Developmental Disorders1992;22(1):47-60. [DOI: 10.1007/BF01046402] [PMID: 1350581]DollfusS , PetitP , MenardJF . Pharmacoclinical study of an agonist and an antagonist of dopamine in early infantile autism. Neuropsychiatrie de l'Enfance et de l'Adolescence1992;40(5-6):300-309. ">Dollfus 1992</a>), compared amisulpride to bromocriptine. Bromocriptine was administered at 0.15 mg/kg/day to 0.20 mg/kg/day for all participants. </p> </li> </ul> </p> </section> <section id="CD011769-sec-0077"> <p><b>Primary outcomes</b></p> <p> <ul id="CD011769-list-0018"> <li> <p>Irritability: 16 of the studies reported irritability; the majority used the ABC‐I subscale (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>). The exceptions were <a href="./references#CD011769-bbs2-0080" title="McDougleCJ , HolmesJP , CarlsonDC , PeltonGH , CohenDJ , PriceLH . A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry1998;55(7):633-41. [DOI: 10.1001/archpsyc.55.7.633] [PMID: 9672054]">McDougle 1998</a> and <a href="./references#CD011769-bbs2-0082" title="MiralS , GencerO , Inal-EmirogluFN , BaykaraB , BaykaraA , DirikE . Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. European Child &amp; Adolescent Psychiatry2008;17(1):1-8. [DOI: 10.1007/s00787-007-0620-5] [PMID: 18080171]">Miral 2008</a>, which both used the Ritvo Freeman Real Life Rating Scale (RFRLRS; <a href="./references#CD011769-bbs2-0323" title="FreemanBJ , RitvoER , YokotaA , RitvoA . A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the American academy of child psychiatry1986;25(1):130-6. [DOI: 10.1016/S0002-7138(09)60610-5] [PMID: 3950262]">Freeman 1986</a>), to report irritability. </p> </li> <li> <p>Improvement and relapse: amongst those taking risperidone (<a href="./references#CD011769-bbs2-0062" title="KentJM , KushnerS , NingX , KarcherK , NessS , AmanM , et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind placebo-controlled study. Journal of Autism and Developmental Disorders2013;43(8):1773-83. [DOI: 10.1007/s10803-012-1723-5] [PMID: 23212807]NCT00576732. A study of the effectiveness and safety of two doses of risperidone in the treatment of children and adolescents with autistic disorder [Risperidone in the treatment of children and adolescents with autistic disorder: a double-blind, placebo-controlled study of efficacy and safety, followed by an open-label extension study of safety]. clinicaltrials.gov/ct2/show/NCT00576732 (first received 19 December 2007). ">Kent 2013</a>; <a href="./references#CD011769-bbs2-0078" title="AmanM , RettigantiM , NagarajaHN , HollwayJA , McCrackenJ , McDougleCJ , et al. Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(6):482-93. [DOI: 10.1089/cap.2015.0005] [PMCID: PMC4545698] [PMID: 26262903]AmanMG , ArnoldLE , McDougleCJ , VitielloB , ScahillL , DaviesMD , et al. Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology2005;15(6):869-84. [DOI: 10.1089/cap.2005.15.869] [PMID: 16379507]AmanMG , HollwayJA , McDougleCJ , ScahillL , TierneyE , McCrackenJT , et al. Cognitive effects of risperidone in children with autism and irritable behavior. Journal of Child and Adolescent Psychopharmacology2008;18(3):227-36. [DOI: 10.1089/cap.2007.0133] [PMCID: PMC2935828] [PMID: 18582177]ArnoldLE , AmanMG , MartinA , Collier-CrespinA , VitielloB , TierneyE , et al. Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology. Journal of Autism and Developmental Disorders2000;30(2):99-111. [DOI: 10.1023/a:1005451304303] [PMID: 10832774]ArnoldLE , FarmerC , KraemerHC , DaviesM , WitwerA , ChuangS , et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. Journal of Child &amp; Adolescent Psychopharmacology2010;20(2):83-93. [DOI: 10.1089/cap.2009.0022] [PMCID: PMC2865212] [PMID: 20415603]ArnoldLE , VitielloB , McDougleC , ScahillL , ShahB , GonzalezNM , et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(12):1443-50. [DOI: 10.1097/00004583-200312000-00011] [PMID: 14627879]CaicedoC , WilliamsSH . Risperidone improves behavior in children with autism. Journal of Family Practice2002;51(11):915. [PMID: 12485538]FombonneE . Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents. Evidence-Based Mental Health2006;9(1):6. [DOI: 10.1136/ebmh.9.1.6] [PMID: 16436546]LevineSZ , KodeshA , GoldbergY , ReichenbergA , FurukawaTA , KolevzonA , et al. Initial severity and efficacy of risperidone in autism: results from the RUPP trial. European Psychiatry2016;32:16-20. [DOI: 10.1016/j.eurpsy.2015.11.004] [PMID: 26802979]McCrackenJT , McGoughJ , ShahB , CroninP , HongD , AmanMG , et al. Risperidone in children with autism and serious behavioural problems. New England journal of medicine2002;347(5):314-21. [DOI: 10.1056/NEJMoa013171] [PMID: 12151468]McDougleC , AmanM , McCrackenJ , ScahillL , TierneyE , VitielloB . A double-blind placebo-controlled trial of risperidone in autistic disorder. European Neuropsychopharmacology2003;13:S327-8. [DOI: 10.1016/S0924-977X(03)92062-1] [POSTER NO: P.2.109]McDougleCJ , ScahillL , AmanMG , McCrackenJT , TierneyE , DaviesM , et al. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry2005;16(2):1142-8. [DOI: 10.1176/appi.ajp.162.6.1142] [PMID: 15930063]NCT00005014. Treatment of autism in children and adolescents [Placebo-controlled study of risperidone for the treatment of children and adolescents with autism and negative behavioral symptoms]. www.clinicaltrials.gov/ct2/show/NCT00005014 (first received 3 April 2000). Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry2005;162(7):1361-9. [DOI: 10.1176/appi.ajp.162.7.1361] [PMID: 15994720]ScahillL , HallettV , AmanMG , McDougleCJ , ArnoldLE , McCrackenJT , et al. Brief report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. Journal of Autism and Developmental Disorders2013;43(3):739-46. [DOI: 10.1007/s10803-012-1689-3] [PMCID: PMC3886122] [PMID: 23104617]ScahillL , Koenig, CarrollDH , PachlerM . Risperidone approved for the treatment of serious behavioral problems in children with autism. Journal of Child &amp; Adolescent Psychiatric Nursing2007;20(3):188-90. [DOI: 10.1111/j.1744-6171.2007.00112.x] [PMID: 17688557]Study of risperidone with autistic children finds no detrimental cognitive effects. Brown University Child &amp; Adolescent Psychopharmacology Update2008;10(9):3. [DOI: 10.1002/cpu.20075]WilliamsSK , ScahillL , VitielloB , AmanMG , ArnoldLE , McDougleCJ , et al. Risperidone and adaptive behavior in children with autism. Journal of the American Academy of Child &amp; Adolescent Psychiatry2006;45(4):431-9. [DOI: 10.1097/01.chi.0000196423.80717.32] [PMID: 16601648]">McCracken 2002</a>), or aripiprazole (<a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a>; <a href="./references#CD011769-bbs2-0102" title="EUCTR2016-005111-40. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A multicenter, double-blind, randomized, placebo-controlled, flexible-dosed parallel-group study of aripiprazole flexibly dosed in thetreatment of children and adolescents with autistic disorder]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-005111-40/results (first received 7 April 2017). LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of flexibly-dosed aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110-1. [DOI: 10.1002/ana.21853]LewisD , OwenR , CouchD . Efficacy and safety of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years): results from two 8-week randomized, double-blind, placebo-controlled trials. Neurology2009;72(11 (Supp 3)):A428. [ABSTRACT NO: S50.005]MankoskiR , StocktonG , ManosG , MarlorS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]NCT00365859. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A 52-week, open-label, multicenter study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder]. clinicaltrials.gov/ct2/show/NCT00365859 (first received 18 August 2006). OwenR , SikichL , MarcusRN , Corey-LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescent with autistic disorder. Pediatrics2009;124(6):1533-40. [DOI: 10.1542/peds.2008-3782] [PMID: 19948625]RobbAS , AnderssonC , BellocchioEE , ManosG , Rojas-FernandezC , MathewS , et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): results from a pooled analysis of 2 studies. Primary Care Companion for CNS Disorders2011;13(1):PCC.10m01008. [DOI: 10.4088/PCC.10m01008gry] [PMCID: PMC3121213] [PMID: 21731831]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. The effect of aripiprazole 2 to 15mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Owen 2009</a>), improvement was defined as a minimum of 25% improvement in ABC‐I (<a href="./references#CD011769-bbs2-0062" title="KentJM , KushnerS , NingX , KarcherK , NessS , AmanM , et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind placebo-controlled study. Journal of Autism and Developmental Disorders2013;43(8):1773-83. [DOI: 10.1007/s10803-012-1723-5] [PMID: 23212807]NCT00576732. A study of the effectiveness and safety of two doses of risperidone in the treatment of children and adolescents with autistic disorder [Risperidone in the treatment of children and adolescents with autistic disorder: a double-blind, placebo-controlled study of efficacy and safety, followed by an open-label extension study of safety]. clinicaltrials.gov/ct2/show/NCT00576732 (first received 19 December 2007). ">Kent 2013</a>), in addition to a rating of much improved or very much improved on the Clinician Global Impression‐Irritability (CGI‐I) scale (<a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a>; <a href="./references#CD011769-bbs2-0078" title="AmanM , RettigantiM , NagarajaHN , HollwayJA , McCrackenJ , McDougleCJ , et al. Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(6):482-93. [DOI: 10.1089/cap.2015.0005] [PMCID: PMC4545698] [PMID: 26262903]AmanMG , ArnoldLE , McDougleCJ , VitielloB , ScahillL , DaviesMD , et al. Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology2005;15(6):869-84. [DOI: 10.1089/cap.2005.15.869] [PMID: 16379507]AmanMG , HollwayJA , McDougleCJ , ScahillL , TierneyE , McCrackenJT , et al. Cognitive effects of risperidone in children with autism and irritable behavior. Journal of Child and Adolescent Psychopharmacology2008;18(3):227-36. [DOI: 10.1089/cap.2007.0133] [PMCID: PMC2935828] [PMID: 18582177]ArnoldLE , AmanMG , MartinA , Collier-CrespinA , VitielloB , TierneyE , et al. Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology. Journal of Autism and Developmental Disorders2000;30(2):99-111. [DOI: 10.1023/a:1005451304303] [PMID: 10832774]ArnoldLE , FarmerC , KraemerHC , DaviesM , WitwerA , ChuangS , et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. Journal of Child &amp; Adolescent Psychopharmacology2010;20(2):83-93. [DOI: 10.1089/cap.2009.0022] [PMCID: PMC2865212] [PMID: 20415603]ArnoldLE , VitielloB , McDougleC , ScahillL , ShahB , GonzalezNM , et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(12):1443-50. [DOI: 10.1097/00004583-200312000-00011] [PMID: 14627879]CaicedoC , WilliamsSH . Risperidone improves behavior in children with autism. Journal of Family Practice2002;51(11):915. [PMID: 12485538]FombonneE . Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents. Evidence-Based Mental Health2006;9(1):6. [DOI: 10.1136/ebmh.9.1.6] [PMID: 16436546]LevineSZ , KodeshA , GoldbergY , ReichenbergA , FurukawaTA , KolevzonA , et al. Initial severity and efficacy of risperidone in autism: results from the RUPP trial. European Psychiatry2016;32:16-20. [DOI: 10.1016/j.eurpsy.2015.11.004] [PMID: 26802979]McCrackenJT , McGoughJ , ShahB , CroninP , HongD , AmanMG , et al. Risperidone in children with autism and serious behavioural problems. New England journal of medicine2002;347(5):314-21. [DOI: 10.1056/NEJMoa013171] [PMID: 12151468]McDougleC , AmanM , McCrackenJ , ScahillL , TierneyE , VitielloB . A double-blind placebo-controlled trial of risperidone in autistic disorder. European Neuropsychopharmacology2003;13:S327-8. [DOI: 10.1016/S0924-977X(03)92062-1] [POSTER NO: P.2.109]McDougleCJ , ScahillL , AmanMG , McCrackenJT , TierneyE , DaviesM , et al. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry2005;16(2):1142-8. [DOI: 10.1176/appi.ajp.162.6.1142] [PMID: 15930063]NCT00005014. Treatment of autism in children and adolescents [Placebo-controlled study of risperidone for the treatment of children and adolescents with autism and negative behavioral symptoms]. www.clinicaltrials.gov/ct2/show/NCT00005014 (first received 3 April 2000). Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry2005;162(7):1361-9. [DOI: 10.1176/appi.ajp.162.7.1361] [PMID: 15994720]ScahillL , HallettV , AmanMG , McDougleCJ , ArnoldLE , McCrackenJT , et al. Brief report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. Journal of Autism and Developmental Disorders2013;43(3):739-46. [DOI: 10.1007/s10803-012-1689-3] [PMCID: PMC3886122] [PMID: 23104617]ScahillL , Koenig, CarrollDH , PachlerM . Risperidone approved for the treatment of serious behavioral problems in children with autism. Journal of Child &amp; Adolescent Psychiatric Nursing2007;20(3):188-90. [DOI: 10.1111/j.1744-6171.2007.00112.x] [PMID: 17688557]Study of risperidone with autistic children finds no detrimental cognitive effects. Brown University Child &amp; Adolescent Psychopharmacology Update2008;10(9):3. [DOI: 10.1002/cpu.20075]WilliamsSK , ScahillL , VitielloB , AmanMG , ArnoldLE , McDougleCJ , et al. Risperidone and adaptive behavior in children with autism. Journal of the American Academy of Child &amp; Adolescent Psychiatry2006;45(4):431-9. [DOI: 10.1097/01.chi.0000196423.80717.32] [PMID: 16601648]">McCracken 2002</a>; <a href="./references#CD011769-bbs2-0102" title="EUCTR2016-005111-40. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A multicenter, double-blind, randomized, placebo-controlled, flexible-dosed parallel-group study of aripiprazole flexibly dosed in thetreatment of children and adolescents with autistic disorder]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-005111-40/results (first received 7 April 2017). LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of flexibly-dosed aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110-1. [DOI: 10.1002/ana.21853]LewisD , OwenR , CouchD . Efficacy and safety of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years): results from two 8-week randomized, double-blind, placebo-controlled trials. Neurology2009;72(11 (Supp 3)):A428. [ABSTRACT NO: S50.005]MankoskiR , StocktonG , ManosG , MarlorS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]NCT00365859. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A 52-week, open-label, multicenter study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder]. clinicaltrials.gov/ct2/show/NCT00365859 (first received 18 August 2006). OwenR , SikichL , MarcusRN , Corey-LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescent with autistic disorder. Pediatrics2009;124(6):1533-40. [DOI: 10.1542/peds.2008-3782] [PMID: 19948625]RobbAS , AnderssonC , BellocchioEE , ManosG , Rojas-FernandezC , MathewS , et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): results from a pooled analysis of 2 studies. Primary Care Companion for CNS Disorders2011;13(1):PCC.10m01008. [DOI: 10.4088/PCC.10m01008gry] [PMCID: PMC3121213] [PMID: 21731831]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. The effect of aripiprazole 2 to 15mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Owen 2009</a>). The two discontinuation studies (<a href="./references#CD011769-bbs2-0110" title="Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment for autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry2005;162(7):1361-9. [DOI: 10.1176/appi.ajp.162.7.1361] [PMID: 15994720]">Research Units 2005</a>; <a href="./references#CD011769-bbs2-0120" title="MaloneRP . Discontinuing risperidone results in relapse in children with autism spectrum disorders. Evidence-Based Mental Health2006;9(2):56. [DOI: 10.1136/ebmh.9.2.56] [PMID: 16638905]TroostPW , AlthausM , LahuisBE , BuitelaarJK , MinderaaRB , HoekstraPJ . Neuropsychological effect of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. Journal of Child and Adolescent Psychopharmacology2006;16(5):561-73. [DOI: 10.1089/cap.2006.16.561] [PMID: 17069545]TroostPW , LahuisBE , Steenhuis M-P, KetelaarsCE , BuitelaarJK , Van EngelandH , et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(11):1137-44. [DOI: 10.1097/01.chi.0000177055.11229.76] [PMID: 16239862]">Troost 2005</a>), reported relapse, defined as a minimum increase of 25% in ABC‐I scores during the discontinuation phase. </p> </li> <li> <p>Aggression: one study (<a href="./references#CD011769-bbs2-0113" title="LightM , DunbarE , SheaS . P2.104 Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. European Neuropsychopharmacology2004;14(Suppl 3):S278. [DOI: 10.1016/S0924-977X(04)80324-9]LightM , DunbarF , SheaM . Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. International Journal of Neuropsychopharmacology2004;7:S275. [DOI: 10.1016/S0924-977X(04)80324-9]PandinaGJ , BossieCA , YoussefE , ZhuY , DunbarF . Risperidone improves behavioural symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders2007;37(2):367-73. [DOI: 10.1007/s10803-006-0234-7] [PMID: 17019624]SheaS , TurgayA , CarrollA , SchulzM , OrlikH , SmithI , et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics2004;114(5):e634-41. [DOI: 10.1542/peds.2003-0264-F] [PMID: 15492353]">Shea 2004</a>), reported aggression using the Nisonger Child Behavior Rating Form (conduct problem subscale; <a href="./references#CD011769-bbs2-0267" title="AmanMG , TasseMJ , RojahnJ , HammerD . The Nisonger CBRG: a child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities1996;17(1):41-57. [DOI: 10.1016/0891-4222(95)00039-9] [PMID: 8750075]">Aman 1996</a>). </p> </li> <li> <p>Self‐injury: three studies reported self‐injurious behaviour. One study (<a href="./references#CD011769-bbs2-0080" title="McDougleCJ , HolmesJP , CarlsonDC , PeltonGH , CohenDJ , PriceLH . A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry1998;55(7):633-41. [DOI: 10.1001/archpsyc.55.7.633] [PMID: 9672054]">McDougle 1998</a>), used the Self‐Injurious Behaviour Questionnaire (SIB‐Q; <a href="./references#CD011769-bbs2-0335" title="GualtieriCT . Psychopharmacology of brain injured and mentally retarded patients. Philadelphia: Lippincott Williams and Wilkins, 2002.">Gualtieri 2002</a>), to measure self‐injurious behaviour, <a href="./references#CD011769-bbs2-0113" title="LightM , DunbarE , SheaS . P2.104 Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. European Neuropsychopharmacology2004;14(Suppl 3):S278. [DOI: 10.1016/S0924-977X(04)80324-9]LightM , DunbarF , SheaM . Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. International Journal of Neuropsychopharmacology2004;7:S275. [DOI: 10.1016/S0924-977X(04)80324-9]PandinaGJ , BossieCA , YoussefE , ZhuY , DunbarF . Risperidone improves behavioural symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders2007;37(2):367-73. [DOI: 10.1007/s10803-006-0234-7] [PMID: 17019624]SheaS , TurgayA , CarrollA , SchulzM , OrlikH , SmithI , et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics2004;114(5):e634-41. [DOI: 10.1542/peds.2003-0264-F] [PMID: 15492353]">Shea 2004</a> used the Nisonger Child Behaviour Rating Form (Self‐injurious/ stereotypic subscale; <a href="./references#CD011769-bbs2-0267" title="AmanMG , TasseMJ , RojahnJ , HammerD . The Nisonger CBRG: a child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities1996;17(1):41-57. [DOI: 10.1016/0891-4222(95)00039-9] [PMID: 8750075]">Aman 1996</a>), and <a href="./references#CD011769-bbs2-0073" title="MaceCF , BlumNJ , SierpBJ , DelaneyBA , MaukJE . Differential response of operant self-Injury to pharmacologic versus behavioral treatment. Journal of Developmental &amp; Behavioral Pediatrics2001;22(2):85-91. [DOI: 10.1097/00004703-200104000-00001] [PMID: 11332784]">Mace 2001</a> used their own scale to rate self‐injurious behaviour (self‐injurious behaviour per hour). </p> </li> <li> <p>AEs: apart from three studies (<a href="./references#CD011769-bbs2-0073" title="MaceCF , BlumNJ , SierpBJ , DelaneyBA , MaukJE . Differential response of operant self-Injury to pharmacologic versus behavioral treatment. Journal of Developmental &amp; Behavioral Pediatrics2001;22(2):85-91. [DOI: 10.1097/00004703-200104000-00001] [PMID: 11332784]">Mace 2001</a>; <a href="./references#CD011769-bbs2-0110" title="Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment for autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry2005;162(7):1361-9. [DOI: 10.1176/appi.ajp.162.7.1361] [PMID: 15994720]">Research Units 2005</a>; <a href="./references#CD011769-bbs2-0120" title="MaloneRP . Discontinuing risperidone results in relapse in children with autism spectrum disorders. Evidence-Based Mental Health2006;9(2):56. [DOI: 10.1136/ebmh.9.2.56] [PMID: 16638905]TroostPW , AlthausM , LahuisBE , BuitelaarJK , MinderaaRB , HoekstraPJ . Neuropsychological effect of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. Journal of Child and Adolescent Psychopharmacology2006;16(5):561-73. [DOI: 10.1089/cap.2006.16.561] [PMID: 17069545]TroostPW , LahuisBE , Steenhuis M-P, KetelaarsCE , BuitelaarJK , Van EngelandH , et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(11):1137-44. [DOI: 10.1097/01.chi.0000177055.11229.76] [PMID: 16239862]">Troost 2005</a>), all studies reported AEs. AEs were analysed and reported based on major categories including cardiovascular, metabolic, gastrointestinal, immune system, neurological, psychological, respiratory, skin, and urinary AEs. We could not include data from three studies in the analysis (<a href="./references#CD011769-bbs2-0076" title="MaloneRP , CaterJ , SheikhRM , ChoudhuryMS , DelaneyMA . Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(8):887-94. [DOI: 10.1097/00004583-200108000-00009] [PMID: 11501687]">Malone 2001</a>; <a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a>; <a href="./references#CD011769-bbs2-0102" title="EUCTR2016-005111-40. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A multicenter, double-blind, randomized, placebo-controlled, flexible-dosed parallel-group study of aripiprazole flexibly dosed in thetreatment of children and adolescents with autistic disorder]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-005111-40/results (first received 7 April 2017). LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of flexibly-dosed aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110-1. [DOI: 10.1002/ana.21853]LewisD , OwenR , CouchD . Efficacy and safety of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years): results from two 8-week randomized, double-blind, placebo-controlled trials. Neurology2009;72(11 (Supp 3)):A428. [ABSTRACT NO: S50.005]MankoskiR , StocktonG , ManosG , MarlorS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]NCT00365859. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A 52-week, open-label, multicenter study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder]. clinicaltrials.gov/ct2/show/NCT00365859 (first received 18 August 2006). OwenR , SikichL , MarcusRN , Corey-LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescent with autistic disorder. Pediatrics2009;124(6):1533-40. [DOI: 10.1542/peds.2008-3782] [PMID: 19948625]RobbAS , AnderssonC , BellocchioEE , ManosG , Rojas-FernandezC , MathewS , et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): results from a pooled analysis of 2 studies. Primary Care Companion for CNS Disorders2011;13(1):PCC.10m01008. [DOI: 10.4088/PCC.10m01008gry] [PMCID: PMC3121213] [PMID: 21731831]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. The effect of aripiprazole 2 to 15mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Owen 2009</a>). Further details can be found in <a href="#CD011769-sec-0118">Effects of interventions</a>. </p> </li> </ul> </p> </section> <section id="CD011769-sec-0078"> <p><b>Secondary outcomes</b></p> <p> <ul id="CD011769-list-0019"> <li> <p>Quality of life: three trials comparing aripiprazole to a placebo reported quality‐of‐life outcomes (<a href="./references#CD011769-bbs2-0029" title="FindlingRL , MankoskiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22-30. [DOI: 10.4088/JCP.13m08500] [PMID: 24502859]NCT01227668. Phase IV long-term maintenance study of aripiprazole in the treatment of irritability associated with autistic disorder. https://clinicaltrials.gov/ct2/show/NCT01227668?term=NCT01227668&amp;draw=2&amp;rank=1 (first received October 2010). ">Findling 2014</a>; <a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a>; <a href="./references#CD011769-bbs2-0102" title="EUCTR2016-005111-40. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A multicenter, double-blind, randomized, placebo-controlled, flexible-dosed parallel-group study of aripiprazole flexibly dosed in thetreatment of children and adolescents with autistic disorder]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-005111-40/results (first received 7 April 2017). LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of flexibly-dosed aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110-1. [DOI: 10.1002/ana.21853]LewisD , OwenR , CouchD . Efficacy and safety of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years): results from two 8-week randomized, double-blind, placebo-controlled trials. Neurology2009;72(11 (Supp 3)):A428. [ABSTRACT NO: S50.005]MankoskiR , StocktonG , ManosG , MarlorS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]NCT00365859. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A 52-week, open-label, multicenter study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder]. clinicaltrials.gov/ct2/show/NCT00365859 (first received 18 August 2006). OwenR , SikichL , MarcusRN , Corey-LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescent with autistic disorder. Pediatrics2009;124(6):1533-40. [DOI: 10.1542/peds.2008-3782] [PMID: 19948625]RobbAS , AnderssonC , BellocchioEE , ManosG , Rojas-FernandezC , MathewS , et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): results from a pooled analysis of 2 studies. Primary Care Companion for CNS Disorders2011;13(1):PCC.10m01008. [DOI: 10.4088/PCC.10m01008gry] [PMCID: PMC3121213] [PMID: 21731831]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. The effect of aripiprazole 2 to 15mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Owen 2009</a>). Each study used the Pediatric Quality of Life Inventory (PedsQL; <a href="./references#CD011769-bbs2-0449" title="VarniJW . The PedsQL measurement model for the pediatric quality of life inventory. https://www.pedsql.org/index.html (last accessed 3rd May 2022).">Varni 2001</a>). </p> </li> <li> <p>Tolerability and acceptability (loss to follow‐up): 231 participants withdrew from studies involving an atypical antipsychotic versus a placebo and were not included in the relevant study analyses. Reasons for withdrawing included lack of efficacy (75), AEs (44), withdrew consent (32), other/not specified (18), lost to follow‐up (14), noncompliance (6), increased behaviours of concern or exacerbation of medical condition (5), missed visits (4), and physician decision (3). </p> </li> </ul> </p> </section> </section> </section> <section id="CD011769-sec-0079"> <h5 class="title">Neurohormones versus placebo or other treatment</h5> <p>Twenty‐four studies (46 reports, 1640 participants, 27 datasets) compared a neurohormone to a placebo. Seven studies involved adult participants only (<a href="./references#CD011769-bbs2-0005" title="AnagnosouE , SooryaL , ChaplinW , BartzJ , HalpernD , WassermanS , et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Molecular Autism2012;3(1):16. [DOI: 10.1186/2040-2392-3-16] [PMCID: PMC3539865] [PMID: 23216716]NCT00490802. Intranasal oxytocin in the treatment of autism. clinicaltrials.gov/ct2/show/NCT00490802 (first received 25 June 2007). ">Anagnostou 2012</a>; <a href="./references#CD011769-bbs2-0014" title="BernaertsS , BoetsB , BosmansG , SteyaertJ , AlaertsK . Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up. Molecular Autism2020;11(1):6. [DOI: 10.1186/s13229-020-0313-1] [PMCID: PMC6964112] [PMID: 31969977]BernaertsS , DillenC , SteyaertJ , AlaertsK . The effects of four weeks of intranasal oxytocinon social responsiveness and repetitive and restricted behaviors in autism spectrum disorders: a randomized controlled trial. Biological Psychiatry2020;81(10):S349-50. [ABSTRACT NO: 864] [DOI: 10.1016/j.biopsych.2017.02.589]Eudract 2014-000586-45. Oxytocin-based pharmacotherapy for autism spectrum disorders: Investigating the neural and behavioral effects of a promising intervention approach. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000586-45 (first registered May 2014). ">Bernaerts 2020</a>; <a href="./references#CD011769-bbs2-0060" title="JacobS , Veenstra-VanderWeeleJ , MurphyD , McCrackenJ , SmithJ , SandersK , et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet2022;9(3):199-210. [DOI: 10.1016/S2215-0366(21)00429-6] [PMID: 35151410]JacobS , Veenstra-VanderWeeleJ , MurphyD , McCrackenJ , SmithJ , SandersK , et al. Phase three randomised controlled trial of balovaptan in adults with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2020;59(10):S163-S163. [DOI: 10.1016/j.jaac.2020.08.108]NCT03504917. A study of balovaptan in adults with autism spectrum disorder with a 2-year open-label extension. clinicaltrials.gov/ct2/show/NCT03504917?term=NCT03504917&amp;draw=2&amp;rank=1 (first received 8 August 2018). ">Jacob 2022</a>; <a href="./references#CD011769-bbs2-0092" title="NCT01337687. Intranasal oxytocin for the treatment of autism spectrum disorders (INOT) [Intranasal oxytocin for the treatment of autism spectrum disorders]. clinicaltrials.gov/ct2/show/NCT01337687 (first received 19 April 2011). ">NCT01337687</a>; <a href="./references#CD011769-bbs2-0096" title="NCT02940574. Neural and behavioral effects of oxytocin in autism spectrum disorders [Oxytocin-based pharmacotherapy for autism spectrum disorders: investigating the neural and behavioral effects of a promising intervention approach]. clinicaltrials.gov/ct2/show/NCT02940574 (first received 21 October 2016). ">NCT02940574</a>; <a href="./references#CD011769-bbs2-0118" title="NCT01793441. A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) [A multi-center, randomized, double-blind, 12-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of rg7314 in individuals with autism spectrum disorders (ASD)]. clinicaltrials.gov/ct2/show/NCT01793441 (first received 15 February 2013). SquassanteL , BolognaniF , SmithJ , MurtaghL , FontouraP , KhwajaO , et al. Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla). Journal of the American Academy of Child and Adolescent Psychiatry2018;57(10):S231. [DOI: 10.1016/j.jaac.2018.09.308] [PRESENTATION NO: 5.13]">Squassante 2018</a>; <a href="./references#CD011769-bbs2-0131" title="JPRN‐UMIN000015264. A multicenter, parallel group, placebo-controlled, double blind, confirmatory trial of intranasal oxytocin in participants with autism spectrum disorders. https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000015264 (first received March 2019). YamasueH , OkadaT , MunesueT , KurodaM , FujiokaT , UnoY , et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Molecular Psychiatry2020;25(8):1849-58. [DOI: 10.1038/s41380-018-0097-2] [PMID: 29955161]">Yamasue 2020</a>), one study involved adolescents and adults (15 to 45 years; <a href="./references#CD011769-bbs2-0087" title="MunesueT , NakamuraH , KikuchiM , MiuraY , TakeuchiN , AnmeT , et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study. Frontiers in Psychiatry2016;7:2. [DOI: 10.3389/fpsyt.2016.00002] [PMCID: PMC4720778] [PMID: 26834651]UMIN000007250. A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008548 (first received 9 February 2012). ">Munesue 2016</a>), one study involved children three to eight years of age (<a href="./references#CD011769-bbs2-0067" title="ChiCTR1900023774. The effects of chronic intranasal oxytocin combined with positive social interaction in the treatment of young children with autism. www.chictr.org.cn/showproj.aspx?proj=39640 (first received 11 June 2019). LeJ , ZhangL , ZhaoW , ZhiS , LanC , KouJ , et al. Infrequent intranasal oxytocin followed by positive social interaction improves symptoms in autistic children: a pilot randomized clinical trial. Psychotherapy and Psychosomatics2022;91(5):335-47. [DOI: 10.1159/000524543] [PMID: 35545057]">Le 2022</a>), one study involved adolescents (12 to 18 years; <a href="./references#CD011769-bbs2-0039" title="ACTRN12609000513213. A course of oxytocin nasal spray (OT) to treat social problems in youth with autism spectrum disorders [A double blind randomised controlled trial of oxytocin nasal spray to treat social problems in autistic youth]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83655 (first received 29 June 2009). GuastellaAJ , GrayKM , RinehartNJ , AlvaresGA , TongeBJ , HickieIB , et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. Journal of Child Psychology and Psychiatry2015;56(4):444-52. [DOI: 10.1111/jcpp.12305] [PMID: 25087908]">Guastella 2015a</a>), and fourteen studies involved only children (&lt; 18 years). Fifteen studies were parallel trials and nine were cross‐over studies. Study duration ranged from four weeks to 24 weeks (<a href="./references#CD011769-bbs2-0058" title="HollanderE , JacobS , JouR , McNamaraN , SikichL , TobeR , et al. A phase 2 randomized controlled trial (RCT) of balovaptan (BAL) in pediatric participants with autism spectrum disorder (ASD). Neuropsychopharmacology2021;46:152. [DOI: 10.1038/s41386-021-01236-7]HollanderE , JacobS , JouRJ , McNamaraN , SikichL , TobeR , et al. Phase 2 randomized controlled trial of balovaptan in pediatric participants with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2020;59(10):S262-S263. [DOI: 10.1016/j.jaac.2020.08.458]NCT02901431. A study to investigate the efficacy and safety of balovaptan (RO5285119) in participants with autism spectrum disorder (ASD). www.clinicaltrials.gov/ct2/show/NCT02901431?term=NCT02901431&amp;draw=2&amp;rank=1 (first received 21 November 2016). ">Hollander 2020b</a>; <a href="./references#CD011769-bbs2-0060" title="JacobS , Veenstra-VanderWeeleJ , MurphyD , McCrackenJ , SmithJ , SandersK , et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet2022;9(3):199-210. [DOI: 10.1016/S2215-0366(21)00429-6] [PMID: 35151410]JacobS , Veenstra-VanderWeeleJ , MurphyD , McCrackenJ , SmithJ , SandersK , et al. Phase three randomised controlled trial of balovaptan in adults with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2020;59(10):S163-S163. [DOI: 10.1016/j.jaac.2020.08.108]NCT03504917. A study of balovaptan in adults with autism spectrum disorder with a 2-year open-label extension. clinicaltrials.gov/ct2/show/NCT03504917?term=NCT03504917&amp;draw=2&amp;rank=1 (first received 8 August 2018). ">Jacob 2022</a>; <a href="./references#CD011769-bbs2-0115" title="NCT01944046. Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B). clinicaltrails.gov/ct2/show/study/NCT01944046?term=NCT01944046&amp;draw=2&amp;rank=1 (first received 1 August 2014). SikichL , KolevzonA , KingB , McDougleC , SandersK , Kim S-J, et al. Intranasal oxytocin in children and adolescents with autism spectrum disorder. New England Journal of Medicine2021;385(16):1462-73. [DOI: 10.1056/NEJMoa2103583] [PMID: 34644471]SpanosM , BetheaT , AldermanC , JohnsonJ , ChandrasekharT , SikichL . Randomized, placebo-controlled trial with open-label extension of intranasal oxytocin for autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2021;60(10):S162. [DOI: 10.1016/j.jaac.2021.09.087]">Sikich 2021</a>). All but nine studies were conducted in the USA. The other studies were conducted in Australia, Belgium, China, two in Canada, the Netherlands, and three in Japan (<a href="./references#CD011769-bbs2-0039" title="ACTRN12609000513213. A course of oxytocin nasal spray (OT) to treat social problems in youth with autism spectrum disorders [A double blind randomised controlled trial of oxytocin nasal spray to treat social problems in autistic youth]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83655 (first received 29 June 2009). GuastellaAJ , GrayKM , RinehartNJ , AlvaresGA , TongeBJ , HickieIB , et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. Journal of Child Psychology and Psychiatry2015;56(4):444-52. [DOI: 10.1111/jcpp.12305] [PMID: 25087908]">Guastella 2015a</a>; <a href="./references#CD011769-bbs2-0014" title="BernaertsS , BoetsB , BosmansG , SteyaertJ , AlaertsK . Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up. Molecular Autism2020;11(1):6. [DOI: 10.1186/s13229-020-0313-1] [PMCID: PMC6964112] [PMID: 31969977]BernaertsS , DillenC , SteyaertJ , AlaertsK . The effects of four weeks of intranasal oxytocinon social responsiveness and repetitive and restricted behaviors in autism spectrum disorders: a randomized controlled trial. Biological Psychiatry2020;81(10):S349-50. [ABSTRACT NO: 864] [DOI: 10.1016/j.biopsych.2017.02.589]Eudract 2014-000586-45. Oxytocin-based pharmacotherapy for autism spectrum disorders: Investigating the neural and behavioral effects of a promising intervention approach. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000586-45 (first registered May 2014). ">Bernaerts 2020</a>; <a href="./references#CD011769-bbs2-0067" title="ChiCTR1900023774. The effects of chronic intranasal oxytocin combined with positive social interaction in the treatment of young children with autism. www.chictr.org.cn/showproj.aspx?proj=39640 (first received 11 June 2019). LeJ , ZhangL , ZhaoW , ZhiS , LanC , KouJ , et al. Infrequent intranasal oxytocin followed by positive social interaction improves symptoms in autistic children: a pilot randomized clinical trial. Psychotherapy and Psychosomatics2022;91(5):335-47. [DOI: 10.1159/000524543] [PMID: 35545057]">Le 2022</a>; <a href="./references#CD011769-bbs2-0094" title="NCT01908205. Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD) (OXY-R) [Intranasal oxytocin for the treatment of children and adolescents with autism]. clinicaltrials.gov/ct2/show/NCT01908205 (first received 25 July 2013). ">NCT01908205</a>; <a href="./references#CD011769-bbs2-0096" title="NCT02940574. Neural and behavioral effects of oxytocin in autism spectrum disorders [Oxytocin-based pharmacotherapy for autism spectrum disorders: investigating the neural and behavioral effects of a promising intervention approach]. clinicaltrials.gov/ct2/show/NCT02940574 (first received 21 October 2016). ">NCT02940574</a>; <a href="./references#CD011769-bbs2-0015" title="BuitelaarJK , Van EngelandH , De KogelKH , De VriesH , Van HooffJA , Van ReeJM . The use of adrenocorticotrophic hormone (4-9) analog ORG 2766 in autistic children: effects on the organization of behavior. Biological Psychiatry1992;31(11):1119-29. [DOI: 10.1016/0006-3223(92)90156-T] [PMID: 1326339]BuitelaarJK , Van EngelandH , Van ReeJM , De WiedD . Behavioral effects of Org 2766, a synthetic analog of the adrenocorticotrophic hormone (4–9), in 14 outpatient autistic children. Journal of Autism and Developmental Disorders1990;20(4):467-78. [DOI: 10.1007/BF02216053] [PMID: 2177746]">Buitelaar 1990</a>; <a href="./references#CD011769-bbs2-0087" title="MunesueT , NakamuraH , KikuchiM , MiuraY , TakeuchiN , AnmeT , et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study. Frontiers in Psychiatry2016;7:2. [DOI: 10.3389/fpsyt.2016.00002] [PMCID: PMC4720778] [PMID: 26834651]UMIN000007250. A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008548 (first received 9 February 2012). ">Munesue 2016</a>; <a href="./references#CD011769-bbs2-0119" title="UMIN000007122. A randomized, double-blind and cross-over trial to examine effects of continuous administration of intranasal oxytocin on social dysfunction in subjects with autism spectrum disorders. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008388 (first received 1 February 2012). WatanabeT , KurodaM , KuwabaraH , AokiY , IwashiroN , TatsunobuN , et al. Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain2015;138(11):3400-12. [DOI: 10.1093/brain/awv249] [PMID: 26336909]">Takamitsu 2015a</a>; <a href="./references#CD011769-bbs2-0131" title="JPRN‐UMIN000015264. A multicenter, parallel group, placebo-controlled, double blind, confirmatory trial of intranasal oxytocin in participants with autism spectrum disorders. https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000015264 (first received March 2019). YamasueH , OkadaT , MunesueT , KurodaM , FujiokaT , UnoY , et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Molecular Psychiatry2020;25(8):1849-58. [DOI: 10.1038/s41380-018-0097-2] [PMID: 29955161]">Yamasue 2020</a>) respectively. </p> <p> <ul id="CD011769-list-0020"> <li> <p>Interventions</p> <ul id="CD011769-list-0021"> <li> <p>Adrenocorticotrophic hormone: one study involving 14 participants compared adrenocorticotrophic hormone to a placebo (<a href="./references#CD011769-bbs2-0015" title="BuitelaarJK , Van EngelandH , De KogelKH , De VriesH , Van HooffJA , Van ReeJM . The use of adrenocorticotrophic hormone (4-9) analog ORG 2766 in autistic children: effects on the organization of behavior. Biological Psychiatry1992;31(11):1119-29. [DOI: 10.1016/0006-3223(92)90156-T] [PMID: 1326339]BuitelaarJK , Van EngelandH , Van ReeJM , De WiedD . Behavioral effects of Org 2766, a synthetic analog of the adrenocorticotrophic hormone (4–9), in 14 outpatient autistic children. Journal of Autism and Developmental Disorders1990;20(4):467-78. [DOI: 10.1007/BF02216053] [PMID: 2177746]">Buitelaar 1990</a>). Doses of either adrenocorticotrophic hormone or placebo were fixed (20 mg/day). </p> </li> <li> <p>Balovaptan (RG7314): three studies involving 657 adult participants compared balovaptan to a placebo (<a href="./references#CD011769-bbs2-0058" title="HollanderE , JacobS , JouR , McNamaraN , SikichL , TobeR , et al. A phase 2 randomized controlled trial (RCT) of balovaptan (BAL) in pediatric participants with autism spectrum disorder (ASD). Neuropsychopharmacology2021;46:152. [DOI: 10.1038/s41386-021-01236-7]HollanderE , JacobS , JouRJ , McNamaraN , SikichL , TobeR , et al. Phase 2 randomized controlled trial of balovaptan in pediatric participants with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2020;59(10):S262-S263. [DOI: 10.1016/j.jaac.2020.08.458]NCT02901431. A study to investigate the efficacy and safety of balovaptan (RO5285119) in participants with autism spectrum disorder (ASD). www.clinicaltrials.gov/ct2/show/NCT02901431?term=NCT02901431&amp;draw=2&amp;rank=1 (first received 21 November 2016). ">Hollander 2020b</a>; <a href="./references#CD011769-bbs2-0060" title="JacobS , Veenstra-VanderWeeleJ , MurphyD , McCrackenJ , SmithJ , SandersK , et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet2022;9(3):199-210. [DOI: 10.1016/S2215-0366(21)00429-6] [PMID: 35151410]JacobS , Veenstra-VanderWeeleJ , MurphyD , McCrackenJ , SmithJ , SandersK , et al. Phase three randomised controlled trial of balovaptan in adults with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2020;59(10):S163-S163. [DOI: 10.1016/j.jaac.2020.08.108]NCT03504917. A study of balovaptan in adults with autism spectrum disorder with a 2-year open-label extension. clinicaltrials.gov/ct2/show/NCT03504917?term=NCT03504917&amp;draw=2&amp;rank=1 (first received 8 August 2018). ">Jacob 2022</a>; <a href="./references#CD011769-bbs2-0118" title="NCT01793441. A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) [A multi-center, randomized, double-blind, 12-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of rg7314 in individuals with autism spectrum disorders (ASD)]. clinicaltrials.gov/ct2/show/NCT01793441 (first received 15 February 2013). SquassanteL , BolognaniF , SmithJ , MurtaghL , FontouraP , KhwajaO , et al. Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla). Journal of the American Academy of Child and Adolescent Psychiatry2018;57(10):S231. [DOI: 10.1016/j.jaac.2018.09.308] [PRESENTATION NO: 5.13]">Squassante 2018</a>). Doses were either 1.5 mg, 4 mg or 10 mg once daily of balovaptan in capsule form. </p> </li> <li> <p>Oxytocin: 13 studies involving 709 participants compared oxytocin to a placebo. All but four studies required participants to take 12 IU of oxytocin twice daily (total of 24 IU daily). <a href="./references#CD011769-bbs2-0087" title="MunesueT , NakamuraH , KikuchiM , MiuraY , TakeuchiN , AnmeT , et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study. Frontiers in Psychiatry2016;7:2. [DOI: 10.3389/fpsyt.2016.00002] [PMCID: PMC4720778] [PMID: 26834651]UMIN000007250. A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008548 (first received 9 February 2012). ">Munesue 2016</a> had a maximum of 8 IU of oxytocin twice daily, <a href="./references#CD011769-bbs2-0039" title="ACTRN12609000513213. A course of oxytocin nasal spray (OT) to treat social problems in youth with autism spectrum disorders [A double blind randomised controlled trial of oxytocin nasal spray to treat social problems in autistic youth]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83655 (first received 29 June 2009). GuastellaAJ , GrayKM , RinehartNJ , AlvaresGA , TongeBJ , HickieIB , et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. Journal of Child Psychology and Psychiatry2015;56(4):444-52. [DOI: 10.1111/jcpp.12305] [PMID: 25087908]">Guastella 2015a</a> and <a href="./references#CD011769-bbs2-0114" title="NCT01944046. Study of oxytocin in autism to improve reciprocal social behaviours (SOARS-B) [Phase II study of oxytocin in autism to improve reciprocal social behaviors]. clinicaltrials.gov/ct2/show/NCT01944046 (first received 17 September 2013). SikichL , AldermanC , HazzardL , BetheaT , GregoryS , JohnsonJ . Pilot study of sustained oxytocin treatment in children and adolescents with autistic disorder. Biological Psychiatry2013;73(9):145S. ">Sikich 2013</a> had varying levels of oxytocin based on age (<a href="./references#CD011769-bbs2-0039" title="ACTRN12609000513213. A course of oxytocin nasal spray (OT) to treat social problems in youth with autism spectrum disorders [A double blind randomised controlled trial of oxytocin nasal spray to treat social problems in autistic youth]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83655 (first received 29 June 2009). GuastellaAJ , GrayKM , RinehartNJ , AlvaresGA , TongeBJ , HickieIB , et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. Journal of Child Psychology and Psychiatry2015;56(4):444-52. [DOI: 10.1111/jcpp.12305] [PMID: 25087908]">Guastella 2015a</a> 18 IU twice daily for children &lt; 16 years, and 24 IU twice daily for participants 16 to 18 years; <a href="./references#CD011769-bbs2-0114" title="NCT01944046. Study of oxytocin in autism to improve reciprocal social behaviours (SOARS-B) [Phase II study of oxytocin in autism to improve reciprocal social behaviors]. clinicaltrials.gov/ct2/show/NCT01944046 (first received 17 September 2013). SikichL , AldermanC , HazzardL , BetheaT , GregoryS , JohnsonJ . Pilot study of sustained oxytocin treatment in children and adolescents with autistic disorder. Biological Psychiatry2013;73(9):145S. ">Sikich 2013</a> administered up to 24 IU for children 3 to 10 years and a maximum of 32 IU for children 11 to 17 years), <a href="./references#CD011769-bbs2-0094" title="NCT01908205. Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD) (OXY-R) [Intranasal oxytocin for the treatment of children and adolescents with autism]. clinicaltrials.gov/ct2/show/NCT01908205 (first received 25 July 2013). ">NCT01908205</a> involved 0.4 IU/kg taken twice daily up to a maximum of 24 IU per dose. </p> </li> <li> <p>Secretin: five studies involving 211 participants compared secretin to a placebo. All studies were either single‐dose (<a href="./references#CD011769-bbs2-0018" title="CareyT , Ratcliff-SchaubK , FunkJ , WeinleC , MyersM , JenksJ , et al. Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism. Journal of Autism and Developmental Disorders2002;32(3):161-7. [DOI: 10.1023/A:1015493412224] [PMID: 12108617]">Carey 2002</a>; <a href="./references#CD011769-bbs2-0069" title="LevySE , SoudersMC , WrayJ , JawadAF , Gallagher PR CoplinJ , et al. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin. Archives of Disease in Childhood2003;88(8):731-6. [DOI: 10.1136/adc.88.8.731] [PMCID: PMC1719589] [PMID: 12876177]">Levy 2003</a>; <a href="./references#CD011769-bbs2-0103" title="OwleyT , MacmahonW , CookEH , LaulhereT , SouthM , MaysLZ , et al. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(11):1293-9. [DOI: 10.1097/00004583-200111000-00009] [PMID: 11699803]">Owley 2001</a>; <a href="./references#CD011769-bbs2-0122" title="NCT00065962. Secretin for the treatment of autism [Multisite controlled secretin trial in autism]. clinicaltrials.gov/ct2/show/NCT00065962 (first received 5 August 2003). UnisAS , MunsonJA , RogersSJ , GoldsonE , OsterlingJ , GabrielsR , et al. A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(11):1315-21. [DOI: 10.1097/00004583-200211000-00012] [PMID: 12410073]">Unis 2002</a>), or two doses separated by two months (<a href="./references#CD011769-bbs2-0042" title="HandenBL , HofkoshD . Secretin in children with autistic disorder: a double-blind, placebo-controlled trial. Journal of Developmental and Physical Disabilities2005;17(2):95-107. [DOI: 10.1007/s10882-005-3682-7]">Handen 2005</a>). All studies used 2 IU/kg per infusion. </p> </li> <li> <p>Vasopressin: two studies (<a href="./references#CD011769-bbs2-0105" title="NCT01962870. The role of vasopressin in the social deficits of autism [Randomized placebo-controlled trial of vasopressin treatment for social deficits in children with autism]. clinicaltrials.gov/ct2/show/NCT01962870 (first receceived 14 October 2013). ParkerKJ , OztanO , LiboveRA , MohsinN , KarhsonDS , SumiyoshiRD , et al. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Science Translational Medicine2019;11(491):eaau7356. [DOI: 10.1126/scitranslmed.aau7356] [PMCID: PMC6716148] [PMID: 31043522]">Parker 2019</a>; <a href="./references#CD011769-bbs2-0121" title="NCT01474278. A study of RO5028442 in adult male high-functioning autistic patients. https://clinicaltrials.gov/ct2/show/NCT01474278?term=NCT01474278&amp;draw=2&amp;rank=1 (first registered December 2011). UmbrichtD , Del Valle RubidoM , HollanderE , McCrackenJT , ShicF , ScahillL , et al. A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology2017;42(9):1914-23. [DOI: 10.1038/npp.2016.232] [PMCID: PMC5520775] [PMID: 27711048]">Umbricht 2017</a>), involving 67 participants compared vasopressin to a placebo. <a href="./references#CD011769-bbs2-0105" title="NCT01962870. The role of vasopressin in the social deficits of autism [Randomized placebo-controlled trial of vasopressin treatment for social deficits in children with autism]. clinicaltrials.gov/ct2/show/NCT01962870 (first receceived 14 October 2013). ParkerKJ , OztanO , LiboveRA , MohsinN , KarhsonDS , SumiyoshiRD , et al. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Science Translational Medicine2019;11(491):eaau7356. [DOI: 10.1126/scitranslmed.aau7356] [PMCID: PMC6716148] [PMID: 31043522]">Parker 2019</a> was a four‐week parallel study with vasopressin doses ranging from 4 IU to a maximum of 12 IU twice daily for children up to 12.9 years of age, and maximum of 16 IU twice daily for children over 12.9 years of age. <a href="./references#CD011769-bbs2-0121" title="NCT01474278. A study of RO5028442 in adult male high-functioning autistic patients. https://clinicaltrials.gov/ct2/show/NCT01474278?term=NCT01474278&amp;draw=2&amp;rank=1 (first registered December 2011). UmbrichtD , Del Valle RubidoM , HollanderE , McCrackenJT , ShicF , ScahillL , et al. A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology2017;42(9):1914-23. [DOI: 10.1038/npp.2016.232] [PMCID: PMC5520775] [PMID: 27711048]">Umbricht 2017</a> was a 20‐mg single‐dose cross‐over study involving male adults. </p> </li> </ul> </li> <li> <p>Comparators: all studies compared a neurohormone to a placebo. Apart from four studies that used saline solution (<a href="./references#CD011769-bbs2-0005" title="AnagnosouE , SooryaL , ChaplinW , BartzJ , HalpernD , WassermanS , et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Molecular Autism2012;3(1):16. [DOI: 10.1186/2040-2392-3-16] [PMCID: PMC3539865] [PMID: 23216716]NCT00490802. Intranasal oxytocin in the treatment of autism. clinicaltrials.gov/ct2/show/NCT00490802 (first received 25 June 2007). ">Anagnostou 2012</a>; <a href="./references#CD011769-bbs2-0018" title="CareyT , Ratcliff-SchaubK , FunkJ , WeinleC , MyersM , JenksJ , et al. Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism. Journal of Autism and Developmental Disorders2002;32(3):161-7. [DOI: 10.1023/A:1015493412224] [PMID: 12108617]">Carey 2002</a>; <a href="./references#CD011769-bbs2-0092" title="NCT01337687. Intranasal oxytocin for the treatment of autism spectrum disorders (INOT) [Intranasal oxytocin for the treatment of autism spectrum disorders]. clinicaltrials.gov/ct2/show/NCT01337687 (first received 19 April 2011). ">NCT01337687</a>; <a href="./references#CD011769-bbs2-0103" title="OwleyT , MacmahonW , CookEH , LaulhereT , SouthM , MaysLZ , et al. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(11):1293-9. [DOI: 10.1097/00004583-200111000-00009] [PMID: 11699803]">Owley 2001</a>), the ingredients of placebo were not outlined. </p> </li> <li> <p>Inclusion criteria: all studies required a clinical diagnosis of ASD, Asperger's, or PDD‐NOS to participate in the trial. Six studies also required a CGI severity score (<a href="./references#CD011769-bbs2-0422" title="SchoplerE , Van BourgondienME , WellmanJ , LoveS . Childhood Autism Rating Scale-second edition (CARS2): Manual. Childhood Autism Rating Scale, Second Edition (CARS-2) | Pearson Clinical Australia &amp; New Zealand 2009.">Schopler 2009</a>), above 4, four studies restricted participation to male participants only (<a href="./references#CD011769-bbs2-0014" title="BernaertsS , BoetsB , BosmansG , SteyaertJ , AlaertsK . Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up. Molecular Autism2020;11(1):6. [DOI: 10.1186/s13229-020-0313-1] [PMCID: PMC6964112] [PMID: 31969977]BernaertsS , DillenC , SteyaertJ , AlaertsK . The effects of four weeks of intranasal oxytocinon social responsiveness and repetitive and restricted behaviors in autism spectrum disorders: a randomized controlled trial. Biological Psychiatry2020;81(10):S349-50. [ABSTRACT NO: 864] [DOI: 10.1016/j.biopsych.2017.02.589]Eudract 2014-000586-45. Oxytocin-based pharmacotherapy for autism spectrum disorders: Investigating the neural and behavioral effects of a promising intervention approach. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000586-45 (first registered May 2014). ">Bernaerts 2020</a>; <a href="./references#CD011769-bbs2-0118" title="NCT01793441. A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) [A multi-center, randomized, double-blind, 12-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of rg7314 in individuals with autism spectrum disorders (ASD)]. clinicaltrials.gov/ct2/show/NCT01793441 (first received 15 February 2013). SquassanteL , BolognaniF , SmithJ , MurtaghL , FontouraP , KhwajaO , et al. Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla). Journal of the American Academy of Child and Adolescent Psychiatry2018;57(10):S231. [DOI: 10.1016/j.jaac.2018.09.308] [PRESENTATION NO: 5.13]">Squassante 2018</a>; <a href="./references#CD011769-bbs2-0119" title="UMIN000007122. A randomized, double-blind and cross-over trial to examine effects of continuous administration of intranasal oxytocin on social dysfunction in subjects with autism spectrum disorders. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008388 (first received 1 February 2012). WatanabeT , KurodaM , KuwabaraH , AokiY , IwashiroN , TatsunobuN , et al. Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain2015;138(11):3400-12. [DOI: 10.1093/brain/awv249] [PMID: 26336909]">Takamitsu 2015a</a>; <a href="./references#CD011769-bbs2-0131" title="JPRN‐UMIN000015264. A multicenter, parallel group, placebo-controlled, double blind, confirmatory trial of intranasal oxytocin in participants with autism spectrum disorders. https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000015264 (first received March 2019). YamasueH , OkadaT , MunesueT , KurodaM , FujiokaT , UnoY , et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Molecular Psychiatry2020;25(8):1849-58. [DOI: 10.1038/s41380-018-0097-2] [PMID: 29955161]">Yamasue 2020</a>), four studies required participants to have an IQ above 70 (<a href="./references#CD011769-bbs2-0087" title="MunesueT , NakamuraH , KikuchiM , MiuraY , TakeuchiN , AnmeT , et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study. Frontiers in Psychiatry2016;7:2. [DOI: 10.3389/fpsyt.2016.00002] [PMCID: PMC4720778] [PMID: 26834651]UMIN000007250. A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008548 (first received 9 February 2012). ">Munesue 2016</a>; <a href="./references#CD011769-bbs2-0114" title="NCT01944046. Study of oxytocin in autism to improve reciprocal social behaviours (SOARS-B) [Phase II study of oxytocin in autism to improve reciprocal social behaviors]. clinicaltrials.gov/ct2/show/NCT01944046 (first received 17 September 2013). SikichL , AldermanC , HazzardL , BetheaT , GregoryS , JohnsonJ . Pilot study of sustained oxytocin treatment in children and adolescents with autistic disorder. Biological Psychiatry2013;73(9):145S. ">Sikich 2013</a>; <a href="./references#CD011769-bbs2-0118" title="NCT01793441. A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) [A multi-center, randomized, double-blind, 12-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of rg7314 in individuals with autism spectrum disorders (ASD)]. clinicaltrials.gov/ct2/show/NCT01793441 (first received 15 February 2013). SquassanteL , BolognaniF , SmithJ , MurtaghL , FontouraP , KhwajaO , et al. Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla). Journal of the American Academy of Child and Adolescent Psychiatry2018;57(10):S231. [DOI: 10.1016/j.jaac.2018.09.308] [PRESENTATION NO: 5.13]">Squassante 2018</a>; <a href="./references#CD011769-bbs2-0131" title="JPRN‐UMIN000015264. A multicenter, parallel group, placebo-controlled, double blind, confirmatory trial of intranasal oxytocin in participants with autism spectrum disorders. https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000015264 (first received March 2019). YamasueH , OkadaT , MunesueT , KurodaM , FujiokaT , UnoY , et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Molecular Psychiatry2020;25(8):1849-58. [DOI: 10.1038/s41380-018-0097-2] [PMID: 29955161]">Yamasue 2020</a>), and some required participants to either be on stable concomitant medication (<a href="./references#CD011769-bbs2-0005" title="AnagnosouE , SooryaL , ChaplinW , BartzJ , HalpernD , WassermanS , et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Molecular Autism2012;3(1):16. [DOI: 10.1186/2040-2392-3-16] [PMCID: PMC3539865] [PMID: 23216716]NCT00490802. Intranasal oxytocin in the treatment of autism. clinicaltrials.gov/ct2/show/NCT00490802 (first received 25 June 2007). ">Anagnostou 2012</a>; <a href="./references#CD011769-bbs2-0087" title="MunesueT , NakamuraH , KikuchiM , MiuraY , TakeuchiN , AnmeT , et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study. Frontiers in Psychiatry2016;7:2. [DOI: 10.3389/fpsyt.2016.00002] [PMCID: PMC4720778] [PMID: 26834651]UMIN000007250. A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008548 (first received 9 February 2012). ">Munesue 2016</a>; <a href="./references#CD011769-bbs2-0103" title="OwleyT , MacmahonW , CookEH , LaulhereT , SouthM , MaysLZ , et al. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(11):1293-9. [DOI: 10.1097/00004583-200111000-00009] [PMID: 11699803]">Owley 2001</a>; <a href="./references#CD011769-bbs2-0114" title="NCT01944046. Study of oxytocin in autism to improve reciprocal social behaviours (SOARS-B) [Phase II study of oxytocin in autism to improve reciprocal social behaviors]. clinicaltrials.gov/ct2/show/NCT01944046 (first received 17 September 2013). SikichL , AldermanC , HazzardL , BetheaT , GregoryS , JohnsonJ . Pilot study of sustained oxytocin treatment in children and adolescents with autistic disorder. Biological Psychiatry2013;73(9):145S. ">Sikich 2013</a>), or not to have trialled the intervention previously (<a href="./references#CD011769-bbs2-0018" title="CareyT , Ratcliff-SchaubK , FunkJ , WeinleC , MyersM , JenksJ , et al. Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism. Journal of Autism and Developmental Disorders2002;32(3):161-7. [DOI: 10.1023/A:1015493412224] [PMID: 12108617]">Carey 2002</a>). </p> </li> <li> <p>Exclusion criteria: most studies excluded people with a clinical diagnosis of psychosis, other mental disorders, or significant neurological or other medical conditions. Additional exclusion criteria included previous use of the intervention (<a href="./references#CD011769-bbs2-0104" title="NCT01624194. Intranasal oxytocin treatment for social deficits in children with autism [Double-blind, randomized, placebo controlled trial of intranasal oxytocin treatment for social deficits in children with autism]. clinicaltrials.gov/ct2/show/NCT01624194 (first received 20 June 2012). ParkerKJ , OztanO , LiboveRA , SumiyoshiRD , JacksonLP , KarhsonDS , et al. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proceedings of the National Academy of Sciences of the United States of America2017;114(30):8119‐24. [DOI: 10.1073/pnas.1705521114] [PMCID: PMC5544319] [PMID: 28696286]">Parker 2017</a>; <a href="./references#CD011769-bbs2-0105" title="NCT01962870. The role of vasopressin in the social deficits of autism [Randomized placebo-controlled trial of vasopressin treatment for social deficits in children with autism]. clinicaltrials.gov/ct2/show/NCT01962870 (first receceived 14 October 2013). ParkerKJ , OztanO , LiboveRA , MohsinN , KarhsonDS , SumiyoshiRD , et al. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Science Translational Medicine2019;11(491):eaau7356. [DOI: 10.1126/scitranslmed.aau7356] [PMCID: PMC6716148] [PMID: 31043522]">Parker 2019</a>; <a href="./references#CD011769-bbs2-0122" title="NCT00065962. Secretin for the treatment of autism [Multisite controlled secretin trial in autism]. clinicaltrials.gov/ct2/show/NCT00065962 (first received 5 August 2003). UnisAS , MunsonJA , RogersSJ , GoldsonE , OsterlingJ , GabrielsR , et al. A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(11):1315-21. [DOI: 10.1097/00004583-200211000-00012] [PMID: 12410073]">Unis 2002</a>), or use of psychotropic or other prohibited medications in the period before and during the trial. </p> </li> <li> <p>Setting: apart from one study conducted in Australia (<a href="./references#CD011769-bbs2-0039" title="ACTRN12609000513213. A course of oxytocin nasal spray (OT) to treat social problems in youth with autism spectrum disorders [A double blind randomised controlled trial of oxytocin nasal spray to treat social problems in autistic youth]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83655 (first received 29 June 2009). GuastellaAJ , GrayKM , RinehartNJ , AlvaresGA , TongeBJ , HickieIB , et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. Journal of Child Psychology and Psychiatry2015;56(4):444-52. [DOI: 10.1111/jcpp.12305] [PMID: 25087908]">Guastella 2015a</a>), two in Belgium (<a href="./references#CD011769-bbs2-0014" title="BernaertsS , BoetsB , BosmansG , SteyaertJ , AlaertsK . Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up. Molecular Autism2020;11(1):6. [DOI: 10.1186/s13229-020-0313-1] [PMCID: PMC6964112] [PMID: 31969977]BernaertsS , DillenC , SteyaertJ , AlaertsK . The effects of four weeks of intranasal oxytocinon social responsiveness and repetitive and restricted behaviors in autism spectrum disorders: a randomized controlled trial. Biological Psychiatry2020;81(10):S349-50. [ABSTRACT NO: 864] [DOI: 10.1016/j.biopsych.2017.02.589]Eudract 2014-000586-45. Oxytocin-based pharmacotherapy for autism spectrum disorders: Investigating the neural and behavioral effects of a promising intervention approach. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000586-45 (first registered May 2014). ">Bernaerts 2020</a>; <a href="./references#CD011769-bbs2-0096" title="NCT02940574. Neural and behavioral effects of oxytocin in autism spectrum disorders [Oxytocin-based pharmacotherapy for autism spectrum disorders: investigating the neural and behavioral effects of a promising intervention approach]. clinicaltrials.gov/ct2/show/NCT02940574 (first received 21 October 2016). ">NCT02940574</a>), one in Canada (<a href="./references#CD011769-bbs2-0094" title="NCT01908205. Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD) (OXY-R) [Intranasal oxytocin for the treatment of children and adolescents with autism]. clinicaltrials.gov/ct2/show/NCT01908205 (first received 25 July 2013). ">NCT01908205</a>), one in China (<a href="./references#CD011769-bbs2-0067" title="ChiCTR1900023774. The effects of chronic intranasal oxytocin combined with positive social interaction in the treatment of young children with autism. www.chictr.org.cn/showproj.aspx?proj=39640 (first received 11 June 2019). LeJ , ZhangL , ZhaoW , ZhiS , LanC , KouJ , et al. Infrequent intranasal oxytocin followed by positive social interaction improves symptoms in autistic children: a pilot randomized clinical trial. Psychotherapy and Psychosomatics2022;91(5):335-47. [DOI: 10.1159/000524543] [PMID: 35545057]">Le 2022</a>), one in the Netherlands (<a href="./references#CD011769-bbs2-0015" title="BuitelaarJK , Van EngelandH , De KogelKH , De VriesH , Van HooffJA , Van ReeJM . The use of adrenocorticotrophic hormone (4-9) analog ORG 2766 in autistic children: effects on the organization of behavior. Biological Psychiatry1992;31(11):1119-29. [DOI: 10.1016/0006-3223(92)90156-T] [PMID: 1326339]BuitelaarJK , Van EngelandH , Van ReeJM , De WiedD . Behavioral effects of Org 2766, a synthetic analog of the adrenocorticotrophic hormone (4–9), in 14 outpatient autistic children. Journal of Autism and Developmental Disorders1990;20(4):467-78. [DOI: 10.1007/BF02216053] [PMID: 2177746]">Buitelaar 1990</a>), and three in Japan (<a href="./references#CD011769-bbs2-0087" title="MunesueT , NakamuraH , KikuchiM , MiuraY , TakeuchiN , AnmeT , et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study. Frontiers in Psychiatry2016;7:2. [DOI: 10.3389/fpsyt.2016.00002] [PMCID: PMC4720778] [PMID: 26834651]UMIN000007250. A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008548 (first received 9 February 2012). ">Munesue 2016</a>; <a href="./references#CD011769-bbs2-0119" title="UMIN000007122. A randomized, double-blind and cross-over trial to examine effects of continuous administration of intranasal oxytocin on social dysfunction in subjects with autism spectrum disorders. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008388 (first received 1 February 2012). WatanabeT , KurodaM , KuwabaraH , AokiY , IwashiroN , TatsunobuN , et al. Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain2015;138(11):3400-12. [DOI: 10.1093/brain/awv249] [PMID: 26336909]">Takamitsu 2015a</a>; <a href="./references#CD011769-bbs2-0131" title="JPRN‐UMIN000015264. A multicenter, parallel group, placebo-controlled, double blind, confirmatory trial of intranasal oxytocin in participants with autism spectrum disorders. https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000015264 (first received March 2019). YamasueH , OkadaT , MunesueT , KurodaM , FujiokaT , UnoY , et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Molecular Psychiatry2020;25(8):1849-58. [DOI: 10.1038/s41380-018-0097-2] [PMID: 29955161]">Yamasue 2020</a>), all studies were conducted in the USA. Studies were conducted at either outpatient clinics, hospitals or clinics and research centres associated with universities. </p> </li> <li> <p>Concomitant medications: six studies provided details of concomitant medications. <a href="./references#CD011769-bbs2-0014" title="BernaertsS , BoetsB , BosmansG , SteyaertJ , AlaertsK . Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up. Molecular Autism2020;11(1):6. [DOI: 10.1186/s13229-020-0313-1] [PMCID: PMC6964112] [PMID: 31969977]BernaertsS , DillenC , SteyaertJ , AlaertsK . The effects of four weeks of intranasal oxytocinon social responsiveness and repetitive and restricted behaviors in autism spectrum disorders: a randomized controlled trial. Biological Psychiatry2020;81(10):S349-50. [ABSTRACT NO: 864] [DOI: 10.1016/j.biopsych.2017.02.589]Eudract 2014-000586-45. Oxytocin-based pharmacotherapy for autism spectrum disorders: Investigating the neural and behavioral effects of a promising intervention approach. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000586-45 (first registered May 2014). ">Bernaerts 2020</a> reported that 27% and 11% of those in the intervention and placebo groups respectively were taking psychostimulants concomitantly, as well as other medications including antidepressants, risperidone and aripiprazole. <a href="./references#CD011769-bbs2-0039" title="ACTRN12609000513213. A course of oxytocin nasal spray (OT) to treat social problems in youth with autism spectrum disorders [A double blind randomised controlled trial of oxytocin nasal spray to treat social problems in autistic youth]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83655 (first received 29 June 2009). GuastellaAJ , GrayKM , RinehartNJ , AlvaresGA , TongeBJ , HickieIB , et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. Journal of Child Psychology and Psychiatry2015;56(4):444-52. [DOI: 10.1111/jcpp.12305] [PMID: 25087908]">Guastella 2015a</a> reported that approximately 35% of participants in both groups were taking other psychotropic medications. <a href="./references#CD011769-bbs2-0069" title="LevySE , SoudersMC , WrayJ , JawadAF , Gallagher PR CoplinJ , et al. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin. Archives of Disease in Childhood2003;88(8):731-6. [DOI: 10.1136/adc.88.8.731] [PMCID: PMC1719589] [PMID: 12876177]">Levy 2003</a> reported that 10 participants out of 62 were taking one concurrent medication, including guanfacine, methylphenidate, fluoxetine (Prozac), and risperidone, and one participant was taking both guanfacine and Prozac concurrently. <a href="./references#CD011769-bbs2-0118" title="NCT01793441. A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) [A multi-center, randomized, double-blind, 12-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of rg7314 in individuals with autism spectrum disorders (ASD)]. clinicaltrials.gov/ct2/show/NCT01793441 (first received 15 February 2013). SquassanteL , BolognaniF , SmithJ , MurtaghL , FontouraP , KhwajaO , et al. Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla). Journal of the American Academy of Child and Adolescent Psychiatry2018;57(10):S231. [DOI: 10.1016/j.jaac.2018.09.308] [PRESENTATION NO: 5.13]">Squassante 2018</a> reported that antipsychotics were being taken concurrently by 15% to 28% of participants and concurrent stimulant use by 13% to 26% of participants. <a href="./references#CD011769-bbs2-0104" title="NCT01624194. Intranasal oxytocin treatment for social deficits in children with autism [Double-blind, randomized, placebo controlled trial of intranasal oxytocin treatment for social deficits in children with autism]. clinicaltrials.gov/ct2/show/NCT01624194 (first received 20 June 2012). ParkerKJ , OztanO , LiboveRA , SumiyoshiRD , JacksonLP , KarhsonDS , et al. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proceedings of the National Academy of Sciences of the United States of America2017;114(30):8119‐24. [DOI: 10.1073/pnas.1705521114] [PMCID: PMC5544319] [PMID: 28696286]">Parker 2017</a> reported concomitant medication use of up to 17% and included SSRIs, benzodiazepines, stimulants, anticonvulsants, and guanfacine, and <a href="./references#CD011769-bbs2-0131" title="JPRN‐UMIN000015264. A multicenter, parallel group, placebo-controlled, double blind, confirmatory trial of intranasal oxytocin in participants with autism spectrum disorders. https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000015264 (first received March 2019). YamasueH , OkadaT , MunesueT , KurodaM , FujiokaT , UnoY , et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Molecular Psychiatry2020;25(8):1849-58. [DOI: 10.1038/s41380-018-0097-2] [PMID: 29955161]">Yamasue 2020</a> reported antidepressants, antipsychotics, anticonvulsants or hypnotics were being taken concurrently by 12 participants. </p> </li> <li> <p>Participant cognitive status: reported IQ varied greatly between studies and ranged from 35 to 120. </p> </li> <li> <p>Length of follow‐up: study duration ranged from four weeks to 12 weeks (<a href="./references#CD011769-bbs2-0118" title="NCT01793441. A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) [A multi-center, randomized, double-blind, 12-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of rg7314 in individuals with autism spectrum disorders (ASD)]. clinicaltrials.gov/ct2/show/NCT01793441 (first received 15 February 2013). SquassanteL , BolognaniF , SmithJ , MurtaghL , FontouraP , KhwajaO , et al. Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla). Journal of the American Academy of Child and Adolescent Psychiatry2018;57(10):S231. [DOI: 10.1016/j.jaac.2018.09.308] [PRESENTATION NO: 5.13]">Squassante 2018</a>), although <a href="./references#CD011769-bbs2-0039" title="ACTRN12609000513213. A course of oxytocin nasal spray (OT) to treat social problems in youth with autism spectrum disorders [A double blind randomised controlled trial of oxytocin nasal spray to treat social problems in autistic youth]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83655 (first received 29 June 2009). GuastellaAJ , GrayKM , RinehartNJ , AlvaresGA , TongeBJ , HickieIB , et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. Journal of Child Psychology and Psychiatry2015;56(4):444-52. [DOI: 10.1111/jcpp.12305] [PMID: 25087908]">Guastella 2015a</a> reported three‐month follow‐up data for primary and secondary outcomes. </p> </li> </ul> </p> <section id="CD011769-sec-0080"> <h6 class="title">Primary outcomes</h6> <p> <ul id="CD011769-list-0022"> <li> <p>Irritability: 10 of the studies reported irritability. All but one study used the ABC‐I scale (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>), whereas <a href="./references#CD011769-bbs2-0069" title="LevySE , SoudersMC , WrayJ , JawadAF , Gallagher PR CoplinJ , et al. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin. Archives of Disease in Childhood2003;88(8):731-6. [DOI: 10.1136/adc.88.8.731] [PMCID: PMC1719589] [PMID: 12876177]">Levy 2003</a> used the Ritvo‐Freeman Real Life Rating Scale (affectual responses subscale; <a href="./references#CD011769-bbs2-0323" title="FreemanBJ , RitvoER , YokotaA , RitvoA . A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the American academy of child psychiatry1986;25(1):130-6. [DOI: 10.1016/S0002-7138(09)60610-5] [PMID: 3950262]">Freeman 1986</a>) to measure irritability. <a href="./references#CD011769-bbs2-0121" title="NCT01474278. A study of RO5028442 in adult male high-functioning autistic patients. https://clinicaltrials.gov/ct2/show/NCT01474278?term=NCT01474278&amp;draw=2&amp;rank=1 (first registered December 2011). UmbrichtD , Del Valle RubidoM , HollanderE , McCrackenJT , ShicF , ScahillL , et al. A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology2017;42(9):1914-23. [DOI: 10.1038/npp.2016.232] [PMCID: PMC5520775] [PMID: 27711048]">Umbricht 2017</a> reported baseline ABC‐I (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>) but did not report endpoint data. </p> </li> <li> <p>Self‐injury: <a href="./references#CD011769-bbs2-0039" title="ACTRN12609000513213. A course of oxytocin nasal spray (OT) to treat social problems in youth with autism spectrum disorders [A double blind randomised controlled trial of oxytocin nasal spray to treat social problems in autistic youth]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83655 (first received 29 June 2009). GuastellaAJ , GrayKM , RinehartNJ , AlvaresGA , TongeBJ , HickieIB , et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. Journal of Child Psychology and Psychiatry2015;56(4):444-52. [DOI: 10.1111/jcpp.12305] [PMID: 25087908]">Guastella 2015a</a> reported self‐injurious behaviour using the Repetitive Behaviour Scale ‐ Revised (self‐injurious subscale) (<a href="./references#CD011769-bbs2-0281" title="BodfishJW , SymonsFS , ParkerDE , LewisMH . Varieties of repetitive behavior in autism: comparisons to mental retardation. Journal of Autism and Developmental Disorders2000;30(3):237-43. [DOI: 10.1023/A:1005596502855] [PMID: 11055459]">Bodfish 2000</a>). </p> </li> <li> <p>AEs: 14 studies reported AEs, although <a href="./references#CD011769-bbs2-0069" title="LevySE , SoudersMC , WrayJ , JawadAF , Gallagher PR CoplinJ , et al. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin. Archives of Disease in Childhood2003;88(8):731-6. [DOI: 10.1136/adc.88.8.731] [PMCID: PMC1719589] [PMID: 12876177]">Levy 2003</a> did not report AEs for both groups and therefore, the AE data from <a href="./references#CD011769-bbs2-0069" title="LevySE , SoudersMC , WrayJ , JawadAF , Gallagher PR CoplinJ , et al. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin. Archives of Disease in Childhood2003;88(8):731-6. [DOI: 10.1136/adc.88.8.731] [PMCID: PMC1719589] [PMID: 12876177]">Levy 2003</a> could not be included. </p> </li> </ul> </p> </section> <section id="CD011769-sec-0081"> <h6 class="title">Secondary outcomes</h6> <p> <ul id="CD011769-list-0023"> <li> <p>Quality of life: five studies (<a href="./references#CD011769-bbs2-0005" title="AnagnosouE , SooryaL , ChaplinW , BartzJ , HalpernD , WassermanS , et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Molecular Autism2012;3(1):16. [DOI: 10.1186/2040-2392-3-16] [PMCID: PMC3539865] [PMID: 23216716]NCT00490802. Intranasal oxytocin in the treatment of autism. clinicaltrials.gov/ct2/show/NCT00490802 (first received 25 June 2007). ">Anagnostou 2012</a>; <a href="./references#CD011769-bbs2-0014" title="BernaertsS , BoetsB , BosmansG , SteyaertJ , AlaertsK . Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up. Molecular Autism2020;11(1):6. [DOI: 10.1186/s13229-020-0313-1] [PMCID: PMC6964112] [PMID: 31969977]BernaertsS , DillenC , SteyaertJ , AlaertsK . The effects of four weeks of intranasal oxytocinon social responsiveness and repetitive and restricted behaviors in autism spectrum disorders: a randomized controlled trial. Biological Psychiatry2020;81(10):S349-50. [ABSTRACT NO: 864] [DOI: 10.1016/j.biopsych.2017.02.589]Eudract 2014-000586-45. Oxytocin-based pharmacotherapy for autism spectrum disorders: Investigating the neural and behavioral effects of a promising intervention approach. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000586-45 (first registered May 2014). ">Bernaerts 2020</a>; <a href="./references#CD011769-bbs2-0094" title="NCT01908205. Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD) (OXY-R) [Intranasal oxytocin for the treatment of children and adolescents with autism]. clinicaltrials.gov/ct2/show/NCT01908205 (first received 25 July 2013). ">NCT01908205</a>; <a href="./references#CD011769-bbs2-0105" title="NCT01962870. The role of vasopressin in the social deficits of autism [Randomized placebo-controlled trial of vasopressin treatment for social deficits in children with autism]. clinicaltrials.gov/ct2/show/NCT01962870 (first receceived 14 October 2013). ParkerKJ , OztanO , LiboveRA , MohsinN , KarhsonDS , SumiyoshiRD , et al. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Science Translational Medicine2019;11(491):eaau7356. [DOI: 10.1126/scitranslmed.aau7356] [PMCID: PMC6716148] [PMID: 31043522]">Parker 2019</a>; <a href="./references#CD011769-bbs2-0119" title="UMIN000007122. A randomized, double-blind and cross-over trial to examine effects of continuous administration of intranasal oxytocin on social dysfunction in subjects with autism spectrum disorders. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008388 (first received 1 February 2012). WatanabeT , KurodaM , KuwabaraH , AokiY , IwashiroN , TatsunobuN , et al. Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain2015;138(11):3400-12. [DOI: 10.1093/brain/awv249] [PMID: 26336909]">Takamitsu 2015a</a>), reported quality of life. <a href="./references#CD011769-bbs2-0005" title="AnagnosouE , SooryaL , ChaplinW , BartzJ , HalpernD , WassermanS , et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Molecular Autism2012;3(1):16. [DOI: 10.1186/2040-2392-3-16] [PMCID: PMC3539865] [PMID: 23216716]NCT00490802. Intranasal oxytocin in the treatment of autism. clinicaltrials.gov/ct2/show/NCT00490802 (first received 25 June 2007). ">Anagnostou 2012</a>, <a href="./references#CD011769-bbs2-0014" title="BernaertsS , BoetsB , BosmansG , SteyaertJ , AlaertsK . Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up. Molecular Autism2020;11(1):6. [DOI: 10.1186/s13229-020-0313-1] [PMCID: PMC6964112] [PMID: 31969977]BernaertsS , DillenC , SteyaertJ , AlaertsK . The effects of four weeks of intranasal oxytocinon social responsiveness and repetitive and restricted behaviors in autism spectrum disorders: a randomized controlled trial. Biological Psychiatry2020;81(10):S349-50. [ABSTRACT NO: 864] [DOI: 10.1016/j.biopsych.2017.02.589]Eudract 2014-000586-45. Oxytocin-based pharmacotherapy for autism spectrum disorders: Investigating the neural and behavioral effects of a promising intervention approach. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000586-45 (first registered May 2014). ">Bernaerts 2020</a> and <a href="./references#CD011769-bbs2-0119" title="UMIN000007122. A randomized, double-blind and cross-over trial to examine effects of continuous administration of intranasal oxytocin on social dysfunction in subjects with autism spectrum disorders. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008388 (first received 1 February 2012). WatanabeT , KurodaM , KuwabaraH , AokiY , IwashiroN , TatsunobuN , et al. Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain2015;138(11):3400-12. [DOI: 10.1093/brain/awv249] [PMID: 26336909]">Takamitsu 2015a</a> used the WHO Quality of Life scale (WHOQoL; <a href="./references#CD011769-bbs2-0457" title="World Health Organization. WHO Quality of Life user manual. file:///U:/Downloads/WHO_HIS_HSI_Rev.2012.03_eng%20(1).pdf 1998.">WHO 1998</a>) and <a href="./references#CD011769-bbs2-0094" title="NCT01908205. Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD) (OXY-R) [Intranasal oxytocin for the treatment of children and adolescents with autism]. clinicaltrials.gov/ct2/show/NCT01908205 (first received 25 July 2013). ">NCT01908205</a> and <a href="./references#CD011769-bbs2-0105" title="NCT01962870. The role of vasopressin in the social deficits of autism [Randomized placebo-controlled trial of vasopressin treatment for social deficits in children with autism]. clinicaltrials.gov/ct2/show/NCT01962870 (first receceived 14 October 2013). ParkerKJ , OztanO , LiboveRA , MohsinN , KarhsonDS , SumiyoshiRD , et al. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Science Translational Medicine2019;11(491):eaau7356. [DOI: 10.1126/scitranslmed.aau7356] [PMCID: PMC6716148] [PMID: 31043522]">Parker 2019</a> used the Pediatric Quality of Life (PedQL) inventory (parent‐rated; <a href="./references#CD011769-bbs2-0449" title="VarniJW . The PedsQL measurement model for the pediatric quality of life inventory. https://www.pedsql.org/index.html (last accessed 3rd May 2022).">Varni 2001</a>). </p> </li> <li> <p>Tolerability and acceptability (loss to follow‐up): 67 participants (7.6%) withdrew and were not included in the relevant study analyses. Reasons included withdrawing consent (26), loss to follow‐up (12), AEs (12), other (5), poor/non‐compliance (3), protocol violation (3), worsening of behaviours of concern (2), physician decision (1), and an administrative error (1). </p> </li> </ul> </p> </section> </section> <section id="CD011769-sec-0082"> <h5 class="title">ADHD‐related medications versus placebo or other treatment</h5> <p>Thirteen studies (28 reports, 482 participants, 18 datasets) compared an ADHD‐related medication to a placebo or other intervention. All studies included children (&lt; 18 years) with study duration ranging from two weeks (<a href="./references#CD011769-bbs2-0108" title="QuintanaH , BirmaherB , StedgeD , LennonS , FreedJ , BridgeJ , et al. Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders1995;25(3):283-94. [DOI: 10.1007/BF02179289] [PMID: 7559293]">Quintana 1995</a>), to 11 weeks (<a href="./references#CD011769-bbs2-0097" title="Impact of combined medication and behavioral treatment for ASD &amp; ADHD. clinicaltrials.gov/ct2/NCT03242772?term=NCT03242772&amp;draw=2&amp;rank=1 (first received 14 December 2018). ">NCT03242772</a>); the mean was 5.5 weeks. Seven of the studies were cross‐overs and six were parallel (<a href="./references#CD011769-bbs2-0027" title="EslamzadehM , HebraniP , BehdaniF , MoghadamMD , PanaghiL , MirzadehM , et al. Assessment the efficacy of atomoxetine in autism spectrum disorders: a randomized, double-blind, placebo-controlled trial. Iranian Journal of Psychiatry and Behavioral Sciences2018;12(2):e10596. [DOI: 10.5812/ijpbs.10596]IRCT2016022826802N1. Assessment the efficacy of atomoxetin(stramox) in autism spectrum disorders 6-17 years old. www.irct.ir/trial/22109 (first received 31 August 2016). ">Eslamzadeh 2018</a>; <a href="./references#CD011769-bbs2-0045" title="ArnoldLE , OberN , AmanMG , HandenB , SmithT , PanX , et al. A 1.5-year follow-up of parent training and atomoxetine for attention-deficit/hyperactivity disorder symptoms and noncompliant/disruptive behavior in autism. Journal of Child and Adolescent Psychopharmacology2018;28(5):322-30. [DOI: 10.1089/cap.2017.0134] [PMCID: PMC5994674] [PMID: 29694241]HandenBL , AmanMG , ArnoldLE , HymanSL , TumuluruRV , LecavalierL , et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2015;54(11):905-15. [DOI: 10.1016/j.jaac.2015.08.013] [PMCID: PMC4625086] [PMID: 26506581]LecavalierL , PanX , SmithT , HandenBL , ArnoldLE , SilvermanL , et al. Parent stress in a randomized clinical trial of atomoxetine and parent training for children with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(4):980-7. [DOI: 10.1007/s10803-017-3345-4] [PMCID: PMC6070148] [PMID: 29022125]NCT00844753. Atomoxetine, placebo and parent management training in autism (Strattera) [Atomoxetine, placebo and parent management training in autism]. clinicaltrials.gov/ct2/show/NCT00844753 (first received 16 February 2016). SmithT , AmanMG , ArnoldLE , SilvermanLB , LecavalierL , HollwayJ , et al. Atomoxetine and parent training for children with autism and attention-deficit/hyperactivity disorder: a 24-week extension study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):868-76.e2. [DOI: 10.1016/j.jaac.2016.06.015] [PMCID: PMC5108566] [PMID: 27663942]TumuluruRV , Corbett-DickP , AmanMG , SmithT , ArnoldLE , PanX , et al. Adverse events of atomoxetine in a double-blind placebo-controlled study in children with autism. Journal of Child and Adolescent Psychopharmacology2017;27(8):708-14. [DOI: 10.1089/cap.2016.0187] [PMCID: PMC5651962] [PMID: 28509573]">Handen 2015</a>; <a href="./references#CD011769-bbs2-0048" title="HarfterkampM , BuitelaarJK , MinderaaRB , Van de Loo-NeusG , Van De Gaag R-J, HoekstraPJ . Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviours; inappropriate speech and fear of change. Journal of Child and Adolescent Psychopharmacology2014;24(9):481-5. [DOI: 10.1089/cap.2014.0026] [PMID: 25369243]HarfterkampM , Van Der MeerJ . Randomized double-blind study of atomoxetine vs. placebo followed by an open label extension period of treatment with atomoxetine for ADHD symptoms in children with ASD. European Child and Adolescent Psychiatry2013;22(2):S216-17. [DOI: 10.1007/s00787-013-0423-9] [ABSTRACT NO: PS-012]HarfterkampM , Van de Loo-NeusG , MinderaaRB , Van der Gaag R-J, EscobarR , SchachtA , et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(7):733-41. [DOI: 10.1016/j.jaac.2012.04.011] [PMID: 22721596]NCT00380692. Atomoxetine versus placebo for symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents with autism spectrum disorder [A randomized, double-blind comparison of atomoxetine hydrochloride and placebo for symptoms of attention-deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder]. clinicaltrials.gov/ct2/show/NCT00380692 (first received 26 September 2006). ">Harfterkamp 2014</a>;<a href="./references#CD011769-bbs2-0097" title="Impact of combined medication and behavioral treatment for ASD &amp; ADHD. clinicaltrials.gov/ct2/NCT03242772?term=NCT03242772&amp;draw=2&amp;rank=1 (first received 14 December 2018). ">NCT03242772</a>; <a href="./references#CD011769-bbs2-0091" title="NCT00498173. Effectiveness of atomoxetine in treating ADHD symptoms in children and adolescents with autism [Targeted pharmacologic interventions for autism: a double-blind, placebo-controlled trial of atomoxetine in children and adolescents with autism]. clinicaltrials.gov/ct2/show/NCT00498173 (first received 9 July 2007). ">NCT00498173</a>; <a href="./references#CD011769-bbs2-0112" title="Munoz MartinezV , Nuevo FernandezL , Mella DominguezL , Mata SaenzB , Asensio AguerriL . Guanfacine as an alternative for autism spectrum disorder with hyperactivity symptoms. European Neuropsychopharmacology2017;27(4):S607. [DOI: 10.1016/S0924-977X(17)31154-9] [POSTER NO: P.1.c.006]NCT01238575. Guanfacine for the treatment of hyperactivity in pervasive developmental disorder. clinicaltrials.gov/ct2/show/NCT01238575 (first received 10 November 2010). PolitteLC , ScahillL , FigueroaJ , McCrackenJT , KingB , McDougleCJ . A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology2018;43(8):1772-8. [DOI: 10.1038/s41386-018-0039-3] [PMCID: PMC6006142] [PMID: 29540864]ScahillL , McCrackenJT , KingBH , RockhillC , ShahB , PolitteL , et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. American Journal of Psychiatry2015;172(12):1197-206. [DOI: 10.1176/appi.ajp.2015.15010055] [PMID: 26315981]">Scahill 2015</a>). </p> <p> <ul id="CD011769-list-0024"> <li> <p>Interventions</p> <ul id="CD011769-list-0025"> <li> <p>Amphetamine: one study involving 18 participants compared amphetamine to a placebo (<a href="./references#CD011769-bbs2-0097" title="Impact of combined medication and behavioral treatment for ASD &amp; ADHD. clinicaltrials.gov/ct2/NCT03242772?term=NCT03242772&amp;draw=2&amp;rank=1 (first received 14 December 2018). ">NCT03242772</a>). Amphetamine was initiated at 3.1 mg once daily for 11 weeks and titrated upwards if tolerated. </p> </li> <li> <p>Atomoxetine: five studies involving 274 participants compared atomoxetine to a placebo (<a href="./references#CD011769-bbs2-0007" title="ArnoldLE , AmanM , CookAM , WitwerAN , HallKL , ThompsonS , et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(10):1196-205. [DOI: 10.1097/01.chi.0000231976.28719.2a] [PMID: 17003665]">Arnold 2006</a>; <a href="./references#CD011769-bbs2-0027" title="EslamzadehM , HebraniP , BehdaniF , MoghadamMD , PanaghiL , MirzadehM , et al. Assessment the efficacy of atomoxetine in autism spectrum disorders: a randomized, double-blind, placebo-controlled trial. Iranian Journal of Psychiatry and Behavioral Sciences2018;12(2):e10596. [DOI: 10.5812/ijpbs.10596]IRCT2016022826802N1. Assessment the efficacy of atomoxetin(stramox) in autism spectrum disorders 6-17 years old. www.irct.ir/trial/22109 (first received 31 August 2016). ">Eslamzadeh 2018</a>; <a href="./references#CD011769-bbs2-0045" title="ArnoldLE , OberN , AmanMG , HandenB , SmithT , PanX , et al. A 1.5-year follow-up of parent training and atomoxetine for attention-deficit/hyperactivity disorder symptoms and noncompliant/disruptive behavior in autism. Journal of Child and Adolescent Psychopharmacology2018;28(5):322-30. [DOI: 10.1089/cap.2017.0134] [PMCID: PMC5994674] [PMID: 29694241]HandenBL , AmanMG , ArnoldLE , HymanSL , TumuluruRV , LecavalierL , et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2015;54(11):905-15. [DOI: 10.1016/j.jaac.2015.08.013] [PMCID: PMC4625086] [PMID: 26506581]LecavalierL , PanX , SmithT , HandenBL , ArnoldLE , SilvermanL , et al. Parent stress in a randomized clinical trial of atomoxetine and parent training for children with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(4):980-7. [DOI: 10.1007/s10803-017-3345-4] [PMCID: PMC6070148] [PMID: 29022125]NCT00844753. Atomoxetine, placebo and parent management training in autism (Strattera) [Atomoxetine, placebo and parent management training in autism]. clinicaltrials.gov/ct2/show/NCT00844753 (first received 16 February 2016). SmithT , AmanMG , ArnoldLE , SilvermanLB , LecavalierL , HollwayJ , et al. Atomoxetine and parent training for children with autism and attention-deficit/hyperactivity disorder: a 24-week extension study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):868-76.e2. [DOI: 10.1016/j.jaac.2016.06.015] [PMCID: PMC5108566] [PMID: 27663942]TumuluruRV , Corbett-DickP , AmanMG , SmithT , ArnoldLE , PanX , et al. Adverse events of atomoxetine in a double-blind placebo-controlled study in children with autism. Journal of Child and Adolescent Psychopharmacology2017;27(8):708-14. [DOI: 10.1089/cap.2016.0187] [PMCID: PMC5651962] [PMID: 28509573]">Handen 2015</a>; <a href="./references#CD011769-bbs2-0048" title="HarfterkampM , BuitelaarJK , MinderaaRB , Van de Loo-NeusG , Van De Gaag R-J, HoekstraPJ . Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviours; inappropriate speech and fear of change. Journal of Child and Adolescent Psychopharmacology2014;24(9):481-5. [DOI: 10.1089/cap.2014.0026] [PMID: 25369243]HarfterkampM , Van Der MeerJ . Randomized double-blind study of atomoxetine vs. placebo followed by an open label extension period of treatment with atomoxetine for ADHD symptoms in children with ASD. European Child and Adolescent Psychiatry2013;22(2):S216-17. [DOI: 10.1007/s00787-013-0423-9] [ABSTRACT NO: PS-012]HarfterkampM , Van de Loo-NeusG , MinderaaRB , Van der Gaag R-J, EscobarR , SchachtA , et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(7):733-41. [DOI: 10.1016/j.jaac.2012.04.011] [PMID: 22721596]NCT00380692. Atomoxetine versus placebo for symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents with autism spectrum disorder [A randomized, double-blind comparison of atomoxetine hydrochloride and placebo for symptoms of attention-deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder]. clinicaltrials.gov/ct2/show/NCT00380692 (first received 26 September 2006). ">Harfterkamp 2014</a>; <a href="./references#CD011769-bbs2-0091" title="NCT00498173. Effectiveness of atomoxetine in treating ADHD symptoms in children and adolescents with autism [Targeted pharmacologic interventions for autism: a double-blind, placebo-controlled trial of atomoxetine in children and adolescents with autism]. clinicaltrials.gov/ct2/show/NCT00498173 (first received 9 July 2007). ">NCT00498173</a>). Atomoxetine commenced at 0.3 mg/kg/day to 0.5 mg/kg/day up to a maximum of 1.8 mg/kg/day. Mean final doses were 1.2 mg/kg/day administered once daily (<a href="./references#CD011769-bbs2-0048" title="HarfterkampM , BuitelaarJK , MinderaaRB , Van de Loo-NeusG , Van De Gaag R-J, HoekstraPJ . Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviours; inappropriate speech and fear of change. Journal of Child and Adolescent Psychopharmacology2014;24(9):481-5. [DOI: 10.1089/cap.2014.0026] [PMID: 25369243]HarfterkampM , Van Der MeerJ . Randomized double-blind study of atomoxetine vs. placebo followed by an open label extension period of treatment with atomoxetine for ADHD symptoms in children with ASD. European Child and Adolescent Psychiatry2013;22(2):S216-17. [DOI: 10.1007/s00787-013-0423-9] [ABSTRACT NO: PS-012]HarfterkampM , Van de Loo-NeusG , MinderaaRB , Van der Gaag R-J, EscobarR , SchachtA , et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(7):733-41. [DOI: 10.1016/j.jaac.2012.04.011] [PMID: 22721596]NCT00380692. Atomoxetine versus placebo for symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents with autism spectrum disorder [A randomized, double-blind comparison of atomoxetine hydrochloride and placebo for symptoms of attention-deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder]. clinicaltrials.gov/ct2/show/NCT00380692 (first received 26 September 2006). ">Harfterkamp 2014</a>), 1.2 mg/kg/day twice daily (<a href="./references#CD011769-bbs2-0027" title="EslamzadehM , HebraniP , BehdaniF , MoghadamMD , PanaghiL , MirzadehM , et al. Assessment the efficacy of atomoxetine in autism spectrum disorders: a randomized, double-blind, placebo-controlled trial. Iranian Journal of Psychiatry and Behavioral Sciences2018;12(2):e10596. [DOI: 10.5812/ijpbs.10596]IRCT2016022826802N1. Assessment the efficacy of atomoxetin(stramox) in autism spectrum disorders 6-17 years old. www.irct.ir/trial/22109 (first received 31 August 2016). ">Eslamzadeh 2018</a>), and 1.38 mg/kg/day administered twice daily (<a href="./references#CD011769-bbs2-0045" title="ArnoldLE , OberN , AmanMG , HandenB , SmithT , PanX , et al. A 1.5-year follow-up of parent training and atomoxetine for attention-deficit/hyperactivity disorder symptoms and noncompliant/disruptive behavior in autism. Journal of Child and Adolescent Psychopharmacology2018;28(5):322-30. [DOI: 10.1089/cap.2017.0134] [PMCID: PMC5994674] [PMID: 29694241]HandenBL , AmanMG , ArnoldLE , HymanSL , TumuluruRV , LecavalierL , et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2015;54(11):905-15. [DOI: 10.1016/j.jaac.2015.08.013] [PMCID: PMC4625086] [PMID: 26506581]LecavalierL , PanX , SmithT , HandenBL , ArnoldLE , SilvermanL , et al. Parent stress in a randomized clinical trial of atomoxetine and parent training for children with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(4):980-7. [DOI: 10.1007/s10803-017-3345-4] [PMCID: PMC6070148] [PMID: 29022125]NCT00844753. Atomoxetine, placebo and parent management training in autism (Strattera) [Atomoxetine, placebo and parent management training in autism]. clinicaltrials.gov/ct2/show/NCT00844753 (first received 16 February 2016). SmithT , AmanMG , ArnoldLE , SilvermanLB , LecavalierL , HollwayJ , et al. Atomoxetine and parent training for children with autism and attention-deficit/hyperactivity disorder: a 24-week extension study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):868-76.e2. [DOI: 10.1016/j.jaac.2016.06.015] [PMCID: PMC5108566] [PMID: 27663942]TumuluruRV , Corbett-DickP , AmanMG , SmithT , ArnoldLE , PanX , et al. Adverse events of atomoxetine in a double-blind placebo-controlled study in children with autism. Journal of Child and Adolescent Psychopharmacology2017;27(8):708-14. [DOI: 10.1089/cap.2016.0187] [PMCID: PMC5651962] [PMID: 28509573]">Handen 2015</a>). </p> </li> <li> <p>Clonidine: two studies (17 participants) compared clonidine to a placebo. <a href="./references#CD011769-bbs2-0028" title="FankhauserMP , KaramanchiVC , GermanML , YatesA , KaramanchiSD . A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry1992;53(3):77-82. [PMID: 1548248]">Fankhauser 1992</a> administered clonidine via a weekly transdermal patch (approx 0.005 mg/kg/day) and <a href="./references#CD011769-bbs2-0061" title="JaselskisCA , CookEH , FletcherKE , LeventhalBL . Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology1992;12(5):322-7. [PMID: 1479049]">Jaselskis 1992</a> administered 0.15 mg/kg/day to 0.20 mg/kg/day across three doses per day. </p> </li> <li> <p>Guanfacine: two studies (73 participants) compared guanfacine to a placebo. The maximum daily dose of guanfacine was 3.0 mg/day across three daily doses (mean daily dose 2.68 mg/day; <a href="./references#CD011769-bbs2-0043" title="HandenBL , SahlR , HardanAY . Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental &amp; Behavioral Pediatrics2008;29(4):303-8. [DOI: 10.1097/DBP.0b013e3181739b9d] [PMID: 18552703]">Handen 2008</a>) or a maximum of 3 mg/day for children less than 25 kg and maximum 4 mg/day for children 25 kg or more (<a href="./references#CD011769-bbs2-0112" title="Munoz MartinezV , Nuevo FernandezL , Mella DominguezL , Mata SaenzB , Asensio AguerriL . Guanfacine as an alternative for autism spectrum disorder with hyperactivity symptoms. European Neuropsychopharmacology2017;27(4):S607. [DOI: 10.1016/S0924-977X(17)31154-9] [POSTER NO: P.1.c.006]NCT01238575. Guanfacine for the treatment of hyperactivity in pervasive developmental disorder. clinicaltrials.gov/ct2/show/NCT01238575 (first received 10 November 2010). PolitteLC , ScahillL , FigueroaJ , McCrackenJT , KingB , McDougleCJ . A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology2018;43(8):1772-8. [DOI: 10.1038/s41386-018-0039-3] [PMCID: PMC6006142] [PMID: 29540864]ScahillL , McCrackenJT , KingBH , RockhillC , ShahB , PolitteL , et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. American Journal of Psychiatry2015;172(12):1197-206. [DOI: 10.1176/appi.ajp.2015.15010055] [PMID: 26315981]">Scahill 2015</a>). </p> </li> <li> <p>Methylphenidate: three studies (7 datasets, 100 participants) compared methylphenidate to a placebo. Methylphenidate was administered two to three times daily using fixed doses. All studies were cross‐over studies: <a href="./references#CD011769-bbs2-0107" title="NCT00025779. Methylphenidate in children and adolescents with pervasive developmental disorders [Methylphenidate for hyperactivity and impulsiveness in children and adolescents with pervasive developmental disorders]. clinicaltrials.gov/ct2/show/NCT00025779 (first received 24 October 2001). Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry2005;62(11):1266-74. [DOI: 10.1001/archpsyc.62.11.1266] [PMID: 16275814]ScahillL , BearssK , SarhangianR , McDougleCJ , ArnoldLE , AmanMG , et al. Using a patient-centered outcome measure to test methylphenidate versus placebo in children with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology2017;27(2):125-31. [DOI: 10.1089/cap.2016.0107] [PMCID: PMC5367913] [PMID: 27893955]">Posey 2005</a> administered three different doses (3 datasets) based on bodyweight (0.125 mg/kg/day, 0.250 mg/kg/day, 0.500 mg/kg/day); <a href="./references#CD011769-bbs2-0108" title="QuintanaH , BirmaherB , StedgeD , LennonS , FreedJ , BridgeJ , et al. Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders1995;25(3):283-94. [DOI: 10.1007/BF02179289] [PMID: 7559293]">Quintana 1995</a> administered a mean methylphenidate dose of 0.397 mg/kg/day; and <a href="./references#CD011769-bbs2-0106" title="NCT00178503. Methylphenidate for attention deficit hyperactivity disorder and autism in children [ADHD symptoms in autism: cognition, behavior, treatment]. www.clinicaltrials.gov/ct2/show/NCT00178503 (first received 15 September 2005). PearsonDA , SantosCW , AmanMG , ArnoldLE , CasatCD , MansourR , et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. Journal of Child and Adolescent Psychopharmacology2013;23(5):337-51. [DOI: 10.1089/cap.2012.0096] [PMCID: PMC3689935] [PMID: 23782128]">Pearson 2013</a> had mean doses of 0.21 mg/kg, 0.35 mg/kg and 0.48 mg/kg for low, medium and high doses respectively. </p> </li> </ul> </li> <li> <p>Comparators: all studies compared an ADHD‐related medication to a placebo. Only one study (<a href="./references#CD011769-bbs2-0045" title="ArnoldLE , OberN , AmanMG , HandenB , SmithT , PanX , et al. A 1.5-year follow-up of parent training and atomoxetine for attention-deficit/hyperactivity disorder symptoms and noncompliant/disruptive behavior in autism. Journal of Child and Adolescent Psychopharmacology2018;28(5):322-30. [DOI: 10.1089/cap.2017.0134] [PMCID: PMC5994674] [PMID: 29694241]HandenBL , AmanMG , ArnoldLE , HymanSL , TumuluruRV , LecavalierL , et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2015;54(11):905-15. [DOI: 10.1016/j.jaac.2015.08.013] [PMCID: PMC4625086] [PMID: 26506581]LecavalierL , PanX , SmithT , HandenBL , ArnoldLE , SilvermanL , et al. Parent stress in a randomized clinical trial of atomoxetine and parent training for children with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(4):980-7. [DOI: 10.1007/s10803-017-3345-4] [PMCID: PMC6070148] [PMID: 29022125]NCT00844753. Atomoxetine, placebo and parent management training in autism (Strattera) [Atomoxetine, placebo and parent management training in autism]. clinicaltrials.gov/ct2/show/NCT00844753 (first received 16 February 2016). SmithT , AmanMG , ArnoldLE , SilvermanLB , LecavalierL , HollwayJ , et al. Atomoxetine and parent training for children with autism and attention-deficit/hyperactivity disorder: a 24-week extension study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):868-76.e2. [DOI: 10.1016/j.jaac.2016.06.015] [PMCID: PMC5108566] [PMID: 27663942]TumuluruRV , Corbett-DickP , AmanMG , SmithT , ArnoldLE , PanX , et al. Adverse events of atomoxetine in a double-blind placebo-controlled study in children with autism. Journal of Child and Adolescent Psychopharmacology2017;27(8):708-14. [DOI: 10.1089/cap.2016.0187] [PMCID: PMC5651962] [PMID: 28509573]">Handen 2015</a>), provided details of the placebo (sugar pill). </p> </li> <li> <p>Inclusion criteria: all studies required participants to meet the DSM criteria for ASD, Asperger's or PDD‐NOS. Other criteria included a minimum mental age of 24 months, and symptoms of hyperactivity or impulsiveness for at least six months. </p> </li> <li> <p>Exclusion criteria: prior exposure to ADHD‐related medication in the past two years, adverse reaction to the intervention, concurrent psychotropic medication use, other significant neurological, psychiatric, or medical conditions that may require medical management </p> </li> <li> <p>Setting: apart from two trials that were conducted in Iran and the Netherlands respectively (<a href="./references#CD011769-bbs2-0027" title="EslamzadehM , HebraniP , BehdaniF , MoghadamMD , PanaghiL , MirzadehM , et al. Assessment the efficacy of atomoxetine in autism spectrum disorders: a randomized, double-blind, placebo-controlled trial. Iranian Journal of Psychiatry and Behavioral Sciences2018;12(2):e10596. [DOI: 10.5812/ijpbs.10596]IRCT2016022826802N1. Assessment the efficacy of atomoxetin(stramox) in autism spectrum disorders 6-17 years old. www.irct.ir/trial/22109 (first received 31 August 2016). ">Eslamzadeh 2018</a>; <a href="./references#CD011769-bbs2-0048" title="HarfterkampM , BuitelaarJK , MinderaaRB , Van de Loo-NeusG , Van De Gaag R-J, HoekstraPJ . Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviours; inappropriate speech and fear of change. Journal of Child and Adolescent Psychopharmacology2014;24(9):481-5. [DOI: 10.1089/cap.2014.0026] [PMID: 25369243]HarfterkampM , Van Der MeerJ . Randomized double-blind study of atomoxetine vs. placebo followed by an open label extension period of treatment with atomoxetine for ADHD symptoms in children with ASD. European Child and Adolescent Psychiatry2013;22(2):S216-17. [DOI: 10.1007/s00787-013-0423-9] [ABSTRACT NO: PS-012]HarfterkampM , Van de Loo-NeusG , MinderaaRB , Van der Gaag R-J, EscobarR , SchachtA , et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2012;51(7):733-41. [DOI: 10.1016/j.jaac.2012.04.011] [PMID: 22721596]NCT00380692. Atomoxetine versus placebo for symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents with autism spectrum disorder [A randomized, double-blind comparison of atomoxetine hydrochloride and placebo for symptoms of attention-deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder]. clinicaltrials.gov/ct2/show/NCT00380692 (first received 26 September 2006). ">Harfterkamp 2014</a>), all studies were conducted in the USA, with participants recruited from either outpatient clinics or clinics and research centres associated with universities. </p> </li> <li> <p>Concomitant medications: all studies required participants to be free of all psychotropic medications for up to one month prior to starting the study apart from <a href="./references#CD011769-bbs2-0106" title="NCT00178503. Methylphenidate for attention deficit hyperactivity disorder and autism in children [ADHD symptoms in autism: cognition, behavior, treatment]. www.clinicaltrials.gov/ct2/show/NCT00178503 (first received 15 September 2005). PearsonDA , SantosCW , AmanMG , ArnoldLE , CasatCD , MansourR , et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. Journal of Child and Adolescent Psychopharmacology2013;23(5):337-51. [DOI: 10.1089/cap.2012.0096] [PMCID: PMC3689935] [PMID: 23782128]">Pearson 2013</a>, which allowed stable (&gt; 3 months) medications to be continued during the trial. </p> </li> <li> <p>Participant cognitive status: the reported IQ ranged from severe intellectual disability to over 90. </p> </li> <li> <p>Length of follow‐up: study duration was between one week (<a href="./references#CD011769-bbs2-0106" title="NCT00178503. Methylphenidate for attention deficit hyperactivity disorder and autism in children [ADHD symptoms in autism: cognition, behavior, treatment]. www.clinicaltrials.gov/ct2/show/NCT00178503 (first received 15 September 2005). PearsonDA , SantosCW , AmanMG , ArnoldLE , CasatCD , MansourR , et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. Journal of Child and Adolescent Psychopharmacology2013;23(5):337-51. [DOI: 10.1089/cap.2012.0096] [PMCID: PMC3689935] [PMID: 23782128]">Pearson 2013</a>), and 10 weeks (<a href="./references#CD011769-bbs2-0045" title="ArnoldLE , OberN , AmanMG , HandenB , SmithT , PanX , et al. A 1.5-year follow-up of parent training and atomoxetine for attention-deficit/hyperactivity disorder symptoms and noncompliant/disruptive behavior in autism. Journal of Child and Adolescent Psychopharmacology2018;28(5):322-30. [DOI: 10.1089/cap.2017.0134] [PMCID: PMC5994674] [PMID: 29694241]HandenBL , AmanMG , ArnoldLE , HymanSL , TumuluruRV , LecavalierL , et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2015;54(11):905-15. [DOI: 10.1016/j.jaac.2015.08.013] [PMCID: PMC4625086] [PMID: 26506581]LecavalierL , PanX , SmithT , HandenBL , ArnoldLE , SilvermanL , et al. Parent stress in a randomized clinical trial of atomoxetine and parent training for children with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(4):980-7. [DOI: 10.1007/s10803-017-3345-4] [PMCID: PMC6070148] [PMID: 29022125]NCT00844753. Atomoxetine, placebo and parent management training in autism (Strattera) [Atomoxetine, placebo and parent management training in autism]. clinicaltrials.gov/ct2/show/NCT00844753 (first received 16 February 2016). SmithT , AmanMG , ArnoldLE , SilvermanLB , LecavalierL , HollwayJ , et al. Atomoxetine and parent training for children with autism and attention-deficit/hyperactivity disorder: a 24-week extension study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):868-76.e2. [DOI: 10.1016/j.jaac.2016.06.015] [PMCID: PMC5108566] [PMID: 27663942]TumuluruRV , Corbett-DickP , AmanMG , SmithT , ArnoldLE , PanX , et al. Adverse events of atomoxetine in a double-blind placebo-controlled study in children with autism. Journal of Child and Adolescent Psychopharmacology2017;27(8):708-14. [DOI: 10.1089/cap.2016.0187] [PMCID: PMC5651962] [PMID: 28509573]">Handen 2015</a>). </p> </li> </ul> </p> <section id="CD011769-sec-0083"> <h6 class="title">Primary outcomes</h6> <p> <ul id="CD011769-list-0026"> <li> <p>Irritability ‐ all studies apart from <a href="./references#CD011769-bbs2-0027" title="EslamzadehM , HebraniP , BehdaniF , MoghadamMD , PanaghiL , MirzadehM , et al. Assessment the efficacy of atomoxetine in autism spectrum disorders: a randomized, double-blind, placebo-controlled trial. Iranian Journal of Psychiatry and Behavioral Sciences2018;12(2):e10596. [DOI: 10.5812/ijpbs.10596]IRCT2016022826802N1. Assessment the efficacy of atomoxetin(stramox) in autism spectrum disorders 6-17 years old. www.irct.ir/trial/22109 (first received 31 August 2016). ">Eslamzadeh 2018</a> and <a href="./references#CD011769-bbs2-0097" title="Impact of combined medication and behavioral treatment for ASD &amp; ADHD. clinicaltrials.gov/ct2/NCT03242772?term=NCT03242772&amp;draw=2&amp;rank=1 (first received 14 December 2018). ">NCT03242772</a> reported irritability. All studies apart from one used the ABC‐I (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>), however, <a href="./references#CD011769-bbs2-0107" title="NCT00025779. Methylphenidate in children and adolescents with pervasive developmental disorders [Methylphenidate for hyperactivity and impulsiveness in children and adolescents with pervasive developmental disorders]. clinicaltrials.gov/ct2/show/NCT00025779 (first received 24 October 2001). Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry2005;62(11):1266-74. [DOI: 10.1001/archpsyc.62.11.1266] [PMID: 16275814]ScahillL , BearssK , SarhangianR , McDougleCJ , ArnoldLE , AmanMG , et al. Using a patient-centered outcome measure to test methylphenidate versus placebo in children with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology2017;27(2):125-31. [DOI: 10.1089/cap.2016.0107] [PMCID: PMC5367913] [PMID: 27893955]">Posey 2005</a> did not report endpoint ABC‐I scores. <a href="./references#CD011769-bbs2-0028" title="FankhauserMP , KaramanchiVC , GermanML , YatesA , KaramanchiSD . A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry1992;53(3):77-82. [PMID: 1548248]">Fankhauser 1992</a> used the Ritvo‐Freeman Real Life Rating Scale (<a href="./references#CD011769-bbs2-0323" title="FreemanBJ , RitvoER , YokotaA , RitvoA . A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the American academy of child psychiatry1986;25(1):130-6. [DOI: 10.1016/S0002-7138(09)60610-5] [PMID: 3950262]">Freeman 1986</a>). </p> </li> <li> <p>Self‐injury ‐ only one study (<a href="./references#CD011769-bbs2-0007" title="ArnoldLE , AmanM , CookAM , WitwerAN , HallKL , ThompsonS , et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(10):1196-205. [DOI: 10.1097/01.chi.0000231976.28719.2a] [PMID: 17003665]">Arnold 2006</a>), reported self‐injurious behaviour using the Repetitive Behaviour Scale ‐ Revised (self‐injury subscale; <a href="./references#CD011769-bbs2-0281" title="BodfishJW , SymonsFS , ParkerDE , LewisMH . Varieties of repetitive behavior in autism: comparisons to mental retardation. Journal of Autism and Developmental Disorders2000;30(3):237-43. [DOI: 10.1023/A:1005596502855] [PMID: 11055459]">Bodfish 2000</a>). </p> </li> <li> <p>AEs ‐ nine of the studies reported AEs.</p> </li> </ul> </p> </section> <section id="CD011769-sec-0084"> <h6 class="title">Secondary outcomes</h6> <p> <ul id="CD011769-list-0027"> <li> <p>Tolerability and acceptability (loss to follow‐up)</p> </li> </ul> </p> </section> </section> <section id="CD011769-sec-0085"> <h5 class="title">Antidepressants versus placebo or other treatment</h5> <p>Ten studies (22 reports, 662 participants, 10 datasets) compared an antidepressant to a placebo or another intervention. An additional study (<a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a>) compared clomipramine to a placebo, however, those numbers have already been included in a previous comparison. Three studies involved children only (&lt; 12 years), four studies included children and adolescents (&lt; 18 years), two studies included children, adolescent and adult participants (<a href="./references#CD011769-bbs2-0038" title="GordonCT , RapoportJL , HamburgerSD , StateRC , MannheimGB . Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry1992;149(3):363-6. [DOI: 10.1176/ajp.149.3.363]GordonCT , StateRC , NelsonJE , HamburgerSD , RapoportJL . A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. JAMA1993;50(6):2441-7. [DOI: 10.1001/archpsyc.1993.01820180039004]">Gordon 1993</a>; <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a>), and two studies included only adult participants (<a href="./references#CD011769-bbs2-0056" title="HollanderE , SooryaL , ChaplinW , AnagnostouE , TaylorBP , FerrettiCJ , et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry2012;169(3):292-9. Erratum in: American Journal of Psychiatry. 2012 May;169(5):540. [DOI: 10.1176/appi.ajp.2011.10050764] [PMID: 22193531]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. https://clinicaltrials.gov/show/NCT00004486 (first received 19 October 1999). ">Hollander 2012</a>; <a href="./references#CD011769-bbs2-0079" title="HuffmanG . Fluvoxamine for the treatment of autistic disorders in adults. American Family Physician1997;55(4):1375-4. McDougleCJ , NaylorST , CohenDJ , VolkmarFR , HeningerGR , PriceLH . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry1996;53(11):1001-8. [DOI: 10.1001/archpsyc.1996.01830110037005] [PMID: 8911223]VegsoSJ . A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]. New Haven (CT): Southern Connecticut State University, 1995. ">McDougle 1996</a>). Seven studies were parallel and four were cross‐over studies (<a href="./references#CD011769-bbs2-0038" title="GordonCT , RapoportJL , HamburgerSD , StateRC , MannheimGB . Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry1992;149(3):363-6. [DOI: 10.1176/ajp.149.3.363]GordonCT , StateRC , NelsonJE , HamburgerSD , RapoportJL . A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. JAMA1993;50(6):2441-7. [DOI: 10.1001/archpsyc.1993.01820180039004]">Gordon 1993</a>; <a href="./references#CD011769-bbs2-0052" title="HollanderE , SwansonE , AnagnostouE , PhillipsA , ChaplinW , WassermanS . Liquid fluoxetine versus placebo for repetitive behaviors in childhood autism. Progress in Neurotherapeutics and Neuropsychopharmacology2006;1(1):105-13. [DOI: 10.1017/S1748232105000108]HollanderE, PhillipsA , ChaplinW , ZagurskyK , NovotnyS , WassermanS , et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism. Neuropsychopharmacology2005;30(3):582-9. [DOI: 10.1038/sj.npp.1300627] [PMID: 15602505]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. clinicaltrials.gov/ct2/show/NCT00004486 (first received 19 October 1999). ">Hollander 2005</a>; <a href="./references#CD011769-bbs2-0099" title="NiederhoferH , StaffenW , MairA . Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder. Human Psychopharmacology2003;18(5):389-93. [DOI: 10.1002/hup.491] [PMID: 12858327]">Niederhofer 2003</a>; <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a>). Study duration ranged from five weeks (<a href="./references#CD011769-bbs2-0038" title="GordonCT , RapoportJL , HamburgerSD , StateRC , MannheimGB . Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry1992;149(3):363-6. [DOI: 10.1176/ajp.149.3.363]GordonCT , StateRC , NelsonJE , HamburgerSD , RapoportJL . A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. JAMA1993;50(6):2441-7. [DOI: 10.1001/archpsyc.1993.01820180039004]">Gordon 1993</a>) to 12 months (<a href="./references#CD011769-bbs2-0088" title="NCT00183339. Early intervention with fluoxetine in autism [A randomized, placebo-controlled trial of fluoxetine in preschool children]. clinicaltrials.gov/ct2/show/NCT00183339 (first received 16 September 2005). ">NCT00183339</a>). </p> <p> <ul id="CD011769-list-0028"> <li> <p>Interventions</p> <ul id="CD011769-list-0029"> <li> <p>Citalopram: one study involving 149 participants compared citalopram to a placebo (<a href="./references#CD011769-bbs2-0065" title="KingBH , HollanderE , SikichL , McCrackenJT , ScahillL , BregmanJD , et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Archives of General Psychiatry2009;66(6):583-90. [DOI: 10.1001/archgenpsychiatry.2009.30] [PMCID: PMC4112556] [PMID: 19487623]MyersSM . Citalopram not effective for repetitive behavior in autistic spectum disorders. Evidence-Based Mental Health2010;13(1):22. [DOI: 10.1136/ebmh.13.1.22] [PMID: 20164519]NCT00086645. Citalopram for children with autism and repetitive behavior (STAART Study 1) [Citalopram treatment in children with autism spectrum disorders and high levels of repetitive behavior]. clinicaltrials.gov/ct2/show/NCT00086645 (first received 13 July 2004). ScahillL , McCrackenJT , BearssK , RobinsonF , HollanderE , KingB , et al. Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders2012;42(3):432-40. [DOI: 10.1007/s10803-011-1251-8] [PMID: 21667200]">King 2009</a>). Maximum citalopram was 20 mg/day (mean maximum dose was 16.5 mg/day (+/‐6.5 mg)). </p> </li> <li> <p>Clomipramine: two studies compared clomipramine to a placebo. <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a> (48 participants) commenced clomipramine at 25 mg once daily and increased incrementally up to 50 mg twice daily. <a href="./references#CD011769-bbs2-0038" title="GordonCT , RapoportJL , HamburgerSD , StateRC , MannheimGB . Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry1992;149(3):363-6. [DOI: 10.1176/ajp.149.3.363]GordonCT , StateRC , NelsonJE , HamburgerSD , RapoportJL . A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. JAMA1993;50(6):2441-7. [DOI: 10.1001/archpsyc.1993.01820180039004]">Gordon 1993</a> (12 participants) commenced clomipramine at 25 mg/day up to a maximum of 5 mg/kg/day or maximum of 250 mg/day. The participants involved with <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a> had previously been counted, so only the 12 participants from <a href="./references#CD011769-bbs2-0038" title="GordonCT , RapoportJL , HamburgerSD , StateRC , MannheimGB . Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry1992;149(3):363-6. [DOI: 10.1176/ajp.149.3.363]GordonCT , StateRC , NelsonJE , HamburgerSD , RapoportJL . A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. JAMA1993;50(6):2441-7. [DOI: 10.1001/archpsyc.1993.01820180039004]">Gordon 1993</a> are included in the official count. </p> </li> <li> <p>Fluoxetine: five studies involving 401 participants compared fluoxetine to a placebo (<a href="./references#CD011769-bbs2-0051" title="HerscuP , HandenBL , ArnoldLE , SnapeMF , BregmanJD , GinsbergL , et al. The SOFIA Study: negative multi‑center study of low dose fluoxetine on repetitive behaviors in children and adolescents with autistic disorder. Journal of Autism and Developmental Disorders2020;50(9):3233-44. [DOI: 10.1007/s10803-019-04120-y] [PMID: 31267292]NCT00515320. Study of fluoxetine in autism (SOFIA) [Study of fluoxetine in autism: a randomised, double-blind, placebo-controlled, parallel-group 14-week study to investigate the effect of fluoxetine orally dissolving tablet (odt) on repetitive behaviors in childhood and adolescent autistic disorder]. clinicaltrials.gov/ct2/show/NCT00515320 (first received 13 August 2007). ">Herscu 2020</a>; <a href="./references#CD011769-bbs2-0052" title="HollanderE , SwansonE , AnagnostouE , PhillipsA , ChaplinW , WassermanS . Liquid fluoxetine versus placebo for repetitive behaviors in childhood autism. Progress in Neurotherapeutics and Neuropsychopharmacology2006;1(1):105-13. [DOI: 10.1017/S1748232105000108]HollanderE, PhillipsA , ChaplinW , ZagurskyK , NovotnyS , WassermanS , et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism. Neuropsychopharmacology2005;30(3):582-9. [DOI: 10.1038/sj.npp.1300627] [PMID: 15602505]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. clinicaltrials.gov/ct2/show/NCT00004486 (first received 19 October 1999). ">Hollander 2005</a>; <a href="./references#CD011769-bbs2-0056" title="HollanderE , SooryaL , ChaplinW , AnagnostouE , TaylorBP , FerrettiCJ , et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry2012;169(3):292-9. Erratum in: American Journal of Psychiatry. 2012 May;169(5):540. [DOI: 10.1176/appi.ajp.2011.10050764] [PMID: 22193531]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. https://clinicaltrials.gov/show/NCT00004486 (first received 19 October 1999). ">Hollander 2012</a>; <a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a>; <a href="./references#CD011769-bbs2-0088" title="NCT00183339. Early intervention with fluoxetine in autism [A randomized, placebo-controlled trial of fluoxetine in preschool children]. clinicaltrials.gov/ct2/show/NCT00183339 (first received 16 September 2005). ">NCT00183339</a>). Four of the studies involved only children (<a href="./references#CD011769-bbs2-0051" title="HerscuP , HandenBL , ArnoldLE , SnapeMF , BregmanJD , GinsbergL , et al. The SOFIA Study: negative multi‑center study of low dose fluoxetine on repetitive behaviors in children and adolescents with autistic disorder. Journal of Autism and Developmental Disorders2020;50(9):3233-44. [DOI: 10.1007/s10803-019-04120-y] [PMID: 31267292]NCT00515320. Study of fluoxetine in autism (SOFIA) [Study of fluoxetine in autism: a randomised, double-blind, placebo-controlled, parallel-group 14-week study to investigate the effect of fluoxetine orally dissolving tablet (odt) on repetitive behaviors in childhood and adolescent autistic disorder]. clinicaltrials.gov/ct2/show/NCT00515320 (first received 13 August 2007). ">Herscu 2020</a>; <a href="./references#CD011769-bbs2-0052" title="HollanderE , SwansonE , AnagnostouE , PhillipsA , ChaplinW , WassermanS . Liquid fluoxetine versus placebo for repetitive behaviors in childhood autism. Progress in Neurotherapeutics and Neuropsychopharmacology2006;1(1):105-13. [DOI: 10.1017/S1748232105000108]HollanderE, PhillipsA , ChaplinW , ZagurskyK , NovotnyS , WassermanS , et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism. Neuropsychopharmacology2005;30(3):582-9. [DOI: 10.1038/sj.npp.1300627] [PMID: 15602505]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. clinicaltrials.gov/ct2/show/NCT00004486 (first received 19 October 1999). ">Hollander 2005</a>; <a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a>; <a href="./references#CD011769-bbs2-0088" title="NCT00183339. Early intervention with fluoxetine in autism [A randomized, placebo-controlled trial of fluoxetine in preschool children]. clinicaltrials.gov/ct2/show/NCT00183339 (first received 16 September 2005). ">NCT00183339</a>). They initiated fluoxetine at 2.0 mg/day to 8.0 mg/day depending on weight up to a maximum of 0.8 mg/kg/day (mean final dose 9.9 mg/day; <a href="./references#CD011769-bbs2-0052" title="HollanderE , SwansonE , AnagnostouE , PhillipsA , ChaplinW , WassermanS . Liquid fluoxetine versus placebo for repetitive behaviors in childhood autism. Progress in Neurotherapeutics and Neuropsychopharmacology2006;1(1):105-13. [DOI: 10.1017/S1748232105000108]HollanderE, PhillipsA , ChaplinW , ZagurskyK , NovotnyS , WassermanS , et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism. Neuropsychopharmacology2005;30(3):582-9. [DOI: 10.1038/sj.npp.1300627] [PMID: 15602505]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. clinicaltrials.gov/ct2/show/NCT00004486 (first received 19 October 1999). ">Hollander 2005</a>), a maximum of 20 mg/day and 30 mg/day for children under 40 kg and 40 kg and above (<a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a>; <a href="./references#CD011769-bbs2-0088" title="NCT00183339. Early intervention with fluoxetine in autism [A randomized, placebo-controlled trial of fluoxetine in preschool children]. clinicaltrials.gov/ct2/show/NCT00183339 (first received 16 September 2005). ">NCT00183339</a>), or a maximum of 18 mg/day (mean final dose 11.8 mg ± 6.5; <a href="./references#CD011769-bbs2-0051" title="HerscuP , HandenBL , ArnoldLE , SnapeMF , BregmanJD , GinsbergL , et al. The SOFIA Study: negative multi‑center study of low dose fluoxetine on repetitive behaviors in children and adolescents with autistic disorder. Journal of Autism and Developmental Disorders2020;50(9):3233-44. [DOI: 10.1007/s10803-019-04120-y] [PMID: 31267292]NCT00515320. Study of fluoxetine in autism (SOFIA) [Study of fluoxetine in autism: a randomised, double-blind, placebo-controlled, parallel-group 14-week study to investigate the effect of fluoxetine orally dissolving tablet (odt) on repetitive behaviors in childhood and adolescent autistic disorder]. clinicaltrials.gov/ct2/show/NCT00515320 (first received 13 August 2007). ">Herscu 2020</a>). <a href="./references#CD011769-bbs2-0056" title="HollanderE , SooryaL , ChaplinW , AnagnostouE , TaylorBP , FerrettiCJ , et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry2012;169(3):292-9. Erratum in: American Journal of Psychiatry. 2012 May;169(5):540. [DOI: 10.1176/appi.ajp.2011.10050764] [PMID: 22193531]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. https://clinicaltrials.gov/show/NCT00004486 (first received 19 October 1999). ">Hollander 2012</a>, which involved adults, followed fixed doses of fluoxetine starting with 10 mg/day up to a maximum of 80 mg/day (mean final dose 64.76 mg/day). Most studies required participants to take fluoxetine once daily. </p> </li> <li> <p>Fluvoxamine: one study involving 30 participants compared fluvoxamine to a placebo (<a href="./references#CD011769-bbs2-0079" title="HuffmanG . Fluvoxamine for the treatment of autistic disorders in adults. American Family Physician1997;55(4):1375-4. McDougleCJ , NaylorST , CohenDJ , VolkmarFR , HeningerGR , PriceLH . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry1996;53(11):1001-8. [DOI: 10.1001/archpsyc.1996.01830110037005] [PMID: 8911223]VegsoSJ . A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]. New Haven (CT): Southern Connecticut State University, 1995. ">McDougle 1996</a>). Fluvoxamine was initiated at 50 mg once daily, increasing to a maximum of 300 mg/day if tolerated. </p> </li> <li> <p>Sertraline: one study involving 58 participants compared sertraline to a placebo (<a href="./references#CD011769-bbs2-0040" title="HagermanR , PotterL , BiagH , ScholzeD , SchneiderA , RiveraS , et al. A controlled trial of sertraline in children 2 to 6 with ASD without fragile X syndrome. Journal of Intellectual Disability Research2018;62(8):667-8. [DOI: 10.1111/jir.12512]NCT02385799. A trial of sertraline in young children with autism spectrum disorder (Sert2). https://clinicaltrials.gov/ct2/show/NCT02385799?term=NCT02385799&amp;draw=2&amp;rank=1 (first received March 2015). PotterLA , ScholzeDA , BiagHM , SchneiderA , ChenY , NguyenDV , et al. A randomized controlled trial of sertraline in young children with autism spectrum disorder. Frontiers in Psychiatry2019;10:810. [DOI: 10.3389/fpsyt.2019.00810] [PMCID: PMC6851992] [PMID: 31780970]">Hagerman 2018</a>). Sertraline was administered using fixed doses of 2.5 mg/day for children under four years of age, and 5.0 mg/day for children four years and over. </p> </li> <li> <p>Tianeptine: one study involving 12 participants compared tianeptine to a placebo (<a href="./references#CD011769-bbs2-0099" title="NiederhoferH , StaffenW , MairA . Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder. Human Psychopharmacology2003;18(5):389-93. [DOI: 10.1002/hup.491] [PMID: 12858327]">Niederhofer 2003</a>). Fixed doses of 37.5 mg/day were administered. </p> </li> </ul> </li> <li> <p>Comparators: all studies compared an antidepressant to a placebo. Details of placebo ingredients were not provided except for <a href="./references#CD011769-bbs2-0079" title="HuffmanG . Fluvoxamine for the treatment of autistic disorders in adults. American Family Physician1997;55(4):1375-4. McDougleCJ , NaylorST , CohenDJ , VolkmarFR , HeningerGR , PriceLH . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry1996;53(11):1001-8. [DOI: 10.1001/archpsyc.1996.01830110037005] [PMID: 8911223]VegsoSJ . A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]. New Haven (CT): Southern Connecticut State University, 1995. ">McDougle 1996</a>, which described placebo as "lactose in identical‐looking tablets". </p> </li> <li> <p>Inclusion criteria: all studies required participants to meet the DSM criteria for ASD, Asperger's or PDD‐NOS. Other criteria included being free of psychotropic medications for up to six weeks prior to the study (<a href="./references#CD011769-bbs2-0056" title="HollanderE , SooryaL , ChaplinW , AnagnostouE , TaylorBP , FerrettiCJ , et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry2012;169(3):292-9. Erratum in: American Journal of Psychiatry. 2012 May;169(5):540. [DOI: 10.1176/appi.ajp.2011.10050764] [PMID: 22193531]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. https://clinicaltrials.gov/show/NCT00004486 (first received 19 October 1999). ">Hollander 2012</a>; <a href="./references#CD011769-bbs2-0099" title="NiederhoferH , StaffenW , MairA . Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder. Human Psychopharmacology2003;18(5):389-93. [DOI: 10.1002/hup.491] [PMID: 12858327]">Niederhofer 2003</a>; <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a>), and free of significant medical conditions (<a href="./references#CD011769-bbs2-0099" title="NiederhoferH , StaffenW , MairA . Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder. Human Psychopharmacology2003;18(5):389-93. [DOI: 10.1002/hup.491] [PMID: 12858327]">Niederhofer 2003</a>). </p> </li> <li> <p>Exclusion criteria: three studies excluded people with other DSM diagnoses or significant medical conditions including schizophrenia, hypersensitivity to or previous use of the intervention (<a href="./references#CD011769-bbs2-0051" title="HerscuP , HandenBL , ArnoldLE , SnapeMF , BregmanJD , GinsbergL , et al. The SOFIA Study: negative multi‑center study of low dose fluoxetine on repetitive behaviors in children and adolescents with autistic disorder. Journal of Autism and Developmental Disorders2020;50(9):3233-44. [DOI: 10.1007/s10803-019-04120-y] [PMID: 31267292]NCT00515320. Study of fluoxetine in autism (SOFIA) [Study of fluoxetine in autism: a randomised, double-blind, placebo-controlled, parallel-group 14-week study to investigate the effect of fluoxetine orally dissolving tablet (odt) on repetitive behaviors in childhood and adolescent autistic disorder]. clinicaltrials.gov/ct2/show/NCT00515320 (first received 13 August 2007). ">Herscu 2020</a>; <a href="./references#CD011769-bbs2-0052" title="HollanderE , SwansonE , AnagnostouE , PhillipsA , ChaplinW , WassermanS . Liquid fluoxetine versus placebo for repetitive behaviors in childhood autism. Progress in Neurotherapeutics and Neuropsychopharmacology2006;1(1):105-13. [DOI: 10.1017/S1748232105000108]HollanderE, PhillipsA , ChaplinW , ZagurskyK , NovotnyS , WassermanS , et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism. Neuropsychopharmacology2005;30(3):582-9. [DOI: 10.1038/sj.npp.1300627] [PMID: 15602505]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. clinicaltrials.gov/ct2/show/NCT00004486 (first received 19 October 1999). ">Hollander 2005</a>; <a href="./references#CD011769-bbs2-0056" title="HollanderE , SooryaL , ChaplinW , AnagnostouE , TaylorBP , FerrettiCJ , et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry2012;169(3):292-9. Erratum in: American Journal of Psychiatry. 2012 May;169(5):540. [DOI: 10.1176/appi.ajp.2011.10050764] [PMID: 22193531]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. https://clinicaltrials.gov/show/NCT00004486 (first received 19 October 1999). ">Hollander 2012</a>), three studies excluded people for concurrent use of psychotropic medications (<a href="./references#CD011769-bbs2-0051" title="HerscuP , HandenBL , ArnoldLE , SnapeMF , BregmanJD , GinsbergL , et al. The SOFIA Study: negative multi‑center study of low dose fluoxetine on repetitive behaviors in children and adolescents with autistic disorder. Journal of Autism and Developmental Disorders2020;50(9):3233-44. [DOI: 10.1007/s10803-019-04120-y] [PMID: 31267292]NCT00515320. Study of fluoxetine in autism (SOFIA) [Study of fluoxetine in autism: a randomised, double-blind, placebo-controlled, parallel-group 14-week study to investigate the effect of fluoxetine orally dissolving tablet (odt) on repetitive behaviors in childhood and adolescent autistic disorder]. clinicaltrials.gov/ct2/show/NCT00515320 (first received 13 August 2007). ">Herscu 2020</a>; <a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a>; <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a>), and two studies excluded people for positive serum pregnancy test results (<a href="./references#CD011769-bbs2-0079" title="HuffmanG . Fluvoxamine for the treatment of autistic disorders in adults. American Family Physician1997;55(4):1375-4. McDougleCJ , NaylorST , CohenDJ , VolkmarFR , HeningerGR , PriceLH . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry1996;53(11):1001-8. [DOI: 10.1001/archpsyc.1996.01830110037005] [PMID: 8911223]VegsoSJ . A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]. New Haven (CT): Southern Connecticut State University, 1995. ">McDougle 1996</a>; <a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a>). </p> </li> <li> <p>Setting: all studies were conducted in the USA apart from <a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a> and <a href="./references#CD011769-bbs2-0099" title="NiederhoferH , StaffenW , MairA . Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder. Human Psychopharmacology2003;18(5):389-93. [DOI: 10.1002/hup.491] [PMID: 12858327]">Niederhofer 2003</a>, which were conducted in Australia and Italy respectively. Participants were recruited from academic medical centres, tertiary hospitals, or research centres associated with universities. </p> </li> <li> <p>Concomitant medications: three studies reported that some participants were taking medications such as anticonvulsants and stimulants concurrently (<a href="./references#CD011769-bbs2-0040" title="HagermanR , PotterL , BiagH , ScholzeD , SchneiderA , RiveraS , et al. A controlled trial of sertraline in children 2 to 6 with ASD without fragile X syndrome. Journal of Intellectual Disability Research2018;62(8):667-8. [DOI: 10.1111/jir.12512]NCT02385799. A trial of sertraline in young children with autism spectrum disorder (Sert2). https://clinicaltrials.gov/ct2/show/NCT02385799?term=NCT02385799&amp;draw=2&amp;rank=1 (first received March 2015). PotterLA , ScholzeDA , BiagHM , SchneiderA , ChenY , NguyenDV , et al. A randomized controlled trial of sertraline in young children with autism spectrum disorder. Frontiers in Psychiatry2019;10:810. [DOI: 10.3389/fpsyt.2019.00810] [PMCID: PMC6851992] [PMID: 31780970]">Hagerman 2018</a>; <a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a>; <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a>), however, most studies did not permit concurrent medication use apart from sleep or antiparkinsonian medications (<a href="./references#CD011769-bbs2-0065" title="KingBH , HollanderE , SikichL , McCrackenJT , ScahillL , BregmanJD , et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Archives of General Psychiatry2009;66(6):583-90. [DOI: 10.1001/archgenpsychiatry.2009.30] [PMCID: PMC4112556] [PMID: 19487623]MyersSM . Citalopram not effective for repetitive behavior in autistic spectum disorders. Evidence-Based Mental Health2010;13(1):22. [DOI: 10.1136/ebmh.13.1.22] [PMID: 20164519]NCT00086645. Citalopram for children with autism and repetitive behavior (STAART Study 1) [Citalopram treatment in children with autism spectrum disorders and high levels of repetitive behavior]. clinicaltrials.gov/ct2/show/NCT00086645 (first received 13 July 2004). ScahillL , McCrackenJT , BearssK , RobinsonF , HollanderE , KingB , et al. Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders2012;42(3):432-40. [DOI: 10.1007/s10803-011-1251-8] [PMID: 21667200]">King 2009</a>; <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a>). </p> </li> <li> <p>Participant cognitive status: three of the studies reported that participants had an IQ of over 70, two studies reported that either all or some participants had an IQ of under 70 (<a href="./references#CD011769-bbs2-0099" title="NiederhoferH , StaffenW , MairA . Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder. Human Psychopharmacology2003;18(5):389-93. [DOI: 10.1002/hup.491] [PMID: 12858327]">Niederhofer 2003</a>; <a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a>), one study included only adults who had an average IQ of over 100 (<a href="./references#CD011769-bbs2-0079" title="HuffmanG . Fluvoxamine for the treatment of autistic disorders in adults. American Family Physician1997;55(4):1375-4. McDougleCJ , NaylorST , CohenDJ , VolkmarFR , HeningerGR , PriceLH . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry1996;53(11):1001-8. [DOI: 10.1001/archpsyc.1996.01830110037005] [PMID: 8911223]VegsoSJ . A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]. New Haven (CT): Southern Connecticut State University, 1995. ">McDougle 1996</a>), and the other four studies did not report cognitive status. </p> </li> <li> <p>Length of follow‐up: ranged from seven weeks (<a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a>), to 12 months (<a href="./references#CD011769-bbs2-0088" title="NCT00183339. Early intervention with fluoxetine in autism [A randomized, placebo-controlled trial of fluoxetine in preschool children]. clinicaltrials.gov/ct2/show/NCT00183339 (first received 16 September 2005). ">NCT00183339</a>). </p> </li> </ul> </p> <section id="CD011769-sec-0086"> <h6 class="title">Primary outcomes</h6> <p> <ul id="CD011769-list-0030"> <li> <p>Irritability: all the studies reported irritability using the ABC‐I subscale (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>), except <a href="./references#CD011769-bbs2-0079" title="HuffmanG . Fluvoxamine for the treatment of autistic disorders in adults. American Family Physician1997;55(4):1375-4. McDougleCJ , NaylorST , CohenDJ , VolkmarFR , HeningerGR , PriceLH . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry1996;53(11):1001-8. [DOI: 10.1001/archpsyc.1996.01830110037005] [PMID: 8911223]VegsoSJ . A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]. New Haven (CT): Southern Connecticut State University, 1995. ">McDougle 1996</a>. </p> </li> <li> <p>Aggression: <a href="./references#CD011769-bbs2-0079" title="HuffmanG . Fluvoxamine for the treatment of autistic disorders in adults. American Family Physician1997;55(4):1375-4. McDougleCJ , NaylorST , CohenDJ , VolkmarFR , HeningerGR , PriceLH . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry1996;53(11):1001-8. [DOI: 10.1001/archpsyc.1996.01830110037005] [PMID: 8911223]VegsoSJ . A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]. New Haven (CT): Southern Connecticut State University, 1995. ">McDougle 1996</a> was the only study that reported aggression. The Brown Aggression Scale was used to measure aggression (<a href="./references#CD011769-bbs2-0285" title="BrownGL , GoodwinFK , BallengerJC , GoyerPF , MajorLF . Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Research1979;1(2):131-9. [DOI: 10.1016/0165-1781(79)90053-2] [PMID: 95232]">Brown 1979</a>). </p> </li> <li> <p>Self‐injury: two studies (<a href="./references#CD011769-bbs2-0065" title="KingBH , HollanderE , SikichL , McCrackenJT , ScahillL , BregmanJD , et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Archives of General Psychiatry2009;66(6):583-90. [DOI: 10.1001/archgenpsychiatry.2009.30] [PMCID: PMC4112556] [PMID: 19487623]MyersSM . Citalopram not effective for repetitive behavior in autistic spectum disorders. Evidence-Based Mental Health2010;13(1):22. [DOI: 10.1136/ebmh.13.1.22] [PMID: 20164519]NCT00086645. Citalopram for children with autism and repetitive behavior (STAART Study 1) [Citalopram treatment in children with autism spectrum disorders and high levels of repetitive behavior]. clinicaltrials.gov/ct2/show/NCT00086645 (first received 13 July 2004). ScahillL , McCrackenJT , BearssK , RobinsonF , HollanderE , KingB , et al. Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders2012;42(3):432-40. [DOI: 10.1007/s10803-011-1251-8] [PMID: 21667200]">King 2009</a>; <a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a>), reported self‐injurious behaviour using the Repetitive Behaviour Scale‐Revised (<a href="./references#CD011769-bbs2-0281" title="BodfishJW , SymonsFS , ParkerDE , LewisMH . Varieties of repetitive behavior in autism: comparisons to mental retardation. Journal of Autism and Developmental Disorders2000;30(3):237-43. [DOI: 10.1023/A:1005596502855] [PMID: 11055459]">Bodfish 2000</a>). </p> </li> <li> <p>AEs: all the studies reported AEs.</p> </li> </ul> </p> </section> <section id="CD011769-sec-0087"> <h6 class="title">Secondary outcomes</h6> <p> <ul id="CD011769-list-0031"> <li> <p>Tolerability and acceptability (loss to follow‐up): 159 participants (23.08%) withdrew and were not included in the relevant study analyses. Reasons included withdrew consent (66), loss to follow‐up (23), lack of efficacy (5), AEs (38), other/reason unknown (16), non‐compliance (3), protocol violation (3), clinician decision (4), and no longer met study criteria (1). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0088"> <h6 class="title">Atypical antipsychotic versus another atypical antipsychotic</h6> <p>Two studies involving 110 participants compared risperidone to aripiprazole (<a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a>; <a href="./references#CD011769-bbs2-0036" title="GhanizadehA , SahraeizadehA , BerkM . A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development2014;45(2):185-92. [DOI: 10.1007/s10578-013-0390-x] [PMID: 23801256]IRCT201110233930N15. Aripiprazole versus risperidone for treatment of autism. www.irct.ir/trial/4094 (first received 12 December 2011). ">Ghanizadeh 2014</a>). Participants were all children (&lt; 18 years). The mean age was 9.6 and 9.5 years for aripiprazole and risperidone respectively. Both studies were parallel RCTs and were 10 weeks (<a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a>) and eight weeks (<a href="./references#CD011769-bbs2-0036" title="GhanizadehA , SahraeizadehA , BerkM . A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development2014;45(2):185-92. [DOI: 10.1007/s10578-013-0390-x] [PMID: 23801256]IRCT201110233930N15. Aripiprazole versus risperidone for treatment of autism. www.irct.ir/trial/4094 (first received 12 December 2011). ">Ghanizadeh 2014</a>) in duration. </p> <p> <ul id="CD011769-list-0032"> <li> <p>Interventions</p> <ul id="CD011769-list-0033"> <li> <p>Risperidone: both studies used twice‐daily doses based on bodyweight. <a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a> required participants who weighed 20 kg to 44 kg to take a maximum of 2.5 mg/day, and children 45 kg or more were allowed a maximum of 3 mg/day. <a href="./references#CD011769-bbs2-0036" title="GhanizadehA , SahraeizadehA , BerkM . A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development2014;45(2):185-92. [DOI: 10.1007/s10578-013-0390-x] [PMID: 23801256]IRCT201110233930N15. Aripiprazole versus risperidone for treatment of autism. www.irct.ir/trial/4094 (first received 12 December 2011). ">Ghanizadeh 2014</a> required children up to 39 kg to take a maximum of 2 mg/day of risperidone, and children 40 kg and above a maximum of 3 mg/day (mean dose 1.12 mg/day). </p> </li> <li> <p>Aripiprazole: <a href="./references#CD011769-bbs2-0036" title="GhanizadehA , SahraeizadehA , BerkM . A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development2014;45(2):185-92. [DOI: 10.1007/s10578-013-0390-x] [PMID: 23801256]IRCT201110233930N15. Aripiprazole versus risperidone for treatment of autism. www.irct.ir/trial/4094 (first received 12 December 2011). ">Ghanizadeh 2014</a> allowed a maximum of 10 mg/day for children who weighed under 40 kg, and 15 mg/day for children who weighed 40 kg or more (mean dose 5.5 mg/day). <a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a> allowed a maximum of 15 mg/day of aripiprazole regardless of weight. </p> </li> </ul> </li> <li> <p>Inclusion criteria: both studies required a clinical diagnosis of ASD and <a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a> required participants to have an ABC‐I (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>), subscale score of &gt; 18 at baseline, a CGI Severity score of 4 or greater (<a href="./references#CD011769-bbs2-0337" title="Guy W (editor). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, U.S.: Department of Health, Education, and Welfare, 1976.">Guy 1976</a>), and a mental age of at least 18 months. </p> </li> <li> <p>Exclusion criteria: participants with a history of or current unstable medical conditions, prior use of risperidone or aripiprazole for more than two weeks within the last three years, medical conditions that may increase the risk of AEs including liver, renal or cardiovascular conditions, psychiatric disorders that are currently managed by psychotropic medications, or seizures within the past six months </p> </li> <li> <p>Setting: <a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a> was conducted in the USA whilst <a href="./references#CD011769-bbs2-0036" title="GhanizadehA , SahraeizadehA , BerkM . A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development2014;45(2):185-92. [DOI: 10.1007/s10578-013-0390-x] [PMID: 23801256]IRCT201110233930N15. Aripiprazole versus risperidone for treatment of autism. www.irct.ir/trial/4094 (first received 12 December 2011). ">Ghanizadeh 2014</a> was conducted in Iran. All participants were recruited from either outpatient clinics, or clinics and research centres associated with universities. </p> </li> <li> <p>Concomitant medications: one study (<a href="./references#CD011769-bbs2-0036" title="GhanizadehA , SahraeizadehA , BerkM . A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development2014;45(2):185-92. [DOI: 10.1007/s10578-013-0390-x] [PMID: 23801256]IRCT201110233930N15. Aripiprazole versus risperidone for treatment of autism. www.irct.ir/trial/4094 (first received 12 December 2011). ">Ghanizadeh 2014</a>), required participants to be off aripiprazole and risperidone for at least two weeks prior to and during the study, although other concomitant medications were allowed during the trial provided they were stable and commenced at least two weeks prior to the trial, while <a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a> did not explicitly state medication requirements except that participants could not have taken either intervention for longer than two weeks in the last three years (<a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a>). </p> </li> <li> <p>Participant cognitive status: neither study reported the cognitive status of participants.</p> </li> <li> <p>Length of follow‐up: <a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a> and <a href="./references#CD011769-bbs2-0036" title="GhanizadehA , SahraeizadehA , BerkM . A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development2014;45(2):185-92. [DOI: 10.1007/s10578-013-0390-x] [PMID: 23801256]IRCT201110233930N15. Aripiprazole versus risperidone for treatment of autism. www.irct.ir/trial/4094 (first received 12 December 2011). ">Ghanizadeh 2014</a> were 10 and 8 weeks in duration respectively. Neither study followed up after the endpoint. </p> </li> </ul> </p> <section id="CD011769-sec-0089"> <p><b>Primary outcomes</b></p> <p> <ul id="CD011769-list-0034"> <li> <p>Irritability: both studies reported irritability using the ABC‐I subscale (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>). The baseline ABC‐I scores of all participants were above 20. </p> </li> <li> <p>AEs: both studies reported AEs.</p> </li> </ul> </p> </section> <section id="CD011769-sec-0090"> <p><b>Secondary outcomes</b></p> <p> <ul id="CD011769-list-0035"> <li> <p>Tolerability and acceptability (loss to follow‐up): 16 participants (14.5%) withdrew from their respective interventions and were not included in the relevant study analyses. Reasons for withdrawing from the risperidone groups included AEs (9), missed visits (4), increased behaviours of concern or exacerbation of medical condition (2), or physician decision (1). </p> </li> </ul> </p> </section> </section> <section id="CD011769-sec-0091"> <h6 class="title">Atypical antipsychotic versus an antidementia drug</h6> <p>One, eight‐week, parallel study involving 34 participants compared risperidone to memantine (<a href="./references#CD011769-bbs2-0101" title="IRCT201204037202N5. Comparing efficacy and side effects of memantine and risperidone in treating autistic patients. www.irct.ir/trial/7627 (first received 20 June 2012). NikvarzN , Alaghband-RadJ , Tehrani-DoostM , AlimadadiA , GhaeliP . Comparing efficacy and side effects of memantine vs risperidone in the treatment of autistic disorder. Pharmacopsychiatry2017;50(1):19-25. [DOI: 10.1055/s-0042-108449] [PMID: 27299475]">Nikvarz 2017</a>). Participants were all under 18 years (mean 6.7 years). </p> <p> <ul id="CD011769-list-0036"> <li> <p>Interventions: once‐daily doses of risperidone commenced at 0.02 mg/kg/day, increasing to a maximum of 0.08 mg/kg/day or 3 mg/day. Memantine was administered in once‐daily doses of 20 mg if tolerated (mean daily dose of 0.4 mg/kg/day). </p> </li> <li> <p>Inclusion criteria: participants were 5 to 17 years of age with a clinical diagnosis of ASD and had not received any pharmacological treatments for ASD or the treatments had been ineffective. </p> </li> <li> <p>Exclusion criteria: people with a neurological disorder except for controlled epilepsy (defined as experiencing no seizures for at least one month prior to the study), history of substance abuse, any other significant medical conditions including cardiac, liver or kidney failure, pregnant or breastfeeding, previous allergic reactions to either risperidone or memantine, and currently taking stimulants. </p> </li> <li> <p>Setting: an outpatient child and adolescent clinic associated with a university in Iran </p> </li> <li> <p>Concomitant medications: details were not provided.</p> </li> <li> <p>Participant cognitive status: details were not provided.</p> </li> </ul> </p> <section id="CD011769-sec-0092"> <p><b>Primary outcomes</b></p> <p> <ul id="CD011769-list-0037"> <li> <p>Irritability: irritability was reported using the ABC‐I subscale (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>). The baseline ABC‐I scores of all participants were above 20. </p> </li> <li> <p>AEs: AEs were not reported fully for both groups apart from somnolence, which we included in the analyses. </p> </li> </ul> </p> </section> <section id="CD011769-sec-0093"> <p><b>Secondary outcomes</b></p> <p> <ul id="CD011769-list-0038"> <li> <p>Tolerability and acceptability (loss to follow‐up): four participants (11.76%) withdrew and were not included in the relevant study analyses. Reasons included changing psychiatrist (1) and lack of efficacy (3). </p> </li> </ul> </p> </section> </section> <section id="CD011769-sec-0094"> <h6 class="title">Atypical antipsychotic versus an antiparkinsonian drug (bromocriptine)</h6> <p>One study involving nine participants compared amisulpride to bromocriptine (<a href="./references#CD011769-bbs2-0026" title="DollfusS , PetitM , MenardJF , LesieurP . Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. Journal of Autism and Developmental Disorders1992;22(1):47-60. [DOI: 10.1007/BF01046402] [PMID: 1350581]DollfusS , PetitP , MenardJF . Pharmacoclinical study of an agonist and an antagonist of dopamine in early infantile autism. Neuropsychiatrie de l'Enfance et de l'Adolescence1992;40(5-6):300-309. ">Dollfus 1992</a>). The four‐week cross‐over study was conducted in France and involved children aged between 4 and 13 years of age. </p> <p> <ul id="CD011769-list-0039"> <li> <p>Intervention (amisulpride plus placebo): amisulpride was administered at 1.5 mg/kg/day over a four‐week period with a six‐week washout period between the two phases. </p> </li> <li> <p>Comparator (bromocriptine plus placebo): bromocriptine was administered at 0.15 mg/kg/day to 0.20 mg/kg/day plus placebo over a four‐week period with a six‐week washout period between the two phases. </p> </li> <li> <p>Inclusion criteria: children aged 4 to 13 years with a clinical diagnosis of ASD, and a Childhood Autism Rating Scale (<a href="./references#CD011769-bbs2-0422" title="SchoplerE , Van BourgondienME , WellmanJ , LoveS . Childhood Autism Rating Scale-second edition (CARS2): Manual. Childhood Autism Rating Scale, Second Edition (CARS-2) | Pearson Clinical Australia &amp; New Zealand 2009.">Schopler 2009</a>), score of at least 36 indicating 'severely autistic'. </p> </li> <li> <p>Exclusion criteria: no neuroleptic or other psychotropic medications were allowed during the trial, except for benzodiazepine, niaprazine, or hydroxyzine for severe sleep disorders. </p> </li> <li> <p>Concomitant medications: three out of nine children were taking other permitted medications during the trial, including one child who was taking three different medications. </p> </li> </ul> </p> <section id="CD011769-sec-0095"> <p><b>Outcomes</b></p> <p> <ul id="CD011769-list-0040"> <li> <p>AEs was the only relevant outcome reported in this study.</p> </li> </ul> </p> </section> </section> </section> <section id="CD011769-sec-0096"> <h5 class="title">Anticonvulsants versus placebo or other treatment</h5> <p>Six studies (12 reports, 165 participants, 6 datasets) compared an anticonvulsant to a placebo. All participants were children (&lt; 18 years) apart from one adult in <a href="./references#CD011769-bbs2-0053" title="HollanderE , SooryaL , WassermanS , EspositoK , ChaplinW , AnagnostouE . Divalproex sodium vs placebo in the treatment of repetitive behaviours in autism spectrum disorder. International Journal of Neuropsychopharmacology2006;9(2):209-13. [DOI: 10.1017/S1461145705005791] [PMID: 16316486]NCT00211757. Divalproex sodium versus placebo in childhood/adolescent autism. https://clinicaltrials.gov/ct2/show/results/NCT00211757?term=NCT00211757&amp;draw=2&amp;rank=1 (first received September 2005). ">Hollander 2006a</a>. All trials were parallel studies, with study duration ranging from eight to 18 weeks (<a href="./references#CD011769-bbs2-0013" title="BelsitoKM , LawPA , KirkKS , LandaRJ , ZimmermanAW . Lamotrigine therapy for autistic disorder: a randomised, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders2001;31(2):175-81. [DOI: 10.1023/A:1010799115457] [PMID: 11450816]BelsitoK , KirkK , LandaR , LawP , ZimmermanA . Lamotrigine therapy for childhood autism: a randomized, double-blind, placebo-controlled trial. Neurology1998;50(4):A85. ">Belsito 2001</a>), (mean 10 weeks) and apart from one study (<a href="./references#CD011769-bbs2-0111" title="IRCT138901141556N9. Topiramate in the treatment of autism [Tpoiramate added to risperidone in patint with autistic disorder: a double-blind placebo controlled trial]. www.irct.ir/trial/859 (first received 29 April 2010). RezaeiV , Mohammadi M-R, GhanizadehA , SahraianA , TabriziM , Rezazadeh S-A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2010;34(7):1269-72. [DOI: 10.1016/j.pnpbp.2010.07.005] [PMID: 20637249]">Rezaei 2010</a> (Iran)) all trials were conducted in the USA. </p> <p> <ul id="CD011769-list-0041"> <li> <p>Interventions</p> <ul id="CD011769-list-0042"> <li> <p>Divalproex sodium: two trials involving 40 participants compared divalproex sodium to a placebo. <a href="./references#CD011769-bbs2-0055" title="AnagnostouE , SooryaL , SwansonE , RusoffJ , ChaplinW , WassermanS , et al. Divalproex sodium vs placebo for the treatment of child and adolescent autism. European Neuropsychopharmacology2006;16:S74-5. [DOI: 10.1016/S0924-977X(06)80088-X]HollanderE , ChaplinW , SooryaL , WassermanS , NovotnyS , RusoffJ , et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology2010;35(4):990-8. [DOI: 10.1038/npp.2009.202] [PMCID: PMC2846602] [PMID: 20010551]HollanderE , SooryaL , WassermanS , EspositoK , ChaplinW , AnagnostouE . Divalproex sodium vs placebo in the treatment of repetitive behaviours in autism spectrum disorder. International Journal of Neuropsychopharmacology2006;9(2):209-13. [DOI: 10.1017/S1461145705005791] [PMID: 16316486]NCT00211757. Divalproex sodium vs. placebo in childhood/adolescent autism. https://clinicaltrials.gov/ct2/show/NCT00211757?term=NCT00211757&amp;draw=1&amp;rank=1 (first received September 2005). ">Hollander 2010</a> commenced divalproex sodium at 125 mg/day once to twice daily for children up to 40 kg, and a maximum of 250 mg/day for children over 40 kg. <a href="./references#CD011769-bbs2-0053" title="HollanderE , SooryaL , WassermanS , EspositoK , ChaplinW , AnagnostouE . Divalproex sodium vs placebo in the treatment of repetitive behaviours in autism spectrum disorder. International Journal of Neuropsychopharmacology2006;9(2):209-13. [DOI: 10.1017/S1461145705005791] [PMID: 16316486]NCT00211757. Divalproex sodium versus placebo in childhood/adolescent autism. https://clinicaltrials.gov/ct2/show/results/NCT00211757?term=NCT00211757&amp;draw=2&amp;rank=1 (first received September 2005). ">Hollander 2006a</a> increased divalproex sodium from 125 mg/day to a maximum of 30 mg/kg/day (mean final dose 822.92 mg/kg/day). </p> </li> <li> <p>Lamotrigine: one study involving 35 participants compared lamotrigine to a placebo. Lamotrigine commenced at 0.5 mg/kg twice daily up to a maximum of 5.0 mg/kg twice daily (<a href="./references#CD011769-bbs2-0013" title="BelsitoKM , LawPA , KirkKS , LandaRJ , ZimmermanAW . Lamotrigine therapy for autistic disorder: a randomised, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders2001;31(2):175-81. [DOI: 10.1023/A:1010799115457] [PMID: 11450816]BelsitoK , KirkK , LandaR , LawP , ZimmermanA . Lamotrigine therapy for childhood autism: a randomized, double-blind, placebo-controlled trial. Neurology1998;50(4):A85. ">Belsito 2001</a>). </p> </li> <li> <p>Levetiracetam: one study involving 20 participants compared levetiracetam to a placebo. <a href="./references#CD011769-bbs2-0125" title="WassermanS , IyengarR , ChaplinWF , WatnerD , WaldoksSE , AnagnostouE , et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. International Clinical Psychopharmacology2006;21(6):363-7. [DOI: 10.1097/01.yic.0000224787.13782.0f] [PMID: 17012983]">Wasserman 2006</a> commenced levetiracetam at 125 mg/day up to a maximum of 20 mg/kg/day to 30 mg/kg/day (mean maximum dose 862.50 mg/day). </p> </li> <li> <p>Topiramate: one study involving 40 participants compared risperidone plus topiramate to risperidone plus placebo (<a href="./references#CD011769-bbs2-0111" title="IRCT138901141556N9. Topiramate in the treatment of autism [Tpoiramate added to risperidone in patint with autistic disorder: a double-blind placebo controlled trial]. www.irct.ir/trial/859 (first received 29 April 2010). RezaeiV , Mohammadi M-R, GhanizadehA , SahraianA , TabriziM , Rezazadeh S-A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2010;34(7):1269-72. [DOI: 10.1016/j.pnpbp.2010.07.005] [PMID: 20637249]">Rezaei 2010</a>). The analysis for this study is topiramate versus placebo. The maximum dose of topiramate was 100 mg/day for children under 30 kg or three to six years of age, and maximum of 200 mg/day for children 30 kg or more, or 7 to 12 years of age. </p> </li> <li> <p>Valproate: one study involving 30 participants compared valproate to a placebo (<a href="./references#CD011769-bbs2-0049" title="HellingsJA , WeckbaughM , NickelEJ , CainSE , ZarconeJR , ReeseRM , et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology2005;15(4):682-92. [DOI: 10.1089/cap.2005.15.682] [PMID: 16190799]">Hellings 2005</a>). The maximum valproate dose was 20 mg/kg/day. </p> </li> </ul> </li> <li> <p>Comparators: all studies compared an anticonvulsant to a placebo. Further details regarding placebo ingredients were not provided. </p> </li> <li> <p>Inclusion criteria: all studies required participants to have a clinical diagnosis of ASD, Asperger's or PDD‐NOS, be free of other medications for at least two weeks prior to the study, and six of the studies required significant overactivity or inattention or a dual diagnosis of ADHD and ASD. </p> </li> <li> <p>Exclusion criteria: most studies excluded people with unstable seizure disorders or other significant medical conditions including past or present psychotic disorders, and the concomitant use of psychotropic medications during the study. </p> </li> <li> <p>Setting: apart from <a href="./references#CD011769-bbs2-0111" title="IRCT138901141556N9. Topiramate in the treatment of autism [Tpoiramate added to risperidone in patint with autistic disorder: a double-blind placebo controlled trial]. www.irct.ir/trial/859 (first received 29 April 2010). RezaeiV , Mohammadi M-R, GhanizadehA , SahraianA , TabriziM , Rezazadeh S-A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2010;34(7):1269-72. [DOI: 10.1016/j.pnpbp.2010.07.005] [PMID: 20637249]">Rezaei 2010</a>, all studies were conducted in the USA at either outpatient clinics, hospitals or clinics and research centres associated with universities. <a href="./references#CD011769-bbs2-0111" title="IRCT138901141556N9. Topiramate in the treatment of autism [Tpoiramate added to risperidone in patint with autistic disorder: a double-blind placebo controlled trial]. www.irct.ir/trial/859 (first received 29 April 2010). RezaeiV , Mohammadi M-R, GhanizadehA , SahraianA , TabriziM , Rezazadeh S-A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2010;34(7):1269-72. [DOI: 10.1016/j.pnpbp.2010.07.005] [PMID: 20637249]">Rezaei 2010</a> was conducted at a hospital associated with a university in Iran. </p> </li> <li> <p>Concomitant medications: all but two studies did not allow the use of psychoactive medications during the study. <a href="./references#CD011769-bbs2-0043" title="HandenBL , SahlR , HardanAY . Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental &amp; Behavioral Pediatrics2008;29(4):303-8. [DOI: 10.1097/DBP.0b013e3181739b9d] [PMID: 18552703]">Handen 2008</a> had eight participants who were taking a range of psychotropic medications, including methylphenidate, risperidone, and anticonvulsants. <a href="./references#CD011769-bbs2-0045" title="ArnoldLE , OberN , AmanMG , HandenB , SmithT , PanX , et al. A 1.5-year follow-up of parent training and atomoxetine for attention-deficit/hyperactivity disorder symptoms and noncompliant/disruptive behavior in autism. Journal of Child and Adolescent Psychopharmacology2018;28(5):322-30. [DOI: 10.1089/cap.2017.0134] [PMCID: PMC5994674] [PMID: 29694241]HandenBL , AmanMG , ArnoldLE , HymanSL , TumuluruRV , LecavalierL , et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2015;54(11):905-15. [DOI: 10.1016/j.jaac.2015.08.013] [PMCID: PMC4625086] [PMID: 26506581]LecavalierL , PanX , SmithT , HandenBL , ArnoldLE , SilvermanL , et al. Parent stress in a randomized clinical trial of atomoxetine and parent training for children with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(4):980-7. [DOI: 10.1007/s10803-017-3345-4] [PMCID: PMC6070148] [PMID: 29022125]NCT00844753. Atomoxetine, placebo and parent management training in autism (Strattera) [Atomoxetine, placebo and parent management training in autism]. clinicaltrials.gov/ct2/show/NCT00844753 (first received 16 February 2016). SmithT , AmanMG , ArnoldLE , SilvermanLB , LecavalierL , HollwayJ , et al. Atomoxetine and parent training for children with autism and attention-deficit/hyperactivity disorder: a 24-week extension study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):868-76.e2. [DOI: 10.1016/j.jaac.2016.06.015] [PMCID: PMC5108566] [PMID: 27663942]TumuluruRV , Corbett-DickP , AmanMG , SmithT , ArnoldLE , PanX , et al. Adverse events of atomoxetine in a double-blind placebo-controlled study in children with autism. Journal of Child and Adolescent Psychopharmacology2017;27(8):708-14. [DOI: 10.1089/cap.2016.0187] [PMCID: PMC5651962] [PMID: 28509573]">Handen 2015</a> allowed the use of a single anticonvulsant for seizure disorders provided that seizures were stable, and the participant had been seizure‐free for at least six months. </p> </li> <li> <p>Participant cognitive status: five of the studies reported IQ, all of which had a mean IQ of less than 90. </p> </li> <li> <p>Length of follow‐up: length of follow‐up ranged from eight to 18 weeks (mean 10 weeks).</p> </li> </ul> </p> <section id="CD011769-sec-0097"> <h6 class="title">Primary outcomes</h6> <p> <ul id="CD011769-list-0043"> <li> <p>Irritability: all studies apart from one (<a href="./references#CD011769-bbs2-0053" title="HollanderE , SooryaL , WassermanS , EspositoK , ChaplinW , AnagnostouE . Divalproex sodium vs placebo in the treatment of repetitive behaviours in autism spectrum disorder. International Journal of Neuropsychopharmacology2006;9(2):209-13. [DOI: 10.1017/S1461145705005791] [PMID: 16316486]NCT00211757. Divalproex sodium versus placebo in childhood/adolescent autism. https://clinicaltrials.gov/ct2/show/results/NCT00211757?term=NCT00211757&amp;draw=2&amp;rank=1 (first received September 2005). ">Hollander 2006a</a>), reported irritability. All studies used the ABC‐I subscale to measure irritability, however, <a href="./references#CD011769-bbs2-0125" title="WassermanS , IyengarR , ChaplinWF , WatnerD , WaldoksSE , AnagnostouE , et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. International Clinical Psychopharmacology2006;21(6):363-7. [DOI: 10.1097/01.yic.0000224787.13782.0f] [PMID: 17012983]">Wasserman 2006</a> only reports baseline ABC‐I data. </p> </li> <li> <p>Aggression: one study (<a href="./references#CD011769-bbs2-0049" title="HellingsJA , WeckbaughM , NickelEJ , CainSE , ZarconeJR , ReeseRM , et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology2005;15(4):682-92. [DOI: 10.1089/cap.2005.15.682] [PMID: 16190799]">Hellings 2005</a>), reports aggression. The Overt Aggression Scale (parent‐rated; <a href="./references#CD011769-bbs2-0466" title="YudofskySC , SilverJM , JacksonW , EndicottJ , WilliamsD . The Overt Aggression Scale for the objective rating of verbal and physical aggression. American Journal of Psychiatry2003;143(1):35-9. [DOI: 10.1176/ajp.143.1.35]">Yudofsky 2003</a>), was used to measure aggression. </p> </li> <li> <p>AEs: all six studies reported AEs.</p> </li> </ul> </p> </section> <section id="CD011769-sec-0098"> <h6 class="title">Secondary outcomes</h6> <p> <ul id="CD011769-list-0044"> <li> <p>Tolerability and acceptability (loss to follow‐up): 21 participants (12.73%) withdrew and were not included in the relevant study analyses. Reasons included withdrawing consent (9), difficulty administering the medication (1); increased behavioural difficulties (4); increased symptoms associated with ASD (3); lack of efficacy (2); seizures (1); and skin rash (1). </p> </li> </ul> </p> </section> </section> <section id="CD011769-sec-0099"> <h5 class="title">Antidementia interventions versus placebo or other treatments</h5> <p>Eight studies (641 participants, 17 reports, 9 datasets) compared an antidementia intervention to a placebo or other treatment. Four studies compared memantine to a placebo, one study compared piracetam, one galantamine, and one compared donepezil to a placebo. All studies were parallel trials, were either 10 or 12 weeks in duration, and involved children (&lt; 18 years). Four studies were conducted in the USA (<a href="./references#CD011769-bbs2-0004" title="AmanMG , FindlingRL , HardanAY , HendrenRL , MelmedRD , Kehinde-NelsonOK , et al. Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension. Journal of Child and Adolescent Psychopharmacology2017;27(5):403-12. [DOI: 10.1089/cap.2015.0146] [PMCID: PMC5510039] [PMID: 26978327]NCT00872898. Study of pharmacokinetics, safety, efficacy, and tolerability of memantine in children with autism [An open-label (part one) and a randomized, double-blind, placebo-controlled (part two) study of the pharmacokinetics, safety, efficacy, and tolerability of memantine in pediatric patients with autism]. clinicaltrials.gov/ct2/show/NCT00872898 (first received 31 March 2009). ">Aman 2017</a>; <a href="./references#CD011769-bbs2-0044" title="HandenBL , JohnsonCR , McAuliffe-BellinS , HardanA . Safety and efficacy of donepezil in children - behavioural measures. International public health journal2010;2(1):125-34. HandenBL , JohnsonCR , Mcauliffe-BellinS , MurrayPJ , HardanAY . Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of Child and Adolescent Psychopharmacology2011;21(1):43-50. [DOI: 10.1089/cap.2010.0024] [PMCID: PMC3037196] [PMID: 21309696]HardanA , JohnsonC , HandenBL . Preliminary findings from a double-blind placebo=controlled study of donepezil in pervasive developmental disorders. Biological Psychiatry2006;59(8):50S-50S. NCT00047697. Donepezil HCl and cognitive deficits in autism. https://clinicaltrials.gov/ct2/show/results/NCT00047697?term=NCT00047697&amp;draw=2&amp;rank=1 (first received October 2002). ">Handen 2011</a>; <a href="./references#CD011769-bbs2-0095" title="NCT01972074. Behavioral and neural response to memantine in adolescents with autism spectrum disorder. clinicaltrials.gov/ct2/show/NCT01972074 (first received 30 October 2013). ">NCT01972074</a>; <a href="./references#CD011769-bbs2-0116" title="NCT01372449. A multi-site double-blind placebo-controlled trial of memantine versus placebo in children with autism (MEM). clinicaltrials.gov/ct2/show/NCT01372449?term=NCT01372449&amp;draw=1&amp;rank=1 (first received December 2011). SooryaL , FoggL , OcampoE , PrintenM , YoungkinS , HalpernD , et al. Neurocognitive outcomes from memantine: a pilot, double-blind, placebo-controlled trial in children with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology2021;31(7):475-84. [DOI: 10.1089/cap.2021.0010] [PMID: 34543081]">Soorya 2021</a>), one study was conducted in multiple countries (<a href="./references#CD011769-bbs2-0047" title="EUCTR 2012-001568-31. A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger’s disorder, or pervasive developmental disorder not otherwise specified (PDD-NOS) previously treated with memantine. www.clinicaltrialsregister.eu/ctr-search/trial/2012-001568-31/results (first posted November 2012). HardanAY , HendrenRL , AmanMG , RobbA , MelmedRD , AndersenKA , et al. Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies. Autism2019;23(8):2096-111. [DOI: 10.1177/1362361318824103] [PMCID: PMC6779018] [PMID: 31027422]NCT01592747. Withdrawal study of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified previously treated with memantine [A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified (pdd-nos) previously treated with memantine]. clinicaltrials.gov/ct2/show/results/NCT01592747 (first received 7 May 2012). ">Hardan 2019</a>), and the other three were conducted in Iran. Most studies included children up to twelve years of age only, apart from <a href="./references#CD011769-bbs2-0044" title="HandenBL , JohnsonCR , McAuliffe-BellinS , HardanA . Safety and efficacy of donepezil in children - behavioural measures. International public health journal2010;2(1):125-34. HandenBL , JohnsonCR , Mcauliffe-BellinS , MurrayPJ , HardanAY . Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of Child and Adolescent Psychopharmacology2011;21(1):43-50. [DOI: 10.1089/cap.2010.0024] [PMCID: PMC3037196] [PMID: 21309696]HardanA , JohnsonC , HandenBL . Preliminary findings from a double-blind placebo=controlled study of donepezil in pervasive developmental disorders. Biological Psychiatry2006;59(8):50S-50S. NCT00047697. Donepezil HCl and cognitive deficits in autism. https://clinicaltrials.gov/ct2/show/results/NCT00047697?term=NCT00047697&amp;draw=2&amp;rank=1 (first received October 2002). ">Handen 2011</a> and <a href="./references#CD011769-bbs2-0095" title="NCT01972074. Behavioral and neural response to memantine in adolescents with autism spectrum disorder. clinicaltrials.gov/ct2/show/NCT01972074 (first received 30 October 2013). ">NCT01972074</a>, which involved children up to 17 years of age. </p> <p> <ul id="CD011769-list-0045"> <li> <p>Interventions</p> <ul id="CD011769-list-0046"> <li> <p>Memantine: five studies involving 527 participants compared memantine to a placebo (<a href="./references#CD011769-bbs2-0004" title="AmanMG , FindlingRL , HardanAY , HendrenRL , MelmedRD , Kehinde-NelsonOK , et al. Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension. Journal of Child and Adolescent Psychopharmacology2017;27(5):403-12. [DOI: 10.1089/cap.2015.0146] [PMCID: PMC5510039] [PMID: 26978327]NCT00872898. Study of pharmacokinetics, safety, efficacy, and tolerability of memantine in children with autism [An open-label (part one) and a randomized, double-blind, placebo-controlled (part two) study of the pharmacokinetics, safety, efficacy, and tolerability of memantine in pediatric patients with autism]. clinicaltrials.gov/ct2/show/NCT00872898 (first received 31 March 2009). ">Aman 2017</a>; <a href="./references#CD011769-bbs2-0030" title="GhaleihaA , AsababadiM , Mohammadi M-R, ShaheiM , TabriziM , HajiaghaeeR , et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology2013;16(4):783-9. [DOI: 10.1017/S1461145712000880] [PMID: 22999292]IRCT1138901151556N10. A double-blind placebo-controlled trial of memantine added to risperidone in patients with autistic disorder. https://www.irct.ir/trial/860 (first received May 2010). ">Ghaleiha 2013a</a>; <a href="./references#CD011769-bbs2-0047" title="EUCTR 2012-001568-31. A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger’s disorder, or pervasive developmental disorder not otherwise specified (PDD-NOS) previously treated with memantine. www.clinicaltrialsregister.eu/ctr-search/trial/2012-001568-31/results (first posted November 2012). HardanAY , HendrenRL , AmanMG , RobbA , MelmedRD , AndersenKA , et al. Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies. Autism2019;23(8):2096-111. [DOI: 10.1177/1362361318824103] [PMCID: PMC6779018] [PMID: 31027422]NCT01592747. Withdrawal study of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified previously treated with memantine [A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified (pdd-nos) previously treated with memantine]. clinicaltrials.gov/ct2/show/results/NCT01592747 (first received 7 May 2012). ">Hardan 2019</a>; <a href="./references#CD011769-bbs2-0095" title="NCT01972074. Behavioral and neural response to memantine in adolescents with autism spectrum disorder. clinicaltrials.gov/ct2/show/NCT01972074 (first received 30 October 2013). ">NCT01972074</a>; <a href="./references#CD011769-bbs2-0116" title="NCT01372449. A multi-site double-blind placebo-controlled trial of memantine versus placebo in children with autism (MEM). clinicaltrials.gov/ct2/show/NCT01372449?term=NCT01372449&amp;draw=1&amp;rank=1 (first received December 2011). SooryaL , FoggL , OcampoE , PrintenM , YoungkinS , HalpernD , et al. Neurocognitive outcomes from memantine: a pilot, double-blind, placebo-controlled trial in children with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology2021;31(7):475-84. [DOI: 10.1089/cap.2021.0010] [PMID: 34543081]">Soorya 2021</a>). All studies administered memantine once daily apart from <a href="./references#CD011769-bbs2-0095" title="NCT01972074. Behavioral and neural response to memantine in adolescents with autism spectrum disorder. clinicaltrials.gov/ct2/show/NCT01972074 (first received 30 October 2013). ">NCT01972074</a>, which involved twice‐daily doses. Two studies had maximum memantine doses of 15 mg/day (<a href="./references#CD011769-bbs2-0030" title="GhaleihaA , AsababadiM , Mohammadi M-R, ShaheiM , TabriziM , HajiaghaeeR , et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology2013;16(4):783-9. [DOI: 10.1017/S1461145712000880] [PMID: 22999292]IRCT1138901151556N10. A double-blind placebo-controlled trial of memantine added to risperidone in patients with autistic disorder. https://www.irct.ir/trial/860 (first received May 2010). ">Ghaleiha 2013a</a>; <a href="./references#CD011769-bbs2-0047" title="EUCTR 2012-001568-31. A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger’s disorder, or pervasive developmental disorder not otherwise specified (PDD-NOS) previously treated with memantine. www.clinicaltrialsregister.eu/ctr-search/trial/2012-001568-31/results (first posted November 2012). HardanAY , HendrenRL , AmanMG , RobbA , MelmedRD , AndersenKA , et al. Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies. Autism2019;23(8):2096-111. [DOI: 10.1177/1362361318824103] [PMCID: PMC6779018] [PMID: 31027422]NCT01592747. Withdrawal study of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified previously treated with memantine [A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified (pdd-nos) previously treated with memantine]. clinicaltrials.gov/ct2/show/results/NCT01592747 (first received 7 May 2012). ">Hardan 2019</a>), <a href="./references#CD011769-bbs2-0004" title="AmanMG , FindlingRL , HardanAY , HendrenRL , MelmedRD , Kehinde-NelsonOK , et al. Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension. Journal of Child and Adolescent Psychopharmacology2017;27(5):403-12. [DOI: 10.1089/cap.2015.0146] [PMCID: PMC5510039] [PMID: 26978327]NCT00872898. Study of pharmacokinetics, safety, efficacy, and tolerability of memantine in children with autism [An open-label (part one) and a randomized, double-blind, placebo-controlled (part two) study of the pharmacokinetics, safety, efficacy, and tolerability of memantine in pediatric patients with autism]. clinicaltrials.gov/ct2/show/NCT00872898 (first received 31 March 2009). ">Aman 2017</a> administered 3 mg/day to 18 mg/day, depending on bodyweight, and children in <a href="./references#CD011769-bbs2-0095" title="NCT01972074. Behavioral and neural response to memantine in adolescents with autism spectrum disorder. clinicaltrials.gov/ct2/show/NCT01972074 (first received 30 October 2013). ">NCT01972074</a> received a maximum of 20 mg/day. </p> </li> <li> <p>Piracetam: one study involving 40 participants compared piracetam to a placebo (<a href="./references#CD011769-bbs2-0002" title="AkhondzadehS , TajdarH , Mohammadi M-R, MohammadiM , Nouroozinejad G-H, ShabstariOL , et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry and Human Development2008;39(3):237-45. [DOI: 10.1007/s10578-007-0084-3] [PMID: 17929164]">Akhondzadeh 2008</a>). Piracetam was administered up to 800 mg/day in addition to 2 mg/day of risperidone for children up to 40 kg, and 3 mg/day for children 41 kg and above. </p> </li> <li> <p>Galantamine: one study involving 40 participants compared galantamine to a placebo (<a href="./references#CD011769-bbs2-0032" title="GhaleihaA , GhyasvandM , Mohammadi M-R, FarokhniaM , YadegariN , TabriziM , et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology2014;28(7):677-85. [DOI: 10.1177/0269881113508830] [PMID: 24132248]IRCT201204081556N40. Galantamine in the treatment of autism [Galantamine added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/890 (first received 14 April 2012). ">Ghaleiha 2014</a>). Galantamine was administered up to 12 mg/day for children up to 19 kg, 16 mg/day for children 20 kg to 30 kg, 20 mg/day for children 31 kg to 40 kg, and 24 mg/day for children over 40 kg. Risperidone was also administered up to 1 mg/day for children less than 20 kg, and 2 mg/day for children 20 kg and above. </p> </li> <li> <p>Donepezil: one study involving 34 participants compared donepezil to a placebo (<a href="./references#CD011769-bbs2-0044" title="HandenBL , JohnsonCR , McAuliffe-BellinS , HardanA . Safety and efficacy of donepezil in children - behavioural measures. International public health journal2010;2(1):125-34. HandenBL , JohnsonCR , Mcauliffe-BellinS , MurrayPJ , HardanAY . Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of Child and Adolescent Psychopharmacology2011;21(1):43-50. [DOI: 10.1089/cap.2010.0024] [PMCID: PMC3037196] [PMID: 21309696]HardanA , JohnsonC , HandenBL . Preliminary findings from a double-blind placebo=controlled study of donepezil in pervasive developmental disorders. Biological Psychiatry2006;59(8):50S-50S. NCT00047697. Donepezil HCl and cognitive deficits in autism. https://clinicaltrials.gov/ct2/show/results/NCT00047697?term=NCT00047697&amp;draw=2&amp;rank=1 (first received October 2002). ">Handen 2011</a>). The trial involved 5 mg/day of donepezil for four weeks and progressed to a maximum of 10 mg/day of donepezil for another four weeks if tolerated. </p> </li> </ul> </li> <li> <p>Comparators: three studies compared the intervention to a placebo plus risperidone, however, the analysis for these studies only included intervention versus placebo because risperidone was also added to the intervention (<a href="./references#CD011769-bbs2-0002" title="AkhondzadehS , TajdarH , Mohammadi M-R, MohammadiM , Nouroozinejad G-H, ShabstariOL , et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry and Human Development2008;39(3):237-45. [DOI: 10.1007/s10578-007-0084-3] [PMID: 17929164]">Akhondzadeh 2008</a>; <a href="./references#CD011769-bbs2-0030" title="GhaleihaA , AsababadiM , Mohammadi M-R, ShaheiM , TabriziM , HajiaghaeeR , et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology2013;16(4):783-9. [DOI: 10.1017/S1461145712000880] [PMID: 22999292]IRCT1138901151556N10. A double-blind placebo-controlled trial of memantine added to risperidone in patients with autistic disorder. https://www.irct.ir/trial/860 (first received May 2010). ">Ghaleiha 2013a</a>; <a href="./references#CD011769-bbs2-0032" title="GhaleihaA , GhyasvandM , Mohammadi M-R, FarokhniaM , YadegariN , TabriziM , et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology2014;28(7):677-85. [DOI: 10.1177/0269881113508830] [PMID: 24132248]IRCT201204081556N40. Galantamine in the treatment of autism [Galantamine added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/890 (first received 14 April 2012). ">Ghaleiha 2014</a>). None of the studies provided details of the placebo. </p> </li> <li> <p>Inclusion criteria: all studies required participants to have a clinical diagnosis of ASD based on DSM criteria; two studies specified a minimum ABC‐I score of 12 (<a href="./references#CD011769-bbs2-0030" title="GhaleihaA , AsababadiM , Mohammadi M-R, ShaheiM , TabriziM , HajiaghaeeR , et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology2013;16(4):783-9. [DOI: 10.1017/S1461145712000880] [PMID: 22999292]IRCT1138901151556N10. A double-blind placebo-controlled trial of memantine added to risperidone in patients with autistic disorder. https://www.irct.ir/trial/860 (first received May 2010). ">Ghaleiha 2013a</a>; <a href="./references#CD011769-bbs2-0032" title="GhaleihaA , GhyasvandM , Mohammadi M-R, FarokhniaM , YadegariN , TabriziM , et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology2014;28(7):677-85. [DOI: 10.1177/0269881113508830] [PMID: 24132248]IRCT201204081556N40. Galantamine in the treatment of autism [Galantamine added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/890 (first received 14 April 2012). ">Ghaleiha 2014</a>), and a maximum ABC‐I score of 16 (<a href="./references#CD011769-bbs2-0047" title="EUCTR 2012-001568-31. A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger’s disorder, or pervasive developmental disorder not otherwise specified (PDD-NOS) previously treated with memantine. www.clinicaltrialsregister.eu/ctr-search/trial/2012-001568-31/results (first posted November 2012). HardanAY , HendrenRL , AmanMG , RobbA , MelmedRD , AndersenKA , et al. Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies. Autism2019;23(8):2096-111. [DOI: 10.1177/1362361318824103] [PMCID: PMC6779018] [PMID: 31027422]NCT01592747. Withdrawal study of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified previously treated with memantine [A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified (pdd-nos) previously treated with memantine]. clinicaltrials.gov/ct2/show/results/NCT01592747 (first received 7 May 2012). ">Hardan 2019</a>). Two studies required either a minimum of 5 on the CGI‐Severity scale (<a href="./references#CD011769-bbs2-0095" title="NCT01972074. Behavioral and neural response to memantine in adolescents with autism spectrum disorder. clinicaltrials.gov/ct2/show/NCT01972074 (first received 30 October 2013). ">NCT01972074</a>), or presentation of severe symptoms related to ASD (<a href="./references#CD011769-bbs2-0002" title="AkhondzadehS , TajdarH , Mohammadi M-R, MohammadiM , Nouroozinejad G-H, ShabstariOL , et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry and Human Development2008;39(3):237-45. [DOI: 10.1007/s10578-007-0084-3] [PMID: 17929164]">Akhondzadeh 2008</a>). </p> </li> <li> <p>Exclusion criteria: most studies excluded people with co‐occurring psychiatric disorders, history of or current significant medical conditions including renal, cardiovascular, neurological, current or recent treatment with psychotropic medications or other medications prohibited for use during the study, and two studies excluded people with severe intellectual disabilities (<a href="./references#CD011769-bbs2-0002" title="AkhondzadehS , TajdarH , Mohammadi M-R, MohammadiM , Nouroozinejad G-H, ShabstariOL , et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry and Human Development2008;39(3):237-45. [DOI: 10.1007/s10578-007-0084-3] [PMID: 17929164]">Akhondzadeh 2008</a>; <a href="./references#CD011769-bbs2-0032" title="GhaleihaA , GhyasvandM , Mohammadi M-R, FarokhniaM , YadegariN , TabriziM , et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology2014;28(7):677-85. [DOI: 10.1177/0269881113508830] [PMID: 24132248]IRCT201204081556N40. Galantamine in the treatment of autism [Galantamine added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/890 (first received 14 April 2012). ">Ghaleiha 2014</a>). </p> </li> <li> <p>Setting: four studies were primarily based in the USA at clinics and hospitals, three studies in Iran at clinics and hospitals associated with a university, and one study was conducted in 15 countries (<a href="./references#CD011769-bbs2-0047" title="EUCTR 2012-001568-31. A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger’s disorder, or pervasive developmental disorder not otherwise specified (PDD-NOS) previously treated with memantine. www.clinicaltrialsregister.eu/ctr-search/trial/2012-001568-31/results (first posted November 2012). HardanAY , HendrenRL , AmanMG , RobbA , MelmedRD , AndersenKA , et al. Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies. Autism2019;23(8):2096-111. [DOI: 10.1177/1362361318824103] [PMCID: PMC6779018] [PMID: 31027422]NCT01592747. Withdrawal study of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified previously treated with memantine [A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified (pdd-nos) previously treated with memantine]. clinicaltrials.gov/ct2/show/results/NCT01592747 (first received 7 May 2012). ">Hardan 2019</a>). </p> </li> <li> <p>Concomitant medications: two studies provided details of concomitant medication use (<a href="./references#CD011769-bbs2-0044" title="HandenBL , JohnsonCR , McAuliffe-BellinS , HardanA . Safety and efficacy of donepezil in children - behavioural measures. International public health journal2010;2(1):125-34. HandenBL , JohnsonCR , Mcauliffe-BellinS , MurrayPJ , HardanAY . Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of Child and Adolescent Psychopharmacology2011;21(1):43-50. [DOI: 10.1089/cap.2010.0024] [PMCID: PMC3037196] [PMID: 21309696]HardanA , JohnsonC , HandenBL . Preliminary findings from a double-blind placebo=controlled study of donepezil in pervasive developmental disorders. Biological Psychiatry2006;59(8):50S-50S. NCT00047697. Donepezil HCl and cognitive deficits in autism. https://clinicaltrials.gov/ct2/show/results/NCT00047697?term=NCT00047697&amp;draw=2&amp;rank=1 (first received October 2002). ">Handen 2011</a>; <a href="./references#CD011769-bbs2-0047" title="EUCTR 2012-001568-31. A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger’s disorder, or pervasive developmental disorder not otherwise specified (PDD-NOS) previously treated with memantine. www.clinicaltrialsregister.eu/ctr-search/trial/2012-001568-31/results (first posted November 2012). HardanAY , HendrenRL , AmanMG , RobbA , MelmedRD , AndersenKA , et al. Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies. Autism2019;23(8):2096-111. [DOI: 10.1177/1362361318824103] [PMCID: PMC6779018] [PMID: 31027422]NCT01592747. Withdrawal study of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified previously treated with memantine [A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified (pdd-nos) previously treated with memantine]. clinicaltrials.gov/ct2/show/results/NCT01592747 (first received 7 May 2012). ">Hardan 2019</a>). <a href="./references#CD011769-bbs2-0044" title="HandenBL , JohnsonCR , McAuliffe-BellinS , HardanA . Safety and efficacy of donepezil in children - behavioural measures. International public health journal2010;2(1):125-34. HandenBL , JohnsonCR , Mcauliffe-BellinS , MurrayPJ , HardanAY . Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of Child and Adolescent Psychopharmacology2011;21(1):43-50. [DOI: 10.1089/cap.2010.0024] [PMCID: PMC3037196] [PMID: 21309696]HardanA , JohnsonC , HandenBL . Preliminary findings from a double-blind placebo=controlled study of donepezil in pervasive developmental disorders. Biological Psychiatry2006;59(8):50S-50S. NCT00047697. Donepezil HCl and cognitive deficits in autism. https://clinicaltrials.gov/ct2/show/results/NCT00047697?term=NCT00047697&amp;draw=2&amp;rank=1 (first received October 2002). ">Handen 2011</a> allowed medications that did not interact with donepezil. Concurrent medication use included atomoxetine (1 participant in each group), stimulants (2 participants in each group), and sertraline (1 participant in intervention group) and citalopram (1 participant in intervention group). <a href="./references#CD011769-bbs2-0047" title="EUCTR 2012-001568-31. A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger’s disorder, or pervasive developmental disorder not otherwise specified (PDD-NOS) previously treated with memantine. www.clinicaltrialsregister.eu/ctr-search/trial/2012-001568-31/results (first posted November 2012). HardanAY , HendrenRL , AmanMG , RobbA , MelmedRD , AndersenKA , et al. Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies. Autism2019;23(8):2096-111. [DOI: 10.1177/1362361318824103] [PMCID: PMC6779018] [PMID: 31027422]NCT01592747. Withdrawal study of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified previously treated with memantine [A double-blind, placebo-controlled, randomized withdrawal study of the safety and efficacy of memantine in pediatric patients with autism, Asperger's disorder, or pervasive developmental disorder not otherwise specified (pdd-nos) previously treated with memantine]. clinicaltrials.gov/ct2/show/results/NCT01592747 (first received 7 May 2012). ">Hardan 2019</a> reported that approximately 10% of participants were taking risperidone, amongst other supplements and medications. </p> </li> <li> <p>Participant cognitive status: not reported</p> </li> <li> <p>Length of follow‐up: all studies were either 10 weeks or 12 weeks in duration and none of the studies followed up after the endpoint of the trial. </p> </li> </ul> </p> <section id="CD011769-sec-0100"> <h6 class="title">Primary outcomes</h6> <p> <ul id="CD011769-list-0047"> <li> <p>Irritability: three studies reported irritability (<a href="./references#CD011769-bbs2-0030" title="GhaleihaA , AsababadiM , Mohammadi M-R, ShaheiM , TabriziM , HajiaghaeeR , et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology2013;16(4):783-9. [DOI: 10.1017/S1461145712000880] [PMID: 22999292]IRCT1138901151556N10. A double-blind placebo-controlled trial of memantine added to risperidone in patients with autistic disorder. https://www.irct.ir/trial/860 (first received May 2010). ">Ghaleiha 2013a</a>; <a href="./references#CD011769-bbs2-0032" title="GhaleihaA , GhyasvandM , Mohammadi M-R, FarokhniaM , YadegariN , TabriziM , et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology2014;28(7):677-85. [DOI: 10.1177/0269881113508830] [PMID: 24132248]IRCT201204081556N40. Galantamine in the treatment of autism [Galantamine added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/890 (first received 14 April 2012). ">Ghaleiha 2014</a>; <a href="./references#CD011769-bbs2-0044" title="HandenBL , JohnsonCR , McAuliffe-BellinS , HardanA . Safety and efficacy of donepezil in children - behavioural measures. International public health journal2010;2(1):125-34. HandenBL , JohnsonCR , Mcauliffe-BellinS , MurrayPJ , HardanAY . Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of Child and Adolescent Psychopharmacology2011;21(1):43-50. [DOI: 10.1089/cap.2010.0024] [PMCID: PMC3037196] [PMID: 21309696]HardanA , JohnsonC , HandenBL . Preliminary findings from a double-blind placebo=controlled study of donepezil in pervasive developmental disorders. Biological Psychiatry2006;59(8):50S-50S. NCT00047697. Donepezil HCl and cognitive deficits in autism. https://clinicaltrials.gov/ct2/show/results/NCT00047697?term=NCT00047697&amp;draw=2&amp;rank=1 (first received October 2002). ">Handen 2011</a>). Two studies used the ABC‐I subscale (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>), to report irritability, while <a href="./references#CD011769-bbs2-0044" title="HandenBL , JohnsonCR , McAuliffe-BellinS , HardanA . Safety and efficacy of donepezil in children - behavioural measures. International public health journal2010;2(1):125-34. HandenBL , JohnsonCR , Mcauliffe-BellinS , MurrayPJ , HardanAY . Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of Child and Adolescent Psychopharmacology2011;21(1):43-50. [DOI: 10.1089/cap.2010.0024] [PMCID: PMC3037196] [PMID: 21309696]HardanA , JohnsonC , HandenBL . Preliminary findings from a double-blind placebo=controlled study of donepezil in pervasive developmental disorders. Biological Psychiatry2006;59(8):50S-50S. NCT00047697. Donepezil HCl and cognitive deficits in autism. https://clinicaltrials.gov/ct2/show/results/NCT00047697?term=NCT00047697&amp;draw=2&amp;rank=1 (first received October 2002). ">Handen 2011</a> used the Ritvo‐Freeman Real Life Rating Scale (affectual responses subscale; <a href="./references#CD011769-bbs2-0323" title="FreemanBJ , RitvoER , YokotaA , RitvoA . A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the American academy of child psychiatry1986;25(1):130-6. [DOI: 10.1016/S0002-7138(09)60610-5] [PMID: 3950262]">Freeman 1986</a>) to report irritability. </p> </li> <li> <p>Aggression: <a href="./references#CD011769-bbs2-0044" title="HandenBL , JohnsonCR , McAuliffe-BellinS , HardanA . Safety and efficacy of donepezil in children - behavioural measures. International public health journal2010;2(1):125-34. HandenBL , JohnsonCR , Mcauliffe-BellinS , MurrayPJ , HardanAY . Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of Child and Adolescent Psychopharmacology2011;21(1):43-50. [DOI: 10.1089/cap.2010.0024] [PMCID: PMC3037196] [PMID: 21309696]HardanA , JohnsonC , HandenBL . Preliminary findings from a double-blind placebo=controlled study of donepezil in pervasive developmental disorders. Biological Psychiatry2006;59(8):50S-50S. NCT00047697. Donepezil HCl and cognitive deficits in autism. https://clinicaltrials.gov/ct2/show/results/NCT00047697?term=NCT00047697&amp;draw=2&amp;rank=1 (first received October 2002). ">Handen 2011</a> reported aggression using the Child Behaviour Checklist (CBCL) (<a href="./references#CD011769-bbs2-0263" title="AchenbachTM , RescorlaL . Manual for the ASEBA preschool forms and profiles. Burlington, Vermont: University of Vermont, Research Center for Children, 2000.">Achenbach 2000</a>). </p> </li> <li> <p>AEs: apart from <a href="./references#CD011769-bbs2-0044" title="HandenBL , JohnsonCR , McAuliffe-BellinS , HardanA . Safety and efficacy of donepezil in children - behavioural measures. International public health journal2010;2(1):125-34. HandenBL , JohnsonCR , Mcauliffe-BellinS , MurrayPJ , HardanAY . Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of Child and Adolescent Psychopharmacology2011;21(1):43-50. [DOI: 10.1089/cap.2010.0024] [PMCID: PMC3037196] [PMID: 21309696]HardanA , JohnsonC , HandenBL . Preliminary findings from a double-blind placebo=controlled study of donepezil in pervasive developmental disorders. Biological Psychiatry2006;59(8):50S-50S. NCT00047697. Donepezil HCl and cognitive deficits in autism. https://clinicaltrials.gov/ct2/show/results/NCT00047697?term=NCT00047697&amp;draw=2&amp;rank=1 (first received October 2002). ">Handen 2011</a>, which reported no AEs associated with donepezil, all studies reported AEs. </p> </li> </ul> </p> </section> <section id="CD011769-sec-0101"> <h6 class="title">Secondary outcomes</h6> <p> <ul id="CD011769-list-0048"> <li> <p>Tolerability and acceptability (loss to follow‐up): 54 participants (8.7%) withdrew from the studies and were not included in the relevant study analyses. Reasons included withdrawing consent (15); AEs (15), protocol violations (5); lost to follow‐up (4); lack of efficacy (5); no longer met inclusion/exclusion criteria (2); other (7); tolerability (2); and increased behaviours of concern (1). </p> </li> </ul> </p> </section> </section> <section id="CD011769-sec-0102"> <h5 class="title">Antiparkinsonian interventions versus placebo or other treatments</h5> <p>Two studies (3 reports, 79 participants, 2 datasets) compared an antiparkinsonian intervention to a placebo (<a href="./references#CD011769-bbs2-0064" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McmahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2001;40(6):658-65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a>; <a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a>). Both studies compared amantadine to a placebo, however, <a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a> compared amantadine plus risperidone to placebo plus risperidone. The analysis for <a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a> only included amantadine versus placebo. Both studies were parallel. <a href="./references#CD011769-bbs2-0064" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McmahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2001;40(6):658-65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a> was five weeks in duration and was conducted in the USA at medical centres associated with universities. <a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a> was 10 weeks in duration and was conducted in Iran at a hospital associated with a university. All participants were children and were approximately the same age (mean age 7.0 years). </p> <p> <ul id="CD011769-list-0049"> <li> <p>Interventions: <a href="./references#CD011769-bbs2-0064" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McmahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2001;40(6):658-65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a> required children to take 5 mg/kg/day of amantadine over two daily doses regardless of weight, whilst <a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a> required children who weighed 30 kg to take 100 mg/day of amantadine or 150 mg/day over two daily doses for children 30 kg or over. </p> </li> <li> <p>Comparators: both studies compared amantadine to a placebo however neither study described the ingredients of the placebo. <a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a> compared amantadine to a placebo plus risperidone, although the analysis is only amantadine versus placebo. </p> </li> <li> <p>Inclusion criteria: both studies required participants to have a diagnosis of ASD based on the DSM criteria and a score of 12 or higher on the ABC‐I subscale. <a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a> also required presentation of severely disruptive symptoms associated with ASD. </p> </li> <li> <p>Exclusion criteria: both studies excluded people with significant medical conditions requiring medications, allergies to the intervention, and psychotropic use in the six weeks prior to enrolment (<a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a>), or taking neuroleptic, anticonvulsant or stimulants (<a href="./references#CD011769-bbs2-0064" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McmahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2001;40(6):658-65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a>). </p> </li> <li> <p>Concomitant medications: <a href="./references#CD011769-bbs2-0064" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McmahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2001;40(6):658-65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a> allowed the use of SSRIs provided the dose had been stable for at least one month prior to the trial and the dose did not change during the trial. <a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a> did not allow the use of any psychotropic medications. </p> </li> <li> <p>Participant cognitive status: neither study provided details.</p> </li> <li> <p>Length of follow‐up: <a href="./references#CD011769-bbs2-0064" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McmahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2001;40(6):658-65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a> was five weeks and <a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a> 10 weeks in duration. Neither study followed up after the endpoint of the trial. </p> </li> </ul> </p> <section id="CD011769-sec-0103"> <h6 class="title">Primary outcomes</h6> <p> <ul id="CD011769-list-0050"> <li> <p>Irritability: both studies reported irritability using the ABC‐I subscale (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>), however, <a href="./references#CD011769-bbs2-0064" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McmahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2001;40(6):658-65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a> did not report endpoint ABC‐I data (only baseline). Participants in both studies had baseline ABC‐I scores of at least 18. </p> </li> <li> <p>AEs: both studies reported AEs.</p> </li> </ul> </p> </section> <section id="CD011769-sec-0104"> <h6 class="title">Secondary outcomes</h6> <p> <ul id="CD011769-list-0051"> <li> <p>Tolerability and acceptability (loss to follow‐up): <a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a> excluded one participant (1.3%) from the analysis but did not provide the reason. </p> </li> </ul> </p> </section> </section> <section id="CD011769-sec-0105"> <h5 class="title">Anxiolytic interventions versus placebo or other treatment</h5> <p>Two studies (4 reports, 200 participants, 3 datasets) compared an anxiolytic to a placebo (<a href="./references#CD011769-bbs2-0020" title="ChuganiDC , ChuganiHT , WiznitzerM , ParikhS , EvansPA , HansenRL , et al. Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial. Journal of Pediatrics2016;170:45-53.e1-4. [DOI: 10.1016/j.jpeds.2015.11.033] [PMID: 26746121]NCT00873509. Buspirone in the treatment of 2-6 year old children with autistic disorder (B-ACE) [A randomized, placebo-controlled, double-masked clinical trial of buspirone in the treatment of 2- 6 year old children with autistic disorder]. (first received 1 April 2009). ">Chugani 2016</a>; <a href="./references#CD011769-bbs2-0037" title="GhanizadehA , AyoobzadehshiraziA . A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology2015;52(1):77-81. [DOI: 10.1016/j.pediatrneurol.2014.09.017] [PMID: 25451017]IRCT201307303930N28. A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders. www.irct.ir/trial/4107 (first received 4 April 2014). ">Ghanizadeh 2015</a>). Both studies compared buspirone, however, <a href="./references#CD011769-bbs2-0037" title="GhanizadehA , AyoobzadehshiraziA . A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology2015;52(1):77-81. [DOI: 10.1016/j.pediatrneurol.2014.09.017] [PMID: 25451017]IRCT201307303930N28. A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders. www.irct.ir/trial/4107 (first received 4 April 2014). ">Ghanizadeh 2015</a> compared buspirone plus risperidone to placebo plus risperidone. The analysis for <a href="./references#CD011769-bbs2-0037" title="GhanizadehA , AyoobzadehshiraziA . A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology2015;52(1):77-81. [DOI: 10.1016/j.pediatrneurol.2014.09.017] [PMID: 25451017]IRCT201307303930N28. A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders. www.irct.ir/trial/4107 (first received 4 April 2014). ">Ghanizadeh 2015</a> was buspirone versus placebo. Both studies were parallel, however <a href="./references#CD011769-bbs2-0020" title="ChuganiDC , ChuganiHT , WiznitzerM , ParikhS , EvansPA , HansenRL , et al. Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial. Journal of Pediatrics2016;170:45-53.e1-4. [DOI: 10.1016/j.jpeds.2015.11.033] [PMID: 26746121]NCT00873509. Buspirone in the treatment of 2-6 year old children with autistic disorder (B-ACE) [A randomized, placebo-controlled, double-masked clinical trial of buspirone in the treatment of 2- 6 year old children with autistic disorder]. (first received 1 April 2009). ">Chugani 2016</a> was 24 weeks in duration and was based at six academic medical centres in the USA, and <a href="./references#CD011769-bbs2-0037" title="GhanizadehA , AyoobzadehshiraziA . A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology2015;52(1):77-81. [DOI: 10.1016/j.pediatrneurol.2014.09.017] [PMID: 25451017]IRCT201307303930N28. A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders. www.irct.ir/trial/4107 (first received 4 April 2014). ">Ghanizadeh 2015</a> was eight weeks in duration and was conducted at a child and adolescent psychiatry clinic associated with a university in Iran. All participants were under 18 years old, however <a href="./references#CD011769-bbs2-0020" title="ChuganiDC , ChuganiHT , WiznitzerM , ParikhS , EvansPA , HansenRL , et al. Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial. Journal of Pediatrics2016;170:45-53.e1-4. [DOI: 10.1016/j.jpeds.2015.11.033] [PMID: 26746121]NCT00873509. Buspirone in the treatment of 2-6 year old children with autistic disorder (B-ACE) [A randomized, placebo-controlled, double-masked clinical trial of buspirone in the treatment of 2- 6 year old children with autistic disorder]. (first received 1 April 2009). ">Chugani 2016</a> only included children under six years of age and <a href="./references#CD011769-bbs2-0037" title="GhanizadehA , AyoobzadehshiraziA . A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology2015;52(1):77-81. [DOI: 10.1016/j.pediatrneurol.2014.09.017] [PMID: 25451017]IRCT201307303930N28. A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders. www.irct.ir/trial/4107 (first received 4 April 2014). ">Ghanizadeh 2015</a> included children up to 17 years of age. </p> <p> <ul id="CD011769-list-0052"> <li> <p>Interventions: <a href="./references#CD011769-bbs2-0020" title="ChuganiDC , ChuganiHT , WiznitzerM , ParikhS , EvansPA , HansenRL , et al. Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial. Journal of Pediatrics2016;170:45-53.e1-4. [DOI: 10.1016/j.jpeds.2015.11.033] [PMID: 26746121]NCT00873509. Buspirone in the treatment of 2-6 year old children with autistic disorder (B-ACE) [A randomized, placebo-controlled, double-masked clinical trial of buspirone in the treatment of 2- 6 year old children with autistic disorder]. (first received 1 April 2009). ">Chugani 2016</a> required participants to take buspirone twice daily at either 2.5 mg/dose (5 mg/day) or 5 mg/dose (10 mg/day). <a href="./references#CD011769-bbs2-0037" title="GhanizadehA , AyoobzadehshiraziA . A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology2015;52(1):77-81. [DOI: 10.1016/j.pediatrneurol.2014.09.017] [PMID: 25451017]IRCT201307303930N28. A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders. www.irct.ir/trial/4107 (first received 4 April 2014). ">Ghanizadeh 2015</a> required children who weighed less than 40 kg to have a maximum of 5 mg twice daily (10 mg/day), or a maximum of 10 mg twice daily (20 mg/day) for children who weighed 40 kg or more. </p> </li> <li> <p>Comparators: both studies compared buspirone to a placebo however <a href="./references#CD011769-bbs2-0037" title="GhanizadehA , AyoobzadehshiraziA . A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology2015;52(1):77-81. [DOI: 10.1016/j.pediatrneurol.2014.09.017] [PMID: 25451017]IRCT201307303930N28. A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders. www.irct.ir/trial/4107 (first received 4 April 2014). ">Ghanizadeh 2015</a> compared buspirone plus risperidone to placebo plus risperidone. As mentioned previously, the analysis only involved buspirone versus placebo. </p> </li> <li> <p>Inclusion criteria: both studies required participants to meet the DSM‐IV criteria for ASD; <a href="./references#CD011769-bbs2-0037" title="GhanizadehA , AyoobzadehshiraziA . A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology2015;52(1):77-81. [DOI: 10.1016/j.pediatrneurol.2014.09.017] [PMID: 25451017]IRCT201307303930N28. A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders. www.irct.ir/trial/4107 (first received 4 April 2014). ">Ghanizadeh 2015</a> required participants to have at least a moderate rating on the CGI‐Severity score. </p> </li> <li> <p>Exclusion criteria: both studies excluded people who had unstable medical conditions that required medication, including neurological, liver, kidney, cardiac or psychotic disorders. <a href="./references#CD011769-bbs2-0020" title="ChuganiDC , ChuganiHT , WiznitzerM , ParikhS , EvansPA , HansenRL , et al. Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial. Journal of Pediatrics2016;170:45-53.e1-4. [DOI: 10.1016/j.jpeds.2015.11.033] [PMID: 26746121]NCT00873509. Buspirone in the treatment of 2-6 year old children with autistic disorder (B-ACE) [A randomized, placebo-controlled, double-masked clinical trial of buspirone in the treatment of 2- 6 year old children with autistic disorder]. (first received 1 April 2009). ">Chugani 2016</a> excluded people who were taking medications such as anticonvulsants, antidepressants, benzodiazepines, or neuroleptics in the six weeks prior to the trial, <a href="./references#CD011769-bbs2-0037" title="GhanizadehA , AyoobzadehshiraziA . A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology2015;52(1):77-81. [DOI: 10.1016/j.pediatrneurol.2014.09.017] [PMID: 25451017]IRCT201307303930N28. A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders. www.irct.ir/trial/4107 (first received 4 April 2014). ">Ghanizadeh 2015</a> excluded people who had taken antipsychotics in the two months prior to the study. </p> </li> <li> <p>Concomitant medications: <a href="./references#CD011769-bbs2-0037" title="GhanizadehA , AyoobzadehshiraziA . A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology2015;52(1):77-81. [DOI: 10.1016/j.pediatrneurol.2014.09.017] [PMID: 25451017]IRCT201307303930N28. A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders. www.irct.ir/trial/4107 (first received 4 April 2014). ">Ghanizadeh 2015</a> allowed participants to take stable medications apart from antipsychotics provided that they were maintained at a constant dose throughout the trial. </p> </li> <li> <p>Participant cognitive status: neither study provided details regarding cognitive status.</p> </li> <li> <p>Length of follow‐up: <a href="./references#CD011769-bbs2-0020" title="ChuganiDC , ChuganiHT , WiznitzerM , ParikhS , EvansPA , HansenRL , et al. Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial. Journal of Pediatrics2016;170:45-53.e1-4. [DOI: 10.1016/j.jpeds.2015.11.033] [PMID: 26746121]NCT00873509. Buspirone in the treatment of 2-6 year old children with autistic disorder (B-ACE) [A randomized, placebo-controlled, double-masked clinical trial of buspirone in the treatment of 2- 6 year old children with autistic disorder]. (first received 1 April 2009). ">Chugani 2016</a> was 24 weeks in duration and <a href="./references#CD011769-bbs2-0037" title="GhanizadehA , AyoobzadehshiraziA . A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology2015;52(1):77-81. [DOI: 10.1016/j.pediatrneurol.2014.09.017] [PMID: 25451017]IRCT201307303930N28. A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders. www.irct.ir/trial/4107 (first received 4 April 2014). ">Ghanizadeh 2015</a> was eight weeks in duration. </p> </li> </ul> </p> <section id="CD011769-sec-0106"> <h6 class="title">Primary outcomes</h6> <p> <ul id="CD011769-list-0053"> <li> <p>Irritability: <a href="./references#CD011769-bbs2-0037" title="GhanizadehA , AyoobzadehshiraziA . A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology2015;52(1):77-81. [DOI: 10.1016/j.pediatrneurol.2014.09.017] [PMID: 25451017]IRCT201307303930N28. A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders. www.irct.ir/trial/4107 (first received 4 April 2014). ">Ghanizadeh 2015</a> reported irritability using the ABC‐I subscale (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>). Baseline ABC‐I scores were above 24. </p> </li> <li> <p>AEs: <a href="./references#CD011769-bbs2-0020" title="ChuganiDC , ChuganiHT , WiznitzerM , ParikhS , EvansPA , HansenRL , et al. Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial. Journal of Pediatrics2016;170:45-53.e1-4. [DOI: 10.1016/j.jpeds.2015.11.033] [PMID: 26746121]NCT00873509. Buspirone in the treatment of 2-6 year old children with autistic disorder (B-ACE) [A randomized, placebo-controlled, double-masked clinical trial of buspirone in the treatment of 2- 6 year old children with autistic disorder]. (first received 1 April 2009). ">Chugani 2016</a> reported AEs. </p> </li> </ul> </p> </section> <section id="CD011769-sec-0107"> <h6 class="title">Secondary outcomes</h6> <p> <ul id="CD011769-list-0054"> <li> <p>Tolerability and acceptability (loss to follow‐up): 30 participants (15%) withdrew and were not included in the relevant study analyses. Reasons included withdrawing consent (6); AEs (13), lost to follow‐up (5); no longer met inclusion/exclusion criteria (2); clinical decision (2); participant moved(1); other (1). </p> </li> </ul> </p> </section> </section> <section id="CD011769-sec-0108"> <h5 class="title">Experimental interventions versus placebo or other treatment:</h5> <p>Forty‐two studies (72 reports, 1920 participants, 43 datasets) compared an experimental interventional drug to a placebo. The majority of studies only included children, however, five studies included only adults (<a href="./references#CD011769-bbs2-0019" title="ChezM , KileS , LepageC , PariseC , BenabidesB , HankinsA . A randomized, placebo-controlled, blinded, crossover, pilot study of the effects of dextromethorphan/quinidine for the treatment of neurobehavioral symptoms in adults with autism. Journal of Autism and Developmental Disorders2020;50(5):1532-8. [DOI: 10.1007/s10803-018-3703-x] [PMID: 30109474]">Chez 2020</a>; <a href="./references#CD011769-bbs2-0023" title="DanforthAL , GrobCS , StrubleC , FeducciaAA , WalkerN , JeromeL , et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmaology2018;235(11):3137-48. [DOI: 10.1007/s00213-018-5010-9] [PMCID: PMC6208958] [PMID: 30196397]NCT02008396. Phase 2 pilot safety study of MDMA-assisted therapy for socail anxiety in autistic adults. (first received 6 December 2013). ">Danforth 2018</a>; <a href="./references#CD011769-bbs2-0057" title="HollanderE , FerrettiCJ , TaylorBP , NooneRH , RacineE . P.7.d.006 Trichuris suis ova (TSO) as an immune-inflammatory treatment for repetitive behaviors in autism spectrum disorders (ASD). European Neuropsychopharmacology2014;24(2):S723. [DOI: 10.1016/S0924-977X(14)71165-4]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]HollanderE , FerrettiC , TaylorB , NooneR , KirschJ , RacineE . Trichuris suis ova (TSO) as an immune inflammatory treatment for repetitive behaviors in ASD. Neuropsychopharmacology2013;38:S391-2. [DOI: 10.1038/npp.2013.280]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]NCT01040221. Trichuris suis ova in autism spectrum disorders (TSO) [Trichuris suis ova in autism spectrum disorders ]. www.clinicaltrials.gov/ct2/show/NCT01040221 (first received November 2012). StarkFS , ChavanneC , Lennon-ChrimesS , DiackC , DerksM , SmithJ . Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431). European Neuropsychopharmacology2020;40:S82-S83. [DOI: 10.1016/j.euroneuro.2020.09.110]">Hollander 2020a</a>; <a href="./references#CD011769-bbs2-0070" title="LewisAS , Van SchalkwyGI , LopezMO , VolkmarFR , PicciottoMR , SukhodolskyDG . An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(8):2748-57. [DOI: 10.1007/s10803-018-3536-7] [PMCID: PMC6394231] [PMID: 29536216]NCT02552147. Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism [Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism]. clinicaltrials.gov/ct2/show/NCT02552147 (first received 16 September 2015). ">Lewis 2018</a>; <a href="./references#CD011769-bbs2-0126" title="Willemsen-SwinkelsSH , BuitelaarJK , NijhofGJ , Van EngelandH . Failure of naltrexone hydrochloride to reduce self-injurious and autistic behaviour in mentally retarded adults. Double-blind placebo-controlled studies. Archives of General Psychiatry1995;52(9):766-73. [DOI: 10.1001/archpsyc.1995.03950210060011] [PMID: 7654128]">Willemsen‐Swinkels 1995</a>), two studies included both adolescents (12 years and over) and adults (<a href="./references#CD011769-bbs2-0124" title="NCT01288716. Study of arbaclofen for the treatment of social withdrawal in subjects with autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT01288716?term=NCT01288716&amp;draw=2&amp;rank=1 (first received February 2011). Veenstra-VanderWeeleJ , CookEH , KingBH , ZarevicsP , CherubiniM , Walton-BowenK , et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology2017;42(7):1390-8. [DOI: 10.1038/npp.2016.237] [PMCID: PMC5436109] [PMID: 27748740]">Veenstra‐VanderWeele 2017</a>; <a href="./references#CD011769-bbs2-0129" title="NCT02081027. Pilot study of riluzole for drug-refractory irritability in autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT02081027?term=NCT02081027&amp;draw=2&amp;rank=1 (first received March 2014). WinkLK , AdamsR , HornPS , TessierCR , BantelAP , HongM , et al. A randomized placebo-controlled cross-over pilot study of riluzole for drug-refractory irritability in autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(9):3051-60. [DOI: 10.1007/s10803-018-3562-5] [PMID: 29644582]">Wink 2018</a>), one study included only adolescents (11 to 17 years; <a href="./references#CD011769-bbs2-0010" title="AyatollahiA , BagheriS , Ashraf-GanjoueiA , MoradiK , Mohammadi M-R, AkhondzadehS . Does pregnenolone adjunct to risperidone ameliorate irritable behavior in adolescents with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial?Clinical Neuropharmacology2020;43(5):139-45. [DOI: 10.1097/WNF.0000000000000405] [PMID: 32947424]IRCT20090117001556N112. Efficacy of pregnenolon in treatment of irritability in teenagers with autism [Efficacy of pregnenolon in treatment of irritability in teeanagers with autism; a double blind and placebo controlled triall]. www.irct.ir/trial/32775 (first received 25 July 2018). ">Ayatollahi 2020</a>), and one study involved children and adults up to 21 years of age (<a href="./references#CD011769-bbs2-0006" title="AranA , HarelM , CassutoH , PolyanskyK , SchnappA , Wattad1N , et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular Autism2021;12(6):6-6. [DOI: 10.1186/s13229-021-00420-2] [PMID: 33536055]NCT02956226. Cannabinoids for behavioral problems in children with ASD (CBA). (first received 2 November 2016). ">Aran 2021</a>). Study duration ranged from seven days (<a href="./references#CD011769-bbs2-0070" title="LewisAS , Van SchalkwyGI , LopezMO , VolkmarFR , PicciottoMR , SukhodolskyDG . An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(8):2748-57. [DOI: 10.1007/s10803-018-3536-7] [PMCID: PMC6394231] [PMID: 29536216]NCT02552147. Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism [Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism]. clinicaltrials.gov/ct2/show/NCT02552147 (first received 16 September 2015). ">Lewis 2018</a>), to six months (<a href="./references#CD011769-bbs2-0022" title="DanforsT , Von Knorring A-L, HartvigP , LangstromB , MoulderR , StrombergB , et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. Journal of Clinical Psychopharmacology2005;25(5):485-9. [DOI: 10.1097/01.jcp.0000177667.35016.e9] [PMID: 16160627]">Danfors 2005</a>), with a mean duration of 10 weeks. Eighteen studies were conducted in Iran, 14 were conducted in the USA, four in the Netherlands (<a href="./references#CD011769-bbs2-0117" title="SprengersJ , Van AndelD , ZuithoffN , Keijzer-VeenM , ScheepersF , LilienM , et al. Bumetanide versus placebo for core symptoms of autism spectrum disorder at 91 days (BAMBI): a single-centre, double-blinded, patient-randomized, placebo-controlled, phase-2-trial. European Neuropsychopharmacology2020;40:S80-S81. [DOI: 10.1016/j.euroneuro.2020.09.108]SprengersJJ , Van AndelDM , ZuithoffNP , Keijzer-VeenMG , SchulpAJ , ScheepersFE , et al. Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial. Journal of the American Academy of Child and Adolescent Psychiatry2021;60(7):865-76. [DOI: 10.1016/j.jaac.2020.07.888] [PMID: 32730977]">Sprengers 2021</a>; <a href="./references#CD011769-bbs2-0123" title="VanAndelD , SprengersJ , Keijzer-VeenM , SchulpA , LillienM , ScheepersF , et al. Bumetanide for irritability in children with sensory processing problems across neurodevelopmental disorders: a pilot randomized controlled trial. Frontiers in Psychiatry2022;13:780281. [DOI: 10.3389/fpsyt.2022.780281] [PMID: 35211042]">VanAndel 2022</a>; <a href="./references#CD011769-bbs2-0127" title="Willemsen-SwinkelsSH , BuitelaarJK , Van EngelandH . The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biological Psychiatry1996;39(12):1023-31. [DOI: 10.1016/0006-3223(95)00297-9] [PMID: 8780837]">Willemsen‐Swinkels 1996</a>; <a href="./references#CD011769-bbs2-0126" title="Willemsen-SwinkelsSH , BuitelaarJK , NijhofGJ , Van EngelandH . Failure of naltrexone hydrochloride to reduce self-injurious and autistic behaviour in mentally retarded adults. Double-blind placebo-controlled studies. Archives of General Psychiatry1995;52(9):766-73. [DOI: 10.1001/archpsyc.1995.03950210060011] [PMID: 7654128]">Willemsen‐Swinkels 1995</a>), one in Israel (<a href="./references#CD011769-bbs2-0006" title="AranA , HarelM , CassutoH , PolyanskyK , SchnappA , Wattad1N , et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular Autism2021;12(6):6-6. [DOI: 10.1186/s13229-021-00420-2] [PMID: 33536055]NCT02956226. Cannabinoids for behavioral problems in children with ASD (CBA). (first received 2 November 2016). ">Aran 2021</a>), China, Sweden, Australia, France and Austria respectively (<a href="./references#CD011769-bbs2-0021" title="DaiY , ZhangL , YuJ , ZhouX , HeH , JiY , et al. Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial. Science Bulletin2021;66(15):1591-8. [DOI: 10.1016/j.scib.2021.01.008]NCT03156153. A study of bumetanide for the treatment of autism spectrum disorders. (first received 15 May 2017). ">Dai 2021</a>; <a href="./references#CD011769-bbs2-0022" title="DanforsT , Von Knorring A-L, HartvigP , LangstromB , MoulderR , StrombergB , et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. Journal of Clinical Psychopharmacology2005;25(5):485-9. [DOI: 10.1097/01.jcp.0000177667.35016.e9] [PMID: 16160627]">Danfors 2005</a>; <a href="./references#CD011769-bbs2-0024" title="ACTRN12610000635066. Efficacy Of N-acetyl cysteine in autism: a double-blind, placebo-controlled randomised trial [Efficacy of n-acetyl cysteine on social skills, communication and behaviour in autistic children: a double-blind, placebo-controlled randomised trial]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=320918 (first received 3 August 2010). DeanOM , GrayK , DoddS , Villagonzalo K-A, BrownE , TongeB , et al. Does N-acetylcysteine improve behaviour in children with autism?: a mixed-methods analysis of the effects of N-acetylcysteine. Journal of Intellectual &amp; Developmental Disability2019;44(4):474-80. [DOI: 10.3109/13668250.2017.1413079]DeanOM , GrayKM , Villagonzalo K-A, DoddS , MohebbiM , VickT , et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian and New Zealand Journal of Psychiatry2017;51(3):241-9. [DOI: 10.1177/0004867416652735] [PMID: 27316706]">Dean 2019</a>; <a href="./references#CD011769-bbs2-0068" title="LemonnierE , VilleneuveN , SonieS , RosierA , RoueM , BrossetP , et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Translational Psychiatry2017;7(3):e1056. [DOI: 10.1038/tp.2017.10] [PMCID: PMC5416661] [PMID: 28291262]NCT01078714. Efficiency of bumetanide in autistic children (BUMEA). https://clinicaltrials.gov/ct2/show/NCT01078714?term=NCT01078714&amp;draw=1&amp;rank=1 (first received March 2010). ">Lemonnier 2017</a>; <a href="./references#CD011769-bbs2-0098" title="NiederhoferH , StaffenW , MairA . Lofexidine In hyperactive and impulsive children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2002;41(12):1396-7. [DOI: 10.1097/00004583-200212000-00010] [PMID: 12447025]">Niederhofer 2002</a>). All were parallel studies apart from 10, which were cross‐over studies. </p> <p> <ul id="CD011769-list-0055"> <li> <p>Interventions</p> <ul id="CD011769-list-0056"> <li> <p>Arbaclofen: one study involving 150 participants compared arbaclofen to a placebo (<a href="./references#CD011769-bbs2-0124" title="NCT01288716. Study of arbaclofen for the treatment of social withdrawal in subjects with autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT01288716?term=NCT01288716&amp;draw=2&amp;rank=1 (first received February 2011). Veenstra-VanderWeeleJ , CookEH , KingBH , ZarevicsP , CherubiniM , Walton-BowenK , et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology2017;42(7):1390-8. [DOI: 10.1038/npp.2016.237] [PMCID: PMC5436109] [PMID: 27748740]">Veenstra‐VanderWeele 2017</a>). Mean age of participants was 11.6 years (range 5 years to 21 years). Arbaclofen was administered twice daily, up to maximum of 10 mg/day for children under 12 years and a maximum of 15 mg for participants 12 years and above. </p> </li> <li> <p>Baclofen plus risperidone: one study involving 58 participants 4 to 12 years of age compared baclofen (plus risperidone) to a placebo (plus risperidone; <a href="./references#CD011769-bbs2-0074" title="IRCT201701131556N95. Baclofen in the treatment of autism [Baclofen as adjunctive treatment of autism: a double blind and placebo controlled trial]. www.irct.ir/trial/944 (first received 13 January 2017). Mahdavinasab S-M, SaghazadehA , Motamed-GorjiN , VaseghiS , Mohammadi M-R, AlichaniR , et al. Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. European Child &amp; Adolescent Psychiatry2019;28(12):1619-28. [DOI: 10.1007/s00787-019-01333-5] [PMID: 30980177]">Mahdavinasab 2019</a>). Risperidone commenced at 0.5 mg/day to a maximum of 1.5 mg/day and baclofen was administered three times daily at 0.6 mg/kg. The analysis was baclofen compared to placebo. </p> </li> <li> <p>Bumetanide: four studies involving 335 participants up to 18 years of age compared bumetanide to a placebo (<a href="./references#CD011769-bbs2-0021" title="DaiY , ZhangL , YuJ , ZhouX , HeH , JiY , et al. Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial. Science Bulletin2021;66(15):1591-8. [DOI: 10.1016/j.scib.2021.01.008]NCT03156153. A study of bumetanide for the treatment of autism spectrum disorders. (first received 15 May 2017). ">Dai 2021</a>; <a href="./references#CD011769-bbs2-0068" title="LemonnierE , VilleneuveN , SonieS , RosierA , RoueM , BrossetP , et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Translational Psychiatry2017;7(3):e1056. [DOI: 10.1038/tp.2017.10] [PMCID: PMC5416661] [PMID: 28291262]NCT01078714. Efficiency of bumetanide in autistic children (BUMEA). https://clinicaltrials.gov/ct2/show/NCT01078714?term=NCT01078714&amp;draw=1&amp;rank=1 (first received March 2010). ">Lemonnier 2017</a>; <a href="./references#CD011769-bbs2-0117" title="SprengersJ , Van AndelD , ZuithoffN , Keijzer-VeenM , ScheepersF , LilienM , et al. Bumetanide versus placebo for core symptoms of autism spectrum disorder at 91 days (BAMBI): a single-centre, double-blinded, patient-randomized, placebo-controlled, phase-2-trial. European Neuropsychopharmacology2020;40:S80-S81. [DOI: 10.1016/j.euroneuro.2020.09.108]SprengersJJ , Van AndelDM , ZuithoffNP , Keijzer-VeenMG , SchulpAJ , ScheepersFE , et al. Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial. Journal of the American Academy of Child and Adolescent Psychiatry2021;60(7):865-76. [DOI: 10.1016/j.jaac.2020.07.888] [PMID: 32730977]">Sprengers 2021</a>; <a href="./references#CD011769-bbs2-0123" title="VanAndelD , SprengersJ , Keijzer-VeenM , SchulpA , LillienM , ScheepersF , et al. Bumetanide for irritability in children with sensory processing problems across neurodevelopmental disorders: a pilot randomized controlled trial. Frontiers in Psychiatry2022;13:780281. [DOI: 10.3389/fpsyt.2022.780281] [PMID: 35211042]">VanAndel 2022</a>). Participants in <a href="./references#CD011769-bbs2-0068" title="LemonnierE , VilleneuveN , SonieS , RosierA , RoueM , BrossetP , et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Translational Psychiatry2017;7(3):e1056. [DOI: 10.1038/tp.2017.10] [PMCID: PMC5416661] [PMID: 28291262]NCT01078714. Efficiency of bumetanide in autistic children (BUMEA). https://clinicaltrials.gov/ct2/show/NCT01078714?term=NCT01078714&amp;draw=1&amp;rank=1 (first received March 2010). ">Lemonnier 2017</a> were allocated to either 0.5 mg, 1 mg, or 2 mg of bumetanide twice daily. <a href="./references#CD011769-bbs2-0117" title="SprengersJ , Van AndelD , ZuithoffN , Keijzer-VeenM , ScheepersF , LilienM , et al. Bumetanide versus placebo for core symptoms of autism spectrum disorder at 91 days (BAMBI): a single-centre, double-blinded, patient-randomized, placebo-controlled, phase-2-trial. European Neuropsychopharmacology2020;40:S80-S81. [DOI: 10.1016/j.euroneuro.2020.09.108]SprengersJJ , Van AndelDM , ZuithoffNP , Keijzer-VeenMG , SchulpAJ , ScheepersFE , et al. Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial. Journal of the American Academy of Child and Adolescent Psychiatry2021;60(7):865-76. [DOI: 10.1016/j.jaac.2020.07.888] [PMID: 32730977]">Sprengers 2021</a> administered bumetanide in liquid form twice daily with a mean dose of 0.0482 mg/kg/day, and <a href="./references#CD011769-bbs2-0021" title="DaiY , ZhangL , YuJ , ZhouX , HeH , JiY , et al. Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial. Science Bulletin2021;66(15):1591-8. [DOI: 10.1016/j.scib.2021.01.008]NCT03156153. A study of bumetanide for the treatment of autism spectrum disorders. (first received 15 May 2017). ">Dai 2021</a> administered 0.5 mg of bumetanide twice daily. </p> </li> <li> <p>Cannabidiol: one cross‐over study involving 88 participants aged 5 to 21 years compared cannabidiol to a placebo (<a href="./references#CD011769-bbs2-0006" title="AranA , HarelM , CassutoH , PolyanskyK , SchnappA , Wattad1N , et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular Autism2021;12(6):6-6. [DOI: 10.1186/s13229-021-00420-2] [PMID: 33536055]NCT02956226. Cannabinoids for behavioral problems in children with ASD (CBA). (first received 2 November 2016). ">Aran 2021</a>). Participants received 1 mg/kg of cannabidiol per day for 12 weeks. </p> </li> <li> <p>Celecoxib plus risperidone: one study involving 40 participants compared celecoxib to a placebo (<a href="./references#CD011769-bbs2-0009" title="AkhondzadehS , AsadabadiM . Risperidone plus celecoxib in children with autistic disorder: a double-blind, randomized trial. British Journal of Clinical Pharmacology2012;73(6):983-4. [DOI: 10.1111/j.1365-2125.2012.04253.x]AsadabadiM , Mohammadi M-R, GhanizadehA , ModabberniaA , AshrafiM , HassanzadehE , et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology2013;225(1):51-9. [DOI: 10.1007/s00213-012-2796-8] [PMID: 22782459]IRCT138711091556N2. Celecoxib and autism [A double-blind placebo controlled trial of celecoxib added to risperidone in patients with autistic disorder]. www.irct.ir/trial/852 (first received 12 February 2009). ">Asadabadi 2013</a>). Maximum celecoxib was 200 mg/day plus 2 mg/day of risperidone for children who weighed 10 kg to 30 kg, and 30 mg/day of celecoxib plus 3 mg/day of risperidone for children 31 kg and over. Equivalent placebo plus risperidone was provided to participants in the placebo group. The analysis for this study is celecoxib versus placebo. </p> </li> <li> <p>Cyproheptadine plus haloperidol: one study involving 40 participants compared cyproheptadine plus haloperidol to a placebo plus haloperidol (<a href="./references#CD011769-bbs2-0001" title="AkhondzadehS , ErfaniS , MohammadiMR , Tehrani-DoostM , AminiH , GudarziSS , et al. Cyproheptadine in the treatment of autistic disorder: a double‐blind placebo‐controlled trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):145-50. [DOI: 10.1111/j.1365-2710.2004.00546.x] [PMID: 15068403]">Akhondzadeh 2004</a>). Maximum cyproheptadine was 0.2 mg/kg/day and maximum haloperidol was 0.05 mg/kg/day. The analysis for this study was cyproheptadine versus placebo. </p> </li> <li> <p>D‐cycloserine plus social skills training: one study involving 67 participants compared D‐cycloserine plus social skills training to a placebo plus social skills training (<a href="./references#CD011769-bbs2-0081" title="MinshawiNF , WinkLK , ShafferR , PlaweckiMH , PoseyDJ , LiuH , et al. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism2016;7(3):2. [DOI: 10.1186/s13229-015-0062-8] [PMCID: PMC4712595] [PMID: 26770664]NCT01086475. D-cycloserine and social skills training in autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT01086475?term=NCT01086475&amp;draw=1&amp;rank=1 (first received March 2010). WinkLK , MinshawiNF , ShafferRC , PlaweckiMH , PoseyDJ , HornPS , et al. D-cycloserine enhances durability of social skills training in autism spectrum disorder. Molecular Autism2017;8:2. [DOI: 10.1186/s13229-017-0116-1] [PMCID: PMC5264460] [PMID: 28138381]">Minshawi 2016</a>). Participants received 50 mg of D‐cycloserine or placebo 30 minutes prior to weekly social skills training sessions. </p> </li> <li> <p>Dextromethorphan: one study involving eight participants compared dextromethorphan to a placebo (sweetened syrup; <a href="./references#CD011769-bbs2-0130" title="WoodardC , GrodenJ , GoodwinM , BodfishJ . A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism. Autism2007;11(1):29-41. [DOI: 10.1177/1362361307070989] [PMID: 17175572]">Woodard 2007</a>). Children aged 6 to 12 years and 13 years and over received 30 mg or 60 mg of dextromethorphan, respectively, every 12 hours. </p> </li> <li> <p>Dextromethorphan plus quinidine: one study involving 14 participants compared dextromethorphan plus quinidine (<a href="./references#CD011769-bbs2-0019" title="ChezM , KileS , LepageC , PariseC , BenabidesB , HankinsA . A randomized, placebo-controlled, blinded, crossover, pilot study of the effects of dextromethorphan/quinidine for the treatment of neurobehavioral symptoms in adults with autism. Journal of Autism and Developmental Disorders2020;50(5):1532-8. [DOI: 10.1007/s10803-018-3703-x] [PMID: 30109474]">Chez 2020</a>). Participants received 20 mg of dextromethorphan plus 10 mg of quinidine in tablet form (Nuedexta) once daily for the first week and then twice daily for the following seven weeks. </p> </li> <li> <p>Fenfluramine: one study involving 11 participants compared fenfluramine to a placebo (<a href="./references#CD011769-bbs2-0016" title="CampbellM , AdamsP , SmallAM , CurrenEL , OverallJE , AndersonLT , et al. Efficacy and safety of fenfluramine in autistic children. Journal of the American Academy of Child &amp; Adolescent Psychiatry1988;27(4):434-9. [DOI: 10.1097/00004583-198807000-00010] [PMID: 3053609]">Campbell 1987</a>). Fenfluramine was initiated at 1.0 mg/kg/day across two daily doses, increasing to a maximum of 60 mg/day. </p> </li> <li> <p>Folinic acid plus risperidone: one study involving 55 participants compared folinic acid plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0011" title="BatebiN , MoghaddamHS , HasanzadehA , FakourY , MohammadiMR , AkhondzadehS . Folinic acid as adjunctive therapy in treatment of inappropriate speech in children with autism: a double-blind and placebo-controlled randomized trial. Child Psychiatry &amp; Human Development2021;52(5):928-38. [DOI: 10.1007/s10578-020-01072-8] [PMID: 33029705]IRCT20090117001556N114. Folinic acid in the treatment of autism spectrum disorder [Folinic acid add on therapy to risperidone in symptoms of children with autism: a randomized double-blind placebo-controlled clinical trial]. www.irct.ir/trial/35172 (first received 15 November 2018). ">Batebi 2021</a>). Folinic acid was administered at 2 mg/kg up to a maximum of 50 mg/day. Maximum risperidone for children who weighed up to 19 kg and 20 kg and over was 1 mg/day and 2 mg/day respectively. The analysis for this study was folinic acid versus placebo. </p> </li> <li> <p>L‐carnosine plus risperidone: one study involving 42 participants compared L‐carnosine plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0041" title="Hajizadeh-ZakerR , GhajarA , MesgarpourB , AfaridehM , Mohammadi M-R, Akhondzadeh S. L-carnosine as an adjunctive therapy to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology2018;28(1):74-81. [DOI: 10.1089/cap.2017.0026] [PMID: 29027815]IRCT201512081556N83. L carnosine in the treatment of autism [L carnosine added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. www.irct.ir/trial/932 (first received 9 December 2015). ">Hajizadeh‐Zaker 2018</a>). Participants received 400 mg of L‐carnosine twice daily plus a maximum of 1 mg/day of risperidone (children under 20 kg) or 2 mg/day of risperidone (children over 20 kg). The analysis for this study was L‐carnosine versus placebo. </p> </li> <li> <p>Lofexedine: one study involving 12 participants compared lofexedine to a placebo (<a href="./references#CD011769-bbs2-0098" title="NiederhoferH , StaffenW , MairA . Lofexidine In hyperactive and impulsive children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2002;41(12):1396-7. [DOI: 10.1097/00004583-200212000-00010] [PMID: 12447025]">Niederhofer 2002</a>). Lofexedine commenced at 0.4 mg/day up to a maximum of 1.2 mg/day over three daily doses. </p> </li> <li> <p>MDMA (methylenedioxymethamphetamine) plus psychotherapy: one study involving 12 adults compared MDMA plus psychotherapy to a placebo plus psychotherapy (<a href="./references#CD011769-bbs2-0023" title="DanforthAL , GrobCS , StrubleC , FeducciaAA , WalkerN , JeromeL , et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmaology2018;235(11):3137-48. [DOI: 10.1007/s00213-018-5010-9] [PMCID: PMC6208958] [PMID: 30196397]NCT02008396. Phase 2 pilot safety study of MDMA-assisted therapy for socail anxiety in autistic adults. (first received 6 December 2013). ">Danforth 2018</a>). Following three 60‐ to 90‐minute psychotherapy sessions, participants received either 75 mg to 125 mg of MDMA or placebo on two occasions approximately one month apart. </p> </li> <li> <p>Mecamylamine: one study involving 20 participants compared mecamylamine to a placebo (<a href="./references#CD011769-bbs2-0008" title="ArnoldLE , AmanMG , HollwayJ , HurtE , BatesB , LiX , et al. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology2012;22(3):198-205. [DOI: 10.1089/cap.2011.0056] [PMCID: PMC3417385] [PMID: 22537359]NCT00773812. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders [Neuronal nicotinic receptor modulation in the treatment of autism: a pilot trial of mecamylamine]. clinicaltrials.gov/ct2/show/NCT00773812 (first received 16 October 2008). ">Arnold 2012a</a>). Mecamylamine was administered in fixed doses starting at 0.5 mg/day up to 5 mg/day if tolerated. </p> </li> <li> <p>Minocycline plus risperidone: one study involving 46 participants compared minocycline plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0034" title="GhaleihaA , AlikhaniR , Kazemi M-R, Mohammadi M-R, MohammadinejadP , ZeinoddiniA , et al. Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology2016;26(9):784-91. [DOI: 10.1089/cap.2015.0175] [PMID: 27128958]IRCT201302201556N50. Minocycline in the treatment of autism [Minocycline added to risperidone in the treatment of autism: a double blind and placebo controlled trial ]. en.irct.ir/trial/900 (first received 21 February 2013). ">Ghaleiha 2016</a>). Minocycline was administered in fixed doses of 100 mg/day plus risperidone 1 mg/day (children under 20 kg) or 2 mg/day (children over 20 kg). The analysis for this study was minocycline versus placebo. </p> </li> <li> <p>N‐acetylcysteine plus risperidone: two studies involving 71 participants compared N‐acetylcysteine plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0035" title="GhanizadehA , Moghimi-SaraniE . A randomized double blind placebo controlled clinical trial of N-acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry2013;13:196. [DOI: 10.1186/1471-244X-13-196] [PMCID: PMC3737121] [PMID: 23886027]IRCT201106103930N6. N-acetylcysteine augmentation with risperidone in treatment of autism in children [N-acetylcysteine augmentation with rispridone in treatment of autism in children: a double blind randomized placebo controlled clinical trial]. www.irct.ir/trial/4085 (first received 8 July 2011). ">Ghanizadeh 2013</a>; <a href="./references#CD011769-bbs2-0100" title="IRCT201110281556N29. N-acetylcysteine in the treatment of autism [N-acetyl cysteine added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/879 (first received 29 October 2011). NikooM , RadniaH , FarokhniaM , Mohammadi M-R, AkhondzadehS . N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clinical Neuropharmacology2015;38(1):11-7. [DOI: 10.1097/WNF.0000000000000063] [PMID: 25580916]">Nikoo 2015</a>). </p> </li> <li> <p>N‐acetylcysteine: three studies involving 156 participants compared N‐acetylcysteine to a placebo (<a href="./references#CD011769-bbs2-0024" title="ACTRN12610000635066. Efficacy Of N-acetyl cysteine in autism: a double-blind, placebo-controlled randomised trial [Efficacy of n-acetyl cysteine on social skills, communication and behaviour in autistic children: a double-blind, placebo-controlled randomised trial]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=320918 (first received 3 August 2010). DeanOM , GrayK , DoddS , Villagonzalo K-A, BrownE , TongeB , et al. Does N-acetylcysteine improve behaviour in children with autism?: a mixed-methods analysis of the effects of N-acetylcysteine. Journal of Intellectual &amp; Developmental Disability2019;44(4):474-80. [DOI: 10.3109/13668250.2017.1413079]DeanOM , GrayKM , Villagonzalo K-A, DoddS , MohebbiM , VickT , et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian and New Zealand Journal of Psychiatry2017;51(3):241-9. [DOI: 10.1177/0004867416652735] [PMID: 27316706]">Dean 2019</a>; <a href="./references#CD011769-bbs2-0046" title="HardanA . Psychopharmacological treatment of anxiety symptoms in autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):S325-6. [DOI: 10.1016/j.jaac.2016.07.369] [ABSTRACT NO: 42.4]HardanAY , FungLK , LiboveRA , ObukhanychTV , NairS , HerzenbergLA , et al. A randomised controlled pilot trial of N-acetylcysteine in children with autism. Biological Psychiatry2012;71(11):956-61. [DOI: 10.1016//j.biopsych.2012.01.014] [PMCID: PMC4914359] [PMID: 22342106]">Hardan 2012</a>; <a href="./references#CD011769-bbs2-0128" title="NCT00453180. A study of oral N-acetylcysteine in children with autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT00453180?term=NCT00453180&amp;draw=2&amp;rank=1 (first received March 2007). WinkLK , AdamsR , WangZ , KlaunigJE , PlaweckiMH , PoseyDJ , et al. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Molecular Autism2016;7:26. [DOI: 10.1186/s13229-016-0088-6] [PMCID: PMC4839099] [PMID: 27103982]">Wink 2016</a>). </p> </li> <li> <p>Naltrexone: three studies involving 93 participants compared naltrexone to a placebo (<a href="./references#CD011769-bbs2-0017" title="CampbellM , AndersonLT , SmallAM , AdamsP , GonzalezNM , ErnstE . Naltrexone in autistic children: behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry1993;32(6):1283-91. [DOI: 10.1097/00004583-199311000-00024] [PMID: 8282676]GonzalezNM , CampbellM , SmallAM , ShayJ , BluhmLD , AdamsPB , et al. Naltrexone plasma levels, clinical response and effect on weight in autistic children. Psychopharmacology Bulletin1994;30(2):203-8. [PMID: 7831456]">Campbell 1993</a>; <a href="./references#CD011769-bbs2-0126" title="Willemsen-SwinkelsSH , BuitelaarJK , NijhofGJ , Van EngelandH . Failure of naltrexone hydrochloride to reduce self-injurious and autistic behaviour in mentally retarded adults. Double-blind placebo-controlled studies. Archives of General Psychiatry1995;52(9):766-73. [DOI: 10.1001/archpsyc.1995.03950210060011] [PMID: 7654128]">Willemsen‐Swinkels 1995</a>; <a href="./references#CD011769-bbs2-0127" title="Willemsen-SwinkelsSH , BuitelaarJK , Van EngelandH . The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biological Psychiatry1996;39(12):1023-31. [DOI: 10.1016/0006-3223(95)00297-9] [PMID: 8780837]">Willemsen‐Swinkels 1996</a>). </p> </li> <li> <p>Nicotine: one study involving seven adult participants compared nicotine to a placebo (<a href="./references#CD011769-bbs2-0070" title="LewisAS , Van SchalkwyGI , LopezMO , VolkmarFR , PicciottoMR , SukhodolskyDG . An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(8):2748-57. [DOI: 10.1007/s10803-018-3536-7] [PMCID: PMC6394231] [PMID: 29536216]NCT02552147. Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism [Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism]. clinicaltrials.gov/ct2/show/NCT02552147 (first received 16 September 2015). ">Lewis 2018</a>). Participants applied 7 mg of nicotine or placebo daily via skin patches. </p> </li> <li> <p>Palmitoylethanolamide plus risperidone: one study involving 62 participants compared palmitoylethanolamide plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0063" title="IRCT201702171556N96. Palmitoylethanolamide as adjunctive treatment of autism: a double blind and placebo controlled trial. en.irct.ir/trial/945 (first received 20 February 2017). KhalajM , SaghazadehA , ShiraziE , Shalbafan M-R, AlaviK , ShooshtariMH , et al. Palmitoylethanolamide as adjunctive therapy for autism: efficacy and safety results from a randomized controlled trial. Journal of Psychiatric Research2018;103:104-11. [DOI: 10.1016/j.jpsychires.2018.04.022] [PMID: 29807317]">Khalaj 2018</a>); 600 mg of palmitoylethanolamide was administered twice daily in addition to 1 mg/day of risperidone (children under 20 kg) or 2 mg/day (children over 20 kg). The analysis for this study was palmitoylethanolamide versus placebo. </p> </li> <li> <p>Pentoxifylline plus risperidone: one study involving 40 participants compared pentoxifylline plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0003" title="AkhondzadehS , FallahJ , Mohammadi M-R, ImaniR , MohammadiM , SalehiB , et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Progress in Neuro-Psychopharmacology and Biological Psychiatry2010;34(1):32-6. [DOI: 10.1016/j.pnpbp.2009.09.012] [PMID: 19772883]">Akhondzadeh 2010</a>). Maximum pentoxifylline was 400 mg/day for children who weighed up to 40 kg, or a maximum of 600 mg/day for children 41 kg and above. Risperidone was administered up to 2 mg/day for children who weighed up to 40 kg, or a maximum of 3 mg/day for children above 40 kg. The analysis for this study was pentoxifylline versus placebo. </p> </li> <li> <p>Pioglitazone plus risperidone: one study involving 44 participants compared pioglitazone plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0033" title="GhaleihaA , RasaSM , NikooM , FarokhniaM , Mohammadi M-R, AkhondzadehS . A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism. Psychiatry Research2015;229(1-2):181-7. [DOI: 10.1016/j.psychres.2015.07.043] [PMID: 26208985]IRCT201202281556N37. Pioglitazone in the treatment of autism [Pioglitazone added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/887 (first received 1 March 2012). ">Ghaleiha 2015</a>); 15 mg of pioglitazone was administered twice daily in addition to an initial 0.5 mg/day of risperidone, increasing to 1 mg/day (children under 20 kg) or 2 mg/day (children over 20 kg). The analysis for this study was pioglitazone versus placebo. </p> </li> <li> <p>Prednisolone plus risperidone: one study involving 26 participants compared prednisolone plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0075" title="IRCT20090117001556N102. Prednisolone in autism spectrum disorders [Prednisolone in regressive autism spectrum disorders: a randomized double-blind placebo-controlled clinical trial]. www.irct.ir/trial/28026 (first received 9 December 2017). MalekM , Ashraf-GanjoueiA , MoradiK , BagheriS , Mohammadi M-R, AkhonzadehS . Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial. Clinical Neuropharmacology2020;43(2):39-45. [DOI: 10.1097/WNF.0000000000000382] [PMID: 32168067]">Malek 2020</a>). Prednisolone was administered at 1 mg/kg/day in addition to an initial 0.5 mg/day of risperidone, increasing to 1 mg/day (children under 20 kg) or 2 mg/day (children over 20 kg). The analysis for this study was prednisolone versus placebo. </p> </li> <li> <p>Pregnenolon plus risperidone: one study involving 59 participants compared pregnenolon plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0010" title="AyatollahiA , BagheriS , Ashraf-GanjoueiA , MoradiK , Mohammadi M-R, AkhondzadehS . Does pregnenolone adjunct to risperidone ameliorate irritable behavior in adolescents with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial?Clinical Neuropharmacology2020;43(5):139-45. [DOI: 10.1097/WNF.0000000000000405] [PMID: 32947424]IRCT20090117001556N112. Efficacy of pregnenolon in treatment of irritability in teenagers with autism [Efficacy of pregnenolon in treatment of irritability in teeanagers with autism; a double blind and placebo controlled triall]. www.irct.ir/trial/32775 (first received 25 July 2018). ">Ayatollahi 2020</a>). Pregnenolon was administered in fixed doses of 100 mg twice daily. Risperidone was administered at maximum doses of 2.5 mg/day for children who weighed 20 kg to 45 kg, or a maximum of 3.5 mg/day for children who weighed above 45 kg. The analysis for this study was pregnenolone versus placebo. </p> </li> <li> <p>Propentofylline plus risperidone: one study involving 48 participants compared propentofylline to a placebo (<a href="./references#CD011769-bbs2-0012" title="BehmaneshH , MoghaddamHS , Mohammadi M-R, AkhondzadehS . Risperidone combination therapy with propentofylline for treatment of irritability in autism spectrum disorders: a randomized, double-blind, placebo-controlled clinical trial. Clinical Neuropharmacology2019;42(6):189-96. [DOI: 10.1097/WNF.0000000000000368] [PMID: 31725473]IRCT20090117001556N113. Effect of propentofylline in children with autism [Effect of propentofylline add on therapy to risperidon in children with autism: a randomized double-blind placebo-controlled clinical trial]. www.irct.ir/trial/35171 (first received 15 November 2018). ">Behmanesh 2019</a>). Propentofylline commenced at 300 mg once daily and increased to 300 mg twice daily (children under 45 kg) or propentofylline increased to 300 mg three times daily (children 45 kg or over). Risperidone commenced at 0.5 mg/day and increased to 1 mg/day for children who weighed under 20 kg or 2 mg/day for those who weighed 20 kg or above. The analysis for this study was propentofylline versus placebo. </p> </li> <li> <p>Resveratrol plus risperidone: one study involving 62 participants compared resveratrol plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0050" title="HendoueiF , MoghaddamHS , MohammadiMR , TaslimiN , RezaeiF , AkhondzadehS . Resveratrol as adjunctive therapy in treatment of irritability in children with autism: a double‐blind and placebo‐controlled randomized trial. Journal of Clinical Pharmacy and Therapeutics2020;45(2):324-34. [DOI: 10.1111/jcpt.13076] [PMID: 31714621]IRCT20090117001556N104. Resveratrol in treatment of autism [Resveratrol add on therapy to risperidone in irritibility of children with autism: a randomized double-blind placebo-controlled clinical trial]. www.irct.ir/trial/28378 (first received 25 December 2012). ">Hendouei 2019</a>). Resveratrol was administered as a fixed dose of 250 mg twice daily in addition to risperidone (initial dose of 0.5 mg/day increasing by 0.5 mg/day each week for the first three weeks). The analysis for this study was resveratrol versus placebo. </p> </li> <li> <p>Riluzole: one study involving seven participants compared riluzole to a placebo (<a href="./references#CD011769-bbs2-0129" title="NCT02081027. Pilot study of riluzole for drug-refractory irritability in autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT02081027?term=NCT02081027&amp;draw=2&amp;rank=1 (first received March 2014). WinkLK , AdamsR , HornPS , TessierCR , BantelAP , HongM , et al. A randomized placebo-controlled cross-over pilot study of riluzole for drug-refractory irritability in autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(9):3051-60. [DOI: 10.1007/s10803-018-3562-5] [PMID: 29644582]">Wink 2018</a>). Riluzole commenced at 50 mg/day and increased to 100 mg twice daily. </p> </li> <li> <p>Riluzole plus risperidone: one study involving 40 participants compared riluzole plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0031" title="GhaleihaA , MohammadiE , Mohammadi M-R, FarokhniaM , ModabberniaA , YekehtazH , et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Pediatric Drugs2013;15(6):505-14. [DOI: 10.1007/s40272-013-0036-2] [PMID: 23821414]IRCT201107281556N27. Riluzole in the treatment of autism [Riluzole added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/877 (first received 30 July 2011). ">Ghaleiha 2013b</a>). Riluzole was administered 25 mg/day to 50 mg/day for children who weighed 10 kg to 40 kg, or a maximum of 100 mg/day for children over 40 kg. Maximum risperidone was 2 mg/day for children who weighed up to 40 kg and a maximum of 3 mg/day for children 41 kg and above. </p> </li> <li> <p>Simvastatin plus risperidone: one study involving 66 participants compared simvastatin plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0083" title="IRCT201602041556N86. Simvastatin added to risperidone in the treatment of autism: a double blind and placebo controlled trial. https://www.irct.ir/trial/935 (first received February 2016). Moazen-ZadehE , ShirzadF , Karkhaneh-Yousefi M-A, KhezriR , Mohammadi M-R, AkhondzadehS . Simvastatin as an adjunctive therapy to risperidone in treatment of autism: a randomized, double-blind, placebo-controlled clinical trial. Journal of Child and Adolescent Psychopharmacology2018;28(1):82-9. [DOI: 10.1089/cap.2017.0055] [PMID: 28719227]">Moazen‐Zadeh 2018</a>). Simvastatin was administered at either 20 mg/day for children under 10 years of age or 40 mg/day for children 10 years and over. The analysis for this study was simvastatin versus placebo. </p> </li> <li> <p>Sulforaphane plus risperidone: one study involving 60 participants compared sulforaphane plus risperidone to a placebo plus risperidone (<a href="./references#CD011769-bbs2-0085" title="IRCT20090117001556N107. Sulforaphane as adjunctive treatment of irritability in children with autism spectrum disorder [Sulforaphane treatment of autism spectrum disorder: a double blind controlled trial]. www.irct.ir/trial/30363 (first received 6 April 2018). MontazmeneshS , Amirimoghaddam-YazdiZ , MoghaddamHS , MohammadiMR , AkhondzadehS . Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial. Psychiatry and Clinical Neurosciences2020;74(7):398-405. [DOI: 10.1111/pcn.13016] [PMID: 32347624]">Montazmenesh 2020</a>). Sulforaphane was administered at 50 μmol /day for children who weighed less than 45 kg, or 100 μmol for children 45 kg to 90 kg. Risperidone was administered at a maximum of 1 mg/day for children under 20 kg, 2.5 mg/day for children 20 kg to 45 kg, and 3.5 mg/day for children who weighed over 45 kg. </p> </li> <li> <p>Tetrahydrobiopterin: two studies involving 58 participants compared tetrahydrobiopterin to a placebo (<a href="./references#CD011769-bbs2-0022" title="DanforsT , Von Knorring A-L, HartvigP , LangstromB , MoulderR , StrombergB , et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. Journal of Clinical Psychopharmacology2005;25(5):485-9. [DOI: 10.1097/01.jcp.0000177667.35016.e9] [PMID: 16160627]">Danfors 2005</a>; <a href="./references#CD011769-bbs2-0066" title="KlaimanC , HuffmanL , MasakiL , ElliottGR . Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology2013;13(5):320-8. [DOI: 10.1089/cap.2012.0127] [PMID: 23782126]NCT00850070. Sapropterin as a treatment for autistic disorder. https://clinicaltrials.gov/ct2/show/results/NCT00850070?term=NCT00850070&amp;draw=2&amp;rank=1 (first received February 2009). ">Klaiman 2013</a>). <a href="./references#CD011769-bbs2-0022" title="DanforsT , Von Knorring A-L, HartvigP , LangstromB , MoulderR , StrombergB , et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. Journal of Clinical Psychopharmacology2005;25(5):485-9. [DOI: 10.1097/01.jcp.0000177667.35016.e9] [PMID: 16160627]">Danfors 2005</a> administered tetrahydrobiopterin at a maximum of 3 mg/kg/day across two daily doses, while <a href="./references#CD011769-bbs2-0066" title="KlaimanC , HuffmanL , MasakiL , ElliottGR . Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology2013;13(5):320-8. [DOI: 10.1089/cap.2012.0127] [PMID: 23782126]NCT00850070. Sapropterin as a treatment for autistic disorder. https://clinicaltrials.gov/ct2/show/results/NCT00850070?term=NCT00850070&amp;draw=2&amp;rank=1 (first received February 2009). ">Klaiman 2013</a> administered tetrahydrobiopterin in tablet form at 20 mg/kg once daily (mean final dose was 385 mg/day). </p> </li> <li> <p><i>Trichuris suis</i> ova: one study involving 10 adult participants compared <i>Trichuris suis</i> ova to a placebo (<a href="./references#CD011769-bbs2-0057" title="HollanderE , FerrettiCJ , TaylorBP , NooneRH , RacineE . P.7.d.006 Trichuris suis ova (TSO) as an immune-inflammatory treatment for repetitive behaviors in autism spectrum disorders (ASD). European Neuropsychopharmacology2014;24(2):S723. [DOI: 10.1016/S0924-977X(14)71165-4]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]HollanderE , FerrettiC , TaylorB , NooneR , KirschJ , RacineE . Trichuris suis ova (TSO) as an immune inflammatory treatment for repetitive behaviors in ASD. Neuropsychopharmacology2013;38:S391-2. [DOI: 10.1038/npp.2013.280]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]NCT01040221. Trichuris suis ova in autism spectrum disorders (TSO) [Trichuris suis ova in autism spectrum disorders ]. www.clinicaltrials.gov/ct2/show/NCT01040221 (first received November 2012). StarkFS , ChavanneC , Lennon-ChrimesS , DiackC , DerksM , SmithJ . Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431). European Neuropsychopharmacology2020;40:S82-S83. [DOI: 10.1016/j.euroneuro.2020.09.110]">Hollander 2020a</a>). Participants received a dose of 2500 ova every two weeks. </p> </li> </ul> </li> <li> <p>Comparators: all studies compared an experimental intervention to a placebo, although 16 of the studies were compared to a placebo plus risperidone, one study was compared to a placebo plus haloperidol (<a href="./references#CD011769-bbs2-0001" title="AkhondzadehS , ErfaniS , MohammadiMR , Tehrani-DoostM , AminiH , GudarziSS , et al. Cyproheptadine in the treatment of autistic disorder: a double‐blind placebo‐controlled trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):145-50. [DOI: 10.1111/j.1365-2710.2004.00546.x] [PMID: 15068403]">Akhondzadeh 2004</a>), and one study compared to placebo plus psychotherapy (<a href="./references#CD011769-bbs2-0023" title="DanforthAL , GrobCS , StrubleC , FeducciaAA , WalkerN , JeromeL , et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmaology2018;235(11):3137-48. [DOI: 10.1007/s00213-018-5010-9] [PMCID: PMC6208958] [PMID: 30196397]NCT02008396. Phase 2 pilot safety study of MDMA-assisted therapy for socail anxiety in autistic adults. (first received 6 December 2013). ">Danforth 2018</a>). Only three studies provided details of the placebo, sugar pill (<a href="./references#CD011769-bbs2-0046" title="HardanA . Psychopharmacological treatment of anxiety symptoms in autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):S325-6. [DOI: 10.1016/j.jaac.2016.07.369] [ABSTRACT NO: 42.4]HardanAY , FungLK , LiboveRA , ObukhanychTV , NairS , HerzenbergLA , et al. A randomised controlled pilot trial of N-acetylcysteine in children with autism. Biological Psychiatry2012;71(11):956-61. [DOI: 10.1016//j.biopsych.2012.01.014] [PMCID: PMC4914359] [PMID: 22342106]">Hardan 2012</a>; <a href="./references#CD011769-bbs2-0081" title="MinshawiNF , WinkLK , ShafferR , PlaweckiMH , PoseyDJ , LiuH , et al. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism2016;7(3):2. [DOI: 10.1186/s13229-015-0062-8] [PMCID: PMC4712595] [PMID: 26770664]NCT01086475. D-cycloserine and social skills training in autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT01086475?term=NCT01086475&amp;draw=1&amp;rank=1 (first received March 2010). WinkLK , MinshawiNF , ShafferRC , PlaweckiMH , PoseyDJ , HornPS , et al. D-cycloserine enhances durability of social skills training in autism spectrum disorder. Molecular Autism2017;8:2. [DOI: 10.1186/s13229-017-0116-1] [PMCID: PMC5264460] [PMID: 28138381]">Minshawi 2016</a>) or sweetened syrup (<a href="./references#CD011769-bbs2-0130" title="WoodardC , GrodenJ , GoodwinM , BodfishJ . A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism. Autism2007;11(1):29-41. [DOI: 10.1177/1362361307070989] [PMID: 17175572]">Woodard 2007</a>). </p> </li> <li> <p>Inclusion criteria: all studies required participants to have a clinical diagnosis of ASD, and additional criteria included a minimum of 15 on the ABC‐I subscale (<a href="./references#CD011769-bbs2-0009" title="AkhondzadehS , AsadabadiM . Risperidone plus celecoxib in children with autistic disorder: a double-blind, randomized trial. British Journal of Clinical Pharmacology2012;73(6):983-4. [DOI: 10.1111/j.1365-2125.2012.04253.x]AsadabadiM , Mohammadi M-R, GhanizadehA , ModabberniaA , AshrafiM , HassanzadehE , et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology2013;225(1):51-9. [DOI: 10.1007/s00213-012-2796-8] [PMID: 22782459]IRCT138711091556N2. Celecoxib and autism [A double-blind placebo controlled trial of celecoxib added to risperidone in patients with autistic disorder]. www.irct.ir/trial/852 (first received 12 February 2009). ">Asadabadi 2013</a>; <a href="./references#CD011769-bbs2-0010" title="AyatollahiA , BagheriS , Ashraf-GanjoueiA , MoradiK , Mohammadi M-R, AkhondzadehS . Does pregnenolone adjunct to risperidone ameliorate irritable behavior in adolescents with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial?Clinical Neuropharmacology2020;43(5):139-45. [DOI: 10.1097/WNF.0000000000000405] [PMID: 32947424]IRCT20090117001556N112. Efficacy of pregnenolon in treatment of irritability in teenagers with autism [Efficacy of pregnenolon in treatment of irritability in teeanagers with autism; a double blind and placebo controlled triall]. www.irct.ir/trial/32775 (first received 25 July 2018). ">Ayatollahi 2020</a>; <a href="./references#CD011769-bbs2-0070" title="LewisAS , Van SchalkwyGI , LopezMO , VolkmarFR , PicciottoMR , SukhodolskyDG . An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(8):2748-57. [DOI: 10.1007/s10803-018-3536-7] [PMCID: PMC6394231] [PMID: 29536216]NCT02552147. Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism [Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism]. clinicaltrials.gov/ct2/show/NCT02552147 (first received 16 September 2015). ">Lewis 2018</a>; <a href="./references#CD011769-bbs2-0129" title="NCT02081027. Pilot study of riluzole for drug-refractory irritability in autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT02081027?term=NCT02081027&amp;draw=2&amp;rank=1 (first received March 2014). WinkLK , AdamsR , HornPS , TessierCR , BantelAP , HongM , et al. A randomized placebo-controlled cross-over pilot study of riluzole for drug-refractory irritability in autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(9):3051-60. [DOI: 10.1007/s10803-018-3562-5] [PMID: 29644582]">Wink 2018</a>; <a href="./references#CD011769-bbs2-0130" title="WoodardC , GrodenJ , GoodwinM , BodfishJ . A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism. Autism2007;11(1):29-41. [DOI: 10.1177/1362361307070989] [PMID: 17175572]">Woodard 2007</a>), or a score of moderate or higher on the CGI‐Severity score (<a href="./references#CD011769-bbs2-0081" title="MinshawiNF , WinkLK , ShafferR , PlaweckiMH , PoseyDJ , LiuH , et al. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism2016;7(3):2. [DOI: 10.1186/s13229-015-0062-8] [PMCID: PMC4712595] [PMID: 26770664]NCT01086475. D-cycloserine and social skills training in autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT01086475?term=NCT01086475&amp;draw=1&amp;rank=1 (first received March 2010). WinkLK , MinshawiNF , ShafferRC , PlaweckiMH , PoseyDJ , HornPS , et al. D-cycloserine enhances durability of social skills training in autism spectrum disorder. Molecular Autism2017;8:2. [DOI: 10.1186/s13229-017-0116-1] [PMCID: PMC5264460] [PMID: 28138381]">Minshawi 2016</a>; <a href="./references#CD011769-bbs2-0124" title="NCT01288716. Study of arbaclofen for the treatment of social withdrawal in subjects with autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT01288716?term=NCT01288716&amp;draw=2&amp;rank=1 (first received February 2011). Veenstra-VanderWeeleJ , CookEH , KingBH , ZarevicsP , CherubiniM , Walton-BowenK , et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology2017;42(7):1390-8. [DOI: 10.1038/npp.2016.237] [PMCID: PMC5436109] [PMID: 27748740]">Veenstra‐VanderWeele 2017</a>), or the presentation of aggressive and disruptive behaviours (<a href="./references#CD011769-bbs2-0001" title="AkhondzadehS , ErfaniS , MohammadiMR , Tehrani-DoostM , AminiH , GudarziSS , et al. Cyproheptadine in the treatment of autistic disorder: a double‐blind placebo‐controlled trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):145-50. [DOI: 10.1111/j.1365-2710.2004.00546.x] [PMID: 15068403]">Akhondzadeh 2004</a>; <a href="./references#CD011769-bbs2-0003" title="AkhondzadehS , FallahJ , Mohammadi M-R, ImaniR , MohammadiM , SalehiB , et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Progress in Neuro-Psychopharmacology and Biological Psychiatry2010;34(1):32-6. [DOI: 10.1016/j.pnpbp.2009.09.012] [PMID: 19772883]">Akhondzadeh 2010</a>; <a href="./references#CD011769-bbs2-0012" title="BehmaneshH , MoghaddamHS , Mohammadi M-R, AkhondzadehS . Risperidone combination therapy with propentofylline for treatment of irritability in autism spectrum disorders: a randomized, double-blind, placebo-controlled clinical trial. Clinical Neuropharmacology2019;42(6):189-96. [DOI: 10.1097/WNF.0000000000000368] [PMID: 31725473]IRCT20090117001556N113. Effect of propentofylline in children with autism [Effect of propentofylline add on therapy to risperidon in children with autism: a randomized double-blind placebo-controlled clinical trial]. www.irct.ir/trial/35171 (first received 15 November 2018). ">Behmanesh 2019</a>; <a href="./references#CD011769-bbs2-0033" title="GhaleihaA , RasaSM , NikooM , FarokhniaM , Mohammadi M-R, AkhondzadehS . A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism. Psychiatry Research2015;229(1-2):181-7. [DOI: 10.1016/j.psychres.2015.07.043] [PMID: 26208985]IRCT201202281556N37. Pioglitazone in the treatment of autism [Pioglitazone added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/887 (first received 1 March 2012). ">Ghaleiha 2015</a>; <a href="./references#CD011769-bbs2-0034" title="GhaleihaA , AlikhaniR , Kazemi M-R, Mohammadi M-R, MohammadinejadP , ZeinoddiniA , et al. Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology2016;26(9):784-91. [DOI: 10.1089/cap.2015.0175] [PMID: 27128958]IRCT201302201556N50. Minocycline in the treatment of autism [Minocycline added to risperidone in the treatment of autism: a double blind and placebo controlled trial ]. en.irct.ir/trial/900 (first received 21 February 2013). ">Ghaleiha 2016</a>; <a href="./references#CD011769-bbs2-0075" title="IRCT20090117001556N102. Prednisolone in autism spectrum disorders [Prednisolone in regressive autism spectrum disorders: a randomized double-blind placebo-controlled clinical trial]. www.irct.ir/trial/28026 (first received 9 December 2017). MalekM , Ashraf-GanjoueiA , MoradiK , BagheriS , Mohammadi M-R, AkhonzadehS . Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial. Clinical Neuropharmacology2020;43(2):39-45. [DOI: 10.1097/WNF.0000000000000382] [PMID: 32168067]">Malek 2020</a>). </p> </li> <li> <p>Exclusion criteria: the majority of studies excluded people with a history of or current medical or psychiatric conditions and also people who had been taking psychotropic medications or other prohibited medications in the period leading up to the trial. Some studies also excluded people with severe intellectual disabilities (<a href="./references#CD011769-bbs2-0003" title="AkhondzadehS , FallahJ , Mohammadi M-R, ImaniR , MohammadiM , SalehiB , et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Progress in Neuro-Psychopharmacology and Biological Psychiatry2010;34(1):32-6. [DOI: 10.1016/j.pnpbp.2009.09.012] [PMID: 19772883]">Akhondzadeh 2010</a>; <a href="./references#CD011769-bbs2-0009" title="AkhondzadehS , AsadabadiM . Risperidone plus celecoxib in children with autistic disorder: a double-blind, randomized trial. British Journal of Clinical Pharmacology2012;73(6):983-4. [DOI: 10.1111/j.1365-2125.2012.04253.x]AsadabadiM , Mohammadi M-R, GhanizadehA , ModabberniaA , AshrafiM , HassanzadehE , et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology2013;225(1):51-9. [DOI: 10.1007/s00213-012-2796-8] [PMID: 22782459]IRCT138711091556N2. Celecoxib and autism [A double-blind placebo controlled trial of celecoxib added to risperidone in patients with autistic disorder]. www.irct.ir/trial/852 (first received 12 February 2009). ">Asadabadi 2013</a>; <a href="./references#CD011769-bbs2-0011" title="BatebiN , MoghaddamHS , HasanzadehA , FakourY , MohammadiMR , AkhondzadehS . Folinic acid as adjunctive therapy in treatment of inappropriate speech in children with autism: a double-blind and placebo-controlled randomized trial. Child Psychiatry &amp; Human Development2021;52(5):928-38. [DOI: 10.1007/s10578-020-01072-8] [PMID: 33029705]IRCT20090117001556N114. Folinic acid in the treatment of autism spectrum disorder [Folinic acid add on therapy to risperidone in symptoms of children with autism: a randomized double-blind placebo-controlled clinical trial]. www.irct.ir/trial/35172 (first received 15 November 2018). ">Batebi 2021</a>; <a href="./references#CD011769-bbs2-0031" title="GhaleihaA , MohammadiE , Mohammadi M-R, FarokhniaM , ModabberniaA , YekehtazH , et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Pediatric Drugs2013;15(6):505-14. [DOI: 10.1007/s40272-013-0036-2] [PMID: 23821414]IRCT201107281556N27. Riluzole in the treatment of autism [Riluzole added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/877 (first received 30 July 2011). ">Ghaleiha 2013b</a>; <a href="./references#CD011769-bbs2-0034" title="GhaleihaA , AlikhaniR , Kazemi M-R, Mohammadi M-R, MohammadinejadP , ZeinoddiniA , et al. Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology2016;26(9):784-91. [DOI: 10.1089/cap.2015.0175] [PMID: 27128958]IRCT201302201556N50. Minocycline in the treatment of autism [Minocycline added to risperidone in the treatment of autism: a double blind and placebo controlled trial ]. en.irct.ir/trial/900 (first received 21 February 2013). ">Ghaleiha 2016</a>; <a href="./references#CD011769-bbs2-0041" title="Hajizadeh-ZakerR , GhajarA , MesgarpourB , AfaridehM , Mohammadi M-R, Akhondzadeh S. L-carnosine as an adjunctive therapy to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology2018;28(1):74-81. [DOI: 10.1089/cap.2017.0026] [PMID: 29027815]IRCT201512081556N83. L carnosine in the treatment of autism [L carnosine added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. www.irct.ir/trial/932 (first received 9 December 2015). ">Hajizadeh‐Zaker 2018</a>; <a href="./references#CD011769-bbs2-0063" title="IRCT201702171556N96. Palmitoylethanolamide as adjunctive treatment of autism: a double blind and placebo controlled trial. en.irct.ir/trial/945 (first received 20 February 2017). KhalajM , SaghazadehA , ShiraziE , Shalbafan M-R, AlaviK , ShooshtariMH , et al. Palmitoylethanolamide as adjunctive therapy for autism: efficacy and safety results from a randomized controlled trial. Journal of Psychiatric Research2018;103:104-11. [DOI: 10.1016/j.jpsychires.2018.04.022] [PMID: 29807317]">Khalaj 2018</a>; <a href="./references#CD011769-bbs2-0085" title="IRCT20090117001556N107. Sulforaphane as adjunctive treatment of irritability in children with autism spectrum disorder [Sulforaphane treatment of autism spectrum disorder: a double blind controlled trial]. www.irct.ir/trial/30363 (first received 6 April 2018). MontazmeneshS , Amirimoghaddam-YazdiZ , MoghaddamHS , MohammadiMR , AkhondzadehS . Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial. Psychiatry and Clinical Neurosciences2020;74(7):398-405. [DOI: 10.1111/pcn.13016] [PMID: 32347624]">Montazmenesh 2020</a>; <a href="./references#CD011769-bbs2-0083" title="IRCT201602041556N86. Simvastatin added to risperidone in the treatment of autism: a double blind and placebo controlled trial. https://www.irct.ir/trial/935 (first received February 2016). Moazen-ZadehE , ShirzadF , Karkhaneh-Yousefi M-A, KhezriR , Mohammadi M-R, AkhondzadehS . Simvastatin as an adjunctive therapy to risperidone in treatment of autism: a randomized, double-blind, placebo-controlled clinical trial. Journal of Child and Adolescent Psychopharmacology2018;28(1):82-9. [DOI: 10.1089/cap.2017.0055] [PMID: 28719227]">Moazen‐Zadeh 2018</a>), were pregnant or breastfeeding (<a href="./references#CD011769-bbs2-0057" title="HollanderE , FerrettiCJ , TaylorBP , NooneRH , RacineE . P.7.d.006 Trichuris suis ova (TSO) as an immune-inflammatory treatment for repetitive behaviors in autism spectrum disorders (ASD). European Neuropsychopharmacology2014;24(2):S723. [DOI: 10.1016/S0924-977X(14)71165-4]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]HollanderE , FerrettiC , TaylorB , NooneR , KirschJ , RacineE . Trichuris suis ova (TSO) as an immune inflammatory treatment for repetitive behaviors in ASD. Neuropsychopharmacology2013;38:S391-2. [DOI: 10.1038/npp.2013.280]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]NCT01040221. Trichuris suis ova in autism spectrum disorders (TSO) [Trichuris suis ova in autism spectrum disorders ]. www.clinicaltrials.gov/ct2/show/NCT01040221 (first received November 2012). StarkFS , ChavanneC , Lennon-ChrimesS , DiackC , DerksM , SmithJ . Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431). European Neuropsychopharmacology2020;40:S82-S83. [DOI: 10.1016/j.euroneuro.2020.09.110]">Hollander 2020a</a>), currently using tobacco or nicotine products (<a href="./references#CD011769-bbs2-0070" title="LewisAS , Van SchalkwyGI , LopezMO , VolkmarFR , PicciottoMR , SukhodolskyDG . An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(8):2748-57. [DOI: 10.1007/s10803-018-3536-7] [PMCID: PMC6394231] [PMID: 29536216]NCT02552147. Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism [Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism]. clinicaltrials.gov/ct2/show/NCT02552147 (first received 16 September 2015). ">Lewis 2018</a>), or had an allergy or intolerance to the intervention (<a href="./references#CD011769-bbs2-0010" title="AyatollahiA , BagheriS , Ashraf-GanjoueiA , MoradiK , Mohammadi M-R, AkhondzadehS . Does pregnenolone adjunct to risperidone ameliorate irritable behavior in adolescents with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial?Clinical Neuropharmacology2020;43(5):139-45. [DOI: 10.1097/WNF.0000000000000405] [PMID: 32947424]IRCT20090117001556N112. Efficacy of pregnenolon in treatment of irritability in teenagers with autism [Efficacy of pregnenolon in treatment of irritability in teeanagers with autism; a double blind and placebo controlled triall]. www.irct.ir/trial/32775 (first received 25 July 2018). ">Ayatollahi 2020</a>; <a href="./references#CD011769-bbs2-0012" title="BehmaneshH , MoghaddamHS , Mohammadi M-R, AkhondzadehS . Risperidone combination therapy with propentofylline for treatment of irritability in autism spectrum disorders: a randomized, double-blind, placebo-controlled clinical trial. Clinical Neuropharmacology2019;42(6):189-96. [DOI: 10.1097/WNF.0000000000000368] [PMID: 31725473]IRCT20090117001556N113. Effect of propentofylline in children with autism [Effect of propentofylline add on therapy to risperidon in children with autism: a randomized double-blind placebo-controlled clinical trial]. www.irct.ir/trial/35171 (first received 15 November 2018). ">Behmanesh 2019</a>; <a href="./references#CD011769-bbs2-0100" title="IRCT201110281556N29. N-acetylcysteine in the treatment of autism [N-acetyl cysteine added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/879 (first received 29 October 2011). NikooM , RadniaH , FarokhniaM , Mohammadi M-R, AkhondzadehS . N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clinical Neuropharmacology2015;38(1):11-7. [DOI: 10.1097/WNF.0000000000000063] [PMID: 25580916]">Nikoo 2015</a>; <a href="./references#CD011769-bbs2-0124" title="NCT01288716. Study of arbaclofen for the treatment of social withdrawal in subjects with autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT01288716?term=NCT01288716&amp;draw=2&amp;rank=1 (first received February 2011). Veenstra-VanderWeeleJ , CookEH , KingBH , ZarevicsP , CherubiniM , Walton-BowenK , et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology2017;42(7):1390-8. [DOI: 10.1038/npp.2016.237] [PMCID: PMC5436109] [PMID: 27748740]">Veenstra‐VanderWeele 2017</a>). </p> </li> <li> <p>Concomitant medications: studies required participants to have been off medications for at least one month and six months prior to the study (<a href="./references#CD011769-bbs2-0098" title="NiederhoferH , StaffenW , MairA . Lofexidine In hyperactive and impulsive children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2002;41(12):1396-7. [DOI: 10.1097/00004583-200212000-00010] [PMID: 12447025]">Niederhofer 2002</a>; <a href="./references#CD011769-bbs2-0011" title="BatebiN , MoghaddamHS , HasanzadehA , FakourY , MohammadiMR , AkhondzadehS . Folinic acid as adjunctive therapy in treatment of inappropriate speech in children with autism: a double-blind and placebo-controlled randomized trial. Child Psychiatry &amp; Human Development2021;52(5):928-38. [DOI: 10.1007/s10578-020-01072-8] [PMID: 33029705]IRCT20090117001556N114. Folinic acid in the treatment of autism spectrum disorder [Folinic acid add on therapy to risperidone in symptoms of children with autism: a randomized double-blind placebo-controlled clinical trial]. www.irct.ir/trial/35172 (first received 15 November 2018). ">Batebi 2021</a>), remain on stable psychotropic medications for at least three months (<a href="./references#CD011769-bbs2-0008" title="ArnoldLE , AmanMG , HollwayJ , HurtE , BatesB , LiX , et al. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology2012;22(3):198-205. [DOI: 10.1089/cap.2011.0056] [PMCID: PMC3417385] [PMID: 22537359]NCT00773812. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders [Neuronal nicotinic receptor modulation in the treatment of autism: a pilot trial of mecamylamine]. clinicaltrials.gov/ct2/show/NCT00773812 (first received 16 October 2008). ">Arnold 2012a</a>; <a href="./references#CD011769-bbs2-0057" title="HollanderE , FerrettiCJ , TaylorBP , NooneRH , RacineE . P.7.d.006 Trichuris suis ova (TSO) as an immune-inflammatory treatment for repetitive behaviors in autism spectrum disorders (ASD). European Neuropsychopharmacology2014;24(2):S723. [DOI: 10.1016/S0924-977X(14)71165-4]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]HollanderE , FerrettiC , TaylorB , NooneR , KirschJ , RacineE . Trichuris suis ova (TSO) as an immune inflammatory treatment for repetitive behaviors in ASD. Neuropsychopharmacology2013;38:S391-2. [DOI: 10.1038/npp.2013.280]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]NCT01040221. Trichuris suis ova in autism spectrum disorders (TSO) [Trichuris suis ova in autism spectrum disorders ]. www.clinicaltrials.gov/ct2/show/NCT01040221 (first received November 2012). StarkFS , ChavanneC , Lennon-ChrimesS , DiackC , DerksM , SmithJ . Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431). European Neuropsychopharmacology2020;40:S82-S83. [DOI: 10.1016/j.euroneuro.2020.09.110]">Hollander 2020a</a>), and two weeks prior to randomisation respectively (<a href="./references#CD011769-bbs2-0016" title="CampbellM , AdamsP , SmallAM , CurrenEL , OverallJE , AndersonLT , et al. Efficacy and safety of fenfluramine in autistic children. Journal of the American Academy of Child &amp; Adolescent Psychiatry1988;27(4):434-9. [DOI: 10.1097/00004583-198807000-00010] [PMID: 3053609]">Campbell 1987</a>; <a href="./references#CD011769-bbs2-0046" title="HardanA . Psychopharmacological treatment of anxiety symptoms in autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):S325-6. [DOI: 10.1016/j.jaac.2016.07.369] [ABSTRACT NO: 42.4]HardanAY , FungLK , LiboveRA , ObukhanychTV , NairS , HerzenbergLA , et al. A randomised controlled pilot trial of N-acetylcysteine in children with autism. Biological Psychiatry2012;71(11):956-61. [DOI: 10.1016//j.biopsych.2012.01.014] [PMCID: PMC4914359] [PMID: 22342106]">Hardan 2012</a>; <a href="./references#CD011769-bbs2-0081" title="MinshawiNF , WinkLK , ShafferR , PlaweckiMH , PoseyDJ , LiuH , et al. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism2016;7(3):2. [DOI: 10.1186/s13229-015-0062-8] [PMCID: PMC4712595] [PMID: 26770664]NCT01086475. D-cycloserine and social skills training in autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT01086475?term=NCT01086475&amp;draw=1&amp;rank=1 (first received March 2010). WinkLK , MinshawiNF , ShafferRC , PlaweckiMH , PoseyDJ , HornPS , et al. D-cycloserine enhances durability of social skills training in autism spectrum disorder. Molecular Autism2017;8:2. [DOI: 10.1186/s13229-017-0116-1] [PMCID: PMC5264460] [PMID: 28138381]">Minshawi 2016</a>), or stable medication with no changes in the past 14 days (<a href="./references#CD011769-bbs2-0070" title="LewisAS , Van SchalkwyGI , LopezMO , VolkmarFR , PicciottoMR , SukhodolskyDG . An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(8):2748-57. [DOI: 10.1007/s10803-018-3536-7] [PMCID: PMC6394231] [PMID: 29536216]NCT02552147. Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism [Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism]. clinicaltrials.gov/ct2/show/NCT02552147 (first received 16 September 2015). ">Lewis 2018</a>). One study allowed the use of anticonvulsants, supplements, or sleep medications, however, any other psychotropic medications were not allowed (<a href="./references#CD011769-bbs2-0066" title="KlaimanC , HuffmanL , MasakiL , ElliottGR . Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology2013;13(5):320-8. [DOI: 10.1089/cap.2012.0127] [PMID: 23782126]NCT00850070. Sapropterin as a treatment for autistic disorder. https://clinicaltrials.gov/ct2/show/results/NCT00850070?term=NCT00850070&amp;draw=2&amp;rank=1 (first received February 2009). ">Klaiman 2013</a>). </p> </li> <li> <p>Participant cognitive status: most studies did not report the average IQ of participants apart from seven studies (<a href="./references#CD011769-bbs2-0008" title="ArnoldLE , AmanMG , HollwayJ , HurtE , BatesB , LiX , et al. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology2012;22(3):198-205. [DOI: 10.1089/cap.2011.0056] [PMCID: PMC3417385] [PMID: 22537359]NCT00773812. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders [Neuronal nicotinic receptor modulation in the treatment of autism: a pilot trial of mecamylamine]. clinicaltrials.gov/ct2/show/NCT00773812 (first received 16 October 2008). ">Arnold 2012a</a>; <a href="./references#CD011769-bbs2-0022" title="DanforsT , Von Knorring A-L, HartvigP , LangstromB , MoulderR , StrombergB , et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. Journal of Clinical Psychopharmacology2005;25(5):485-9. [DOI: 10.1097/01.jcp.0000177667.35016.e9] [PMID: 16160627]">Danfors 2005</a>; <a href="./references#CD011769-bbs2-0024" title="ACTRN12610000635066. Efficacy Of N-acetyl cysteine in autism: a double-blind, placebo-controlled randomised trial [Efficacy of n-acetyl cysteine on social skills, communication and behaviour in autistic children: a double-blind, placebo-controlled randomised trial]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=320918 (first received 3 August 2010). DeanOM , GrayK , DoddS , Villagonzalo K-A, BrownE , TongeB , et al. Does N-acetylcysteine improve behaviour in children with autism?: a mixed-methods analysis of the effects of N-acetylcysteine. Journal of Intellectual &amp; Developmental Disability2019;44(4):474-80. [DOI: 10.3109/13668250.2017.1413079]DeanOM , GrayKM , Villagonzalo K-A, DoddS , MohebbiM , VickT , et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian and New Zealand Journal of Psychiatry2017;51(3):241-9. [DOI: 10.1177/0004867416652735] [PMID: 27316706]">Dean 2019</a>; <a href="./references#CD011769-bbs2-0081" title="MinshawiNF , WinkLK , ShafferR , PlaweckiMH , PoseyDJ , LiuH , et al. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism2016;7(3):2. [DOI: 10.1186/s13229-015-0062-8] [PMCID: PMC4712595] [PMID: 26770664]NCT01086475. D-cycloserine and social skills training in autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT01086475?term=NCT01086475&amp;draw=1&amp;rank=1 (first received March 2010). WinkLK , MinshawiNF , ShafferRC , PlaweckiMH , PoseyDJ , HornPS , et al. D-cycloserine enhances durability of social skills training in autism spectrum disorder. Molecular Autism2017;8:2. [DOI: 10.1186/s13229-017-0116-1] [PMCID: PMC5264460] [PMID: 28138381]">Minshawi 2016</a>; <a href="./references#CD011769-bbs2-0098" title="NiederhoferH , StaffenW , MairA . Lofexidine In hyperactive and impulsive children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2002;41(12):1396-7. [DOI: 10.1097/00004583-200212000-00010] [PMID: 12447025]">Niederhofer 2002</a>; <a href="./references#CD011769-bbs2-0117" title="SprengersJ , Van AndelD , ZuithoffN , Keijzer-VeenM , ScheepersF , LilienM , et al. Bumetanide versus placebo for core symptoms of autism spectrum disorder at 91 days (BAMBI): a single-centre, double-blinded, patient-randomized, placebo-controlled, phase-2-trial. European Neuropsychopharmacology2020;40:S80-S81. [DOI: 10.1016/j.euroneuro.2020.09.108]SprengersJJ , Van AndelDM , ZuithoffNP , Keijzer-VeenMG , SchulpAJ , ScheepersFE , et al. Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial. Journal of the American Academy of Child and Adolescent Psychiatry2021;60(7):865-76. [DOI: 10.1016/j.jaac.2020.07.888] [PMID: 32730977]">Sprengers 2021</a>; <a href="./references#CD011769-bbs2-0128" title="NCT00453180. A study of oral N-acetylcysteine in children with autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT00453180?term=NCT00453180&amp;draw=2&amp;rank=1 (first received March 2007). WinkLK , AdamsR , WangZ , KlaunigJE , PlaweckiMH , PoseyDJ , et al. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Molecular Autism2016;7:26. [DOI: 10.1186/s13229-016-0088-6] [PMCID: PMC4839099] [PMID: 27103982]">Wink 2016</a>). IQ ranged from 53 to 100 across these studies. </p> </li> <li> <p>Length of follow‐up: study duration ranged from seven days (<a href="./references#CD011769-bbs2-0070" title="LewisAS , Van SchalkwyGI , LopezMO , VolkmarFR , PicciottoMR , SukhodolskyDG . An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(8):2748-57. [DOI: 10.1007/s10803-018-3536-7] [PMCID: PMC6394231] [PMID: 29536216]NCT02552147. Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism [Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism]. clinicaltrials.gov/ct2/show/NCT02552147 (first received 16 September 2015). ">Lewis 2018</a>), to six months (<a href="./references#CD011769-bbs2-0022" title="DanforsT , Von Knorring A-L, HartvigP , LangstromB , MoulderR , StrombergB , et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. Journal of Clinical Psychopharmacology2005;25(5):485-9. [DOI: 10.1097/01.jcp.0000177667.35016.e9] [PMID: 16160627]">Danfors 2005</a>). Mean duration was 9.6 weeks. </p> </li> </ul> </p> <section id="CD011769-sec-0109"> <h6 class="title">Primary outcomes</h6> <p> <ul id="CD011769-list-0057"> <li> <p>Irritability: 32 of the studies reported irritability and all used the ABC‐I subscale (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>), to measure irritability. Most studies required participants to have a minimum baseline ABC‐I of 12 or higher while some studies required a baseline ABC‐I of 15 or higher (<a href="./references#CD011769-bbs2-0010" title="AyatollahiA , BagheriS , Ashraf-GanjoueiA , MoradiK , Mohammadi M-R, AkhondzadehS . Does pregnenolone adjunct to risperidone ameliorate irritable behavior in adolescents with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial?Clinical Neuropharmacology2020;43(5):139-45. [DOI: 10.1097/WNF.0000000000000405] [PMID: 32947424]IRCT20090117001556N112. Efficacy of pregnenolon in treatment of irritability in teenagers with autism [Efficacy of pregnenolon in treatment of irritability in teeanagers with autism; a double blind and placebo controlled triall]. www.irct.ir/trial/32775 (first received 25 July 2018). ">Ayatollahi 2020</a>; <a href="./references#CD011769-bbs2-0070" title="LewisAS , Van SchalkwyGI , LopezMO , VolkmarFR , PicciottoMR , SukhodolskyDG . An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(8):2748-57. [DOI: 10.1007/s10803-018-3536-7] [PMCID: PMC6394231] [PMID: 29536216]NCT02552147. Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism [Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism]. clinicaltrials.gov/ct2/show/NCT02552147 (first received 16 September 2015). ">Lewis 2018</a>; <a href="./references#CD011769-bbs2-0074" title="IRCT201701131556N95. Baclofen in the treatment of autism [Baclofen as adjunctive treatment of autism: a double blind and placebo controlled trial]. www.irct.ir/trial/944 (first received 13 January 2017). Mahdavinasab S-M, SaghazadehA , Motamed-GorjiN , VaseghiS , Mohammadi M-R, AlichaniR , et al. Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. European Child &amp; Adolescent Psychiatry2019;28(12):1619-28. [DOI: 10.1007/s00787-019-01333-5] [PMID: 30980177]">Mahdavinasab 2019</a>; <a href="./references#CD011769-bbs2-0129" title="NCT02081027. Pilot study of riluzole for drug-refractory irritability in autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT02081027?term=NCT02081027&amp;draw=2&amp;rank=1 (first received March 2014). WinkLK , AdamsR , HornPS , TessierCR , BantelAP , HongM , et al. A randomized placebo-controlled cross-over pilot study of riluzole for drug-refractory irritability in autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(9):3051-60. [DOI: 10.1007/s10803-018-3562-5] [PMID: 29644582]">Wink 2018</a>). </p> </li> <li> <p>Self‐injury: five studies reported self‐injurious behaviour (<a href="./references#CD011769-bbs2-0021" title="DaiY , ZhangL , YuJ , ZhouX , HeH , JiY , et al. Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial. Science Bulletin2021;66(15):1591-8. [DOI: 10.1016/j.scib.2021.01.008]NCT03156153. A study of bumetanide for the treatment of autism spectrum disorders. (first received 15 May 2017). ">Dai 2021</a>; <a href="./references#CD011769-bbs2-0024" title="ACTRN12610000635066. Efficacy Of N-acetyl cysteine in autism: a double-blind, placebo-controlled randomised trial [Efficacy of n-acetyl cysteine on social skills, communication and behaviour in autistic children: a double-blind, placebo-controlled randomised trial]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=320918 (first received 3 August 2010). DeanOM , GrayK , DoddS , Villagonzalo K-A, BrownE , TongeB , et al. Does N-acetylcysteine improve behaviour in children with autism?: a mixed-methods analysis of the effects of N-acetylcysteine. Journal of Intellectual &amp; Developmental Disability2019;44(4):474-80. [DOI: 10.3109/13668250.2017.1413079]DeanOM , GrayKM , Villagonzalo K-A, DoddS , MohebbiM , VickT , et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian and New Zealand Journal of Psychiatry2017;51(3):241-9. [DOI: 10.1177/0004867416652735] [PMID: 27316706]">Dean 2019</a>; <a href="./references#CD011769-bbs2-0046" title="HardanA . Psychopharmacological treatment of anxiety symptoms in autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):S325-6. [DOI: 10.1016/j.jaac.2016.07.369] [ABSTRACT NO: 42.4]HardanAY , FungLK , LiboveRA , ObukhanychTV , NairS , HerzenbergLA , et al. A randomised controlled pilot trial of N-acetylcysteine in children with autism. Biological Psychiatry2012;71(11):956-61. [DOI: 10.1016//j.biopsych.2012.01.014] [PMCID: PMC4914359] [PMID: 22342106]">Hardan 2012</a>; <a href="./references#CD011769-bbs2-0057" title="HollanderE , FerrettiCJ , TaylorBP , NooneRH , RacineE . P.7.d.006 Trichuris suis ova (TSO) as an immune-inflammatory treatment for repetitive behaviors in autism spectrum disorders (ASD). European Neuropsychopharmacology2014;24(2):S723. [DOI: 10.1016/S0924-977X(14)71165-4]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]HollanderE , FerrettiC , TaylorB , NooneR , KirschJ , RacineE . Trichuris suis ova (TSO) as an immune inflammatory treatment for repetitive behaviors in ASD. Neuropsychopharmacology2013;38:S391-2. [DOI: 10.1038/npp.2013.280]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]NCT01040221. Trichuris suis ova in autism spectrum disorders (TSO) [Trichuris suis ova in autism spectrum disorders ]. www.clinicaltrials.gov/ct2/show/NCT01040221 (first received November 2012). StarkFS , ChavanneC , Lennon-ChrimesS , DiackC , DerksM , SmithJ . Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431). European Neuropsychopharmacology2020;40:S82-S83. [DOI: 10.1016/j.euroneuro.2020.09.110]">Hollander 2020a</a>; <a href="./references#CD011769-bbs2-0123" title="VanAndelD , SprengersJ , Keijzer-VeenM , SchulpA , LillienM , ScheepersF , et al. Bumetanide for irritability in children with sensory processing problems across neurodevelopmental disorders: a pilot randomized controlled trial. Frontiers in Psychiatry2022;13:780281. [DOI: 10.3389/fpsyt.2022.780281] [PMID: 35211042]">VanAndel 2022</a>). Each study used the Repetitive Behaviour Scale ‐ Revised (self‐injury subscale; <a href="./references#CD011769-bbs2-0281" title="BodfishJW , SymonsFS , ParkerDE , LewisMH . Varieties of repetitive behavior in autism: comparisons to mental retardation. Journal of Autism and Developmental Disorders2000;30(3):237-43. [DOI: 10.1023/A:1005596502855] [PMID: 11055459]">Bodfish 2000</a>) to measure self‐injurious behaviour. </p> </li> <li> <p>AEs: apart from five studies, all studies reported AEs (<a href="./references#CD011769-bbs2-0019" title="ChezM , KileS , LepageC , PariseC , BenabidesB , HankinsA . A randomized, placebo-controlled, blinded, crossover, pilot study of the effects of dextromethorphan/quinidine for the treatment of neurobehavioral symptoms in adults with autism. Journal of Autism and Developmental Disorders2020;50(5):1532-8. [DOI: 10.1007/s10803-018-3703-x] [PMID: 30109474]">Chez 2020</a>; <a href="./references#CD011769-bbs2-0070" title="LewisAS , Van SchalkwyGI , LopezMO , VolkmarFR , PicciottoMR , SukhodolskyDG . An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders2018;48(8):2748-57. [DOI: 10.1007/s10803-018-3536-7] [PMCID: PMC6394231] [PMID: 29536216]NCT02552147. Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism [Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism]. clinicaltrials.gov/ct2/show/NCT02552147 (first received 16 September 2015). ">Lewis 2018</a>; <a href="./references#CD011769-bbs2-0074" title="IRCT201701131556N95. Baclofen in the treatment of autism [Baclofen as adjunctive treatment of autism: a double blind and placebo controlled trial]. www.irct.ir/trial/944 (first received 13 January 2017). Mahdavinasab S-M, SaghazadehA , Motamed-GorjiN , VaseghiS , Mohammadi M-R, AlichaniR , et al. Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. European Child &amp; Adolescent Psychiatry2019;28(12):1619-28. [DOI: 10.1007/s00787-019-01333-5] [PMID: 30980177]">Mahdavinasab 2019</a>; <a href="./references#CD011769-bbs2-0075" title="IRCT20090117001556N102. Prednisolone in autism spectrum disorders [Prednisolone in regressive autism spectrum disorders: a randomized double-blind placebo-controlled clinical trial]. www.irct.ir/trial/28026 (first received 9 December 2017). MalekM , Ashraf-GanjoueiA , MoradiK , BagheriS , Mohammadi M-R, AkhonzadehS . Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial. Clinical Neuropharmacology2020;43(2):39-45. [DOI: 10.1097/WNF.0000000000000382] [PMID: 32168067]">Malek 2020</a>; <a href="./references#CD011769-bbs2-0127" title="Willemsen-SwinkelsSH , BuitelaarJK , Van EngelandH . The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biological Psychiatry1996;39(12):1023-31. [DOI: 10.1016/0006-3223(95)00297-9] [PMID: 8780837]">Willemsen‐Swinkels 1996</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0110"> <h6 class="title">Secondary outcomes</h6> <p> <ul id="CD011769-list-0058"> <li> <p>Tolerability and acceptability (loss to follow‐up): 230 participants (13%) withdrew and were not included in the relevant study analyses. Reasons included withdrawing consent (103); AEs (32), lost to follow‐up (23) ; poor/non‐compliance (20), protocol violations (10); lack of efficacy (9); due to an error (4); no longer met inclusion/exclusion criteria (4); clinical decision (2); participant moved (1); other (22). </p> </li> </ul> </p> </section> </section> </section> <section id="CD011769-sec-0111"> <h4 class="title">Excluded studies</h4> <p>The full‐text screening resulted in 88 references (as 81 studies) being excluded due to ineligible criteria. Full‐text copies of the studies listed in this section were reviewed as it was not clear whether they met the inclusion criteria for the review based on title and abstract. Further screening of the full‐text reports of these studies found that they did not meet our inclusion criteria. Reasons for exclusion included: did not focus on population of interest; did not have a focus on unwanted behaviours (irritability, aggression, self‐injury); ineligible study design (non‐RCT); non‐pharmacological intervention; irrelevant comparator; and terminated studies. </p> </section> </section> <section id="CD011769-sec-0112"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD011769-fig-0003">Figure 3</a> for a risk of bias summary, and <a href="#CD011769-fig-0004">Figure 4</a> for a risk of bias graph. </p> <div class="figure" id="CD011769-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias in included studies" data-id="CD011769-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias in included studies</p> </div> </div> </div> <div class="figure" id="CD011769-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Visual representation of risk of bias across all included studies" data-id="CD011769-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Visual representation of risk of bias across all included studies</p> </div> </div> </div> <p>See below for more detailed information on risk of bias.</p> <section id="CD011769-sec-0113"> <h4 class="title">Allocation</h4> <p> <ul id="CD011769-list-0059"> <li> <p><b>Atypical or typical antipsychotics versus placebo or other treatment:</b> we rated 16 studies as unclear risk of bias for randomisation and allocation concealment, mostly due to a lack of details regarding methods of randomisation and allocation concealment. We rated three studies (20%) as low because they conducted randomisation using a computer‐generated code, and one study as high due to a clear lack of randomisation and allocation concealment. </p> </li> <li> <p><b>Neurohormones versus placebo or other treatment:</b> we rated 12 studies as unclear and 12 studies as having a low risk of bias. Studies rated as unclear either did not provide details or provided very vague details regarding the randomisation and allocation of participants. We rated studies as low risk of bias because randomisation was conducted using a computer‐generated code. </p> </li> <li> <p><b>ADHD‐related medications versus placebo or other treatment:</b> we rated 10 studies as unclear risk of bias due to a lack of details regarding methods of randomisation and allocation concealment. We rated one study as low and two studies as high. The reason for the high ratings was because the investigators used 'sequential assignment'. The study rated as low randomised using a computer‐generated method. </p> </li> <li> <p><b>Antidepressants versus placebo or other treatment:</b> we rated eight studies as unclear due to a lack of details regarding methods of randomisation and allocation concealment. We rated the other two studies as low risk of bias as randomisation was conducted externally to the trial. </p> </li> <li> <p><b>Atypical antipsychotic versus another atypical antipsychotic:</b> we rated allocation concealment as unclear for both of the studies due to a lack of information. </p> </li> <li> <p><b>Atypical antipsychotic versus an anti‐dementia drug:</b> we rated allocation concealment as unclear for <a href="./references#CD011769-bbs2-0101" title="IRCT201204037202N5. Comparing efficacy and side effects of memantine and risperidone in treating autistic patients. www.irct.ir/trial/7627 (first received 20 June 2012). NikvarzN , Alaghband-RadJ , Tehrani-DoostM , AlimadadiA , GhaeliP . Comparing efficacy and side effects of memantine vs risperidone in the treatment of autistic disorder. Pharmacopsychiatry2017;50(1):19-25. [DOI: 10.1055/s-0042-108449] [PMID: 27299475]">Nikvarz 2017</a> because although referred to as "simple balanced blocked randomisation", the study authors did not provide information on how allocation was concealed. </p> </li> <li> <p><b>Atypical antipsychotic versus an antiparkinsonian drug (bromocriptine):</b> we rated allocation concealment as unclear for <a href="./references#CD011769-bbs2-0026" title="DollfusS , PetitM , MenardJF , LesieurP . Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. Journal of Autism and Developmental Disorders1992;22(1):47-60. [DOI: 10.1007/BF01046402] [PMID: 1350581]DollfusS , PetitP , MenardJF . Pharmacoclinical study of an agonist and an antagonist of dopamine in early infantile autism. Neuropsychiatrie de l'Enfance et de l'Adolescence1992;40(5-6):300-309. ">Dollfus 1992</a> due to a lack of information. </p> </li> <li> <p><b>Anticonvulsants versus placebo or other treatment:</b> we rated five studies as having an unclear risk of bias due to a lack of details and one study as low because it conducted randomisation using a computer‐generated code. </p> </li> <li> <p><b>Antidementia interventions versus placebo or other treatments:</b> we rated six studies as low risk of bias because they conducted randomisation using a computer‐generated code, and the other two studies as unclear due to a lack of detail regarding the allocation process. </p> </li> <li> <p><b>Antiparkinsonian interventions versus placebo or other treatments:</b> we rated one study as low because it conducted randomisation using a computer‐generated code and the other study as having an unclear risk of bias due to insufficient details regarding allocation concealment. </p> </li> <li> <p><b>Anxiolytic interventions versus placebo or other treatment:</b> we rated one study as unclear due to a lack of details and the other study as low risk of bias because it conducted randomisation using a computer‐generated code. </p> </li> <li> <p><b>Experimental interventions versus placebo or other treatment:</b> we rated 24 studies as low risk of bias because they conducted randomisation using a computer‐generated code. We rated the remaining 18 studies as unclear, mainly due to a lack of details regarding randomisation methods and allocation concealment. </p> </li> </ul> </p> </section> <section id="CD011769-sec-0114"> <h4 class="title">Blinding</h4> <p> <ul id="CD011769-list-0060"> <li> <p><b>Atypical or typical antipsychotics versus placebo or other treatment:</b> we rated 14 studies as unclear risk of bias due to a lack of details regarding blinding and who was blinded, and the remaining six studies as low risk of bias. </p> </li> <li> <p><b>Neurohormones versus placebo or other treatment:</b> we rated 13 studies as unclear and the remaining 11 studies as having low risk of bias. Studies with an unclear risk of bias usually did not provide further details apart from stating that they used double‐blinding. </p> </li> <li> <p><b>ADHD‐related medications versus placebo or other treatment:</b> we rated eight studies as unclear risk of bias, three as low risk of bias and the remaining two studies as high risk of bias. This was due to investigators being unblinded. </p> </li> <li> <p><b>Antidepressants versus placebo or other treatment:</b> we rated seven studies as unclear risk of bias, with the remaining three studies at low risk of bias. </p> </li> <li> <p><b>Atypical antipsychotic versus another atypical antipsychotic:</b> we rated one study as a low risk of bias and the other as high due to some participants being unblinded and an unblinded clinician. </p> </li> <li> <p><b>Atypical antipsychotic versus an anti‐dementia drug:</b> we rated this study as having a high risk of bias due to being an open‐label (randomised) study and therefore lacking blinding. </p> </li> <li> <p><b>Atypical antipsychotic versus an antiparkinsonian (bromocriptine):</b> we rated this study as having an unclear risk of bias because it did not provide details regarding blinding. </p> </li> <li> <p><b>Anticonvulsants versus placebo or other treatment:</b> we rated three studies as being of low risk of bias and three studies as unclear, mainly due to lack of details. </p> </li> <li> <p><b>Antidementia interventions versus placebo or other treatments:</b> we rated six studies as having low risk of bias because they clearly stated the blinding methods that they used, and the other two studies as unclear risk of bias due to lack of further details apart from stating the study was double‐blinded. </p> </li> <li> <p><b>Antiparkinsonian interventions versus placebo or other treatments:</b> we rated one study as low risk of bias because different people were involved in the allocation of participants and the measurement of outcomes. We rated the other study as unclear risk of bias due to insufficient details regarding blinding. </p> </li> <li> <p><b>Anxiolytic interventions versus placebo or other treatment:</b> we rated one study as low risk of bias because an external person, who was not involved in enrolment or allocation, monitored outcomes. We rated the other study as unclear risk of bias because although the study stated that they used double‐blinding, the person who allocated participants to groups was unblinded. </p> </li> <li> <p><b>Experimental interventions versus placebo or other treatment:</b> we rated 30 studies as low risk of bias, 11 as unclear, and one as high risk of bias due to the use of single‐blinding only. The studies rated as unclear were due to a lack of details regarding blinding and who was blinded, and the high risk of bias was because the assessors were unblinded. </p> </li> </ul> </p> </section> <section id="CD011769-sec-0115"> <h4 class="title">Incomplete outcome data</h4> <p> <ul id="CD011769-list-0061"> <li> <p><b>Atypical or typical antipsychotics versus placebo or other treatment:</b> we rated 12 studies at low risk of bias, with a further four studies being rated as unclear and four studies as high risk of bias due to high rates of attrition, not including some participants in the analysis due to lack of efficacy, or lack of details regarding participants lost to follow‐up. We rated studies as unclear due to vague details regarding imputation of missing data, or an intention‐to‐treat analysis that did not include all participants. </p> </li> <li> <p><b>Neurohormones versus placebo or other treatment:</b> we rated 13 studies as low, six studies as unclear and five as high risk of bias. Studies rated as high had up to 50% missing data or did not provide reasons for loss to follow‐up. Studies rated as unclear did not provide reasons for participants lost to follow‐up, or some participants were not accounted for in analysis or numbers of participants lost to follow‐up. Studies rated as low had included all participants in the analysis and used an intention‐to‐treat analysis for any participants who did not complete the trial. </p> </li> <li> <p><b>ADHD‐related medications versus placebo or other treatment:</b> we rated five studies as unclear, two as low and six as high. We judged studies as high risk due to unexplained loss to follow‐up, incomplete data or lack of post‐baseline ratings. Ratings of unclear were because the study authors did not clearly report numbers of participants who completed the study and any who were lost to follow‐up throughout the study. Studies with ratings of low had included all participants in the final analysis or used an intention‐to‐treat analysis, or both. </p> </li> <li> <p><b>Antidepressants versus placebo or other treatment:</b> we rated four studies as having an unclear risk of bias, three studies as high and three studies as low risk of bias. 'Unclear' ratings were because it was not clear how many participants were included in the analysis, or loss to follow‐up was not reported by group. Reasons for a judgement of high risk of bias included high attrition of 20% to 25%, and not providing reasons for participant loss to follow‐up. The studies rated as low risk of bias used an intention‐to‐treat analysis and included all participants in the final analysis. </p> </li> <li> <p><b>Atypical antipsychotic versus another atypical antipsychotic:</b> we rated both studies as having a low risk of bias as all participants were included in the analysis. </p> </li> <li> <p><b>Atypical antipsychotic versus an anti‐dementia drug:</b> we rated the study as high risk of bias because data were not imputed for participants who discontinued. </p> </li> <li> <p><b>Atypical antipsychotic versus an antiparkinsonian (bromocriptine):</b> we rated the study as having a low risk of bias because only one participant did not complete the study, and it used a last observation carried forward. </p> </li> <li> <p><b>Anticonvulsants versus placebo or other treatment:</b> we rated three studies as unclear risk of bias and three studies as high risk of bias. The ratings of unclear were mainly due to unaccounted for participants, not imputing data where participants were lost to follow‐up, or lack of clarity regarding the number included in the analysis. The studies rated as high risk of bias were because of incomplete data. </p> </li> <li> <p><b>Anti‐dementia interventions versus placebo or other treatments:</b> we rated six studies as having low risk of bias, one study as high and one study as unclear risk of bias. The study with a high risk of bias had almost 50% attrition and the study rated as unclear provided vague details regarding loss to follow‐up and number analysed. Studies rated as low risk of bias included all participants in the analysis and used an intention‐to‐treat analysis for any participants who did not complete the trial. </p> </li> <li> <p><b>Antiparkinsonian interventions versus placebo or other treatments:</b> we rated one study as low risk of bias because all participants were included in the analysis, while we rated the other study as unclear due to imputation using last observation carried forward for all participants with at least one measurement post‐baseline. </p> </li> <li> <p><b>Anxiolytic interventions versus placebo or other treatment:</b> we rated one study as unclear and the other study as high risk of bias. The high risk of bias was due to not reporting outcome data at one of the prespecified time points and the study rated as unclear was due to "unavailable data" for almost half of the discontinued participants. </p> </li> <li> <p><b>Experimental interventions versus placebo or other treatment:</b> we rated 17 studies as low risk of bias, 14 as unclear and 11 studies as high risk of bias. The studies rated at high risk of bias were mainly due to significant attrition or not reporting reasons for loss to follow‐up. The ratings of unclear were because it was unclear how many were included in the analysis, or no further statistical measures such as intention‐to‐treat were used for those lost to follow‐up. </p> </li> </ul> </p> </section> <section id="CD011769-sec-0116"> <h4 class="title">Selective reporting</h4> <p> <ul id="CD011769-list-0062"> <li> <p><b>Atypical or typical antipsychotics versus placebo or other treatment:</b> we rated nine studies as high risk of bias, seven studies as low and four studies as unclear risk of bias. We rated the nine studies as high because of incomplete or absent reporting of outcomes, and not reporting AEs when it is highly likely they would have occurred. The studies rated as low were because all outcomes listed in the protocol or on the trial registry were reported in the published paper. The unclear ratings were due to lack of a protocol. </p> </li> <li> <p><b>Neurohormones versus placebo or other treatment:</b> we rated 11 studies as low risk of bias because outcomes reported matched those listed in the protocol, seven studies as unclear due to an absence of a published protocol or trial registration, and six as high risk of bias. Studies rated as high risk of bias did not report outcomes that were mentioned or listed on the clinical trials registry. </p> </li> <li> <p><b>ADHD‐related medications versus placebo or other treatment:</b> we rated seven studies as high risk of bias, three studies as low and two were unclear. The reasons for the high ratings were either incomplete or absent outcome data. The ratings of unclear were because of the absence of a published paper and details only provided on the trial registry. The ratings of low were because all outcomes listed in the protocol or on the trial registry were reported in the published paper. </p> </li> <li> <p><b>Antidepressants versus placebo or other treatment:</b> we rated four studies as low risk of bias, four studies as unclear and two studies as high risk of bias. Reasons for a rating of high were incomplete or absent outcome data. We rated studies as low because all outcomes listed in the protocol or on the trials registry were reported in the published paper. The unclear ratings were because of an absence of a published paper and details only provided on the trial registry. </p> </li> <li> <p><b>Atypical antipsychotic versus another atypical antipsychotic:</b> we rated one study as having a high risk of bias, due to conflicting statements that disagree with the statistics that they provided, and the other study as low risk of bias. </p> </li> <li> <p><b>Atypical antipsychotic versus an antidementia drug:</b> we rated this study as having an unclear risk of bias due to lack of a protocol. </p> </li> <li> <p><b>Atypical antipsychotic versus an antiparkinsonian (bromocriptine):</b> we rated this study as having an unclear risk of bias due to lack of a protocol. </p> </li> <li> <p><b>Anticonvulsants versus placebo or other treatment:</b> we rated five studies as high risk of bias and one as low risk. The ratings of high risk of bias were due to lack of outcome data, the use of P values or t‐values to report data, or differences between information in published papers and the clinical trials registry. The rating of low was because outcomes reported matched those listed in the protocol or on the trials registry. </p> </li> <li> <p><b>Antidementia interventions versus placebo or other treatments:</b> we rated three studies as having a high risk of bias, four studies as low and one study as having an unclear risk of bias. The unclear rating was because of an absence of a published protocol, and the low ratings were because all outcomes listed in a protocol or trial registry were reported by the study authors in the published paper. The ratings of high were because outcome data were not reported. </p> </li> <li> <p><b>Antiparkinsonian interventions versus placebo or other treatments:</b> we rated one study as low risk of bias and the other as unclear because it used last observation carried forward for any participant with at least one post‐baseline measure. </p> </li> <li> <p><b>Anxiolytic interventions versus placebo or other treatment:</b> we rated one study as low risk of bias because all outcomes listed in a protocol or trial registry were reported by the study authors in the published paper, and the study rated as high risk of bias was due to outcome measures not reported at the time points mentioned. </p> </li> <li> <p><b>Experimental interventions versus placebo or other treatment:</b> we rated 21 studies as low risk of bias because outcomes reported matched those listed in the protocol, 12 as unclear due to an absence of a published protocol or trial registry, and nine studies as high. The reasons for high risk of bias were failure to report outcomes mentioned in protocols or on trial registries, or reporting data at different time points to that mentioned in the protocol or trial registry. </p> </li> </ul> </p> </section> <section id="CD011769-sec-0117"> <h4 class="title">Other potential sources of bias</h4> <p> <ul id="CD011769-list-0063"> <li> <p><b>Atypical or typical antipsychotics versus placebo or other treatment:</b> we rated six studies as low risk of bias, eight as high risk of bias, and six as unclear. Most of the studies rated as high risk of bias were because of funding or other support by pharmaceutical companies, agreements between study authors and sponsors regarding the publishing of results, a small proportion of the sample with a diagnosis of autism despite the title mentioning autism spectrum disorder, or study authors' direct involvement in the ethics committee or funding process. The studies rated as unclear were because of some financial or other support from pharmaceutical companies. The six studies rated as low were because we identified no other sources of bias. </p> </li> <li> <p><b>Neurohormones versus placebo or other treatment:</b> we rated nine studies as high risk of bias, 10 as low and five studies as unclear risk of bias. All studies rated as high risk of bias were either funded by pharmaceutical companies, the pharmaceutical companies were involved in the analysis, or participants were responders to the intervention in a previous trial. Studies rated as low were because we did not identify any other sources of bias, and the studies rated as unclear were due to some involvement by pharmaceutical companies in the study. </p> </li> <li> <p><b>ADHD‐related medications versus placebo or other treatment:</b> we rated five studies as high risk of bias due to a lack of standardised measures, having received funding by pharmaceutical companies, or study authors' direct involvement in the ethics committee or funding process. We rated five studies as unclear due to highly divergent samples in addition to small sample sizes or lack of details regarding sponsorship or funding, and three studies as low because we did not identify any other sources of bias. </p> </li> <li> <p><b>Antidepressants versus placebo or other treatment:</b> we rated five studies as unclear risk of bias because of lack of details regarding funding, a published paper not being available, or a lack of baseline comparisons reported by group. We rated one study as low and four as high risk of bias. We rated studies as high risk of bias due to involvement or employment of study authors by pharmaceutical companies, study authors' direct involvement in the ethics committee or funding process, or an imbalance in baseline characteristics between the two groups. The one study rated as low was because we did not identify any other sources of bias. </p> </li> <li> <p><b>Atypical antipsychotic versus another atypical antipsychotic:</b> we rated both studies as having a low risk of bias because we did not identify any other sources of bias. </p> </li> <li> <p><b>Atypical antipsychotic versus an antidementia drug:</b> we rated this study as having a low risk of bias because we did not identify any other sources of bias. </p> </li> <li> <p><b>Atypical antipsychotic versus an antiparkinsonian (bromocriptine):</b> we rated this study as having an unclear risk of bias because we did not identify any other sources of bias. However, without a protocol or trial registry entry, it is difficult to know. </p> </li> <li> <p><b>Anticonvulsants versus placebo or other treatment:</b> we rated three studies as unclear risk of bias, two as high and one as low risk of bias. The studies rated as unclear were due to funding or other support from pharmaceutical companies, and the studies rated as high were due to a change in study duration without explanation or study authors' direct involvement in the ethics committee or funding process. The study rated as low was because we did not identify any other sources of bias. </p> </li> <li> <p><b>Antidementia interventions versus placebo or other treatments:</b> we rated one study as a low risk of bias because we did not identify any other sources of bias. We rated seven studies as high risk of bias due to funding and other involvement by pharmaceutical companies or study authors' direct involvement in the ethics committee or funding process. </p> </li> <li> <p><b>Antiparkinsonian interventions versus placebo or other treatments:</b> we rated one study as unclear risk of bias due to pharmaceutical companies providing funding and the unknown role they may have had in the study. We rated the other study as high risk of bias due to study authors' direct involvement in the ethics committee or funding process. </p> </li> <li> <p><b>Anxiolytic interventions versus placebo or other treatment:</b> we rated one study as unclear and the other as a high risk of bias because the study was retrospectively registered on the clinical trials website. </p> </li> <li> <p><b>Experimental interventions versus placebo or other treatment:</b> we rated six studies as low risk of bias because we did not identify any other sources of bias, six studies as unclear and 30 studies as high risk of bias. The reasons for high risk of bias were funding or other involvement by pharmaceutical companies in the studies, study authors being employed by the pharmaceutical companies funding the study, or study authors' direct involvement in the ethics committee or funding process. The reasons for an unclear rating were because of some involvement of pharmaceutical companies, or study authors did not provide baseline details regarding group differences. </p> </li> </ul> </p> </section> </section> <section id="CD011769-sec-0118"> <h3 class="title" id="CD011769-sec-0118">Effects of interventions</h3> <p>See: <a href="./full#CD011769-tbl-0001"><b>Summary of findings 1</b> Atypical antipsychotics compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</a>; <a href="./full#CD011769-tbl-0002"><b>Summary of findings 2</b> Neurohormones compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</a>; <a href="./full#CD011769-tbl-0003"><b>Summary of findings 3</b> Attention deficit hyperactivity disorder (ADHD)‐related drugs compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</a>; <a href="./full#CD011769-tbl-0004"><b>Summary of findings 4</b> Antidepressants compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</a> </p> <section id="CD011769-sec-0119"> <h4 class="title">Atypical antipsychotics versus placebo</h4> <section id="CD011769-sec-0120"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0121"> <h6 class="title">Behaviours of concern</h6> <section id="CD011769-sec-0122"> <p><b>Irritability</b></p> <p>Atypical antipsychotics probably reduce irritability in the short term when compared to participants taking placebo (SMD −0.90, 95% CI −1.25 to −0.55; I<sup>2</sup> = 83%; 12 studies, 973 participants; moderate‐certainty evidence; <a href="./references#CD011769-fig-0011" title="">Analysis 1.1</a>). The high level of heterogeneity across these 12 studies was reduced to 42% when we removed <a href="./references#CD011769-bbs2-0059" title="IchikawaH , MikamiK , OkadaT , YamashitaY , IshizakiY , TomodaA , et al. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study. Child Psychiatry &amp; Human Development2017;48(5):796-806. [DOI: 10.1007/s10578-016-0704-x] [PMCID: PMC5617873] [PMID: 28004215]NCT01617447. A short treatment study of aripiprazole in pediatric patients with autistic disorder [A short-term administration study of aripiprazole in children and adolescents (age: 6 to 17 years) with autistic disorder]. clinicaltrials.gov/ct2/show/NCT01617447 (first received 12 June 2012). ">Ichikawa 2017</a> and <a href="./references#CD011769-bbs2-0120" title="MaloneRP . Discontinuing risperidone results in relapse in children with autism spectrum disorders. Evidence-Based Mental Health2006;9(2):56. [DOI: 10.1136/ebmh.9.2.56] [PMID: 16638905]TroostPW , AlthausM , LahuisBE , BuitelaarJK , MinderaaRB , HoekstraPJ . Neuropsychological effect of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. Journal of Child and Adolescent Psychopharmacology2006;16(5):561-73. [DOI: 10.1089/cap.2006.16.561] [PMID: 17069545]TroostPW , LahuisBE , Steenhuis M-P, KetelaarsCE , BuitelaarJK , Van EngelandH , et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(11):1137-44. [DOI: 10.1097/01.chi.0000177055.11229.76] [PMID: 16239862]">Troost 2005</a> from the analysis (SMD −0.67, 95% CI −0.87 to −0.48; I<sup>2</sup> = 42%; 10 studies; 857 participants). Please refer to <a href="./full#CD011769-tbl-0001">summary of findings Table 1</a> for more information. </p> <p>There were differences between types of atypical antipsychotics (P = 0.0005), however, there were no clear differences between atypical antipsychotics (P = 0.76) when we removed <a href="./references#CD011769-bbs2-0071" title="LoebelA , BramsM , GoldmanRS , SilvaR , HernandezD , DengL , et al. Lurasidone for the treatment of irritability associated with autistic disorder. Journal of Autism and Developmental Disorders2016;46(4):1153-63. [DOI: 10.1007/s10803-015-2628-x] [PMCID: PMC4786592] [PMID: 26659550]NCT01911442. Lurasidone pediatric autism study. https://clinicaltrials.gov/ct2/show/results/NCT01911442?term=NCT01911442&amp;draw=2&amp;rank=1 (first received July 2013). ">Loebel 2016</a> (lurasidone) from the analysis. </p> <p>There were no clear differences between groups when we compared children only, and adults only (P = 0.87). There was insufficient information to conduct a subgroup analysis of irritability by cognitive or communication ability. </p> <p>We were unable to include irritability data from one study in the meta‐analyses because the data were skewed (<a href="./references#CD011769-bbs2-0029" title="FindlingRL , MankoskiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22-30. [DOI: 10.4088/JCP.13m08500] [PMID: 24502859]NCT01227668. Phase IV long-term maintenance study of aripiprazole in the treatment of irritability associated with autistic disorder. https://clinicaltrials.gov/ct2/show/NCT01227668?term=NCT01227668&amp;draw=2&amp;rank=1 (first received October 2010). ">Findling 2014</a>). Details can be found in <a href="#CD011769-tbl-0008">Table 4</a>. </p> <div class="table" id="CD011769-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Atypical antipsychotics versus placebo: irritability results that could not be used in meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0029" title="FindlingRL , MankoskiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22-30. [DOI: 10.4088/JCP.13m08500] [PMID: 24502859]NCT01227668. Phase IV long-term maintenance study of aripiprazole in the treatment of irritability associated with autistic disorder. https://clinicaltrials.gov/ct2/show/NCT01227668?term=NCT01227668&amp;draw=2&amp;rank=1 (first received October 2010). ">Findling 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole (max 15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 (10.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6 (10.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> </tbody> </table> </div> <p>As there were more than 10 studies in this analysis, we created a funnel plot for this outcome but found no evidence of asymmetry (<a href="#CD011769-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD011769-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="SE: standard error; SMD: standardised mean differenceAtypical antipsychotics versus placebo (12 studies, 973 participants; Analysis 1.1)" data-id="CD011769-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>SE:</b> standard error; <b>SMD:</b> standardised mean difference </p> <p>Atypical antipsychotics versus placebo (12 studies, 973 participants; <a href="./references#CD011769-fig-0011" title="">Analysis 1.1</a>) </p> </div> </div> </div> </section> <section id="CD011769-sec-0123"> <p><b>Improvement</b></p> <p>Participants were twice as likely to improve, defined as a minimum 25% decrease in the ABC‐I scores (RR 2.08, 95% CI 1.39 to 3.12; I<sup>2</sup> = 53%; 4 studies, 470 participants; <a href="./references#CD011769-fig-0013" title="">Analysis 1.3</a>). There were no clear differences between groups when risperidone and aripiprazole were compared (P = 0.17). </p> </section> <section id="CD011769-sec-0124"> <p><b>Relapse</b></p> <p>Participants were less likely to relapse, defined as a minimum 25% increase in ABC‐I scores, if they received risperidone compared to the placebo group (RR 0.30, 95% CI 0.13 to 0.68; I<sup>2</sup> = 0%; 2 studies, 56 participants; <a href="./references#CD011769-fig-0012" title="">Analysis 1.2</a>). </p> <p>Because both studies involved children, we could not conduct a subgroup analysis. There was insufficient information to conduct a subgroup analysis by communication or cognitive ability. </p> </section> <section id="CD011769-sec-0125"> <p><b>Aggression</b></p> <p>There was no clear evidence of an effect of atypical antipsychotics (risperidone) on aggression in the short term (SMD −0.44; 95% CI −0.89 to 0.01; I<sup>2</sup> = not applicable (NA); 1 study, 77 participants; very low‐certainty evidence; <a href="./references#CD011769-fig-0014" title="">Analysis 1.4</a>). Please refer to <a href="./full#CD011769-tbl-0001">summary of findings Table 1</a> for more information. </p> <p>Only one study provided data for this outcome, so we were unable to conduct subgroup analyses. </p> <p>We could not include data from one study in the meta‐analyses because the paper did not report endpoint data (<a href="./references#CD011769-bbs2-0054" title="HollanderE , WassermanS , SwansonEN , ChaplinW , SchapiroML , ZagurskyK , et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology2006;16(5):541-8. [DOI: 10.1089/cap.2006.16.541] [PMID: 17069543]">Hollander 2006b</a>). Details can be found in <a href="#CD011769-tbl-0009">Table 5</a>. </p> <div class="table" id="CD011769-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Atypical antipsychotic versus placebo: aggression results that could not be used in meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/ long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0053" title="HollanderE , SooryaL , WassermanS , EspositoK , ChaplinW , AnagnostouE . Divalproex sodium vs placebo in the treatment of repetitive behaviours in autism spectrum disorder. International Journal of Neuropsychopharmacology2006;9(2):209-13. [DOI: 10.1017/S1461145705005791] [PMID: 16316486]NCT00211757. Divalproex sodium versus placebo in childhood/adolescent autism. https://clinicaltrials.gov/ct2/show/results/NCT00211757?term=NCT00211757&amp;draw=2&amp;rank=1 (first received September 2005). ">Hollander 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine max 20 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"we did not find any evidence for significant change on the CY‐BOCS, the OAS‐M irritability measure, or the OAS‐M aggression measure" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CY‐BOCS:</b> Children's Yale Bown Obsessive compulsive Scale; <b>OAS‐M:</b> Overt Aggression Scale ‐ Modified </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011769-sec-0126"> <p><b>Self‐injury</b></p> <p>The evidence is very uncertain about the effect of atypical antipsychotics compared with placebo on self‐injurious behaviour in the short term (SMD −1.43 95% CI −2.24 to −0.61; P &lt; 0.0001; I<sup>2</sup> = NA; 1 study, 30 participants; very low‐certainty evidence; <a href="./references#CD011769-fig-0015" title="">Analysis 1.5</a>). Please refer to <a href="./full#CD011769-tbl-0001">summary of findings Table 1</a> for more information. </p> <p>We could not include data from one study in the meta‐analyses because the data were skewed. Please refer to <a href="#CD011769-tbl-0010">Table 6</a> for more information. </p> <div class="table" id="CD011769-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Atypical antipsychotic versus placebo: self‐injurious behaviour results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0113" title="LightM , DunbarE , SheaS . P2.104 Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. European Neuropsychopharmacology2004;14(Suppl 3):S278. [DOI: 10.1016/S0924-977X(04)80324-9]LightM , DunbarF , SheaM . Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. International Journal of Neuropsychopharmacology2004;7:S275. [DOI: 10.1016/S0924-977X(04)80324-9]PandinaGJ , BossieCA , YoussefE , ZhuY , DunbarF . Risperidone improves behavioural symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders2007;37(2):367-73. [DOI: 10.1007/s10803-006-0234-7] [PMID: 17019624]SheaS , TurgayA , CarrollA , SchulzM , OrlikH , SmithI , et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics2004;114(5):e634-41. [DOI: 10.1542/peds.2003-0264-F] [PMID: 15492353]">Shea 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone maximum 0.02 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−2.6 (3.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.3 (2.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> </tbody> </table> </div> <p>Only one study provided data for this outcome, so we could not conduct subgroup analyses.</p> </section> </section> <section id="CD011769-sec-0127"> <h6 class="title">Adverse effects</h6> <section id="CD011769-sec-0128"> <p><b>Cardiovascular</b></p> <p>Participants were more likely to have tachycardia than those receiving placebo (RR 7.53, 95% CI 1.40 to 40.52; I<sup>2</sup> = 0%; 2 studies, 179 participants; <a href="./references#CD011769-fig-0016" title="">Analysis 1.6</a>). </p> </section> <section id="CD011769-sec-0129"> <p><b>Gastrointestinal</b></p> <p>There was no clear evidence of a difference between participants receiving atypical antipsychotics and those receiving placebo (<a href="./references#CD011769-fig-0017" title="">Analysis 1.7</a>), in the reported rates of: </p> <p> <ul id="CD011769-list-0064"> <li> <p>diarrhoea (RR 0.93, 95% CI 0.46 to 1.88; I<sup>2</sup> = 0%; 5 studies, 318 participants; low‐certainty evidence); </p> </li> <li> <p>dry mouth (RR 1.97, 95% CI 0.75 to 5.20; I<sup>2</sup> = 0%; 2 studies, 131 participants; low‐certainty evidence); </p> </li> <li> <p>dyspepsia (RR 3.19, 95% CI 0.14 to 72.69; I<sup>2</sup> = NA; 1 study, 31 participants; low‐certainty evidence); </p> </li> <li> <p>nausea (RR 1.47, 95% CI 0.61 to 3.56; I<sup>2</sup> = 0%; 4 studies, 531 participants; low‐certainty evidence); or </p> </li> <li> <p>stomach ache (RR 0.50, 95% CI 0.19 to 1.32; I<sup>2</sup> = 0%; 2 studies, 166 participants; low‐certainty evidence) </p> </li> </ul> </p> <p>However, participants receiving atypical antipsychotics were more likely to report:</p> <p> <ul id="CD011769-list-0065"> <li> <p>abdominal pain (RR 2.70, 95% CI 1.04 to 7.07; I<sup>2</sup> = 0%; 4 studies, 400 participants; low‐certainty evidence); </p> </li> <li> <p>constipation (RR 2.36, 95% CI 1.28 to 4.34; 7 studies, 596 participants; I<sup>2</sup> = 0%, low‐certainty evidence); </p> </li> <li> <p>drooling (RR 9.64, 95% CI 1.29 to 72.10; 2 studies, 313 participants; I<sup>2</sup> = 0%, low‐certainty evidence); </p> </li> <li> <p>hypersalivation (RR 4.15, 95% CI 1.77 to 9.71; 5 studies, 449 participants; I<sup>2</sup> = 0%, low‐certainty evidence); and </p> </li> <li> <p>vomiting/nausea (RR 1.79, 95% CI 1.16 to 2.74; 9 studies, 920 participants; I<sup>2</sup> = 0%, low‐certainty evidence). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0130"> <p><b>Immune system</b></p> <p>There was no clear evidence of a difference between atypical antipsychotics and placebo groups (<a href="./references#CD011769-fig-0018" title="">Analysis 1.8</a>), in: </p> <p> <ul id="CD011769-list-0066"> <li> <p>pyrexia (RR 1.81, 95% CI 0.85 to 3.86; I<sup>2</sup> = 0%; 5 studies, 540 participants); </p> </li> <li> <p>cough (RR 1.50, 95% CI 0.67 to 3.34; I<sup>2</sup> = 0%; 3 studies, 444 participants); </p> </li> <li> <p>flu‐like symptoms (RR 1.95, 95% CI 0.38 to 10.04; I<sup>2</sup> = NA; 1 study, 79 participants); </p> </li> <li> <p>sore throat (RR 5.20, 95% CI 0.63 to 42.96; I<sup>2</sup> = NA; 1 study, 100 participants); and </p> </li> <li> <p>earache (RR 0.52, 95% CI 0.10 to 2.71; I<sup>2</sup> = NA; 1 study, 100 participants) </p> </li> </ul> </p> </section> <section id="CD011769-sec-0131"> <p><b>Metabolic</b></p> <p>The antipsychotic group may be more likely to have an increase in appetite than the placebo group (RR 2.38, 95% CI 1.69 to 3.34; I<sup>2</sup> = 0%; 8 studies, 702 participants; low‐certainty evidence; <a href="./references#CD011769-fig-0019" title="">Analysis 1.9</a>). </p> <p>There was no difference between groups in:</p> <p> <ul id="CD011769-list-0067"> <li> <p>decreased appetite (RR 2.12, 95% CI 0.84 to 5.33; I<sup>2</sup> = 0%; 4 studies, 426 participants; moderate‐certainty evidence; <a href="./references#CD011769-fig-0019" title="">Analysis 1.9</a>); </p> </li> <li> <p>thirst (RR 1.51, 95% CI 0.59 to 3.87; I<sup>2</sup> = 0%; 3 studies, 382 participants; <a href="./references#CD011769-fig-0019" title="">Analysis 1.9</a>); </p> </li> <li> <p>weight gain (RR 2.30, 95% CI 0.84 to 6.30; I<sup>2</sup> = 0%; 4 studies, 470 participants; <a href="./references#CD011769-fig-0019" title="">Analysis 1.9</a>); or </p> </li> <li> <p>weight gain in kilograms (MD 2.35, 95% CI 0.73 to 3.97; I<sup>2</sup> = NA; 1 study, 23 participants; <a href="./references#CD011769-fig-0020" title="">Analysis 1.10</a>). </p> </li> </ul> </p> <p>We could not include data from one study in the analysis because it did not report data for both groups, and described weight gain by change in BMI (<a href="./references#CD011769-bbs2-0227" title="MaloneR , WestS , GhaffariM , DelaneyM , HardisonH . Metabolic effects of olanzapine in children with autistic disorder. Journal of Child and Adolescent Psychopharmacology2010;20(6):531-2. [DOI: 10.1089/cap.2010.2064]NCT00057408. A controlled sudy of olanzapine in children with autism. clinicaltrials.gov/ct2/show/NCT00057408 (first received 2 April 2003). ">Malone 2010</a>). In addition, we could not include data from <a href="./references#CD011769-bbs2-0102" title="EUCTR2016-005111-40. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A multicenter, double-blind, randomized, placebo-controlled, flexible-dosed parallel-group study of aripiprazole flexibly dosed in thetreatment of children and adolescents with autistic disorder]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-005111-40/results (first received 7 April 2017). LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of flexibly-dosed aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110-1. [DOI: 10.1002/ana.21853]LewisD , OwenR , CouchD . Efficacy and safety of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years): results from two 8-week randomized, double-blind, placebo-controlled trials. Neurology2009;72(11 (Supp 3)):A428. [ABSTRACT NO: S50.005]MankoskiR , StocktonG , ManosG , MarlorS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]NCT00365859. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A 52-week, open-label, multicenter study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder]. clinicaltrials.gov/ct2/show/NCT00365859 (first received 18 August 2006). OwenR , SikichL , MarcusRN , Corey-LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescent with autistic disorder. Pediatrics2009;124(6):1533-40. [DOI: 10.1542/peds.2008-3782] [PMID: 19948625]RobbAS , AnderssonC , BellocchioEE , ManosG , Rojas-FernandezC , MathewS , et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): results from a pooled analysis of 2 studies. Primary Care Companion for CNS Disorders2011;13(1):PCC.10m01008. [DOI: 10.4088/PCC.10m01008gry] [PMCID: PMC3121213] [PMID: 21731831]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. The effect of aripiprazole 2 to 15mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Owen 2009</a> and the three datasets from <a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a> because the data were skewed. Further details can be found in <a href="#CD011769-tbl-0011">Table 7</a>. </p> <div class="table" id="CD011769-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Atypical antipsychotics versus placebo: adverse effects data that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0076" title="MaloneRP , CaterJ , SheikhRM , ChoudhuryMS , DelaneyMA . Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(8):887-94. [DOI: 10.1097/00004583-200108000-00009] [PMID: 11501687]">Malone 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine 2.5‐2 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described. 33 in total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described. 33 in total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not outlined for each group. Weight gain was described as change in BMI category from baseline to endpoint and summarised as a group BMI change. </p> <p>AEs were measured at baseline and after week 12 (not after blinded phase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not outlined for each group. See Group 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At baseline, 70.3% of children were at a healthy weight, 21.6% were overweight, 2.7% were obese, and 5.4% were underweight. By week 12, 42.4% were healthy weight, 21.2% were overweight, and 36.4% were obese. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Short‐term weight gain (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole 5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 (2.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 (1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"All aripiprazole treatment groups were associated with significantly greater change in weight compared with the placebo at endpoint. Aripiprazole 5 mg/day and aripiprazole 15 mg/day were associated with a greater prevalence of clinically significant weight gain than the placebo, and aripiprazole 15 mg/day was also associated with significantly greater increases in body mass index than the placebo" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 (2.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 (1.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole 15 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 (1.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0102" title="EUCTR2016-005111-40. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A multicenter, double-blind, randomized, placebo-controlled, flexible-dosed parallel-group study of aripiprazole flexibly dosed in thetreatment of children and adolescents with autistic disorder]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-005111-40/results (first received 7 April 2017). LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of flexibly-dosed aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110-1. [DOI: 10.1002/ana.21853]LewisD , OwenR , CouchD . Efficacy and safety of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years): results from two 8-week randomized, double-blind, placebo-controlled trials. Neurology2009;72(11 (Supp 3)):A428. [ABSTRACT NO: S50.005]MankoskiR , StocktonG , ManosG , MarlorS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]NCT00365859. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A 52-week, open-label, multicenter study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder]. clinicaltrials.gov/ct2/show/NCT00365859 (first received 18 August 2006). OwenR , SikichL , MarcusRN , Corey-LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescent with autistic disorder. Pediatrics2009;124(6):1533-40. [DOI: 10.1542/peds.2008-3782] [PMID: 19948625]RobbAS , AnderssonC , BellocchioEE , ManosG , Rojas-FernandezC , MathewS , et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): results from a pooled analysis of 2 studies. Primary Care Companion for CNS Disorders2011;13(1):PCC.10m01008. [DOI: 10.4088/PCC.10m01008gry] [PMCID: PMC3121213] [PMID: 21731831]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. The effect of aripiprazole 2 to 15mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Owen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term weight gain (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole</p> <p>(2‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 (12.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 (12.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Aripiprazole treatment was associated with significantly greater mean weight change compared with placebo at endpoint (LOCF: 2.0 vs 0.8 kg (P .005); observed case: 1.9 vs 0.5 kg (P .01)). Aripiprazole was also associated with a greater incidence of clinically significant weight gain (&gt;7% increase from baseline) than placebo (LOCF: 28.9% vs 6.1%; P.01)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>AE:</b> adverse effect; <b>BMI:</b> body mass index; <b>LOCF:</b> Last observation carried forward </p> </td> </tr> </tbody> </table> </div> <p>As there were more than 10 studies in this analysis, we created a funnel plot for this outcome but found no evidence of asymmetry (<a href="#CD011769-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD011769-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="log: logarithm; SE: standard error; RR: risk ratioAtypical antipsychotics versus placebo (8 studies, 702 participants; Analysis 1.9)" data-id="CD011769-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>log:</b> logarithm; <b>SE:</b> standard error; <b>RR:</b> risk ratio </p> <p>Atypical antipsychotics versus placebo (8 studies, 702 participants; <a href="./references#CD011769-fig-0019" title="">Analysis 1.9</a>) </p> </div> </div> </div> </section> <section id="CD011769-sec-0132"> <p><b>Musculoskeletal</b></p> <p>In the one study with 100 participants that compared atypical antipsychotics and placebo (<a href="./references#CD011769-fig-0021" title="">Analysis 1.11</a>), there was no difference in: </p> <p> <ul id="CD011769-list-0068"> <li> <p>rigidity (RR 5.20, 95% CI 0.63 to 42.96; low‐certainty evidence);</p> </li> <li> <p>movement disorder (RR 5.50, 95% CI 0.27 to 111.14; low‐certainty evidence); or</p> </li> <li> <p>dyskinesia (RR 2.08, 95% CI 0.55 to 7.87; low‐certainty evidence).</p> </li> </ul> </p> </section> <section id="CD011769-sec-0133"> <p><b>Neurological</b></p> <p>A number of neurological AEs may be more likely to be reported in participants receiving atypical antipsychotics compared with placebo (<a href="./references#CD011769-fig-0022" title="">Analysis 1.12</a>). These were: </p> <p> <ul id="CD011769-list-0069"> <li> <p>dizziness (RR 4.19, 95% CI 1.10 to 16.00; I<sup>2</sup> = 0%; 2 studies, 139 participants, low‐certainty evidence); </p> </li> <li> <p>fatigue (RR 2.58, 95% CI 1.68 to 3.97; I<sup>2</sup> = 0%; 8 studies, 881 participants; low‐certainty evidence); </p> </li> <li> <p>sedation (RR 2.98, 95% CI 1.15 to 7.73; I<sup>2</sup> = 21%; 5 studies, 366 participants; low‐certainty evidence); </p> </li> <li> <p>somnolence (RR 4.84, 95% CI 3.18 to 7.36; I<sup>2</sup> = 0%; 9 studies, 869 participants, low‐certainty evidence); and </p> </li> <li> <p>tremor (RR 5.99, 95% CI 1.87 to 19.19; I<sup>2</sup> = 0%; 5 studies, 574 participants; low‐certainty evidence). </p> </li> </ul> </p> <p>There was no clear evidence of a difference between atypical antipsychotics and placebo groups in: </p> <p> <ul id="CD011769-list-0070"> <li> <p>agitation/excitation (RR 0.46, 95% CI 0.13 to 1.62; I<sup>2</sup> = 0%; 2 studies, 97 participants); </p> </li> <li> <p>aggression (dichotomous) (RR 0.34, 95% CI 0.12 to 0.98; I<sup>2</sup> = 0%; 4 studies, 461 participants); </p> </li> <li> <p>apathy (RR 10.73, 95% CI 0.61 to 187.79; P = 0.10; I<sup>2</sup> = NA; 1 study, 79 participants); </p> </li> <li> <p>drowsiness (RR 4.26, 95% CI 0.95 to 19.02; P = 0.06; I<sup>2</sup> = NA; 1 study, 97 participants); </p> </li> <li> <p>extrapyramidal disorder (RR 7.83, 95% CI 0.47 to 130.01; P = 0.15; I<sup>2</sup> = NA; 1 study, 216 participants); </p> </li> <li> <p>hypersomnia (RR 2.67, 95% CI 0.43 to 16.52; I<sup>2</sup> = 0%; 2 studies, 282 participants); </p> </li> <li> <p>insomnia (RR 0.72, 95% CI 0.50 to 1.04; I<sup>2</sup> = 0%; 7 studies, 679 participants); </p> </li> <li> <p>presyncope (RR 0.94, 95% CI 0.04 to 22.72; I<sup>2</sup> = NA; 1 study, 216 participants); </p> </li> <li> <p>headache (RR 1.17, 95% CI 0.63 to 2.15; I<sup>2</sup> = 9%; 6 studies, 597 participants); </p> </li> <li> <p>lethargy (RR 6.58, 95% CI 0.39 to 110.35; I<sup>2</sup> = NA; 1 study, 216 participants); </p> </li> <li> <p>hyperactivity (RR 0.47, 95% CI 0.13 to 1.70; I<sup>2</sup> = 0%; 3 studies, 305 participants); and </p> </li> <li> <p>restlessness (akathisia) (RR 0.99, 95% CI 0.40 to 2.43; I<sup>2</sup> = 1%; 4 studies, 531 participants). </p> </li> </ul> </p> <p>As there were more than 10 studies in this analysis, we created a funnel plot for this outcome but found no evidence of asymmetry (<a href="#CD011769-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD011769-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="log: logarithm; RR: risk ratio; SE: standard error; SMD: standardised mean differenceAtypical antipsychotics versus placebo (11 studies, 974 participants; Analysis 1.12)" data-id="CD011769-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>log:</b> logarithm; <b>RR:</b> risk ratio; <b>SE:</b> standard error; <b>SMD:</b> standardised mean difference </p> <p>Atypical antipsychotics versus placebo (11 studies, 974 participants; <a href="./references#CD011769-fig-0022" title="">Analysis 1.12</a>) </p> </div> </div> </div> </section> <section id="CD011769-sec-0134"> <p><b>Psychological</b></p> <p>There was no clear evidence of a difference between atypical antipsychotic and placebo groups in </p> <p> <ul id="CD011769-list-0071"> <li> <p>anxiety (RR 1.34, 95% CI 0.65 to 2.76; I<sup>2</sup> = 0%; 2 studies, 139 participants; very low‐certainty evidence); or </p> </li> <li> <p>depression (RR 3.86, 95% CI 0.46 to 32.60; I<sup>2</sup> = 0%; 2 studies, 79 participants; very low‐certainty evidence; <a href="./references#CD011769-fig-0023" title="">Analysis 1.13</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0135"> <p><b>Respiratory</b></p> <p>There was no clear evidence of a difference between the atypical antipsychotic and placebo groups in the respiratory symptoms of: </p> <p> <ul id="CD011769-list-0072"> <li> <p>ear infection (RR 5.63, 95% CI 0.28 to 112.84; I<sup>2</sup> = NA; 1 study, 66 participants); </p> </li> <li> <p>epistaxis (RR 5.63, 95% CI 0.28 to 112.84; I<sup>2</sup> = NA; 1 study, 66 participants); </p> </li> <li> <p>nasal congestion (RR 2.39, 95% CI 0.52 to 11.00; I<sup>2</sup> = 0%; 2 studies, 313 participants); </p> </li> <li> <p>nasopharyngitis (RR 1.26, 95% CI 0.73 to 2.17; I<sup>2</sup> = 0%; 6 studies, 702 participants); </p> </li> <li> <p>pharyngolaryngeal pain (RR 0.31, 95% CI 0.06 to 1.48; I<sup>2</sup> = NA; 1 study, 216 participants); or </p> </li> <li> <p>rhinitis (RR 2.68, 95% CI 0.93 to 7.71; I<sup>2</sup> = NA; 1 study, 79 participants). </p> </li> </ul> </p> <p>However, there was a higher rate of upper respiratory tract infection in the antipsychotic group (RR 2.15, 95% CI 1.08 to 4.27; I<sup>2</sup> = 8%; 6 studies, 640 participants; <a href="./references#CD011769-fig-0024" title="">Analysis 1.14</a>). </p> </section> <section id="CD011769-sec-0136"> <p><b>Skin</b></p> <p>There was no clear evidence of a difference between groups in the likelihood of:</p> <p> <ul id="CD011769-list-0073"> <li> <p>bruise (RR 0.32, 95% CI 0.03 to 2.96; I<sup>2</sup> = NA; 1 study, 92 participants); or </p> </li> <li> <p>rash (RR 0.79, 95% CI 0.14 to 4.62; I<sup>2</sup> = 0%; 2 studies, 228 participants; <a href="./references#CD011769-fig-0025" title="">Analysis 1.15</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0137"> <p><b>Urinary</b></p> <p>Enuresis was not different between the atypical antipsychotic and placebo groups (RR 1.12, 95% CI 0.67 to 1.86; I<sup>2</sup> = 0%; 6 studies, 552 participants; <a href="./references#CD011769-fig-0026" title="">Analysis 1.16</a>). </p> </section> <section id="CD011769-sec-0138"> <p><b>Other adverse effects</b></p> <p>No other AEs were reported.</p> </section> </section> </section> <section id="CD011769-sec-0139"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0140"> <h6 class="title">Quality of life</h6> <section id="CD011769-sec-0141"> <p><b>Child, adolescent or adult with autism</b></p> <p>Quality of life was not different at endpoint in participants receiving aripiprazole compared to those receiving placebo (SMD 0.95, 95% CI 0.14 to 1.76; I<sup>2</sup> = 75%; 2 studies, 135 participants; <a href="./references#CD011769-fig-0027" title="">Analysis 1.17</a>). </p> <p>We could not include two of the quality‐of‐life datasets (5 mg/day and 10 mg/day) from <a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a> in the meta‐analysis because the data were skewed. Details can be found in <a href="#CD011769-tbl-0012">Table 8</a>. </p> <div class="table" id="CD011769-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Atypical antipsychotics versus placebo: quality‐of‐life results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Short‐term QoL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole 5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (15.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6 (15.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Although patients receiving aripiprazole 5 and 10 mg/day had improvement in these 3 (QoL) scale scores compared with those receiving placebo, the 95% CIs of the treatment differences included zero" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4 (15.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6 (15.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>QoL:</b> Quality of Life </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD011769-sec-0142"> <h6 class="title">Tolerability/acceptability</h6> <p>Participants were less likely to be lost to follow‐up in the antipsychotic group than the placebo group (RR 0.54, 95% CI 0.41 to 0.71; I<sup>2</sup> = 12%; 13 studies, 1004 participants; <a href="./references#CD011769-fig-0028" title="">Analysis 1.18</a>). </p> <p>Apart from one study, all studies involved children and adolescents, and therefore, we could not conduct a subgroup analysis of differences in tolerability based on age. </p> </section> </section> </section> <section id="CD011769-sec-0143"> <h4 class="title">Neurohormones versus placebo</h4> <section id="CD011769-sec-0144"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0145"> <h6 class="title">Challenging behaviours</h6> <section id="CD011769-sec-0146"> <p><b>Irritability</b></p> <p>At short‐term follow‐up, there was some evidence that neurohormones may have a minimal to no effect on irritability (SMD −0.18, 95% CI −0.37 to −0.00; I<sup>2</sup> = 0%; 8 studies, 466 participants; low‐certainty evidence; <a href="./references#CD011769-fig-0032" title="">Analysis 2.1</a>). </p> <p>There were no differences between types of neurohormones (P = 0.54) or when male participants were compared to a mixed population of male and female participants (P = 0.94). There was insufficient information to conduct subgroup analyses of irritability by communication ability or cognitive ability. </p> <p>We could not include data from three studies in the analysis because the data were skewed (<a href="./references#CD011769-bbs2-0069" title="LevySE , SoudersMC , WrayJ , JawadAF , Gallagher PR CoplinJ , et al. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin. Archives of Disease in Childhood2003;88(8):731-6. [DOI: 10.1136/adc.88.8.731] [PMCID: PMC1719589] [PMID: 12876177]">Levy 2003</a>; <a href="./references#CD011769-bbs2-0118" title="NCT01793441. A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) [A multi-center, randomized, double-blind, 12-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of rg7314 in individuals with autism spectrum disorders (ASD)]. clinicaltrials.gov/ct2/show/NCT01793441 (first received 15 February 2013). SquassanteL , BolognaniF , SmithJ , MurtaghL , FontouraP , KhwajaO , et al. Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla). Journal of the American Academy of Child and Adolescent Psychiatry2018;57(10):S231. [DOI: 10.1016/j.jaac.2018.09.308] [PRESENTATION NO: 5.13]">Squassante 2018</a>; <a href="./references#CD011769-bbs2-0122" title="NCT00065962. Secretin for the treatment of autism [Multisite controlled secretin trial in autism]. clinicaltrials.gov/ct2/show/NCT00065962 (first received 5 August 2003). UnisAS , MunsonJA , RogersSJ , GoldsonE , OsterlingJ , GabrielsR , et al. A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(11):1315-21. [DOI: 10.1097/00004583-200211000-00012] [PMID: 12410073]">Unis 2002</a>). Details can be found in <a href="#CD011769-tbl-0013">Table 9</a>. </p> <div class="table" id="CD011769-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Neurohormones versus placebo: irritability results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0069" title="LevySE , SoudersMC , WrayJ , JawadAF , Gallagher PR CoplinJ , et al. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin. Archives of Disease in Childhood2003;88(8):731-6. [DOI: 10.1136/adc.88.8.731] [PMCID: PMC1719589] [PMID: 12876177]">Levy 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term (single‐dose secretin (2 CU/kg))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.18 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011769-bbs2-0118" title="NCT01793441. A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) [A multi-center, randomized, double-blind, 12-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of rg7314 in individuals with autism spectrum disorders (ASD)]. clinicaltrials.gov/ct2/show/NCT01793441 (first received 15 February 2013). SquassanteL , BolognaniF , SmithJ , MurtaghL , FontouraP , KhwajaO , et al. Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla). Journal of the American Academy of Child and Adolescent Psychiatry2018;57(10):S231. [DOI: 10.1016/j.jaac.2018.09.308] [PRESENTATION NO: 5.13]">Squassante 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan 1.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.99 (14.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−2.85 (24.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan 4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.64 (24.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.07 (4.95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.42 (34.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−2.99 (9.49)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0122" title="NCT00065962. Secretin for the treatment of autism [Multisite controlled secretin trial in autism]. clinicaltrials.gov/ct2/show/NCT00065962 (first received 5 August 2003). UnisAS , MunsonJA , RogersSJ , GoldsonE , OsterlingJ , GabrielsR , et al. A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(11):1315-21. [DOI: 10.1097/00004583-200211000-00012] [PMID: 12410073]">Unis 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term synthetic secretin (single infusion of 0.4 μg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.3 (3.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.5 (3.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> </tbody> </table> </div> <p>Please refer to <a href="./full#CD011769-tbl-0002">summary of findings Table 2</a> for further information. </p> </section> <section id="CD011769-sec-0147"> <p><b>Self‐injury</b></p> <p>There was no clear evidence of a difference in self‐injury between participants receiving neurohormones compared to those receiving placebo at endpoint (SMD −0.37, 95% CI −0.93 to 0.19; I<sup>2</sup> = NA; 1 study, 50 participants; <a href="./references#CD011769-fig-0033" title="">Analysis 2.2</a>) and at three‐month follow‐up (SMD −0.32, 95% CI −0.88 to 0.23; I<sup>2</sup> = NA; 1 study, 50 participants; <a href="./references#CD011769-fig-0033" title="">Analysis 2.2</a>). </p> <p>We could not include data from one study in the analysis because the data were skewed (<a href="./references#CD011769-bbs2-0039" title="ACTRN12609000513213. A course of oxytocin nasal spray (OT) to treat social problems in youth with autism spectrum disorders [A double blind randomised controlled trial of oxytocin nasal spray to treat social problems in autistic youth]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83655 (first received 29 June 2009). GuastellaAJ , GrayKM , RinehartNJ , AlvaresGA , TongeBJ , HickieIB , et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. Journal of Child Psychology and Psychiatry2015;56(4):444-52. [DOI: 10.1111/jcpp.12305] [PMID: 25087908]">Guastella 2015a</a>). Details can be found in <a href="#CD011769-tbl-0014">Table 10</a>. </p> <div class="table" id="CD011769-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Neurohormones versus placebo: adverse effects data that could not be used in the meta‐analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Name of study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0114" title="NCT01944046. Study of oxytocin in autism to improve reciprocal social behaviours (SOARS-B) [Phase II study of oxytocin in autism to improve reciprocal social behaviors]. clinicaltrials.gov/ct2/show/NCT01944046 (first received 17 September 2013). SikichL , AldermanC , HazzardL , BetheaT , GregoryS , JohnsonJ . Pilot study of sustained oxytocin treatment in children and adolescents with autistic disorder. Biological Psychiatry2013;73(9):145S. ">Sikich 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term oxytocin (max 24 IU children 3‐10 years or max 32 IU children 11‐17 years) adverse effects (metabolic) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64 (1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD011769-sec-0148"> <h6 class="title">Adverse effects</h6> <section id="CD011769-sec-0149"> <p><b>Cardiovascular</b></p> <p>There was no clear evidence of a difference between participants receiving neurohormones compared to those receiving placebo in the likelihood of: </p> <p> <ul id="CD011769-list-0074"> <li> <p>cardiac disorders (RR 1.45, 95% CI 0.23 to 9.05; I<sup>2</sup> = 0%; 3 studies, 456 participants); </p> </li> <li> <p>palpitations (RR 2.96, 95% CI 0.12 to 72.04; I<sup>2</sup> = NA; 1 study, 290 participants); or </p> </li> <li> <p>vascular disorders (RR 1.00, 95% CI 0.06 to 15.57; I<sup>2</sup> = NA; 1 study, 106 participants <a href="./references#CD011769-fig-0034" title="">Analysis 2.3</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0150"> <p><b>Gastrointestinal</b></p> <p>Only vomiting showed a difference between groups when oxytocin was compared to a placebo (RR 0.45, 95% CI 0.21 to 0.97; I<sup>2</sup> = 0%; 4 studies, 409 participants, low‐certainty evidence; <a href="./references#CD011769-fig-0035" title="">Analysis 2.4</a>). </p> <p>There was no clear evidence of differences between the neurohormone and placebo groups in any of the other gastrointestinal AEs: </p> <p> <ul id="CD011769-list-0075"> <li> <p>abdominal pain or discomfort (RR 0.42, 95% CI 0.17 to 1.07; I<sup>2</sup> = NA; 1 study, 290 participants); </p> </li> <li> <p>constipation (RR 0.89, 95% CI 0.46 to 1.73; 3 studies, 361 participants);</p> </li> <li> <p>diarrhoea (RR 0.71, 95% CI 0.39 to 1.28; I<sup>2</sup> = 0%; 5 studies, 450 participants); </p> </li> <li> <p>dry mouth (RR 0.43, 95% CI 0.06 to 2.88; I<sup>2</sup> = 0%; 2 studies, 350 participants); </p> </li> <li> <p>encopresis (RR 0.74, 95% CI 0.17 to 3.25, I<sup>2</sup> = NA; 1 study, 290 participants); </p> </li> <li> <p>gastrointestinal disorders (RR 1.25, 95% CI 0.35 to 4.49; I<sup>2</sup> = 0%; 2 studies, 166 participants); </p> </li> <li> <p>nausea (RR 0.14, 95% CI 0.01 to 2.65; I<sup>2</sup> = NA; 1 study, 60 participants); </p> </li> <li> <p>salivary hypersecretion (RR 0.32, 95% CI 0.03 to 2.99; I<sup>2</sup> = 0%; 2 studies 319 participants); and </p> </li> <li> <p>stomatitis (RR 0.13, 95% CI 0.02 to 1.11; I<sup>2</sup> = 0%; 2 studies, 321 participants, low‐certainty evidence <a href="./references#CD011769-fig-0035" title="">Analysis 2.4</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0151"> <p><b>Immune system</b></p> <p>Infections and infestations were not different between groups (RR 2.00, 95% CI 0.81 to 4.93; I<sup>2</sup> = NA; 1 study, 106 participants; <a href="./references#CD011769-fig-0036" title="">Analysis 2.5</a>). </p> </section> <section id="CD011769-sec-0152"> <p><b>Metabolic</b></p> <p>There was no clear evidence of a difference between neurohormone and placebo groups in any of the metabolic AEs. These included: </p> <p> <ul id="CD011769-list-0076"> <li> <p>decreased appetite (RR 0.67, 95% CI 0.37 to 1.22; I<sup>2</sup> = 0%; 4 studies, 409 participants; very low‐certainty evidence); </p> </li> <li> <p>increased appetite (RR 1.74, 95% CI 0.96 to 3.16; I<sup>2</sup> = 0%; 2 studies, 350 participants); </p> </li> <li> <p>metabolism and nutrition disorders (RR 0.50, 95% CI 0.05 to 5.35; I<sup>2</sup> = NA; 1 study, 106 participants; very low‐certainty evidence); </p> </li> <li> <p>thirst (RR 1.42, 95% CI 0.35 to 5.67; I<sup>2</sup> = 15%; 2 studies, 319 participants); </p> </li> <li> <p>weight gain (RR 1.21, 95% CI 0.52 to 2.82; I<sup>2</sup> = NA; 1 study, 290 participants); </p> </li> <li> <p>weight change (RR ‐0.45, 95% CI ‐1.76 to 0.86; I<sup>2</sup> = NA; 1 study, 24 participants) or </p> </li> <li> <p>weight loss (RR 1.97, 95% CI 0.69 to 5.63; I<sup>2</sup> = NA; 1 study, 290 participants; <a href="./references#CD011769-fig-0037" title="">Analysis 2.6</a>). </p> </li> </ul> </p> <p>We could not include one study in the analysis because the data were skewed (<a href="./references#CD011769-bbs2-0114" title="NCT01944046. Study of oxytocin in autism to improve reciprocal social behaviours (SOARS-B) [Phase II study of oxytocin in autism to improve reciprocal social behaviors]. clinicaltrials.gov/ct2/show/NCT01944046 (first received 17 September 2013). SikichL , AldermanC , HazzardL , BetheaT , GregoryS , JohnsonJ . Pilot study of sustained oxytocin treatment in children and adolescents with autistic disorder. Biological Psychiatry2013;73(9):145S. ">Sikich 2013</a>). Details can be found in <a href="#CD011769-tbl-0014">Table 10</a>. </p> <p>There was no clear evidence of a difference between neurohormones and placebo groups in mean change in weight in kilograms (SMD −0.45; 95% CI −1.76 to 0.86; 1 study, 24 participants; <a href="./references#CD011769-fig-0038" title="">Analysis 2.7</a>). </p> </section> <section id="CD011769-sec-0153"> <p><b>Musculoskeletal</b></p> <p>There was no difference between participants receiving neurohormones and those receiving placebo in: </p> <p> <ul id="CD011769-list-0077"> <li> <p>muscle spasms (RR 2.81, 95% CI 0.12 to 63.83; I<sup>2</sup> = NA; 1 study, 29 participants; very low‐certainty evidence); </p> </li> <li> <p>musculoskeletal and connective tissue disorders (RR 3.00, 95% CI 0.12 to 72.02; I<sup>2</sup> = NA; 1 study, 106 participants); and </p> </li> <li> <p>rhabdomyolysis (RR 1.47, 95% CI 0.06 to 35.64; I<sup>2</sup> = NA; 1 study, 220 participants); <a href="./references#CD011769-fig-0039" title="">Analysis 2.8</a>. </p> </li> </ul> </p> </section> <section id="CD011769-sec-0154"> <p><b>Neurological</b></p> <p>Numerous neurological AEs were reported in studies comparing neurohormones to placebo. We found low‐certainty evidence that neurohormones may decrease the risk of headaches (RR 0.58, 95% CI 0.38 to 0.89; I<sup>2</sup> = 0%; 7 studies, 689 participants; <a href="./references#CD011769-fig-0040" title="">Analysis 2.9</a>). </p> <p>The other neurological AEs showed no differences between the groups and included:</p> <p> <ul id="CD011769-list-0078"> <li> <p>absence seizures (RR 2.73, 95% CI 0.12 to 59.57; 1 study, 19 participants);</p> </li> <li> <p>agitation (RR 1.12, 95% CI 0.65 to 1.94; I² = 0%; 3 studies, 344 participants; low‐certainty evidence); </p> </li> <li> <p>aggression (dichotomous) (RR 0.91, 95% CI 0.57 to 1.44; I² = 9%; 3 studies, 356 participants; low‐certainty evidence); </p> </li> <li> <p>decreased attention (RR 1.46, 95% CI 0.24 to 8.84; 3 studies, 108 participants);</p> </li> <li> <p>dizziness (RR 0.65, 95% CI 0.08 to 5.27; I² = 44%; 3 studies, 369 participants; low‐certainty evidence); </p> </li> <li> <p>excessive talking (RR 2.81, 95% CI 0.12 to 63.83; 1 study, 29 participants, low‐certainty evidence); </p> </li> <li> <p>fatigue (RR 0.91, 95% CI 0.50 to 1.65; I<sup>2</sup> = 0%; 3 studies, 120 participants; low‐certainty evidence); </p> </li> <li> <p>insomnia (RR 0.72, 95% CI 0.50 to 1.04; I<sup>2</sup> = 0%; 6 studies, 477 participants; low‐certainty evidence); </p> </li> <li> <p>irritability (dichotomous) (RR 0.86, 95% CI 0.68 to 1.10; I<sup>2</sup> = 0%; 6 studies, 655 participants); </p> </li> <li> <p>leg shaking (RR 2.73, 95% CI 0.12 to 59.57; I<sup>2</sup> = NA; 1 study, 19 participants; low‐certainty evidence); </p> </li> <li> <p>nervous system disorders (RR 1.67, 95% CI 0.42 to 6.62; I<sup>2</sup> = NA; 1 study, 106 participants); </p> </li> <li> <p>oppositional behaviour (RR 0.72, 95% CI 0.14 to 3.61; I<sup>2</sup> = NA; 1 study, 25 participants; low‐certainty evidence); </p> </li> <li> <p>restlessness (RR 1.64, 95% CI 0.17 to 15.47; I² = 51%; 2 studies, 319 participants; low‐certainty evidence); </p> </li> <li> <p>seizure (RR 2.81, 95% CI 0.12 to 63.83; I<sup>2</sup> = NA; 1 study 29 participants; low‐certainty evidence); </p> </li> <li> <p>sedation (RR 1.69, 95% CI 0.87 to 3.27; I<sup>2</sup> = 0%; 2 studies, 350 participants; low‐certainty evidence); </p> </li> <li> <p>somnolence (RR 3.81, 95% CI 0.44 to 32.96; I<sup>2</sup> = 0%; 2 studies, 89 participants; low‐certainty evidence); or </p> </li> <li> <p>tics (RR 0.63, 95% CI 0.16 to 2.38; I<sup>2</sup> = 0%; 2 studies, 309 participants; low‐certainty evidence; <a href="./references#CD011769-fig-0040" title="">Analysis 2.9</a>). </p> </li> </ul> </p> <p>As there were more than 10 studies in this analysis, we created a funnel plot for this outcome but found no evidence of asymmetry (<a href="#CD011769-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD011769-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="log: logarithm; RR: risk ratio; SE: standard error; SMD: standardised mean differenceNeurohormone versus placebo (10 studies, 863 participants; Analysis 2.9)" data-id="CD011769-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>log:</b> logarithm; <b>RR:</b> risk ratio; <b>SE:</b> standard error; <b>SMD:</b> standardised mean difference </p> <p>Neurohormone versus placebo (10 studies, 863 participants; <a href="./references#CD011769-fig-0040" title="">Analysis 2.9</a>) </p> </div> </div> </div> </section> <section id="CD011769-sec-0155"> <p><b>Psychological</b></p> <p>The psychological outcomes were not different between those receiving neurohormones and those receiving placebo. These included: </p> <p> <ul id="CD011769-list-0079"> <li> <p>anxiety (RR 3.05, 95% CI 0.50 to 18.55; I<sup>2</sup> = 0%; 2 studies, 97 participants); </p> </li> <li> <p>depression (RR 0.89, 95% CI 0.29 to 2.68; I<sup>2</sup> = 0%; 4 studies, 427 participants); </p> </li> <li> <p>panic attack (RR 0.30, 95% CI 0.01 to 6.62; I<sup>2</sup> = NA; 1 study, 19 participants); </p> </li> <li> <p>psychiatric (RR 4.00, 95% CI 0.46 to 34.61; I<sup>2</sup> = NA; 1 study, 106 participants); and </p> </li> <li> <p>self‐injury (dichotomous) (RR 1.00, 95% CI 0.11 to 9.35; 2 studies, 118 participants; I<sup>2</sup> = 0%; <a href="./references#CD011769-fig-0041" title="">Analysis 2.10</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0156"> <p><b>Respiratory</b></p> <p>There was no clear evidence of a difference between neurohormone and placebo groups in respiratory symptoms. These included: </p> <p> <ul id="CD011769-list-0080"> <li> <p>cold symptoms (RR 0.65, 95% CI 0.26 to 1.65; ² = 0%; 2 studies, 73 participants);</p> </li> <li> <p>cough (RR 1.35, 95% CI 0.81 to 2.25; I<sup>2</sup> = 0%; 5 studies, 430 participants;); </p> </li> <li> <p>croup (RR 3.23, 95% CI 0.14 to 72.46; I<sup>2</sup> = NA; 1 study, 25 participants); </p> </li> <li> <p>epistaxis (RR 1.21, 95% CI 0.63 to 2.31; I<sup>2</sup> = 0%; 3 studies, 379 participants); </p> </li> <li> <p>nasal congestion (RR 0.79, 95% CI 0.59 to 1.05; I<sup>2</sup> = 0%; 5 studies, 468 participants); </p> </li> <li> <p>nasal irritation/runny nose (RR 0.55, 95% CI 0.10 to 2.92; I<sup>2</sup> = NA; 1 study, 40 participants); </p> </li> <li> <p>nasopharyngitis (RR 0.93, 95% CI 0.15 to 5.76; I<sup>2</sup> = NA; 1 study, 29 participants); </p> </li> <li> <p>respiratory, thoracic and mediastinal disorders (RR 0.49, 95% CI 0.09 to 2.56; I² = 0%; 2 studies, 147 participants); </p> </li> <li> <p>sinusitis (RR 0.47, 95% CI 0.05 to 4.60; I<sup>2</sup> = NA; 1 study, 29 participants); </p> </li> <li> <p>upper respiratory tract infection (RR 1.10, 95% CI 0.35 to 3.47; I<sup>2</sup> = 0%; 2 studies, 273 participants; <a href="./references#CD011769-fig-0042" title="">Analysis 2.11</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0157"> <p><b>Skin</b></p> <p>There was no clear evidence of a difference in the neurohormone group compared to placebo in: </p> <p> <ul id="CD011769-list-0081"> <li> <p>general/systemic disorders and administration site conditions (RR 4.00, 95% CI 0.46 to 34.61; I<sup>2</sup> = NA; 1 study, 106 participants); or </p> </li> <li> <p>rash (RR 1.12, 95% CI 0.63 to 1.97; I<sup>2</sup> = 0%; 4 studies, 416 participants; <a href="./references#CD011769-fig-0043" title="">Analysis 2.12</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0158"> <p><b>Urinary</b></p> <p>There was no difference between the neurohormone group and the placebo group in renal and urinary disorders (RR 3.00, 95% CI 0.12 to 72.02; I<sup>2</sup> = NA; 1 study, 106 participants). However, neurohormones (oxytocin) showed a reduced risk of enuresis when compared to placebo (RR 0.18, 95% CI 0.06 to 0.62; I<sup>2</sup> = NA; 1 study, 290 participants; <a href="./references#CD011769-fig-0044" title="">Analysis 2.13</a>). </p> </section> <section id="CD011769-sec-0159"> <p><b>Other adverse effects</b></p> <p>There was no clear evidence of a difference in the neurohormone group compared to placebo in: </p> <p> <ul id="CD011769-list-0082"> <li> <p>injury, poisoning, and procedural complications (RR 3.00, 95% CI 0.12 to 72.02; I<sup>2</sup> = NA; 1 study, 106 participants); </p> </li> <li> <p>investigations (RR 0.50, 95% CI 0.05 to 5.35; I<sup>2</sup> = NA; 1 study, 106 participants); </p> </li> <li> <p>lymphadenopathy (RR 0.33, 95% CI 0.01 to 7.87; I<sup>2</sup> = NA; 1 study, 60 participants); </p> </li> <li> <p>neoplasms benign, malignant, and unspecified (RR 3.00, 95% CI 0.12 to 72.02; I<sup>2</sup> = NA; 1 study, 106 participants); or </p> </li> <li> <p>increased troponin 1 (RR 1.47, 95% CI 0.06 to 35.64; I<sup>2</sup> = NA; 1 study, 220 participants, <a href="./references#CD011769-fig-0045" title="">Analysis 2.14</a>). </p> </li> </ul> </p> <p>Please refer to <a href="./full#CD011769-tbl-0002">summary of findings Table 2</a> for further information. </p> </section> </section> </section> <section id="CD011769-sec-0160"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0161"> <h6 class="title">Quality of life</h6> <p>There was no clear evidence of a difference in quality of life between neurohormone and placebo groups in the short term (SMD 0.70, 95% CI −0.12 to 1.53; P = 0.001, I² = 81%; 4 studies, 191 participants; <a href="./references#CD011769-fig-0046" title="">Analysis 2.15</a>). </p> <p>We were unable to include data from five studies because the data were skewed (<a href="./references#CD011769-bbs2-0014" title="BernaertsS , BoetsB , BosmansG , SteyaertJ , AlaertsK . Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up. Molecular Autism2020;11(1):6. [DOI: 10.1186/s13229-020-0313-1] [PMCID: PMC6964112] [PMID: 31969977]BernaertsS , DillenC , SteyaertJ , AlaertsK . The effects of four weeks of intranasal oxytocinon social responsiveness and repetitive and restricted behaviors in autism spectrum disorders: a randomized controlled trial. Biological Psychiatry2020;81(10):S349-50. [ABSTRACT NO: 864] [DOI: 10.1016/j.biopsych.2017.02.589]Eudract 2014-000586-45. Oxytocin-based pharmacotherapy for autism spectrum disorders: Investigating the neural and behavioral effects of a promising intervention approach. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000586-45 (first registered May 2014). ">Bernaerts 2020</a>; <a href="./references#CD011769-bbs2-0060" title="JacobS , Veenstra-VanderWeeleJ , MurphyD , McCrackenJ , SmithJ , SandersK , et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet2022;9(3):199-210. [DOI: 10.1016/S2215-0366(21)00429-6] [PMID: 35151410]JacobS , Veenstra-VanderWeeleJ , MurphyD , McCrackenJ , SmithJ , SandersK , et al. Phase three randomised controlled trial of balovaptan in adults with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2020;59(10):S163-S163. [DOI: 10.1016/j.jaac.2020.08.108]NCT03504917. A study of balovaptan in adults with autism spectrum disorder with a 2-year open-label extension. clinicaltrials.gov/ct2/show/NCT03504917?term=NCT03504917&amp;draw=2&amp;rank=1 (first received 8 August 2018). ">Jacob 2022</a>; <a href="./references#CD011769-bbs2-0094" title="NCT01908205. Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD) (OXY-R) [Intranasal oxytocin for the treatment of children and adolescents with autism]. clinicaltrials.gov/ct2/show/NCT01908205 (first received 25 July 2013). ">NCT01908205</a>; <a href="./references#CD011769-bbs2-0096" title="NCT02940574. Neural and behavioral effects of oxytocin in autism spectrum disorders [Oxytocin-based pharmacotherapy for autism spectrum disorders: investigating the neural and behavioral effects of a promising intervention approach]. clinicaltrials.gov/ct2/show/NCT02940574 (first received 21 October 2016). ">NCT02940574</a>; <a href="./references#CD011769-bbs2-0118" title="NCT01793441. A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) [A multi-center, randomized, double-blind, 12-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of rg7314 in individuals with autism spectrum disorders (ASD)]. clinicaltrials.gov/ct2/show/NCT01793441 (first received 15 February 2013). SquassanteL , BolognaniF , SmithJ , MurtaghL , FontouraP , KhwajaO , et al. Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla). Journal of the American Academy of Child and Adolescent Psychiatry2018;57(10):S231. [DOI: 10.1016/j.jaac.2018.09.308] [PRESENTATION NO: 5.13]">Squassante 2018</a>). Details can be found in <a href="#CD011769-tbl-0015">Table 11</a> </p> <div class="table" id="CD011769-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Neurohormones versus placebo: quality‐of‐life results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results Group 1</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results Group 2</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0014" title="BernaertsS , BoetsB , BosmansG , SteyaertJ , AlaertsK . Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up. Molecular Autism2020;11(1):6. [DOI: 10.1186/s13229-020-0313-1] [PMCID: PMC6964112] [PMID: 31969977]BernaertsS , DillenC , SteyaertJ , AlaertsK . The effects of four weeks of intranasal oxytocinon social responsiveness and repetitive and restricted behaviors in autism spectrum disorders: a randomized controlled trial. Biological Psychiatry2020;81(10):S349-50. [ABSTRACT NO: 864] [DOI: 10.1016/j.biopsych.2017.02.589]Eudract 2014-000586-45. Oxytocin-based pharmacotherapy for autism spectrum disorders: Investigating the neural and behavioral effects of a promising intervention approach. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000586-45 (first registered May 2014). ">Bernaerts 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term oxytocin (24 IU once daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.77 (8.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.35 (6.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0060" title="JacobS , Veenstra-VanderWeeleJ , MurphyD , McCrackenJ , SmithJ , SandersK , et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet2022;9(3):199-210. [DOI: 10.1016/S2215-0366(21)00429-6] [PMID: 35151410]JacobS , Veenstra-VanderWeeleJ , MurphyD , McCrackenJ , SmithJ , SandersK , et al. Phase three randomised controlled trial of balovaptan in adults with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2020;59(10):S163-S163. [DOI: 10.1016/j.jaac.2020.08.108]NCT03504917. A study of balovaptan in adults with autism spectrum disorder with a 2-year open-label extension. clinicaltrials.gov/ct2/show/NCT03504917?term=NCT03504917&amp;draw=2&amp;rank=1 (first received 8 August 2018). ">Jacob 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan (10 mg once daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 (13.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0 (11.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0094" title="NCT01908205. Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD) (OXY-R) [Intranasal oxytocin for the treatment of children and adolescents with autism]. clinicaltrials.gov/ct2/show/NCT01908205 (first received 25 July 2013). ">NCT01908205</a><br/>(2013) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term oxytocin (twice daily dose of max 24 IUs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2 (17.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6 (21.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0096" title="NCT02940574. Neural and behavioral effects of oxytocin in autism spectrum disorders [Oxytocin-based pharmacotherapy for autism spectrum disorders: investigating the neural and behavioral effects of a promising intervention approach]. clinicaltrials.gov/ct2/show/NCT02940574 (first received 21 October 2016). ">NCT02940574</a><br/>(2016) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term oxytocin (24 IU once daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.14 (5.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35 (4.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011769-bbs2-0118" title="NCT01793441. A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) [A multi-center, randomized, double-blind, 12-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of rg7314 in individuals with autism spectrum disorders (ASD)]. clinicaltrials.gov/ct2/show/NCT01793441 (first received 15 February 2013). SquassanteL , BolognaniF , SmithJ , MurtaghL , FontouraP , KhwajaO , et al. Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla). Journal of the American Academy of Child and Adolescent Psychiatry2018;57(10):S231. [DOI: 10.1016/j.jaac.2018.09.308] [PRESENTATION NO: 5.13]">Squassante 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan (1.5 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 (13.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9 (13.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan (4 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2 (10.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan (10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 (10.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.98 (13.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011769-sec-0162"> <h6 class="title">Tolerability/acceptability</h6> <p>There was no clear evidence of a difference in loss to follow‐up between neurohormone and placebo groups (RR 1.10, 95% CI 0.87 to 1.40; I<sup>2</sup> = 0%; 14 studies, 1312 participants; <a href="./references#CD011769-fig-0047" title="">Analysis 2.16</a>). </p> <section id="CD011769-sec-0163"> <p><b>Outcomes not reported</b></p> <p>No data were available for the outcome of aggression.</p> </section> </section> </section> </section> <section id="CD011769-sec-0164"> <h4 class="title">Comparison 3: ADHD‐related medications versus placebo</h4> <section id="CD011769-sec-0165"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0166"> <h6 class="title">Challenging behaviours</h6> <section id="CD011769-sec-0167"> <p><b>Irritability</b></p> <p>ADHD‐related medications may reduce irritability in the short term when compared to placebo (SMD −0.20, 95% CI −0.40 to −0.01; 10 studies, 400 participants; P = 0.86, I<sup>2</sup> = 0%; low‐certainty evidence; <a href="./references#CD011769-fig-0049" title="">Analysis 3.1</a>). Please refer to <a href="./full#CD011769-tbl-0003">summary of findings Table 3</a> for further information. </p> <p>There was no difference between groups when we compared stimulant to non‐stimulant ADHD‐related medication (P = 0.33), when we compared children only to children and adults (P = 0.74) and when we compared male participants to a mixed male and female sample (P = 0.58). There was insufficient information to conduct subgroup analyses of irritability by communication ability or cognitive ability. </p> </section> <section id="CD011769-sec-0168"> <p><b>Self‐injury</b></p> <p>At short‐term follow‐up, there was no clear evidence that ADHD‐related medications have an effect on self‐injurious behaviour (SMD −0.62; 95% CI −1.63 to 0.39, I<sup>2</sup> = NA; 1 study, 16 participants, very low‐certainty evidence; <a href="./references#CD011769-fig-0050" title="">Analysis 3.2</a>). Please refer to <a href="./full#CD011769-tbl-0003">summary of findings Table 3</a> for further information. </p> <p>There was only one study, so we could not conduct a subgroup analysis.</p> </section> </section> <section id="CD011769-sec-0169"> <h6 class="title">Adverse effects</h6> <section id="CD011769-sec-0170"> <p><b>Cardiovascular</b></p> <p>There was no clear evidence of a difference between groups in ADHD‐related medications AEs (bradycardia and tachycardia) (RR 0.64, 95% CI 0.16 to 2.54; 2 studies, 114 participants). There was no difference between the ADHD‐related medication and placebo groups in the likelihood of: </p> <p> <ul id="CD011769-list-0083"> <li> <p>bradycardia (RR 0.36, 95% CI 0.09 to 1.37; I<sup>2</sup> = NA; 1 study, 66 participants), or </p> </li> <li> <p>tachycardia (RR 3.52, 95% CI 0.44 to 27.85; I<sup>2</sup> = 0%; 2 studies, 48 participants; <a href="./references#CD011769-fig-0051" title="">Analysis 3.3</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0171"> <p><b>Gastrointestinal</b></p> <p>When ADHD‐related medications were compared to placebo (<a href="./references#CD011769-fig-0052" title="">Analysis 3.4</a>) there was no clear evidence of a difference in the gastrointestinal side effects of: </p> <p> <ul id="CD011769-list-0084"> <li> <p>diarrhoea (RR 0.81, 95% CI 0.46 to 1.40; I<sup>2</sup> = 0%; 6 studies, 426 participants); </p> </li> <li> <p>stomach ache (RR 2.58, 95% CI 1.10 to 6.06; I<sup>2</sup> = 0%; 2 studies, 86 participants; <a href="./references#CD011769-fig-0052" title="">Analysis 3.4</a>); or </p> </li> <li> <p>vomiting (RR 1.35, 95% CI 0.81 to 2.25; I<sup>2</sup> = 0%; 4 studies, 347 participants). </p> </li> </ul> </p> <p>However, ADHD‐related medications may increase the risk of:</p> <p> <ul id="CD011769-list-0085"> <li> <p>constipation (RR 2.68, 95% CI 1.61 to 4.45; I<sup>2</sup> = 0%; 5 studies, 220 participants); </p> </li> <li> <p>dry mouth (RR 5.92, 95% CI 1.86 to 18.81; I<sup>2</sup> = 0%; 3 studies, 102 participants); </p> </li> <li> <p>nausea (RR 3.08, 95% CI 1.51 to 6.29; I<sup>2</sup> = 0%; 5 studies, 239 participants), and </p> </li> <li> <p>stomach or abdominal discomfort (RR 2.26, 95% CI 1.41 to 3.63; I<sup>2</sup> = 0%; 6 studies, 504 participants). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0172"> <p><b>Immune system</b></p> <p>There was no clear evidence of differences between groups on the immune effects of:</p> <p> <ul id="CD011769-list-0086"> <li> <p>fever (RR 0.27, 95% CI 0.06 to 1.27; I<sup>2</sup> = 0%; 3 studies, 183 participants); </p> </li> <li> <p>influenza (RR 7.14, 95% CI 0.38 to 134.69; I<sup>2</sup> = NA; 1 study, 97 participants); </p> </li> <li> <p>myalgia (RR 4.72, 95% CI 0.56 to 39.55; I<sup>2</sup> = 0%; 2 studies, 115 participants); or </p> </li> <li> <p>weakness (RR 3.20, 95% CI 0.35 to 29.10; I<sup>2</sup> = NA; 1 study, 62 participants; <a href="./references#CD011769-fig-0053" title="">Analysis 3.5</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0173"> <p><b>Metabolic</b></p> <p>ADHD‐related medications may increase the risk of decreased appetite when compared to placebo (RR 2.15, 95% CI 1.55 to 2.99; I<sup>2</sup> = 0%; 9 studies, 511 participants; low‐certainty evidence; <a href="./references#CD011769-fig-0054" title="">Analysis 3.6</a>). </p> <p>There were no clear differences between groups in:</p> <p> <ul id="CD011769-list-0087"> <li> <p>increased appetite (RR 0.67, 95% CI 0.14 to 3.34; I<sup>2</sup> = 0%; 2 studies, 121 participants; low‐certainty evidence); and </p> </li> <li> <p>increased energy (RR 1.60, 95% CI 0.65 to 3.95; I<sup>2</sup> = NA; 1 study, 62 participants; <a href="./references#CD011769-fig-0054" title="">Analysis 3.6</a>). </p> </li> </ul> </p> <p>We were unable to include one study in the analysis because the data were skewed (<a href="./references#CD011769-bbs2-0061" title="JaselskisCA , CookEH , FletcherKE , LeventhalBL . Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology1992;12(5):322-7. [PMID: 1479049]">Jaselskis 1992</a>). Details can be found in <a href="#CD011769-tbl-0016">Table 12</a>. </p> <div class="table" id="CD011769-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">ADHD versus placebo: adverse effects data that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD011769-bbs2-0061" title="JaselskisCA , CookEH , FletcherKE , LeventhalBL . Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology1992;12(5):322-7. [PMID: 1479049]">Jaselskis 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term adverse effects (increased thirst)</p> <p>clonidine (0.15‐0.20 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (0.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term adverse effects (appetite change)</p> <p>clonidine (0.15‐0.20 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (2.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 (0.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term adverse effects (sleep disturbance)</p> <p>clonidine (0.15‐0.20 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (2.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 (2.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term adverse effects (depression)</p> <p>clonidine (0.15‐0.20 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 (2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 (1.4)</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011769-sec-0174"> <p><b>Neurological</b></p> <p>Very uncertain evidence shows that ADHD‐related medications compared to placebo may increase: </p> <p> <ul id="CD011769-list-0088"> <li> <p>drowsiness (RR 3.42, 95% CI 1.54 to 7.59; I<sup>2</sup> = 20%; 4 studies, 186 participants; very low‐certainty evidence); </p> </li> <li> <p>emotion/tearfulness (RR 6.32, 95% CI 2.47 to 16.18; I<sup>2</sup> = 0%; 2 studies, 128 participants; very low‐certainty evidence); </p> </li> <li> <p>fatigue (RR 3.73, 95% CI 1.98 to 7.03; I<sup>2</sup> = 0%; 4 studies, 235 participants; very low‐certainty evidence); </p> </li> <li> <p>headache (RR 1.63, 95% CI 1.09 to 2.44; I<sup>2</sup> = 0%; 8 studies, 383 participants; very low‐certainty evidence); </p> </li> <li> <p>insomnia (RR 1.58, 95% CI 1.01 to 2.47; I<sup>2</sup> = 5%; 7 studies, 411 participants; very low‐certainty evidence); </p> </li> <li> <p>irritability (dichotomous) (RR 1.61, 95% CI 1.25 to 2.07; I<sup>2</sup> = 0%; 6 studies, 336 participants; very low‐certainty evidence; <a href="./references#CD011769-fig-0055" title="">Analysis 3.7</a>). </p> </li> </ul> </p> <p>There was no clear evidence (all very low‐certainty evidence) of differences between groups in: </p> <p> <ul id="CD011769-list-0089"> <li> <p>agitation (RR 0.95, 95% CI 0.56 to 1.60; I<sup>2</sup> = NA; 1 study, 128 participants); </p> </li> <li> <p>aggression (dichotomous) (RR 0.95, 95% CI 0.58 to 1.53; I<sup>2</sup> = 0%; 5 studies, 365 participants); </p> </li> <li> <p>dizziness (RR 2.17, 95% CI 0.63 to 7.53; I<sup>2</sup> = 0%; 3 studies, 175 participants); </p> </li> <li> <p>hyperactivity (RR 0.68, 95% CI 0.06 to 7.20; I<sup>2</sup> = 39%; 2 studies, 115 participants); </p> </li> <li> <p>increased motor activity (RR 1.89, 95% CI 0.48 to 7.47; I<sup>2</sup> = NA; 1 study, 66 participants); </p> </li> <li> <p>motor tics (RR 2.33, 95% CI 0.51 to 10.69; I<sup>2</sup> = 20%; 3 studies, 118 participants); </p> </li> <li> <p>nightmares (RR 1.48, 95% CI 0.38 to 5.75; I<sup>2</sup> = 0%; 2 studies, 122 participants); </p> </li> <li> <p>repetitive behaviour (RR 1.59, 95% CI 0.74 to 3.39; I<sup>2</sup> = 0%; 2 studies, 128 participants); </p> </li> <li> <p>restlessness (RR 1.52, 95% CI 0.06 to 40.44; I<sup>2</sup> = 71%; 2 studies, 76 participants); </p> </li> <li> <p>sleep disturbance (RR 1.12, 95% CI 0.54 to 2.31; I<sup>2</sup> = 0%; 2 studies, 84 participants); </p> </li> <li> <p>talking excessively (RR 0.24, 95% CI 0.06 to 1.01, I<sup>2</sup> = NA; 1 study, 62 participants); </p> </li> <li> <p>waking (RR 1.60, 95% CI 0.29 to 8.92, I<sup>2</sup> = NA; 1 study, 62 participants); and </p> </li> <li> <p>tremor (RR 3.00, 95% CI 0.14 to 64.26; I<sup>2</sup> = NA; 1 study, 16 participants; <a href="./references#CD011769-fig-0055" title="">Analysis 3.7</a>). </p> </li> </ul> </p> <p>There was also no clear evidence of a difference in the continuous neurological AEs of: </p> <p> <ul id="CD011769-list-0090"> <li> <p>drowsiness (SMD 4.80, 95% CI 0.55 to 9.05; I<sup>2</sup> = NA; 1 study, 8 participants); and </p> </li> <li> <p>decreased activity (SMD 2.00, 95% CI −2.66 to 6.66; I<sup>2</sup> = NA; 1 study, 8 participants; <a href="./references#CD011769-fig-0056" title="">Analysis 3.8</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0175"> <p><b>Psychological</b></p> <p>ADHD‐related medications may increase the risk of depression in the ADHD‐related medication group when compared to placebo although the evidence is very uncertain (RR 2.45, 95% CI 1.12 to 5.36; I<sup>2</sup> = 0%; 3 studies, 152 participants, very low‐certainty evidence). </p> <p>There was no clear evidence of differences between groups in:</p> <p> <ul id="CD011769-list-0091"> <li> <p>anxiety (RR 1.39, 95% CI 0.74 to 2.62; I<sup>2</sup> = 10%; 5 studies, 252 participants); </p> </li> <li> <p>mood change (RR 13.00, 95% CI 0.78 to 216.39; I<sup>2</sup> = NA; 1 study, 40 participants); </p> </li> <li> <p>self‐injury (dichotomous) (RR 1.67, 95% CI 0.78 to 3.58; I² = 0%; 3 studies, 188 participants; moderate‐certainty evidence); </p> </li> <li> <p>'silly' behaviour (RR 0.64, 95% CI 0.17 to 2.45; I<sup>2</sup> = NA; 1 study, 62 participants); or </p> </li> <li> <p>social withdrawal (RR 2.28, 95% CI 0.39 to 13.37; 2 studies, 126 participants; I<sup>2</sup> = 43%) <a href="./references#CD011769-fig-0057" title="">Analysis 3.9</a>. </p> </li> </ul> </p> </section> <section id="CD011769-sec-0176"> <p><b>Respiratory</b></p> <p>There was no clear evidence of a difference between groups in cough (RR 0.81, 95% CI 0.26 to 2.46; I<sup>2</sup> = 0%; 2 studies, 122 participants; <a href="./references#CD011769-fig-0058" title="">Analysis 3.10</a>). </p> </section> <section id="CD011769-sec-0177"> <p><b>Skin</b></p> <p>There was no clear evidence of a difference in the likelihood of:</p> <p> <ul id="CD011769-list-0092"> <li> <p>rash (RR 2.21, 95% CI 0.79 to 6.16; I<sup>2</sup> = 14%; 3 studies, 102 participants); or </p> </li> <li> <p>skin picking (RR 0.36, 95% CI 0.04 to 3.23; I<sup>2</sup> = NA; 1 study, 62 participants; <a href="./references#CD011769-fig-0059" title="">Analysis 3.11</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0178"> <p><b>Urinary</b></p> <p>Enuresis was not different between groups (RR 0.81, 95% CI 0.19 to 3.55; P = 0.65, I<sup>2</sup> = 0%; 2 studies, 122 participants; <a href="./references#CD011769-fig-0060" title="">Analysis 3.12</a>). </p> </section> </section> </section> <section id="CD011769-sec-0179"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0180"> <h6 class="title">Quality of life</h6> <p>There was no clear evidence of a difference between groups in quality of life (SMD 0.21. 95% CI −0.33 to 0.75; I<sup>2</sup> = NA; 1 study, 54 participants; <a href="./references#CD011769-fig-0061" title="">Analysis 3.13</a>). </p> </section> <section id="CD011769-sec-0181"> <h6 class="title">Tolerability/acceptability</h6> <p>Follow‐up was not different in the ADHD‐related and placebo groups (RR 0.91, 95% CI 0.50 to 1.69; I<sup>2</sup> = 7%; 9 studies, 380 participants; <a href="./references#CD011769-fig-0062" title="">Analysis 3.14</a>). </p> <section id="CD011769-sec-0182"> <p><b>Outcomes not reported</b></p> <p>No data were available for the outcomes of aggression, musculoskeletal AEs, or other AEs. </p> </section> </section> </section> </section> <section id="CD011769-sec-0183"> <h4 class="title">Antidepressants versus placebo</h4> <section id="CD011769-sec-0184"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0185"> <h6 class="title">Challenging behaviours</h6> <section id="CD011769-sec-0186"> <p><b>Irritability</b></p> <p>There was no clear evidence of a difference in irritability in the short term when antidepressants were compared to placebo (SMD −0.06, 95% CI −0.30 to 0.18; I<sup>2</sup> = 0%, 3 studies, 267 participants; low‐certainty evidence; <a href="./references#CD011769-fig-0065" title="">Analysis 4.1</a>). There were no clear differences between groups when we compared types of antidepressants (P = 0.76), or when we compared male participants to a mixed population of male and female participants (P = 0.67). </p> <p>We were unable to include data from five studies in the analysis because data were either not reported, reported without standard deviation, reported as median and range, or were skewed (<a href="./references#CD011769-bbs2-0216" title="CarminatiGG , GerberF , DarbellayB , KoselMM , DeriazN , ChabertJ , et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2016;65:85-95. [DOI: 10.1016/j.pnpbp.2015.09.002] [PMID: 26361994]">Carminati 2016</a>; <a href="./references#CD011769-bbs2-0038" title="GordonCT , RapoportJL , HamburgerSD , StateRC , MannheimGB . Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry1992;149(3):363-6. [DOI: 10.1176/ajp.149.3.363]GordonCT , StateRC , NelsonJE , HamburgerSD , RapoportJL . A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. JAMA1993;50(6):2441-7. [DOI: 10.1001/archpsyc.1993.01820180039004]">Gordon 1993</a>; <a href="./references#CD011769-bbs2-0056" title="HollanderE , SooryaL , ChaplinW , AnagnostouE , TaylorBP , FerrettiCJ , et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry2012;169(3):292-9. Erratum in: American Journal of Psychiatry. 2012 May;169(5):540. [DOI: 10.1176/appi.ajp.2011.10050764] [PMID: 22193531]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. https://clinicaltrials.gov/show/NCT00004486 (first received 19 October 1999). ">Hollander 2012</a>; <a href="./references#CD011769-bbs2-0088" title="NCT00183339. Early intervention with fluoxetine in autism [A randomized, placebo-controlled trial of fluoxetine in preschool children]. clinicaltrials.gov/ct2/show/NCT00183339 (first received 16 September 2005). ">NCT00183339</a>; <a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a>). Details of these studies can be found in <a href="#CD011769-tbl-0017">Table 13</a>. </p> <div class="table" id="CD011769-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Antidepressant versus placebo: irritability results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> <p><b>Short‐/medium‐/ long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 3</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 3 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 3 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0216" title="CarminatiGG , GerberF , DarbellayB , KoselMM , DeriazN , ChabertJ , et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2016;65:85-95. [DOI: 10.1016/j.pnpbp.2015.09.002] [PMID: 26361994]">Carminati 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venlafaxine (18.75 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 10 (range 0‐40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 9 (range 5‐17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results presented as median and range</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0038" title="GordonCT , RapoportJL , HamburgerSD , StateRC , MannheimGB . Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry1992;149(3):363-6. [DOI: 10.1176/ajp.149.3.363]GordonCT , StateRC , NelsonJE , HamburgerSD , RapoportJL . A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. JAMA1993;50(6):2441-7. [DOI: 10.1001/archpsyc.1993.01820180039004]">Gordon 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term irritabilty</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clomipromine mean dose 4.3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABC‐I data not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABC‐I data not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0056" title="HollanderE , SooryaL , ChaplinW , AnagnostouE , TaylorBP , FerrettiCJ , et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry2012;169(3):292-9. Erratum in: American Journal of Psychiatry. 2012 May;169(5):540. [DOI: 10.1176/appi.ajp.2011.10050764] [PMID: 22193531]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. https://clinicaltrials.gov/show/NCT00004486 (first received 19 October 1999). ">Hollander 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine (max 80 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability was an outcome; however, it was not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0088" title="NCT00183339. Early intervention with fluoxetine in autism [A randomized, placebo-controlled trial of fluoxetine in preschool children]. clinicaltrials.gov/ct2/show/NCT00183339 (first received 16 September 2005). ">NCT00183339</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐term irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine (max 20 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABC‐I</p> <p>‐8.5 (10.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABC‐I</p> <p>‐0.7 (2.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clompramine (max 150 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol</p> <p>(max 150 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results presented graphically without SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>ABC‐I:</b> Aberrant Behaviour Checklist ‐ Irritability; <b>SD:</b> standard deviation </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011769-sec-0187"> <p><b>Aggression</b></p> <p>We were unable to pool data from two studies because the data were reported as a median and range or not reported fully (<a href="./references#CD011769-bbs2-0216" title="CarminatiGG , GerberF , DarbellayB , KoselMM , DeriazN , ChabertJ , et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2016;65:85-95. [DOI: 10.1016/j.pnpbp.2015.09.002] [PMID: 26361994]">Carminati 2016</a>; <a href="./references#CD011769-bbs2-0079" title="HuffmanG . Fluvoxamine for the treatment of autistic disorders in adults. American Family Physician1997;55(4):1375-4. McDougleCJ , NaylorST , CohenDJ , VolkmarFR , HeningerGR , PriceLH . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry1996;53(11):1001-8. [DOI: 10.1001/archpsyc.1996.01830110037005] [PMID: 8911223]VegsoSJ . A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]. New Haven (CT): Southern Connecticut State University, 1995. ">McDougle 1996</a>). Details of the studies can be found in <a href="#CD011769-tbl-0018">Table 14</a>. </p> <div class="table" id="CD011769-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Antidepressant versus placebo: aggression results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/ medium‐/ long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0216" title="CarminatiGG , GerberF , DarbellayB , KoselMM , DeriazN , ChabertJ , et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2016;65:85-95. [DOI: 10.1016/j.pnpbp.2015.09.002] [PMID: 26361994]">Carminati 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venlafaxine 18.75 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 3.5 (range 0‐18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 4 (range 1‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only median and range provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0079" title="HuffmanG . Fluvoxamine for the treatment of autistic disorders in adults. American Family Physician1997;55(4):1375-4. McDougleCJ , NaylorST , CohenDJ , VolkmarFR , HeningerGR , PriceLH . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry1996;53(11):1001-8. [DOI: 10.1001/archpsyc.1996.01830110037005] [PMID: 8911223]VegsoSJ . A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]. New Haven (CT): Southern Connecticut State University, 1995. ">McDougle 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluvoxamine max 300 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported; only t scores and P value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported; only t scores and P value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As measured by total score on the Brown Aggression Scale, fluvoxamine was superior to placebo in reducing aggression (F = 4.57; d = 3.84; P &lt; 0.03). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011769-sec-0188"> <p><b>Self‐injury</b></p> <p>We were unable to include data from three studies in the analysis because the data were reported as median and range or the data were skewed (<a href="./references#CD011769-bbs2-0216" title="CarminatiGG , GerberF , DarbellayB , KoselMM , DeriazN , ChabertJ , et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2016;65:85-95. [DOI: 10.1016/j.pnpbp.2015.09.002] [PMID: 26361994]">Carminati 2016</a>; <a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a>; <a href="./references#CD011769-bbs2-0065" title="KingBH , HollanderE , SikichL , McCrackenJT , ScahillL , BregmanJD , et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Archives of General Psychiatry2009;66(6):583-90. [DOI: 10.1001/archgenpsychiatry.2009.30] [PMCID: PMC4112556] [PMID: 19487623]MyersSM . Citalopram not effective for repetitive behavior in autistic spectum disorders. Evidence-Based Mental Health2010;13(1):22. [DOI: 10.1136/ebmh.13.1.22] [PMID: 20164519]NCT00086645. Citalopram for children with autism and repetitive behavior (STAART Study 1) [Citalopram treatment in children with autism spectrum disorders and high levels of repetitive behavior]. clinicaltrials.gov/ct2/show/NCT00086645 (first received 13 July 2004). ScahillL , McCrackenJT , BearssK , RobinsonF , HollanderE , KingB , et al. Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders2012;42(3):432-40. [DOI: 10.1007/s10803-011-1251-8] [PMID: 21667200]">King 2009</a>). Details can be found in <a href="./full#CD011769-tbl-0005">Table 1</a>. </p> </section> </section> <section id="CD011769-sec-0189"> <h6 class="title">Adverse effects</h6> <section id="CD011769-sec-0190"> <p><b>Cardiovascular</b></p> <p>There was no clear evidence of a difference between antidepressants and placebo in the cardiovascular AEs of: </p> <p> <ul id="CD011769-list-0093"> <li> <p>flushing (RR 2.00, 95% CI 0.24 to 16.61; I<sup>2</sup> = NA; 1 study 12 participants); or </p> </li> <li> <p>tachycardia (RR 2.67, 95% CI 0.31 to 23.25; I<sup>2</sup> = 0%; 2 studies, 35 participants; <a href="./references#CD011769-fig-0066" title="">Analysis 4.2</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0191"> <p><b>Gastrointestinal</b></p> <p>Antidepressants were no more likely to be associated with gastrointestinal AEs than placebo. These included: </p> <p> <ul id="CD011769-list-0094"> <li> <p>constipation (RR 0.95, 95% CI 0.09 to 10.03; I<sup>2</sup> = 61%; 2 studies, 70 participants); </p> </li> <li> <p>diarrhoea (RR 0.94, 95% CI 0.33 to 2.64; I<sup>2</sup> = 81%; 4 studies, 409 participants); </p> </li> <li> <p>dry mouth (RR 2.00, 95% CI 0.24 to 16.61; I<sup>2</sup> = NA; 1 study, 12 participants); </p> </li> <li> <p>gastrointestinal disturbance (RR 1.41, 95% CI 0.97 to 2.05; I<sup>2</sup> = 0%; 3 studies, 341 participants); </p> </li> <li> <p>nausea/abdominal pain (RR 1.67, 95% CI 0.85 to 3.27; I² = 0%; 5 studies, 251 participants); and </p> </li> <li> <p>vomiting (RR 1.49, 95% CI 0.76 to 2.92; I<sup>2</sup> = 17%; 5 studies, 400 participants; <a href="./references#CD011769-fig-0067" title="">Analysis 4.3</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0192"> <p><b>Immune system</b></p> <p>There were no differences between participants receiving antidepressants and those receiving placebo in: </p> <p> <ul id="CD011769-list-0095"> <li> <p>allergies (RR 1.42, 95% CI 0.70 to 2.88; I<sup>2</sup> = NA; 1 study, 149 participants); </p> </li> <li> <p>cold, flu or other systemic infection (RR 1.24, 95% CI 0.82 to 1.87; I<sup>2</sup> = NA; 1 study, 149 participants); and </p> </li> <li> <p>infections (RR 1.15, 95% CI 0.85 to 1.56; I<sup>2</sup> = 0%; 3 studies, 472 participants; <a href="./references#CD011769-fig-0068" title="">Analysis 4.4</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0193"> <p><b>Metabolic</b></p> <p>There was no clear evidence of a difference between antidepressant and placebo groups for: </p> <p> <ul id="CD011769-list-0096"> <li> <p>appetite disturbance (RR 0.55, 95% CI 0.14 to 2.23; I<sup>2</sup> = NA; 1 study, 165 participants; very low‐certainty evidence); </p> </li> <li> <p>decreased appetite (RR 1.35, 95% CI 0.68 to 2.69; I<sup>2</sup> = 0%; 4 studies, 242 participants; very low‐certainty evidence); </p> </li> <li> <p>increased appetite (RR 0.91, 95% CI 0.35 to 2.38; I<sup>2</sup> = NA; 1 study, 149 participants; very low‐certainty evidence); or </p> </li> <li> <p>weight gain (RR 1.47, 95% CI 0.08 to 27.39; I<sup>2</sup> = 46%; 2 studies, 93 participants; very low‐certainty evidence; <a href="./references#CD011769-fig-0069" title="">Analysis 4.5</a>). </p> </li> </ul> </p> <p>There may be higher levels of decreased energy (RR 1.94, 95% CI 1.13 to 3.33; P = 0.02; I<sup>2</sup> = NA; 1 study, 149 participants, very low‐certainty evidence) in the antidepressant group although the evidence is very uncertain. </p> </section> <section id="CD011769-sec-0194"> <p><b>Musculoskeletal</b></p> <p>There was no clear evidence of a difference between antidepressants and placebo in the musculoskeletal AEs of: </p> <p> <ul id="CD011769-list-0097"> <li> <p>motor disturbance (RR 0.31, 95% CI 0.03 to 2.88; I<sup>2</sup> = NA; 1 study, 165 participants; very low‐certainty evidence); or </p> </li> <li> <p>neck pain (RR 2.09, 95% CI 0.09 to 48.04; I<sup>2</sup> = NA; 1 study, 37 participants; <a href="./references#CD011769-fig-0070" title="">Analysis 4.6</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0195"> <p><b>Neurological</b></p> <p>There was no clear evidence of a difference between antidepressant and placebo groups in most of the reported neurological AEs (<a href="./references#CD011769-fig-0071" title="">Analysis 4.7</a>). These included: </p> <p> <ul id="CD011769-list-0098"> <li> <p>activation syndrome (RR 0.80, 95% CI 0.31 to 2.04; I<sup>2</sup> = NA; 1 study, 159 participants); </p> </li> <li> <p>agitation (RR 1.01, 95% CI 0.59 to 1.75; I<sup>2</sup> = 40%; 2 studies, 197 participants; low‐certainty evidence); </p> </li> <li> <p>aggression or hostility (dichotomous) (RR 1.07, 95% CI 0.59 to 1.95; I<sup>2</sup> = 42%; 3 studies, 225 participants; low‐certainty evidence); </p> </li> <li> <p>anger/irritability (dichotomous) (RR 1.31, 95% CI 0.75 to 2.29; I<sup>2</sup> = 0%; 2 studies, 167 participants; low‐certainty evidence); </p> </li> <li> <p>autonomic disturbance (RR 1.15, 95% CI 0.32 to 4.12; I<sup>2</sup> = NA; 1 study, 165 participants; low‐certainty evidence); </p> </li> <li> <p>central nervous system disturbance (RR 0.75, 95% CI 0.33 to 1.72; I<sup>2</sup> = NA; 1 study, 165 participants; low‐certainty evidence); </p> </li> <li> <p>diaphoresis (sweating) (RR 3.00, 95% CI 0.13 to 69.09; I<sup>2</sup> = NA; 1 study, 36 participants; low‐certainty evidence); </p> </li> <li> <p>drowsiness/fatigue (RR 1.25, 95% CI 0.65 to 2.41; I<sup>2</sup> = 16%; 4 studies, 282 participants; low‐certainty evidence); </p> </li> <li> <p>headache (RR 1.53, 95% CI 0.77 to 3.07; I<sup>2</sup> = 0%; 3 studies, 244 participants; low‐certainty evidence); </p> </li> <li> <p>hyperactivity (RR 1.93, 95% CI 0.47 to 7.82; I<sup>2</sup> = 67%; 2 studies, 207 participants; low‐certainty evidence); </p> </li> <li> <p>increased speech (RR 2.08, 95% CI 0.66 to 6.62; I<sup>2</sup> = NA; 1 study, 149 participants; low‐certainty evidence); </p> </li> <li> <p>insomnia (RR 1.19, 95% CI 0.87 to 1.63; I<sup>2</sup> = 18%; 7 studies, 449 participants; low‐certainty evidence); </p> </li> <li> <p>mood disturbance (RR 1.32, 95% CI 0.75 to 2.31; I<sup>2</sup> = NA; 1 study, 165 participants; low‐certainty evidence); </p> </li> <li> <p>mood lability (RR 0.69, 95% CI 0.27 to 1.74; I<sup>2</sup> = 2%; 2 studies, 167 participants; low‐certainty evidence); </p> </li> <li> <p>numbness (RR 2.09, 95% CI 0.09 to 48.04; I<sup>2</sup> = NA; 1 study, 37 participants; low‐certainty evidence); </p> </li> <li> <p>restlessness (RR 1.93, 95% CI 0.82 to 4.57; I<sup>2</sup> = NA; 1 study, 149 participants; low‐certainty evidence); </p> </li> <li> <p>sedation (RR 1.91, 95% CI 0.77 to 4.72; I<sup>2</sup> = 0%; 3 studies, 117 participants; low‐certainty evidence); </p> </li> <li> <p>sleep disturbance (RR 1.24, 95% CI 0.31 to 4.92; I<sup>2</sup> = 75%; 2 studies, 223 participants; low‐certainty evidence); </p> </li> <li> <p>tremor (RR 2.56, 95% CI 0.57 to 11.60; I<sup>2</sup> = 0%; 3 studies, 85 participants; low‐certainty evidence); </p> </li> <li> <p>twitching (RR 7.00, 95% CI 0.44 to 111.91; I<sup>2</sup> = NA; 1 study, 12 participants; low‐certainty evidence); or </p> </li> <li> <p>vertigo (RR 2.09, 95% CI 0.09 to 48.04; I<sup>2</sup> = NA; 1 study, 37 participants; low‐certainty evidence). </p> </li> </ul> </p> <p>There may be evidence of higher levels of decreased attention in the antidepressant group (RR 4.16, 95% CI 1.07 to 16.11; I<sup>2</sup> = 0%; 2 studies, 207 participants; low‐certainty evidence; <a href="./references#CD011769-fig-0071" title="">Analysis 4.7</a>). </p> <p>As there were more than 10 studies in this analysis, we created a funnel plot for this outcome (<a href="#CD011769-fig-0009">Figure 9</a>) but found no evidence of asymmetry. </p> <div class="figure" id="CD011769-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="log: logarithm; RR: risk ratio; SE: standard error; SMD: standardised mean differenceAntidepressant versus placebo (4 studies, 243 participants; Analysis 4.7)" data-id="CD011769-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>log:</b> logarithm; <b>RR:</b> risk ratio; <b>SE:</b> standard error; <b>SMD:</b> standardised mean difference </p> <p>Antidepressant versus placebo (4 studies, 243 participants; <a href="./references#CD011769-fig-0071" title="">Analysis 4.7</a>) </p> </div> </div> </div> </section> <section id="CD011769-sec-0196"> <p><b>Psychological</b></p> <p>There was no clear evidence of a difference between antidepressant and placebo groups in the likelihood of: </p> <p> <ul id="CD011769-list-0099"> <li> <p>anorexia (RR 1.58, 95% CI 0.53 to 4.74; I<sup>2</sup> = NA; 1 study, 39 participants; very low‐certainty evidence); </p> </li> <li> <p>anxiety/nervousness (RR 0.66, 95% CI 0.37 to 1.18; I<sup>2</sup> = 0%; 2 studies, 188 participants; very low‐certainty evidence); </p> </li> <li> <p>depression (RR 1.36, 95% CI 0.14 to 13.72; I<sup>2</sup> = NA; 1 study, 37 participants; very low‐certainty evidence); </p> </li> <li> <p>self‐injury (dichotomous) (RR 1.25, 95% CI 0.09 to 17.02; I<sup>2</sup> = NA; 1 study, 18 participants, very low‐certainty evidence), </p> </li> <li> <p>silliness (RR 0.94, 95% CI 0.40 to 2.17; I<sup>2</sup> = NA; 1 study, 149 participants); very low‐certainty evidence; </p> </li> <li> <p>suicidal ideation (RR 2.09, 95% CI 0.09 to 48.04; I<sup>2</sup> = NA; 1 study, 37 participants; very low‐certainty evidence); </p> </li> <li> <p>unstable mood (RR 0.81, 95% CI 0.32 to 2.06; I<sup>2</sup> = NA; 1 study, 149 participants; very low‐certainty evidence); </p> </li> <li> <p>verbal aggression (RR 0.23, 95% CI 0.01 to 5.34; I<sup>2</sup> = NA; 1 study, 37 participants; very low‐certainty evidence); or </p> </li> <li> <p>vivid or bad dreams (RR 4.87, 95% CI 0.27 to 87.94; I<sup>2</sup> = NA; 1 study, 37 participants; very low‐certainty evidence). </p> </li> </ul> </p> <p>There may be evidence in the antidepressant group of increased rates of:</p> <p> <ul id="CD011769-list-0100"> <li> <p>impulsive/intrusive behaviour (RR 2.92, 95% CI 1.11 to 7.68; I<sup>2</sup> = NA; 1 study, 149 participants; very low‐certainty evidence); and </p> </li> <li> <p>stereotypy (RR 8.33, 95% CI 1.07 to 64.95; I<sup>2</sup> = NA; 1 study, 149 participants; very low‐certainty evidence; <a href="./references#CD011769-fig-0072" title="">Analysis 4.8</a>) </p> </li> </ul> </p> <p>although the evidence is very uncertain.</p> <p>As there were more than 10 studies in this analysis, we created a funnel plot for this outcome but found no evidence of asymmetry (<a href="#CD011769-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD011769-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="log: logarithm; RR: risk ratio; SE: standard error; SMD: standardised mean differenceAntidepressant versus placebo (4 studies, 243 participants; Analysis 4.8)" data-id="CD011769-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-10.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>log:</b> logarithm; <b>RR:</b> risk ratio; <b>SE:</b> standard error; <b>SMD:</b> standardised mean difference </p> <p>Antidepressant versus placebo (4 studies, 243 participants; <a href="./references#CD011769-fig-0072" title="">Analysis 4.8</a>) </p> </div> </div> </div> </section> <section id="CD011769-sec-0197"> <p><b>Respiratory</b></p> <p>There was no clear evidence of a difference between antidepressant and placebo groups in: </p> <p> <ul id="CD011769-list-0101"> <li> <p>overall respiratory effects (RR 2.19, 95% CI 0.86 to 5.55; I<sup>2</sup> = 0%; 2 studies, 314 participants); </p> </li> <li> <p>upper respiratory infection (RR 0.98, 95% CI 0.73 to 1.31; I<sup>2</sup> = 0%; 2 studies, 216 participants; or </p> </li> <li> <p>cough (RR 1.67, 95% CI 0.52 to 5.39; 1 study, 18 participants; <a href="./references#CD011769-fig-0073" title="">Analysis 4.9</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0198"> <p><b>Skin</b></p> <p>There was no clear evidence of a difference between antidepressant and placebo groups in the likelihood of rash or skin irritation (RR 1.00, 95% CI 0.36 to 2.78; I<sup>2</sup> = 74%; 3 studies, 332 participants; <a href="./references#CD011769-fig-0074" title="">Analysis 4.10</a>). </p> </section> <section id="CD011769-sec-0199"> <p><b>Urinary</b></p> <p>There was no clear evidence of a difference in:</p> <p> <ul id="CD011769-list-0102"> <li> <p>enuresis (RR 3.13, 95% CI 0.81 to 12.06; I<sup>2</sup> = NA; 1 study, 18 participants); </p> </li> <li> <p>polyuria (RR 2.09, 95% CI 0.09 to 48.04; I<sup>2</sup> = NA; 1 study, 37 participants); or </p> </li> <li> <p>urinary tract infection (RR 0.60, 95% CI 0.21 to 1.73; I<sup>2</sup> = NA; 1 study, 39 participants; <a href="./references#CD011769-fig-0075" title="">Analysis 4.11</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0200"> <p><b>Other adverse effects</b></p> <p>There was no clear evidence of a difference in:</p> <p> <ul id="CD011769-list-0103"> <li> <p>salty taste (RR 2.09, 95% CI 0.09 to 48.04; I<sup>2</sup> = NA; 1 study, 37 participants); or </p> </li> <li> <p>mild trembling (RR 2.09, 95% CI 0.09 to 48.04; I<sup>2</sup> = NA; 1 study, 37 participants; <a href="./references#CD011769-fig-0076" title="">Analysis 4.12</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD011769-sec-0201"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0202"> <h6 class="title">Tolerability/acceptability</h6> <p>Loss to follow‐up was not different in the antidepressant group compared to the placebo group (RR 1.22, 95% CI 0.93 to 1.59; I<sup>2</sup> = 0%; 7 studies, 564 participants; <a href="./references#CD011769-fig-0077" title="">Analysis 4.13</a>). </p> <section id="CD011769-sec-0203"> <p><b>Outcomes not reported</b></p> <p>No data were available for the outcome of quality of life.</p> </section> </section> </section> </section> <section id="CD011769-sec-0204"> <h4 class="title">Atypical versus typical antipsychotics</h4> <section id="CD011769-sec-0205"> <h5 class="title">Challenging behaviours</h5> <section id="CD011769-sec-0206"> <h6 class="title">Irritability</h6> <p>There was no clear evidence of differences in irritability at endpoint when atypical antipsychotics were compared to typical antipsychotics (SMD −0.23, 95% CI −0.95 to 0.48; I<sup>2</sup> = NA; 1 study, 30 participants; <a href="./references#CD011769-fig-0080" title="">Analysis 5.1</a>). </p> <p>There were insufficient studies (1 study) to conduct subgroup analyses.</p> </section> </section> <section id="CD011769-sec-0207"> <h5 class="title">Adverse effects</h5> <section id="CD011769-sec-0208"> <h6 class="title">Cardiovascular</h6> <p>There was no clear evidence of a difference between groups in tachycardia when atypical antipsychotics (olanzapine) were compared to typical antipsychotics (haloperidol) (RR 0.33, 95% CI 0.02 to 6.86; I<sup>2</sup> = NA; 1 study 12 participants; <a href="./references#CD011769-fig-0081" title="">Analysis 5.2</a>). </p> </section> <section id="CD011769-sec-0209"> <h6 class="title">Gastrointestinal</h6> <p>There was no clear evidence of differences in:</p> <p> <ul id="CD011769-list-0104"> <li> <p>constipation (RR 1.00, 95% CI 0.24 to 4.18; I<sup>2</sup> = NA; 1 study, 30 participants); </p> </li> <li> <p>dry mouth (RR 1.00, 95% CI 0.08 to 12.56; I<sup>2</sup> = NA; 1 study, 12 participants); or </p> </li> <li> <p>nausea/vomiting (RR 5.00, 95% CI 0.29 to 86.43; I<sup>2</sup> = NA; 1 study, 12 participants; <a href="./references#CD011769-fig-0082" title="">Analysis 5.3</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0210"> <h6 class="title">Metabolic</h6> <p>There was no difference between atypical antipsychotics (olanzapine) compared to typical antipsychotics (haloperidol) in: </p> <p> <ul id="CD011769-list-0105"> <li> <p>weight gain (RR 1.18, 95% CI 0.76 to 1.83; I<sup>2</sup> = NA; 1 study, 12 participants); and </p> </li> <li> <p>weight loss (RR 0.33, 95% CI 0.02 to 6.86; I<sup>2</sup> = NA; 1 study, 12 participants; <a href="./references#CD011769-fig-0083" title="">Analysis 5.4</a>). </p> </li> </ul> </p> <p>There was also no change in weight (SMD 0.26 kg, 95% CI −1.54 to 2.06; I<sup>2</sup> = 83%; 2 studies, 42 participants; <a href="./references#CD011769-fig-0084" title="">Analysis 5.5</a>). </p> </section> <section id="CD011769-sec-0211"> <h6 class="title">Neurological</h6> <p>There was no clear evidence of a difference between those receiving typical and atypical antipsychotics in the neurological AEs: </p> <p> <ul id="CD011769-list-0106"> <li> <p>ataxia (RR 0.33, 95% CI 0.02 to 6.86; I<sup>2</sup> = NA; 1 study, 12 participants); </p> </li> <li> <p>blunted effect (RR 0.11, 95% CI 0.01 to 1.90; I<sup>2</sup> = NA; 1 study, 30 participants); </p> </li> <li> <p>insomnia (RR 3.00, 95% CI 0.15 to 61.74; I<sup>2</sup> = NA; 1 study, 12 participants); </p> </li> <li> <p>rigidity (RR 0.33, 95% CI 0.02 to 6.86; I<sup>2</sup> = NA; 1 study, 12 participants); or </p> </li> <li> <p>sedation (RR 2.50, 95% CI 0.76 to 8.19; I<sup>2</sup> = NA; 1 study, 12 participants; <a href="./references#CD011769-fig-0085" title="">Analysis 5.6</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0212"> <h6 class="title">Respiratory</h6> <p>There was no clear evidence of a difference between participants receiving typical (haloperidol) and atypical antipsychotics (risperidone) in the likelihood of respiratory tract infection (RR 0.88, 95% CI 0.43 to 1.80; 1 study, 30 participants; <a href="./references#CD011769-fig-0086" title="">Analysis 5.7</a>). </p> </section> <section id="CD011769-sec-0213"> <h6 class="title">Skin</h6> <p>There was no clear difference in rash between typical and atypical antipsychotic groups (RR 0.33, 95% CI 0.02 to 6.86; I<sup>2</sup> = NA; 1 study, 12 participants; <a href="./references#CD011769-fig-0087" title="">Analysis 5.8</a>). </p> </section> <section id="CD011769-sec-0214"> <h6 class="title">Urinary</h6> <p>Enuresis was not different between groups (RR 1.00, 95% CI 0.29 to 3.48; I<sup>2</sup> = 0%; 2 studies, 42 participants; <a href="./references#CD011769-fig-0088" title="">Analysis 5.9</a>). </p> </section> </section> <section id="CD011769-sec-0215"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0216"> <h6 class="title">Tolerability/acceptability</h6> <p>There was no clear evidence of a difference between groups in follow‐up (RR 5.00, 95% CI 0.26 to 96.13; P = 0.29, I<sup>2</sup> = 0%; 2 studies, 42 participants; <a href="./references#CD011769-fig-0089" title="">Analysis 5.10</a>). </p> </section> <section id="CD011769-sec-0217"> <h6 class="title">Outcomes not reported</h6> <p>No data were available for the outcomes of aggression, self‐injury and quality of life, or immune, musculoskeletal, psychological, or other AEs. </p> </section> </section> </section> <section id="CD011769-sec-0218"> <h4 class="title">Atypical antipsychotics versus atypical antipsychotics</h4> <section id="CD011769-sec-0219"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0220"> <h6 class="title">Challenging behaviours</h6> <section id="CD011769-sec-0221"> <p><b>Irritability</b></p> <p>Compared to risperidone, there was evidence of an increased risk of irritability in the aripiprazole group at endpoint (SMD 0.40, 95% CI 0.02 to 0.78; P = 0.92, I<sup>2</sup> = 0%; 2 studies, 110 participants; <a href="./references#CD011769-fig-0090" title="">Analysis 6.1</a>). </p> <p>There was insufficient information to conduct subgroup analyses of irritability by age, gender, communication ability, or cognitive ability. </p> </section> </section> <section id="CD011769-sec-0222"> <h6 class="title">Adverse effects</h6> <section id="CD011769-sec-0223"> <p><b>Cardiovascular</b></p> <p>There was no clear evidence of a difference between different types of atypical antipsychotics in the likelihood of tachycardia (RR 1.07, 95% CI 0.16 to 7.04; I<sup>2</sup> = 0%; 2 studies, 120 participants; <a href="./references#CD011769-fig-0091" title="">Analysis 6.2</a>). </p> </section> <section id="CD011769-sec-0224"> <p><b>Gastrointestinal</b></p> <p>There was no clear evidence of differences between atypical antipsychotics in any of the gastrointestinal side effects: </p> <p> <ul id="CD011769-list-0107"> <li> <p>abdominal pain (RR 3.10, 95% CI 0.34 to 28.15; 1 study, 59 participants);</p> </li> <li> <p>constipation (RR 1.30, 95% CI 0.34 to 4.91; I<sup>2</sup> = 0%; 2 studies, 120 participants); </p> </li> <li> <p>diarrhoea (RR 3.10, 95% CI 0.13 to 73.14; 1 study, 59 participants);</p> </li> <li> <p>drooling (RR 0.72, 95% CI 0.38 to 1.37; I<sup>2</sup> = 0%; 2 studies, 120 participants); </p> </li> <li> <p>dry mouth (RR 5.17, 95% CI 0.26 to 103.21; 1 study, 59 participants);</p> </li> <li> <p>nausea (RR 0.52, 95% CI 0.05 to 5.40; 1 study, 59 participants); and</p> </li> <li> <p>vomiting (RR 1.61, 95% CI 0.20 to 12.65; I<sup>2</sup> = 0%; 2 studies, 120 participants; <a href="./references#CD011769-fig-0092" title="">Analysis 6.3</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0225"> <p><b>Metabolic</b></p> <p>There was no clear evidence of a difference between groups in:</p> <p> <ul id="CD011769-list-0108"> <li> <p>decreased appetite (RR 1.67, 95% CI 0.56 to 4.96; I<sup>2</sup> = 0%; 2 studies, 120 participants); and </p> </li> <li> <p>increased appetite (RR 0.61, 95% CI 0.15 to 2.47; I<sup>2</sup> = 30%; 2 studies, 120 participants). </p> </li> </ul> </p> <p>However, there was a reduced risk of weight gain in the aripiprazole group when compared to risperidone (RR 0.37, 95% CI 0.19 to 0.70; 1 study, 61 participants; <a href="./references#CD011769-fig-0093" title="">Analysis 6.4</a>). </p> </section> <section id="CD011769-sec-0226"> <p><b>Musculoskeletal</b></p> <p>There was no clear evidence of a difference between groups in muscle rigidity (RR 2.91, 95% CI 0.12 to 68.66; 1 study, 61 participants; <a href="./references#CD011769-fig-0094" title="">Analysis 6.5</a>). </p> </section> <section id="CD011769-sec-0227"> <p><b>Neurological</b></p> <p>There was no clear evidence of differences in neurological side effects including:</p> <p> <ul id="CD011769-list-0109"> <li> <p>agitation (RR 4.84, 95% CI 0.24 to 96.89; 1 study, 61 participants);</p> </li> <li> <p>difficulty sleeping (RR 6.78, 95% CI 0.37 to 125.95; 1 study, 61 participants);</p> </li> <li> <p>dizziness (RR 0.73, 95% CI 0.10 to 5.39; I<sup>2</sup> = 15%; 2 studies, 120 participants); </p> </li> <li> <p>fatigue (RR 1.03, 95% CI 0.29 to 3.75; 1 study, 59 participants);</p> </li> <li> <p>headache (RR 0.97, 95% CI 0.06 to 14.78; 1 study, 61 participants);</p> </li> <li> <p>nausea (RR 2.91, 95% CI 0.12 to 68.66; 1 study, 61 participants);</p> </li> <li> <p>nervousness (RR 2.07, 95% CI 0.20 to 21.60; 1 study, 59 participants);</p> </li> <li> <p>restlessness (RR 0.44, 95% CI 0.07 to 2.88; I<sup>2</sup> = 0%; 2 studies, 120 participants); </p> </li> <li> <p>sedation (RR 3.39, 95% CI 0.76 to 15.02; 1 study, 61 participants);</p> </li> <li> <p>somnolence (RR 8.72, 95% CI 0.49 to 155.27; 1 study, 61 participants); or</p> </li> <li> <p>tremor (RR 1.55, 95% CI 0.28 to 8.62; 1 study, 59 participants; <a href="./references#CD011769-fig-0095" title="">Analysis 6.6</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0228"> <p><b>Psychological</b></p> <p>There was no clear evidence of a difference in depression when different atypical antipsychotics were compared (RR 0.34, 95% CI 0.01 to 8.13; 1 study, 59 participants; <a href="./references#CD011769-fig-0096" title="">Analysis 6.7</a>). </p> </section> <section id="CD011769-sec-0229"> <p><b>Skin</b></p> <p>The likelihood of rash was not different when different atypical antipsychotics were compared (RR 1.03, 95% CI 0.07 to 15.77; 1 study, 59 participants; <a href="./references#CD011769-fig-0097" title="">Analysis 6.8</a>). </p> </section> <section id="CD011769-sec-0230"> <p><b>Urinary</b></p> <p>Enuresis did not differ between atypical antipsychotic groups (RR 1.37, 95% CI 0.04 to 53.78; I<sup>2</sup> = 68%; 2 studies, 120 participants; <a href="./references#CD011769-fig-0098" title="">Analysis 6.9</a>). </p> </section> </section> </section> <section id="CD011769-sec-0231"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0232"> <h6 class="title">Tolerability/acceptability</h6> <p>There was no clear evidence of a difference in loss to follow‐up between typical and atypical antipsychotic groups (MD 0.71, 95% CI 0.36 to 1.37; 2 studies, 120 participants; P = 0.31, I<sup>2</sup> = 0%; <a href="./references#CD011769-fig-0099" title="">Analysis 6.10</a>). </p> <section id="CD011769-sec-0233"> <p><b>Outcomes not reported</b></p> <p>No data were available for the outcomes of aggression, self‐injury, and quality of life, or immune, respiratory, and other AEs. </p> </section> </section> </section> </section> <section id="CD011769-sec-0234"> <h4 class="title">Atypical antipsychotics versus antidementia medications</h4> <section id="CD011769-sec-0235"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0236"> <h6 class="title">Challenging behaviours</h6> <section id="CD011769-sec-0237"> <p><b>Irritability</b></p> <p>There was no clear evidence of a difference in irritability at endpoint when atypical antipsychotics (risperidone) were compared to antidementia medications (memantine) (SMD 0.46, 95% CI −0.27 to 1.19; 1 study, 30 participants; <a href="./references#CD011769-fig-0100" title="">Analysis 7.1</a>). </p> <p>There were insufficient studies (1) to conduct subgroup analyses.</p> </section> </section> <section id="CD011769-sec-0238"> <h6 class="title">Adverse effects</h6> <section id="CD011769-sec-0239"> <p><b>Neurological</b></p> <p>There was no clear evidence of a difference in somnolence when we compared atypical antipsychotics to antidementia medications (RR 1.30, 95% CI 0.86 to 1.96; 1 study, 30 participants; <a href="./references#CD011769-fig-0101" title="">Analysis 7.2</a>) </p> </section> </section> </section> <section id="CD011769-sec-0240"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0241"> <h6 class="title">Tolerability/acceptability</h6> <p>There was no clear evidence of a difference in loss to follow‐up between atypical antipsychotic and antidementia groups (RR 0.38, 95% CI 0.04 to 3.25; 1 study, 34 participants; <a href="./references#CD011769-fig-0102" title="">Analysis 7.3</a>). </p> <section id="CD011769-sec-0242"> <p><b>Outcomes not reported</b></p> <p>No data were available for the outcomes of aggression, self‐injury, and quality of life, or cardiovascular, gastrointestinal, immune, metabolic, musculoskeletal, psychological, respiratory, skin, urinary, or other AEs. </p> </section> </section> </section> </section> <section id="CD011769-sec-0243"> <h4 class="title">Atypical antipsychotics versus antiparkinsonians</h4> <section id="CD011769-sec-0244"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0245"> <h6 class="title">Challenging behaviours</h6> <p>None of the studies reported these outcomes.</p> </section> </section> <section id="CD011769-sec-0246"> <h5 class="title">Adverse effects</h5> <section id="CD011769-sec-0247"> <h6 class="title">Gastrointestinal</h6> <p>There was no clear evidence of a difference in any of the gastrointestinal side effects when atypical antipsychotics (amulsipride) were compared to antiparkinsonians (bromocriptine): </p> <p> <ul id="CD011769-list-0110"> <li> <p>diarrhoea (RR 3.00, 95% CI 0.14 to 65.16; 1 study, 9 participants);</p> </li> <li> <p>increased salivation (RR 3.00, 95% CI 0.14 to 65.16; 1 study, 9 participants); or</p> </li> <li> <p>vomiting (RR 0.20, 95% CI 0.01 to 3.66; 1 study, 9 participants; <a href="./references#CD011769-fig-0103" title="">Analysis 8.1</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0248"> <h6 class="title">Metabolic</h6> <p>There was no clear evidence of a difference between those receiving atypical antipsychotics and antiparkinsonian medications in decreased appetite (RR 0.09, 95% CI 0.01 to 1.44; 1 study, 9 participants; <a href="./references#CD011769-fig-0104" title="">Analysis 8.2</a>). </p> </section> <section id="CD011769-sec-0249"> <h6 class="title">Neurological</h6> <p>There was no clear evidence of a difference between those receiving atypical antipsychotics and antiparkinsonian medications in any of the neurological side effects: agitation/ excitement (RR 1.50, 95% CI 0.32 to 6.94; 1 study, 9 participants); increased hyperactivity (RR 7.00, 95% CI 0.41 to 118.69; 1 study, 9 participants); insomnia (RR 2.00, 95% CI 0.48 to 8.31; 1 study, 9 participants); or sedation (RR 0.14, 95% CI 0.01 to 2.42; 1 study, 9 participants) <a href="./references#CD011769-fig-0105" title="">Analysis 8.3</a>. </p> </section> </section> <section id="CD011769-sec-0250"> <h5 class="title">Secondary outcomes</h5> <p>None of the studies reported these outcomes.</p> <section id="CD011769-sec-0251"> <h6 class="title">Outcomes not reported</h6> <p>No data were available for the outcomes of irritability, aggression, self‐injury, quality of life, or tolerability/acceptability, and cardiovascular, immune, musculoskeletal, psychological, respiratory, skin, urinary, and other AEs. </p> </section> </section> </section> <section id="CD011769-sec-0252"> <h4 class="title">Anticonvulsants versus placebo</h4> <section id="CD011769-sec-0253"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0254"> <h6 class="title">Challenging behaviours</h6> <section id="CD011769-sec-0255"> <p><b>Irritability</b></p> <p>There was no clear evidence of a difference in measures of irritability at endpoint between participants receiving anticonvulsants and those receiving placebo (SMD −0.67, 95% CI −1.93 to 0.59; P = 0.30, I<sup>2</sup> = 88%; 3 studies, 97 participants; <a href="./references#CD011769-fig-0106" title="">Analysis 9.1</a>). </p> <p>There was insufficient information to conduct subgroup analyses of irritability by age, gender, communication ability, or cognitive ability. </p> </section> <section id="CD011769-sec-0256"> <p><b>Aggression</b></p> <p>There was no clear evidence of a difference in measures of aggression at endpoint between participants receiving anticonvulsants and those receiving placebo (SMD −0.18, 95% CI −0.71 to 0.35; I<sup>2</sup> = 0%; 2 studies, 57 participants; <a href="./references#CD011769-fig-0107" title="">Analysis 9.2</a>). </p> <p>There was insufficient information to conduct subgroup analyses of aggression by age, gender, communication ability, or cognitive ability. </p> </section> </section> <section id="CD011769-sec-0257"> <h6 class="title">Adverse effects</h6> <section id="CD011769-sec-0258"> <p><b>Gastrointestinal</b></p> <p>There was no clear evidence of a difference between anticonvulsants and placebo groups in: </p> <p> <ul id="CD011769-list-0111"> <li> <p>abdominal pain (RR 1.75, 95% CI 0.38 to 8.15; 1 study 30 participants);</p> </li> <li> <p>constipation (RR 0.58, 95% CI 0.11 to 3.00; 1 study, 30 participants);</p> </li> <li> <p>diarrhoea (RR 3.50, 95% CI 0.44 to 27.75; 1 study, 30 participants);</p> </li> <li> <p>nausea (RR 2.32, 95% CI 0.80 to 6.72; I<sup>2</sup> = 0%; 2 studies, 70 participants); or </p> </li> <li> <p>vomiting (RR 3.50, 95% CI 0.44 to 27.75; 1 study, 30 participants; <a href="./references#CD011769-fig-0108" title="">Analysis 9.3</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0259"> <p><b>Immune system</b></p> <p>There was no difference between anticonvulsant and placebo groups in:</p> <p> <ul id="CD011769-list-0112"> <li> <p>chills (RR 2.63, 95% CI 0.31 to 22.46; 1 study, 30 participants); or</p> </li> <li> <p>fever (RR 3.50, 95% CI 0.44 to 27.75; 1 study, 30 participants; <a href="./references#CD011769-fig-0109" title="">Analysis 9.4</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0260"> <p><b>Metabolic</b></p> <p>There were higher rates of decreased appetite in anticonvulsant groups when compared to placebo groups (RR 5.45, 95% CI 1.02 to 29.23; I<sup>2</sup> = 0%; 2 studies, 60 participants). </p> <p>There was no clear evidence of a difference between anticonvulsant and placebo groups in: </p> <p> <ul id="CD011769-list-0113"> <li> <p>increased appetite (RR 0.99, 95% CI 0.05 to 18.14; I<sup>2</sup> = 82%; 2 studies, 70 participants); </p> </li> <li> <p>weight gain (RR 1.48, 95% CI 0.61 to 3.62; I<sup>2</sup> = 0%; 3 studies, 77 participants); </p> </li> <li> <p>weight loss (RR 3.00, 95% CI 0.14 to 65.90; 1 study, 20 participants; <a href="./references#CD011769-fig-0110" title="">Analysis 9.5</a>); or </p> </li> <li> <p>weight gain in kilograms (SMD 0.48 kg, 95% CI −0.77 to 1.74; 1 study, 11 participants; <a href="./references#CD011769-fig-0111" title="">Analysis 9.6</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0261"> <p><b>Neurological</b></p> <p>There was no clear evidence of a difference between anticonvulsant and placebo groups in any of the neurological AEs: </p> <p> <ul id="CD011769-list-0114"> <li> <p>aggression (dichotomous) (RR 2.29, 95% CI 0.37 to 14.12; 2 studies, 48 participants);</p> </li> <li> <p>agitation (RR 1.20, 95% CI 0.21 to 6.70; I<sup>2</sup> = 0%; 2 studies, 47 participants); </p> </li> <li> <p>dizziness (RR 4.00, 95% CI 0.49 to 32.72; 1 study, 40 participants);</p> </li> <li> <p>drowsiness (RR 0.88, 95% CI 0.21 to 3.66; 1 study, 30 participants);</p> </li> <li> <p>echolalia (RR 1.00, 95% CI 0.07 to 14.45; 1 study, 28 participants);</p> </li> <li> <p>headache (RR 2.12, 95% CI 0.09 to 47.68; 1 study, 27 participants);</p> </li> <li> <p>hyperactivity (RR 3.00, 95% CI 0.14 to 65.90; 1 study, 20 participants);</p> </li> <li> <p>hypersomnolence (RR 0.10, 95% CI 0.01 to 1.78; 1 study, 27 participants);</p> </li> <li> <p>insomnia (RR 1.69, 95% CI 0.44 to 6.56; I<sup>2</sup> = 25%; 4 studies, 115 participants); </p> </li> <li> <p>lethargy (RR 6.18, 95% CI 0.35 to 110.11; 1 study, 30 participants);</p> </li> <li> <p>paresthesia (RR 5.00, 95% CI 0.64 to 39.06; 1 study 40 participants);</p> </li> <li> <p>sedation (RR 0.25, 95% CI 0.03 to 2.05, 1 study, 40 participants);</p> </li> <li> <p>self‐injurious behaviour (dichotomous) (RR 3.00, 95% CI 0.14 to 65.90; 1 study, 20 participants); or </p> </li> <li> <p>somnolence (RR 7.00, 95% CI 0.95 to 51.80; 1 study, 20 participants; <a href="./references#CD011769-fig-0112" title="">Analysis 9.7</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0262"> <p><b>Psychological</b></p> <p>There was no clear evidence of a difference in impulsivity when anticonvulsants were compared to placebo (RR 3.00, 95% CI 0.14 to 65.90; 1 study, 20 participants; <a href="./references#CD011769-fig-0113" title="">Analysis 9.8</a>). </p> </section> <section id="CD011769-sec-0263"> <p><b>Skin</b></p> <p>There was no difference in the risk of rash between anticonvulsant and placebo groups (RR 4.63, 95% CI 0.89 to 24.13; I<sup>2</sup> = 0%; 2 studies, 57 participants; <a href="./references#CD011769-fig-0114" title="">Analysis 9.9</a>). </p> </section> <section id="CD011769-sec-0264"> <p><b>Urinary</b></p> <p>Enuresis was not different between groups (RR 0.33, 95% CI 0.02 to 7.32; 1 study, 20 participants; <a href="./references#CD011769-fig-0115" title="">Analysis 9.10</a>). </p> </section> </section> </section> <section id="CD011769-sec-0265"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0266"> <h6 class="title">Tolerability/acceptability</h6> <p>There was no clear evidence of a difference in loss to follow‐up between anticonvulsants and placebo groups (RR 1.98, 95% CI 0.84 to 4.66; I² = 0%; 6 studies, 167 participants; <a href="./references#CD011769-fig-0116" title="">Analysis 9.11</a>). </p> <section id="CD011769-sec-0267"> <p><b>Outcomes not reported</b></p> <p>No data were available for the outcomes of self‐injury or quality of life, or cardiovascular, respiratory, musculoskeletal, and other AEs. </p> </section> </section> </section> </section> <section id="CD011769-sec-0268"> <h4 class="title">Antidepressants versus antidepressants</h4> <section id="CD011769-sec-0269"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0270"> <h6 class="title">Challenging behaviours</h6> <section id="CD011769-sec-0271"> <p><b>Irritability</b></p> <p>One study with 36 participants compared two antidepressants, clomipramine and desipramine, but did not report any data on irritability. </p> </section> <section id="CD011769-sec-0272"> <p><b>Aggression</b></p> <p>One study with 36 participants compared two antidepressants, clomipramine and desipramine, but did not report any data on aggression. </p> </section> <section id="CD011769-sec-0273"> <p><b>Self‐injury</b></p> <p>One study with 36 participants compared two antidepressants, clomipramine and desipramine, but did not report any data on self‐injury. </p> </section> </section> <section id="CD011769-sec-0274"> <h6 class="title">Adverse effects</h6> <section id="CD011769-sec-0275"> <p><b>Cardiovascular</b></p> <p>There was no clear evidence of a difference in tachycardia in the one study with 36 participants that compared clomipramine with desipramine (RR 2.60, 95% CI 0.13 to 50.25; 1 study, 24 participants; <a href="./references#CD011769-fig-0117" title="">Analysis 10.1</a>). </p> </section> <section id="CD011769-sec-0276"> <p><b>Gastrointestinal</b></p> <p>There was no clear evidence of a difference in any gastrointestinal AEs when clomipramine was compared to desipramine. The effects that were reported were: </p> <p> <ul id="CD011769-list-0115"> <li> <p>constipation (RR 1.50, 95% CI 0.35 to 6.35; 1 study, 36 participants);</p> </li> <li> <p>dry mouth (RR 0.50, 95% CI 0.12 to 2.12; 1 study, 36 participants);</p> </li> <li> <p>nausea/abdominal pain (RR 1.00, 95% CI 0.10 to 9.96; 1 study, 36 participants); and</p> </li> <li> <p>vomiting (RR 1.56, 95% CI 0.07 to 35.67; 1 study, 36 participants; <a href="./references#CD011769-fig-0118" title="">Analysis 10.2</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD011769-sec-0277"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0278"> <h6 class="title">Quality of life</h6> <p>One study with 36 participants compared two antidepressants, clomipramine and desipramine, but did not report any data on quality of life. </p> </section> <section id="CD011769-sec-0279"> <h6 class="title">Tolerability/acceptability</h6> <p>One study with 36 participants compared two antidepressants, clomipramine and desipramine, but did not report any data on loss to follow‐up. </p> <section id="CD011769-sec-0280"> <p><b>Outcomes not reported</b></p> <p>No data were available for the outcomes of irritability, aggression, or self‐injury, or immune, metabolic, musculoskeletal, neurological, psychological, respiratory, skin, urinary, and other AEs, or quality of life, and tolerability/acceptability. </p> </section> </section> </section> </section> <section id="CD011769-sec-0281"> <h4 class="title">Antidementia interventions versus placebo or other treatment</h4> <section id="CD011769-sec-0282"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0283"> <h6 class="title">Challenging behaviours</h6> <section id="CD011769-sec-0284"> <p><b>Irritability</b></p> <p>There was no clear evidence of a difference in continuous irritability scores at endpoint when antidementia medications were compared to placebo (SMD −0.40, 95% CI −1.31 to 0.52; I<sup>2</sup> = 83%; 3 studies, 140 participants; <a href="./references#CD011769-fig-0119" title="">Analysis 11.1</a>). </p> <p>There was also no clear evidence of a difference in partial response (≥ 25% reduction in irritability score; RR 1.38, 95% CI 0.97 to 1.97; 1 study, 40 participants); or complete response (≥ 50% reduction in irritability score; RR 1.60, 95% CI 0.98 to 2.61; 1 study, 40 participants); or dichotomous irritability (RR 0.51, 95% CI 0.16 to 1.66; 1 study, 317 participants; <a href="./references#CD011769-fig-0120" title="">Analysis 11.2</a>). </p> <p>There was no clear evidence of a difference between groups when children were compared to adults (P = 0.40). There was insufficient information to conduct subgroup analyses of irritability by gender, communication ability, or cognitive ability. </p> </section> <section id="CD011769-sec-0285"> <p><b>Aggression</b></p> <p>There was no clear evidence of a difference in aggression at endpoint when antidementia medications were compared to placebo (SMD 0.54, 95% CI ‐0.05 to 1.13; 1 study, 50 participants; <a href="./references#CD011769-fig-0121" title="">Analysis 11.3</a>). </p> <p>There were insufficient studies (1 study) to conduct a subgroup analysis.</p> </section> </section> <section id="CD011769-sec-0286"> <h6 class="title">Adverse effects</h6> <section id="CD011769-sec-0287"> <p><b>Gastrointestinal</b></p> <p>Gastrointestinal AEs were not increased in the group receiving antidementia medications. The reported gastrointestinal effects were: </p> <p> <ul id="CD011769-list-0116"> <li> <p>abdominal pain (RR 0.97, 95% CI 0.21 to 4.50; I<sup>2</sup> = 0%; 2 studies, 83 participants); </p> </li> <li> <p>constipation (RR 0.33, 95% CI 0.04 to 3.01; I<sup>2</sup> = 0%; 2 studies, 83 participants); </p> </li> <li> <p>diarrhoea (RR 2.87, 95% CI 0.12 to 66.75; 1 study, 43 participants);</p> </li> <li> <p>dry mouth (RR 0.14, 95% CI 0.01 to 2.60; 1 study, 40 participants);</p> </li> <li> <p>gastroenteritis (RR 7.13, 95% CI 0.37 to 136.97; 1 study, 317 participants);</p> </li> <li> <p>nausea (RR 2.00, 95% CI 0.41 to 9.71; 1 study, 40 participants);</p> </li> <li> <p>vomiting (RR 0.54, 95% CI 0.18 to 1.67; I<sup>2</sup> = 0%; 2 studies, 438 participants; <a href="./references#CD011769-fig-0122" title="">Analysis 11.4</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0288"> <p><b>Metabolic</b></p> <p>There was no clear evidence of a difference in the effects of antidementia medications on: </p> <p> <ul id="CD011769-list-0117"> <li> <p>decreased appetite (RR 0.99, 95% CI 0.24 to 4.07; I<sup>2</sup> = 0%; 4 studies, 163 participants); or </p> </li> <li> <p>increased appetite (RR 1.14, 95% CI 0.54 to 2.43; I<sup>2</sup> = 0%; 4 studies, 163 participants; <a href="./references#CD011769-fig-0123" title="">Analysis 11.5</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0289"> <p><b>Musculoskeletal</b></p> <p>There was no clear evidence of a difference in effects of antidementia medications compared to placebo on musculoskeletal pain (RR 0.32, 95% CI 0.01 to 7.42; 1 study, 43 participants; <a href="./references#CD011769-fig-0124" title="">Analysis 11.6</a>). </p> </section> <section id="CD011769-sec-0290"> <p><b>Neurological</b></p> <p>Neurological AEs were not different between participants receiving antidementia medications and those receiving placebo. The neurological AEs that were reported included: </p> <p> <ul id="CD011769-list-0118"> <li> <p>daytime drowsiness (RR 0.85, 95% CI 0.41 to 1.77; I<sup>2</sup> = 0%; 2 studies, 80 participants); </p> </li> <li> <p>decreased energy (RR 0.37, 95% CI 0.09 to 1.52, 1 study, 23 participants);</p> </li> <li> <p>dizziness (RR 0.99, 95% CI 0.27 to 3.61; I<sup>2</sup> = 0%; 2 studies, 83 participants); </p> </li> <li> <p>fatigue (RR 1.39, 95% CI 0.48 to 4.02; I<sup>2</sup> = 0%; 2 studies, 83 participants); </p> </li> <li> <p>headache (RR 0.85, 95% CI 0.26 to 2.75; I<sup>2</sup> = 0%; 2 studies, 438 participants); </p> </li> <li> <p>hyperactivity (RR 0.35, 95% CI 0.07 to 1.73; I<sup>2</sup> = 0%; 2 studies, 438 participants); </p> </li> <li> <p>insomnia (RR 0.98, 95% CI 0.37 to 2.59; I<sup>2</sup> = 2%; 4 studies, 227 participants); </p> </li> <li> <p>morning drowsiness (RR 1.38, 95% CI 0.71 to 2.68; 1 study, 40 participants);</p> </li> <li> <p>sedation (RR 1.34, 95% CI 0.30 to 5.98; I<sup>2</sup> = 5%; 2 studies, 83 participants); </p> </li> <li> <p>tremor (RR 3.00, 95% CI 0.13 to 69.52; 1 study, 40 participants; <a href="./references#CD011769-fig-0125" title="">Analysis 11.7</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0291"> <p><b>Psychological</b></p> <p>Psychological AEs were not different between participants receiving antidementia medications and those receiving placebo. The psychological AEs that were reported included: </p> <p> <ul id="CD011769-list-0119"> <li> <p>agitation (RR 1.89, 95% CI 0.45 to 8.05; I<sup>2</sup> = 0%; 2 studies, 438 participants); </p> </li> <li> <p>aggression (dichotomous) (RR 1.69, 95% CI 0.42 to 6.78; 1 study, 121 participants);</p> </li> <li> <p>anger (RR 0.31, 95% CI 0.01 to 6.85; 1 study, 23 participants);</p> </li> <li> <p>anxiety (RR 0.41, 95% CI 0.03 to 5.61; I<sup>2</sup> = 67%; 3 studies, 478 participants); </p> </li> <li> <p>emotional lability (RR 1.83, 95% CI 0.19 to 17.51, 1 study, 23 participants);</p> </li> <li> <p>irritability (dichotomous) (RR 0.87, 95% CI 0.43 to 1.76; I<sup>2</sup> = 0%; 3 studies, 461 participants); </p> </li> <li> <p>mood changes (RR 1.68, 95% CI 0.95 to 2.96; 1 study, 23 participants);</p> </li> <li> <p>self‐injurious behaviour (dichotomous) (RR 2.77, 95% CI 0.12 to 61.65, 1 study, 23 participants; <a href="./references#CD011769-fig-0127" title="">Analysis 11.9</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0292"> <p><b>Respiratory</b></p> <p>Respiratory AEs were not different between participants receiving antidementia medications and those receiving placebo. The respiratory AEs that were reported included: </p> <p> <ul id="CD011769-list-0120"> <li> <p>cough (RR 1.83, 95% CI 0.63 to 5.34; I<sup>2</sup> = 0%; 2 studies, 438 participants); and </p> </li> <li> <p>nasopharyngitis (RR 0.61, 95% CI 0.08 to 4.35; I<sup>2</sup> = 51%; 2 studies, 438 participants; <a href="./references#CD011769-fig-0128" title="">Analysis 11.10</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0293"> <p><b>Skin</b></p> <p>There was no difference between participants receiving antidementia medications and those receiving placebo in: </p> <p> <ul id="CD011769-list-0121"> <li> <p>rash (RR 2.00, 95% CI 0.20 to 20.33; 1 study, 40 participants); and</p> </li> <li> <p>skin irritation (RR 0.46, 95% CI 0.15 to 1.40, 1 study, 23 participants; <a href="./references#CD011769-fig-0129" title="">Analysis 11.11</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0294"> <p><b>Other adverse effects</b></p> <p>Other AEs were not different between participants receiving antidementia medications and those receiving placebo. The other AEs reported were: </p> <p> <ul id="CD011769-list-0122"> <li> <p>pyrexia (RR 0.68, 95% CI 0.19 to 2.41; I<sup>2</sup> = 0%; 2 studies, 438 participants); and </p> </li> <li> <p>increased infections (RR 0.69, 95% CI 0.35 to 1.35; 1 study, 23 participants).</p> </li> </ul> </p> </section> </section> </section> <section id="CD011769-sec-0295"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0296"> <h6 class="title">Tolerability/acceptability</h6> <p>There was no clear evidence of a difference in loss to follow‐up between antidementia and placebo groups (RR 0.95, 95% CI 0.83 to 1.09; P = 0.56, I² = 0%; 5 studies, 553 participants; <a href="./references#CD011769-fig-0131" title="">Analysis 11.13</a>). </p> <section id="CD011769-sec-0297"> <p><b>Outcomes not reported</b></p> <p>No data were available for the outcomes of self‐injury, or cardiovascular, immune, and urinary AEs, or quality of life. </p> </section> </section> </section> </section> <section id="CD011769-sec-0298"> <h4 class="title">Antiparkinsonian medications versus placebo or other treatment</h4> <section id="CD011769-sec-0299"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0300"> <h6 class="title">Challenging behaviours</h6> <section id="CD011769-sec-0301"> <p><b>Irritability</b></p> <p>There was a reduction in irritability at endpoint in the one study with 40 participants that compared antiparkinsonians (amantadine) with placebo and reported this outcome (SMD −0.75, 95% CI −1.39 to −0.11; 1 study, 40 participants; <a href="./references#CD011769-fig-0133" title="">Analysis 12.1</a>). </p> <p>There were insufficient studies (1 study) to conduct a subgroup analysis.</p> </section> </section> <section id="CD011769-sec-0302"> <h6 class="title">Adverse effects</h6> <section id="CD011769-sec-0303"> <p><b>Gastrointestinal</b></p> <p>One study with 40 participants reported gastrointestinal AEs. There was no difference between the antiparkinsonian and placebo groups. Gastrointestinal effects reported included: </p> <p> <ul id="CD011769-list-0123"> <li> <p>abdominal pain (RR 0.33, 95% CI 0.01 to 7.72; 1 study, 40 participants);</p> </li> <li> <p>constipation (RR 0.20, 95% CI 0.01 to 3.92; 1 study, 40 participants); and</p> </li> <li> <p>drooling (RR 0.33, 95% CI 0.01 to 7.72; 1 study, 40 participants; <a href="./references#CD011769-fig-0134" title="">Analysis 12.2</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0304"> <p><b>Metabolic</b></p> <p>There was no clear evidence of an effect of antiparkinsonians compared with placebo on: </p> <p> <ul id="CD011769-list-0124"> <li> <p>increased appetite (RR 3.00, 95% CI 0.69 to 13.12; 1 study, 40 participants); or</p> </li> <li> <p>decreased appetite (RR 0.11, 95% CI 0.01 to 1.94; 1 study, 40 participants; <a href="./references#CD011769-fig-0135" title="">Analysis 12.3</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0305"> <p><b>Neurological</b></p> <p>Across two studies that compared antiparkinsonians (amantadine) to placebo, there was no difference in neurological AEs including: </p> <p> <ul id="CD011769-list-0125"> <li> <p>daytime drowsiness (RR 3.00, 95% CI 0.13 to 69.52; 1 study, 40 participants);</p> </li> <li> <p>insomnia (RR 2.26, 95% CI 0.55 to 9.26; I<sup>2</sup> = 0%; 2 studies, 79 participants); </p> </li> <li> <p>nervousness (RR 0.33, 95% CI 0.04 to 2.94; 1 study, 40 participants);</p> </li> <li> <p>somnolence (RR 5.25, 95% CI 0.27 to 102.74; 1 study 39 participants); and</p> </li> <li> <p>tremor (RR 3.00, 95% CI 0.13 to 69.52; 1 study, 40 participants; <a href="./references#CD011769-fig-0136" title="">Analysis 12.4</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0306"> <p><b>Psychological</b></p> <p>There was no evidence of a change in adverse behaviour (dichotomous) (RR 0.53, 95% CI 0.11 to 2.55; 1 study, 39 participants) when antiparkinsonians were compared to placebo (<a href="./references#CD011769-fig-0137" title="">Analysis 12.5</a>). </p> </section> </section> </section> <section id="CD011769-sec-0307"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0308"> <h6 class="title">Tolerability/acceptability</h6> <p>There was no clear evidence of a difference in loss to follow‐up between antiparkinsonian and placebo groups (RR 0.33, 95% CI 0.01 to 7.72, 1 study, 40 participants; <a href="./references#CD011769-fig-0138" title="">Analysis 12.6</a>). </p> </section> <section id="CD011769-sec-0309"> <h6 class="title">Outcomes not reported</h6> <p>No data were available for the outcomes of aggression, self‐injury, quality of life, and cardiovascular, immune, musculoskeletal, respiratory, skin, urinary, and other AEs. </p> </section> </section> </section> <section id="CD011769-sec-0310"> <h4 class="title">Anxiolytic interventions versus placebo or other treatment</h4> <section id="CD011769-sec-0311"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0312"> <h6 class="title">Challenging behaviours</h6> <section id="CD011769-sec-0313"> <p><b>Irritability</b></p> <p>There was no clear evidence of a difference in continuous measures of irritability at endpoint (SMD −0.20, 95% CI −0.88 to 0.47; 1 study, 34 participants; <a href="./references#CD011769-fig-0139" title="">Analysis 13.1</a>), although dichotomous measures of irritability (&gt; 25% decrease in irritability score) showed a reduction in irritability (RR 1.83, 95% CI 1.04 to 3.22; 1 study, 34 participants; <a href="./references#CD011769-fig-0140" title="">Analysis 13.2</a>) when anxiolytics were compared to placebo. </p> <p>There were insufficient studies (1 study) to conduct a subgroup analysis.</p> </section> </section> <section id="CD011769-sec-0314"> <h6 class="title">Adverse effects</h6> <section id="CD011769-sec-0315"> <p><b>Gastrointestinal</b></p> <p>There was no clear evidence of differences between anxiolytics and placebo in any of the gastrointestinal AEs: </p> <p> <ul id="CD011769-list-0126"> <li> <p>constipation (RR 0.97, 95% CI 0.35 to 2.67; 1 study, 166 participants);</p> </li> <li> <p>diarrhoea (RR 1.04, 95% CI 0.68 to 1.61; 1 study, 166 participants); or</p> </li> <li> <p>vomiting (RR 1.02, 95% CI 0.68 to 1.53; 1 study, 166 participants; <a href="./references#CD011769-fig-0141" title="">Analysis 13.3</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0316"> <p><b>Immune system</b></p> <p>There was no difference between anxiolytic and placebo groups in the likelihood of:</p> <p> <ul id="CD011769-list-0127"> <li> <p>nasopharyngitis (RR 0.87, 95% CI 0.33 to 2.28; 1 study, 166 participants); and</p> </li> <li> <p>pyrexia (RR 1.00, 95% CI 0.73 to 1.37; 1 study, 166 participants).</p> </li> </ul> </p> <p>However, upper respiratory tract infection was reduced in the anxiolytic group (RR 0.40, 95% CI 0.18 to 0.91; 1 study, 166 participants; <a href="./references#CD011769-fig-0142" title="">Analysis 13.4</a>). </p> </section> <section id="CD011769-sec-0317"> <p><b>Metabolic</b></p> <p>There was no difference between anxiolytic and placebo groups in:</p> <p> <ul id="CD011769-list-0128"> <li> <p>decreased appetite (RR 1.11, 95% CI 0.62 to 1.99; 1 study, 166 participants); and</p> </li> <li> <p>increased appetite (RR 1.50, 95% CI 0.93 to 2.42; I<sup>2</sup> = 0%; 2 studies, 200 participants; <a href="./references#CD011769-fig-0143" title="">Analysis 13.5</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0318"> <p><b>Neurological</b></p> <p>Neurological AEs were not different between anxiolytics and placebo groups in one study with 166 participants. These included: </p> <p> <ul id="CD011769-list-0129"> <li> <p>hyperactivity (RR 0.79, 95% CI 0.47 to 1.30);</p> </li> <li> <p>increased aggression (RR 0.91, 95% CI 0.60 to 1.38);</p> </li> <li> <p>insomnia (RR 1.26, 95% CI 0.90 to 1.78); irritability (RR 0.84, 95% CI 0.48 to 1.47);</p> </li> <li> <p>irritability (dichotomous) (RR 0.84, 95% CI 0.48 to 1.47); and</p> </li> <li> <p>somnolence (RR 1.70, 95% CI 0.58 to 4.97; <a href="./references#CD011769-fig-0144" title="">Analysis 13.6</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0319"> <p><b>Psychological</b></p> <p>Anxiety was not decreased in the anxiolytic group in one study with 166 participants (RR 2.76, 95% CI 0.48 to 15.83; <a href="./references#CD011769-fig-0145" title="">Analysis 13.7</a>). </p> </section> <section id="CD011769-sec-0320"> <p><b>Respiratory</b></p> <p>There was no difference between anxiolytic and placebo groups in one study with 166 participants in: </p> <p> <ul id="CD011769-list-0130"> <li> <p>cough (RR 0.90, 95% CI 0.64 to 1.26);</p> </li> <li> <p>epistaxis (RR 0.52, 95% CI 0.19 to 1.43);</p> </li> <li> <p>nasal congestion (RR 0.80, 95% CI 0.36 to 1.77);</p> </li> <li> <p>rhinorrhea (RR 1.12, 95% CI 0.66 to 1.88); and</p> </li> <li> <p>sinus congestion (RR 0.90, 95% CI 0.55 to 1.47; <a href="./references#CD011769-fig-0146" title="">Analysis 13.8</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0321"> <p><b>Skin</b></p> <p>There was no difference in rash between anxiolytic and placebo groups in one study with 166 participants (RR 1.19, 95% CI 0.52 to 2.73; <a href="./references#CD011769-fig-0147" title="">Analysis 13.9</a>). </p> </section> </section> </section> <section id="CD011769-sec-0322"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0323"> <h6 class="title">Tolerability/acceptability</h6> <p>There was no clear evidence of a difference in loss to follow‐up between anxiolytic and placebo groups (RR 0.88, 95% CI 0.45 to 1.73; I² = 0%; 2 studies, 206 participants; <a href="./references#CD011769-fig-0149" title="">Analysis 13.11</a>). </p> <section id="CD011769-sec-0324"> <p><b>Outcomes not reported</b></p> <p>No data were available for the outcomes of aggression, self‐injury, or quality of life, and cardiovascular, musculoskeletal, urinary, and other AEs. </p> </section> </section> </section> </section> <section id="CD011769-sec-0325"> <h4 class="title">Experimental interventions versus placebo or other treatment</h4> <section id="CD011769-sec-0326"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0327"> <h6 class="title">Challenging behaviours</h6> <section id="CD011769-sec-0328"> <p><b>Irritability</b></p> <p>Studies compared a variety of interventions to placebo. As they covered a range of different pharmacological classes, we categorised them as experimental drugs. These interventions included: celecoxib (NSAID); d‐cycloserine; dextromethorphan; mecamylamine; riluzole; pioglitazone; n‐acetylcysteine; <i>Trichuris suis</i> ova; tetrahydrobiopterin; lofexedine; naltrexone; minocycline; propentofylline; sulforaphane; folinic acid; carnosine; prednisolone (corticosteroid); dextromethorphan/quinidine; pregnenolone; baclofen; palmitoylethanolamide; bumetanide; resveratrol; arbaclofen; simvastatin; and nicotine. </p> <p>There was some evidence that irritability was reduced at endpoint in participants in the experimental intervention groups compared to placebo (SMD −0.30, 95% CI −0.53 to −0.07; I² = 72%, 28 studies, 1205 participants; <a href="./references#CD011769-fig-0150" title="">Analysis 14.1</a>). There were no differences between groups when we compared children to children and adults, and adults (P = 0.94), however, there was evidence of a difference between types of experimental interventions when we conducted a subgroup analysis of interventions by age group (children, children and adults, or adults; P &lt; 0.00001). There was insufficient information to conduct subgroup analyses of irritability by gender, communication ability, or cognitive ability. </p> <p>We were unable to include data from three studies because the data were skewed (<a href="./references#CD011769-bbs2-0008" title="ArnoldLE , AmanMG , HollwayJ , HurtE , BatesB , LiX , et al. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology2012;22(3):198-205. [DOI: 10.1089/cap.2011.0056] [PMCID: PMC3417385] [PMID: 22537359]NCT00773812. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders [Neuronal nicotinic receptor modulation in the treatment of autism: a pilot trial of mecamylamine]. clinicaltrials.gov/ct2/show/NCT00773812 (first received 16 October 2008). ">Arnold 2012a</a>; <a href="./references#CD011769-bbs2-0057" title="HollanderE , FerrettiCJ , TaylorBP , NooneRH , RacineE . P.7.d.006 Trichuris suis ova (TSO) as an immune-inflammatory treatment for repetitive behaviors in autism spectrum disorders (ASD). European Neuropsychopharmacology2014;24(2):S723. [DOI: 10.1016/S0924-977X(14)71165-4]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]HollanderE , FerrettiC , TaylorB , NooneR , KirschJ , RacineE . Trichuris suis ova (TSO) as an immune inflammatory treatment for repetitive behaviors in ASD. Neuropsychopharmacology2013;38:S391-2. [DOI: 10.1038/npp.2013.280]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]NCT01040221. Trichuris suis ova in autism spectrum disorders (TSO) [Trichuris suis ova in autism spectrum disorders ]. www.clinicaltrials.gov/ct2/show/NCT01040221 (first received November 2012). StarkFS , ChavanneC , Lennon-ChrimesS , DiackC , DerksM , SmithJ . Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431). European Neuropsychopharmacology2020;40:S82-S83. [DOI: 10.1016/j.euroneuro.2020.09.110]">Hollander 2020a</a>; <a href="./references#CD011769-bbs2-0081" title="MinshawiNF , WinkLK , ShafferR , PlaweckiMH , PoseyDJ , LiuH , et al. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism2016;7(3):2. [DOI: 10.1186/s13229-015-0062-8] [PMCID: PMC4712595] [PMID: 26770664]NCT01086475. D-cycloserine and social skills training in autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT01086475?term=NCT01086475&amp;draw=1&amp;rank=1 (first received March 2010). WinkLK , MinshawiNF , ShafferRC , PlaweckiMH , PoseyDJ , HornPS , et al. D-cycloserine enhances durability of social skills training in autism spectrum disorder. Molecular Autism2017;8:2. [DOI: 10.1186/s13229-017-0116-1] [PMCID: PMC5264460] [PMID: 28138381]">Minshawi 2016</a>). Details can be found in <a href="#CD011769-tbl-0019">Table 15</a>. </p> <div class="table" id="CD011769-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Experimental versus placebo: irritability results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0008" title="ArnoldLE , AmanMG , HollwayJ , HurtE , BatesB , LiX , et al. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology2012;22(3):198-205. [DOI: 10.1089/cap.2011.0056] [PMCID: PMC3417385] [PMID: 22537359]NCT00773812. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders [Neuronal nicotinic receptor modulation in the treatment of autism: a pilot trial of mecamylamine]. clinicaltrials.gov/ct2/show/NCT00773812 (first received 16 October 2008). ">Arnold 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term mecamylamine (max 5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.17 (8.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−5.0 (10.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No significant differences were found for age, weight, sex, diagnosis, IQ, or entry scores for the OACIS, RBS, ABC Irritability, ABC Hyperactivity, ABC Lethargy/ Social Withdrawal, ABC Inappropriate Speech, ADI‐R Qualitative Abnormalities in Reciprocal Social Interaction or ADI‐R Qualitative Abnormalities in Communication" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0057" title="HollanderE , FerrettiCJ , TaylorBP , NooneRH , RacineE . P.7.d.006 Trichuris suis ova (TSO) as an immune-inflammatory treatment for repetitive behaviors in autism spectrum disorders (ASD). European Neuropsychopharmacology2014;24(2):S723. [DOI: 10.1016/S0924-977X(14)71165-4]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]HollanderE , FerrettiC , TaylorB , NooneR , KirschJ , RacineE . Trichuris suis ova (TSO) as an immune inflammatory treatment for repetitive behaviors in ASD. Neuropsychopharmacology2013;38:S391-2. [DOI: 10.1038/npp.2013.280]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]NCT01040221. Trichuris suis ova in autism spectrum disorders (TSO) [Trichuris suis ova in autism spectrum disorders ]. www.clinicaltrials.gov/ct2/show/NCT01040221 (first received November 2012). StarkFS , ChavanneC , Lennon-ChrimesS , DiackC , DerksM , SmithJ . Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431). European Neuropsychopharmacology2020;40:S82-S83. [DOI: 10.1016/j.euroneuro.2020.09.110]">Hollander 2020a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term <i>Trichuris suis</i> ova (a dose of 2500 <i>Trichurissuis</i> ova every 2 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−4.0 (18.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.14 (6.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.0687, 95% CI −4.82 to 91.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0081" title="MinshawiNF , WinkLK , ShafferR , PlaweckiMH , PoseyDJ , LiuH , et al. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism2016;7(3):2. [DOI: 10.1186/s13229-015-0062-8] [PMCID: PMC4712595] [PMID: 26770664]NCT01086475. D-cycloserine and social skills training in autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT01086475?term=NCT01086475&amp;draw=1&amp;rank=1 (first received March 2010). WinkLK , MinshawiNF , ShafferRC , PlaweckiMH , PoseyDJ , HornPS , et al. D-cycloserine enhances durability of social skills training in autism spectrum disorder. Molecular Autism2017;8:2. [DOI: 10.1186/s13229-017-0116-1] [PMCID: PMC5264460] [PMID: 28138381]">Minshawi 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term D‐cycloserine (50 mg once weekly)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.55 (6.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.23 (6.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"teacher‐rated ABC data was returned for 23.5 % of the DCS group, and 30.3 % of the placebo group with no significant difference noted for any of the ABC subscales (irritability p = 0.623, social withdrawal p = 0.845" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>ABC:</b> Aberrant Behaviour checklist; <b>DCS:</b> D‐cycloserine; <b>OACIS:</b> Ohio Autism Clinical Impressions Scale; <b>RBS:</b> Repetitive Behaviour Scale </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011769-sec-0329"> <p><b>Self‐injury</b></p> <p>There was no clear evidence of a difference in self‐injurious behaviour at endpoint between participants receiving any of the experimental interventions compared to participants receiving placebo: </p> <p> <ul id="CD011769-list-0131"> <li> <p>bumetanide (SMD 0.20, 95% CI −0.21 to 0.60, P = 0.34; I² = 22%, 2 studies, 148 participants;</p> </li> <li> <p>N‐acetyl cysteine (SMD 0.08, 95% CI −0.29 to 0.44; P = 0.69; I² = 5%, 2 studies, 127 participants); </p> </li> <li> <p><i>Trichuris suis</i> ova (SMD −0.30, 95% CI −1.55 to 0.95; P = 0.64; 1 study, 10 participants; <a href="./references#CD011769-fig-0151" title="">Analysis 14.2</a>). </p> </li> </ul> </p> <p>We were unable to include data from three studies in the analysis because the data were skewed (<a href="./references#CD011769-bbs2-0024" title="ACTRN12610000635066. Efficacy Of N-acetyl cysteine in autism: a double-blind, placebo-controlled randomised trial [Efficacy of n-acetyl cysteine on social skills, communication and behaviour in autistic children: a double-blind, placebo-controlled randomised trial]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=320918 (first received 3 August 2010). DeanOM , GrayK , DoddS , Villagonzalo K-A, BrownE , TongeB , et al. Does N-acetylcysteine improve behaviour in children with autism?: a mixed-methods analysis of the effects of N-acetylcysteine. Journal of Intellectual &amp; Developmental Disability2019;44(4):474-80. [DOI: 10.3109/13668250.2017.1413079]DeanOM , GrayKM , Villagonzalo K-A, DoddS , MohebbiM , VickT , et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian and New Zealand Journal of Psychiatry2017;51(3):241-9. [DOI: 10.1177/0004867416652735] [PMID: 27316706]">Dean 2019</a>; <a href="./references#CD011769-bbs2-0046" title="HardanA . Psychopharmacological treatment of anxiety symptoms in autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):S325-6. [DOI: 10.1016/j.jaac.2016.07.369] [ABSTRACT NO: 42.4]HardanAY , FungLK , LiboveRA , ObukhanychTV , NairS , HerzenbergLA , et al. A randomised controlled pilot trial of N-acetylcysteine in children with autism. Biological Psychiatry2012;71(11):956-61. [DOI: 10.1016//j.biopsych.2012.01.014] [PMCID: PMC4914359] [PMID: 22342106]">Hardan 2012</a>; <a href="./references#CD011769-bbs2-0057" title="HollanderE , FerrettiCJ , TaylorBP , NooneRH , RacineE . P.7.d.006 Trichuris suis ova (TSO) as an immune-inflammatory treatment for repetitive behaviors in autism spectrum disorders (ASD). European Neuropsychopharmacology2014;24(2):S723. [DOI: 10.1016/S0924-977X(14)71165-4]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]HollanderE , FerrettiC , TaylorB , NooneR , KirschJ , RacineE . Trichuris suis ova (TSO) as an immune inflammatory treatment for repetitive behaviors in ASD. Neuropsychopharmacology2013;38:S391-2. [DOI: 10.1038/npp.2013.280]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]NCT01040221. Trichuris suis ova in autism spectrum disorders (TSO) [Trichuris suis ova in autism spectrum disorders ]. www.clinicaltrials.gov/ct2/show/NCT01040221 (first received November 2012). StarkFS , ChavanneC , Lennon-ChrimesS , DiackC , DerksM , SmithJ . Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431). European Neuropsychopharmacology2020;40:S82-S83. [DOI: 10.1016/j.euroneuro.2020.09.110]">Hollander 2020a</a>). Details can be found in <a href="#CD011769-tbl-0020">Table 16</a>. </p> <div class="table" id="CD011769-tbl-0020"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Experimental versus placebo: self‐injurious behaviour results that could not be used in the meta‐analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0024" title="ACTRN12610000635066. Efficacy Of N-acetyl cysteine in autism: a double-blind, placebo-controlled randomised trial [Efficacy of n-acetyl cysteine on social skills, communication and behaviour in autistic children: a double-blind, placebo-controlled randomised trial]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=320918 (first received 3 August 2010). DeanOM , GrayK , DoddS , Villagonzalo K-A, BrownE , TongeB , et al. Does N-acetylcysteine improve behaviour in children with autism?: a mixed-methods analysis of the effects of N-acetylcysteine. Journal of Intellectual &amp; Developmental Disability2019;44(4):474-80. [DOI: 10.3109/13668250.2017.1413079]DeanOM , GrayKM , Villagonzalo K-A, DoddS , MohebbiM , VickT , et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian and New Zealand Journal of Psychiatry2017;51(3):241-9. [DOI: 10.1177/0004867416652735] [PMID: 27316706]">Dean 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour</p> <p>(N‐acetylcysteine 500 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (2.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 (2.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"There were no differences between N‐acetyl cysteine and placebo‐treated groups on any of the outcome measures for either primary or secondary endpoints. There was no significant difference in the number and severity of adverse events between groups" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0046" title="HardanA . Psychopharmacological treatment of anxiety symptoms in autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):S325-6. [DOI: 10.1016/j.jaac.2016.07.369] [ABSTRACT NO: 42.4]HardanAY , FungLK , LiboveRA , ObukhanychTV , NairS , HerzenbergLA , et al. A randomised controlled pilot trial of N-acetylcysteine in children with autism. Biological Psychiatry2012;71(11):956-61. [DOI: 10.1016//j.biopsych.2012.01.014] [PMCID: PMC4914359] [PMID: 22342106]">Hardan 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour (N‐acetylcysteine maz 900 mg/day 3 times daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (2.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (3.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Compared with placebo, NAC resulted in significant improvements on ABC irritability subscale (F= 6.80; P &lt;.001;d.= 0.96)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0057" title="HollanderE , FerrettiCJ , TaylorBP , NooneRH , RacineE . P.7.d.006 Trichuris suis ova (TSO) as an immune-inflammatory treatment for repetitive behaviors in autism spectrum disorders (ASD). European Neuropsychopharmacology2014;24(2):S723. [DOI: 10.1016/S0924-977X(14)71165-4]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]HollanderE , FerrettiC , TaylorB , NooneR , KirschJ , RacineE . Trichuris suis ova (TSO) as an immune inflammatory treatment for repetitive behaviors in ASD. Neuropsychopharmacology2013;38:S391-2. [DOI: 10.1038/npp.2013.280]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]NCT01040221. Trichuris suis ova in autism spectrum disorders (TSO) [Trichuris suis ova in autism spectrum disorders ]. www.clinicaltrials.gov/ct2/show/NCT01040221 (first received November 2012). StarkFS , ChavanneC , Lennon-ChrimesS , DiackC , DerksM , SmithJ . Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431). European Neuropsychopharmacology2020;40:S82-S83. [DOI: 10.1016/j.euroneuro.2020.09.110]">Hollander 2020a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour (<i>Trichuris suis</i> ova, dose of 2500 ova every 2 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.37 (2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42 (2.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Trending improvements were observed in irritability using the overall percent change from baseline to endpoint on the Aberrant Behavior Checklist (ABC)–Irritability subscale" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>NAC:</b> N‐acetylcysteine </p> </td> </tr> </tbody> </table> </div> <p>There was no clear evidence of a difference in self‐injury between groups when we compared interventions by age (children only versus adults; P = 0.65). There was insufficient information to conduct subgroup analyses of self‐injury by gender, communication ability, or cognitive ability. </p> </section> </section> <section id="CD011769-sec-0330"> <h6 class="title">Adverse effects</h6> <p>The AEs from one study (<a href="./references#CD011769-bbs2-0035" title="GhanizadehA , Moghimi-SaraniE . A randomized double blind placebo controlled clinical trial of N-acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry2013;13:196. [DOI: 10.1186/1471-244X-13-196] [PMCID: PMC3737121] [PMID: 23886027]IRCT201106103930N6. N-acetylcysteine augmentation with risperidone in treatment of autism in children [N-acetylcysteine augmentation with rispridone in treatment of autism in children: a double blind randomized placebo controlled clinical trial]. www.irct.ir/trial/4085 (first received 8 July 2011). ">Ghanizadeh 2013</a>), could not be included in the analysis because AEs were reported as a percentage of all participants who experienced an AE, rather than percentage by group. See <a href="#CD011769-tbl-0021">Table 17</a>. </p> <div class="table" id="CD011769-tbl-0021"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Experimental versus placebo: adverse effects data that could not be used in the meta‐analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0035" title="GhanizadehA , Moghimi-SaraniE . A randomized double blind placebo controlled clinical trial of N-acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry2013;13:196. [DOI: 10.1186/1471-244X-13-196] [PMCID: PMC3737121] [PMID: 23886027]IRCT201106103930N6. N-acetylcysteine augmentation with risperidone in treatment of autism in children [N-acetylcysteine augmentation with rispridone in treatment of autism in children: a double blind randomized placebo controlled clinical trial]. www.irct.ir/trial/4085 (first received 8 July 2011). ">Ghanizadeh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term adverse effects (NAC 1200 mg/day, risperidone 2‐3 mg/day depending on weight). 20+ AEs included fatigue, increased appetite, decreased appetite, diarrhoea, and constipation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N‐acetylcysteine + risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs were reported for each group although percentage was out of total number of participants, not participants for each group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>AE:</b> adverse effect; <b>NAC:</b> N‐acetylcysteine </p> </td> </tr> </tbody> </table> </div> <section id="CD011769-sec-0331"> <p><b>Gastrointestinal</b></p> <p>There was some evidence of a difference between experimental interventions compared to placebo for thirst (RR 3.32, 95% CI 1.10 to 10.01; I² = 0%; 4 studies, 224 participants; <a href="./references#CD011769-fig-0152" title="">Analysis 14.3</a>). </p> <p>There was no clear evidence of a difference in any of the other gastrointestinal AEs including: </p> <p> <ul id="CD011769-list-0132"> <li> <p>abdominal pain (RR 1.38, 95% CI 0.95 to 2.01; I² = 0%; 14 studies, 734 participants);</p> </li> <li> <p>change in bowel habits (RR 0.39, 95% CI 0.05 to 3.26; I² = 25%; 2 studies, 54 participants);</p> </li> <li> <p>constipation (RR 1.29, 95% CI 0.77 to 2.16; I² = 0%; 13 studies, 665 participants);</p> </li> <li> <p>diarrhoea (RR 0.83, 95% CI 0.55 to 1.25; I² = 0%; 18 studies, 982 participants);</p> </li> <li> <p>drooling (RR 0.29, 95% CI 0.01 to 5.79; 1 study, 11 participants);</p> </li> <li> <p>dry mouth (RR 0.87, 95% CI 0.37 to 2.09; I² = 0%; 5 studies, 173 participants);</p> </li> <li> <p>dyspepsia (RR 0.31, 95% CI 0.01 to 7.15; 1 study, 31 participants);</p> </li> <li> <p>encopresis (RR 0.31, 95% CI 0.01 to 7.15; 1 study, 31 participants);</p> </li> <li> <p>flatulence (RR 3.00, 95% CI 0.15 to 59.89; 1 study, 10 participants);</p> </li> <li> <p>increased salivation (RR 1.00, 95% CI 0.39 to 2.58; 1 study, 40 participants);</p> </li> <li> <p>nausea (RR 1.36, 95% CI 0.90 to 2.06; I² = 0%; 15 studies, 768 participants); or</p> </li> <li> <p>vomiting (RR 1.34, 95% CI 0.91 to 1.98; I² = 0%; 13 studies, 793 participants; <a href="./references#CD011769-fig-0152" title="">Analysis 14.3</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0332"> <p><b>Immune system</b></p> <p>There was no clear evidence of a difference between experimental and placebo groups in: </p> <p> <ul id="CD011769-list-0133"> <li> <p>fever (RR 2.94, 95% CI 0.46 to 18.53; I² = 0%; 2 studies, 102 participants); or</p> </li> <li> <p>influenza (RR 0.31, 95% CI 0.01 to 7.15; 1 study, 31 participants; <a href="./references#CD011769-fig-0153" title="">Analysis 14.4</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0333"> <p><b>Metabolic</b></p> <p>Participants receiving experimental interventions (bumetanide) compared to placebo were more likely to experience: </p> <p> <ul id="CD011769-list-0134"> <li> <p>hypokalemia (RR 12.48, 95% CI 4.04 to 38.62, I<sup>2</sup> = 0%; 4 studies, 331 participants); and </p> </li> <li> <p>increased appetite (RR 1.42, 95% CI 1.02 to 1.98, I<sup>2</sup> = 0%; 14 studies, 676 participants; <a href="./references#CD011769-fig-0154" title="">Analysis 14.5</a>). </p> </li> </ul> </p> <p>The other metabolic effects were no different to placebo:</p> <p> <ul id="CD011769-list-0135"> <li> <p>decreased appetite (RR 1.62, 95% CI 0.95 to 2.75; I² = 0%; 15 studies, 806 participants);</p> </li> <li> <p>hypoglycaemia (RR 0.71, 95% CI 0.09 to 5.68; I² = 21%; 2 studies, 120 participants);</p> </li> <li> <p>hyponatremia (RR 3.00, 95% CI 0.13 to 69.31; 1 study, 38 participants);</p> </li> <li> <p>weight gain (RR 0.32, 95% CI 0.04 to 2.77; I² = 0%; 2 studies, 39 participants);</p> </li> <li> <p>weight loss (RR 1.49, 95% CI 0.50 to 4.39; I² = 0%; 4 studies, 306 participants);</p> </li> <li> <p>weight loss (0.12 kg to 0.67 kg) (RR 9.43, 95% CI 0.65 to 137.77; 1 study, 11 participants); or </p> </li> <li> <p>weight loss (0.45 kg to 2.19 kg) (RR 0.17, 95% CI 0.01 to 2.92; 1 study, 11 participants; <a href="./references#CD011769-fig-0154" title="">Analysis 14.5</a>); </p> </li> <li> <p>weight change in kilograms (MD 0.13, 95% CI −0.24 to 0.50; 1 study, 23 participants; <a href="./references#CD011769-fig-0155" title="">Analysis 14.6</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0334"> <p><b>Musculoskeletal</b></p> <p>There was no clear evidence of a difference between any of the experimental medications compared to placebo for any musculoskeletal AEs including: </p> <p> <ul id="CD011769-list-0136"> <li> <p>arthralgia (RR 0.33, 95% CI 0.02 to 6.65; 1 study, 10 participants);</p> </li> <li> <p>difficulty walking (RR 0.20, 95% CI 0.01 to 3.92; 1 study, 40 participants);</p> </li> <li> <p>impaired balance (RR 1.67, 95% CI 0.08 to 33.75; 1 study, 12 participants);</p> </li> <li> <p>myalgia (RR 1.54, 95% CI 0.79 to 3.04; I² = 0%; 2 studies, 155 participants);</p> </li> <li> <p>slow movement (RR 4.17, 95% CI 0.22 to 80.25; 1 study, 31 participants);</p> </li> <li> <p>stiffness (RR 2.03, 95% CI 0.41 to 10.15; I² = 0%; 2 studies, 43 participants); or</p> </li> <li> <p>weakness (RR 0.63, 95% CI 0.21 to 1.89; I² = 0%; 3 studies, 90 participants; <a href="./references#CD011769-fig-0156" title="">Analysis 14.7</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0335"> <p><b>Neurological</b></p> <p>There was some evidence of an increased risk of drowsiness in participants receiving an experimental intervention compared to placebo (RR 3.45, 95% CI 1.21 to 9.81, 5 studies, 298 participants). </p> <p>There was no clear evidence of a difference between any of the experimental medications compared to placebo for any of the other neurological AEs including: </p> <p> <ul id="CD011769-list-0137"> <li> <p>agitation/excitement (RR 0.76, 95% CI 0.39 to 1.48; I² = 0%; 5 studies, 220 participants);</p> </li> <li> <p>anxiety (RR 1.06, 95% CI 0.44 to 2.57; I² = 0%; 3 studies, 250 participants);</p> </li> <li> <p>daytime drowsiness (RR 1.57, 95% CI 0.75 to 3.28; I² = 0%; 6 studies, 172 participants);</p> </li> <li> <p>dazed (RR 2.57, 95% CI 0.13 to 52.12; 1 study, 11 participants);</p> </li> <li> <p>difficulty concentrating (RR 2.50, 95% CI 0.42 to 14.83; 1 study, 12 participants);</p> </li> <li> <p>difficulty sleeping (RR 0.81, 95% CI 0.44 to 1.50; I² = 0%; 6 studies, 326 participants);</p> </li> <li> <p>dizziness (RR 1.21, 95% CI 0.67 to 2.18; I² = 0%; 9 studies, 441 participants);</p> </li> <li> <p>fatigue (RR 1.23, 95% CI 0.70 to 2.17; I² = 0%; 7 studies, 338 participants);</p> </li> <li> <p>headache (RR 0.91, 95% CI 0.66 to 1.26; I² = 0%; 18 studies, 943 participants);</p> </li> <li> <p>hypoactivity (RR 0.44, 95% CI 0.07 to 2.95; I² = 23%; 3 studies, 28 participants);</p> </li> <li> <p>increased aggression (dichotomous) (RR 0.78, 95% CI 0.36 to 1.70; I² = 0%; 4 studies, 149 participants); </p> </li> <li> <p>increased hyperactivity (RR 0.75, 95% CI 0.35 to 1.58; I² = 0%; 6 studies, 321 participants);</p> </li> <li> <p>increased irritability (dichotomous) (RR 1.11, 95% CI 0.71 to 1.72; I² = 0%; 5 studies, 177 participants); </p> </li> <li> <p>increased stereotypies (RR 0.52, 95% CI 0.10 to 2.80; 1 study, 41 participants);</p> </li> <li> <p>insomnia (RR 1.04, 95% CI 0.66 to 1.65; I² = 0%; 8 studies, 488 participants);</p> </li> <li> <p>migraine (RR 3.00, 95% CI 0.15 to 59.89; 1 study, 10 participants);</p> </li> <li> <p>nervousness (RR 1.86, 95% CI 0.47 to 7.37; I² = 51%; 4 studies, 159 participants);</p> </li> <li> <p>new onset seizures (RR 0.33, 95% CI 0.01 to 7.78; 1 study, 46 participants);</p> </li> <li> <p>restlessness (RR 1.22, 95% CI 0.53 to 2.82; I² = 0%; 5 studies, 158 participants);</p> </li> <li> <p>rocking (RR 0.29, 95% CI 0.01 to 5.79; 1 study, 11 participants);</p> </li> <li> <p>sedation (RR 0.93, 95% CI 0.61 to 1.42; I² = 0%; 13 studies, 624 participants);</p> </li> <li> <p>syncope (RR 2.80, 95% CI 0.30 to 25.94; 1 study, 89 participants);</p> </li> <li> <p>tremor (RR1.80, 95% CI 0.44 to 7.37; I² = 0%; 4 studies, 140 participants); or</p> </li> <li> <p>twitching (RR 3.60, 95% CI 0.42 to 31.04; I² = 0%; 2 studies, 71 participants; <a href="./references#CD011769-fig-0157" title="">Analysis 14.8</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0336"> <p><b>Psychological</b></p> <p>There was no clear evidence of a difference between any of the experimental medications compared to placebo for any psychological AEs including: </p> <p> <ul id="CD011769-list-0138"> <li> <p>anorexia (RR 0.53, 95% CI 0.20 to 1.40; 1 study, 20 participants);</p> </li> <li> <p>aggression (dichotomous) (RR 1.17, 95% CI 0.37 to 3.66; 1 study, 150 participants);</p> </li> <li> <p>depression (RR 1.93, 95% CI 0.62 to 6.00; I² = 0%; 3 studies, 108 participants);</p> </li> <li> <p>increased self‐injurious behaviour (RR 0.46, 95% CI 0.11 to 1.84; I² = 0%; 3 studies, 105 participants); </p> </li> <li> <p>irritability (dichotomous) (RR 0.91, 95% CI 0.36 to 2.27; I² = 0%; 2 studies, 162 participants); </p> </li> <li> <p>worsening of temper tantrums (dichotomous) (RR 1.88, 95% CI 0.30 to 11.83; I² = 0%; 2 studies, 52 participants); </p> </li> <li> <p>mental symptoms (RR 1.00, 95% CI 0.41 to 2.45; 1 study, 20 participants); and</p> </li> <li> <p>repetitive behaviour (RR 0.50, 95% CI 0.05 to 5.14; 1 study, 46 participants; <a href="./references#CD011769-fig-0158" title="">Analysis 14.9</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0337"> <p><b>Respiratory</b></p> <p>There was no clear evidence of a difference between any of the experimental medications when compared to placebo for any respiratory AEs including: </p> <p> <ul id="CD011769-list-0139"> <li> <p>aggravation of asthma (RR 3.26, 95% CI 0.14 to 77.35; 1 study, 71 participants);</p> </li> <li> <p>congestion/cold (RR 1.02, 95% CI 0.62 to 1.68; I² = 0%; 4 studies, 256 participants);</p> </li> <li> <p>cough (RR 1.16, 95% CI 0.55 to 2.49; I² = 0%; 3 studies, 248 participants);</p> </li> <li> <p>ear infection (RR 1.88, 95% CI 0.19 to 18.60; 1 study, 31 participants);</p> </li> <li> <p>lung congestion (RR 1.00, 95% CI 0.60 to 1.68; 1 study, 20 participants) ;</p> </li> <li> <p>nasopharyngitis (RR 0.78, 95% CI 0.22 to 2.79; 1 study, 150 participants); or</p> </li> <li> <p>respiratory AEs (RR 5.43, 95% CI 0.27 to 109.19; 1 study, 71 participants; <a href="./references#CD011769-fig-0159" title="">Analysis 14.10</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0338"> <p><b>Skin</b></p> <p>There was no clear evidence of a difference between experimental and placebo groups in: </p> <p> <ul id="CD011769-list-0140"> <li> <p>hives (RR 0.31, 95% CI 0.01 to 7.15; 1 study, 31 participants);</p> </li> <li> <p>itches (RR 0.55, 95% CI 0.07 to 4.19; I² = 0%; 2 studies, 62 participants);</p> </li> <li> <p>rash (RR 0.76, 95% CI 0.30 to 1.92; I² = 0%; 7 studies, 440 participants);</p> </li> <li> <p>skin lesion (RR 1.66, 95% CI 0.74 to 3.70; I² = 0%; 2 studies, 98 participants); or</p> </li> <li> <p>overall skin AEs (RR 1.09, 95% CI 0.16 to 7.30; 1 study, 71 participants; <a href="./references#CD011769-fig-0160" title="">Analysis 14.11</a>). </p> </li> </ul> </p> </section> <section id="CD011769-sec-0339"> <p><b>Urinary</b></p> <p>There was no clear evidence of a difference between experimental and placebo groups in: </p> <p> <ul id="CD011769-list-0141"> <li> <p>diuresis (RR 0.93, 95% CI 0.25 to 3.51; 1 study, 89 participants);</p> </li> <li> <p>enuresis (RR 2.70, 95% CI 0.82 to 8.87; I² = 0%; 3 studies, 205 participants);</p> </li> <li> <p>urinary retention (RR 0.74, 95% CI 0.05 to 10.49; I² = 33%; 2 studies, 88 participants);</p> </li> <li> <p>urinary tract infection (RR 0.31, 95% CI 0.01 to 7.15; 1 study, 31 participants; <a href="./references#CD011769-fig-0161" title="">Analysis 14.12</a>) </p> </li> </ul> </p> </section> <section id="CD011769-sec-0340"> <p><b>Other adverse effects</b></p> <p>There was no clear evidence of a difference between any of the experimental medications compared to placebo for any other AEs including: </p> <p> <ul id="CD011769-list-0142"> <li> <p>blurred vision (RR 2.50, 95% CI 0.11 to 56.98; 1 study, 31 participants);</p> </li> <li> <p>dilated pupils (RR 0.67, 95% CI 0.05 to 9.19; 1 study, 20 participants);</p> </li> <li> <p>fever (RR 0.49, 95% CI 0.13 to 1.88; 1 study, 150 participants);</p> </li> <li> <p>sweating (RR 0.75, 95% CI 0.15 to 3.86; I² = 0%; 3 studies, 129 participants)</p> </li> <li> <p>conjunctivitis (RR 0.33, 95% CI 0.02 to 6.65; 1 study, 10 participants) <a href="./references#CD011769-fig-0162" title="">Analysis 14.13</a>. </p> </li> </ul> </p> </section> </section> </section> <section id="CD011769-sec-0341"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0342"> <h6 class="title">Tolerability/acceptability</h6> <p>There was no clear evidence of a difference in loss to follow‐up between experimental and placebo groups (RR 1.07, 95% CI 0.89 to 1.28; 30 studies, 1913 participants; <a href="./references#CD011769-fig-0163" title="">Analysis 14.14</a>). </p> <section id="CD011769-sec-0343"> <p><b>Outcomes not reported</b></p> <p>No data were available for the outcomes of aggression, quality of life, and cardiovascular AEs. </p> </section> </section> </section> </section> <section id="CD011769-sec-0344"> <h4 class="title">Typical antipsychotics versus placebo</h4> <section id="CD011769-sec-0345"> <h5 class="title">Primary outcomes</h5> <section id="CD011769-sec-0346"> <h6 class="title">Challenging behaviours</h6> <section id="CD011769-sec-0347"> <p><b>Self‐injury</b></p> <p>There was no clear evidence of a difference between haloperidol and placebo on levels of self‐injury in the short term (SMD −0.54, 95% CI −1.52 to 0.43; 1 study, 17 participants; <a href="./references#CD011769-fig-0168" title="">Analysis 15.1</a>). </p> <p>There were insufficient studies (1 study) to conduct a subgroup analysis.</p> </section> </section> <section id="CD011769-sec-0348"> <h6 class="title">Adverse effects</h6> <section id="CD011769-sec-0349"> <p><b>Musculoskeletal</b></p> <p>There was no clear evidence of a difference between haloperidol and placebo in risk of dystonia in the short term (RR 2.36, 95% CI 0.11 to 52.41; 1 study, 23 participants; <a href="./references#CD011769-fig-0169" title="">Analysis 15.2</a>). </p> </section> <section id="CD011769-sec-0350"> <p><b>Neurological</b></p> <p>There was no clear evidence of a difference between haloperidol and placebo groups in risk of fatigue (RR 8.64, 95% CI 0.53 to 140.05; 1 study, 23 participants; <a href="./references#CD011769-fig-0170" title="">Analysis 15.3</a>). </p> </section> <section id="CD011769-sec-0351"> <p><b>Psychological</b></p> <p>There was some evidence of a reduction in risk of behaviour problems in the haloperidol group compared to the placebo group (RR 0.34, 95% CI 0.16 to 0.73; 1 study, 23 participants; <a href="./references#CD011769-fig-0171" title="">Analysis 15.4</a>). </p> </section> </section> </section> <section id="CD011769-sec-0352"> <h5 class="title">Secondary outcomes</h5> <section id="CD011769-sec-0353"> <h6 class="title">Tolerability/acceptability</h6> <p>There was no difference in loss to follow‐up when participants receiving haloperidol were compared to those receiving placebo (RR 0.46, 95% CI 0.14 to 1.49; I<sup>2</sup> = 0%; 2 studies, 40 participants; <a href="./references#CD011769-fig-0172" title="">Analysis 15.5</a>). </p> <section id="CD011769-sec-0354"> <p><b>Outcomes not reported</b></p> <p>No data were available for the outcomes of irritability, aggression, quality of life, and cardiovascular, gastrointestinal, immune, metabolic, respiratory, skin, urinary, and other AEs. </p> </section> </section> </section> </section> <section id="CD011769-sec-0355"> <h4 class="title">Sensitivity analyses</h4> <p>Where we had sufficient data, we carried out sensitivity analyses on irritability data excluding studies at: </p> <p> <ul id="CD011769-list-0143"> <li> <p>high risk of attrition bias;</p> </li> <li> <p>high risk of other bias; and</p> </li> <li> <p>with a sample size less than 50.</p> </li> </ul> </p> <section id="CD011769-sec-0356"> <h5 class="title">Atypical antipsychotics versus placebo</h5> <section id="CD011769-sec-0357"> <h6 class="title">Aripiprazole</h6> <p><a href="./references#CD011769-bbs2-0059" title="IchikawaH , MikamiK , OkadaT , YamashitaY , IshizakiY , TomodaA , et al. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study. Child Psychiatry &amp; Human Development2017;48(5):796-806. [DOI: 10.1007/s10578-016-0704-x] [PMCID: PMC5617873] [PMID: 28004215]NCT01617447. A short treatment study of aripiprazole in pediatric patients with autistic disorder [A short-term administration study of aripiprazole in children and adolescents (age: 6 to 17 years) with autistic disorder]. clinicaltrials.gov/ct2/show/NCT01617447 (first received 12 June 2012). ">Ichikawa 2017</a> was at high risk of other bias. We found evidence of an effect of aripiprazole on irritability regardless of whether it was included in meta‐analysis (SMD −0.90, 95% CI −1.52 to −0.29) or excluded (SMD −0.64, 95% CI −0.86 to −0.42). </p> <p>There was also evidence of an effect on irritability whether we included <a href="./references#CD011769-bbs2-0090" title="NCT00468130. Efficacy of aripiprazole versus placebo in the reduction of aggressive and aberrant behavior in autistic children (Abilify) [Efficacy of aripiprazole versus placebo in the reduction of aggressive and aberrant behavior in autistic children]. clinicaltrials.gov/ct2/show/NCT00468130 (first received 2 May 2007). ">NCT00468130</a> in the analysis (SMD −0.90, 95% CI −1.52 to −0.29) or excluded it because it was at high risk of bias and had fewer than 50 participants (SMD −0.99, 95% CI −1.65 to −0.33). </p> </section> <section id="CD011769-sec-0358"> <h6 class="title">Risperidone</h6> <p><a href="./references#CD011769-bbs2-0062" title="KentJM , KushnerS , NingX , KarcherK , NessS , AmanM , et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind placebo-controlled study. Journal of Autism and Developmental Disorders2013;43(8):1773-83. [DOI: 10.1007/s10803-012-1723-5] [PMID: 23212807]NCT00576732. A study of the effectiveness and safety of two doses of risperidone in the treatment of children and adolescents with autistic disorder [Risperidone in the treatment of children and adolescents with autistic disorder: a double-blind, placebo-controlled study of efficacy and safety, followed by an open-label extension study of safety]. clinicaltrials.gov/ct2/show/NCT00576732 (first received 19 December 2007). ">Kent 2013</a> and <a href="./references#CD011769-bbs2-0120" title="MaloneRP . Discontinuing risperidone results in relapse in children with autism spectrum disorders. Evidence-Based Mental Health2006;9(2):56. [DOI: 10.1136/ebmh.9.2.56] [PMID: 16638905]TroostPW , AlthausM , LahuisBE , BuitelaarJK , MinderaaRB , HoekstraPJ . Neuropsychological effect of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. Journal of Child and Adolescent Psychopharmacology2006;16(5):561-73. [DOI: 10.1089/cap.2006.16.561] [PMID: 17069545]TroostPW , LahuisBE , Steenhuis M-P, KetelaarsCE , BuitelaarJK , Van EngelandH , et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(11):1137-44. [DOI: 10.1097/01.chi.0000177055.11229.76] [PMID: 16239862]">Troost 2005</a> were both at high risk of attrition bias and <a href="./references#CD011769-bbs2-0120" title="MaloneRP . Discontinuing risperidone results in relapse in children with autism spectrum disorders. Evidence-Based Mental Health2006;9(2):56. [DOI: 10.1136/ebmh.9.2.56] [PMID: 16638905]TroostPW , AlthausM , LahuisBE , BuitelaarJK , MinderaaRB , HoekstraPJ . Neuropsychological effect of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. Journal of Child and Adolescent Psychopharmacology2006;16(5):561-73. [DOI: 10.1089/cap.2006.16.561] [PMID: 17069545]TroostPW , LahuisBE , Steenhuis M-P, KetelaarsCE , BuitelaarJK , Van EngelandH , et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(11):1137-44. [DOI: 10.1097/01.chi.0000177055.11229.76] [PMID: 16239862]">Troost 2005</a> had multiple domains at high risk of bias. We found evidence of an effect of risperidone when we included both studies in meta‐analysis (SMD −1.11, 95% CI −1.47 to −0.76), when we excluded <a href="./references#CD011769-bbs2-0062" title="KentJM , KushnerS , NingX , KarcherK , NessS , AmanM , et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind placebo-controlled study. Journal of Autism and Developmental Disorders2013;43(8):1773-83. [DOI: 10.1007/s10803-012-1723-5] [PMID: 23212807]NCT00576732. A study of the effectiveness and safety of two doses of risperidone in the treatment of children and adolescents with autistic disorder [Risperidone in the treatment of children and adolescents with autistic disorder: a double-blind, placebo-controlled study of efficacy and safety, followed by an open-label extension study of safety]. clinicaltrials.gov/ct2/show/NCT00576732 (first received 19 December 2007). ">Kent 2013</a> from the meta‐analysis (SMD −1.17, 95% CI −1.62 to 0.72) and when we excluded <a href="./references#CD011769-bbs2-0120" title="MaloneRP . Discontinuing risperidone results in relapse in children with autism spectrum disorders. Evidence-Based Mental Health2006;9(2):56. [DOI: 10.1136/ebmh.9.2.56] [PMID: 16638905]TroostPW , AlthausM , LahuisBE , BuitelaarJK , MinderaaRB , HoekstraPJ . Neuropsychological effect of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. Journal of Child and Adolescent Psychopharmacology2006;16(5):561-73. [DOI: 10.1089/cap.2006.16.561] [PMID: 17069545]TroostPW , LahuisBE , Steenhuis M-P, KetelaarsCE , BuitelaarJK , Van EngelandH , et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(11):1137-44. [DOI: 10.1097/01.chi.0000177055.11229.76] [PMID: 16239862]">Troost 2005</a> from the meta‐analysis SMD −1.00, 95% CI −1.23 to −0.76). </p> <p><a href="./references#CD011769-bbs2-0113" title="LightM , DunbarE , SheaS . P2.104 Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. European Neuropsychopharmacology2004;14(Suppl 3):S278. [DOI: 10.1016/S0924-977X(04)80324-9]LightM , DunbarF , SheaM . Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. International Journal of Neuropsychopharmacology2004;7:S275. [DOI: 10.1016/S0924-977X(04)80324-9]PandinaGJ , BossieCA , YoussefE , ZhuY , DunbarF . Risperidone improves behavioural symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders2007;37(2):367-73. [DOI: 10.1007/s10803-006-0234-7] [PMID: 17019624]SheaS , TurgayA , CarrollA , SchulzM , OrlikH , SmithI , et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics2004;114(5):e634-41. [DOI: 10.1542/peds.2003-0264-F] [PMID: 15492353]">Shea 2004</a> had multiple domains at high risk of bias. We found evidence of an effect of risperidone on irritability whether it was excluded from the meta‐analysis or not (SMD −1.21, 95% CI −1.63 to −0.79). </p> </section> </section> <section id="CD011769-sec-0359"> <h5 class="title">Neurohormone versus placebo</h5> <p>The effect of neurohormone (oxytocin) on irritability compared with placebo with all three included oxytocin studies in the meta‐analysis was SMD −0.24 (95% CI −0.45 to −0.03). When we excluded <a href="./references#CD011769-bbs2-0115" title="NCT01944046. Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B). clinicaltrails.gov/ct2/show/study/NCT01944046?term=NCT01944046&amp;draw=2&amp;rank=1 (first received 1 August 2014). SikichL , KolevzonA , KingB , McDougleC , SandersK , Kim S-J, et al. Intranasal oxytocin in children and adolescents with autism spectrum disorder. New England Journal of Medicine2021;385(16):1462-73. [DOI: 10.1056/NEJMoa2103583] [PMID: 34644471]SpanosM , BetheaT , AldermanC , JohnsonJ , ChandrasekharT , SikichL . Randomized, placebo-controlled trial with open-label extension of intranasal oxytocin for autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2021;60(10):S162. [DOI: 10.1016/j.jaac.2021.09.087]">Sikich 2021</a> (due to high risk of attrition bias) from the meta‐analysis, the effect was SMD −0.41 (95% CI −0.91 to 0.09), when we excluded <a href="./references#CD011769-bbs2-0087" title="MunesueT , NakamuraH , KikuchiM , MiuraY , TakeuchiN , AnmeT , et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study. Frontiers in Psychiatry2016;7:2. [DOI: 10.3389/fpsyt.2016.00002] [PMCID: PMC4720778] [PMID: 26834651]UMIN000007250. A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008548 (first received 9 February 2012). ">Munesue 2016</a> and <a href="./references#CD011769-bbs2-0104" title="NCT01624194. Intranasal oxytocin treatment for social deficits in children with autism [Double-blind, randomized, placebo controlled trial of intranasal oxytocin treatment for social deficits in children with autism]. clinicaltrials.gov/ct2/show/NCT01624194 (first received 20 June 2012). ParkerKJ , OztanO , LiboveRA , SumiyoshiRD , JacksonLP , KarhsonDS , et al. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proceedings of the National Academy of Sciences of the United States of America2017;114(30):8119‐24. [DOI: 10.1073/pnas.1705521114] [PMCID: PMC5544319] [PMID: 28696286]">Parker 2017</a> (both because they included fewer than 50 participants) from the meta‐analysis, the effect was SMD −0.20 (95% CI −0.43 to 0.03), and when we excluded <a href="./references#CD011769-bbs2-0087" title="MunesueT , NakamuraH , KikuchiM , MiuraY , TakeuchiN , AnmeT , et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study. Frontiers in Psychiatry2016;7:2. [DOI: 10.3389/fpsyt.2016.00002] [PMCID: PMC4720778] [PMID: 26834651]UMIN000007250. A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008548 (first received 9 February 2012). ">Munesue 2016</a> only (because it was a cross‐over study), the effect was SMD −0.21 (95% CI −0.43 to 0.01). This shows that, after removing the relevant studies, there was no longer any evidence of an effect of oxytocin. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011769-sec-0360" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011769-sec-0360"></div> <section id="CD011769-sec-0361"> <h3 class="title" id="CD011769-sec-0361">Summary of main results</h3> <p>This large review included 15 major comparisons with data from 131 studies. The major drug classes that the included studies compared to placebo were typical and atypical antipsychotics, ADHD‐related drugs, anticonvulsants, antidementia drugs, antidepressants, antiparkinsonian drugs, anxiolytics, neurohormones, and a number of drugs that did not fall into any of these classes, which we grouped under an 'experimental' category. Studies also compared atypical antipsychotics to typical antipsychotics, antidementia drugs, and antiparkinsonian drugs. They also compared three different types of antidepressants. </p> <section id="CD011769-sec-0362"> <h4 class="title">Antipsychotics</h4> <p>At short‐term follow‐up (up to 6 months), atypical antipsychotics compared with placebo probably reduce irritability (moderate‐certainty evidence) and may also reduce self‐injury (low‐certainty evidence). However, there was no clear evidence of a difference in aggression between groups (very low‐certainty evidence) in participants with ASD. Some AEs may be higher in participants who receive atypical antipsychotics. These include the neurological AEs of dizziness, fatigue, sedation, somnolence, and tremor (low‐certainty evidence), the metabolic AE of increased appetite (low‐certainty evidence), and the gastrointestinal AEs of abdominal pain, constipation, drooling, hypersalivation, and vomiting or nausea, but there was no clear evidence of a difference between groups for any of the other AEs. </p> <p>Studies that investigated typical antipsychotics reported only self‐injury, with no clear evidence of a difference compared to placebo in the short term. Similarly, the two trials of typical antipsychotics versus placebo showed no clear differences in reported musculoskeletal, neurological or psychological AEs. </p> <p>There was no clear evidence of a difference between typical and atypical antipsychotics on behaviours of concern or AEs. </p> </section> <section id="CD011769-sec-0363"> <h4 class="title">Neurohormones</h4> <p>Eight studies reported irritability (466 participants). There was minimal to no clear evidence of a difference in irritability in the short term when neurohormones were compared to placebo (very low‐certainty evidence). None of the neurohormone studies reported aggression or self‐injury. </p> <p>Neurohormones may reduce the risk of headaches (very low‐certainty evidence) but there were no clear differences between groups for any of the other neurological AEs. Neurohormones may decrease the rates of vomiting (low‐certainty evidence), but there were no clear differences between groups for any other gastrointestinal AEs. There were no clear differences between groups for any metabolic or psychological AEs (low‐certainty evidence), or musculoskeletal AEs (very low‐certainty evidence). </p> </section> <section id="CD011769-sec-0364"> <h4 class="title">ADHD‐related medications</h4> <p>At short term follow‐up, ADHD‐related medications may reduce irritability when compared to placebo (low‐certainty evidence). There was no clear evidence of a difference in self‐injury between those receiving ADHD‐related medications compared to a placebo (very low‐certainty evidence). No data were reported for aggression. </p> <p>We found very uncertain evidence that participants who receive ADHD‐related medications have higher rates of AEs compared to those who receive placebo. ADHD‐related medications may increase rates of drowsiness, emotion/tearfulness, fatigue, headache, insomnia, and irritability (very low‐certainty evidence) but there was no clear difference between groups for other neurological AEs: dizziness, motor tics, agitation, repetitive behaviour, or restlessness. ADHD‐related medications may increase rates of depression (very low‐certainty evidence) but there were no clear differences between groups for any of the other psychological AEs. ADHD‐related medications may lead to higher rates of decreased appetite (very low‐certainty evidence) but there were no clear differences between groups for the metabolic AEs of increased appetite or increased motor activity (very low‐certainty evidence). ADHD‐related medications may increase rates of constipation, dry mouth, and stomach or abdominal discomfort, but there were lower rates of diarrhoea in the ADHD‐related medication group compared to placebo. None of the studies in this comparison reported musculoskeletal AEs. </p> </section> <section id="CD011769-sec-0365"> <h4 class="title">Antidepressants</h4> <p>At short‐term follow‐up, there was no clear evidence of a difference in irritability between those receiving antidepressants and those receiving placebo (low‐certainty evidence). Data for aggression and self‐injury were either not reported or could not be included in the analysis. </p> <p>Antidepressants may lead to higher rates of decreased attention (low‐certainty evidence), but there was little to no difference between groups for the other neurological AEs. Antidepressants may increase rates of impulsive behaviour and stereotypy (very low‐certainty evidence) but there were no clear differences between groups for any of the other psychological AEs (very low‐certainty evidence). Antidepressants may increase the rates of decreased energy (very low‐certainty evidence) but there were no clear differences between groups for any of the other metabolic AEs. There were no clear differences between groups for any musculoskeletal AEs (very low‐certainty evidence). </p> </section> </section> <section id="CD011769-sec-0366"> <h3 class="title" id="CD011769-sec-0366">Overall completeness and applicability of evidence</h3> <p>The included studies in this review were conducted over approximately a 30‐year period. Most of the studies were short term (less than 3 months) and as such it is unclear if these AEs and improvements would be observed beyond three months. Several antipsychotic studies did not report sedation as an AE when it is very likely to have occurred. However, sedation is usually a short‐term AE and the reporting and awareness of long‐term effects of antipsychotic use is more important considering the lack of long‐term studies and the risk of serious metabolic disorders such as diabetes mellitus and significant weight gain following antipsychotic use. </p> <p>Prior to the <a href="./references#CD011769-bbs2-0313" title="American Psychiatric Association. DSM-5. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.">DSM‐5 2013</a>, the DSM did not permit a diagnosis of ADHD with an existing diagnosis of ASD or PDD‐NOS (<a href="./references#CD011769-bbs2-0297" title="CorteseS , CastelnauP , MorcilloC , RouxS , Bonnet-BrilhaultF . Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders. Expert Review of Neurotherapeutics2012;12(4):461-73. [DOI: 10.1586/ern.12.23] [PMID: 22449217]">Cortese 2012</a>). The DSM‐5 has removed this criterion for an ADHD diagnosis (<a href="./references#CD011769-bbs2-0270" title="AntshelKM , Zhang-JamesY , FaraoneSV . The comorbidity of ADHD and autism spectrum disorder. Expert Review of Neurotherapeutics2013;13(10):1117-28. [DOI: 10.1586/14737175.2013.840417] [PMID: 24117274]">Antshel 2013</a>; <a href="./references#CD011769-bbs2-0318" title="EpsteinJN , LorenRE . Changes in the definition of ADHD in DSM-5: subtle but important. Neuropsychiatry2013;3(5):455-8. [DOI: 10.2217/npy.13.59] [PMCID: PMC3955126] [PMID: 24644516]">Epstein 2013</a>). As such, there is uncertainty whether improvements in behaviours of concern with ADHD‐related medications in this review are due to improvements in concurrent ADHD symptoms that previously may not have been diagnosed in participants with ASD, rather than improvements in behaviours of concern associated with ASD. </p> <p>Large studies have shown that people with ASD are at least two to three times more likely to have comorbid psychiatric conditions such as anxiety or depression (<a href="./references#CD011769-bbs2-0284" title="BrooksJ , BronskillS , FuL , SaxenaF , ArnejaJ , PinzaruV , et al. Identifying children and youth with autism spectrum disorder in electronic medical records: examining health system utilisation and comorbidities. Autism Research2021;14(2):400-410. [DOI: 10.1002/aur.2419] [PMID: 33098262]">Brooks 2021</a>; <a href="./references#CD011769-bbs2-0420" title="SchendelDA , OvergaardM , ChristensenJ , JorgensenM , VestergaardM , Parner ET. Association of psychiatric and neurologic comorbidity with mortality among persons with autism spectrum disorder in a Danish population. JAMA Pediatrics2016;170(3):243-50. [DOI: 10.1001/jamapediatrics.2015.3935] [PMID: 26752506]">Schendel 2016</a>; <a href="./references#CD011769-bbs2-0452" title="VohraR , MadhavenS , SambamoorthiU . Comorbidity prevalence, healthcare utilization, and expenditures of Medicaid enrolled adults with autism spectrum disorders. Autism2017;21(8):995-1009. [DOI: 10.1177/1362361316665222] [PMID: 27875247]">Vohra 2017</a>). As such, there is uncertainty whether improvements in behaviours of concern observed with antipsychotics or other agents are due to improvements in undiagnosed or unreported psychiatric conditions rather than improvements in ASD‐related behaviours of concern. </p> <p>The vast majority of the studies did not provide details such as severity of ASD, other diagnoses apart from ASD, or the presence of comorbid psychiatric conditions. Furthermore, only some of the studies reported baseline scores of behaviours of concern. Therefore, there are many varying factors and inconsistencies across both the population of interest and the included studies, and the heterogeneity creates a limitation in the synthesis of data. </p> <p>There are also challenges associated with obtaining an accurate record of AEs in people with cognitive or communication limitations. Similarly, the outcome of quality of life is often reported by the family member or caregivers rather than self‐rated by the person with the disability. Although the studies often did not report the severity of ASD, this may introduce bias. </p> <p>A lack of studies involving adults emerged as a major theme in the included trials, with only 22 of 131 trials involving adults as the target population. This highlights the need for more studies involving adults to identify the effectiveness and AEs associated with pharmacological intervention use amongst adults with ASD and behaviours of concern. </p> </section> <section id="CD011769-sec-0367"> <h3 class="title" id="CD011769-sec-0367">Quality of the evidence</h3> <p>Of the comparisons in the summary of findings tables, we downgraded the majority of results by at least one level due to study limitations (refer to <a href="./full#CD011769-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD011769-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011769-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD011769-tbl-0004">summary of findings Table 4</a> for further details). Approximately only 25% of included studies appropriately detailed their random sequence generation and allocation concealment processes. The remaining studies in the review either provided insufficient information to allow us to make a judgement, or we judged them to be at high risk of bias due to 'sequential assignment' methods. We judged approximately 50% of the studies to be at either unclear or high risk of performance and detection bias. In addition, 25% to 30% of the studies were at high risk of attrition or reporting bias. </p> <p>Despite the large number of included studies in this review, we downgraded many of the outcomes by at least one level due to imprecision. This was because important outcomes were often only reported by a few studies, providing a small evidence base of fewer than 200 participants. In addition, the 95% CIs of many of the results were wide and included the possibility of both benefit and harm. </p> <p>As the focus of this review was the effect of these interventions on the ASD population regardless of age, we decided to downgrade some outcomes for indirectness if the only available evidence related to children, as these results may not be directly applicable to the population as a whole. </p> <p>We downgraded many of the outcomes in this review due to inconsistency, based on the high I² statistic values in many of the analyses. We explored reasons for this heterogeneity via subgroup analyses, but the subjective nature of these analyses means we cannot be confident about their results, and therefore cannot attribute the high I² statistic values to these potential effect modifiers. </p> <p>For many of the outcomes included in this review, it was not possible to create a funnel plot to assess publication bias due to an insufficient number of studies. When it was possible to construct these forest plots, there was no evidence of asymmetry, and therefore no reason to downgrade for publication bias. </p> </section> <section id="CD011769-sec-0368"> <h3 class="title" id="CD011769-sec-0368">Potential biases in the review process</h3> <p>Although we made every attempt to adhere to the protocol (<a href="./references#CD011769-bbs2-0471" title="LivingstoneN , MacdonaldG , WilliamsK , CaldwellDM , BakerLB , HazellP . Pharmacological intervention for irritability, aggression, and self‐injury in Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD011769. [DOI: 10.1002/14651858.CD011769]">Livingstone 2015</a>), there remains the possibility of bias in this review process. The search was extensive, but there is a chance that we did not identify important unpublished evidence. Many of the included studies were lacking important details, and although we contacted some study authors to ask for clarification on these issues, in most cases we did not receive confirmation prior to publication. We judged many of the studies to be at unclear or high risk of bias, but we made the decision to pool together all evidence regardless of the results of the risk of bias assessment. If we had chosen to restrict analyses to low risk of bias studies only, the evidence base would be substantially smaller, but perhaps more certain. One aspect that we had not prepared for in our protocol was our choice of relevant 'adverse events'. Although we attempted to account for this post‐protocol, our ultimate choice of which AEs to prioritise may have been biased. </p> <p>There are a number of included studies involving one research group that were conducted within a short period of time. We believe there are some conflicts of interests that have not been disclosed by the authors. It is also uncertain whether different participants are involved in each study due to the consistency of numbers reported and the same comparison used in all trials. We attempted to contact the study authors regarding some of these issues, but we did not receive any correspondence from the contact authors involved. </p> </section> <section id="CD011769-sec-0369"> <h3 class="title" id="CD011769-sec-0369">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, this is the first systematic review that has assessed the effectiveness and AEs of multiple classes of drugs commonly prescribed for behaviours of concern in people with ASD. Two previous systematic reviews focused on the atypical antipsychotics aripiprazole (<a href="./references#CD011769-bbs2-0293" title="ChingH , PringsheimT . Aripiprazole for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD009043. [DOI: 10.1002/14651858.CD009043.pub2] [PMID: 22592735]">Ching 2012</a>), and risperidone (<a href="./references#CD011769-bbs2-0359" title="JesnerOS , Aref-AdibM , CorenE . Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005040. [DOI: 10.1002/14651858.CD005040.pub2] [PMID: 17253538]">Jesner 2007</a>), and two systematic reviews focused on antidepressants, namely tricyclic antidepressants (<a href="./references#CD011769-bbs2-0355" title="HurwitzR , BlackmoreR , HazellP , WilliamsK , WoolfendenS . Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD008372. [DOI: 10.1002/14651858.CD008372.pub2] [PMID: 22419332]">Hurwitz 2012</a>), and SSRIs (<a href="./references#CD011769-bbs2-0460" title="WilliamsK , BrignellA , RandallM , SiloveN , HazellP . Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD004677. [DOI: 10.1002/14651858.CD004677.pub3] [PMID: 23959778]">Williams 2013</a>), for children and adults with ASDs. </p> <section id="CD011769-sec-0370"> <h4 class="title">Antipsychotics</h4> <p>Since the protocol for this review was published, seven systematic reviews of the effectiveness of antipsychotics in people with autism, predominantly children and adolescents, and reported behaviours of concern were published (<a href="./references#CD011769-bbs2-0314" title="D’AlòGL , De CrescenzoF , AmatoL , CrucianiF , DavoliM , FulceriF , et al. Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Health and Quality of Life Outcomes2021;19(1):33. [DOI: 10.1186/s12955-021-01669-0] [PMCID: PMC7831175] [PMID: 33494757]">D’Alò 2021</a>; <a href="./references#CD011769-bbs2-0321" title="FallahMS , ShaikhMR , NeupaneB , RusieckiD , BennettTA , BeyeneJ . Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. Journal of Child and Adolescent Psychopharmacology2019;29(3):168-80. [DOI: 10.1089/cap.2018.0115] [PMID: 30707602]">Fallah 2019</a>; <a href="./references#CD011769-bbs2-0325" title="FungLK , MahajanR , NozzolilloA , BernalP , KrasnerA , JoB , et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics2016;137(Suppl 2):S124-5. [DOI: 10.1542/peds.2015-2851K] [PMID: 26908468]">Fung 2016</a>; <a href="./references#CD011769-bbs2-0347" title="HirschLE , PringsheimT . Aripiprazole for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2016, Issue 6. Art. No: CD009043. [DOI: 10.1002/14651858.CD009043.pub3] [PMCID: PMC7120220] [PMID: 2734413]">Hirsch 2016</a>; <a href="./references#CD011769-bbs2-0375" title="ManeetonN , ManeetonB , PutthisriS , SuttajitS , LikhitsathianS , Srisurapanont M. Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Neuropsychiatric Disease and Treatment2018;14:3063-72. [PMCID: PMC6237245] [PMID: 10.2147/NDT.S174622] [PMID: 30519027]">Maneeton 2018a</a>; <a href="./references#CD011769-bbs2-0376" title="ManeetonN , ManeetonB , PutthisriS , WoottilukP , NarkpongphunA , SrisurapanontM . Risperidone for children and adolescents with autism spectrum disorder: a systematic review. Neuropsychiatric Disease and Treatment2018;14:1811-20. [DOI: 10.2147/NDT.S151802] [PMCID: PMC6045903] [PMID: 30022830]">Maneeton 2018b</a>; <a href="./references#CD011769-bbs2-0377" title="Mano-SousaBJ , PedrosaAM , AlvesBC , GaldurózJC , BeloVS , ChavesVE , et al. Effects of risperidone in autistic children and young adults: a systematic review and meta-analysis. Current Neuropharmacology2021;19(4):538-52. [DOI: 10.2174/1570159X18666200529151741] [PMCID: PMC8206457] [PMID: 32469700]">Mano‐Sousa 2021</a>), in addition to the review by <a href="./references#CD011769-bbs2-0359" title="JesnerOS , Aref-AdibM , CorenE . Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005040. [DOI: 10.1002/14651858.CD005040.pub2] [PMID: 17253538]">Jesner 2007</a>. These included network meta‐analyses (<a href="./references#CD011769-bbs2-0321" title="FallahMS , ShaikhMR , NeupaneB , RusieckiD , BennettTA , BeyeneJ . Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. Journal of Child and Adolescent Psychopharmacology2019;29(3):168-80. [DOI: 10.1089/cap.2018.0115] [PMID: 30707602]">Fallah 2019</a>), meta‐analyses and narrative syntheses. Five of these systematic reviews were on the effectiveness of atypical antipsychotics, one systematic review was on multiple drug classes (<a href="./references#CD011769-bbs2-0325" title="FungLK , MahajanR , NozzolilloA , BernalP , KrasnerA , JoB , et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics2016;137(Suppl 2):S124-5. [DOI: 10.1542/peds.2015-2851K] [PMID: 26908468]">Fung 2016</a>), and the other review was on both typical and atypical antipsychotics (<a href="./references#CD011769-bbs2-0314" title="D’AlòGL , De CrescenzoF , AmatoL , CrucianiF , DavoliM , FulceriF , et al. Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Health and Quality of Life Outcomes2021;19(1):33. [DOI: 10.1186/s12955-021-01669-0] [PMCID: PMC7831175] [PMID: 33494757]">D’Alò 2021</a>). All of these reviews involved children and adolescents, and the outcomes included irritability using the ABC‐I subscale (all reviews), aggression (<a href="./references#CD011769-bbs2-0325" title="FungLK , MahajanR , NozzolilloA , BernalP , KrasnerA , JoB , et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics2016;137(Suppl 2):S124-5. [DOI: 10.1542/peds.2015-2851K] [PMID: 26908468]">Fung 2016</a>), and AEs (all reviews). Across these reviews, as with our current review, there was evidence for the effectiveness of aripiprazole and risperidone in reducing irritability. </p> <p>However, as with this current review, there was evidence for AEs across a range of systematic reviews. This included an overall increase (<a href="./references#CD011769-bbs2-0264" title="AlfagehBH , WangZ , MongkhonP , BesagFM , AlhawassiTM , BrauerR , et al. Safety and tolerability of antipsychotic medication in individuals with autism spectrum disorder: a systematic review and meta-analysis. Pediatric Drugs2019;21(3):153-67. [DOI: 10.1007/s40272-019-00333-x] [PMID: 31134563]">Alfageh 2019</a>; <a href="./references#CD011769-bbs2-0314" title="D’AlòGL , De CrescenzoF , AmatoL , CrucianiF , DavoliM , FulceriF , et al. Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Health and Quality of Life Outcomes2021;19(1):33. [DOI: 10.1186/s12955-021-01669-0] [PMCID: PMC7831175] [PMID: 33494757]">D’Alò 2021</a>), but also increased serious adverse events (<a href="./references#CD011769-bbs2-0314" title="D’AlòGL , De CrescenzoF , AmatoL , CrucianiF , DavoliM , FulceriF , et al. Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Health and Quality of Life Outcomes2021;19(1):33. [DOI: 10.1186/s12955-021-01669-0] [PMCID: PMC7831175] [PMID: 33494757]">D’Alò 2021</a>), in children and adolescents with ASD. </p> <p>Mean weight was also higher in trials of olanzapine, risperidone and aripiprazole (<a href="./references#CD011769-bbs2-0321" title="FallahMS , ShaikhMR , NeupaneB , RusieckiD , BennettTA , BeyeneJ . Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. Journal of Child and Adolescent Psychopharmacology2019;29(3):168-80. [DOI: 10.1089/cap.2018.0115] [PMID: 30707602]">Fallah 2019</a>; <a href="./references#CD011769-bbs2-0325" title="FungLK , MahajanR , NozzolilloA , BernalP , KrasnerA , JoB , et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics2016;137(Suppl 2):S124-5. [DOI: 10.1542/peds.2015-2851K] [PMID: 26908468]">Fung 2016</a>; <a href="./references#CD011769-bbs2-0359" title="JesnerOS , Aref-AdibM , CorenE . Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005040. [DOI: 10.1002/14651858.CD005040.pub2] [PMID: 17253538]">Jesner 2007</a>; <a href="./references#CD011769-bbs2-0347" title="HirschLE , PringsheimT . Aripiprazole for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2016, Issue 6. Art. No: CD009043. [DOI: 10.1002/14651858.CD009043.pub3] [PMCID: PMC7120220] [PMID: 2734413]">Hirsch 2016</a>; <a href="./references#CD011769-bbs2-0375" title="ManeetonN , ManeetonB , PutthisriS , SuttajitS , LikhitsathianS , Srisurapanont M. Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Neuropsychiatric Disease and Treatment2018;14:3063-72. [PMCID: PMC6237245] [PMID: 10.2147/NDT.S174622] [PMID: 30519027]">Maneeton 2018a</a>; <a href="./references#CD011769-bbs2-0377" title="Mano-SousaBJ , PedrosaAM , AlvesBC , GaldurózJC , BeloVS , ChavesVE , et al. Effects of risperidone in autistic children and young adults: a systematic review and meta-analysis. Current Neuropharmacology2021;19(4):538-52. [DOI: 10.2174/1570159X18666200529151741] [PMCID: PMC8206457] [PMID: 32469700]">Mano‐Sousa 2021</a>). Systematic reviews also found that haloperidol, risperidone, and aripiprazole were associated with somnolence or sedation (<a href="./references#CD011769-bbs2-0325" title="FungLK , MahajanR , NozzolilloA , BernalP , KrasnerA , JoB , et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics2016;137(Suppl 2):S124-5. [DOI: 10.1542/peds.2015-2851K] [PMID: 26908468]">Fung 2016</a>; <a href="./references#CD011769-bbs2-0347" title="HirschLE , PringsheimT . Aripiprazole for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2016, Issue 6. Art. No: CD009043. [DOI: 10.1002/14651858.CD009043.pub3] [PMCID: PMC7120220] [PMID: 2734413]">Hirsch 2016</a>; <a href="./references#CD011769-bbs2-0375" title="ManeetonN , ManeetonB , PutthisriS , SuttajitS , LikhitsathianS , Srisurapanont M. Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Neuropsychiatric Disease and Treatment2018;14:3063-72. [PMCID: PMC6237245] [PMID: 10.2147/NDT.S174622] [PMID: 30519027]">Maneeton 2018a</a>; <a href="./references#CD011769-bbs2-0376" title="ManeetonN , ManeetonB , PutthisriS , WoottilukP , NarkpongphunA , SrisurapanontM . Risperidone for children and adolescents with autism spectrum disorder: a systematic review. Neuropsychiatric Disease and Treatment2018;14:1811-20. [DOI: 10.2147/NDT.S151802] [PMCID: PMC6045903] [PMID: 30022830]">Maneeton 2018b</a>). Extrapyramidal symptoms were also increased in the review by <a href="./references#CD011769-bbs2-0325" title="FungLK , MahajanR , NozzolilloA , BernalP , KrasnerA , JoB , et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics2016;137(Suppl 2):S124-5. [DOI: 10.1542/peds.2015-2851K] [PMID: 26908468]">Fung 2016</a>; and hypersalivation in the review by <a href="./references#CD011769-bbs2-0376" title="ManeetonN , ManeetonB , PutthisriS , WoottilukP , NarkpongphunA , SrisurapanontM . Risperidone for children and adolescents with autism spectrum disorder: a systematic review. Neuropsychiatric Disease and Treatment2018;14:1811-20. [DOI: 10.2147/NDT.S151802] [PMCID: PMC6045903] [PMID: 30022830]">Maneeton 2018b</a>. </p> </section> <section id="CD011769-sec-0371"> <h4 class="title">Neurohormones</h4> <p>We found that neurohormones may have a minimal to small effect on behaviours of concern (irritability). In the Cochrane Review of intravenous secretin compared to a placebo treatment in children or adults diagnosed with ASD, there was no effect of secretin in any of the three studies that reported irritability (<a href="./references#CD011769-bbs2-0459" title="WilliamsK , WrayJA , WheelerDM . Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2012, Issue 4. Art. No: CD003495. [DOI: 10.1002/14651858.CD003495.pub3] [PMCID: PMC7154585] [PMID: 22513913]">Williams 2012</a>). </p> </section> <section id="CD011769-sec-0372"> <h4 class="title">ADHD‐related medications</h4> <p>The current review found that there was low‐certainty evidence that overall ADHD‐related medications decreased irritability. Findings from two previous reviews did not find evidence that ADHD medications had an effect on irritability. A narrative synthesis by <a href="./references#CD011769-bbs2-0328" title="GhanizadehA , MollaM , OlangaGJ . The effect of stimulants on irritability in autism comorbid with ADHD: a systematic review. Neuropsychiatric Disease and Treatment2019;15:1547-55. [DOI: 10.2147/NDT.S194022] [PMCID: PMC6559223] [PMID: 31239689]">Ghanizadeh 2019</a> of clinical trials of stimulants in children and adolescents with both autism and ADHD, concluded inadequate evidence to support or refute their effect on irritability. While a Cochrane Review by <a href="./references#CD011769-bbs2-0435" title="SturmanN , DeckxL , Van DrielML . Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD011144. [DOI: 10.1002/14651858.CD011144.pub2] [PMCID: PMC6486133] [PMID: 29159857]">Sturman 2017</a> found that methylphenidate did change reports of irritability that were reported as AEs in children and adolescents with ASD. </p> </section> <section id="CD011769-sec-0373"> <h4 class="title">Antidepressants</h4> <p>We found no clear differences between antidepressants and placebo in behaviours of concern and this seems to be in line with previous evidence from trials of antidepressants. </p> <p>In the Cochrane Review of SSRIs for ASD there was no evidence that fenfluramine and fluoxetine had an effect, and only limited evidence that citalopram reduced irritability (<a href="./references#CD011769-bbs2-0460" title="WilliamsK , BrignellA , RandallM , SiloveN , HazellP . Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD004677. [DOI: 10.1002/14651858.CD004677.pub3] [PMID: 23959778]">Williams 2013</a>). In addition, citalopram and fenfluramine were associated with increased AEs. </p> <p>A Cochrane Review of tricyclic antidepressants for ASD in children and adolescents also found no evidence that clomipramine or tianeptine improved irritability, although clomipramine was associated with cardiac and neurological AEs, and tianeptine with sedation (<a href="./references#CD011769-bbs2-0355" title="HurwitzR , BlackmoreR , HazellP , WilliamsK , WoolfendenS . Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD008372. [DOI: 10.1002/14651858.CD008372.pub2] [PMID: 22419332]">Hurwitz 2012</a>). </p> <p>A more recent systematic review by <a href="./references#CD011769-bbs2-0306" title="DebS , RoyM , LeeR , MajidM , LimbuB , SantambrogioJ , et al. Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: systematic review and meta-analysis. BJPsych Open2021;7(6):e179. [DOI: 10.1192/bjo.2021.1003] [PMCID: PMC8503912] [PMID: 34593083]">Deb 2021</a>, found no evidence that citalopram, clomipramine, venlafaxine or the SSRI fluoxetine decreased behaviours of concern, though one of two trials of fluvoxamine reduced aggression. </p> </section> <section id="CD011769-sec-0374"> <h4 class="title">Anticonvulsants</h4> <p>As with our findings, there is little evidence that anticonvulsants decrease behaviours of concern. In a systematic review of anticonvulsants in children and adolescents by <a href="./references#CD011769-bbs2-0302" title="DavicoC , CanaveseC , VittoriniR , GandioneM , VitielloB . Anticonvulsants for psychiatric disorders in children and adolescents: a systematic review of their efficacy. Frontiers in Psychiatry2018;9:270. [DOI: 10.3389/fpsyt.2018.00270] [PMCID: PMC6024111] [PMID: 29988399]">Davico 2018</a>, there was limited evidence of valproate having an effect on irritability and aggression in a single trial at 12 but not eight weeks, and no evidence that levetiracetam had any effect. In the narrative review by <a href="./references#CD011769-bbs2-0283" title="BrondinoN , Fusar-PoliL , PanisiC , DamianiS , BaraleF , PolitiP . Pharmacological modulation of GABA function in autism spectrum disorders: a systematic review of human studies. Journal of Autism and Developmental Disorders2016;46(3):825-39. [DOI: 10.1007/s10803-015-2619-y] [PMID: 26443675]">Brondino 2016</a> there were mixed findings with one of two trials finding no effect of valproate on aggression and irritability, while the other reported that valproate reduced irritability. Similarly, one of the two trials in the systematic review by <a href="./references#CD011769-bbs2-0325" title="FungLK , MahajanR , NozzolilloA , BernalP , KrasnerA , JoB , et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics2016;137(Suppl 2):S124-5. [DOI: 10.1542/peds.2015-2851K] [PMID: 26908468]">Fung 2016</a> reported that valproate decreased irritability with no apparent effect in the other trial. </p> <p>The review of valproate use in <a href="./references#CD011769-bbs2-0283" title="BrondinoN , Fusar-PoliL , PanisiC , DamianiS , BaraleF , PolitiP . Pharmacological modulation of GABA function in autism spectrum disorders: a systematic review of human studies. Journal of Autism and Developmental Disorders2016;46(3):825-39. [DOI: 10.1007/s10803-015-2619-y] [PMID: 26443675]">Brondino 2016</a> also reported mild side effects but no serious adverse events were reported. The review by <a href="./references#CD011769-bbs2-0325" title="FungLK , MahajanR , NozzolilloA , BernalP , KrasnerA , JoB , et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics2016;137(Suppl 2):S124-5. [DOI: 10.1542/peds.2015-2851K] [PMID: 26908468]">Fung 2016</a> also reported that valproate was associated with weight gain. </p> </section> <section id="CD011769-sec-0375"> <h4 class="title">Antiparkinsonians</h4> <p>As with the current review, there was no evidence that antiparkinsonians decreased behaviours of concern compared with placebo. The systematic review by <a href="./references#CD011769-bbs2-0325" title="FungLK , MahajanR , NozzolilloA , BernalP , KrasnerA , JoB , et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics2016;137(Suppl 2):S124-5. [DOI: 10.1542/peds.2015-2851K] [PMID: 26908468]">Fung 2016</a> found no evidence that amantadine decreased irritability in the one small placebo‐controlled trial, and amantadine was also associated with somnolence and sedation. </p> </section> <section id="CD011769-sec-0376"> <h4 class="title">Anxiolytics</h4> <p>A recent review showed contradictory findings for the effectiveness of anxiolytics on behaviours of concern. In the systematic review by <a href="./references#CD011769-bbs2-0306" title="DebS , RoyM , LeeR , MajidM , LimbuB , SantambrogioJ , et al. Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: systematic review and meta-analysis. BJPsych Open2021;7(6):e179. [DOI: 10.1192/bjo.2021.1003] [PMCID: PMC8503912] [PMID: 34593083]">Deb 2021</a>, only one of two trials of buspirone showed a decrease in irritability. No major adverse events were reported, with the most common adverse events being changes in appetite, drowsiness, and fatigue. </p> </section> <section id="CD011769-sec-0377"> <h4 class="title">Experimental</h4> <p>Systematic reviews were identified for several individual drugs or drug classes that we categorised as experimental for the purposes of this review. They were reviews of the GABA modulators acamprosate, arbaclofen, bumetanide, carnosine, flumazenil, riluzole and valproate in autism reviewed by <a href="./references#CD011769-bbs2-0283" title="BrondinoN , Fusar-PoliL , PanisiC , DamianiS , BaraleF , PolitiP . Pharmacological modulation of GABA function in autism spectrum disorders: a systematic review of human studies. Journal of Autism and Developmental Disorders2016;46(3):825-39. [DOI: 10.1007/s10803-015-2619-y] [PMID: 26443675]">Brondino 2016</a> (the findings with valproate are discussed under anticonvulsants); a review of riluzole by <a href="./references#CD011769-bbs2-0303" title="De BoerJN , VingerhoetsC , HirdesM , McAlonanGM , AmelsvoortTV , ZinkstokJR . Efficacy and tolerability of riluzole in psychiatric disorders: a systematic review and preliminary meta-analysis. Psychiatry Research2019;278:294-302. [DOI: 10.1016/j.psychres.2019.06.020] [PMID: 31254879]">De Boer 2019</a>; and a review of n‐acetylcysteine by <a href="./references#CD011769-bbs2-0368" title="Lee T-M, Lee K-M, Lee C-Y, Lee H-C, Tam K-W, Loh E-W. Effectiveness of N-acetylcysteine in autism spectrum disorders: a meta-analysis of randomized controlled trials. Australian and New Zealand Journal of Psychiatry2021;55(2):196-206. [DOI: 10.1177/0004867420952540] [PMID: 32900213]">Lee 2021</a>. </p> <p>As with our findings, in the systematic review by <a href="./references#CD011769-bbs2-0283" title="BrondinoN , Fusar-PoliL , PanisiC , DamianiS , BaraleF , PolitiP . Pharmacological modulation of GABA function in autism spectrum disorders: a systematic review of human studies. Journal of Autism and Developmental Disorders2016;46(3):825-39. [DOI: 10.1007/s10803-015-2619-y] [PMID: 26443675]">Brondino 2016</a>, the authors concluded that there was insufficient evidence to suggest the use of the GABA modulators in autism. Though a later review of riluzole by <a href="./references#CD011769-bbs2-0303" title="De BoerJN , VingerhoetsC , HirdesM , McAlonanGM , AmelsvoortTV , ZinkstokJR . Efficacy and tolerability of riluzole in psychiatric disorders: a systematic review and preliminary meta-analysis. Psychiatry Research2019;278:294-302. [DOI: 10.1016/j.psychres.2019.06.020] [PMID: 31254879]">De Boer 2019</a> found that riluzole decreased irritability in one trial with no apparent effect in the other trial. </p> <p>In the meta‐analysis of N‐acetylcysteine by <a href="./references#CD011769-bbs2-0368" title="Lee T-M, Lee K-M, Lee C-Y, Lee H-C, Tam K-W, Loh E-W. Effectiveness of N-acetylcysteine in autism spectrum disorders: a meta-analysis of randomized controlled trials. Australian and New Zealand Journal of Psychiatry2021;55(2):196-206. [DOI: 10.1177/0004867420952540] [PMID: 32900213]">Lee 2021</a>, there was no effect across all four identified studies in ASD, although mild AEs were reported. This was in line with our findings in this review. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011769-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Original search November 2020" data-id="CD011769-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Original search November 2020</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Search update June 2022" data-id="CD011769-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Search update June 2022</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias in included studies" data-id="CD011769-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias in included studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Visual representation of risk of bias across all included studies" data-id="CD011769-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Visual representation of risk of bias across all included studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-FIG-05" target="_blank"><b></b></a></p> </div><img alt="SE: standard error; SMD: standardised mean differenceAtypical antipsychotics versus placebo (12 studies, 973 participants; Analysis 1.1)" data-id="CD011769-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p><b>SE:</b> standard error; <b>SMD:</b> standardised mean difference </p> <p>Atypical antipsychotics versus placebo (12 studies, 973 participants; <a href="./references#CD011769-fig-0011" title="">Analysis 1.1</a>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-FIG-06" target="_blank"><b></b></a></p> </div><img alt="log: logarithm; SE: standard error; RR: risk ratioAtypical antipsychotics versus placebo (8 studies, 702 participants; Analysis 1.9)" data-id="CD011769-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p><b>log:</b> logarithm; <b>SE:</b> standard error; <b>RR:</b> risk ratio </p> <p>Atypical antipsychotics versus placebo (8 studies, 702 participants; <a href="./references#CD011769-fig-0019" title="">Analysis 1.9</a>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-FIG-07" target="_blank"><b></b></a></p> </div><img alt="log: logarithm; RR: risk ratio; SE: standard error; SMD: standardised mean differenceAtypical antipsychotics versus placebo (11 studies, 974 participants; Analysis 1.12)" data-id="CD011769-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p><b>log:</b> logarithm; <b>RR:</b> risk ratio; <b>SE:</b> standard error; <b>SMD:</b> standardised mean difference </p> <p>Atypical antipsychotics versus placebo (11 studies, 974 participants; <a href="./references#CD011769-fig-0022" title="">Analysis 1.12</a>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-FIG-08" target="_blank"><b></b></a></p> </div><img alt="log: logarithm; RR: risk ratio; SE: standard error; SMD: standardised mean differenceNeurohormone versus placebo (10 studies, 863 participants; Analysis 2.9)" data-id="CD011769-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p><b>log:</b> logarithm; <b>RR:</b> risk ratio; <b>SE:</b> standard error; <b>SMD:</b> standardised mean difference </p> <p>Neurohormone versus placebo (10 studies, 863 participants; <a href="./references#CD011769-fig-0040" title="">Analysis 2.9</a>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-FIG-09" target="_blank"><b></b></a></p> </div><img alt="log: logarithm; RR: risk ratio; SE: standard error; SMD: standardised mean differenceAntidepressant versus placebo (4 studies, 243 participants; Analysis 4.7)" data-id="CD011769-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p><b>log:</b> logarithm; <b>RR:</b> risk ratio; <b>SE:</b> standard error; <b>SMD:</b> standardised mean difference </p> <p>Antidepressant versus placebo (4 studies, 243 participants; <a href="./references#CD011769-fig-0071" title="">Analysis 4.7</a>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-FIG-10" target="_blank"><b></b></a></p> </div><img alt="log: logarithm; RR: risk ratio; SE: standard error; SMD: standardised mean differenceAntidepressant versus placebo (4 studies, 243 participants; Analysis 4.8)" data-id="CD011769-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p><b>log:</b> logarithm; <b>RR:</b> risk ratio; <b>SE:</b> standard error; <b>SMD:</b> standardised mean difference </p> <p>Antidepressant versus placebo (4 studies, 243 participants; <a href="./references#CD011769-fig-0072" title="">Analysis 4.8</a>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-FIG-10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 1: Irritability" data-id="CD011769-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 1: Irritability</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 2: Relapse" data-id="CD011769-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 2: Relapse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 3: Improvement" data-id="CD011769-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 3: Improvement</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 4: Aggression" data-id="CD011769-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 4: Aggression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 5: Self‐injury" data-id="CD011769-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 5: Self‐injury</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 6: Adverse effects: cardiovascular" data-id="CD011769-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 6: Adverse effects: cardiovascular</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 7: Adverse effects: gastrointestinal" data-id="CD011769-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 7: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 8: Adverse effects: immune system" data-id="CD011769-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 8: Adverse effects: immune system </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 9: Adverse effects: metabolic (dichotomous)" data-id="CD011769-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 9: Adverse effects: metabolic (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 10: Adverse effects: metabolic (continuous)" data-id="CD011769-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 10: Adverse effects: metabolic (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 11: Adverse effects: musculoskeletal" data-id="CD011769-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 11: Adverse effects: musculoskeletal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 12: Adverse effects: neurological" data-id="CD011769-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 12: Adverse effects: neurological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 13: Adverse effects: psychological" data-id="CD011769-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 13: Adverse effects: psychological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 14: Adverse effects: respiratory" data-id="CD011769-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 14: Adverse effects: respiratory</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 15: Adverse effects: skin" data-id="CD011769-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 15: Adverse effects: skin</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 16: Adverse effects: urinary" data-id="CD011769-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 16: Adverse effects: urinary</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 17: Quality of life" data-id="CD011769-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 17: Quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 18: Tolerability/acceptability: loss to follow‐up" data-id="CD011769-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 18: Tolerability/acceptability: loss to follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 19: Subgroup analysis: age ‐ irritability" data-id="CD011769-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 19: Subgroup analysis: age ‐ irritability </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 20: Subgroup analysis: age ‐ aggression" data-id="CD011769-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 20: Subgroup analysis: age ‐ aggression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Atypical antipsychotic vs placebo, Outcome 21: Subgroup analysis: cognitive ability ‐ irritability" data-id="CD011769-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Atypical antipsychotic vs placebo, Outcome 21: Subgroup analysis: cognitive ability ‐ irritability </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 1: Irritability" data-id="CD011769-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 1: Irritability</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 2: Self‐injury" data-id="CD011769-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 2: Self‐injury</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 3: Adverse effects: cardiovascular" data-id="CD011769-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 3: Adverse effects: cardiovascular</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 4: Adverse effects: gastrointestinal" data-id="CD011769-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 4: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 5: Adverse effects: immune system" data-id="CD011769-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 5: Adverse effects: immune system</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 6: Adverse effects: metabolic (dichotomous)" data-id="CD011769-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 6: Adverse effects: metabolic (dichotomous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 7: Adverse effects: metabolic (continuous)" data-id="CD011769-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 7: Adverse effects: metabolic (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 8: Adverse effects: musculoskeletal" data-id="CD011769-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 8: Adverse effects: musculoskeletal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 9: Adverse effects: neurological" data-id="CD011769-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 9: Adverse effects: neurological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 10: Adverse effects: psychological" data-id="CD011769-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 10: Adverse effects: psychological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 11: Adverse effects: respiratory" data-id="CD011769-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 11: Adverse effects: respiratory</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 12: Adverse effects: skin" data-id="CD011769-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 12: Adverse effects: skin</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 13: Adverse effects: urinary" data-id="CD011769-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 13: Adverse effects: urinary</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 14: Adverse effects: other" data-id="CD011769-fig-0045" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 14: Adverse effects: other</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 15: Quality of life" data-id="CD011769-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 15: Quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 16: Tolerability/acceptability: loss to follow‐up" data-id="CD011769-fig-0047" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 16: Tolerability/acceptability: loss to follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Neurohormone versus placebo, Outcome 17: Subgroup analyses: gender ‐ irritability" data-id="CD011769-fig-0048" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Neurohormone versus placebo, Outcome 17: Subgroup analyses: gender ‐ irritability </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 1: Irritability" data-id="CD011769-fig-0049" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 1: Irritability</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 2: Self‐injury" data-id="CD011769-fig-0050" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 2: Self‐injury</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 3: Adverse effects: cardiovascular" data-id="CD011769-fig-0051" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 3: Adverse effects: cardiovascular</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 4: Adverse effects: gastrointestinal" data-id="CD011769-fig-0052" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 4: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 5: Adverse effects: immune system" data-id="CD011769-fig-0053" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 5: Adverse effects: immune system </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 6: Adverse effects: metabolic (dichotomous)" data-id="CD011769-fig-0054" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 6: Adverse effects: metabolic (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 7: Adverse effects: neurological (dichotomous)" data-id="CD011769-fig-0055" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 7: Adverse effects: neurological (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 8: Adverse effects: neurological (continuous)" data-id="CD011769-fig-0056" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 8: Adverse effects: neurological (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 9: Adverse effects: psychological (dichotomous)" data-id="CD011769-fig-0057" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 9: Adverse effects: psychological (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 10: Adverse effects: respiratory" data-id="CD011769-fig-0058" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 10: Adverse effects: respiratory</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 11: Adverse effects: skin" data-id="CD011769-fig-0059" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 11: Adverse effects: skin</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 12: Adverse effects: urinary" data-id="CD011769-fig-0060" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 12: Adverse effects: urinary</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 13: Quality of life" data-id="CD011769-fig-0061" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 13: Quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 14: Tolerability/acceptability: loss to follow‐up" data-id="CD011769-fig-0062" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 14: Tolerability/acceptability: loss to follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 15: Subgroup analyses: gender ‐ irritability" data-id="CD011769-fig-0063" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 15: Subgroup analyses: gender ‐ irritability </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-003.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ADHD‐related medications vs placebo, Outcome 16: Subgroup analyses: age ‐ irritability" data-id="CD011769-fig-0064" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-003.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3: ADHD‐related medications vs placebo, Outcome 16: Subgroup analyses: age ‐ irritability </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-003.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 1: Irritability" data-id="CD011769-fig-0065" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 1: Irritability</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 2: Adverse effects: cardiovascular" data-id="CD011769-fig-0066" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 2: Adverse effects: cardiovascular</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 3: Adverse effects: gastrointestinal" data-id="CD011769-fig-0067" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 3: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 4: Adverse effect: immune system" data-id="CD011769-fig-0068" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 4: Adverse effect: immune system</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 5: Adverse effects: metabolic" data-id="CD011769-fig-0069" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 5: Adverse effects: metabolic</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 6: Adverse effect: musculoskeletal" data-id="CD011769-fig-0070" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 6: Adverse effect: musculoskeletal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 7: Adverse effects: neurological" data-id="CD011769-fig-0071" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 7: Adverse effects: neurological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 8: Adverse effects: psychological" data-id="CD011769-fig-0072" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 8: Adverse effects: psychological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 9: Adverse effects: respiratory" data-id="CD011769-fig-0073" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 9: Adverse effects: respiratory</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 10: Adverse effects: skin" data-id="CD011769-fig-0074" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 10: Adverse effects: skin</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 11: Adverse effects: urinary" data-id="CD011769-fig-0075" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 11: Adverse effects: urinary</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 12: Adverse effects: other" data-id="CD011769-fig-0076" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 12: Adverse effects: other</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 13: Tolerability/acceptability: loss to follow‐up" data-id="CD011769-fig-0077" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 13: Tolerability/acceptability: loss to follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 14: Subgroup analyses: gender ‐ irritability" data-id="CD011769-fig-0078" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 14: Subgroup analyses: gender ‐ irritability</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-004.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antidepressant vs placebo, Outcome 15: Serious adverse events" data-id="CD011769-fig-0079" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-004.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4: Antidepressant vs placebo, Outcome 15: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-004.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Atypical vs typical antipsychotics, Outcome 1: Irritability" data-id="CD011769-fig-0080" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Atypical vs typical antipsychotics, Outcome 1: Irritability</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Atypical vs typical antipsychotics, Outcome 2: Adverse effects: cardiovascular (tachycardia)" data-id="CD011769-fig-0081" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Atypical vs typical antipsychotics, Outcome 2: Adverse effects: cardiovascular (tachycardia) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Atypical vs typical antipsychotics, Outcome 3: Adverse effects: gastrointestinal" data-id="CD011769-fig-0082" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Atypical vs typical antipsychotics, Outcome 3: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Atypical vs typical antipsychotics, Outcome 4: Adverse effects: metabolic (dichotomous)" data-id="CD011769-fig-0083" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Atypical vs typical antipsychotics, Outcome 4: Adverse effects: metabolic (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Atypical vs typical antipsychotics, Outcome 5: Adverse effects: metabolic (continuous)" data-id="CD011769-fig-0084" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Atypical vs typical antipsychotics, Outcome 5: Adverse effects: metabolic (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Atypical vs typical antipsychotics, Outcome 6: Adverse effects: neurological" data-id="CD011769-fig-0085" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Atypical vs typical antipsychotics, Outcome 6: Adverse effects: neurological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Atypical vs typical antipsychotics, Outcome 7: Adverse effects: respiratory" data-id="CD011769-fig-0086" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Atypical vs typical antipsychotics, Outcome 7: Adverse effects: respiratory</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Atypical vs typical antipsychotics, Outcome 8: Adverse effects: skin" data-id="CD011769-fig-0087" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Atypical vs typical antipsychotics, Outcome 8: Adverse effects: skin</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Atypical vs typical antipsychotics, Outcome 9: Adverse effects: urinary" data-id="CD011769-fig-0088" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Atypical vs typical antipsychotics, Outcome 9: Adverse effects: urinary</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Atypical vs typical antipsychotics, Outcome 10: Tolerability/acceptability: loss to follow‐up" data-id="CD011769-fig-0089" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Atypical vs typical antipsychotics, Outcome 10: Tolerability/acceptability: loss to follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Atypical vs atypical antipsychotics, Outcome 1: Irritability" data-id="CD011769-fig-0090" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Atypical vs atypical antipsychotics, Outcome 1: Irritability</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Atypical vs atypical antipsychotics, Outcome 2: Adverse effects: cardiovascular" data-id="CD011769-fig-0091" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Atypical vs atypical antipsychotics, Outcome 2: Adverse effects: cardiovascular</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Atypical vs atypical antipsychotics, Outcome 3: Adverse effects: gastrointestinal" data-id="CD011769-fig-0092" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Atypical vs atypical antipsychotics, Outcome 3: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Atypical vs atypical antipsychotics, Outcome 4: Adverse effects: metabolic" data-id="CD011769-fig-0093" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Atypical vs atypical antipsychotics, Outcome 4: Adverse effects: metabolic</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Atypical vs atypical antipsychotics, Outcome 5: Adverse effects: musculoskeletal" data-id="CD011769-fig-0094" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Atypical vs atypical antipsychotics, Outcome 5: Adverse effects: musculoskeletal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Atypical vs atypical antipsychotics, Outcome 6: Adverse effects: neurological" data-id="CD011769-fig-0095" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Atypical vs atypical antipsychotics, Outcome 6: Adverse effects: neurological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Atypical vs atypical antipsychotics, Outcome 7: Adverse effects: psychological" data-id="CD011769-fig-0096" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Atypical vs atypical antipsychotics, Outcome 7: Adverse effects: psychological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Atypical vs atypical antipsychotics, Outcome 8: Adverse effects: skin" data-id="CD011769-fig-0097" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Atypical vs atypical antipsychotics, Outcome 8: Adverse effects: skin</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-006.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Atypical vs atypical antipsychotics, Outcome 9: Adverse effects: urinary" data-id="CD011769-fig-0098" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-006.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6: Atypical vs atypical antipsychotics, Outcome 9: Adverse effects: urinary</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-006.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Atypical vs atypical antipsychotics, Outcome 10: Tolerability/acceptability: loss to follow‐up" data-id="CD011769-fig-0099" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-006.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6: Atypical vs atypical antipsychotics, Outcome 10: Tolerability/acceptability: loss to follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-006.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Atypical antipsychotic vs antidementia, Outcome 1: Irritability" data-id="CD011769-fig-0100" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Atypical antipsychotic vs antidementia, Outcome 1: Irritability</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Atypical antipsychotic vs antidementia, Outcome 2: Adverse effects: neurological" data-id="CD011769-fig-0101" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Atypical antipsychotic vs antidementia, Outcome 2: Adverse effects: neurological </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Atypical antipsychotic vs antidementia, Outcome 3: Tolerability" data-id="CD011769-fig-0102" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Atypical antipsychotic vs antidementia, Outcome 3: Tolerability</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Atypical antipsychotic vs antiparkinsonian, Outcome 1: Adverse effects: gastrointestinal" data-id="CD011769-fig-0103" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Atypical antipsychotic vs antiparkinsonian, Outcome 1: Adverse effects: gastrointestinal </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Atypical antipsychotic vs antiparkinsonian, Outcome 2: Adverse effects: metabolic" data-id="CD011769-fig-0104" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Atypical antipsychotic vs antiparkinsonian, Outcome 2: Adverse effects: metabolic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Atypical antipsychotic vs antiparkinsonian, Outcome 3: Adverse effects: neurological" data-id="CD011769-fig-0105" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Atypical antipsychotic vs antiparkinsonian, Outcome 3: Adverse effects: neurological </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anticonvulsant vs placebo, Outcome 1: Irritability" data-id="CD011769-fig-0106" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Anticonvulsant vs placebo, Outcome 1: Irritability</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anticonvulsant vs placebo, Outcome 2: Aggression" data-id="CD011769-fig-0107" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Anticonvulsant vs placebo, Outcome 2: Aggression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anticonvulsant vs placebo, Outcome 3: Adverse effects: gastrointestinal" data-id="CD011769-fig-0108" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Anticonvulsant vs placebo, Outcome 3: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anticonvulsant vs placebo, Outcome 4: Adverse effects: immune system" data-id="CD011769-fig-0109" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Anticonvulsant vs placebo, Outcome 4: Adverse effects: immune system</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anticonvulsant vs placebo, Outcome 5: Adverse effects: metabolic (dichotomous)" data-id="CD011769-fig-0110" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Anticonvulsant vs placebo, Outcome 5: Adverse effects: metabolic (dichotomous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-009.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anticonvulsant vs placebo, Outcome 6: Adverse effects: metabolic (continuous)" data-id="CD011769-fig-0111" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-009.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9: Anticonvulsant vs placebo, Outcome 6: Adverse effects: metabolic (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-009.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anticonvulsant vs placebo, Outcome 7: Adverse Effects: neurological" data-id="CD011769-fig-0112" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-009.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9: Anticonvulsant vs placebo, Outcome 7: Adverse Effects: neurological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-009.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anticonvulsant vs placebo, Outcome 8: Adverse effects: psychological" data-id="CD011769-fig-0113" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-009.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9: Anticonvulsant vs placebo, Outcome 8: Adverse effects: psychological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-009.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anticonvulsant vs placebo, Outcome 9: Adverse effects: skin" data-id="CD011769-fig-0114" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-009.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9: Anticonvulsant vs placebo, Outcome 9: Adverse effects: skin</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-009.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anticonvulsant vs placebo, Outcome 10: Adverse effects: urinary" data-id="CD011769-fig-0115" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-009.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9: Anticonvulsant vs placebo, Outcome 10: Adverse effects: urinary</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-009.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Anticonvulsant vs placebo, Outcome 11: Tolerability/acceptability: loss to follow‐up" data-id="CD011769-fig-0116" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-009.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9: Anticonvulsant vs placebo, Outcome 11: Tolerability/acceptability: loss to follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-009.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Antidepressant vs antidepressant, Outcome 1: Adverse effects: cardiovascular" data-id="CD011769-fig-0117" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Antidepressant vs antidepressant, Outcome 1: Adverse effects: cardiovascular</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Antidepressant vs antidepressant, Outcome 2: Adverse effects: gastrointestinal" data-id="CD011769-fig-0118" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Antidepressant vs antidepressant, Outcome 2: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 1: Irritability (continuous)" data-id="CD011769-fig-0119" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 1: Irritability (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 2: Irritability (dichotomous)" data-id="CD011769-fig-0120" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 2: Irritability (dichotomous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 3: Aggression" data-id="CD011769-fig-0121" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 3: Aggression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 4: Adverse effects: gastrointestinal" data-id="CD011769-fig-0122" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 4: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 5: Adverse events: metabolic" data-id="CD011769-fig-0123" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 5: Adverse events: metabolic</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 6: Adverse effects: musculoskeletal pain" data-id="CD011769-fig-0124" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 6: Adverse effects: musculoskeletal pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 7: Adverse effects: neurological" data-id="CD011769-fig-0125" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 7: Adverse effects: neurological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 8: Adverse events: other" data-id="CD011769-fig-0126" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.8</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 8: Adverse events: other</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 9: Adverse events: psychological" data-id="CD011769-fig-0127" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.9</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 9: Adverse events: psychological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 10: Adverse events: respiratory" data-id="CD011769-fig-0128" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.10</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 10: Adverse events: respiratory</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 11: Adverse effects: skin" data-id="CD011769-fig-0129" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.11</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 11: Adverse effects: skin</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 12: Serious adverse events" data-id="CD011769-fig-0130" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.12</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 12: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 13: Tolerability/acceptability: loss to follow‐up" data-id="CD011769-fig-0131" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.13</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 13: Tolerability/acceptability: loss to follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-011.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Antidementia versus placebo, Outcome 14: Subgroup analysis: age ‐ irritability (continuous)" data-id="CD011769-fig-0132" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-011.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.14</div> <div class="figure-caption"> <p>Comparison 11: Antidementia versus placebo, Outcome 14: Subgroup analysis: age ‐ irritability (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-011.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Antiparkinsonian vs placebo, Outcome 1: Irritability" data-id="CD011769-fig-0133" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Antiparkinsonian vs placebo, Outcome 1: Irritability</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Antiparkinsonian vs placebo, Outcome 2: Adverse effects: gastrointestinal" data-id="CD011769-fig-0134" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Antiparkinsonian vs placebo, Outcome 2: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Antiparkinsonian vs placebo, Outcome 3: Adverse effects: metabolic" data-id="CD011769-fig-0135" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Antiparkinsonian vs placebo, Outcome 3: Adverse effects: metabolic</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Antiparkinsonian vs placebo, Outcome 4: Adverse effects: neurological" data-id="CD011769-fig-0136" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Antiparkinsonian vs placebo, Outcome 4: Adverse effects: neurological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-012.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Antiparkinsonian vs placebo, Outcome 5: Adverse effects: psychological" data-id="CD011769-fig-0137" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-012.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-012.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12: Antiparkinsonian vs placebo, Outcome 5: Adverse effects: psychological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-012.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-012.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Antiparkinsonian vs placebo, Outcome 6: Tolerability/acceptability: loss to follow‐up" data-id="CD011769-fig-0138" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-012.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-012.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.6</div> <div class="figure-caption"> <p>Comparison 12: Antiparkinsonian vs placebo, Outcome 6: Tolerability/acceptability: loss to follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-012.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Anxiolytic versus placebo, Outcome 1: Irritabilty (continuous)" data-id="CD011769-fig-0139" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Anxiolytic versus placebo, Outcome 1: Irritabilty (continuous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Anxiolytic versus placebo, Outcome 2: Irritability (dichotomous)" data-id="CD011769-fig-0140" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Anxiolytic versus placebo, Outcome 2: Irritability (dichotomous)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Anxiolytic versus placebo, Outcome 3: Adverse effects: gastrointestinal" data-id="CD011769-fig-0141" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Anxiolytic versus placebo, Outcome 3: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Anxiolytic versus placebo, Outcome 4: Adverse effects: immune System" data-id="CD011769-fig-0142" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Anxiolytic versus placebo, Outcome 4: Adverse effects: immune System</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-013.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Anxiolytic versus placebo, Outcome 5: Adverse effects: metabolic" data-id="CD011769-fig-0143" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-013.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13: Anxiolytic versus placebo, Outcome 5: Adverse effects: metabolic</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-013.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Anxiolytic versus placebo, Outcome 6: Adverse effects: neurological" data-id="CD011769-fig-0144" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-013.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.6</div> <div class="figure-caption"> <p>Comparison 13: Anxiolytic versus placebo, Outcome 6: Adverse effects: neurological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-013.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Anxiolytic versus placebo, Outcome 7: Adverse effects: psychological" data-id="CD011769-fig-0145" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-013.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.7</div> <div class="figure-caption"> <p>Comparison 13: Anxiolytic versus placebo, Outcome 7: Adverse effects: psychological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-013.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Anxiolytic versus placebo, Outcome 8: Adverse effects: respiratory system" data-id="CD011769-fig-0146" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-013.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.8</div> <div class="figure-caption"> <p>Comparison 13: Anxiolytic versus placebo, Outcome 8: Adverse effects: respiratory system </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-013.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Anxiolytic versus placebo, Outcome 9: Adverse effects: skin" data-id="CD011769-fig-0147" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-013.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.9</div> <div class="figure-caption"> <p>Comparison 13: Anxiolytic versus placebo, Outcome 9: Adverse effects: skin</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-013.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Anxiolytic versus placebo, Outcome 10: Other adverse effects" data-id="CD011769-fig-0148" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-013.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.10</div> <div class="figure-caption"> <p>Comparison 13: Anxiolytic versus placebo, Outcome 10: Other adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-013.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Anxiolytic versus placebo, Outcome 11: Tolerability/acceptability: loss to follow‐up" data-id="CD011769-fig-0149" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-013.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.11</div> <div class="figure-caption"> <p>Comparison 13: Anxiolytic versus placebo, Outcome 11: Tolerability/acceptability: loss to follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-013.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 1: Irritability" data-id="CD011769-fig-0150" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 1: Irritability</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 2: Self‐injury" data-id="CD011769-fig-0151" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 2: Self‐injury</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 3: Adverse effects: gastrointestinal" data-id="CD011769-fig-0152" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 3: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 4: Adverse effects: immune system" data-id="CD011769-fig-0153" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 4: Adverse effects: immune system</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 5: Adverse effects: metabolic (dichotomous)" data-id="CD011769-fig-0154" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 5: Adverse effects: metabolic (dichotomous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 6: Adverse effects: metabolic (continuous)" data-id="CD011769-fig-0155" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.6</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 6: Adverse effects: metabolic (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 7: Adverse effects: musculoskeletal" data-id="CD011769-fig-0156" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.7</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 7: Adverse effects: musculoskeletal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 8: Adverse effects: neurological" data-id="CD011769-fig-0157" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.8</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 8: Adverse effects: neurological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 9: Adverse effects: psychological" data-id="CD011769-fig-0158" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.9</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 9: Adverse effects: psychological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 10: Adverse effects: respiratory" data-id="CD011769-fig-0159" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.10</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 10: Adverse effects: respiratory</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 11: Adverse effects: skin" data-id="CD011769-fig-0160" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.11</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 11: Adverse effects: skin</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 12: Adverse effects: urinary" data-id="CD011769-fig-0161" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.12</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 12: Adverse effects: urinary</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 13: Adverse effects: other" data-id="CD011769-fig-0162" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.13</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 13: Adverse effects: other</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 14: Tolerability/acceptability: loss to follow‐up" data-id="CD011769-fig-0163" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.14</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 14: Tolerability/acceptability: loss to follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 15: Subgroup analyses: age ‐ irritability (option 1)" data-id="CD011769-fig-0164" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.15</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 15: Subgroup analyses: age ‐ irritability (option 1) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 16: Subgroup analyses: age ‐ irritability (option 2)" data-id="CD011769-fig-0165" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.16</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 16: Subgroup analyses: age ‐ irritability (option 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 17: Subgroup analyses: age ‐ self‐injury (option 1)" data-id="CD011769-fig-0166" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.17</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 17: Subgroup analyses: age ‐ self‐injury (option 1) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-014.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Experimental versus placebo, Outcome 18: Subgroup analyses: age ‐ self‐injury (option 2)" data-id="CD011769-fig-0167" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-014.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.18</div> <div class="figure-caption"> <p>Comparison 14: Experimental versus placebo, Outcome 18: Subgroup analyses: age ‐ self‐injury (option 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-014.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Typical antipsychotic vs placebo, Outcome 1: Self‐injury" data-id="CD011769-fig-0168" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Typical antipsychotic vs placebo, Outcome 1: Self‐injury</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Typical antipsychotic vs placebo, Outcome 2: Adverse effects: musculoskeletal" data-id="CD011769-fig-0169" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: Typical antipsychotic vs placebo, Outcome 2: Adverse effects: musculoskeletal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-015.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Typical antipsychotic vs placebo, Outcome 3: Adverse effects: neurological" data-id="CD011769-fig-0170" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-015.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-015.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15: Typical antipsychotic vs placebo, Outcome 3: Adverse effects: neurological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-015.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-015.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Typical antipsychotic vs placebo, Outcome 4: Adverse effects: psychological" data-id="CD011769-fig-0171" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-015.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-015.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15: Typical antipsychotic vs placebo, Outcome 4: Adverse effects: psychological</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-015.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011769-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/urn:x-wiley:14651858:media:CD011769:CD011769-CMP-015.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Typical antipsychotic vs placebo, Outcome 5: Tolerability/acceptabiity: loss to follow‐up" data-id="CD011769-fig-0172" src="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-015.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_t/tCD011769-CMP-015.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15: Typical antipsychotic vs placebo, Outcome 5: Tolerability/acceptabiity: loss to follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/media/CDSR/CD011769/image_n/nCD011769-CMP-015.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011769-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Atypical antipsychotics compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Atypical antipsychotics compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline assessment<br/><b>Setting:</b> hospital inpatient or outpatient centres, education or disability settings, mental health settings, or clinics and research centres associated with universities<br/><b>Intervention:</b> atypical antipsychotics <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with atypical antipsychotics</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Irritability</b> </p> <p>Follow‐up: short term (up to 6 months)</p> <p>Measured via Aberrant Behaviour Checklist (Irritability subscale (ABC‐I), score range 0‐45; <a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>) and the Ritvo Freeman RealLife Rating Scale (RFRLRS; <a href="./references#CD011769-bbs2-0323" title="FreemanBJ , RitvoER , YokotaA , RitvoA . A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the American academy of child psychiatry1986;25(1):130-6. [DOI: 10.1016/S0002-7138(09)60610-5] [PMID: 3950262]">Freeman 1986</a>). </p> <p>Lower scores indicate lower severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the placebo group ranged from −8.40 to 25.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.90 lower<br/>(95% CI 1.25 lower to 0.55 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>973<br/>(12 studies: risperidone 6 studies; aripiprazole 5 studies; lurasidone 1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.90 may represent a large effect</p> <p>(small = 0.2; medium = 0.5; and large = 0.8; <a href="./references#CD011769-bbs2-0295" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Erlbaum, 1988. [ISBN: 0-8058-0283-5]">Cohen 1988</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Aggression</b> </p> <p>Follow‐up: short term (up to 6 months)</p> <p>Measured via: Nisonger Child Behaviour Rating Form (conduct problem subscale; <a href="./references#CD011769-bbs2-0267" title="AmanMG , TasseMJ , RojahnJ , HammerD . The Nisonger CBRG: a child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities1996;17(1):41-57. [DOI: 10.1016/0891-4222(95)00039-9] [PMID: 8750075]">Aman 1996</a>) </p> <p>Score range 0‐48: lower scores indicate lower severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the placebo group was −6.6</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.44 lower<br/>(95% CI 0.89 lower to 0.01 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/>(1 study, risperidone) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no clear evidence of a difference however, results are uncertain.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Self‐injury</b> </p> <p>Follow‐up: short term (up to 6 months)</p> <p>Measured via: Self‐Injurious Behaviour Questionnaire (SIB‐Q Self‐injury subscale; <a href="./references#CD011769-bbs2-0335" title="GualtieriCT . Psychopharmacology of brain injured and mentally retarded patients. Philadelphia: Lippincott Williams and Wilkins, 2002.">Gualtieri 2002</a>) </p> <p>Score range 0‐20; lower scores indicate lower severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the placebo group was −4.90</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 1.43 lower<br/>(95% CI 2.24 lower to 0.61 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study, risperidone) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 1.43 may represent a large effect (small = 0.2; medium = 0.5; and large =0.8; <a href="./references#CD011769-bbs2-0295" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Erlbaum, 1988. [ISBN: 0-8058-0283-5]">Cohen 1988</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p><b>Adverse effects (AEs)</b> </p> <p>Follow‐up: short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Neurological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>dizziness</b> (14% vs 3%, P = 0.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 4.19 (95% CI 1.10 higher to 16.00 higher; 2 studies, risperidone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>974</p> <p>(11 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>fatigue</b> (15% vs 5%, P &lt; 0.001) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.58 (95% CI 1.68 higher to 3.97 higher; aripiprazole 2 studies; risperidone 4 studies) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>sedation</b> (18% vs 3%, P = 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.98 (95% CI 1.15 higher to 7.73 higher; aripiprazole 1 study; lurasidone 1 study; risperidone 4 studies) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>somnolence</b> (26% vs 6%, P &lt; 0.00001) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.84 (95% CI 3.18 higher to 7.36 higher; aripiprazole 3 studies; lurasidone 1 study; risperidone 5 studies) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>tremor</b> (10% vs 1%, P = 0.003) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.99 (95% CI 1.87 higher to 19.19 higher; aripiprazole 3 studies; risperidone 2 studies) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>There was little to no evidence of a difference between groups for: <b>drowsiness</b> (P = 0.06); <b>extrapyramidal</b> disorder (P = 0.15); <b>hypersomnia</b> (P = 0.29); <b>lethargy</b> (P = 0.19); <b>restlessness</b> (P = 0.98); or <b>agitation</b> (P = 0.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psychological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There was little to no evidence of a difference between groups for <b>anxiety</b> (P = 0.42) or <b>depression</b> (P = 0.21). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Metabolic</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>increased appetite</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.38 (95% CI 1.69 higher to 3.34 higher; aripiprazole 3 studies; risperidone 5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>702</p> <p>(8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>There was little to no evidence of a difference between groups for <b>decreased appetite</b> (P = 0.11), <b>weight gain</b> (P = 0.10) or <b>thirst</b> (P = 0.39). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Musculoskeletal</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There was little to no evidence of a difference between groups for <b>rigidity</b> (P = 0.13), <b>movement disorder</b> (P = 0.27) or <b>dyskinesia</b> (P = 0.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>AE:</b> adverse effect; <b>ASD:</b> autism spectrum disorder; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains). Not downgraded for inconsistency, as high I<sup>2</sup> statistic (83%) can be attributed to 2 outlier studies.<br/><sup>b</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), 1 level for imprecision (small sample size of 77 participants) and 1 level for imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>c</sup>Downgraded 1 level for imprecision (small sample size of 30 participants), and 1 level for indirectness (available evidence relates to adults only).<br/><sup>d</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains) and 1 level for inconsistency (direction of effect varies across studies).<br/><sup>e</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), 1 level for imprecision (small sample size of 79 participants), and 1 level for indirectness (available evidence relates to children only).<br/><sup>f</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), and 1 level for indirectness (available evidence relates to children only) and 1 level for imprecision (small sample size of 182 participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Atypical antipsychotics compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011769-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Neurohormones compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Neurohormones compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline assessment <br/><b>Setting:</b> hospital inpatient or outpatient centres, education or disability settings, mental health settings, or clinics and research centres associated with universities<br/><b>Intervention:</b> neurohormones <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with neurohormones</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Irritability</b> </p> <p>Follow‐up: short term (up to six months)</p> <p>Measured via Aberrant Behaviour Checklist (Irritability subscale) (ABC‐I) (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>, Score range (0‐45)). </p> <p>Lower scores indicate lower severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.18 lower<br/>(95% CI 0.37 lower to 0.00 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>466<br/>(8 studies: secretin 3 studies; ACTH 1 study; oxytocin 3 studies; vasopressin 1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.18 may represent a small effect</p> <p>(small = 0.2; medium = 0.5; and large = 0.8; <a href="./references#CD011769-bbs2-0295" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Erlbaum, 1988. [ISBN: 0-8058-0283-5]">Cohen 1988</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Aggression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data were reported for this outcome in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Self Injury</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data were reported for this outcome in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Adverse effects</b> </p> <p>Follow‐up: short term (up to six months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a lower rate of AEs for <b>headaches</b> in the neurohormone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58 (95% CI 0.38 to 0.89) (7 studies: oxytocin 6 studies; balovaptan 1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>863 participants</p> <p>(10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The was little to no evidence of a difference between groups for <b>absence seizures</b> (P = 0.52), <b>aggression</b> (P = 0.68), <b>agitation</b> (P = 0.67), <b>decreased attention</b> (P = 0.68), <b>dizziness</b> (P = 0.69), <b>dysphoria</b> (P = 0.49); <b>excessive talking</b> (P = 0.52), <b>fatigue</b> (P = 0.76), <b>forgetfulness</b> (P = 0.52), <b>insomnia</b> (P = 0.08), <b>irritability</b> (P = 0.22), <b>leg shaking</b> (P = 0.52), <b>nervous sytem disorders</b> (P = 0.47), <b>oppositional</b> (P = 0.69), <b>restlessness</b> (P = 0.67), <b>seizure</b> (P = 0.52), <b>sedation</b> (P = 0.16), <b>somnolence</b> (P = 0.22), <b>tics</b> (P = 0.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psychological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The was little to no evidence of a difference between groups for <b>anxiety</b> (P = 0.23), <b>depression</b> (P = 0.83), <b>panic attacks</b> (P = 0.45), <b>psychiatric events</b> (P = 0.21), or <b>self‐injury</b> (P = 1.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>570 participants</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metabolic</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The was little to no evidence of a difference between groups for any of the metabolic AEs including <b>decreased appetite</b> (P = 0.19), <b>increased appetite</b> (P = 0.07), <b>metabolism and nutrition disorders</b> (P = 0.57), thirst (P = 0.62), <b>weight change</b> (P = 0.50), <b>weight gain</b> (P = 0.67), and <b>weight loss</b> (P = 0.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>515 participants</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Musculoskeletal</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The was little to no evidence of a difference between groups for <b>muscle spasms</b> (P = 0.52), <b>musculoskeletal and connective tissues disorder</b> (P = 0.50) and <b>rhabdomyolysis</b> (P = 0.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355 participants</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>AE:</b> adverse effect; <b>ASD:</b> autism spectrum disorder; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level for imprecision (95% CI includes both benefit and harm), 1 level for study limitations (all studies involved children) and 1 level for imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>b</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), 1 level due to inconsistency (direction of effect varies across studies) and 1 level for imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>c</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), and 1 level for imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>d</sup>Downgraded 1 level for imprecision (95% CI includes both benefit and harm), 1 level for study limitations (high risk of bias across multiple domains) and 1 level for imprecision (95% confidence intervals includes both benefit and harm). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Neurohormones compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011769-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Attention deficit hyperactivity disorder (ADHD)‐related drugs compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ADHD‐related medications compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline assessment<br/><b>Setting:</b> hospital inpatient or outpatient centres, education or disability settings, mental health settings, or clinics and research centres associated with universities<br/><b>Intervention:</b> ADHD‐related medications<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ADHD‐related drugs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Irritability</b> </p> <p>All ADHD‐related medications</p> <p>Follow‐up: short term (up to six months)</p> <p>Measured via Aberrant Behaviour Checklist (Irritability subscale) (Score range (0‐45))</p> <p>(<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>) and the Ritvo‐Freeman Real Life Rating Scale (<a href="./references#CD011769-bbs2-0323" title="FreemanBJ , RitvoER , YokotaA , RitvoA . A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the American academy of child psychiatry1986;25(1):130-6. [DOI: 10.1016/S0002-7138(09)60610-5] [PMID: 3950262]">Freeman 1986</a> (score range 0‐15). </p> <p>Lower scores indicate lower severity.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.20 lower<br/>(95% CI 0.40 lower to 0.01 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/>(10 studies: methylphenidate 2 studies; clonidine 2 studies; guanfacine 2 studies; atomoxetine 4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.20 may represent a small effect size (small = 0.2; medium =0.5; large = 0.8, <a href="./references#CD011769-bbs2-0295" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Erlbaum, 1988. [ISBN: 0-8058-0283-5]">Cohen 1988</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aggression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No data were reported for this outcome in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐injury</b> </p> <p>Follow‐up: short term (up to six months)</p> <p>Measured via the Repetitive Behaviour Scale ‐ Revised (self‐injury subscale) (<a href="./references#CD011769-bbs2-0281" title="BodfishJW , SymonsFS , ParkerDE , LewisMH . Varieties of repetitive behavior in autism: comparisons to mental retardation. Journal of Autism and Developmental Disorders2000;30(3):237-43. [DOI: 10.1023/A:1005596502855] [PMID: 11055459]">Bodfish 2000</a>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.62 lower (95% CI 1.63 lower to 0.39 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 participants (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no clear evidence of a difference, but results are uncertain.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><b>Adverse effects</b> </p> <p>Follow‐up: short term (up to six months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="7" valign="top"> <p><b>Neurological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>drowsiness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.42 (95% CI 1.54 higher to 7.59 higher); atomoxetine 2 studies; guanfacine 1 study; methylphenidate 1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>511</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>emotional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 6.32 (95% CI 2.47 higher to 16.18 higher); methylphenidate 1 study; guanfacine 1 study </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.73 (95% CI 1.98 higher to 7.03higher); atomoxetine 3 studies; guanfacine 1 study</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>headache</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.63 (95% CI 1.09 higher to 2.44 higher); atomoxetine 4 studies; methylphenidate 2 studies; guanfacine 1 study; amphetamine 1 study </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>insomnia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.58 (95% CI 1.01 higher to 2.47 higher); methylphenidate 2 studies; atomoxetine 3 studies; guanfacine 1 study; amphetamine 1 study </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>irritability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.61 (95% CI 1.25 to 2.07 higher); atomoxetine 3 studies; guanfacine 1 study; methylphenidate 2 studies </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>There was little to no evidence of a difference between groups for <b>aggression</b> (P = 0.82), <b>agitation</b> (P = 0.85), <b>dizziness</b> (P = 0.22), <b>drowsiness</b> (P = 0.003), <b>hyperactivity</b> (P = 0.75), <b>increased motor activity</b> (P = 0.36), <b>motor tics</b> (P = 0.28), <b>nightmares</b> (P = 0.57), <b>repetitive behaviour</b> (P = 0.23), <b>restlessness</b> (P = 0.80), <b>sleep disturbance</b> (P = 0.76), <b>talking excessively</b> (P = 0.05), <b>waking</b> (P = 0.59), or <b>tremor</b> (P = 0.48). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Psychological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of <b>depression</b> in the intervention group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.45 higher (95% CI 1.12 higher to 5.36 higher); methylphenidate 2 studies; guanfacine 1 study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>252</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>There was little to no evidence of a difference between groups for <b>anxiety</b> (P = 0.30); <b>mood change</b> (P = 0.07), "<b>silly behaviour</b> " (P = 0.51), <b>self‐injury</b> (P = 0.19), or <b>social withdrawal</b> (P = 0.36). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Metabolic</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>There was evidence of a higher rate of AEs in the intervention group for <b>decreased appetite</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.15 (95% CI 1.55 higher to 2.99 higher); atomoxetine 5 studies; guanfacine 1 study; amphetamine 1 study; methylphenidate 2 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>511</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>There was little to no evidence of a difference between groups for increased appetite (P = 0.63) and increased energy (P = 0.31). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Musculoskeletal</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data were reported for this outcome in this comparison.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AE:</b> adverse effect; <b>ASD:</b> autism spectrum disorder; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level due to study limitations (high risk of bias across multiple domains) and 1 level due to imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>b</sup>Downgraded 1 level due to study limitations (high risk of bias across multiple domains) and 1 level for indirectness (available evidence relates to children only) and 1 level for imprecision (small sample size of n = 16 and 95% confidence intervals includes both benefit and harm).<br/><sup>c</sup>Downgraded 1 level due to study limitations (only involving children), 1 level due to inconsistency (direction of effect varies across studies) and 1 level due to imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>d</sup>Downgraded 1 level due to study limitations (high risk of bias across multiple domains), 1 level due to inconsistency (direction of effect varies across studies) and 1 level due to imprecision (95% confidence intervals includes both benefit and harm). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Attention deficit hyperactivity disorder (ADHD)‐related drugs compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011769-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antidepressants compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Antidepressants compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline assessment <br/><b>Setting:</b> hospital inpatient or outpatient centres, education or disability settings, mental health settings, or clinics and research centres associated with universities<br/><b>Intervention:</b> antidepressants <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antidepressants</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Irritability</b> </p> <p>Follow‐up: short term (up to six months)</p> <p>Measured via Aberrant Behaviour Checklist (Irritability subscale) (ABC‐I) (<a href="./references#CD011769-bbs2-0266" title="AmanM , G, SinghNN , StewartAW , Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985;89(5):485-91. [PMID: 3993694]">Aman 1985</a>), Score range (0‐45) </p> <p>Lower scores indicate lower severity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the placebo group ranged from 10.2 to 13.8</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.06 lower<br/>(95% CI 0.30 lower to 0.18 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>267<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no evidence of a difference, but results are uncertain.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Aggression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No data were reported for this outcome in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Self‐injurious behaviour</b> ‐ no data could be used for this outcome because of skewness (see <a href="./full#CD011769-tbl-0005">Table 1</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p><b>Adverse effects</b> </p> <p>Follow‐up: short term (up to six months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Neurological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of <b>decreased attention</b> in the intervention group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.16 (95% CI 1.07 higher to 16.11 higher); citalopram 1 study; clomipramine 1 study; fluoxetine 5 studies; fluvoxamine 1 study; sertraline 1 study; tianeptine 1 study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>815</p> <p>(10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The was little to no evidence of a difference between groups for any of the other neurological adverse effects including <b>activation syndrome</b> (P = 0.64), agitation (P = 0.96), <b>aggression or hostility</b> (P = 0.83), <b>anger or irritability</b> (P = 0.35), <b>autonomic disturbance</b> (P = 0.83), <b>CNS disturbance</b> (P = 0.50), <b>diaphoresis</b> (sweating) (P = 0.49), <b>drowsiness</b> (P = 0.50), <b>headache</b> (P = 0.23), <b>hyperactivity</b> (P = 0.36), <b>insomnia</b> (P = 0.29), <b>sedation</b> (P = 0.16), <b>sleep disturbance</b> (P = 0.76), <b>mood lability</b> (P = 0.43), <b>restlessness</b> (P = 0.13), <b>twitching</b> (P = 0.17), <b>tremor</b> (P = 0.22), or <b>vertigo</b> (P = 0.65) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Psychological</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The was evidence of a higher rate of AEs in the intervention group for</p> <p><b>impulsive behaviour</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.92 (95% CI 1.11 higher to 7.68 higher); citalopram 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>243</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The was evidence of a higher rate of AEs in the intervention group for <b>stereotypy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 8.33 (95% CI 1.07 higher to 64.95 higher); citalopram 1 study</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The was little to no evidence of a difference between groups for <b>anorexia</b> (P = 0.42), <b>verbal aggression</b> (P = 0.36), <b>suicidal ideation</b> (P = 0.65), <b>bad dreams</b> (P = 0.28), <b>unstable mood</b> (P = 0.66), <b>anxiety</b> (P = 0.16) and <b>depression</b> (P = 0.79) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Metabolic</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was evidence of a higher rate of <b>decreased energy</b> in the antidepressant group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.94 (95% CI 1.13 higher to 3.33 higher); citalopram 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>512</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The was little to no evidence of a difference between groups for <b>appetite disturbance</b> (P = 0.40), <b>decreased appetite</b> (P = 0.39), <b>increased appetite</b> (P = 0.85), and <b>weight gain</b> (P = 0.80) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Musculoskeletal</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The was little to no evidence of a difference between groups for <b>motor disturbance</b> (P = 0.30) or <b>neck pain</b> (P = 0.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>AE:</b> adverse effect; <b>ASD:</b> autism spectrum disorder; <b>CI:</b> confidence interval; <b>CNS:</b> central nervous system; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level for imprecision (95% confidence intervals includes both benefit and harm), and 1 level for imprecision (small sample size of n = 267). <br/><sup>b</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains) and 1 level for imprecision (95% confidence intervals include both benefit and harm).<br/><sup>c</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), 1 level for inconsistency (direction of effect varied across studies) and 1 level for imprecision (small sample size of n = 279). <br/><sup>d</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), 1 level for inconsistency (direction of effect varied across studies and 1 level for imprecision (95% confidence intervals includes both benefit and harm).<br/><sup>e</sup>Downgraded 1 level for study limitations (high risk of bias across multiple domains), 1 level for imprecision (small sample size of n=202), and 1 level for imprecision (95% confidence intervals includes both benefit and harm). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antidepressants compared to placebo for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Antidepressant versus placebo: self‐injurious behaviour results that could not be used in meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/ medium‐/ long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0216" title="CarminatiGG , GerberF , DarbellayB , KoselMM , DeriazN , ChabertJ , et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2016;65:85-95. [DOI: 10.1016/j.pnpbp.2015.09.002] [PMID: 26361994]">Carminati 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venlafaxine 18.75 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 1 (range 0‐13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 3 (range 0‐8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0064" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McmahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2001;40(6):658-65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Citalopram (max 20 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4 (2.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 (2.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine (max 20‐30 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.09 (3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.55 (4.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Antidepressant versus placebo: self‐injurious behaviour results that could not be used in meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Authors contacted</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Name of contact author</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Response from author</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0009" title="AkhondzadehS , AsadabadiM . Risperidone plus celecoxib in children with autistic disorder: a double-blind, randomized trial. British Journal of Clinical Pharmacology2012;73(6):983-4. [DOI: 10.1111/j.1365-2125.2012.04253.x]AsadabadiM , Mohammadi M-R, GhanizadehA , ModabberniaA , AshrafiM , HassanzadehE , et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology2013;225(1):51-9. [DOI: 10.1007/s00213-012-2796-8] [PMID: 22782459]IRCT138711091556N2. Celecoxib and autism [A double-blind placebo controlled trial of celecoxib added to risperidone in patients with autistic disorder]. www.irct.ir/trial/852 (first received 12 February 2009). ">Asadabadi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0013" title="BelsitoKM , LawPA , KirkKS , LandaRJ , ZimmermanAW . Lamotrigine therapy for autistic disorder: a randomised, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders2001;31(2):175-81. [DOI: 10.1023/A:1010799115457] [PMID: 11450816]BelsitoK , KirkK , LandaR , LawP , ZimmermanA . Lamotrigine therapy for childhood autism: a randomized, double-blind, placebo-controlled trial. Neurology1998;50(4):A85. ">Belsito 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>K. Belsito</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0020" title="ChuganiDC , ChuganiHT , WiznitzerM , ParikhS , EvansPA , HansenRL , et al. Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: a randomized trial. Journal of Pediatrics2016;170:45-53.e1-4. [DOI: 10.1016/j.jpeds.2015.11.033] [PMID: 26746121]NCT00873509. Buspirone in the treatment of 2-6 year old children with autistic disorder (B-ACE) [A randomized, placebo-controlled, double-masked clinical trial of buspirone in the treatment of 2- 6 year old children with autistic disorder]. (first received 1 April 2009). ">Chugani 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D. Chugani</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0030" title="GhaleihaA , AsababadiM , Mohammadi M-R, ShaheiM , TabriziM , HajiaghaeeR , et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology2013;16(4):783-9. [DOI: 10.1017/S1461145712000880] [PMID: 22999292]IRCT1138901151556N10. A double-blind placebo-controlled trial of memantine added to risperidone in patients with autistic disorder. https://www.irct.ir/trial/860 (first received May 2010). ">Ghaleiha 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0033" title="GhaleihaA , RasaSM , NikooM , FarokhniaM , Mohammadi M-R, AkhondzadehS . A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism. Psychiatry Research2015;229(1-2):181-7. [DOI: 10.1016/j.psychres.2015.07.043] [PMID: 26208985]IRCT201202281556N37. Pioglitazone in the treatment of autism [Pioglitazone added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/887 (first received 1 March 2012). ">Ghaleiha 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0034" title="GhaleihaA , AlikhaniR , Kazemi M-R, Mohammadi M-R, MohammadinejadP , ZeinoddiniA , et al. Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology2016;26(9):784-91. [DOI: 10.1089/cap.2015.0175] [PMID: 27128958]IRCT201302201556N50. Minocycline in the treatment of autism [Minocycline added to risperidone in the treatment of autism: a double blind and placebo controlled trial ]. en.irct.ir/trial/900 (first received 21 February 2013). ">Ghaleiha 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0218" title="HandenBL , JohnsonCR , LubetskyM . Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders2000;30(3):245-55. [DOI: 10.1023/A:1005548619694] [PMID: 11055460]">Handen 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>B. Handen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0042" title="HandenBL , HofkoshD . Secretin in children with autistic disorder: a double-blind, placebo-controlled trial. Journal of Developmental and Physical Disabilities2005;17(2):95-107. [DOI: 10.1007/s10882-005-3682-7]">Handen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>B. Handen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0043" title="HandenBL , SahlR , HardanAY . Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental &amp; Behavioral Pediatrics2008;29(4):303-8. [DOI: 10.1097/DBP.0b013e3181739b9d] [PMID: 18552703]">Handen 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>B. Handen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0044" title="HandenBL , JohnsonCR , McAuliffe-BellinS , HardanA . Safety and efficacy of donepezil in children - behavioural measures. International public health journal2010;2(1):125-34. HandenBL , JohnsonCR , Mcauliffe-BellinS , MurrayPJ , HardanAY . Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of Child and Adolescent Psychopharmacology2011;21(1):43-50. [DOI: 10.1089/cap.2010.0024] [PMCID: PMC3037196] [PMID: 21309696]HardanA , JohnsonC , HandenBL . Preliminary findings from a double-blind placebo=controlled study of donepezil in pervasive developmental disorders. Biological Psychiatry2006;59(8):50S-50S. NCT00047697. Donepezil HCl and cognitive deficits in autism. https://clinicaltrials.gov/ct2/show/results/NCT00047697?term=NCT00047697&amp;draw=2&amp;rank=1 (first received October 2002). ">Handen 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>B. Handen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0084" title="IRCT201106101556N25. Amantadine in the treatment of autism [A double - blind placebo controlled traial of amantadine added to risperidone in patint with autistic disorder]. www.irct.ir/trial/875 (first received 12 June 2011). Mohammadi M-R, YadegariN , HassanzadehE , FarokhM , YekehtazH , MirshafieeO , et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology2013;36(6):179-84. [DOI: 10.1097/WNF.0b013e3182a9339d] [PMID: 24201232]">Mohammadi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0100" title="IRCT201110281556N29. N-acetylcysteine in the treatment of autism [N-acetyl cysteine added to risperidone in the treatment of autism: a double blind and placebo controlled trial]. en.irct.ir/trial/879 (first received 29 October 2011). NikooM , RadniaH , FarokhniaM , Mohammadi M-R, AkhondzadehS . N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clinical Neuropharmacology2015;38(1):11-7. [DOI: 10.1097/WNF.0000000000000063] [PMID: 25580916]">Nikoo 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD011769-bbs2-0056" title="HollanderE , SooryaL , ChaplinW , AnagnostouE , TaylorBP , FerrettiCJ , et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry2012;169(3):292-9. Erratum in: American Journal of Psychiatry. 2012 May;169(5):540. [DOI: 10.1176/appi.ajp.2011.10050764] [PMID: 22193531]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. https://clinicaltrials.gov/show/NCT00004486 (first received 19 October 1999). ">Hollander 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E. AnagNostou</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E. Hollander</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0224" title="KernJK , MillerVS , CaullerL , KendallR , MehtaJ , DoddM . Effectiveness of N,N-Dimethylglycine in autism and pervasive developmental disorder. Journal of Child Neurology2000;16(3):169-73. [DOI: 10.2310/7010.2001.17515] [PMID: 11305684]">Kern 2001a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>J. Kern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0225" title="KernJK , Van MillerS , EvansPA , TravediMH . Efficacy of porcine secretin in children with autism and pervasive developmental disorder. Journal of Autism and Developmental Disorders2002;32(3):153-60. [DOI: 10.1023/A:1015441428154] [PMID: 12108616]">Kern 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>J. Kern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0363" title="KingBH , WrightDM , HandenBL , SikichL , ZimmermanAW , McMahonW , et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(6):658–65. [DOI: 10.1097/00004583-200106000-00010] [PMID: 11392343]">King 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>B. King</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0073" title="MaceCF , BlumNJ , SierpBJ , DelaneyBA , MaukJE . Differential response of operant self-Injury to pharmacologic versus behavioral treatment. Journal of Developmental &amp; Behavioral Pediatrics2001;22(2):85-91. [DOI: 10.1097/00004703-200104000-00001] [PMID: 11332784]">Mace 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N. Blum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0079" title="HuffmanG . Fluvoxamine for the treatment of autistic disorders in adults. American Family Physician1997;55(4):1375-4. McDougleCJ , NaylorST , CohenDJ , VolkmarFR , HeningerGR , PriceLH . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry1996;53(11):1001-8. [DOI: 10.1001/archpsyc.1996.01830110037005] [PMID: 8911223]VegsoSJ . A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]. New Haven (CT): Southern Connecticut State University, 1995. ">McDougle 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C. McDougle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Email bounced</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0082" title="MiralS , GencerO , Inal-EmirogluFN , BaykaraB , BaykaraA , DirikE . Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. European Child &amp; Adolescent Psychiatry2008;17(1):1-8. [DOI: 10.1007/s00787-007-0620-5] [PMID: 18080171]">Miral 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Miral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0230" title="MolloyCA , Manning-CourtneyP , SwayneS , BeanJ , BrownJM , MurrayDS , et al. Lack of benefit of intravenous synthetic human secretin in the treatment of autism. Journal of Autism and Developmental Disorders2002;32(6):545-51. [DOI: 10.1023/A:1021202930206] [PMID: 12553591]">Molloy 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C. Molloy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011769-bbs2-0086" title="MoutiA , ReddihoughD , MarraffaC , HazellP , WrayJ , LeeKL , et al. Fluoxetine for autistic behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism. Trials2014;15:230. [DOI: 10.1186/1745-6215-15-230] [PMCID: PMC4067505] [PMID: 24934401]ReddihoughDS , MarraffaC , MoutiA , O'SullivanM , LeeKJ , OrsiniF , et al. Effect of fluoxetine on obsessive-compulsive behaviours in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA2019;322(16):1561-9. [DOI: 10.1001/jama.2019.14685] [PMCID: PMC6806436] [PMID: 31638682]">Mouti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>M. O'Sullivan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A. Mouti</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Received response but referred to another author</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>D. Reddinhough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Was provided with a full‐text paper containing the additional data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0087" title="MunesueT , NakamuraH , KikuchiM , MiuraY , TakeuchiN , AnmeT , et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study. Frontiers in Psychiatry2016;7:2. [DOI: 10.3389/fpsyt.2016.00002] [PMCID: PMC4720778] [PMID: 26834651]UMIN000007250. A randomized, double-blind, placebo-controlled, cross-over trial of oxytocin in patients with autism spectrum disorder. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008548 (first received 9 February 2012). ">Munesue 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>T. Munesue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0233" title="NovotnyS , HollanderE , PhillipsA , AllenA , WassermanS , IyengarR . Increased repetitive behaviours and prolactin responsivity to oral m-chlorophenylpiperazine in adults with autism spectrum disorders. International Journal of Neuropsychopharmacology2004;7(3):249-54. [DOI: 10.1017/S146114570400433X] [PMID: 15132762]">Novotny 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E. Hollander</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>G. Remington</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0111" title="IRCT138901141556N9. Topiramate in the treatment of autism [Tpoiramate added to risperidone in patint with autistic disorder: a double-blind placebo controlled trial]. www.irct.ir/trial/859 (first received 29 April 2010). RezaeiV , Mohammadi M-R, GhanizadehA , SahraianA , TabriziM , Rezazadeh S-A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2010;34(7):1269-72. [DOI: 10.1016/j.pnpbp.2010.07.005] [PMID: 20637249]">Rezaei 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Akhonzadeh</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0234" title="SandlerAD , SuttonKA , DeWesseJ , GirardiMA , SheppardV , BodfishJW . Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. New England Journal of Medicine1999;341(24):1801-6. [DOI: 10.1056/NEJM199912093412404] [PMID: 10588965]">Sandler 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AD. Sandler</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0125" title="WassermanS , IyengarR , ChaplinWF , WatnerD , WaldoksSE , AnagnostouE , et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. International Clinical Psychopharmacology2006;21(6):363-7. [DOI: 10.1097/01.yic.0000224787.13782.0f] [PMID: 17012983]">Wasserman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>S. Wasserman</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011769-bbs2-0125" title="WassermanS , IyengarR , ChaplinWF , WatnerD , WaldoksSE , AnagnostouE , et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. International Clinical Psychopharmacology2006;21(6):363-7. [DOI: 10.1097/01.yic.0000224787.13782.0f] [PMID: 17012983]">Wasserman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>E. AnagNostou</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Authors contacted</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of all antipsychotic comparisons</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Antipsychotics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bromocriptine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Haloperidol</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Memantine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risperidone</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Amisulpride</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0026" title="DollfusS , PetitM , MenardJF , LesieurP . Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. Journal of Autism and Developmental Disorders1992;22(1):47-60. [DOI: 10.1007/BF01046402] [PMID: 1350581]DollfusS , PetitP , MenardJF . Pharmacoclinical study of an agonist and an antagonist of dopamine in early infantile autism. Neuropsychiatrie de l'Enfance et de l'Adolescence1992;40(5-6):300-309. ">Dollfus 1992</a> (n = 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0029" title="FindlingRL , MankoskiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22-30. [DOI: 10.4088/JCP.13m08500] [PMID: 24502859]NCT01227668. Phase IV long-term maintenance study of aripiprazole in the treatment of irritability associated with autistic disorder. https://clinicaltrials.gov/ct2/show/NCT01227668?term=NCT01227668&amp;draw=2&amp;rank=1 (first received October 2010). ">Findling 2014</a> (n = 85) </p> <p><a href="./references#CD011769-bbs2-0059" title="IchikawaH , MikamiK , OkadaT , YamashitaY , IshizakiY , TomodaA , et al. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study. Child Psychiatry &amp; Human Development2017;48(5):796-806. [DOI: 10.1007/s10578-016-0704-x] [PMCID: PMC5617873] [PMID: 28004215]NCT01617447. A short treatment study of aripiprazole in pediatric patients with autistic disorder [A short-term administration study of aripiprazole in children and adolescents (age: 6 to 17 years) with autistic disorder]. clinicaltrials.gov/ct2/show/NCT01617447 (first received 12 June 2012). ">Ichikawa 2017</a> (n = 92) </p> <p><a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a> (n = 105) </p> <p><a href="./references#CD011769-bbs2-0089" title="NCT00198107. Evaluating the effectiveness of aripiprazole and D-cycloserine to treat symptoms associated with autism [Novel pharmacological strategies in autism]. clinicaltrials.gov/ct2/show/NCT00198107 (first received 20 September 2005). ">NCT00198107</a> (n = 81) </p> <p><a href="./references#CD011769-bbs2-0090" title="NCT00468130. Efficacy of aripiprazole versus placebo in the reduction of aggressive and aberrant behavior in autistic children (Abilify) [Efficacy of aripiprazole versus placebo in the reduction of aggressive and aberrant behavior in autistic children]. clinicaltrials.gov/ct2/show/NCT00468130 (first received 2 May 2007). ">NCT00468130</a> (n=15) </p> <p><a href="./references#CD011769-bbs2-0102" title="EUCTR2016-005111-40. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A multicenter, double-blind, randomized, placebo-controlled, flexible-dosed parallel-group study of aripiprazole flexibly dosed in thetreatment of children and adolescents with autistic disorder]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-005111-40/results (first received 7 April 2017). LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of flexibly-dosed aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110-1. [DOI: 10.1002/ana.21853]LewisD , OwenR , CouchD . Efficacy and safety of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years): results from two 8-week randomized, double-blind, placebo-controlled trials. Neurology2009;72(11 (Supp 3)):A428. [ABSTRACT NO: S50.005]MankoskiR , StocktonG , ManosG , MarlorS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]NCT00365859. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A 52-week, open-label, multicenter study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder]. clinicaltrials.gov/ct2/show/NCT00365859 (first received 18 August 2006). OwenR , SikichL , MarcusRN , Corey-LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescent with autistic disorder. Pediatrics2009;124(6):1533-40. [DOI: 10.1542/peds.2008-3782] [PMID: 19948625]RobbAS , AnderssonC , BellocchioEE , ManosG , Rojas-FernandezC , MathewS , et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): results from a pooled analysis of 2 studies. Primary Care Companion for CNS Disorders2011;13(1):PCC.10m01008. [DOI: 10.4088/PCC.10m01008gry] [PMCID: PMC3121213] [PMID: 21731831]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. The effect of aripiprazole 2 to 15mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Owen 2009</a> (n = 98) </p> <p>6 studies (n = 476)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0025" title="DeVaneCL , CharlesJM , AbramsonRK , WilliamsJE , CarpenterLA , RavenS , et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy2019;39(6):626-35. [DOI: 10.1002/phar.2271] [PMCID: PMC6555676] [PMID: 31063671]NCT01333072. Biomarkers in autism of aripiprazole and risperidone treatment (BAART) [Biomarkers in autism of aripiprazole and risperidone treatment]. clinicaltrials.gov/ct2/show/NCT01333072 (first received 11 April 2011). ">DeVane 2019</a> (n = 61) </p> <p><a href="./references#CD011769-bbs2-0036" title="GhanizadehA , SahraeizadehA , BerkM . A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development2014;45(2):185-92. [DOI: 10.1007/s10578-013-0390-x] [PMID: 23801256]IRCT201110233930N15. Aripiprazole versus risperidone for treatment of autism. www.irct.ir/trial/4094 (first received 12 December 2011). ">Ghanizadeh 2014</a> (n = 59) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haloperidol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0073" title="MaceCF , BlumNJ , SierpBJ , DelaneyBA , MaukJE . Differential response of operant self-Injury to pharmacologic versus behavioral treatment. Journal of Developmental &amp; Behavioral Pediatrics2001;22(2):85-91. [DOI: 10.1097/00004703-200104000-00001] [PMID: 11332784]">Mace 2001</a> (n = 7) </p> <p><a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a> (n = 36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lurasidone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0071" title="LoebelA , BramsM , GoldmanRS , SilvaR , HernandezD , DengL , et al. Lurasidone for the treatment of irritability associated with autistic disorder. Journal of Autism and Developmental Disorders2016;46(4):1153-63. [DOI: 10.1007/s10803-015-2628-x] [PMCID: PMC4786592] [PMID: 26659550]NCT01911442. Lurasidone pediatric autism study. https://clinicaltrials.gov/ct2/show/results/NCT01911442?term=NCT01911442&amp;draw=2&amp;rank=1 (first received July 2013). ">Loebel 2016</a> (n = 148) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Olanzapine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0054" title="HollanderE , WassermanS , SwansonEN , ChaplinW , SchapiroML , ZagurskyK , et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology2006;16(5):541-8. [DOI: 10.1089/cap.2006.16.541] [PMID: 17069543]">Hollander 2006b</a> (n = 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0076" title="MaloneRP , CaterJ , SheikhRM , ChoudhuryMS , DelaneyMA . Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(8):887-94. [DOI: 10.1097/00004583-200108000-00009] [PMID: 11501687]">Malone 2001</a> (n = 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risperidone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0062" title="KentJM , KushnerS , NingX , KarcherK , NessS , AmanM , et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind placebo-controlled study. Journal of Autism and Developmental Disorders2013;43(8):1773-83. [DOI: 10.1007/s10803-012-1723-5] [PMID: 23212807]NCT00576732. A study of the effectiveness and safety of two doses of risperidone in the treatment of children and adolescents with autistic disorder [Risperidone in the treatment of children and adolescents with autistic disorder: a double-blind, placebo-controlled study of efficacy and safety, followed by an open-label extension study of safety]. clinicaltrials.gov/ct2/show/NCT00576732 (first received 19 December 2007). ">Kent 2013</a> (n = 66) </p> <p><a href="./references#CD011769-bbs2-0072" title="LubyJ , MrakotskyC , StaletsMM , BeldenA , HeffelfingerA , WilliamsM , et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. Journal of Child and Adolescent Psychopharmacology2006;16(5):575-87. [DOI: 10.1089/cap.2006.16.575] [PMID: 17069546]">Luby 2006</a> (n = 23) </p> <p><a href="./references#CD011769-bbs2-0078" title="AmanM , RettigantiM , NagarajaHN , HollwayJA , McCrackenJ , McDougleCJ , et al. Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. Journal of Child &amp; Adolescent Psychopharmacology2015;25(6):482-93. [DOI: 10.1089/cap.2015.0005] [PMCID: PMC4545698] [PMID: 26262903]AmanMG , ArnoldLE , McDougleCJ , VitielloB , ScahillL , DaviesMD , et al. Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology2005;15(6):869-84. [DOI: 10.1089/cap.2005.15.869] [PMID: 16379507]AmanMG , HollwayJA , McDougleCJ , ScahillL , TierneyE , McCrackenJT , et al. Cognitive effects of risperidone in children with autism and irritable behavior. Journal of Child and Adolescent Psychopharmacology2008;18(3):227-36. [DOI: 10.1089/cap.2007.0133] [PMCID: PMC2935828] [PMID: 18582177]ArnoldLE , AmanMG , MartinA , Collier-CrespinA , VitielloB , TierneyE , et al. Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology. Journal of Autism and Developmental Disorders2000;30(2):99-111. [DOI: 10.1023/a:1005451304303] [PMID: 10832774]ArnoldLE , FarmerC , KraemerHC , DaviesM , WitwerA , ChuangS , et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. Journal of Child &amp; Adolescent Psychopharmacology2010;20(2):83-93. [DOI: 10.1089/cap.2009.0022] [PMCID: PMC2865212] [PMID: 20415603]ArnoldLE , VitielloB , McDougleC , ScahillL , ShahB , GonzalezNM , et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(12):1443-50. [DOI: 10.1097/00004583-200312000-00011] [PMID: 14627879]CaicedoC , WilliamsSH . Risperidone improves behavior in children with autism. Journal of Family Practice2002;51(11):915. [PMID: 12485538]FombonneE . Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents. Evidence-Based Mental Health2006;9(1):6. [DOI: 10.1136/ebmh.9.1.6] [PMID: 16436546]LevineSZ , KodeshA , GoldbergY , ReichenbergA , FurukawaTA , KolevzonA , et al. Initial severity and efficacy of risperidone in autism: results from the RUPP trial. European Psychiatry2016;32:16-20. [DOI: 10.1016/j.eurpsy.2015.11.004] [PMID: 26802979]McCrackenJT , McGoughJ , ShahB , CroninP , HongD , AmanMG , et al. Risperidone in children with autism and serious behavioural problems. New England journal of medicine2002;347(5):314-21. [DOI: 10.1056/NEJMoa013171] [PMID: 12151468]McDougleC , AmanM , McCrackenJ , ScahillL , TierneyE , VitielloB . A double-blind placebo-controlled trial of risperidone in autistic disorder. European Neuropsychopharmacology2003;13:S327-8. [DOI: 10.1016/S0924-977X(03)92062-1] [POSTER NO: P.2.109]McDougleCJ , ScahillL , AmanMG , McCrackenJT , TierneyE , DaviesM , et al. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry2005;16(2):1142-8. [DOI: 10.1176/appi.ajp.162.6.1142] [PMID: 15930063]NCT00005014. Treatment of autism in children and adolescents [Placebo-controlled study of risperidone for the treatment of children and adolescents with autism and negative behavioral symptoms]. www.clinicaltrials.gov/ct2/show/NCT00005014 (first received 3 April 2000). Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry2005;162(7):1361-9. [DOI: 10.1176/appi.ajp.162.7.1361] [PMID: 15994720]ScahillL , HallettV , AmanMG , McDougleCJ , ArnoldLE , McCrackenJT , et al. Brief report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. Journal of Autism and Developmental Disorders2013;43(3):739-46. [DOI: 10.1007/s10803-012-1689-3] [PMCID: PMC3886122] [PMID: 23104617]ScahillL , Koenig, CarrollDH , PachlerM . Risperidone approved for the treatment of serious behavioral problems in children with autism. Journal of Child &amp; Adolescent Psychiatric Nursing2007;20(3):188-90. [DOI: 10.1111/j.1744-6171.2007.00112.x] [PMID: 17688557]Study of risperidone with autistic children finds no detrimental cognitive effects. Brown University Child &amp; Adolescent Psychopharmacology Update2008;10(9):3. [DOI: 10.1002/cpu.20075]WilliamsSK , ScahillL , VitielloB , AmanMG , ArnoldLE , McDougleCJ , et al. Risperidone and adaptive behavior in children with autism. Journal of the American Academy of Child &amp; Adolescent Psychiatry2006;45(4):431-9. [DOI: 10.1097/01.chi.0000196423.80717.32] [PMID: 16601648]">McCracken 2002</a> (n = 101) </p> <p><a href="./references#CD011769-bbs2-0080" title="McDougleCJ , HolmesJP , CarlsonDC , PeltonGH , CohenDJ , PriceLH . A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry1998;55(7):633-41. [DOI: 10.1001/archpsyc.55.7.633] [PMID: 9672054]">McDougle 1998</a> (n = 31) </p> <p><a href="./references#CD011769-bbs2-0110" title="Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment for autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry2005;162(7):1361-9. [DOI: 10.1176/appi.ajp.162.7.1361] [PMID: 15994720]">Research Units 2005</a> (n = 32) </p> <p><a href="./references#CD011769-bbs2-0093" title="NCT01624675. A study to evaluate the efficacy and safety of risperidone (R064766) in children and adolescents with irritability associated with autistic disorder [A double-blind, placebo-controlled study, followed by an open-label extension study evaluating the efficacy and safety of risperidone (r064766) in children and adolescents with irritability associated with autistic disorder]. clinicaltrials.gov/ct2/show/NCT01624675 (first received 21 June 2012). ">NCT01624675</a> (n = 39) </p> <p><a href="./references#CD011769-bbs2-0113" title="LightM , DunbarE , SheaS . P2.104 Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. European Neuropsychopharmacology2004;14(Suppl 3):S278. [DOI: 10.1016/S0924-977X(04)80324-9]LightM , DunbarF , SheaM . Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. International Journal of Neuropsychopharmacology2004;7:S275. [DOI: 10.1016/S0924-977X(04)80324-9]PandinaGJ , BossieCA , YoussefE , ZhuY , DunbarF . Risperidone improves behavioural symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders2007;37(2):367-73. [DOI: 10.1007/s10803-006-0234-7] [PMID: 17019624]SheaS , TurgayA , CarrollA , SchulzM , OrlikH , SmithI , et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics2004;114(5):e634-41. [DOI: 10.1542/peds.2003-0264-F] [PMID: 15492353]">Shea 2004</a> (n = 79) </p> <p><a href="./references#CD011769-bbs2-0120" title="MaloneRP . Discontinuing risperidone results in relapse in children with autism spectrum disorders. Evidence-Based Mental Health2006;9(2):56. [DOI: 10.1136/ebmh.9.2.56] [PMID: 16638905]TroostPW , AlthausM , LahuisBE , BuitelaarJK , MinderaaRB , HoekstraPJ . Neuropsychological effect of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. Journal of Child and Adolescent Psychopharmacology2006;16(5):561-73. [DOI: 10.1089/cap.2006.16.561] [PMID: 17069545]TroostPW , LahuisBE , Steenhuis M-P, KetelaarsCE , BuitelaarJK , Van EngelandH , et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(11):1137-44. [DOI: 10.1097/01.chi.0000177055.11229.76] [PMID: 16239862]">Troost 2005</a> (n = 24) </p> <p>8 studies (n = 395)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0082" title="MiralS , GencerO , Inal-EmirogluFN , BaykaraB , BaykaraA , DirikE . Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. European Child &amp; Adolescent Psychiatry2008;17(1):1-8. [DOI: 10.1007/s00787-007-0620-5] [PMID: 18080171]">Miral 2008</a> (n = 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0101" title="IRCT201204037202N5. Comparing efficacy and side effects of memantine and risperidone in treating autistic patients. www.irct.ir/trial/7627 (first received 20 June 2012). NikvarzN , Alaghband-RadJ , Tehrani-DoostM , AlimadadiA , GhaeliP . Comparing efficacy and side effects of memantine vs risperidone in the treatment of autistic disorder. Pharmacopsychiatry2017;50(1):19-25. [DOI: 10.1055/s-0042-108449] [PMID: 27299475]">Nikvarz 2017</a> (n = 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>n:</b> number of participants </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of all antipsychotic comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Atypical antipsychotics versus placebo: irritability results that could not be used in meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0029" title="FindlingRL , MankoskiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22-30. [DOI: 10.4088/JCP.13m08500] [PMID: 24502859]NCT01227668. Phase IV long-term maintenance study of aripiprazole in the treatment of irritability associated with autistic disorder. https://clinicaltrials.gov/ct2/show/NCT01227668?term=NCT01227668&amp;draw=2&amp;rank=1 (first received October 2010). ">Findling 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole (max 15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 (10.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6 (10.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Atypical antipsychotics versus placebo: irritability results that could not be used in meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Atypical antipsychotic versus placebo: aggression results that could not be used in meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/ long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0053" title="HollanderE , SooryaL , WassermanS , EspositoK , ChaplinW , AnagnostouE . Divalproex sodium vs placebo in the treatment of repetitive behaviours in autism spectrum disorder. International Journal of Neuropsychopharmacology2006;9(2):209-13. [DOI: 10.1017/S1461145705005791] [PMID: 16316486]NCT00211757. Divalproex sodium versus placebo in childhood/adolescent autism. https://clinicaltrials.gov/ct2/show/results/NCT00211757?term=NCT00211757&amp;draw=2&amp;rank=1 (first received September 2005). ">Hollander 2006a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine max 20 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"we did not find any evidence for significant change on the CY‐BOCS, the OAS‐M irritability measure, or the OAS‐M aggression measure" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CY‐BOCS:</b> Children's Yale Bown Obsessive compulsive Scale; <b>OAS‐M:</b> Overt Aggression Scale ‐ Modified </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Atypical antipsychotic versus placebo: aggression results that could not be used in meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Atypical antipsychotic versus placebo: self‐injurious behaviour results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0113" title="LightM , DunbarE , SheaS . P2.104 Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. European Neuropsychopharmacology2004;14(Suppl 3):S278. [DOI: 10.1016/S0924-977X(04)80324-9]LightM , DunbarF , SheaM . Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial. International Journal of Neuropsychopharmacology2004;7:S275. [DOI: 10.1016/S0924-977X(04)80324-9]PandinaGJ , BossieCA , YoussefE , ZhuY , DunbarF . Risperidone improves behavioural symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders2007;37(2):367-73. [DOI: 10.1007/s10803-006-0234-7] [PMID: 17019624]SheaS , TurgayA , CarrollA , SchulzM , OrlikH , SmithI , et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics2004;114(5):e634-41. [DOI: 10.1542/peds.2003-0264-F] [PMID: 15492353]">Shea 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risperidone maximum 0.02 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−2.6 (3.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.3 (2.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Atypical antipsychotic versus placebo: self‐injurious behaviour results that could not be used in the meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0011"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Atypical antipsychotics versus placebo: adverse effects data that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0076" title="MaloneRP , CaterJ , SheikhRM , ChoudhuryMS , DelaneyMA . Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(8):887-94. [DOI: 10.1097/00004583-200108000-00009] [PMID: 11501687]">Malone 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine 2.5‐2 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described. 33 in total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described. 33 in total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not outlined for each group. Weight gain was described as change in BMI category from baseline to endpoint and summarised as a group BMI change. </p> <p>AEs were measured at baseline and after week 12 (not after blinded phase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not outlined for each group. See Group 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At baseline, 70.3% of children were at a healthy weight, 21.6% were overweight, 2.7% were obese, and 5.4% were underweight. By week 12, 42.4% were healthy weight, 21.2% were overweight, and 36.4% were obese. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Short‐term weight gain (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole 5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 (2.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 (1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"All aripiprazole treatment groups were associated with significantly greater change in weight compared with the placebo at endpoint. Aripiprazole 5 mg/day and aripiprazole 15 mg/day were associated with a greater prevalence of clinically significant weight gain than the placebo, and aripiprazole 15 mg/day was also associated with significantly greater increases in body mass index than the placebo" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 (2.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 (1.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole 15 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 (1.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0102" title="EUCTR2016-005111-40. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A multicenter, double-blind, randomized, placebo-controlled, flexible-dosed parallel-group study of aripiprazole flexibly dosed in thetreatment of children and adolescents with autistic disorder]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-005111-40/results (first received 7 April 2017). LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of flexibly-dosed aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110-1. [DOI: 10.1002/ana.21853]LewisD , OwenR , CouchD . Efficacy and safety of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years): results from two 8-week randomized, double-blind, placebo-controlled trials. Neurology2009;72(11 (Supp 3)):A428. [ABSTRACT NO: S50.005]MankoskiR , StocktonG , ManosG , MarlorS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]NCT00365859. Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) [A 52-week, open-label, multicenter study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder]. clinicaltrials.gov/ct2/show/NCT00365859 (first received 18 August 2006). OwenR , SikichL , MarcusRN , Corey-LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescent with autistic disorder. Pediatrics2009;124(6):1533-40. [DOI: 10.1542/peds.2008-3782] [PMID: 19948625]RobbAS , AnderssonC , BellocchioEE , ManosG , Rojas-FernandezC , MathewS , et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): results from a pooled analysis of 2 studies. Primary Care Companion for CNS Disorders2011;13(1):PCC.10m01008. [DOI: 10.4088/PCC.10m01008gry] [PMCID: PMC3121213] [PMID: 21731831]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. The effect of aripiprazole 2 to 15mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Owen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term weight gain (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole</p> <p>(2‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 (12.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 (12.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Aripiprazole treatment was associated with significantly greater mean weight change compared with placebo at endpoint (LOCF: 2.0 vs 0.8 kg (P .005); observed case: 1.9 vs 0.5 kg (P .01)). Aripiprazole was also associated with a greater incidence of clinically significant weight gain (&gt;7% increase from baseline) than placebo (LOCF: 28.9% vs 6.1%; P.01)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>AE:</b> adverse effect; <b>BMI:</b> body mass index; <b>LOCF:</b> Last observation carried forward </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Atypical antipsychotics versus placebo: adverse effects data that could not be used in the meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0012"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Atypical antipsychotics versus placebo: quality‐of‐life results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD011769-bbs2-0077" title="BentonTD . Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial. Current Psychiatric Reports2011;13(2):77-9. [DOI: 10.1007/s11920-010-0172-0] [PMID: 21286868]CurranMP . Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs2011;25(9):801-2. [DOI: 10.2165/11208280-000000000-00000] [PMID: 21870890]LewisD , CouchD , MarcusR , ManosG , MankoskiR , CarsonW , et al. Efficacy and safety of fixed-dose aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years). Annals of Neurology2009;66:S110. MankoskyR , StocktonG , ManosG , MarlerS , McQuadeR , ForbesRA , et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. Journal of Child and Adolescent Psychopharmacology2013;23(8):572-6. [DOI: 10.1089/cap.2012.0075] [PMCID: PMC3804231] [PMID: 24138011]MarcusRN , OwenR , KamenL , ManosG , McQuadeRD , CarsonWH , et al. A placebo-controlled, fixed-dose aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110-9. [DOI: 10.1097/CHI.0b013e3181b76658] [PMID: 19797985]VarniJW , HandenBL , Corey-LislePK , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/day on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post-hoc analysis of two controlled trials. Clinical Therapeutics2012;34(4):980-92. [DOI: 10.1016/j.clinthera.2012.02.023] [PMID: 22444782]">Marcus 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Short‐term QoL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole 5 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (15.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6 (15.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Although patients receiving aripiprazole 5 and 10 mg/day had improvement in these 3 (QoL) scale scores compared with those receiving placebo, the 95% CIs of the treatment differences included zero" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole 10 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4 (15.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6 (15.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>QoL:</b> Quality of Life </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Atypical antipsychotics versus placebo: quality‐of‐life results that could not be used in the meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0013"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Neurohormones versus placebo: irritability results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0069" title="LevySE , SoudersMC , WrayJ , JawadAF , Gallagher PR CoplinJ , et al. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin. Archives of Disease in Childhood2003;88(8):731-6. [DOI: 10.1136/adc.88.8.731] [PMCID: PMC1719589] [PMID: 12876177]">Levy 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term (single‐dose secretin (2 CU/kg))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.18 (0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011769-bbs2-0118" title="NCT01793441. A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) [A multi-center, randomized, double-blind, 12-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of rg7314 in individuals with autism spectrum disorders (ASD)]. clinicaltrials.gov/ct2/show/NCT01793441 (first received 15 February 2013). SquassanteL , BolognaniF , SmithJ , MurtaghL , FontouraP , KhwajaO , et al. Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla). Journal of the American Academy of Child and Adolescent Psychiatry2018;57(10):S231. [DOI: 10.1016/j.jaac.2018.09.308] [PRESENTATION NO: 5.13]">Squassante 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan 1.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.99 (14.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−2.85 (24.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan 4 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.64 (24.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.07 (4.95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.42 (34.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−2.99 (9.49)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0122" title="NCT00065962. Secretin for the treatment of autism [Multisite controlled secretin trial in autism]. clinicaltrials.gov/ct2/show/NCT00065962 (first received 5 August 2003). UnisAS , MunsonJA , RogersSJ , GoldsonE , OsterlingJ , GabrielsR , et al. A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(11):1315-21. [DOI: 10.1097/00004583-200211000-00012] [PMID: 12410073]">Unis 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term synthetic secretin (single infusion of 0.4 μg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.3 (3.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.5 (3.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Neurohormones versus placebo: irritability results that could not be used in the meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0014"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Neurohormones versus placebo: adverse effects data that could not be used in the meta‐analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Name of study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0114" title="NCT01944046. Study of oxytocin in autism to improve reciprocal social behaviours (SOARS-B) [Phase II study of oxytocin in autism to improve reciprocal social behaviors]. clinicaltrials.gov/ct2/show/NCT01944046 (first received 17 September 2013). SikichL , AldermanC , HazzardL , BetheaT , GregoryS , JohnsonJ . Pilot study of sustained oxytocin treatment in children and adolescents with autistic disorder. Biological Psychiatry2013;73(9):145S. ">Sikich 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term oxytocin (max 24 IU children 3‐10 years or max 32 IU children 11‐17 years) adverse effects (metabolic) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64 (1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Neurohormones versus placebo: adverse effects data that could not be used in the meta‐analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0015"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Neurohormones versus placebo: quality‐of‐life results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results Group 1</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results Group 2</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0014" title="BernaertsS , BoetsB , BosmansG , SteyaertJ , AlaertsK . Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up. Molecular Autism2020;11(1):6. [DOI: 10.1186/s13229-020-0313-1] [PMCID: PMC6964112] [PMID: 31969977]BernaertsS , DillenC , SteyaertJ , AlaertsK . The effects of four weeks of intranasal oxytocinon social responsiveness and repetitive and restricted behaviors in autism spectrum disorders: a randomized controlled trial. Biological Psychiatry2020;81(10):S349-50. [ABSTRACT NO: 864] [DOI: 10.1016/j.biopsych.2017.02.589]Eudract 2014-000586-45. Oxytocin-based pharmacotherapy for autism spectrum disorders: Investigating the neural and behavioral effects of a promising intervention approach. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000586-45 (first registered May 2014). ">Bernaerts 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term oxytocin (24 IU once daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.77 (8.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.35 (6.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0060" title="JacobS , Veenstra-VanderWeeleJ , MurphyD , McCrackenJ , SmithJ , SandersK , et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet2022;9(3):199-210. [DOI: 10.1016/S2215-0366(21)00429-6] [PMID: 35151410]JacobS , Veenstra-VanderWeeleJ , MurphyD , McCrackenJ , SmithJ , SandersK , et al. Phase three randomised controlled trial of balovaptan in adults with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2020;59(10):S163-S163. [DOI: 10.1016/j.jaac.2020.08.108]NCT03504917. A study of balovaptan in adults with autism spectrum disorder with a 2-year open-label extension. clinicaltrials.gov/ct2/show/NCT03504917?term=NCT03504917&amp;draw=2&amp;rank=1 (first received 8 August 2018). ">Jacob 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan (10 mg once daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 (13.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0 (11.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0094" title="NCT01908205. Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD) (OXY-R) [Intranasal oxytocin for the treatment of children and adolescents with autism]. clinicaltrials.gov/ct2/show/NCT01908205 (first received 25 July 2013). ">NCT01908205</a><br/>(2013) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term oxytocin (twice daily dose of max 24 IUs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2 (17.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6 (21.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0096" title="NCT02940574. Neural and behavioral effects of oxytocin in autism spectrum disorders [Oxytocin-based pharmacotherapy for autism spectrum disorders: investigating the neural and behavioral effects of a promising intervention approach]. clinicaltrials.gov/ct2/show/NCT02940574 (first received 21 October 2016). ">NCT02940574</a><br/>(2016) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term oxytocin (24 IU once daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.14 (5.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35 (4.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011769-bbs2-0118" title="NCT01793441. A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASD) [A multi-center, randomized, double-blind, 12-week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of rg7314 in individuals with autism spectrum disorders (ASD)]. clinicaltrials.gov/ct2/show/NCT01793441 (first received 15 February 2013). SquassanteL , BolognaniF , SmithJ , MurtaghL , FontouraP , KhwajaO , et al. Effects of balovaptan on health-related quality of life of adult men with ASD: results from a phase 2 randomized double-blind placebo controlled study (Vanilla). Journal of the American Academy of Child and Adolescent Psychiatry2018;57(10):S231. [DOI: 10.1016/j.jaac.2018.09.308] [PRESENTATION NO: 5.13]">Squassante 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan (1.5 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 (13.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9 (13.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan (4 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2 (10.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term balovaptan (10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8 (10.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.98 (13.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Neurohormones versus placebo: quality‐of‐life results that could not be used in the meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0016"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">ADHD versus placebo: adverse effects data that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD011769-bbs2-0061" title="JaselskisCA , CookEH , FletcherKE , LeventhalBL . Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology1992;12(5):322-7. [PMID: 1479049]">Jaselskis 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term adverse effects (increased thirst)</p> <p>clonidine (0.15‐0.20 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (0.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term adverse effects (appetite change)</p> <p>clonidine (0.15‐0.20 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (2.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 (0.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term adverse effects (sleep disturbance)</p> <p>clonidine (0.15‐0.20 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (2.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 (2.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term adverse effects (depression)</p> <p>clonidine (0.15‐0.20 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 (2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 (1.4)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">ADHD versus placebo: adverse effects data that could not be used in the meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0017"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Antidepressant versus placebo: irritability results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> <p><b>Short‐/medium‐/ long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 3</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 3 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 3 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0216" title="CarminatiGG , GerberF , DarbellayB , KoselMM , DeriazN , ChabertJ , et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2016;65:85-95. [DOI: 10.1016/j.pnpbp.2015.09.002] [PMID: 26361994]">Carminati 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venlafaxine (18.75 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 10 (range 0‐40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 9 (range 5‐17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results presented as median and range</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0038" title="GordonCT , RapoportJL , HamburgerSD , StateRC , MannheimGB . Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry1992;149(3):363-6. [DOI: 10.1176/ajp.149.3.363]GordonCT , StateRC , NelsonJE , HamburgerSD , RapoportJL . A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. JAMA1993;50(6):2441-7. [DOI: 10.1001/archpsyc.1993.01820180039004]">Gordon 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term irritabilty</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clomipromine mean dose 4.3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABC‐I data not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABC‐I data not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0056" title="HollanderE , SooryaL , ChaplinW , AnagnostouE , TaylorBP , FerrettiCJ , et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry2012;169(3):292-9. Erratum in: American Journal of Psychiatry. 2012 May;169(5):540. [DOI: 10.1176/appi.ajp.2011.10050764] [PMID: 22193531]NCT00004486. Randomized study of fluoxetine in children and adolescents with autism. https://clinicaltrials.gov/show/NCT00004486 (first received 19 October 1999). ">Hollander 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine (max 80 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability was an outcome; however, it was not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0088" title="NCT00183339. Early intervention with fluoxetine in autism [A randomized, placebo-controlled trial of fluoxetine in preschool children]. clinicaltrials.gov/ct2/show/NCT00183339 (first received 16 September 2005). ">NCT00183339</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medium‐term irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine (max 20 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABC‐I</p> <p>‐8.5 (10.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABC‐I</p> <p>‐0.7 (2.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0109" title="RemingtonG , SlomanL , KonstantareasM , ParkerK , GowR . Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology2001;21(4):440-4. [DOI: 10.1097/00004714-200108000-00012] [PMID: 11476129]SlomanL , RemingtonG , KonstantareasM , ParkerK . Haloperidol versus clomipramine in autistic disorder. In: 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 to June 4; Toronto (ON), Canada. Vol. 17. 1998. [PRESENTATION NO: 17]">Remington 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clompramine (max 150 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol</p> <p>(max 150 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results presented graphically without SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="12" rowspan="1" valign=""> <p><b>ABC‐I:</b> Aberrant Behaviour Checklist ‐ Irritability; <b>SD:</b> standard deviation </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Antidepressant versus placebo: irritability results that could not be used in the meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0018"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Antidepressant versus placebo: aggression results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/ medium‐/ long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0216" title="CarminatiGG , GerberF , DarbellayB , KoselMM , DeriazN , ChabertJ , et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2016;65:85-95. [DOI: 10.1016/j.pnpbp.2015.09.002] [PMID: 26361994]">Carminati 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Venlafaxine 18.75 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 3.5 (range 0‐18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 4 (range 1‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only median and range provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0079" title="HuffmanG . Fluvoxamine for the treatment of autistic disorders in adults. American Family Physician1997;55(4):1375-4. McDougleCJ , NaylorST , CohenDJ , VolkmarFR , HeningerGR , PriceLH . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry1996;53(11):1001-8. [DOI: 10.1001/archpsyc.1996.01830110037005] [PMID: 8911223]VegsoSJ . A double-blind placebo-controlled study of fluvoxamine in treating the symptoms of autism [Master's thesis]. New Haven (CT): Southern Connecticut State University, 1995. ">McDougle 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluvoxamine max 300 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported; only t scores and P value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported; only t scores and P value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As measured by total score on the Brown Aggression Scale, fluvoxamine was superior to placebo in reducing aggression (F = 4.57; d = 3.84; P &lt; 0.03). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Antidepressant versus placebo: aggression results that could not be used in the meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0019"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Experimental versus placebo: irritability results that could not be used in the meta‐analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0008" title="ArnoldLE , AmanMG , HollwayJ , HurtE , BatesB , LiX , et al. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology2012;22(3):198-205. [DOI: 10.1089/cap.2011.0056] [PMCID: PMC3417385] [PMID: 22537359]NCT00773812. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders [Neuronal nicotinic receptor modulation in the treatment of autism: a pilot trial of mecamylamine]. clinicaltrials.gov/ct2/show/NCT00773812 (first received 16 October 2008). ">Arnold 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term mecamylamine (max 5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−3.17 (8.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−5.0 (10.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No significant differences were found for age, weight, sex, diagnosis, IQ, or entry scores for the OACIS, RBS, ABC Irritability, ABC Hyperactivity, ABC Lethargy/ Social Withdrawal, ABC Inappropriate Speech, ADI‐R Qualitative Abnormalities in Reciprocal Social Interaction or ADI‐R Qualitative Abnormalities in Communication" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0057" title="HollanderE , FerrettiCJ , TaylorBP , NooneRH , RacineE . P.7.d.006 Trichuris suis ova (TSO) as an immune-inflammatory treatment for repetitive behaviors in autism spectrum disorders (ASD). European Neuropsychopharmacology2014;24(2):S723. [DOI: 10.1016/S0924-977X(14)71165-4]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]HollanderE , FerrettiC , TaylorB , NooneR , KirschJ , RacineE . Trichuris suis ova (TSO) as an immune inflammatory treatment for repetitive behaviors in ASD. Neuropsychopharmacology2013;38:S391-2. [DOI: 10.1038/npp.2013.280]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]NCT01040221. Trichuris suis ova in autism spectrum disorders (TSO) [Trichuris suis ova in autism spectrum disorders ]. www.clinicaltrials.gov/ct2/show/NCT01040221 (first received November 2012). StarkFS , ChavanneC , Lennon-ChrimesS , DiackC , DerksM , SmithJ . Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431). European Neuropsychopharmacology2020;40:S82-S83. [DOI: 10.1016/j.euroneuro.2020.09.110]">Hollander 2020a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term <i>Trichuris suis</i> ova (a dose of 2500 <i>Trichurissuis</i> ova every 2 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−4.0 (18.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.14 (6.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.0687, 95% CI −4.82 to 91.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0081" title="MinshawiNF , WinkLK , ShafferR , PlaweckiMH , PoseyDJ , LiuH , et al. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism2016;7(3):2. [DOI: 10.1186/s13229-015-0062-8] [PMCID: PMC4712595] [PMID: 26770664]NCT01086475. D-cycloserine and social skills training in autism spectrum disorders. https://clinicaltrials.gov/ct2/show/NCT01086475?term=NCT01086475&amp;draw=1&amp;rank=1 (first received March 2010). WinkLK , MinshawiNF , ShafferRC , PlaweckiMH , PoseyDJ , HornPS , et al. D-cycloserine enhances durability of social skills training in autism spectrum disorder. Molecular Autism2017;8:2. [DOI: 10.1186/s13229-017-0116-1] [PMCID: PMC5264460] [PMID: 28138381]">Minshawi 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term D‐cycloserine (50 mg once weekly)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.55 (6.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.23 (6.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"teacher‐rated ABC data was returned for 23.5 % of the DCS group, and 30.3 % of the placebo group with no significant difference noted for any of the ABC subscales (irritability p = 0.623, social withdrawal p = 0.845" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>ABC:</b> Aberrant Behaviour checklist; <b>DCS:</b> D‐cycloserine; <b>OACIS:</b> Ohio Autism Clinical Impressions Scale; <b>RBS:</b> Repetitive Behaviour Scale </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Experimental versus placebo: irritability results that could not be used in the meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0020"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Experimental versus placebo: self‐injurious behaviour results that could not be used in the meta‐analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results</b> <br/><b>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0024" title="ACTRN12610000635066. Efficacy Of N-acetyl cysteine in autism: a double-blind, placebo-controlled randomised trial [Efficacy of n-acetyl cysteine on social skills, communication and behaviour in autistic children: a double-blind, placebo-controlled randomised trial]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=320918 (first received 3 August 2010). DeanOM , GrayK , DoddS , Villagonzalo K-A, BrownE , TongeB , et al. Does N-acetylcysteine improve behaviour in children with autism?: a mixed-methods analysis of the effects of N-acetylcysteine. Journal of Intellectual &amp; Developmental Disability2019;44(4):474-80. [DOI: 10.3109/13668250.2017.1413079]DeanOM , GrayKM , Villagonzalo K-A, DoddS , MohebbiM , VickT , et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian and New Zealand Journal of Psychiatry2017;51(3):241-9. [DOI: 10.1177/0004867416652735] [PMID: 27316706]">Dean 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour</p> <p>(N‐acetylcysteine 500 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (2.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 (2.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"There were no differences between N‐acetyl cysteine and placebo‐treated groups on any of the outcome measures for either primary or secondary endpoints. There was no significant difference in the number and severity of adverse events between groups" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0046" title="HardanA . Psychopharmacological treatment of anxiety symptoms in autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):S325-6. [DOI: 10.1016/j.jaac.2016.07.369] [ABSTRACT NO: 42.4]HardanAY , FungLK , LiboveRA , ObukhanychTV , NairS , HerzenbergLA , et al. A randomised controlled pilot trial of N-acetylcysteine in children with autism. Biological Psychiatry2012;71(11):956-61. [DOI: 10.1016//j.biopsych.2012.01.014] [PMCID: PMC4914359] [PMID: 22342106]">Hardan 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour (N‐acetylcysteine maz 900 mg/day 3 times daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (2.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0 (3.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Compared with placebo, NAC resulted in significant improvements on ABC irritability subscale (F= 6.80; P &lt;.001;d.= 0.96)" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0057" title="HollanderE , FerrettiCJ , TaylorBP , NooneRH , RacineE . P.7.d.006 Trichuris suis ova (TSO) as an immune-inflammatory treatment for repetitive behaviors in autism spectrum disorders (ASD). European Neuropsychopharmacology2014;24(2):S723. [DOI: 10.1016/S0924-977X(14)71165-4]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]HollanderE , FerrettiC , TaylorB , NooneR , KirschJ , RacineE . Trichuris suis ova (TSO) as an immune inflammatory treatment for repetitive behaviors in ASD. Neuropsychopharmacology2013;38:S391-2. [DOI: 10.1038/npp.2013.280]HollanderE , UzunovaG , TaylorBP , NooneR , RacineE , DoernbergE , et al. Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. World Journal of Biological Psychiatry2020;21(4):291-9. [DOI: 10.1080/15622975.2018.1523561] [PMID: 30230399]NCT01040221. Trichuris suis ova in autism spectrum disorders (TSO) [Trichuris suis ova in autism spectrum disorders ]. www.clinicaltrials.gov/ct2/show/NCT01040221 (first received November 2012). StarkFS , ChavanneC , Lennon-ChrimesS , DiackC , DerksM , SmithJ . Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a Phase 2 study (aV1ation; NCT02901431). European Neuropsychopharmacology2020;40:S82-S83. [DOI: 10.1016/j.euroneuro.2020.09.110]">Hollander 2020a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term self‐injurious behaviour (<i>Trichuris suis</i> ova, dose of 2500 ova every 2 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.37 (2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42 (2.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Trending improvements were observed in irritability using the overall percent change from baseline to endpoint on the Aberrant Behavior Checklist (ABC)–Irritability subscale" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>NAC:</b> N‐acetylcysteine </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Experimental versus placebo: self‐injurious behaviour results that could not be used in the meta‐analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011769-tbl-0021"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Experimental versus placebo: adverse effects data that could not be used in the meta‐analysis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐/medium‐/long‐term outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 sample size</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 1 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Group 2 results<br/>Mean (standard deviation)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011769-bbs2-0035" title="GhanizadehA , Moghimi-SaraniE . A randomized double blind placebo controlled clinical trial of N-acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry2013;13:196. [DOI: 10.1186/1471-244X-13-196] [PMCID: PMC3737121] [PMID: 23886027]IRCT201106103930N6. N-acetylcysteine augmentation with risperidone in treatment of autism in children [N-acetylcysteine augmentation with rispridone in treatment of autism in children: a double blind randomized placebo controlled clinical trial]. www.irct.ir/trial/4085 (first received 8 July 2011). ">Ghanizadeh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term adverse effects (NAC 1200 mg/day, risperidone 2‐3 mg/day depending on weight). 20+ AEs included fatigue, increased appetite, decreased appetite, diarrhoea, and constipation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N‐acetylcysteine + risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs were reported for each group although percentage was out of total number of participants, not participants for each group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>AE:</b> adverse effect; <b>NAC:</b> N‐acetylcysteine </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Experimental versus placebo: adverse effects data that could not be used in the meta‐analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/full#CD011769-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Atypical antipsychotic vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.25, ‐0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Aripiprazole vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.52, ‐0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Risperidone vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐1.47, ‐0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Lurasidone vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.50, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.13, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [1.39, 3.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Risperidone vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.37 [1.21, 9.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Ariprazole vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.09, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Aggression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Risperidone vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐0.89, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Self‐injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.43 [‐2.24, ‐0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Risperidone vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.43 [‐2.24, ‐0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Adverse effects: cardiovascular <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.53 [1.40, 40.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [1.04, 7.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [1.28, 4.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.46, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Drooling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.64 [1.29, 72.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.5 Dyspepsia (indigestion)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.19 [0.14, 72.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.6 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [0.75, 5.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.7 Hypersalivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.15 [1.77, 9.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.8 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.61, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.9 Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.19, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.10 Vomiting/nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.16, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Adverse effects: immune system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.67, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Earache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.10, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Flu‐like symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.38, 10.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.85, 3.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.5 Sore throat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.20 [0.63, 42.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Adverse effects: metabolic (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.84, 5.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [1.69, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [0.84, 6.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 Thirst</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.59, 3.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Adverse effects: metabolic (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Weight gain (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [0.73, 3.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Adverse effects: musculoskeletal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.55, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Movement disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.50 [0.27, 111.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.4 Rigidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.20 [0.63, 42.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Adverse effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.12, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Agitation/excitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.13, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 Apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.73 [0.61, 187.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.19 [1.10, 16.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.5 Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.26 [0.95, 19.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.6 Extrapyramidal disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.83 [0.47, 130.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.7 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [1.68, 3.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.8 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.63, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.9 Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.13, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.10 Hypersomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [0.43, 16.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.11 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.50, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.12 Lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.58 [0.39, 110.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.13 Presyncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.04, 22.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.14 Restlessness (akathisia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.40, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.15 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.98 [1.15, 7.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.16 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.84 [3.18, 7.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.17 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.99 [1.87, 19.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Adverse effects: psychological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.65, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.86 [0.46, 32.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Adverse effects: respiratory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Ear infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.62 [0.28, 112.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.62 [0.28, 112.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [0.52, 11.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.4 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.73, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.5 Pharyngolaryngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.06, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.6 Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.93, 7.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.7 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.08, 4.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Adverse effects: skin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Bruise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.14, 4.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Adverse effects: urinary <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.67, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Tolerability/acceptability: loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Subgroup analysis: age ‐ irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.87 [‐1.24, ‐0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 Adults only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.94 [‐1.70, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 Children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.87 [‐1.26, ‐0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Subgroup analysis: age ‐ aggression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.80 [‐7.61, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.80 [‐7.61, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Subgroup analysis: cognitive ability ‐ irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.91 [‐1.29, ‐0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 Mixed IQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.91 [‐1.29, ‐0.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Atypical antipsychotic vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Neurohormone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.37, ‐0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Secretin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.46, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 ACTH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.66, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.45, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Vasopressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐1.02, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Self‐injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.74, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.93, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Three month follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐0.88, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Adverse effects: cardiovascular <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Cardiac disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.23, 9.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Vascular disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 15.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.96 [0.12, 72.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Abdominal pain or discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.17, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.46, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.39, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.4 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.06, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.5 Encopresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.17, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.6 Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.35, 4.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.7 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.8 Salivary hypersecretion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.9 Stomatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.10 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.21, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Adverse effects: immune system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 infections and infestations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.81, 4.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Adverse effects: metabolic (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.37, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.96, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 Metabolism and nutrition disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.4 Thirst</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.35, 5.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.5 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.52, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.6 Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [0.69, 5.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Adverse effects: metabolic (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐1.76, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Mean change in weight (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐1.76, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Adverse effects: musculoskeletal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Muscle spasms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.12, 63.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Musculoskeletal and connective tissue disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.12, 72.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.3 Rhabdomyolysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.06, 35.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Adverse effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Absence seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [0.12, 59.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.57, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.3 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.65, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.4 Decreased attention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.24, 8.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.5 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.08, 5.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.6 Dysphoria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.7 Excessive talking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.12, 63.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.8 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.50, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.9 Forgetfulness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [0.12, 59.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.10 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.38, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.11 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.50, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.12 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.68, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.13 Leg shaking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [0.12, 59.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.14 Nervous systems disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.42, 6.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.15 Oppositional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.14, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.16 Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.17, 15.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.17 Seizure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.12, 63.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.18 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.87, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.19 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.81 [0.44, 32.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.20 Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.16, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Adverse effects: psychological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.50, 18.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.29, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.3 Panic attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 6.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.4 Psychiatric</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [0.46, 34.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.5 Self‐injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.11, 9.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Adverse effects: respiratory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Cold symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.26, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.81, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.3 Croup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.23 [0.14, 72.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.4 Epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.63, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.5 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.59, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.6 Nasal irritation/runny nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.10, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.7 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.15, 5.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.8 Respiratory, thoracic and mediastinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.09, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.9 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.05, 4.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.10 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.35, 3.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Adverse effects: skin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 General/systemic disorders and administration site conditions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [0.46, 34.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 Skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.63, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.3 Skin and subcutaneous tissue disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 101.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Adverse effects: urinary <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 Renal and urinary disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.12, 72.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.2 Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.06, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Adverse effects: other <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 Injury, poisoning, and procedural complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.12, 72.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.2 Investigations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.3 Lymphadenopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.4 Neoplasms: benign, malignant, and unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.12, 72.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.5 Troponin I increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.06, 35.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐0.12, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 Oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐0.74, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.2 Vasopressin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [‐0.19, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.3 Balovaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.14, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Tolerability/acceptability: loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.87, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Subgroup analyses: gender ‐ irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.28, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 Male and female participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.30, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.2 Male participants only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.76, 0.54]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Neurohormone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ADHD‐related medications vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.40, ‐0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Irritability: non‐stimulant ADHD‐related drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.38, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Irritability: stimulant ADHD‐related drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.97, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Self‐injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐1.63, 0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Adverse effects: cardiovascular <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.16, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.09, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.52 [0.44, 27.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [1.61, 4.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.46, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.92 [1.86, 18.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.4 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [1.51, 6.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.5 Stomachache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [1.10, 6.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.6 Stomach or abdominal discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [1.41, 3.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.7 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.81, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Adverse effects: immune system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.06, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Influenza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.14 [0.38, 134.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.72 [0.56, 39.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.4 Weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.20 [0.35, 29.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Adverse effects: metabolic (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.55, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.14, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 Increased energy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.65, 3.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Adverse effects: neurological (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.58, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.56, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.3 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [0.63, 7.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.4 Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.42 [1.54, 7.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.5 Emotional / tearful</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.32 [2.47, 16.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.6 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.73 [1.98, 7.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.7 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.09, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.8 Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.06, 7.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.9 Increased motor activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [0.48, 7.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.10 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.01, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.11 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.25, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.12 Motor tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [0.51, 10.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.13 Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.38, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.14 Repetitive behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.74, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.15 Restless</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.06, 40.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.16 Sleep disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.54, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.17 Talking excessively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.06, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.18 Waking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.29, 8.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.19 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 64.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Adverse effects: neurological (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.80 [0.55, 9.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 Decreased activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [‐2.66, 6.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Adverse effects: psychological (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.74, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [1.12, 5.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.3 Mood change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.00 [0.78, 216.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.4 Self‐injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.78, 3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.5 Silly behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.17, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.6 Social withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [0.39, 13.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Adverse effects: respiratory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.26, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Adverse effects: skin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.79, 6.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.2 Skin picking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.04, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Adverse effects: urinary <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.19, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.33, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Tolerability/acceptability: loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.50, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.1 ADHD‐related drugs: loss to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.50, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Subgroup analyses: gender ‐ irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.48, ‐0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.1 Male participants only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐1.50, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.2 Male and female participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.47, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.16 Subgroup analyses: age ‐ irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.48, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.1 Adults and children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐1.83, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.2 Children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.48, ‐0.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ADHD‐related medications vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antidepressant vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.30, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.29, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Dibenzoxazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐1.37, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Adverse effects: cardiovascular <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.24, 16.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [0.31, 23.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.09, 10.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.33, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.24, 16.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 Gastrointestinal disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.97, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.5 Nausea/abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.85, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.6 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.76, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Adverse effect: immune system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Allergies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.70, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Cold, flu or other systemic infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.82, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.85, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Adverse effects: metabolic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Appetite disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.14, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.68, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.3 Decreased energy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [1.13, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.4 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.35, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.5 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.08, 27.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Adverse effect: musculoskeletal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Motor disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.03, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 Neck pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.09, 48.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Adverse effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Activation syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.31, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.59, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.3 Aggression or hostility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.59, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.4 Anger/irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.75, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.5 Autonomic disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.32, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.6 CNS disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.33, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.7 Decreased attention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.16 [1.07, 16.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.8 Diaphoresis (sweating)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 69.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.9 Drowsiness/fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.65, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.10 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.77, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.11 Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.47, 7.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.12 Increased speech</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.66, 6.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.13 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.87, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.14 Mood disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.75, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.15 Mood lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.27, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.16 Numbness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.09, 48.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.17 Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.82, 4.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.18 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.77, 4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.19 Sleep disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.31, 4.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.20 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [0.57, 11.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.21 Twitching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.44, 111.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.22 Vertigo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.09, 48.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Adverse effects: psychological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.53, 4.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 Anxiety/nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.37, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.3 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.14, 13.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.4 Impulsive/intrusive behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [1.11, 7.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.5 Self‐injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.09, 17.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.6 Silliness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.40, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.7 Stereotypy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.33 [1.07, 64.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.8 Suicidal ideation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.09, 48.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.9 Unstable mood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.32, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.10 Verbal aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.11 Vivid or bad dreams</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.87 [0.27, 87.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Adverse effects: respiratory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.1 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.52, 5.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.2 Respiratory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [0.86, 5.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.3 Upper respiratory infection (URI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.73, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Adverse effects: skin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.1 Rash or skin irritation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.36, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 Adverse effects: urinary <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.1 Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.81, 12.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.2 Polyuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.09, 48.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.3 Urinary tract infection (UTI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.21, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.12 Adverse effects: other <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.1 Salty taste</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.09, 48.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.2 Trembling (mild)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.09, 48.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.13 Tolerability/acceptability: loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.93, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.14 Subgroup analyses: gender ‐ irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.1 Male and female participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐2.79, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.2 Male participants only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐8.37, 5.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.15 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.11, 8.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.1 Hospitalisation for dehydration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.10, 57.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.2 Severe diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.02, 8.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antidepressant vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Atypical vs typical antipsychotics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.95, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Adverse effects: cardiovascular (tachycardia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.24, 4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.08, 12.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.3 Nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.29, 86.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Adverse effects: metabolic (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.76, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Adverse effects: metabolic (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Weight gain (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [‐1.54, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Adverse effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 Ataxia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Blunted effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.3 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.15, 61.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.4 Rigidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.5 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.76, 8.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Adverse effects: respiratory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.1 Respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.43, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Adverse effects: skin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.1 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Adverse effects: urinary <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.1 Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.29, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Tolerability/acceptability: loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.26, 96.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Atypical vs typical antipsychotics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Atypical vs atypical antipsychotics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.02, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Adverse effects: cardiovascular <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.16, 7.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [0.34, 28.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.34, 4.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [0.13, 73.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.4 Drooling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.38, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.5 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.17 [0.26, 103.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.6 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.05, 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.7 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.20, 12.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Adverse effects: metabolic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.56, 4.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.2 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.15, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.3 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.19, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Adverse effects: musculoskeletal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 Muscle rigidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [0.12, 68.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Adverse effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.84 [0.24, 96.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.2 Difficulty sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.78 [0.37, 125.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.3 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.10, 5.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.4 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.29, 3.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.5 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 14.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.6 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [0.12, 68.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.7 Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [0.20, 21.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.8 Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.07, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.9 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.28, 8.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.10 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.39 [0.76, 15.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.11 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.72 [0.49, 155.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Adverse effects: psychological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.1 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Adverse effects: skin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8.1 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.07, 15.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.9 Adverse effects: urinary <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9.1 Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.04, 53.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.10 Tolerability/acceptability: loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Atypical vs atypical antipsychotics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Atypical antipsychotic vs antidementia</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [‐0.27, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Adverse effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.86, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Tolerability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.04, 3.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Atypical antipsychotic vs antidementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Atypical antipsychotic vs antiparkinsonian</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Increased salivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.3 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Adverse effects: metabolic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Adverse effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 Agitation/excitement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.32, 6.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 Increased hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.41, 118.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.3 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.48, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.4 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Atypical antipsychotic vs antiparkinsonian</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Anticonvulsant vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐1.93, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Aggression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.71, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.38, 8.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.2 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.11, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [0.44, 27.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.4 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [0.80, 6.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.5 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [0.44, 27.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Adverse effects: immune system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.1 Chills</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.62 [0.31, 22.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.2 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [0.44, 27.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Adverse effects: metabolic (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.1 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.45 [1.02, 29.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.2 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.05, 18.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.3 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.61, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.4 Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.6 Adverse effects: metabolic (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6.1 Weight gain (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [‐0.77, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.7 Adverse Effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.1 Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [0.37, 14.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.2 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.21, 6.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.3 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [0.49, 32.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.4 Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.21, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.5 Echolalia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.07, 14.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.6 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.09, 47.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.7 Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.8 Hypersomnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.9 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.44, 6.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.10 Lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.18 [0.35, 110.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.11 Paraesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.64, 39.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.12 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.13 Self‐injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7.14 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.95, 51.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.8 Adverse effects: psychological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8.5 Impulsivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.14, 65.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.9 Adverse effects: skin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.63 [0.89, 24.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9.1 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.63 [0.89, 24.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.10 Adverse effects: urinary <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.10.1 Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.11 Tolerability/acceptability: loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.84, 4.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Anticonvulsant vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Antidepressant vs antidepressant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Adverse effects: cardiovascular <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [0.13, 50.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.35, 6.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.12, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.3 Nausea/abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.10, 9.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.4 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.07, 35.67]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Antidepressant vs antidepressant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Antidementia versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Irritability (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.31, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Irritability (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 Partial response (≥ 25% reduction in irritability score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.97, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.2 Complete response (≥ 50% reduction in irritability score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.98, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.3 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.16, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Aggression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [‐0.05, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.1 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.21, 4.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.2 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.12, 66.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.4 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.5 Gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.13 [0.37, 136.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.6 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.41, 9.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.7 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.18, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.5 Adverse events: metabolic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.1 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.24, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.2 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.54, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.6 Adverse effects: musculoskeletal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.7 Adverse effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7.1 Daytime drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.41, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7.2 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.27, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7.3 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.48, 4.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7.4 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.26, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7.5 Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.07, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7.6 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.37, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7.7 Morning drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.71, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7.8 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.30, 5.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7.9 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7.10 Decreased energy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.09, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.8 Adverse events: other <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.8.1 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.19, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.8.2 Increased infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.35, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.9 Adverse events: psychological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.9.1 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [0.45, 8.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.9.2 Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.42, 6.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.9.3 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.03, 5.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.9.4 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.43, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.9.5 Mood changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.95, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.9.6 Emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.19, 17.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.9.7 Anger</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 6.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.9.8 Self‐injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [0.12, 61.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.10 Adverse events: respiratory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.10.1 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.63, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.10.2 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.08, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.10.3 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.13 [0.37, 136.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.11 Adverse effects: skin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.11.1 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.20, 20.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.11.2 Skin irritation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.15, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.12 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.12.1 Affective disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.13, 73.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.13 Tolerability/acceptability: loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.14 Subgroup analysis: age ‐ irritability (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐1.24, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.14.1 Children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.31, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.14.2 Adults only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.75 [‐2.06, 0.56]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Antidementia versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Antiparkinsonian vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.75 [‐1.39, ‐0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.2 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.3 Drooling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Adverse effects: metabolic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.2 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.69, 13.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Adverse effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.1 Daytime drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.2 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [0.55, 9.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.3 Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.4 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.25 [0.27, 102.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.5 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.5 Adverse effects: psychological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5.2 Adverse behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.11, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.6 Tolerability/acceptability: loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Antiparkinsonian vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Anxiolytic versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Irritabilty (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.88, 0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 Anxiolytics vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.88, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Irritability (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.1 Response rate (&gt; 25% decrease in irritability score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.04, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.1 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.35, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.2 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.68, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.3 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.68, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Adverse effects: immune System <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.1 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.33, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.2 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.73, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.3 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.18, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.5 Adverse effects: metabolic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5.1 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.62, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5.2 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.93, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.6 Adverse effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6.1 Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.47, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6.2 Increased aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.60, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6.3 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.90, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6.4 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.48, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6.5 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.58, 4.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.7 Adverse effects: psychological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.7.1 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [0.48, 15.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.8 Adverse effects: respiratory system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.8.1 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.64, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.8.2 Epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.19, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.8.3 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.36, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.8.4 Rhinorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.66, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.8.5 Sinus congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.55, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.9 Adverse effects: skin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.9.1 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.52, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.10 Other adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.10.1 Ear infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.50, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.10.2 Ear and labyrinth disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.51, 16.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.10.3 Eye disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [0.72, 13.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.10.4 Renal and urinary disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.41, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.11 Tolerability/acceptability: loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.45, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Anxiolytic versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Experimental versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Irritability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.53, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 Arbaclofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.68, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.2 Baclofen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.34, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.3 Bumetanide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.84, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.4 Celecoxib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.27 [‐1.95, ‐0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.5 Dextromethorphan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐1.52, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.6 Dextromethorphan/quinidine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐1.43, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.7 Folinic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.08, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.8 Lofexedine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.66, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.9 L‐carnosine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.41, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.10 Minocycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.28, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.11 N‐acetylcysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.61 [‐1.16, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.12 Naltrexone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.80, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.13 Nicotine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐2.19, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.14 Pioglitazone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐1.42, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.15 Palmitoylethanolamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐1.00, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.16 Prednisolone (steroid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.96, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.17 Pregnenolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐1.07, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.18 Propentofylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [‐0.01, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.19 Resveratol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.79, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.20 Riluzole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐1.10, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.21 Simvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.88 [‐1.38, ‐0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.22 Sulforaphane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.86 [‐1.39, ‐0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.23 Tetrahydrobiopterin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.68, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Self‐injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.09, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.1 Bumetanide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.21, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.2 N‐acetylcysteine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.29, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.3 Trichuris suris ova</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.55, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.1 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.95, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.2 Change in bowel habits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.05, 3.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.3 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.77, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.4 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.55, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.5 Drooling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 5.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.6 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.37, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.7 Dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.8 Encopresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.9 Flatulance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.15, 59.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.10 Increased salivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.39, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.11 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.90, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.12 Thirst</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.32 [1.10, 10.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.13 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.91, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.4 Adverse effects: immune system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.1 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [0.46, 18.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.2 Influenza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.5 Adverse effects: metabolic (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.1 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.95, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.2 Hypoglycemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.09, 5.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.3 Hypokalemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.48 [4.04, 38.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.4 Hyponatremia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 69.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.5 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.02, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.6 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.04, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.7 Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.50, 4.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.8 Weight loss (0.12‐0.67 kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.43 [0.65, 137.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.9 Weight loss (0.45‐2.19 kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.6 Adverse effects: metabolic (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.24, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.6.1 Change in weight (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.24, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.7 Adverse effects: musculoskeletal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7.1 Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7.2 Difficulty walking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7.3 Impaired balance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.08, 33.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7.4 Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.79, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7.5 Slow movement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.17 [0.22, 80.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7.6 Stiffness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [0.41, 10.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7.7 Weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.21, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.8 Adverse effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.1 Agitation/excitement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.39, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.2 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.44, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.3 Daytime drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.75, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.4 Dazed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.13, 52.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.5 Difficulty concentrating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.42, 14.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.6 Difficulty sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.44, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.7 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.67, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.8 Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.45 [1.21, 9.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.9 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.70, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.10 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.66, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.11 Hypoactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.07, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.12 Increased aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.36, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.13 Increased hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.35, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.14 Increased irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.71, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.15 Increased stereotypies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.10, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.16 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.66, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.17 Migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.15, 59.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.18 Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.47, 7.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.19 New onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.20 Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.53, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.21 Rocking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 5.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.22 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.61, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.23 Syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [0.30, 25.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.24 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.44, 7.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8.25 Twitching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [0.42, 31.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.9 Adverse effects: psychological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9.1 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.20, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9.2 Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.37, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9.3 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.62, 6.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9.4 Increased self‐injurious behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.11, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9.5 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.36, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9.6 Mental symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.41, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9.7 Repetitive behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9.8 Worsening of temper tantrums</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.30, 11.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.10 Adverse effects: respiratory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.10.1 Aggravation of asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [0.14, 77.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.10.2 Congestion/cold</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.62, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.10.3 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.55, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.10.4 Ear infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.19, 18.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.10.5 Lung congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.60, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.10.6 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.22, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.10.7 Respiratory adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.43 [0.27, 109.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.11 Adverse effects: skin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.11.1 Hives</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.11.2 Itches</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.07, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.11.3 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.30, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.11.4 Skin adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.16, 7.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.11.5 Skin lesion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.74, 3.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.12 Adverse effects: urinary <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.12.1 Diuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.25, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.12.2 Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [0.82, 8.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.12.3 Urinary retention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.05, 10.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.12.4 Urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.13 Adverse effects: other <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.13.1 Blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.11, 56.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.13.2 Dilated pupils</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.05, 9.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.13.3 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.13, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.13.4 Sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.15, 3.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.13.5 Vision: conjunctivitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.14 Tolerability/acceptability: loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.89, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.15 Subgroup analyses: age ‐ irritability (option 1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.42, ‐0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.15.1 Children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.46, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.15.2 Adults only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.69, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.15.3 Children and adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.61, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.16 Subgroup analyses: age ‐ irritability (option 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.42, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.1 Celecoxib: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.27 [‐1.95, ‐0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.2 D‐cycloserine: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.53, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.3 Dextromethorphan: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐1.52, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.4 Mecamylamine: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.71, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.5 Riluzole: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐1.27, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.6 Riluzole: children and adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.87, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.7 Pioglitazone: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐1.42, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.8 N‐acetylcysteine: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.61 [‐1.16, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.9 Trichuris suis ova: adults only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐1.50, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.10 Tetrahydrobiopterin: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.68, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.11 Lofexedine: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.66, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.12 Naltrexone: adults only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐1.05, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.13 Minocycline: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.28, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.14 Propentofylline: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [‐0.01, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.15 Sulforaphane: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.86 [‐1.39, ‐0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.16 Folinic acid: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.08, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.17 L‐carnosine: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.41, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.18 Prednisolone (steroid): children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.96, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.19 Dextromethorphan/quinidine: adults only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐1.43, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.20 Pregnenolone: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐1.07, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.21 Baclofen: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.34, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.22 Palmitoylethanolamide: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐1.00, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.23 Bumetanide: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.55, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.24 Resveratol: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.79, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.16.25 Arbaclofen: children and adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.68, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.17 Subgroup analyses: age ‐ self‐injury (option 1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.30, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.17.1 Children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.29, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.17.2 Adults only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐1.20, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.18 Subgroup analyses: age ‐ self‐injury (option 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.09, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.18.1 N‐acetylcysteine: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.22, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.18.2 N‐acetylcysteine: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.99, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.18.3 Trichuris suis ova: adults only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.55, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.18.4 Bumetanide: children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.21, 0.60]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Experimental versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011769-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Typical antipsychotic vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Self‐injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Adverse effects: musculoskeletal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.1 Dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [0.11, 52.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.3 Adverse effects: neurological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.2 Fatigue/lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.64 [0.53, 140.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.4 Adverse effects: psychological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4.1 Behaviour problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.16, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.5 Tolerability/acceptabiity: loss to follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.14, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Typical antipsychotic vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011769.pub2/references#CD011769-tbl-0036">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011769.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011769-note-0010">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011769-note-0021">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011769-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011769-note-0019">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011769-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD011769-note-0018">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD011769-note-0015">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD011769-note-0013">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011769-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011769-note-0020">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011769-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011769-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011769\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011769\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011769\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011769\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011769\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011769.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011769.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011769.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011769.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011769.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726147067"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011769.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726147071"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011769.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8c7a5e309379',t:'MTc0MDcyNjE0Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 